"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT06224608","Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis","Biological: Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)","Incidence of adverse events (AEs) at the skin test site and non-skin test site within 28 days after skin testing, with particular attention to the incidence of AEs within 7 days after skin testing.|Incidence of abnormal blood routine, blood biochemistry, urine routine, and electrocardiogram detection indexes on the 3rd day after skin testing.|Incidence of abnormal vital signs within 7 days after skin testing.|Incidence of serious adverse events (SAEs) within 28 days after skin testing.|Specific skin reactions at the skin test site at 30 minutes, 2 hours, 4 , 8 , 24 , 48 , 72 , 96 hours, and 7 days after skin testing for different doses of EEC.|Agreement between skin test results and IGRA test results for different doses of EEC.|Agreement between IGRA test results before and after skin testing.","Chengdu CoenBiotech Co., Ltd|Beijing Chest Hospital, Capital Medical University|Beijing Friendship Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","60","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KN-EEC-I","January 17, 2023","May 9, 2023","May 9, 2023","January 25, 2024",,"January 25, 2024","Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT06224608"
2,"NCT03667742","Diagnosing of Acute Tuberculosis","SwEaTB","Completed","No Results Available","Tuberculosis","Diagnostic Test: analysis of sweat and serum samples for protein markers","Change in protein markers (ESAT-6 and CFP-10 and CRP and Amyloid A2 and C1q) in patients with tuberculosis and other pulmonary diseases|change of protein markers during tuberculostatic therapy|Differences in protein markers in patients with other pulmonary diseases|Differences in protein markers in patients with positive and negative tuberculosis ELISpot","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"35","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-01455; me17Eckstein2","November 17, 2017","November 4, 2020","November 4, 2020","September 12, 2018",,"December 1, 2020","University Hospital Basel, Basel, Switzerland|Hochschule für Lifescience, Muttenz, Switzerland",,"https://ClinicalTrials.gov/show/NCT03667742"
3,"NCT04285905","Male Partner-assisted Contact Tracing for HIV and Tuberculosis in Malawi","mPATCH-TB","Terminated","No Results Available","Tuberculosis","Other: Access to Fast Track TB clinic|Other: Information leaflet for male partner|Other: Home sputum collection|Other: Home HIV testing|Other: Financial incentive","TB screening|TB case detection|Acceptability|Completion of HIV testing","Liverpool School of Tropical Medicine|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|London School of Hygiene and Tropical Medicine|University of Liverpool","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","18-020","April 10, 2019","March 28, 2020","March 28, 2020","February 26, 2020",,"February 25, 2021","Bangwe Health Centre, Blantyre, Southern Region, Malawi",,"https://ClinicalTrials.gov/show/NCT04285905"
4,"NCT05284812","A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)",,"Suspended","No Results Available","Tuberculosis","Biological: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Biological: High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Biological: High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Biological: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo","The number of adverse events after intramuscular injection|Laboratory markers of immunity","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","LKM-2021-BJH01","February 10, 2022","June 30, 2024","December 31, 2024","March 17, 2022",,"November 28, 2023","Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT05284812"
5,"NCT04545788","Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis",,"Unknown status","No Results Available","Tuberculosis","Drug: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.","Culture of Mycobacterium tuberculosis in sputum.|Adverse effect.","Beijing Chest Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCP-TB","August 1, 2020","December 31, 2022","December 31, 2022","September 11, 2020",,"September 16, 2020","Beijing Chest Hospital affiliated to Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04545788"
6,"NCT04538911","Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients",,"Recruiting","No Results Available","Tuberculosis","Drug: BCG-PPD","Evaluate the incidence of all adverse event and results of laboratory tests|Evaluate the effectiveness of the product by measuring the size of the skin response","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shenzhen Third People's Hospital|Beijing Kangterike Statistical Technology Co., Ltd.|Wuhan Pulmonary Hospital","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 1","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","LKM-2020-PPD02","July 2, 2021","July 2023","August 2023","September 4, 2020",,"May 9, 2023","The Third People's Hospital Of Shenzhen, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04538911"
7,"NCT03691883","Design of an Integrative Algorithm for Staging Tuberculosis","STAGE-TB","Recruiting","No Results Available","Tuberculosis",,"Clinical changes|Microbiological changes|Changes in Biomarkers values|Radiological Score Value|Changes in SGRQ score|Changes in Kessler-10 score|Changes in Health Quality of Life measures along time using BCN-Q questionnaire","Fundació Institut Germans Trias i Pujol|Hospital Universitari Vall d'Hebron (Drassanes)|Servicios Clínicos de Barcelona|Germans Trias i Pujol Hospital|Hospital Sant Joan de Deu|Hospital del Mar","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STAGE-TB","April 19, 2018","September 2024","December 2024","October 2, 2018",,"March 25, 2024","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Sant Joan de Déu, Esplugues De Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron-Drassanes, Barcelona, Spain|Servicios Clínicos de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03691883"
8,"NCT06054334","Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis","ISOBK","Recruiting","No Results Available","Tuberculosis",,"Serum isoniazid Cmax","Centre Hospitalier Universitaire, Amiens","All","18 Years to 99 Years   (Adult, Older Adult)",,"138","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PI2023_843_0003","January 4, 2023","January 2024","October 2024","September 26, 2023",,"October 2, 2023","CHU Amiens Picardie, Amiens, Picardie, France",,"https://ClinicalTrials.gov/show/NCT06054334"
9,"NCT05847491","Latent Tuberculosis in Healthcare Workers - the Reality of a Portuguese Tertiary Hospital",,"Recruiting","No Results Available","Tuberculosis","Diagnostic Test: IGRA/Tuberculin skin test","Number and percentage of latent tuberculosis diagnosis in healthcare workers|Treatment acceptance for latent tuberculosis|Treatment completion","Centro Hospitalar do Oeste","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LTBCHO23","September 1, 2022","September 30, 2023","December 31, 2023","May 6, 2023",,"May 6, 2023","Centro Hospitalar do Oeste - Torres Vedras, Torres Vedras, Lisboa, Portugal",,"https://ClinicalTrials.gov/show/NCT05847491"
10,"NCT05941052","Assessing Diagnostics At Point-of-care for Tuberculosis","ADAPT","Recruiting","No Results Available","Tuberculosis","Diagnostic Test: Tongue swab-based molecular assays","Proportion with positive index test result among participants with tuberculosis (TB)|Proportion with negative index test result among participants without tuberculosis (TB)","University of California, San Francisco|University Hospital Heidelberg|KNCV Tuberculosis Foundation|Bingham University|University of California, Irvine|De La Salle University Medical Center|Centre for Infectious Disease Research in Zambia|Johns Hopkins University","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","1350","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","7200AA22RFA00004","August 28, 2023","September 30, 2028","September 30, 2028","July 12, 2023",,"September 22, 2023","Zankli Research Center, Bingham University, Abuja, Nigeria|De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines|Centre for Infectious Disease Research in Zambia, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT05941052"
11,"NCT04239313","A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)",,"Completed","No Results Available","Tuberculosis","Biological: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Biological: Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Biological: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo","The number of adverse events after intramuscular injection|Laboratory markers of immunity","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AEC/BC02-Ⅰb-healthy","May 27, 2020","February 24, 2021","June 20, 2022","January 27, 2020",,"September 6, 2022","Wuhan Infectious Disease Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04239313"
12,"NCT05364593","Evaluation of Point-of-care Ultrasound in Children From 6 Months to 15 Years With Presumptive Tuberculosis",,"Completed","No Results Available","Tuberculosis",,"To describe the sonographic findings obtained by TB-focused POCUS methodology|To establish the sensitivity, specificity, positive predictive value and negative predictive value of POCUS positive as a composite against a composite reference of the final diagnosis|To describe the sonographic signs according to HIV status (positive, negative)|To describe the sonographic signs according to nutritional status (severe acute malnutrition (SAM) or not SAM)|To determine the proportion of children with improvement / resolution of sonographic signs and the proportion without improvement of sonographic signs at 2 months of follow-up in children with and without TB|To describe operational aspects of POCUS: compliance|To describe operational aspects of POCUS: duration of POCUS|To describe operational aspects of POCUS: mean time to diagnosis","Medecins Sans Frontieres, Spain","All","6 Months to 15 Years   (Child)",,"576","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MSF18116","June 26, 2019","June 30, 2023","December 15, 2023","May 6, 2022",,"January 9, 2024","Simao Mendes Hospital, Bissau, Guinea-Bissau|Malakal hospital, Malakal, Upper Nile, South Sudan","""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT05364593/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05364593"
13,"NCT05259254","Effectiveness Of Mobile Application To Improve Adherence To Tuberculosis Treatment",,"Recruiting","No Results Available","Tuberculosis","Other: Mobile Application|Other: Direct Observed Therapy","Adherence Level assessed by number of participants completed daily medication observation|Retention and Completion Rate assessed by number of active users of mobile application and number of participants who can complete intervention from the date of randomization|Usability Score assessed by validated English and Malay version of Usability Scale Questionnaire for the Assessment of Mobile Apps|Health-related quality of life (HR-QOL) assessed by English and Malay Version of EUROQOL EQ5D-3L Questionnaire|Patient satisfaction assessed by the English and Malay Version of Short-Form Patient Satisfaction Questionnaire (PSQ-18)|Employment assessed by asking the total monthly household income and total time needed for medication observation","Mohd Fazeli bin Sazali|Ministry of Health, Malaysia|Universiti Malaysia Sabah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PatuhTB01","June 1, 2022","May 28, 2023","May 28, 2023","February 28, 2022",,"November 7, 2022","Mohd Fazeli bin Sazali, Kota Kinabalu, Sabah, Malaysia",,"https://ClinicalTrials.gov/show/NCT05259254"
14,"NCT03230409","Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents",,"Completed","No Results Available","Tuberculosis","Behavioral: Leaflet written in the patient's/family mother tongue|Behavioral: A follow-up telephone call|Biological: Eidus-Hamilton Test|Behavioral: A written questionnaire","Adherence to treatment|Risk Factors","Hospital Sant Joan de Deu|Official Barcelona Nurses Association (COIB)","All","up to 18 Years   (Child, Adult)","Not Applicable","359","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PIC-68-13","January 1, 2014","September 30, 2016","January 15, 2017","July 26, 2017",,"July 26, 2017",,,"https://ClinicalTrials.gov/show/NCT03230409"
15,"NCT05994144","""Conducting A Study On Video Observed Therapy In The Management Of Tuberculosis""","VOT","Not yet recruiting","No Results Available","Tuberculosis","Other: VIDEO OBSERVED THERAPY","Treatment adherence in percentage from both arms|Seroconversion rate|Side effects incidents report|Patients suffering with side effects|Degree of patient's satisfaction|Time save|Cost saving","University of Malaya","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","AISH7","December 1, 2023","March 30, 2024","June 30, 2024","August 16, 2023",,"August 16, 2023","Hospital Sultanah Nur Zahira, Kuala Terengganu, Terengganu, Malaysia",,"https://ClinicalTrials.gov/show/NCT05994144"
16,"NCT04608955","Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081","WX-081","Completed","No Results Available","Pulmonary Tuberculosis","Drug: WX-081|Drug: Bedaquiline|Drug: Standard treatment|Drug: Multi-drug background treatment (MBT)","Time to positive (TTP)|Early bactericidal activity (EBA) of WX-081|change of electrocardiogram QT interval|The percentage of participants with sputum culture-negative conversion.|Rate of change of colony forming units (CFU)|The percentage of participants with sputum smear-negative conversion.|heart rate|blood pressure|Maximum plasma concentration (Cmax)|Time to reach maximum plasma concentration (Tmax)|Area under the plasma concentration versus time curve (AUC(0-t))|Terminal plasma half-life (t1/2)","Shanghai Jiatan Pharmatech Co., Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JYB0201","October 16, 2020","April 13, 2022","April 13, 2022","October 30, 2020",,"September 11, 2023","Beijing Chest Hospital affiliated to Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04608955"
17,"NCT04187313","Increasing Notifications of Tuberculosis From Private Practitioners","INSTEP2","Completed","No Results Available","Tuberculosis","Other: INSTEP2 intervention package","Increased notification of tuberculosis (TB) by study participants|Proportion of referred patients in the intervention and control arms that are actually diagnosed with TB|Restricted analysis of primary outcome","Universitas Padjadjaran|University of Otago|Harvard University","All","Child, Adult, Older Adult","Not Applicable","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","TB-201911.02","July 1, 2020","August 31, 2022","August 31, 2022","December 5, 2019",,"October 18, 2023","Universitas Padjadjaran Teaching Hospital, Bandung, Jawa Barat, Indonesia","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/13/NCT04187313/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/13/NCT04187313/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04187313"
18,"NCT04768231","Rifampicin at High Dose for Difficult-to-Treat Tuberculosis","RIAlta","Unknown status","No Results Available","Tuberculosis","Drug: Rifampin","Safety of rifampicin at 35mg/kg/day|Efficacy of rifampicin at 35mg/kg/day in pulmonary tuberculosis|Tolerability of rifampicin at 35mg/kg/day","Hospital Universitari Vall d'Hebron Research Institute|University Medical Center Groningen|Radboud University Medical Center|Centro Hospitalar De São João, E.P.E.|Instituto Nacional de Enfermedades Respiratorias y del Ambiente, Paraguay","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIAlta-1|2020-003146-36","April 1, 2021","December 31, 2022","December 31, 2023","February 24, 2021",,"February 24, 2021","University Medical Center, Groningen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Instituto Nacional de Enfermedades Respiratorias y del Ambiente, Asunción, Paraguay|Centro Hospitalario Universitario de Sao Joao, Porto, Portugal|Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04768231"
19,"NCT06118619","A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis",,"Recruiting","No Results Available","Respiratory Tuberculosis","Drug: Interferon-Gamma","Proportion of abacillated patients|Proportion of patients who died|Proportion of patients who required a change in therapy|Proportion of patients with adverse reactions|Changes in the level of CD4 lymphocytes and HIV viral load in the blood","SPP Pharmaclon Ltd.","All","18 Years to 78 Years   (Adult, Older Adult)",,"350","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GAM2022","June 1, 2022","December 31, 2023","March 1, 2024","November 7, 2023",,"November 9, 2023","Astrakhan Oblast Tuberculosis Clinic, Astrakhan, Astrakhan Oblast, Russian Federation|Tuberculosis Clinic of the Chuvash Republic, Cheboksary, Chuvash Republic, Russian Federation|Leningrad Oblast Tuberculosis Clinic, Slantsy, Leningrad Oblast, Russian Federation|Leningrad Oblast Tuberculosis Hospital in Tikhvin, Tikhvin, Leningrad Oblast, Russian Federation|Clinical Phthisiopulmonological Medical Center, Perm, Perm Region, Russian Federation|Tuberculosis Clinic of the Republic of Bashkortostan, Ufa, Republic Of Bashkortostan, Russian Federation|Republican Tuberculosis Clinic, Kazan, Republic Of Tatarstan, Russian Federation|Ryazan Oblast Tuberculosis Clinic, Ryazan, Ryazan Oblast, Russian Federation|Sverdlovsk Oblast Clinical Medical Center of Phthisiopulmonology and Infectious Diseases, Yekaterinburg, Sverdlovsk Oblast, Russian Federation|Volgograd Oblast Tuberculosis Clinic, Volgograd, Volgograd Oblast, Russian Federation|N. S. Pokhvisneva Voronezh Oblast Clinical Tuberculosis Dispensary, Voronezh, Voronezh Oblast, Russian Federation|Yaroslavl regional tuberculosis clinic, Yaroslavl, Yaroslavl Region, Russian Federation|City tuberculosis clinic, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT06118619"
20,"NCT05772065","Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management",,"Completed","No Results Available","Latent Tuberculosis","Behavioral: CDC/NTCA guidelines only|Behavioral: LTBI ASSIST and CDC/NTCA guidelines only","Reported confidence with LTBI management [using a Likert scale questionnaire developed by study team]|Proportion of appropriate LTBI care selection|Time to LTBI care selection","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00376488","June 1, 2023","July 17, 2023","July 17, 2023","March 16, 2023",,"January 3, 2024","Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05772065"
21,"NCT04709159","Impact of Mobile Health Interactive Software on Tuberculosis Outcomes; The Call for Life (CFLU-TB) Project","CFLU-TB","Unknown status","No Results Available","Tuberculosis","Other: Call for Life Uganda","Treatment success|TB cure for patients with bacteriologically diagnosed TB|Treatment completion for patients with clinically diagnosed TB|Retention in care|Experiences of patients and care providers towards CFLU™|Cost effectiveness of the CFLU™ intervention|Adherence to TB medicines|Appointment keeping|Knowledge about HIV/TB|Drug resistant TB rates|Uptake of intervention","Makerere University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","274","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ST/263/2020","October 19, 2020","July 2022","July 2022","January 14, 2021",,"January 26, 2021","Kasangati Health Centre IV, Kampala, Uganda|Kisenyi Health Centre IV, Kampala, Uganda|Kiryandongo Hospital, Kiryandongo, Uganda",,"https://ClinicalTrials.gov/show/NCT04709159"
22,"NCT03800888","Real-time Tuberculosis Medication Adherence Intervention in Rural Southwestern Uganda","MAT K43","Unknown status","No Results Available","Tuberculosis","Other: Daily SMS reminders for TB patients|Other: SMS Notifications for social supporters|Other: Weekly SMS remiders","Percent adherence|Treatment success rate.","Mbarara University of Science and Technology|Massachusetts General Hospital|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MUST-16/10-16","January 10, 2019","June 2021","July 2021","January 11, 2019",,"February 7, 2019","Mbarara Regional Referral Hospital, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT03800888"
23,"NCT05455112","Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis","CONSTAN-ARG","Recruiting","No Results Available","Tuberculosis, Pulmonary","Biological: RUTI® Vaccine|Biological: Placebo","Early bactericidal activity (EBA) 0-14|Adverse events|Grade 3-4 adverse events|Time to sputum culture conversion (SCC)|Proportion of SCC at week 16|Early bactericidal activity (EBA) 2-14|Early bactericidal activity (EBA) 7-14|Early bactericidal activity (EBA) 24 weeks|Proportion of SCC per weeks|Clinical worsening|Improvement of clinical signs and symptoms|Improvement of quality of life|Discontinuation of TB treatment","Archivel Farma S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CONSTAN-ARG","October 29, 2022","August 2024","December 2024","July 13, 2022",,"January 31, 2024","Hospital José Nestor Lencinas, Godoy Cruz, Mendoza, Argentina|Hospital de Clínicas Presidente Dr. Nicolás Avellaneda, San Miguel De Tucumán, Tucumán, Argentina",,"https://ClinicalTrials.gov/show/NCT05455112"
24,"NCT05047055","Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients",,"Active, not recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: Isoniazid|Drug: Rifampicin|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Moxifloxacin","TB recurrence free cure|Adverse drug reaction|TB Sustained treatment Success, failure, death, loss to follow up|TB Relapse and Reinfection","Tuberculosis Research Centre, India|Indira Gandhi Government Medical College and Hospital (IGGMCH), Nagpur|King George's Medical University, Lucknow|Mahavir Hospital and Research Centre, Hyderabad|Government Vellore Medical College and Hospital, Adukkamparai|Lok Nayak hospital, New Delhi","All","18 Years to 65 Years   (Adult, Older Adult)",,"550","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021010","March 15, 2022","March 31, 2025","March 31, 2025","September 16, 2021",,"January 5, 2024","National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT05047055"
25,"NCT05656287","My Mobile Wallet: An Intervention for Tuberculosis Medication Adherence in Rural Uganda","M_wallet","Recruiting","No Results Available","Tuberculosis","Other: SMS texts + incentives + Wisepill device for medication monitoring|Other: SMS texts only + Wisepill device for medication monitoring|Other: Wisepill device for medication monitoring only","Medication adherence rates among patients|Number of patients who used the intervention|TB treatment completion|Clinic Attendance|Mortality|Cure rate","Mbarara University of Science and Technology","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","242","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MUST-2021-102","April 14, 2022","December 2025","May 2026","December 19, 2022",,"December 19, 2022","Mbarara Regional Referral Hospital, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT05656287"
26,"NCT04547738","Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon","MAP-TB","Unknown status","No Results Available","Tuberculosis","Drug: TB treatment according to national guidelines","Influence of filariae infection on TB disease outcome and BCG vaccination|Biomarkers for TB severity and BCG vaccination","University Hospital, Bonn","All","5 Years and older   (Child, Adult, Older Adult)",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HO2009/14-1","December 1, 2020","October 1, 2023","October 1, 2023","September 14, 2020",,"November 23, 2021","University of Buea, Buea, Cameroon",,"https://ClinicalTrials.gov/show/NCT04547738"
27,"NCT05537038","Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers",,"Recruiting","No Results Available","Tuberculosis","Biological: BNT164a1|Biological: BNT164b1|Other: Placebo","Frequency of solicited local reactions (pain, erythema/redness, induration/swelling) at the injection site up to 7 days after each dose|Frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue, muscle pain and joint pain, chills, and fever) up to 7 days after each dose|Proportion of participants with at least one adverse event (AE) occurring from each dose to 28 days after each dose|Proportion of participants with at least one AE occurring from Dose 1 to 28 days post-Dose 3|Proportion of participants with at least one serious adverse event (SAE) or medically attended adverse event (MAAE) occurring from Dose 1 up to 168 days post-Dose 3|Number of AEs from Dose 1 to 28 days post-Dose 3","BioNTech SE","All","18 Years to 55 Years   (Adult)","Phase 1","128","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BNT164-01|2022-000911-29","April 18, 2023","September 2024","September 2025","September 13, 2022",,"February 8, 2024","emovis GmbH, Berlin, Germany|CRS Clinical Research Services Berlin GmbH, Berlin, Germany|CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT05537038"
28,"NCT01587677","Evaluation of a LAM FLISA for the Diagnosis of Tuberculosis","LAM FLISA","Completed","No Results Available","Tuberculosis",,"Rate of patients with false positive and false negative urine LAM detection|Rate of patients with false negative and false positive blood LAM detection","Research Center Borstel|German Cancer Research Center","All","18 Years and older   (Adult, Older Adult)",,"92","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RCBorstel001","February 2012","November 2012","February 2013","April 30, 2012",,"October 6, 2016","Research Center Borstel, Borstel, Germany",,"https://ClinicalTrials.gov/show/NCT01587677"
29,"NCT04567498","eNose-TB: Electronic Nose for Tuberculosis Screening",,"Unknown status","No Results Available","Tuberculosis","Other: exhaled breath sampling","diagnostic accuracy of electronic nose signal in tuberculosis","Gadjah Mada University","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","1778","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Screening","002/2019","December 2, 2021","December 31, 2022","December 31, 2022","September 28, 2020",,"April 6, 2022","Balai Kesehatan Masyarakat Klaten, Klaten, Central Java, Indonesia|Primary health centers, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04567498"
30,"NCT05203068","Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers",,"Completed","Has Results","Tuberculosis","Diagnostic Test: Recombinant tuberculosis allergen (RTA)","Number of the Volunteers With the True Negative RTA Result|Number of Subjects With Local Adverse Reactions Within 72 Hours Following the Intradermal Test Application|Number of Participants With General and Local Adverse Reactions Within 28 Days After Administration of RTA","National Medical Research Center of Phthisiopulmonology and Infectious Diseases","All","18 Years to 30 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","102/1","November 24, 2021","January 18, 2022","January 26, 2022","January 24, 2022","August 25, 2023","August 25, 2023","National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT05203068/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05203068"
31,"NCT05215990","Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Drug: MetFORMIN 500 Mg Oral Tablet|Drug: Placebo","To study about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients between metformin and placebo drug with pulmonary tuberculosis standard treatment.|To study about side effect such as nausea, vomit, hepatitis between patients use metformin with pulmonary tuberculosis standard treatment and patients use placebo drug with pulmonary tuberculosis standard treatment.","Mahidol University|Ministry of Health, Thailand","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MURA2021/816","January 15, 2022","December 31, 2022","March 31, 2023","January 31, 2022",,"February 14, 2022","Angsana Phuphuakrat, Ratchathewi, ฺBangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT05215990"
32,"NCT02687529","Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection",,"Completed","Has Results","Tuberculosis","Device: CST001","Number of Participants With Concordant CST001 Assay Results for All Replicates Across Three Testing Sites","QIAGEN Gaithersburg, Inc","All","18 Years to 80 Years   (Adult, Older Adult)",,"66","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CST001_USA7","October 27, 2015","November 7, 2015","May 26, 2016","February 22, 2016","June 6, 2019","June 19, 2019","VA Palo Alto Health Care System (VAPAHCS), Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT02687529"
33,"NCT01660646","Determining the Impact of Enhanced Case Finding on Tuberculosis Notification in The Gambia","ECF","Completed","No Results Available","Tuberculosis","Behavioral: Behavioral: community sensitization","The total number of successive TB cases notified in the intervention area compared to the total number of successive TB cases notified in the control areas|The total cost of making diagnosis and receiving treatment will be compared between ECF and passive case finding","London School of Hygiene and Tropical Medicine","All","Child, Adult, Older Adult","Not Applicable","650000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SCC 1205","June 2012","December 2014","October 2015","August 9, 2012",,"March 22, 2018","Medical Research Council Unit, The Gambia, Fajara,, Near Banjul, Gambia",,"https://ClinicalTrials.gov/show/NCT01660646"
34,"NCT05202431","The Effect of Telephone Follow-up and Training on Treatment Adherence in Tuberculosis Patients and Contacts","Tuberculosis","Completed","No Results Available","Tuberculosis","Behavioral: Treatment adherence","Change in treatment adherence during the Follow-up","Tuberculosis Network European Trialsgroup","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","TBNET","July 1, 2018","July 30, 2019","July 30, 2019","January 21, 2022",,"January 21, 2022","Gaziantep University, Gaziantep, Turkey",,"https://ClinicalTrials.gov/show/NCT05202431"
35,"NCT02512939","Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection","NextGen","Completed","No Results Available","Tuberculosis","Procedure: blood test, not yet marketed, no trade name","assess prognostic ability of blood test by assessing development of active TB disease compared to the current gold standard|assess the sensitivity of new blood tests for detecting TB infection in patients with active TB disease compared to teh current godl standard|estimate the risk of infection with M. tuberculosis and other respiratory pathogens amongst UK pilgrims undertaking the Hajj.","University College, London|Public Health England","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","675","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Next gen","July 2015","November 30, 2016","November 30, 2016","July 31, 2015",,"May 16, 2023","Barts NHS Trust, London, United Kingdom|Ealing Hospital, London, United Kingdom|North Middlesex Hospital, London, United Kingdom|Northwick Park Hospital, London, United Kingdom|West Middlesex Hospital NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02512939"
36,"NCT01601275","Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection",,"Completed","No Results Available","Tuberculosis",,"Final outcomes of patients who have been diagnosed with microbiologically proven mycobacteria tuberculosis infection at Singapore General Hospital","Singapore General Hospital","All","21 Years and older   (Adult, Older Adult)",,"4600","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2005/060/CTBdatabase","May 2012","May 2018","May 2018","May 17, 2012",,"May 15, 2019","Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01601275"
37,"NCT04002869","Innovation in Tuberculosis","INNOVA4TB","Unknown status","No Results Available","Tuberculosis","Diagnostic Test: Immunologic, molecular, metabolomic and radiolologic diagnostic","Diagnostic accuracy","Fundació Institut Germans Trias i Pujol|Consorcio Centro de Investigación Biomédica en Red (CIBER)|Umeå University|North-Western State Medical University named after I.I.Mechnikov|INSTITUTUL DE FTIZIOPNEUMOLOGIE CHIRIL DRAGANIUC|ODESA SIGNIFICANT DISEASES CENTER|Vinnitsa National Medical University|SERVICIOS CLINICOS SA|Genome Identification Diagnostics GmbH|EMPE DIAGNOSTICS AB|MAGRITEK GMBH|Universidad de La Frontera","All","1 Month to 99 Years   (Child, Adult, Older Adult)",,"550","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","823854","January 1, 2019","December 31, 2021","December 31, 2022","July 1, 2019",,"February 3, 2021","Institut D'Investigació Germans Trias I Pujol, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04002869"
38,"NCT03255278","Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine ""GamTBvac"" Against the Tuberculosis.","GamTBvac","Completed","No Results Available","Tuberculosis","Biological: Single GamTBvac vaccination (0.25 dose)|Biological: Placebo administration|Biological: Double GamTBvac vaccination (0.25 dose)|Biological: Double GamTBvac vaccination (0.5 dose)|Biological: Double GamTBvac vaccination (1.0 dose)","The number and severity of adverse effects|immunogenicity control","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","All","18 Years to 49 Years   (Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","GamTBvac Ph1","January 15, 2017","December 13, 2017","December 13, 2017","August 21, 2017",,"December 27, 2017","Sechenov First Moscow State Medical University, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03255278"
39,"NCT02680470","Virtual Observed Therapy for Patients With Tuberculosis",,"Completed","No Results Available","Tuberculosis","Device: Virtual observed therapy","Treatment completion rates using VOT compared with historical completion rates.|% Cure from TB treatment|number of VOT actually observed divided by the expected VOT observed|patient satisfaction questionnaire at end of treatment|Mortality","University of Edinburgh|NHS Lothian","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","15/WS/0004","August 2015","May 2017","May 2017","February 11, 2016",,"May 8, 2017","Royal Infirmary of Edinburgh, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02680470"
40,"NCT06110533","Epidemiological Study of Hospitalized Children for Pulmonary Tuberculosis at Strasbourg University Hospitals","TPE","Recruiting","No Results Available","Pulmonary Tuberculosis",,"Incidence and risk factors for pulmonary tuberculosis in children hospitalized at Strasbourg University Hospital between 2012 and 2022","University Hospital, Strasbourg, France","All","1 Year to 17 Years   (Child)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","8907","April 4, 2023","April 2024","April 14, 2024","October 31, 2023",,"October 31, 2023","Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) - CHU de Strasbourg - France, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT06110533"
41,"NCT05547464","Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers",,"Recruiting","No Results Available","Tuberculosis","Biological: BNT164a1|Biological: BNT164b1|Other: Placebo","Frequency of solicited local reactions (pain, erythema/redness, induration/swelling) at the injection site up to 7 days after each dose|Frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue, muscle pain & joint pain, chills, and fever) up to 7 days after each dose|Proportion of participants with at least one adverse event (AE) occurring from each dose to 28 days after each dose|Proportion of participants with at least one unsolicited AE occurring from Dose 1 to 28 days post-Dose 3|Proportion of participants with at least one serious AE or AE of special interest occurring from Dose 1 up to 168 days post-Dose 3|Number of unsolicited AEs from Dose 1 to 28 days post-Dose 3","BioNTech SE","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","732","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","BNT164-02|SANCTR","July 31, 2023","March 2026","February 2027","September 21, 2022",,"April 10, 2024","CAPRISA eThekweni Clinical Research Site, Berea, South Africa|South African Tuberculosis Vaccine Initiative SATVI, Cape Town, South Africa|Africa Health Research Institute (AHRI), Mtubatuba, South Africa|The Aurum Institute Tembisa CRC Clinic 4, Tembisa, South Africa",,"https://ClinicalTrials.gov/show/NCT05547464"
42,"NCT04916899","Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program",,"Completed","No Results Available","Tuberculosis","Drug: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol","To detect adverse events|Frequency of occurrence of adverse events|Severity of each of the adverse events|Causality of each of the adverse events|Apparatus and systems affected with adverse events|Factors associated with the presentation of adverse events","Laboratorios Silanes S.A. de C.V.","All","12 Years and older   (Child, Adult, Older Adult)",,"47","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","DoTBal_FVI_001","November 2014","September 2016","September 2016","June 8, 2021",,"June 8, 2021","Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04916899"
43,"NCT05048381","miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis (TB)",,"Withdrawn","No Results Available","Active Tuberculosis","Diagnostic Test: Next Generation Sequencing","Detection of miRNA (non-coding ribonucleic acid) in sweat|Detection of miRNA (non-coding ribonucleic acid) in blood","University Hospital, Basel, Switzerland|Fachhochschule Nordwestschweiz","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2021-01810; am21Eckstein2","September 6, 2021","October 31, 2022","October 31, 2022","September 17, 2021",,"November 1, 2023",,,"https://ClinicalTrials.gov/show/NCT05048381"
44,"NCT00170638","Tuberculosis Immunity in Children",,"Completed","No Results Available","Tuberculosis",,,"National Institute of Allergy and Infectious Diseases (NIAID)","All","1 Day and older   (Child, Adult, Older Adult)",,"260","NIH","Observational","Time Perspective: Prospective","03-202","April 2005",,"April 2010","September 15, 2005",,"April 25, 2008","Oregon Health Sciences University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00170638"
45,"NCT03767946","Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal","MTBVAC-EPI","Completed","No Results Available","Tuberculosis","Diagnostic Test: Quantiferon Gold Plus Test","Tuberculosis prevalence in children living in urban area in Senegal.|health survey of the cohort","Biomedical Research Center EPLS|Biofabri, S.L|TuBerculosis Vaccine Initiative|Universidad de Zaragoza|University of Cape Town|Institut Pasteur de Madagascar","All","11 Months to 12 Years   (Child)",,"500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIA2016V-1637","July 27, 2018","December 20, 2020","July 27, 2022","December 7, 2018",,"July 28, 2022","Biomedical Research Center EPLS, Saint Louis, France",,"https://ClinicalTrials.gov/show/NCT03767946"
46,"NCT03017378","Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine",,"Completed","No Results Available","Tuberculosis","Biological: TB/FLU-01L","Adverse Events (AE) - Immediate reactions|Solicited local and systemic reactions|Unsolicited AEs|Serious adverse events (SAEs), including abnormal laboratory findings","Research Institute for Biological Safety Problems|Ministry of Health, Kazakhstan|Research Institute of Influenza, Russia","All","18 Years to 50 Years   (Adult)","Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VIT-I-01/2013","October 2013","April 2014","February 2015","January 11, 2017",,"January 11, 2017","National Center for Tuberculosis Problems, Kazakhstan, Almaty Qalasy, Almaty, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT03017378"
47,"NCT04236349","Tuberculosis Cohort in the North of Paris",,"Unknown status","No Results Available","Pulmonary Tuberculosis|Extra Pulmonary Tuberculosis","Genetic: immunogenetics","Number of known treatment outcomes|number of inclusions by center|Number of opposition to study participation among eligible patients|Number of lost to follow-up|Number of variables filled in for each consultation or follow-up call|Genetics: identification of rare variants with strong effect for the earliest forms of pulmonary tuberculosis (before 25 y.o) and / or belonging to families with several patients and / or with recurrent forms of tuberculosis.|immunology: identification of pro or anti inflammatory markers","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2016FM961","May 1, 2018","January 31, 2020","January 31, 2021","January 22, 2020",,"January 22, 2020","Avicenne, Bobigny, Seine Saint Denis, France",,"https://ClinicalTrials.gov/show/NCT04236349"
48,"NCT05526885","Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa",,"Recruiting","No Results Available","Tuberculosis","Diagnostic Test: CAD4TB|Diagnostic Test: POC-CRP|Diagnostic Test: Xpert MTB/RIF Ultra","Yield of detected TB cases per study approach: number of positive Xpert MTB/RIF Ultra results per hypothetical study approach.|Cost-effectiveness of approach 2 using approach 1 as a comparator: the incremental (differential) costs per for each additional positive Xpert MTB/RIF Ultra case detected in approach 2 compared to approach 1.|Yield of detected TB cases per study approach in defined subgroups (HIV infected vs. uninfected participants, participants with and without TB history and with and without TB symptoms)|Economic costs of approach 1 versus approach 2 of the TB active-case finding campaign","Klaus Reither|SolidarMed Lesotho|Institute of Tropical Medicine, Belgium|Radboud University Medical Center|Charite University, Berlin, Germany|Human Sciences Research Council|Swiss Tropical & Public Health Institute","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","20000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P1685-22B","September 7, 2022","August 31, 2024","December 31, 2024","September 2, 2022",,"December 6, 2022","SolidarMed, Maseru, Lesotho|Human Sciences Research Council, Pietermaritzburg, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT05526885"
49,"NCT01098474","Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants",,"Completed","Has Results","Tuberculosis","Biological: GSK's investigational vaccine 692342|Biological: Tritanrix™ HB+Hib|Biological: Prevnar™|Biological: Polio Sabin™|Biological: Menjugate™","Number of Subjects With Grade 3 Solicited Local Symptoms After Dose 1, Dose 2 and Across Doses|Number of Subjects With Grade 3 Solicited Local Symptoms After Dose 2, Dose 3 and Across Doses.|Number of Subjects With Grade 3 Solicited General Symptoms After Dose 1, Dose 2 and Across Doses.|Number of Subjects With Grade 3 Solicited General Symptoms After Dose 2, Dose 3 and Across Doses.|Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Grade 3 Haematological and Biochemical Levels|Frequency of M. Tuberculosis Fusion Protein M72 (M72)-Specific Cluster of Differentiation (CD)4+ T Cells Per Million Cells Expressing at Least Two Different Immune Markers|Frequency of M. Tuberculosis Fusion Protein M72 (M72)-Specific Cluster of Differentiation (CD)8+ T Cells Per Million Cells Expressing at Least Two Different Immune Markers|Number of Seropositive Subjects Against M72 Antigen|Concentration of Antibodies Against M72 Antigen|Number of Seroprotected Subjects Against Diphtheria Toxoid (Anti-D) and Tetanus Toxoid (Anti-T)|Anti-D, Anti-T Antibody Concentrations|Number of Seroprotected Subjects Against Haemophilus Influenzae Type B (Anti-PRP)|Anti-PRP Antibody Concentrations|Number of Seropositive Subjects Against Bordetella Pertussis (Anti-BPT)|Anti-BPT Antibody Concentrations|Number of Seropositive Subjects Against Hepatitis B (Anti-HB)|Number of Seropositive Subjects Against Hepatitis B (Anti-HB) With Antibody Concentrations ≥100mIU/mL|Anti-HB Antibody Concentrations|Number of Seropositive Subjects Against Polio (Anti-Polio1, Anti-Polio2, Anti-Polio3)|Anti-Polio1, Anti-Polio2, Anti-Polio3 Antibody Titers|Number of Seropositive Subjects Against Streptococcus Pneumoniae (Anti-4, Anti-6B, Anti-9V, Anti-14, Anti-18C, Anti-19F, Anti-23F)|Number of Subjects With S. Pneumoniae Antibody Concentrations ≥ 0.2 Microgram/Milliliter|Anti-4, Anti-6B, Anti-9V, Anti-14, Anti-18C, Anti-19F, Anti-23F Antibody Concentrations|Number of Subjects With Normal, Grade 1 (G1), Grade 2 (G2) or Grade 4 (G4) Haematological and Biochemical Markers|Number of Subjects With Normal, G1, G2, or G4 Haematological and Biochemical Markers","GlaxoSmithKline|Aeras","All","2 Months to 7 Months   (Child)","Phase 2","301","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","112899|2012-004380-44","July 7, 2010","April 30, 2011","March 16, 2012","April 2, 2010","November 27, 2018","June 27, 2019","GSK Investigational Site, Banjul, Gambia",,"https://ClinicalTrials.gov/show/NCT01098474"
50,"NCT01262976","Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults",,"Completed","Has Results","Tuberculosis","Biological: GSK's investigational vaccine 692342|Biological: Physiological saline","Number of Subjects With Grade 3 Solicited Local Symptoms|Number of Subjects With Grade 3 Solicited General Symptoms|Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels|Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels|Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels|Number of Subjects With Grade 3-4 Haematological and Biochemical Levels|Number of Subjects With Grade 3-4 Haematological/Biochemical Levels|Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations|Number of Seroconverted Subjects for M72-specific Antibodies|Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers|Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines|M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines|M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines|Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers|Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines|M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines|M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines|Number of Subjects With Any Solicited Local Symptoms|Number of Subjects With Any Solicited General Symptoms|Number of Subjects With Any Unsolicited AEs|Number of Subjects With SAEs|Number of Subjects Presenting Different Grades of Haematological and Biochemical Values","GlaxoSmithKline","All","18 Years to 59 Years   (Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","113935","January 17, 2011","July 17, 2012","June 4, 2015","December 20, 2010","September 17, 2018","September 17, 2018","GSK Investigational Site, Tharamani Chennai, India",,"https://ClinicalTrials.gov/show/NCT01262976"
51,"NCT01167647","The Role of Routine Bacterial Culture Including Tuberculosis During Bronchoscopy: A Prospective Study",,"Completed","No Results Available","Tuberculosis",,"number of positive tuberculosis culture","Meir Medical Center","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MMC10-087-10.CTIL","July 2010","October 2012","October 2012","July 22, 2010",,"March 6, 2013","Pulmonary department, Meir Medical Center, Kfar Saba, Israel",,"https://ClinicalTrials.gov/show/NCT01167647"
52,"NCT02778828","Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis","LINEZOLIDE","Completed","No Results Available","Tuberculosis","Drug: Linezolid","Air Under the Curve (AUC) of Linezolid concentration|Minimum Inhibitory Concentration (MIC) of Linezolid","Fondation Hôpital Saint-Joseph","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","LINEZOLIDE","November 4, 2015","December 31, 2017","December 31, 2018","May 20, 2016",,"February 4, 2019","Sanatorium du Petit Fontainebleau Centre Médical de Bligny, Briis-sous-Forges, Essonne, France",,"https://ClinicalTrials.gov/show/NCT02778828"
53,"NCT04985994","Potential Role of Microbiome in Tuberculosis","Micro-STOP","Recruiting","No Results Available","Tuberculosis",,"Gut microbiome diversity and functional potential|Baseline Gut microbiome|Baseline Oral microbiome|Gut microbiome and associated factors|Microbial dysbiosis|Microbial signatures","Khyber Medical University Peshawar|University of Reading|TB Control Program Khyber Pakhtunkhwa","All","18 Years to 65 Years   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Microbiome & Tuberculosis|10289/KPK/NRPU/R&D/HEC/2019","August 22, 2021","March 31, 2024","August 31, 2024","August 2, 2021",,"October 5, 2023","DTO Peshawar, Peshawar, KP, Pakistan|Khyber Medical University, Peshawar, KP, Pakistan",,"https://ClinicalTrials.gov/show/NCT04985994"
54,"NCT04176250","Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis",,"Completed","Has Results","Pulmonary Tuberculosis","Drug: TBA-7371|Drug: HRZE","Average Change Per Day (Slope) of Log Colony Forming Units (CFU) Counts From Day 0 to Day 14 (BACFU [0-14]) to Assess Bactericidal Activity|Number of Participants Reporting ≥Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs)|Average Change Per Day (Slope) of Log CFU Counts From Day 0 to Day 2 (BACFU [0-2]) and From Day 2 to Day 14 (BACFU [2-14]) to Assess Bactericidal Activity|Average Change Per Day(Slope)of Time to Sputum Culture Positivity(TTP) in Mycobacteria Growth Indicator Tube (MGIT) System From Day0 to Day14 (BATTP[0-14]),From Day0 to Day2(BATTP[0-2]), and From Day2 to Day14(BATTP [2-14]) to Assess Bactericidal Activity|Average Change Per Day (Slope) of the log10 Sputum Lipoarabinomannan (LAM) Measurements From Day 0 to Day 14 (BALAM [0-14]), From Day 0 to Day 2 (BALAM [0-2]) and From Day 2 to Day 14 (BALAM [2-14]) to Assess Bactericidal Activity|Number of Participants Reporting Any Adverse Events (AEs)|Number of Participants Reporting Grade >=3 AEs by Preferred Term|Number of Participants Reporting AEs (Presented by Severity)|Number of Participants Experiencing AEs Related to Study Intervention|Number of Participants With Any New Eye Symptom in One or Both Eyes|Average Duration of New Eye Symptom in One or Both Eyes|Total Number of Days With New Eye Symptoms in One or Both Eyes|Change From Baseline in Visual Acuity Score|Number of Participants With Color Vision Abnormality in One or Both Eyes|Change From Baseline in Heart Rate (HR)|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in HR as Measured by Electrocardiogram (ECG)|Number of Participants With ≥25% Intraday Increase in HR, ≥25% Intraday Decrease in SBP, ≥25% Intraday Decrease in DBP at Any Intraday Time|Mean Number of Days With ≥25% Increase in HR From Baseline|Mean Number of Days With ≥25% Decrease in SBP and Decrease in DBP From Baseline|Change From Baseline in Electrocardiogram (ECG) Parameters|Change From Baseline in HR|Change From Baseline in SBP and DBP|Number of Participants With New Eye Symptoms in Any Eye|Number of Participants With Shift From Baseline in Hematology Parameters|Number of Participants With Shift From Baseline in Clinical Chemistry Parameters|Number of Participants With Shift From Baseline in Serum Coagulation Parameters|Change From Baseline in Urinalysis Parameter: Urine Specific Gravity|Change From Baseline in Urinalysis Parameter: Urine Potential of Hydrogen (pH)|Maximum Observed Serum Concentration (Cmax) After Administration of TBA7371|Time at Maximum Plasma Concentration (Tmax) After Administration of TBA7371|Last Quantifiable Concentration (Clast) After Administration of TBA7371|Time at Last Quantifiable Concentration (Tlast) After Administration of TBA7371|Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 Extrapolated to Infinity (AUCinf) After Administration of TBA7371|Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) After Administration of TBA7371|Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Tau (AUCtau) After Administration of TBA7371|Minimum Observed Plasma Concentration (Cmin) After Administration of TBA7371|Half-life (T1/2) After Administration of TBA7371|Accumulation Ratio After Administration of TBA7371","Bill & Melinda Gates Medical Research Institute","All","18 Years to 60 Years   (Adult)","Phase 2","93","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Gates MRI-TBD03-201","January 16, 2020","October 5, 2022","October 5, 2022","November 25, 2019","April 11, 2024","April 11, 2024","TASK, Bellville, Cape Town, South Africa|University of Cape Town (UCT) Lung Institute, Mowbray, Cape Town, South Africa|The Aurum Institute, Pretoria, Gauteng, South Africa|Perinatal HIV Research Unit (PHRU), Jouberton, North West Province, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/50/NCT04176250/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/50/NCT04176250/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04176250"
55,"NCT05555303","Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis","Stake","Recruiting","No Results Available","Tuberculosis, Multidrug-Resistant","Drug: Amikacin","grade 3-4 AE likely or definitively related to amikacin|turnaround times|testing coverage|AE likely or definitely related to amikacin|amikacin concentration|post-injection pain|all AE, relationship with TB drugs|treatment outcomes|post-treatment outcomes","Rwanda Biomedical Centre|Institute of Tropical Medicine|World Health Organization","All","19 Years to 64 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RBC/RIDS012022","March 1, 2023","March 2024","February 2026","September 26, 2022",,"March 29, 2023","Kabutare hospital, Kabutare, Rwanda",,"https://ClinicalTrials.gov/show/NCT05555303"
56,"NCT06113861","Diagnostic Innovations for Pediatric Tuberculosis in Bolivia",,"Not yet recruiting","No Results Available","Tuberculosis","Diagnostic Test: Quantiferon Gold|Diagnostic Test: HIV serology|Diagnostic Test: Respiratory secretion culture (sputum or gastric aspirate_|Diagnostic Test: Chest radiograph|Diagnostic Test: Lung ultrasound|Diagnostic Test: cell free DNA test","Cell free DNA level|CAD4TB score","Tulane University|Asociacion Benefica Prisma|Universidad Peruana Cayetano Heredia|Johns Hopkins Bloomberg School of Public Health","All","2 Months to 14 Years   (Child)",,"1220","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","R01AI173021","May 2024","October 2027","October 2028","November 2, 2023",,"February 28, 2024",,,"https://ClinicalTrials.gov/show/NCT06113861"
57,"NCT04331262","Implementation of an Integrated Care Strategy for Children Contacts of Patients With Tuberculosis",,"Completed","No Results Available","Latent Tuberculosis",,"Treatment Compliance","Corporacion para Investigaciones Biologicas|Universidad Pontificia Bolivariana|Universidad de Antioquia|Secretaría de Salud de Medellín|Secretaría Seccional de Salud y Protección Social de Antioquia|Hospital Pablo Tobón Uribe","All","up to 5 Years   (Child)",,"163","Other","Observational","Observational Model: Other|Time Perspective: Prospective","68722","July 26, 2021","December 30, 2022","July 31, 2023","April 2, 2020",,"August 30, 2023","Corporación para Investigaciones Biológicas, Medellín, Colombia",,"https://ClinicalTrials.gov/show/NCT04331262"
58,"NCT00950612","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents",,"Completed","Has Results","Tuberculosis","Biological: GSK's investigational vaccine 692342|Biological: Placebo","Number of Subjects With Solicited Local Symptoms|Number of Subjects With Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Normal Biochemical and Haematological Levels|Number of Subjects With Normal Haematological Levels|Number of Subjects With Biochemical and Haematological Above Normal Levels|Number of Subjects With Haematological Levels Above Normal|Number of Subjects With Biochemical and Haematological Below Normal Levels|Number of Subjects With Haematological Levels Below Normal|Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines|Frequency of M72 Specific CD4+ T Cells Expressing Any Combination of Cytokines|Frequency of M72 Specific CD8+ T Cells Expressing Any Combination of Cytokines|Anti-M72 Specific Antibody Concentrations","GlaxoSmithKline|Aeras","All","13 Years to 17 Years   (Child)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","112898","December 8, 2009","September 30, 2010","September 30, 2010","August 3, 2009","January 9, 2017","August 17, 2018","GSK Investigational Site, Worcester, Western Province, South Africa",,"https://ClinicalTrials.gov/show/NCT00950612"
59,"NCT05805878","KAP Regarding Tuberculosis Among Physicians in Assiut City",,"Not yet recruiting","No Results Available","Tuberculosis",,"To assess knowledge, attitudes and practices (KAP) on tuberculosis among physicians working in Assiut city.|To explore the factors associated with the physicians' knowledge, attitudes and practices regarding tuberculosis.","Assiut University","All","26 Years to 40 Years   (Adult)",,"280","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","KAP regarding Tuberculosis","October 2023","October 2025","October 2026","April 10, 2023",,"April 10, 2023",,,"https://ClinicalTrials.gov/show/NCT05805878"
60,"NCT00707967","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.",,"Completed","Has Results","Tuberculosis","Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342|Biological: Control vaccine with the adjuvant system.|Biological: Control vaccine with physiological saline","Number of Subjects With Solicited Local Symptoms|Number of Subjects With Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Normal Biochemical and Haematological Levels|Number of Subjects With Normal Haematological Levels|Number of Subjects With Biochemical and Haematological Levels Below Normal|Number of Subjects With Haematological Levels Below Normal|Number of Subjects With Biochemical and Haematological Levels Above Normal|Number of Subjects With Haematological Levels Above Normal|Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines|Frequency of M72 Specific CD4/8+ T Cells Expressing at Least One Cytokine and Another Signal Molecule|Cell Count of CD4+ T Cells|Anti-M72 Specific Antibody Concentrations|Number of Subjects With Significant Highly Active Anti-Retroviral Therapy (HAART) Changes","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","111517","June 30, 2008","May 27, 2009","May 27, 2009","July 1, 2008","January 6, 2017","August 24, 2018","GSK Investigational Site, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT00707967"
61,"NCT05401071","Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)","ORIENT","Recruiting","No Results Available","Tuberculosis, Pulmonary","Other: Short Regimen with Rifapentine 10mg/kg|Combination Product: Standardized Regimen|Other: Short Regimen with Rifapentine 15mg/kg|Other: Short Regimen with Rifapentine 20mg/kg","Treatment success rate of the short regimen during drug treatment and follow-up.|The frequency of grade 3 or greater adverse events among patients Over the 108 Week Treatment and Follow-up Period.|Relapse rate during follow-up.|the percentage of participants found to be culture-negative at the end of intensive phase and the end of treatment phase","Huashan Hospital","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","2442","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ORIENT","January 13, 2023","October 1, 2024","November 1, 2027","June 2, 2022",,"December 11, 2023","Guiyang Public Health Clinical Center, Guiyang, Guizhou, China|People's Hospital of Qiandongnan, Kaili, Guizhou, China|The Third People's Hospital of Liupanshui, Liupanshui, Guizhou, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China|Department of Infectious Disease, Huashan Hospital, Shanghai, Shanghai, China|People's Hospital of Zhuji, Zhejiang Province, Zhuji, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05401071"
62,"NCT05541952","BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison Population","PPT-BCG","Withdrawn","No Results Available","Latent Tuberculosis","Biological: BCG","Incidence of Latent Tuberculosis Infection (LTBI)|Percentage of sustained IGRA conversion|Incidence of active tuberculosis","Federal University of Mato Grosso|Stanford University|Oswaldo Cruz Foundation","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","U1111-1236-5940|07657119.8.0000.0021","August 17, 2020","August 17, 2020","August 17, 2020","September 15, 2022",,"October 19, 2023","Roberto Oliveira, Dourados, Mato Grosso Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT05541952"
63,"NCT01119521","Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination",,"Completed","No Results Available","Tuberculosis","Biological: BCG strain Danish|Drug: Isoniazid","Adverse reactions/events [and whether they meet the definition of a serious adverse event (SAE)], the severity of these reactions, and related measurements, and assessed relationship to vaccine administration.|Direct Ex-vivo gene expression signature (RNA)|Effector T cell function by whole blood cytokine production (WBA),flow cytometric measures of intra-cellular cytokine production (ICS) or ELISA assays to measure immune function|Memory T cell function by whole blood cytokine production (WBA),flow cytometric measures of intra-cellular cytokine production (ICS) or ELISA assays to measure immune function.|Precursor frequencies of mycobacterial antigen-specific T cells will be measured by ELISPOT using standard methods and SOPs","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 40 Years   (Adult)","Phase 1","82","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-0083","October 2010","July 2013","July 2013","May 7, 2010",,"January 9, 2017","University of Cape Town - Institute of Infectious Disease and Molecular Medicine, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT01119521"
64,"NCT03010111","Latent Tuberculosis Infection in Korean Health Care Workers",,"Unknown status","No Results Available","Latent Tuberculosis","Other: QFT-IT Test and other blood sampling","Percentage of latent tuberculosis infection developed in Korean health care workers|Annual incidence of latent tuberculosis infection in Korean health care workers","Hanyang University","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","HYUMC_CM_001","December 2016","December 2017","December 2017","January 4, 2017",,"January 4, 2017","Hanyang University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03010111"
65,"NCT05359315","Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis",,"Unknown status","No Results Available","Pulmonary Tuberculosis","Drug: Interferon-Gamma","Sputum smear conversion according to microscopy.|Sputum smear conversion by culture.|The effectiveness of therapy according to X-ray examination of the chest.|The effectiveness of therapy according to computed tomography of the chest.|The effectiveness of therapy according to clinical examination.|Change in immunological status (CD4 and CD8 lymphocyte populations) compared with baseline values (before therapy).|Mortality rate.","SPP Pharmaclon Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)",,"84","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","STING-2021","April 15, 2022","August 1, 2022","May 1, 2023","May 3, 2022",,"June 1, 2022","FSBI ""NMIC FPI"" of the Ministry of Health of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05359315"
66,"NCT03042754","Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals",,"Active, not recruiting","No Results Available","Tuberculosis","Diagnostic Test: XpertMTB/RIF","Sensitivity of sputum from patients suspected with TB|Sensitivity of urine LAM from patients suspected with TB","The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University|Bamrasnaradura Infectious Diseases Institute|Rajavithi Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TB NRU","June 6, 2011","December 1, 2030","December 1, 2030","February 3, 2017",,"February 28, 2024","Chulalongkorn University, Bangkok, Thailand|HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand|Rajavithi Hospital, Bangkok, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand",,"https://ClinicalTrials.gov/show/NCT03042754"
67,"NCT04825327","Predicting the Future: Incipient Tuberculosis","PreFIT","Active, not recruiting","No Results Available","Tuberculosis",,"Predictive accuracy of each assay for incident TB occurring over a 12-month period from enrolment.|Assay turnaround time and error rates|Accuracy of predictive algorithms|Diagnostic cost","Amsterdam Institute for Global Health and Development|University of Stellenbosch|Makerere University|Centro de Investigacao em Saude de Manhica|Barcelona Institute for Global Health|Foundation for Innovative New Diagnostics, Switzerland","All","12 Years to 60 Years   (Child, Adult)",,"3016","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIA2018D-2509","April 21, 2021","July 31, 2025","September 30, 2025","April 1, 2021",,"March 8, 2024","Centro de Invesigação em Saúde de Manhiça, Manhiça, Mozambique|University of Stellenbosch, Cape Town, South Africa|Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04825327"
68,"NCT04766307","A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Drug: Interleukin-2","The primary study endpoint was the proportion of subjects who had converted their sputum cultures to negative at the end of treatment.","Beijing Chest Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","1100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015ZX10003001-002","July 20, 2016","December 31, 2021","December 31, 2021","February 23, 2021",,"February 23, 2021","the Second hospital of Fuyang, Fuyang, Anhui, China|Fuzhou Chest Hospital, Fuzhou, Fujian, China|Shenzhen third people's Hospital, Shenzhen, Guangzhou, China|Guiyang Public Health Treatment Center, Guiyang, Guizhou, China|The Infectious Hospital of Handan, Handan, Hebei, China|Hebei Chest Hospital, Shijiazhuang, Hebei, China|Jiamusi Insititute For Tuberculosis Control, Jiamusi, Heilongjiang, China|The Infectious Hospital of mudanjiang, Mudanjiang, Heilongjiang, China|Zhengzhou Sixth People's Hospital, Zhengzhou, Henan, China|the central hospital of Changsha, Changsha, Hunan, China|the people's hospital of Jiangsu province, Nanjing, Jiangsu, China|Jiangxi Chest Hospital, Nanchang, Jiangxi, China|Dalian Tuberculosis Hospital, Dalian, Liaoning, China|Qingdao Chest Hospital, Qingdao, Shandong, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|Xian Chest Hospital, Xi'an, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT04766307"
69,"NCT00621322","Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults",,"Completed","Has Results","Tuberculosis","Biological: GSK Biologicals' AS01B adjuvant|Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Biological: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2","Number of Subjects With Solicited Local Symptoms|Number of Subjects With Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Different Biochemical and Haematological Levels|Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines|Frequency of M72 Specific CD4/8+ T Cells Expressing at Least One Cytokine and Another Signal Molecule|Anti-M72 Specific Antibody Concentrations","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","110345","April 3, 2008","April 3, 2009","April 3, 2009","February 22, 2008","February 3, 2017","August 24, 2018","GSK Investigational Site, Manila, Philippines",,"https://ClinicalTrials.gov/show/NCT00621322"
70,"NCT00608790","Rapid Diagnosis of Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis","Drug: Salbutamol|Drug: Sodium chloride 5%","Sputum direct smear positive for acid-fast bacilli.|Sputum culture positive for Mycobacterium tuberculosis.","University of Cape Town|National Institute of Allergy and Infectious Diseases (NIAID)","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","600","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","07-0058|5R01AI075603-04","February 2008","December 2012","April 2013","February 6, 2008",,"July 24, 2012","University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT00608790"
71,"NCT02623556","Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen",,"Completed","No Results Available","Tuberculosis","Biological: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|Biological: ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm","Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patients|Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patients|Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung disease|Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung disease|Number of participants with Adverse Events","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shanghai Public Health Clinical Center|Tianjin Haihe Hospital|Air Force Military Medical University, China|Proswell Medical Corporation|Wuhan Institute for Tuberculosis Control|Beijing Chest Hospital|Wuxi Hospital for Infectious Diseases|First Affiliated Hospital of Chongqing Medical University|Fuzhou Pulmonary Hospital of Fujian|Zhenjiang Third People's Hospital|Anhui Provincial Hospital|Shenzhen Third People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1090","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","LTao-EC III-patient","December 2015","March 2018","March 2018","December 7, 2015",,"April 12, 2018","Wuxi NO.5 People's Hospital, Wuxi, Jiangsu, China|Shanghai Public Health clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02623556"
72,"NCT01424501","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease",,"Terminated","Has Results","Tuberculosis","Biological: GSK Biologicals' investigational TB vaccine GSK 692342|Biological: Placebo","Number of Subjects With Any and Grade 3 Solicited Local Symptoms|Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of Subjects With Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Anti-Mycobacterium Tuberculosis Fusion Protein M72 Antibodies|Concentrations of Anti-M72 Antibodies|Frequency of M72-specific Cluster of Differentiation 4 (CD4+) T-cells Expressing Any Combination of the Different Immune Markers|Frequency of M72-specific CD4+ T-cells Expressing at Least 2 Immune Markers Among 6|Frequency of M72-specific CD4+ T-cells Expressing Any Combination of Cytokines|Frequency of M72-specific CD4+ T-cells Expressing Any Combination of Immune Markers|Frequency of CD4+ T-cells M72-specific Expressing Any Combination of Cytokines|Frequency of CD4+ T-cells M72-specific Expressing Any Combination of Immune Markers|Frequency of M72-specific CD4+ T-cells Expressing Cytokines in Any Combination|Frequency of M72-specific CD4+ T-cells Expressing Immune Markers in Any Combination|Frequency of CD4+ T-cells M72-specific Expressing Cytokines in Any Combination|Frequency of CD4+ T-cells M72-specific Expressing Immune Markers in Any Combination|Frequency of M72-specific Cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers|Frequency of M72-specific CD8+ T-cells Expressing at Least 2 Immune Markers Among 6|Frequency of M72-specific CD8+ T-cells Expressing Any Combination of Immune Markers|Frequency of M72-specific CD8+ T-cells Expressing Any Combination of Cytokines|Frequency of CD8+ T-cells M72-specific Expressing Any Combination of Immune Markers|Frequency of CD8+ T-cells M72-specific Expressing Any Combination of Cytokines|Frequency of M72-specific CD8+ T-cells Expressing Cytokines in Any Combination|Frequency of M72-specific CD8+ T-cells Expressing Immune Markers in Any Combination|Frequency of CD8+ T-cells M72-specific Expressing Cytokines in Any Combination|Frequency of CD8+ T-cells M72-specific Expressing Immune Markers in Any Combination","GlaxoSmithKline","All","18 Years to 59 Years   (Adult)","Phase 2","142","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","114886","November 14, 2011","April 1, 2014","April 10, 2014","August 29, 2011","January 24, 2017","August 20, 2018","GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taoyuan Hsien, Taiwan",,"https://ClinicalTrials.gov/show/NCT01424501"
73,"NCT01124929","Treatment Duration for Abdominal Tuberculosis","RNTCP-DOTS","Completed","No Results Available","Tuberculosis","Drug: RNTCP Category I treatment for 6 months|Drug: RNTCP Category I treatment for 9months","Response to treatment (after 6 months and nine months of RNTCP Category I treatment)|Recurrence of symptoms of abdominal tuberculosis (intestinal and peritoneal) after 1 year of follow up in those who receive 6 months or 9 months of Cat I treatment","All India Institute of Medical Sciences, New Delhi|Sanjay Gandhi Postgraduate Institute of Medical Sciences|Christian Medical College, Vellore, India","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","197","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Abdominal TB_RCT (RNTCP-DOTS)","July 2008","July 2012","April 2014","May 18, 2010",,"July 3, 2015","Dr Govind K Makharia, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01124929"
74,"NCT05865626","Evaluation of the VOT Among Tuberculosis Patients From Lambaréné","dotsapp","Completed","No Results Available","Tuberculosis","Other: VOT with and without cash incentive","feasibility assessment|adherence to the VOT|effect of cash incentives on adherence to the VOT","Centre de Recherche Médicale de Lambaréné","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","dotsapp1","October 10, 2018","June 30, 2020","June 30, 2022","May 19, 2023",,"May 19, 2023","Centre de recherches médicales de Lambaréné, Lambaréné, Gabon",,"https://ClinicalTrials.gov/show/NCT05865626"
75,"NCT03967353","Study on the Management Model of ""Home Treatment"" for Tuberculosis Patients",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Behavioral: New management mode intervention","treatment adherence|treatment success rate","Beijing Chest Hospital","All","Child, Adult, Older Adult","Not Applicable","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D 181100000418002","March 22, 2018","March 2022","December 2022","May 30, 2019",,"May 30, 2019","Beijing Chest Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03967353"
76,"NCT05283967","Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults","PEE-TB","Unknown status","No Results Available","Tuberculosis","Diagnostic Test: urine colorimetric assay","Urine Cmax|Urine rifampin AUC|Urine isoniazid Cmax|Urine isoniazid AUC|Urine pyrazinamide Cmax|Urine pyrazinamide AUC","University of Virginia|Rutgers, The State University of New Jersey|University of Florida","All","4 Years and older   (Child, Adult, Older Adult)",,"190","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20944","January 1, 2019","December 30, 2022","December 30, 2023","March 17, 2022",,"March 17, 2022","Rutgers, The State University of New Jersey, Newark, New Jersey, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05283967"
77,"NCT06021041","A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients",,"Active, not recruiting","No Results Available","Tuberculosis",,"2-year survival rate|2-year disability rate|The number of participants with the presence of clinical symptoms|Incidence of complications in patients with different treatment regimens|Length of hospital stay for patients|Proportion of patients admitted to the ICU","Tongji Hospital","All","Child, Adult, Older Adult",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RETUBO-S","January 13, 2018","February 1, 2024","February 1, 2024","September 1, 2023",,"September 1, 2023","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital(Wuhan Institute for Tuberculosis Control), Hubei, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT06021041"
78,"NCT02234908","Rewards for Tuberculosis Contact Screening","RECON","Completed","No Results Available","Tuberculosis|Drug-resistant Tuberculosis","Behavioral: Contacts|Behavioral: Index","Proportion of household contacts volunteering for TB symptom screening","Boston University|University of Witwatersrand, South Africa|City of Johannesburg|Helen Joseph Hospital|National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult","Not Applicable","301","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H-33047|M140529|1U01AI100015-01","October 2014","January 2016","December 2016","September 9, 2014",,"January 8, 2021","Helen Joseph Hospital, Johannesburg, South Africa|OR Tambo Clinic, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT02234908"
79,"NCT02313610","Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Qinbudan|Drug: Qinbudan Placebo","The time of sputum conversion between the 2 groups will be evaluated|Time to resolution of all pulmonary tuberculosis symptoms|Resolution of chest X-ray changes of patients|T cell classification in peripheral blood|Erythrocyte Sedimentation Rata|The cure rate will be evaluated as the primary parameter of efficacy|The relapse in patients of both groups will be compared","Shanghai University of Traditional Chinese Medicine|Ministry of Science and Technology of the People´s Republic of China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","253","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DS11036","April 2011","March 2013","March 2013","December 10, 2014",,"October 17, 2016","Hebei provincial chest hospital, Shijiazhuang, Hebei, China|The first affiliated hospital of Xinxiang Medical University, Xinxiang, Henan, China|Wuhan tuberculosis dispensary, Wuhan, Hubei, China|Jiangxi provincial chest hospital, Nanchang, Jiangxi, China|Shenyang chest hospital, Shenyang, Liaoning, China|Uygur Autonomous Region of Xinjiang Chest Hospital, Urumqi, Xinjiang, China|Beijing chest hospital,Capital medical university, Beijing, China|The first affiliated hospital of chongqing medical university, Chongqing, China|The 85th hospital of chinese people's liberation army, Shanghai, China|Shanghai pulmonary hospital affiliated Tongji University, Shanghai, China|Shenzhen Donghu hospital, Shenzhen, China|Tianjin Haihe hospital, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02313610"
80,"NCT05539014","Tuberculosis Cohort Avicenne Hospital","COTB-AVC","Recruiting","No Results Available","Tuberculosis, Pulmonary","Other: Data collection","Proportion of patients followed for tuberculosis with unfavourable treatment outcome at month12.|1) Proportion for each unfavourable treatment outcome at M12 (death, treatment not completed at 12 months, treatment stopped and not resumed, lost to follow-up, transferred to another establishment and lack of information concerning the patient).|Risk factors (patient characteristics and other determinants) for unfavourable tuberculosis treatment outcomes at 12 months.|Socio-economic, clinical, bacteriological","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP220889","January 18, 2023","October 15, 2027","December 15, 2027","September 14, 2022",,"November 18, 2023","Hopital Avicenne, Bobigny, France|Hôpital Avicenne, Bobigny, France",,"https://ClinicalTrials.gov/show/NCT05539014"
81,"NCT00306319","Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia",,"Completed","No Results Available","Tuberculosis","Drug: moxifloxacin","Pharmacokinetic (24 hrs) curves will be drawn|at day 5 in period I and period II.","Radboud University Medical Center","All","18 Years to 55 Years   (Adult)","Phase 2","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCN-AKF 05.02|Primo study","January 2006","May 2006","May 2006","March 23, 2006",,"November 12, 2020","Rumah Sakit Hasan Sadikin (RSHS), Bandung, Indonesia",,"https://ClinicalTrials.gov/show/NCT00306319"
82,"NCT00889759","The Role of High Resolution-Computed Tomography (CT) in Tuberculosis (TB) Outbreak Investigation",,"Completed","No Results Available","Tuberculosis",,,"Armed Forces Capital Hospital, Republic of Korea","Male","Child, Adult, Older Adult",,"92","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TBoutbreak","December 2007","January 2009","April 2009","April 29, 2009",,"September 23, 2009",,,"https://ClinicalTrials.gov/show/NCT00889759"
83,"NCT05724212","Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for Monitoring Anti-Tuberculosis Treatment","IGRA/MAT-1","Active, not recruiting","No Results Available","Tuberculosis","Diagnostic Test: Interferon gamma release assay (IGRA)","Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for monitoring anti-Tuberculosis treatment","Paola Mantegani|Ospedale San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"220","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IGRA/MAT-1","January 27, 2017","May 13, 2021","February 1, 2024","February 13, 2023",,"February 15, 2023","IRCCS San Raffaele Scientific Institute, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT05724212"
84,"NCT05655702","DRug Use & Infections in ViEtnam: TuBerculosis Control","DRIVE-TB","Recruiting","No Results Available","Tuberculosis","Other: Community based TB intervention","Prevalence of confirmed TB cases at RDSS 1 and RDSS 4|Assess TB awareness|The feasibility and efficacy of the TB mass screening|Proportion of confirmed TB cases who have initiated TB treatment among those who have attended the referral TB center for confirmation in RDSS 1, 2, 3.|Prevalence of active TB and LTBI among PWID contacts|The incidence of active TB and LTBI among PWID contacts at 6 and 12 months.|The proportion of PWID contacts actually screened for TB at the community study site.|The incidence of TB infection (LTBI and active TB) among PWID in Hai Phong|HIV viremia prevalence at RDSS1|Incremental cost-effectiveness ratio (ICER) and cost per DALY averted.|Acceptability of the 3HP regimen,|Safety of the 3HP regimen,|Proportion of participants who have completed a 12-dose once-weekly regimen of isoniazid/rifapentine (3HP) among those who have initiated 3HP.","ANRS, Emerging Infectious Diseases|Haiphong University of Medicine and Pharmacy|Expertise France|Université Montpellier|New York University|CENTER FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","ANRS 0092s DRIVE-TB","October 2, 2023","June 2025","June 2025","December 19, 2022",,"November 30, 2023","Hai Phong University of Medecine and Pharmacy, Hải Phòng, Vietnam|Viettiep 2 Hospital, Hải Phòng, Vietnam",,"https://ClinicalTrials.gov/show/NCT05655702"
85,"NCT03557281","An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis",,"Completed","Has Results","Tuberculosis","Drug: GSK3036656|Drug: Rifafour e-275","Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14|Change in log10 CFU/mL of Direct Respiratory Sputum Samples From Baseline to Day 2|Change in log10 CFU Per mL of Direct Respiratory Sputum Samples From Day 2 to Day 14|Change in log10 Time to Sputum Culture Positivity (TTP) From Baseline to Day 14|Change in log10 TTP From Baseline to Day 2|Change in log10 TTP From Day 2 to Day 14|Area Under the Plasma Drug Concentration Versus Time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) Following Once Daily Dosing of GSK3036656|Area Under the Plasma Concentration Time Curve From Zero to 24 Hours (AUC[0-24]) Following Once Daily Dosing of GSK3036656|Maximum Observed Plasma Drug Concentration (Cmax) Following Once Daily Dosing of GSK3036656|Time to Reach Cmax (Tmax) Following Once Daily Dosing of GSK3036656|Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)|Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count|Change From Baseline in Hematology Parameter: Hemoglobin|Change From Baseline in Hematology Parameter: Hematocrit|Change From Baseline in Hematology Parameter: Red Blood Cells Count|Change From Baseline in Hematology Parameter: Mean Corpuscular Volume|Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin|Change From Baseline in Hematology Parameter: Reticulocytes|Change From Baseline in Chemistry Parameters: Glucose, Calcium, Chloride, Potassium, Sodium, Blood Urea Nitrogen|Change From Baseline in Chemistry Parameters: Lactate Dehydrogenase (LDH), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT)|Change From Baseline in Chemistry Parameters: Creatinine, Indirect Bilirubin, Direct Bilirubin and Total Bilirubin|Change From Baseline in Chemistry Parameter: Total Protein|Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method|Number of Participants With Worst Case Vital Sign Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline|Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings|Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201214","March 22, 2019","December 3, 2021","December 14, 2021","June 15, 2018","October 26, 2023","October 26, 2023","GSK Investigational Site, Cape Town, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT03557281/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT03557281/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03557281"
86,"NCT04134689","DOT Selfie: A Mobile Technology Intervention to Evaluate Treatment Adherence Among Tuberculosis Patients",,"Completed","No Results Available","Tuberculosis","Device: DOT Selfie Intervention|Other: In-person DOT","Adherence level|Sputum conversion|Treatment completion|Clinical response","University of Georgia|Makerere University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PROJECT00000571","July 13, 2020","March 31, 2022","April 30, 2023","October 22, 2019",,"July 25, 2023","University of Makerere School of Public Health, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04134689"
87,"NCT03639038","Tuberculosis Diagnosis by Flow Cytometry",,"Withdrawn","No Results Available","Tuberculosis",,"ATB assay for differentiation of latent and active TB infection using Blood samples|DTB assay for rapid detection and drug sensitivity testing of Mtb using sputum specimens","University of Alabama at Birmingham","All","5 Years to 100 Years   (Child, Adult, Older Adult)",,"0","Other","Observational","Observational Model: Other|Time Perspective: Prospective","IRB-300001699","September 30, 2018","April 1, 2019","July 1, 2019","August 20, 2018",,"November 20, 2018","Center for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT03639038"
88,"NCT05609552","Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET",,"Recruiting","No Results Available","Tuberculosis","Combination Product: 18F-Pretomanid PET/CT","Biodistribution of 18F-pretomanid","Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)",,"20","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","IRB00303845|R01HL131829","May 22, 2023","February 1, 2025","February 1, 2026","November 8, 2022",,"January 30, 2024","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05609552"
89,"NCT00397943","Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults",,"Completed","Has Results","Tuberculosis","Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342|Biological: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Biological: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Biological: Control vaccine with the adjuvant system.","Number of Subjects With Any and Grade 3 Solicited Local Symptoms|Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With SAEs|Number of Subjects With Normal or Abnormal Haematological and Biochemical Levels|Number of Subjects With Normal and Abnormal Haematological and Biochemical Levels|Levels of C-reactive Protein|Levels of Immunoglobulin E|Antibody Concentrations Against Mycobacterium Tuberculosis (M. Tuberculosis) Fusion Proteins M72 and Mtb72F|Antibody Concentrations Against M. Tuberculosis Fusion Protein M72|Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/CD8+) T-cells Expressing at Least Two Different Cytokines|Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Different Cytokines|Frequency of M72 Specific CD4+ T-cells Expressing at Least One Cytokine and Another Signal Molecule|Number of Subjects With Response to M72-specific CD4+ T-cells Secreting at Least Two Different Cytokines/Activation Markers|Concentrations of IFN-γ Produced in Serum Samples","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","106227|106228|108736|108738|2005-004497-24","November 15, 2006","December 1, 2009","December 1, 2009","November 10, 2006","August 13, 2018","June 19, 2019","GSK Investigational Site, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT00397943"
90,"NCT01290081","Enhanced Tuberculosis Case Detection Among Substitution Treatment Patients","TBIDU","Completed","No Results Available","Tuberculosis","Other: Case management approach in referral to health care services",,"National Institute for Health Development, Estonia|LLC Corrigo|Ida-Viru Central Hospital, Department of Tuberculosis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","TBIDU-1230","October 2007","January 2008","January 2008","February 4, 2011",,"February 4, 2011","LLC Corrigo, Jõhvi, Ida-Virumaa, Estonia",,"https://ClinicalTrials.gov/show/NCT01290081"
91,"NCT04094350","Effect of Community Active Case Finding Strategies for Detection of Tuberculosis in Cambodia",,"Completed","No Results Available","Tuberculosis","Other: ACF with a seed-and-recruit model|Other: ACF targeting household and neighborhood contacts|Other: ACF targeting the older population using mobile screening units|Other: Passive case finding","Number of TB cases notified per 10000 population|Additional number of TB cases|Number of TB cases diagnosed per 1000 population screened|Number of people with TB who have completed TB treatment and successfully treated|Number of people needed to screen to detect one case|Cost-effectiveness","National University of Singapore|KHANA Center for Population Health Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2004","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","NIHA-2018-005","December 16, 2019","November 30, 2021","January 31, 2022","September 18, 2019",,"November 29, 2022","KHANA Center for Population Health Research, Phnom Penh, Cambodia|Cambodia Anti-Tuberculosis Association, Phnom Penh, Cambodia|National Center for Tuberculosis and Leprosy Control, Phnom Penh, Cambodia",,"https://ClinicalTrials.gov/show/NCT04094350"
92,"NCT05406453","Whole Genome Sequencing of Tuberculosis for Disease Control in Madagascar","TB_WGS_cRCT","Recruiting","No Results Available","Tuberculosis","Other: Whole Genome Sequencing testing","the total number of TB cases detected / 100 000 inhabitants","Institut Pasteur de Madagascar|The National Tuberculosis Program, Madagascar|Centre de Recherche du Centre Hospitalier de l'Université de Montréal","All","Child, Adult, Older Adult","Not Applicable","86400","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2022-01|PJT 75243","May 16, 2022","September 1, 2025","September 1, 2025","June 6, 2022",,"September 29, 2023","Fokontany Vohibato, Vohibato, Madagascar",,"https://ClinicalTrials.gov/show/NCT05406453"
93,"NCT02467608","Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Isoniazid with HUEXC030 and RZE|Drug: HRZE","ALT change from baseline to the 8 weeks of study treatment|Incidence of ATDH in high risk genotype subjects treated with investigational drugs|Percentage of patients cured by the end of treatment|The overall reduced incidence of ATDH in subjects treated with investigational drugs|The lowering average level of liver function tests","Orient Pharma Co., Ltd.|National Defense Medical Center, Taiwan|National Research Program for Biopharmaceuticals, Taiwan","All","20 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","557","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NDMC HUEXC030-TB1","December 6, 2012","January 9, 2019","January 9, 2019","June 10, 2015",,"June 15, 2022","Changhua Christian Hospital, Changhua, Taiwan|Changhua Hosiptal Ministry of Health And Welfare, Changhua, Taiwan|Chang Gung Memorial Hospital, ChiaYi, Chiayi City, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|E-DA Hospital, I-Shou University, Kaohsiung, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital ,Linkou, Linkou, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Buddhist Tzu Chi General Hospital, Taipei, Taiwan|Cheng Hsin General Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei City Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan|Taipei Wanfang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02467608"
94,"NCT02662829","Preventing Childhood Tuberculosis in Lesotho (PREVENT Study)",,"Completed","No Results Available","Tuberculosis","Behavioral: Community-based intervention|Other: Standard of care","Yield of child contacts|Percentage of IPT initiation|Percentage of IPT completion|Percentage of HIV testing","Columbia University|National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult","Not Applicable","562","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AAAN7358|K01AI104351","December 2015","January 2019","January 2019","January 26, 2016",,"April 6, 2022","Berea Hospital, Berea, Berea District, Lesotho|Holy Family Health Center, Berea, Berea District, Lesotho|Khubetsoana Health Center, Berea, Berea District, Lesotho|Koali Health Center, Berea, Berea District, Lesotho|Kolojane Health Center, Berea, Berea District, Lesotho|Maluti Hospital, Berea, Berea District, Lesotho|Pilot Health Center, Berea, Berea District, Lesotho|St Magdalena Health Center, Berea, Berea District, Lesotho|St. David Health Center, Berea, Berea District, Lesotho|St. Theresa Health Center, Berea, Berea District, Lesotho",,"https://ClinicalTrials.gov/show/NCT02662829"
95,"NCT02082340","Innovative Approach in Tuberculosis Care in Armenia",,"Completed","Has Results","Tuberculosis","Behavioral: TB knowledge and socio-psychological counseling session|Other: SMS text messages|Other: phone calls|Behavioral: Self-administered drug intake strategy|Behavioral: Educational leaflet","TB Treatment Success Rates Defined by the World Health Organization (WHO)|Knowledge About TB Infection|Stigma Level Towards TB Patients|Family Support Towards TB Patients|TB Treatment Adherence|Depression Status of TB Patients|Quality of Life of TB Patients","Varduhi Petrosyan|Grand Challenges Canada|National Tuberculosis Control Center, Ministry of Health, Republic of Armenia|American University of Armenia Fund","All","18 Years and older   (Adult, Older Adult)","Not Applicable","392","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","S5 0399-01_GCC","March 2014","May 2015","May 2015","March 10, 2014","February 18, 2020","February 18, 2020","School of Public Health, American University of Armenia Fund, Yerevan, Armenia",,"https://ClinicalTrials.gov/show/NCT02082340"
96,"NCT05971602","Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis",,"Recruiting","No Results Available","Pulmonary Tuberculosis","Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)|Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)|Drug: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)|Drug: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)","Stage 1: Percentage of participants with DS-TB reporting severe Adverse events (AEs) (≥ Grade 3) and/or Serious adverse events (SAEs), by treatment group|Stage 1: Percentage of participants with pulmonary DS-TB with unfavorable outcome, by treatment group|Stage 2: Percentage of participants with DS-TB reporting severe AEs (≥ Grade 3) and/or SAEs, by treatment group|Stage 2: Percentage of participants with pulmonary DS-TB reporting unfavorable outcome, by treatment group|Stage 1: Percentage of participants reporting all-cause trial treatment discontinuation, by treatment group|Stage 1: Percentage of participants reporting severe AEs (≥ Grade 3) and/or SAEs, by treatment group|Stage 1: Percentage of participants with pulmonary DS-TB and Human immunodeficiency virus (HIV) co-infection reporting severe AEs (≥ Grade 3) and/or SAEs, by treatment group|Stage 1: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting severe AEs (≥ Grade 3) and/or SAEs, by treatment group|Stage 1: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting all-cause trial treatment discontinuation, by treatment group|Stage 1: Percentage of participants with pulmonary DS-TB reporting unfavorable outcome, by treatment group|Stage 1: Percentage of participants with DS-TB and HIV co-infection reporting unfavorable outcome, by treatment group|Stage 1: Percentage of participants reporting unfavorable outcome, by treatment group|Stage 1: Time to sustained sputum culture conversion to negative for Mtb growth in Mycobacteria Growth Indicator Tube (MGIT) culture in participants receiving combination of DBOS and PBOS relative to 2HRZE/4HR|Stage 1: Mean change from Baseline in sputum MGIT culture time to detection (TTD) in participants receiving combination of DBOS and PBOS relative to 2HRZE/4HR|Stage 1: Percentage of participants with sustained sputum culture conversion in MGIT culture through Week 26, by treatment group|Stage 1: Time to sustained sputum culture conversion to negative in solid culture, by treatment group|Stage 1: Percentage of participants with sustained sputum culture conversion in solid culture, by treatment group|Stage 1: Percentage of participants developing resistance against each drug|Stage 1: Geometric mean concentration of DBOS in participants with pulmonary DS-TB|Stage 1: Geometric mean concentration of PBOS in participants with pulmonary DS-TB|Stage 1: Geometric mean concentration of DBOS in participants with DS-TB and HIV co-infection|Stage 1: Geometric mean concentration of PBOS in participants with DS-TB and HIV co-infection|Stage 1: Geometric coefficient of variation of DBOS in participants with pulmonary DS-TB|Stage 1: Geometric coefficient of variation of PBOS in participants with pulmonary DS-TB|Stage 1: Geometric coefficient of variation of DBOS in participants with DS-TB and HIV co-infection|Stage 1: Geometric coefficient of variation of PBOS in participants with DS-TB and HIV co-infection|Stage 2: Percentage of participants with DS-TB receiving XBOS reporting all-cause trial treatment discontinuation|Stage 2: Percentage of participants with DS-TB receiving 2HRZE/4HR reporting all-cause trial treatment discontinuation|Stage 2: Percentage of participants with DS-TB reporting Severe AEs (≥ Grade 3) and/or SAEs, by treatment group|Stage 2: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting severe AEs (≥ Grade 3) and/or SAEs, by treatment group|Stage 2: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting all-cause trial treatment discontinuation, by treatment group|Stage 2: Percentage of participants with RR/MDR-TB reporting severe AEs (≥ Grade 3) and/or SAEs in participants who receive XBOS for four months|Stage 2: Percentage of participants with RR/MDR-TB reporting all-cause trial treatment discontinuation in participants who receive XBOS for four months|Stage 2: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting unfavorable outcome, by treatment group|Stage 2: Percentage of participants reporting unfavorable outcome, by treatment group|Stage 2: Time to sustained sputum culture conversion to negative for Mtb growth in MGIT culture in participants receiving combination of XBOS relative to 2HRZE/4HR|Stage 2: Mean change from Baseline in sputum MGIT culture TTD in participants receiving combination of XBOS relative to 2HRZE/4HR|Stage 2: Percentage of participants with sustained sputum culture conversion to negative at Week 8 and end of treatment, by treatment group|Stage 2: Time to sustained sputum culture conversion to negative in solid culture in participants receiving combination of XBOS relative to 2HRZE/4HR|Stage 2: Percentage of participants with sustained sputum culture conversion in solid culture, by treatment group|Stage 2: Percentage of participants developing resistance against each drug|Stage 2: Geometric mean concentration of XBOS in participants with pulmonary DS-TB and RR/MDR-TB|Stage 2: Geometric mean concentration of XBOS in participants with DS-TB and HIV co-infection|Stage 2: Geometric coefficient of variation of XBOS in participants with pulmonary DS-TB and RR/MDR-TB|Stage 2: Geometric coefficient of variation of XBOS in participants with DS-TB and HIV co-infection","Bill & Melinda Gates Medical Research Institute|Global Alliance for TB Drug Development|Janssen Pharmaceutica|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","514","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Gates MRI-TBD06-201","July 26, 2023","March 2027","March 2027","August 2, 2023",,"December 8, 2023","De La Salle Health Sciences Institute, Dasmarinas, Philippines|Tropical Disease Foundation, Makati, Philippines|Lung Center of the Philippines, Quezon City, Philippines|Bio-Medical Research Institute; Faculty of Medicine and Health Sciences, Stellenbosch University; Tygerberg Medical Campus, Cape Town, South Africa|TASK - Central (Brooklyn), Cape Town, South Africa|UCT (Cape Town); General Medicine & Global Health (GMGH); Hatter Heart Research Institute, Cape Town, South Africa|UCT South African Tuberculosis Vaccine Initiative (SATVI), Cape Town, South Africa|University of Cape Town (UCT) Lung Institute, Cape Town, South Africa|The Aurum Institute (Tembisa CRS), Johannesburg, South Africa|Perinatal HIV Research Unit (PHRU), Klerksdorp, South Africa",,"https://ClinicalTrials.gov/show/NCT05971602"
97,"NCT03507816","A Multidrug-resistant (MDR) and Extensively Drug- Resistant (XDR) Tuberculosis Study in Alsace",,"Unknown status","No Results Available","Tuberculosis",,"Study of clinical characteristics of patients hospitalized at Strasbourg University Hospital from 2006 to 2016, with proven MDR or XDR tuberculosis","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"22","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","7002","February 23, 2018","February 2020","February 2020","April 25, 2018",,"April 30, 2019","Service de Maladies Infectieuses et Tropicales, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT03507816"
98,"NCT00174083","Diagnosis of Active Tuberculosis by ELISPOT",,"Unknown status","No Results Available","Tuberculosis",,,"National Taiwan University Hospital","All","0 Years and older   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Defined Population|Time Perspective: Other","9461700717","August 2005",,"December 2006","September 15, 2005",,"September 15, 2005","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00174083"
99,"NCT02329730","Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10",,"Completed","Has Results","Tuberculosis","Biological: 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Biological: 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Biological: 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Biological: 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Biological: 1μg/ml ESAT6-CFP10 and placebo|Biological: 5μg/ml ESAT6-CFP10 and placebo|Biological: 10μg/ml ESAT6-CFP10 and placebo|Biological: 20μg/ml ESAT6-CFP10 and placebo","Number of Healthy Participants Negative for Reaction at 24 Hours After Intradermal Injection With ESAT6-CFP10|Number of Tuberculosis (TB) Participants Positive for Reaction at 24 Hours After Intradermal Injection With ESAT6-CFP10|Number of Healthy Participants Negative for Reaction at 48 Hours After Intradermal Injection With ESAT6-CFP10|Number of Tuberculosis (TB) Participants Positive for Reaction at 48 Hours After Intradermal Injection With ESAT6-CFP10|Number of Healthy Participants Negative for Reaction at 72 Hours After Intradermal Injection With ESAT6-CFP10|Number of Tuberculosis (TB) Participants Positive for Reaction at 72 Hours After Intradermal Injection With ESAT6-CFP10|Number of Healthy Participants Negative for Reaction at 96 Hours After Intradermal Injection With ESAT6-CFP10|Number of Tuberculosis (TB) Participants Positive for Reaction at 96 Hours After Intradermal Injection With ESAT6-CFP10|the Number of Participants With Adverse Events|the Number of Healthy Participants Negative for IFN-γ(Gamma Interferon ) Before Injection|the Number of Tuberculosis (TB) Participants Positive for IFN-γ(Gamma Interferon ) Before Injection|the Number of Healthy Participants Negative for IFN-γ(Gamma Interferon ) at 72 Hours After Intradermal Injection With ESAT6-CFP10|the Number of Tuberculosis (TB) Participants Positive for IFN-γ(Gamma Interferon ) at 72 Hours After Intradermal Injection With ESAT6-CFP10|the Number of Healthy Participants Negative for IFN-γ(Gamma Interferon ) at 144 Hours After Intradermal Injection With ESAT6-CFP10|the Number of Tuberculosis (TB) Participants Positive for IFN-γ(Gamma Interferon ) at 144 Hours After Intradermal Injection With ESAT6-CFP10","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shanghai Public Health Clinical Center|Tianjin Haihe Hospital|Air Force Military Medical University, China|Proswell Medical Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","144","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LTao-EC IIa","February 2014","June 2014","August 2014","January 1, 2015","April 9, 2015","April 9, 2015",,,"https://ClinicalTrials.gov/show/NCT02329730"
100,"NCT02387242","Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers",,"Suspended","No Results Available","Tuberculosis","Drug: Rifampicin","Cumulative WBA (reported as change in Mtb log CFU per day)|The pharmacokinetic profile of rifampicin","National University Hospital, Singapore","All","21 Years and older   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","High Rif-WBA","February 2015","December 2017","December 2017","March 12, 2015",,"April 13, 2017","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02387242"
101,"NCT00780546","Spatial Epidemiology of Tuberculosis (TB) Infection",,"Unknown status","No Results Available","Tuberculosis",,,"National Taiwan University Hospital","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","200808047R","October 2008","May 2009","July 2009","October 27, 2008",,"October 27, 2008","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00780546"
102,"NCT02532036","MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection",,"Terminated","Has Results","Tuberculosis","Biological: Aerosol inhaled MVA85A|Biological: Intramuscular MVA85A|Biological: Intramuscular Saline placebo|Biological: Aerosol inhaled Saline placebo","Adverse Events (AE)|Laboratory Markers of Immunity","University of Oxford|University of Birmingham","All","18 Years to 55 Years   (Adult)","Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TB040","September 2015","October 4, 2018","October 4, 2018","August 25, 2015","August 31, 2020","August 31, 2020","Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford, Oxfordshire, United Kingdom|John Warin Ward, Churchill Hospital, Oxford, Oxfordshire, United Kingdom|NIHR Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom|NIHR/Wellcome Trust King's Clinical Research Facility, London, United Kingdom|Royal Free Hospital NHS Foundation Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/36/NCT02532036/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02532036"
103,"NCT01539005","Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy","TRuTH","Completed","No Results Available","Tuberculosis",,"Tuberculosis","Centre for the AIDS Programme of Research in South Africa|United States President's Emergency Plan for AIDS Relief|Howard Hughes Medical Institute|K-RITH","All","18 Years and older   (Adult, Older Adult)",,"402","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAP005","November 2009","April 23, 2014","April 23, 2014","February 27, 2012",,"February 2, 2017","CAPRISA eThekwini Clinical Research Site, Durban, KwaZulu Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT01539005"
104,"NCT00918086","Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment",,"Completed","No Results Available","Tuberculosis","Dietary Supplement: Vitamin D pill|Dietary Supplement: Placebo","The primary outcome for this intent-to-treat trial is the time to Mycobacterium tuberculosis sputum culture conversion to negative|Sputum culture result (positive or negative)","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 2","199","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","IRB00014641|Vitamin D Georgia Study","July 2009","September 2012","July 2014","June 11, 2009",,"July 11, 2014","National Center for tuberculosis and Lung diseases, Tbilisi, Georgia",,"https://ClinicalTrials.gov/show/NCT00918086"
105,"NCT02781909","Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis","NSAIDS-XDRTB","Completed","No Results Available","Tuberculosis","Drug: Ibuprofen|Drug: Standard of Care TB treatment","Number of pilot study participants with microbiological efficacy-related events that are related to treatment.|Number of pilot study participants with radiological efficacy-related events that are related to treatment.|Number of pilot study participants with clinical efficacy-related events that are related to treatment.|Microbiological efficacy-related events: Time to stable culture conversion up to M6|Number of pilot study participants with Safety-related events.|Proportion of pilot study participants showing differences in Health Quality of Life (HQoL).|Proportion of pilot study participants showing differences in Immune Responses at M2 and M6 relative to baseline.","Fundació Institut Germans Trias i Pujol|National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSAIDS4TB_01","September 2016","January 2019","January 2019","May 25, 2016",,"December 17, 2019","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Perinatal HIV Unit (PHRU), Soweto, South Africa",,"https://ClinicalTrials.gov/show/NCT02781909"
106,"NCT00814671","Study of Daily Rifapentine for Pulmonary Tuberculosis",,"Completed","Has Results","Tuberculosis","Drug: Rifapentine 450|Drug: Rifapentine 600|Drug: Rifampin","Percentage of Participants With Negative Lowenstein Jensen Cultures at Week 8|Tolerability|Time to Stable Culture Conversion on Solid Medium|Time to Stable Culture Conversion on Liquid MGIT Media|Pharmacokinetics of Rifapentine","Johns Hopkins University|University of Cape Town Lung Institute|University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Phase 2","153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00019095","April 2010","June 2013","September 2014","December 25, 2008","September 28, 2016","February 6, 2018","Universiy of Cape Town Lung Institute, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00814671"
107,"NCT04333485","Tuberculosis (TB) Aftermath",,"Recruiting","No Results Available","Tuberculosis (TB)","Other: Home-based Active Case Finding (HACF)|Other: Telephonic Active Case Finding (TACF)","Rate per 100 person-years of people diagnosed with new or recurrent TB by study arm.|Proportion of eligible household contacts (HHCs) <6 years of age, by study arm, initiated on TB preventive treatment (TPT) after ruling out active TB disease.","Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|Dr. D.Y. Patil Medical College, Hospital and Research Centre","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","3228","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IRB00247239|1R01AI143748-01A1","January 29, 2021","August 1, 2024","August 1, 2024","April 3, 2020",,"August 16, 2023","Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pune, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04333485"
108,"NCT04670120","Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)",,"Unknown status","No Results Available","Sensitive Pulmonary Tuberculosis","Drug: Pyrifazimine (TBI-166)","EBA","Beijing Chest Hospital|Shandong Chest Hospital|Zhengzhou Sixth People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCP-TB-Pyrifazimine (TBI-166)","March 1, 2021","June 30, 2021","December 31, 2021","December 17, 2020",,"September 20, 2021","Beijing Chest Hospital, Beijing, Beijing, China|Zhengzhou Sixth People's Hospital, Zhengzhou, Henan, China|Shandong Chest Hospital, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04670120"
109,"NCT01434758","Evaluating Diagnostics for Paediatric Tuberculosis by Blood Culture",,"Completed","No Results Available","Tuberculosis Infection",,"Diagnostic yield of TB culture|Diagnostic yield of urine versus expectorate or gastric aspirate for TB culture","Oxford University Clinical Research Unit, Vietnam|National Children's Hospital, Vietnam","All","up to 15 Years   (Child)",,"560","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09TB","April 2011","December 2014","September 2015","September 15, 2011",,"November 15, 2016","National Hospital of Pediatrics, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT01434758"
110,"NCT04734236","Development of Molecular Diagnostic Platform for Tuberculosis",,"Unknown status","No Results Available","Tuberculosis","Diagnostic Test: New technique vs Xpert","The effectiveness of new diagnostic technique","Asan Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","RapidassaytestforTB","January 28, 2021","December 31, 2021","December 31, 2021","February 2, 2021",,"February 2, 2021","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Songpa, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04734236"
111,"NCT02393586","Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: Faropenem|Drug: Amoxicillin/clavulanic acid 500mg/125mg|Drug: Rifampicin","Cumulative WBA|The pharmacokinetic profile of study drug(s)","National University Hospital, Singapore","All","21 Years and older   (Adult, Older Adult)","Phase 1","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Faro-WBA","February 2015","October 2015","October 2015","March 19, 2015",,"April 5, 2017","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02393586"
112,"NCT05382312","Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis",,"Recruiting","No Results Available","Tuberculosis","Drug: GSK3036656|Drug: Bedaquiline|Drug: Delamanid|Drug: RIFAFOUR e-275|Drug: BTZ-043","Change from Baseline in log10 CFU of Mycobacterium tuberculosis (MTB) (per milliliters of respiratory sputum samples)|Change from Baseline in time to sputum culture positivity|Number of participants with serious adverse events|Number of participants with adverse events of Grade 3 severity or higher|Number of participants with adverse events related to study drug|Number of participants withdrawn from the treatment due to adverse events|Number of participants withdrawn from the study due to adverse events|Number of participants with electrocardiogram (ECG) values of potential clinical importance (PCI)|Number of participants with hematology laboratory values of PCI|Number of participants with clinical chemistry laboratory values of PCI|Number of participants with vital signs of PCI","GlaxoSmithKline|Click-TB Consortium","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","128","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","214912","July 26, 2022","November 1, 2024","November 1, 2024","May 19, 2022",,"February 22, 2024","GSK Investigational Site, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT05382312"
113,"NCT00523926","TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: TMC207","Assess the effects of 3 doses of TMC207 administered over a 7 day period on M. tuberculosis in sputum compared to effects of treatment with standard doses of isoniazid and rifampin|Assess the short term safety, tolerability and PK of multiple oral doses of TMC207 in treatment-naïve subjects with pulmonary M.tuberculosis infection","Tibotec BVBA","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR002725","May 2005",,"October 2005","September 3, 2007",,"August 15, 2012",,,"https://ClinicalTrials.gov/show/NCT00523926"
114,"NCT04583904","Prospective Evaluation of Novel Diagnostics for Tuberculosis in KwaZulu-Natal, South Africa","PROVE-TB","Unknown status","No Results Available","Tuberculosis",,"Number of Participants Classified with TB Case Definition|Number of Participants with TB Treatment Outcome","University of Washington|Umkhuseli Innovation and Research Management (UIRM)|University of KwaZulu|PATH|KwaZulu Natal Department of Health|Salus Ltd.","All","12 Months and older   (Child, Adult, Older Adult)",,"900","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY00009092|OPP1213504","September 18, 2019","September 2021","September 2021","October 12, 2020",,"October 14, 2020","Edendale Hospital, Pietermaritzburg, South Africa",,"https://ClinicalTrials.gov/show/NCT04583904"
115,"NCT04995406","Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis","ISIT-TB","Completed","No Results Available","TUBERCULOSIS, PULMONARY","Diagnostic Test: ISIT-TB prototype","Evaluation of performance of the diagnostic tool","BioMérieux","All","18 Years and older   (Adult, Older Adult)",,"722","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ISIT-TB 001","January 3, 2022","May 1, 2023","December 31, 2023","August 9, 2021",,"March 8, 2024","University of Cape Town Lung Institute, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT04995406"
116,"NCT03832023","Community-based Tuberculosis Tracing and Preventive Therapy","CONTACT","Completed","No Results Available","Tuberculosis","Other: Screening and initiating preventive therapy in communities","Completion of preventive therapy|Proportion of children screened|Proportion of children eligible for PT|Proportion of children started on PT|Proportion of children who did not complete PT|Proportion of children with presumptive TB|Proportion of children investigated for TB|Proportion of children diagnosed with TB|Proportion of children started on TB treatment|Proportion of adult contacts screened|Proportion of adults presumptive TB cases|Proportion of adults diagnosed with TB|Proportion of children with serious adverse events|Proportion of children with adverse event of interest|Treatment adherence|Treatment outcomes of children started on TB treatment|TB case detection during pre-intervention period|Proportion of children among all registered TB cases during pre-intervention period|TB treatment outcome of registered TB patients during pre-intervention period|Number of children started on PT during pre-intervention period|Completion rate of children started on PT intervention during pre-intervention period|Number of household visits by CHW|Proportion of parents/guardians who accept household visit|Reasons of refusal of household visit|Preference for household visit versus facility visit|Critical events experienced by CHW during household visit|Transport cost for household visit by CHW|Transport cost for parents/guardian for facility-based screening|Time spent to perform household contact screening visit|Proportion of delivered activities compared to the intended activities of the model","Elizabeth Glaser Pediatric AIDS Foundation|Epicentre|University of Sheffield|Institut de Recherche pour le Developpement","All","Child, Adult, Older Adult","Not Applicable","1400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","EG0211","October 14, 2019","August 1, 2022","August 1, 2022","February 6, 2019",,"February 16, 2023","Hôpital de district Bonassama, Bonabéri, Cameroon|Hôpital de district Log-Baba, Douala, Cameroon|Centre Médical d'arrondissement Delangue, Edéa, Cameroon|Hôpital de district Mbalmayo, Mbalmayo, Cameroon|Hôpital de district Mfou, Mfou, Cameroon|Hôpital régional Nkongsamba, Nkongsamba, Cameroon|Hôpital de district Okola, Okola, Cameroon|Hôpital de district Olembe, Olembe, Cameroon|Hôpital de district St Jean de Malte, Penja, Cameroon|Hôpital de district Yoko, Yoko, Cameroon|Ishongororo HC IV, Ibanda, Uganda|Ruhoko HC IV, Ibanda, Uganda|Kabwohe Clinical Research Center HC II, Kabwohe, Uganda|Kabwohe HC IV, Kabwohe, Uganda|Kitagata Hospital, Kitagata, Uganda|Bubaare HC III, Mbarara, Uganda|Bwizibwera HC IV, Mbarara, Uganda|Kakoba HC III, Mbarara, Uganda|Mbarara Municipal Council HC IV, Mbarara, Uganda|Bwongyera HC III, Ntungamo, Uganda|Itojo Hospital, Ntungamo, Uganda|Kitwe HC IV, Ntungamo, Uganda|Ntungamo Ngoma HC III, Ntungamo, Uganda|Rubaare HC IV, Ntungamo, Uganda|Rwashamaire HC IV, Ntungamo, Uganda",,"https://ClinicalTrials.gov/show/NCT03832023"
117,"NCT00551226","Follow up of Autoantibodies in Active Tuberculosis",,"Unknown status","No Results Available","Tuberculosis",,"Follow up after levels of autoantibodies","Tel-Aviv Sourasky Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","314-07","November 2007",,"November 2008","October 30, 2007",,"October 30, 2007","Tel Aviv Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00551226"
118,"NCT02861768","Improving the Diagnostic of Tuberculosis",,"Completed","No Results Available","Tuberculosis","Biological: Pharyngeal swab","Percentage of patients with microbiological diagnosis of M. tuberculosis infection|pulmonary tuberculosis diagnostic time.|Prevalence of diagnosed patients Beijing|Direct cost of microbiological diagnosis of extra Beijing genotype","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","991","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2012-49|2012-A01598-35","March 22, 2013","February 8, 2019","February 8, 2019","August 10, 2016",,"April 21, 2023","Assistance Publique Hopitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT02861768"
119,"NCT04968886","TuBerculosis Viability Interregional Study and Agreement on Biological Tests","TBVISA","Not yet recruiting","No Results Available","Tuberculosis, Pulmonary","Diagnostic Test: Diagnostic Test: viability test on sputum and comparision with culture results (reference test)","Result of the viability test (positive or negative) compared to culture results (reference test). - The reference test will be considered as positive (C+) if Mtb are grown on solid or liquid media et negative (C-) if the cultures remain sterile after 42|Evaluate the diagnostic performance of the molecular test for the viability of tuberculosis bacilli|Study the correlation between the quantitative results of viability tests and the quantitative results of the culture|Evaluate the potential benefit of viability tests for the patient and the hospital over the duration of isolation and the time to discharge from hospital|Describe the cohort of patients hospitalized for pulmonary tuberculosis with positive microscopic examination in the 10 participating centers","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"104","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP180578","September 2022","December 2023","December 2023","July 20, 2021",,"June 28, 2022",,,"https://ClinicalTrials.gov/show/NCT04968886"
120,"NCT02336542","Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10",,"Completed","No Results Available","Tuberculosis","Biological: 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|Biological: 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|Biological: 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|Biological: 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm","the diameter of induraton or redness within 72 hours after intradermal injection with ESAT6-CFP10 in TB patients|the proportion of positive reaction within 72 hours after administered intradermally TB-PPD in TB patient|Immune response of of ESAT6-CFP10 from the size of induration OR redness in non-TB patients with lung diseases|The proportion of positive reaction after receiving specificity γ-IFN test in TB subjects and non-TB subjects with lung disease|the proportion of positive reaction within 72 hours after intradermal injection with TB-PPD in non-TB patients with lung diseases|the occurrence of adverse events within 72 hours after injection in TB subjects and non-TB subjects with lung disease|the consistency between ESAT6-CFP10 and TB-PPD in TB subjects and non-TB subjects with lung disease|the consistency between ESAT6-CFP10 and γ-IFN in TB subjects and non-TB subjects with lung disease|the consistency between TB-PPD and γ-IFN in TB subjects and non-TB subjects with lung disease","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shanghai Public Health Clinical Center|Tianjin Haihe Hospital|Wuhan Institute for Tuberculosis Control|Proswell Medical Corporation|Air Force Military Medical University, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","192","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","LTao-IIb-patient","November 2014","July 2015","July 2015","January 13, 2015",,"March 23, 2017",,,"https://ClinicalTrials.gov/show/NCT02336542"
121,"NCT00801606","Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis","ICTBSG","Completed","No Results Available","Tuberculosis","Drug: Zinc|Drug: Micronutrient without zinc|Drug: Micronutrient with zinc|Drug: Placebo","Change in Z score for weight and improvement in X ray film|Resolution of symptoms and interferon gamma activity at 2 and 6 months","All India Institute of Medical Sciences, New Delhi|University of Bergen","All","6 Months to 15 Years   (Child)","Phase 3","403","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ICTBSG","December 2008","June 2012","June 2012","December 3, 2008",,"February 10, 2016","Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00801606"
122,"NCT04593524","The Role of Vitamin D, A, and Beta Carotene in Tuberculosis Patients With Vitamin D Receptor Gene Polymorphism",,"Completed","No Results Available","Tuberculosis","Dietary Supplement: vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|Other: nutritional Counseling","vitamin D|vitamin A|beta carotene","Universitas Sumatera Utara","Female","20 Years to 60 Years   (Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","USU 2","May 14, 2019","August 15, 2019","September 22, 2019","October 20, 2020",,"October 20, 2020","Faculty of Medicine Universitas Sumatera Utara, Medan, North Sumatra, Indonesia","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/24/NCT04593524/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/24/NCT04593524/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04593524"
123,"NCT01585532","Alere Mycobacterium Tuberculosis Urine Study",,"Completed","No Results Available","Tuberculosis",,"Sensitivity and specificity","Research Center Borstel|Alere Technologies GmbH","All","18 Years and older   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RCBorstel002|CLDG-0402","January 2012","August 2013","December 2013","April 26, 2012",,"November 5, 2015","Research Center Borstel, Borstel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT01585532"
124,"NCT02744469","Benin Population Diversity of Tuberculosis and Implications","BeniDiT","Completed","No Results Available","Tuberculosis","Other: No intervention (observational study)","Lineage|Spoligotype (family)|Treatment failure or success as evidenced by microscopy result (for new and retreatment patients)|Treatment failure or success as evidenced by culture result (for rifampicin resistant patients)|Relapse ascertainment (by questioning and retrospective check of microscopy evidence in TB clinics)|Chest X-ray findings|Culture positivity|Phenotypic Drug-resistance or susceptibility|Genotypic resistance to rifampin (GeneXpert)|(Phenotypic)Type of Mycobacteria (tuberculous or non-tuberculous)|(Mpt64's)Type of Mycobacteria (tuberculous or non-tuberculous)","Laboratoire de Référence des Mycobactéries|Direction Générale de la Coopération au Développement, Belgique|Institute of Tropical Medicine, Belgium|Universiteit Antwerpen|Laboratoire de Référence des Mycobactéries, Benin republic|Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou, Benin|Centres de Diagnostic et de Traitement de la tuberculose, National Tuberculosis Programme, Benin","All","15 Years and older   (Child, Adult, Older Adult)",,"1490","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LRM-N°030-15/12/2015|CNERS N°030 of 15th/12/2015|ITM- N°1040/15|EC UZA 15/49/532|Belg registN°:B300201526865","April 12, 2016","January 8, 2018","December 12, 2019","April 20, 2016",,"February 23, 2021","Institute of Tropical Medicine, Antwerp, Belgium|Centre de Diagnostic et de Traitement de la Tuberculose de Djougou, Djougou, Atacora/Donga, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Matéri, Matéri, Atacora/Donga, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Natitingou, Natitingou, Atacora/Donga, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Tanguiéta, Tanguiéta, Atacora/Donga, Benin|Centre de Diagnostic et de Traitement de la tuberculose d'Abomey-Calavi, Abomey-Calavi, Atlantique/Littoral, Benin|Centre de Diagnostic et de Traitement de la Tuberculose d'Allada, Allada, Atlantique/Littoral, Benin|Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou, Cotonou, Atlantique/Littoral, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Ouidah, Ouidah, Atlantique/Littoral, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Bembèrèkè HE, Bembèrèkè, Borgou/Alibori, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Kandi, Kandi, Borgou/Alibori, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Nikki Hopital Sounou-Séro, Nikki, Borgou/Alibori, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Parakou CSCom, Parakou, Borgou/Alibori, Benin|Laboratoire de Référence des Mycobactéries, Cotonou, Littoral, Benin|Centre de Diagnostic et de Traitement de la Tuberculose d'Aplahoué, Aplahoué, Mono/Couffo, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Bopa, Bopa, Mono/Couffo, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Comè, Comè, Mono/Couffo, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Houéyogbé, Houéyogbé, Mono/Couffo, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Avrankou, Avrankou, Oueme/Plateau, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Pobè, Pobe, Oueme/Plateau, Benin|Centre de Pneumo-Phtisiologie d'Akron, Porto-Novo, Oueme/Plateau, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Sakété, Sakété, Oueme/Plateau, Benin|Centre de Diagnostic et de Traitement de la Tuberculose d'Abomey, Abomey, Zou/Collines, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Bohicon, Bohicon, Zou/Collines, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Dassa-Zoumè, Dassa-Zoumè, Zou/Collines, Benin|Centre de Diagnostic et de Traitement de la Tuberculose de Zagnanado, Zagnanado, Zou/Collines, Benin",,"https://ClinicalTrials.gov/show/NCT02744469"
125,"NCT01960257","Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis",,"Completed","Has Results","Tuberculosis","Device: Digital Health Feedback System|Other: SOC DOT","Step 1: Positive Detection Accuracy (PDA)|Step 2: Percentage of Witnessed Doses|Characterize Subject Responses to Post-study Questionnaires to Collect Information Regarding Their Experience With the DHFS Using Summary Statistics.","University of California, San Diego|Department of Health and Human Services|Proteus Digital Health, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","92","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AHF TB 001","October 25, 2013","January 31, 2017","January 31, 2017","October 10, 2013","May 12, 2021","May 12, 2021","UCSD AntiViral Research Center, San Diego, California, United States|San Diego County Public Health Services, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/57/NCT01960257/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01960257"
126,"NCT04975737","Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac",,"Recruiting","No Results Available","Tuberculosis","Biological: GamTBvac|Biological: Placebo","Preventive efficacy (Ep)","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","All","18 Years to 45 Years   (Adult)","Phase 3","7180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","02-GamTBvac-2020","January 20, 2022","November 2025","November 2025","July 23, 2021",,"November 30, 2022","City hospital #40, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04975737"
127,"NCT05473520","Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis","Doxy-TB","Recruiting","No Results Available","Tuberculosis","Drug: Doxycycline|Drug: Placebo","Forced expiratory volume in 1 second (FEV1) at 26 weeks measured by spirometry|Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC ratio)|Safety profile|Resolution of pulmonary cavities on CT scan|Cumulative lung cavity volume|St George's Respiratory Questionnaire Score|Sputum TB culture|Sputum culture conversion|Sputum matrix metalloproteinase (MMP) concentration|Sputum functional assays|Host transcriptome|Host plasma matrix metalloproteinase (MMP) concentration|Pharmacokinetics and pharmacodynamics of drug concentrations","National University Hospital, Singapore|Tan Tock Seng Hospital|Hospital Queen Elizabeth, Malaysia|National University of Singapore","All","21 Years and older   (Adult, Older Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Phase III Doxy-TB","May 24, 2023","April 23, 2026","January 27, 2027","July 26, 2022",,"January 25, 2024","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05473520"
128,"NCT01021124","Latent Tuberculosis Infection in Bone Marrow Transplant Recipients",,"Completed","No Results Available","Tuberculosis",,"development of tuberculosis|all cause mortality","Asan Medical Center","All","16 Years and older   (Child, Adult, Older Adult)",,"409","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009-0077","January 2010","June 2013","June 2013","November 26, 2009",,"July 18, 2013","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01021124"
129,"NCT04613258","Soy, Catfish, Anchovy, and Rice Supplementation Increases 25(OH)D Serum Levels in Tuberculosis Patients With Complications",,"Completed","No Results Available","Tuberculosis","Dietary Supplement: SCAR Porridge|Other: Counseling","Vitamin D|Calcium|albumin|Hs CRP|blood glucose","Universitas Sumatera Utara","All","20 Years to 60 Years   (Adult)","Not Applicable","43","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","USU","May 11, 2019","August 17, 2019","September 17, 2019","November 3, 2020",,"November 3, 2020","Faculty of Medicine Universitas Sumatera Utara, Medan, North Sumatra, Indonesia","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/58/NCT04613258/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/58/NCT04613258/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04613258"
130,"NCT02607449","FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis","FS-1","Completed","No Results Available","Tuberculosis, MDR","Drug: FS-1|Drug: Placebo","Time to persistently negative sputum cultures|Proportion of Patients with persistently negative sputum cultures (SCC)|The proportion of subjects with relapse of tuberculosis|Patients body weight dynamics for the period of 18 months.|The median time to occurrence of negative sputum microscopy result|The time when TB clinical symptoms not observed|Dynamics of the tuberculosis process based on subjects chest x-ray diagnosis.|The incidence and severity of Adverse Events, Serious Adverse Events and drug related Adverse Drug Reactions|Assessment of the study drug effect on thyroid gland function","Scientific Center for Anti-infectious Drugs, Kazakhstan|Phthisiopulmonology Center of Almaty, Kazakhstan|National Scientific Center of Phthisiopulmonology, Kazakhstan|Karaganda Medical University|West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan|Semey State Medical University|National Center of Phthisiatry, Bishkek, Kyrgyzstan|Invivo laboratory, Kazakhstan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","344","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TP-004 V 5.1","December 2013","August 2020","October 2020","November 18, 2015",,"May 24, 2022","Semey Medical University, Semey, East-Kazakhstan Region, Kazakhstan|West Kazakhstan Marat Ospanov Medical University, Aktobe, West Kazakhstan Region, Kazakhstan|National scientific center of phthisiopulmonology Ministry of health of the Republic of Kazakhstan, Almaty, Kazakhstan|Center of Phthisiopulmonology of the Public Health Administration of Almaty, Almaty, Kazakhstan|Karaganda Medical University, Karaganda, Kazakhstan|National Center of Phthisiatry, Bishkek, Kyrgyzstan",,"https://ClinicalTrials.gov/show/NCT02607449"
131,"NCT00145184","Effect of Multivitamin Supplements on Clinical and Immunological Response in Childhood Tuberculosis",,"Terminated","No Results Available","Tuberculosis","Dietary Supplement: Multivitamin supplement containing vitamins B, C, and E|Drug: Placebo","weight gain in childhood tuberculosis|clearance of chest x-ray in childhood tuberculosis|immunological parameters: ex-vivo lymphocyte proliferation; cytokines production including IL-2, IL-12, TNF - alpha, interferon-gamma; and CD4 and CD8 T-lymphocyte counts","Harvard School of Public Health (HSPH)|National Institute of Allergy and Infectious Diseases (NIAID)","All","6 Weeks to 5 Years   (Child)","Phase 3","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","03-117","May 2005","August 2007","August 2007","September 5, 2005",,"March 31, 2015","Muhimbili University, College of Health Sciences, Dar Es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT00145184"
132,"NCT05889364","AI-based System for Lung Tuberculosis Screening: Diagnostic Accuracy Evaluation",,"Active, not recruiting","No Results Available","Tuberculosis, Pulmonary","Diagnostic Test: AI-based x-ray analysis and triage (""normal/tuberculosis suspected"")","Diagnostic accuracy metric 1|Diagnostic accuracy metric 2|Diagnostic accuracy metric 3|Diagnostic accuracy metric 4|Diagnostic accuracy metric 5|Diagnostic accuracy metric 6","Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department","All","18 Years to 80 Years   (Adult, Older Adult)",,"308","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","2018-1","February 1, 2018","March 15, 2018","December 30, 2023","June 5, 2023",,"June 5, 2023","Research and Practical Center of Medical Radiology, Department of Health Care of Moscow, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05889364"
133,"NCT05116098","Randomized Clinical Trial: IS Zinc and Zinc Ionophere EGCG as Supplement Improve Outcome of Active Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis","Combination Product: zinc 50 mg + Epigallocatechin gallate","sputum analysis at start of treatment and after one month|measurement of serum or plasma zinc at all participants|measurement of serum interleukin 6|serum Adenosine deaminase (ADA)","Ministry of Health, Saudi Arabia","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","tuberculosis treatment","November 30, 2021","June 30, 2022","November 30, 2022","November 10, 2021",,"November 10, 2021",,,"https://ClinicalTrials.gov/show/NCT05116098"
134,"NCT04485156","Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)","Hi-DoRi-3","Not yet recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: High-dose rifampicin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Rifampicin","Incidence of unfavorable treatment outcomes between two arms|Time to unfavorable treatment outcomes|Time to culture conversion on liquid media|Proportion of participants with treatment success|Proportion of participants with relapse of same strain|Time to relapse with same strain|Occurrence of AEs grade 3 and above","Seoul National University Hospital|Chonnam National University Hospital|National Medical Center, Seoul|Pusan National University Hospital|Pusan National University Yangsan Hospital|Seoul National University Bundang Hospital|SMG-SNU Boramae Medical Center|Severance Hospital|Korean Institute of Tuberculosis|International Tuberculosis Research Center|Korean Center for Disease Control and Prevention","All","19 Years to 85 Years   (Adult, Older Adult)","Phase 3","926","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Hi-DoRi-3","September 2020","August 2025","December 2026","July 24, 2020",,"July 24, 2020","Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04485156"
135,"NCT02901288","Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Drug: Isoniazid|Drug: Rifampicin|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Levofloxacin","The percentage of participants with TB recurrence/relapse by 24 months after the end of treatment.|Percentage of participants with treatment failure at either 4.5 months or 6 months after randomization.|Treatment adverse reactions occuring|Time to sputum smear or culture conversion within intensive phase .|Sputum smear or culture conversion proportion at the treatment completion.|Radiological manifestation change of TB lesion or cavity.|Patiens adherence rate","Beijing Chest Hospital|Hubei Provincial Center for Disease Control and Prevention|Centre for Tuberculosis Control of Guangdong Province|Hunan Institute For Tuberculosis Control|Anhui Chest Hospital|Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control|Wuhan Institute for Tuberculosis Control|Shanghai Pulmonary Hospital, Shanghai, China|Shenyang Chest Hospital|Changchun Infectious Disease Hospital|First Affiliated Hospital of Xinjiang Medical University|Public Health Clinical Center of Chengdu|Taiyuan Fourth People's Hospital|The Sixth People's Hospital of Nantong|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province|Beijing Research Institute for Tuberculosis Control|Infectious Disease Prevention Hospital in Heilongjiang Province|The Third People's Hospital of Zhenjiang|Tianjin centers for Disease Control and Prevention|Harbin Chest Hospital|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC|Heilongjiang Province center for tuberculosis Control and Prevention|Tianjin Haihe Hospital|The Infectious Disease Hospital of Wangkai Zaozhuang|The Third People's Hospital of Kunming City|Kaifeng Central Hospital|The Infectious Hospital of Hebi|Pulmonary Hospital of Lanzhou|The Fourth People's Hospital of Ningxia Autonomous Region|The 4th People's Hospital of Qinghai Province|The Fifth People's Hospital of Suzhou|Chongqing Infectious Disease Medical Center|Tuberculosis Hospital in Jilin Province|Sixth People's Hospital of Nanyang City|Wuhan Union Hospital, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","3900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015ZX10003001","August 2016","December 2018","December 2018","September 15, 2016",,"March 20, 2017","Anhui Chest Hospital, Hefei, Anhui, China|Beijing Research Institute for Tuberculosis Control, Beijing, Beijing, China|Beijing Chest Hospital,Capital Meical University, Beijing, Beijing, China|Chongqing Infectious Disease Medical Center, Chongqing, Chongqing, China|Pulmonary Hospital of Lanzhou, Lanzhou, Gansu, China|Centre for Tuberculosis Control of Guangdong Province, Guangzhou, Guangdong, China|Guangxi Center for Disease Prevention and Control, Nanning, Guangxi, China|HeBei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei, China|Infectious Disease Prevention Hospital in Heilongjiang Province, Ha'erbin, Heilongjiang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, Heilongjiang, China|Harbin Chest Hospital, Harbin, Heilongjiang, China|The Infectious Hospital of Hebi, Hebi, Henan, China|Kaifeng Pulmonary Disease Hospital, Kaifeng, Henan, China|Sixth People's Hospital of Nanyang City, Nanyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xianxiang, Henan, China|Wuhan medical treatment center, Wuhan, Hubei, China|Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China|Hunan Institute For Tuberculosis Control, Changsha, Hunan, China|The Sixth People's Hospital of Nantong, Nantong, Jiangsu, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Third People's Hospital of Zenjiang, Zhenjiang, Jiangsu, China|Changchun Infectious Disease Hospital, Changchun, Jilin, China|Tuberculosis Hospital in Jilin Province, Jilin, Jilin, China|China Shenyang Chest Hospital, Shenyang, Jilin, China|The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan, Ningxia, China|The 4th People's Hospital of Qinghai Province, Xining Shi, Qinghai, China|The Infectious Disease Hospital of Wangkai Zaozhuang, Tengzhou, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an, Shanxi, China|Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China|Tianjin Haihe Hospital, Tianjin, Tianjin, China|Tianjin centers for Disease Control and Prevention, Tianjin, Tianjin, China|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Wulumuqi, Xinjiang, China|The Third People's Hospital of Kunming City, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT02901288"
136,"NCT02073240","Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand","EnTIC","Completed","No Results Available","Tuberculosis","Behavioral: Enhanced TB IC Package","Change in prevalence and incidence of latent Tuberculosis infection in healthcare workers|Change in institutional safety culture|Adherence to recommended TB Infection Control practices","Centers for Disease Control and Prevention|United States President's Emergency Plan for AIDS Relief","All","18 Years to 45 Years   (Adult)",,"22","U.S. Fed","Observational","Observational Model: Other|Time Perspective: Prospective","CDC-DTBE-6498","February 17, 2014","November 18, 2016","November 18, 2016","February 27, 2014",,"February 2, 2021","Buddhasothorn Hospital, Maruphong, Cha Cherng Sao, Thailand|Chaiyaphum Hosptial, Nai Mueang, Chaiyaphum, Thailand|Banpong Hospital, Banpong, Changwat Ratchaburi, Thailand|Chumponkhetudomsak Hospital, Mueang, Chumpon, Thailand|Nakhon Nayok Hospital, Mueang Nakhonnayok, Nakhonnayok, Thailand|Nan Hospital, Nai Wiang, Mueang Nan, Nan, Thailand|Pichit Hospital, Nai Mueang, Pichit, Thailand|Chao Phraya Abhaibhubejhr Hosptial, Mueang Prachinburi, Prachinburi, Thailand|Praputtabat Hosptial, Saraburi, Praputtabat, Thailand|Singburi Hospital, Mueang Singburi, Singburi, Thailand|Binh Phuoc General Hospital, Binh Phuoc, Vietnam|Dong Nai TB Hospital, Dong Nai, Vietnam|Dong Thap TB Hospial, Dong Thap, Vietnam|Hai Duong TB Hospital, Hai Duong, Vietnam|Hoa Binh General Hospital, Hoa Binh, Vietnam|Hung Yen Provincial Hospital, Hung Yen, Vietnam|Long An General Hospital, Long An, Vietnam|Nam Dinh General Hospital, Nam Dinh, Vietnam|Quang Ninh TB Hospital, Quang Ninh, Vietnam|Tien Giang General Hospital, Tien Giang, Vietnam|Vinh Long General Hosptial, Vinh Long, Vietnam|Vinh Phuc General Hospital, Vinh Phuc, Vietnam",,"https://ClinicalTrials.gov/show/NCT02073240"
137,"NCT06289660","Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age",,"Recruiting","No Results Available","Tuberculosis Infection",,"Epidemiology of Tuberculosis","Meyer Children's Hospital IRCCS","All","1 Week to 18 Years   (Child, Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PED-TB22","December 22, 2022","January 2, 2033","March 1, 2033","March 4, 2024",,"March 4, 2024","Meyer Children's Hospital IRCCS, Florence, Firenze, Italy|Ospedale Pediatrico Giovanni XXIII, Bari, Italy|Ospedale di Belluno, Belluno, Italy|Università di Bologna, Bologna, Italy|IRCCS Istituto Giannina Gaslini, Genova, Italy|Fondazione IRCCS Ca' Granda, Ospedale Maggiore, Policlinico, Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|Policlinico di Modena, Modena, Italy|Università Federico II, Napoli, Italy|Ospedale dei Bambini ""G.Di Cristina"", Palermo, Italy|Ospedale di Parma, Parma, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Azienda USL Toscana Centro, Prato, Italy|IRCCS Ospedale Pediatrico Bambin Gesù, Roma, Italy|Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|Ospedale Regina Margherita, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT06289660"
138,"NCT03625739","Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis",,"Recruiting","No Results Available","Tuberculosis","Drug: anti-tuberculosis drug","maximum concentration (Cmax)|time to achieve maximum concentration (Tmax)|absorption rate constant (ka)|elimination rate constant (kel)|half-life (t1/2)","Beijing Children's Hospital|Shandong University|Hopital Universitaire Robert-Debre|Rennes University Hospital","All","1 Day to 18 Years   (Child, Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BCH_PPK003","July 1, 2018","October 1, 2026","December 31, 2026","August 10, 2018",,"August 15, 2018","Beijing Children's Hospital of Capital Medical University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03625739"
139,"NCT05896930","Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Meropenem 6g IV over 6 hours|Drug: Ertapenem 1g IM|Drug: Meropenem 3g IV|Drug: Ertapenem 1g IV|Drug: Amoxicillin/CA twice daily|Drug: Rifampicin 35 mg/kg|Drug: Meropenem 6g IV over 60 minutes|Drug: Rifafour e-275|Drug: Meropenem 4g IV|Drug: Amoxicillin/CA once daily","Early bactericidal activity by change in logCFU over 14 days|Early bactericidal activity by change in time-to-positivity over 14 days|Early bactericidal activity by change in logCFU and TTP per ml over 0-2 days, 0-7 days, and 2-14 days","TASK Applied Science","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TASK 003","November 9, 2017","January 4, 2021","January 4, 2021","June 9, 2023",,"June 9, 2023","TASK Clinical Research Centre, Cape Town, Western Cape, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/30/NCT05896930/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05896930"
140,"NCT05534750","Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)","TEDITUB","Recruiting","No Results Available","Tuberculosis|Multidrug Resistant Tuberculosis","Drug: Tedizolid arm (SIVEXTRO®)|Drug: Linezolid arm (ZYVOXID®)|Drug: Standard quadruple therapy arm","Assessment of the early bactericidal activity (EBA) of tedizolid (200mg / day) at the end of the first 2 days of treatment (D3).|Evaluation of the early bactericidal activity (EBA) of tedizolid between Day 3 and Day 8|Comparison of the early bactericidal activity (EBA) of tedizolid between Day 1 and Day 3|Comparison of the early bactericidal activity (EBA) of tedizolid between Day 3 and Day 8|Comparison of the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 1 and Day 3|Comparison of the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 3 and Day 8|Tedizolid pharmacokinetics'measurement|Evaluation of Tedizolid's tolerance on hemoglobin|Evaluation of Tedizolid's tolerance on polynuclear neutrophils|Evaluation of Tedizolid's tolerance on platelets|Evaluation of Tedizolid's tolerance on creatinine clearance|Evaluation of Tedizolid's tolerance on AST/ALT|Evaluation of Tedizolid's tolerance on bilirubin|Evaluation of Tedizolid's tolerance on dress syndrome|Evaluation of Tedizolid's tolerance on optic neuropathy|Evaluation of Tedizolid's tolerance on peripheral neuropathy","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP210084","April 20, 2023","April 2025","May 2025","September 9, 2022",,"October 6, 2023","Bacteriology department- Hôpital Saint-Antoine, Paris, France",,"https://ClinicalTrials.gov/show/NCT05534750"
141,"NCT03568383","Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients","PHOENIx MDR-TB","Recruiting","No Results Available","Tuberculosis, MDR","Drug: Delamanid (DLM)|Drug: Isoniazid (INH)|Dietary Supplement: Pyridoxine (vitamin B6)","Percent of participants with confirmed or probable active TB at any time between Day 0 and the week 96 study visit|Percent of participants who permanently discontinue randomized study drug (DLM or INH) due to a treatment-related adverse event|Percent of participants with confirmed active MDR-TB at any time between Day 0 and the week 96 study visit|Percent of participants who died from any cause at any time between Day 0 and 96 weeks of follow-up|Percent of participants who died from any cause at any time between Day 0 and 96 weeks of follow-up, or with confirmed or probable active TB at any time between Day 0 and the week 96 study visit|Percent of participants with a Grade 3 or higher adverse event during the period receiving randomized study drug (DLM or INH)","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Otsuka Pharmaceutical Development & Commercialization, Inc.","All","Child, Adult, Older Adult","Phase 3","5610","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A5300B/I2003B/PHOENIx|12041","June 3, 2019","September 30, 2026","September 30, 2026","June 26, 2018",,"October 10, 2023","Gaborone CRS, Gaborone, South-East District, Botswana|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince, Haiti|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|YRG CARE CRS [Site ID: 32075], Chennai, Tamil Nadu, India|Chennai Antiviral Research and Treatment (CART) CRS, Chennai, Tamil Nadu, India|Moi University Clinical Research Center (MUCRC) CRS, Eldoret, Rift Valley, Kenya|Socios En Salud Sucursal Perú CRS, Lima, Peru|Barranco CRS, Lima, Peru|San Miguel CRS, Lima, Peru|De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC), Cavite, Philippines|Soweto ACTG CRS, Johannesburg, Gauteng, South Africa|Wits Helen Joseph Hospital CRS (Wits HJH CRS), Johannesburg, Gauteng, South Africa|Durban International Clinical Research Site CRS, Durban, Kwa Zulu Natal, South Africa|PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa|Rustenburg CRS, Rustenburg, North West Province, South Africa|Task Applied Science (TASK) CRS, Cape Town, Western Cape Province, South Africa|University of Cape Town Lung Institute (UCTLI) CRS, Cape Town, Western Cape Province, South Africa|South African Tuberculosis Vaccine Initiative (SATVI) CRS, Cape Town, Western Cape Province, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape, South Africa|CAPRISA eThekwini CRS, Durban, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Pathum Wan, Bangkok, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site, Kampala, Uganda|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda|National Lung Hospital CRS (Site ID: 32483), Vĩnh Phúc, Hanoi, Vietnam|Milton Park CRS, Milton Park, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT03568383"
142,"NCT01436929","Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs","PESOHHERZ","Unknown status","No Results Available","Tuberculosis","Drug: Silymarin|Drug: Placebo","incidence of hepatotoxicity|incidence of hepatotoxicity by genotypic variants","Seoul National University Hospital","All","35 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BRMH-06-2011-75","September 2011","October 2013","December 2013","September 20, 2011",,"December 17, 2012","Deog Kyeom Kim, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01436929"
143,"NCT00788320","Vitamin D in Active Tuberculosis (TB) Study",,"Withdrawn","No Results Available","Tuberculosis","Drug: Vitamin D3|Drug: Placebo","LL-37 level|Sputum Conversion|25-hydroxyvitamin D and serum calcium","Atlanta VA Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vitamin D in TB","October 2008","February 2010","February 2010","November 10, 2008",,"January 20, 2012","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00788320"
144,"NCT03802812","Thin Bronchoscope and Virtual Bronchoscopic Navigation System for Tuberculosis",,"Completed","No Results Available","Tuberculosis","Device: Thin bronchoscope and VBN","detection of M. tuberculosis and resistant-conferring mutations|time to appropriate treatment and stain/culture conversion","Pusan National University Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TBVBN study|2018R1C1B5085364","February 1, 2019","April 19, 2022","April 19, 2022","January 14, 2019",,"April 20, 2022","Pusan National University Hospital, Busan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03802812"
145,"NCT02076139","Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis",,"Completed","No Results Available","Tuberculosis","Dietary Supplement: Nyaditum resae® 10e4|Dietary Supplement: Nyaditum resae® 10e5|Other: Distilled water","Change from Baseline in Specific Treg memory cells at week 1|Global tolerability of Nyaditum resae ®, proportion of participants with adverse events related to study treatment.|Local tolerability (gastrointestinal duct), proportion of participants with gastrointestinal adverse events related to study treatment.|Systemic tolerability (vital signs, physical exam, laboratory tests), proportion of participants with systemic adverse events related to study treatment.|Change from Baseline in Specific Treg memory cells at week 2|Change from Baseline in Specific Treg memory cells at month 12","Manresana de Micobacteriologia, SL","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","NYADATREG","March 2014","June 2014","July 2015","March 3, 2014",,"October 31, 2018","Germans Trias I Pujol Hospital, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02076139"
146,"NCT00449644","TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).",,"Completed","Has Results","Tuberculosis","Drug: TMC207|Drug: Placebo|Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)","The Time to Sputum Culture Conversion at Week 8 (Stage 1)|The Time to Sputum Culture Conversion at Week 24 (Stage 2)|The Time to Sputum Culture Conversion at Week 24 (Stage 1)|The Time to Sputum Culture Conversion at Week 72 (Stage 2)|The Percentage of Participants With Sputum Culture Conversion (Stage 1)|The Percentage of Participants With Sputum Culture Conversion (Stage 2)","Janssen Infectious Diseases BVBA","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR011929|TMC207-TIDP13-C208|2007-004462-40","June 2007","March 2010","October 2012","March 20, 2007","June 25, 2013","April 29, 2014","Rio De Janeiro, Brazil|Chennai, India|New Delhi, India|Stopinu Region, Latvia|Lima, Peru|Quezon City, Philippines|Moscow, Russian Federation|Bethelsdorp, South Africa|Cape Town, South Africa|Durban, South Africa|George, South Africa|Klerksdorp, South Africa|Sandringham, South Africa|Chiang Mai, Thailand|Nakhon, Thailand|Nonthaburi, Thailand",,"https://ClinicalTrials.gov/show/NCT00449644"
147,"NCT01841541","The Impact of Involving Informal Health Providers for Tuberculosis Control in Sudan","Triage-Plus","Completed","No Results Available","Tuberculosis","Behavioral: Referral of presumptive of TB cases by informal providers","Total number of TB patients registered and start receiving treatment in formal health care facilities","Liverpool School of Tropical Medicine|The Epidemiological Laboratory (EpiLab), Khartoum-Sudan.|The Norwegian Heart and Lung Patients Association (LHL)","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","11.03RS","January 2009","March 2012","April 2012","April 26, 2013",,"April 26, 2013","The Epidemiological Laboratory (EpiLab), Khartoum, Sudan",,"https://ClinicalTrials.gov/show/NCT01841541"
148,"NCT03941496","Azacytidine During Anti-tuberculosis Therapy","AZA","Withdrawn","No Results Available","Tuberculosis, Pulmonary","Drug: Azacitidine Injection","Overall incidence of all IP-related adverse events|Overall severity of all IP-related adverse events|Measurement of epigenetic-mediated immune exhaustion","Andrew Dinardo|Bristol-Myers Squibb|Baylor College of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-45051","October 2022","May 2023","May 2023","May 8, 2019",,"February 8, 2023","Harris Health System - Ben Taub Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03941496"
149,"NCT02477852","The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis",,"Unknown status","No Results Available","Tuberculosis, Spinal","Drug: Isoniazid|Drug: Rifampicin|Drug: Ethambutol|Drug: Pyrazinamide","Vertebral side width of soft tissue is measured by CT after operation.|Amount of bone trabecula between bone graft surfaces is measured by X-ray after operation.","Beijing Chest Hospital|Beijing Municipal Science & Technology Commission","All","15 Years to 75 Years   (Child, Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D141107005214002","April 2015","December 2017","December 2017","June 23, 2015",,"June 23, 2015","Beijing chest hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02477852"
150,"NCT00857116","Deworming Against Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: Albendazole|Drug: Placebo","Change in TB-score compared to baseline (Wejse et al 2007)|Sputum smear conversion|Final outcome according to WHO|Difference in ELIspot pattern (IL5, IFN-gamma and IL-10)|Immunological response (IgE, Eosinophils, CD4-count)|Chest X-ray improvement","Linkoeping University|University of Gondar|Armauer Hansen Research Institute, Ethiopia","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","ALBP|HLF-20060245","March 2009","June 2013","August 2013","March 6, 2009",,"August 29, 2013","University of Gondar, Gondar, Region 3, Ethiopia, Gondar, Ethiopia",,"https://ClinicalTrials.gov/show/NCT00857116"
151,"NCT03044509","Diagnosis of Tuberculosis in Swiss Children","CITRUS","Recruiting","No Results Available","Tuberculosis|Mycobacterium Tuberculosis","Diagnostic Test: Secreted cytokine assay|Diagnostic Test: Intracellular cytokine assay","Improvement of immunodiagnostic tests for TB in children.|Indicative markers identification for TB infection and disease distinction","University Children's Hospital Basel|Ospedale Regionale Bellinzona e Valli|Insel Gruppe AG, University Hospital Bern|University of Lausanne Hospitals|University Hospital, Geneva|Luzerner Kantonsspital|Cantonal Hospital of St. Gallen|University Children's Hospital, Zurich|Kantonsspital Aarau","All","up to 17 Years   (Child)",,"190","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CITRUS","May 12, 2017","December 2022","December 2022","February 7, 2017",,"May 17, 2022","Kantonspital Aarau, Aarau, Switzerland|Nora Fritschi, Basel, Switzerland|Ospedale Regionale di Bellinzona, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Hôpital des enfants - HUG, Genève, Switzerland|Kinserspital Luzern, Luzern, Switzerland|Kinderspital St Gallen, St. Gallen, Switzerland|Kinderklinik Zürich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03044509"
152,"NCT04433195","Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis",,"Unknown status","No Results Available","Pulmonary Tuberculosis Confirmation by Culture","Diagnostic Test: Xpert MTB/RIF test","diagnostic turnaround time|culture positive pulmonary TB|change diagnosis|treatment outcomes","Taipei Medical University WanFang Hospital|Buddhist Tzu Chi General Hospital|Chest Hospital, Ministry of Health and Welfare, Taiwan|Chang-Hua Hospital|Taichung Veterans General Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","6900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","N202002038","June 15, 2020","October 31, 2021","December 31, 2022","June 16, 2020",,"May 12, 2022","Chang-Hua Hospital, Chang-Hua, Taiwan|Buddhist Tzu Chi General Hospital, Hualien City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chest Hospital, Ministry of Health and Welfare, Tainan, Taiwan|Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04433195"
153,"NCT03423550","Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis",,"Unknown status","No Results Available","Tuberculosis",,"The effectiveness of new diagnostic technique","Asan Medical Center","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-0020","January 16, 2018","October 31, 2021","December 30, 2021","February 6, 2018",,"October 28, 2021","Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03423550"
154,"NCT02231229","Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation","FAST-TB","Completed","No Results Available","Tuberculosis","Other: PCR-based strategy|Drug: conventional therapy","Proportion of patients with treatment success at the end of TB treatment|Proportion of patients with relapse|Proportion of patients with failure|Capillary drug concentration, for each of the prescribed treatment in hair segments|Incidence and nature of grade 3 or grade 4 adverse events related or not to TB treatments|Direct medical costs associated with each strategy","Assistance Publique - Hôpitaux de Paris","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 4","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P120130 AOM12317|IDRCB2013-A01406-39","July 23, 2014","July 4, 2018","February 18, 2020","September 4, 2014",,"March 18, 2020","Bichat Claude Bernard Hospital, Paris, France|Bichat hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02231229"
155,"NCT06033807","Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients",,"Recruiting","No Results Available","Tuberculosis|Latent Tuberculosis Infection","Diagnostic Test: QuantiFERON-TB Gold (QFT) test","The prevalence of tuberculosis (TB) infection in school contacts|Age|Sex|Vaccination history checklist|Patterns of contacting checklist|Co-morbidities / medical history checklist","Huashan Hospital|Guizhou Center for Disease Control and Prevention","All","13 Years and older   (Child, Adult, Older Adult)",,"31440","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","TB-Youth Screening","September 1, 2023","September 1, 2025","December 31, 2025","September 13, 2023",,"September 26, 2023","Dafang Center for Disease Control and Prevention, Bijie, Guizhou, China|Qixingguan Center for Disease Control and Prevention, Bijie, Guizhou, China|Nayong Center for Disease Control and Prevention, Bijie, Guizhou, China|Liping Center for Disease Control and Prevention, Linping, Guizhou, China|Qingzhen Center for Disease Control and Prevention, Qingzhen, Guizhou, China",,"https://ClinicalTrials.gov/show/NCT06033807"
156,"NCT02874755","Quality of Tuberculosis Care in Mumbai, India",,"Completed","No Results Available","Tuberculosis","Other: Tuberculosis Program","Correct case management|Essential history checklist|Referral for further management|Suspicion of tuberculosis|Initiation of TB treatment|Number of lab tests ordered|Lab tests ordered|Number of medicines|Medicine type|Rates of case registration|Vouchers received|Patient costs|Consultation, medicine, and test costs to patients","McGill University|World Bank|Institute of Socio-Economic Research on Development and Democracy (ISERDD)|ACCESS Health International","All","Child, Adult, Older Adult","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","OPP1091843-2","January 2015","March 10, 2017","March 10, 2017","August 22, 2016",,"August 29, 2017",,,"https://ClinicalTrials.gov/show/NCT02874755"
157,"NCT02874716","Quality of Tuberculosis Care in Urban Patna, India",,"Completed","No Results Available","Tuberculosis","Other: Tuberculosis Program (PPIA)","Correct case management|Essential history checklist|Referral for further management|Suspicion of tuberculosis|Initiation of TB treatment|Number of lab tests ordered|Lab tests ordered|Number of medicines|Medicine type|Rates of case registration for practitioners networked in the program|Vouchers received|Patient costs|Consultation, medicine, and test costs to patients","McGill University|World Bank|Institute of Socio-Economic Research on Development and Democracy (ISERDD)|ACCESS Health International","All","Child, Adult, Older Adult","Not Applicable","321","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","OPP1091843-1","January 2015","July 31, 2016","December 2016","August 22, 2016",,"March 22, 2017",,,"https://ClinicalTrials.gov/show/NCT02874716"
158,"NCT04271397","Immunological Biomarkers in Tuberculosis Management","OPTI-4TB","Unknown status","No Results Available","Tuberculosis|Tuberculosis Infection","Other: Multiple blood samples|Other: Single blood sample","Concordance of the kinetics of biomarkers with the evolution of the disease|Analytical characteristics of a combination of 2 IGRAs (QuantiFERON-TB Gold Plus (QFT-P) and HBHA) in the diagnosis / prognosis of tuberculosis disease.|Performance of an immunomonitoring test by mass or flow cytometry in the diagnosis / prognosis of tuberculosis by measuring the dynamics of the blood population of T lymphocytes over time.|Evaluate the performance of a test based on the interpretation of a transcriptomic signature in plasma in the diagnosis / prognosis of TB.|Assess the performance of a test based on the interpretation of a protein signature in the diagnosis / prognosis of tuberculosis.|Determine the achievement of target concentrations of rifampicin|Establish the rate of metabolic self-induction of rifampicin","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL18_0757","September 30, 2019","April 9, 2023","April 9, 2023","February 17, 2020",,"February 17, 2020","Service des Maladies Infectieuses - Hôpital de la Croix Rousse - Hospices Civils de Lyon, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04271397"
159,"NCT00595907","Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis",,"Completed","No Results Available","Tuberculosis",,"Interferon gamma response to M. tuberculosis antigens by peripheral lymphocytes after treatment for tuberculosis","University Hospital, Geneva|Ligue Pulmonaire Genevoise","All","18 Years and older   (Adult, Older Adult)",,"89","Other","Observational","Time Perspective: Prospective","Janssens1/2008","October 2004","July 2006","July 2006","January 16, 2008",,"January 16, 2008","Centre antituberculeux; Geneva University Hospital, Geneva, Geneva 14, Switzerland",,"https://ClinicalTrials.gov/show/NCT00595907"
160,"NCT00730795","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults",,"Completed","No Results Available","Tuberculosis (TB)","Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342","Occurrence of dose limiting toxicity|Occurrence of serious adverse events|Occurrence of adverse events|Laboratory measurements of serum chemistry and hematology|Resting vital signs (blood pressure, pulse, temperature)|Chest X-ray findings|Evaluation of T cell and antibody responses to the fusion protein and to each of the three Mycobacterium tuberculosis antigen domains.|Evaluation of PPD skin reactivity","GlaxoSmithKline|Corixa Corporation","All","18 Years to 40 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","692342/001|CCTB001-01","January 2004","December 2004",,"August 8, 2008",,"August 8, 2008","GSK Clinical Trials Call Center, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00730795"
161,"NCT06081361","Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","INSPIRE-CODA","Recruiting","No Results Available","Pulmonary Tuberculosis|Rifampicin-resistant Tuberculosis","Drug: Bedaquiline|Drug: Delamanid|Drug: Contezolid|Drug: Levofloxacin|Drug: Moxifloxacin|Drug: Clofazimine|Drug: Linezolid|Drug: Cycloserine|Drug: Prothionamide|Drug: Pyrazinamide|Drug: Para-Aminosalicylic Acid|Drug: Ethambutol","Favourable outcome rate at 24 months after randomization|Unfavourable outcome rate at 24 months after randomization|Time to culture conversion|Grade 3 or higher adverse event rate","Beijing Chest Hospital|National Medical Center for Infectious Diseases","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BJCH-202301","December 22, 2023","October 1, 2026","December 31, 2026","October 13, 2023",,"March 15, 2024","Beijing Chest Hospital affiliated to Capital Medical University, Beijing, Beijing, China|Hebei Chest Hospital, Shijiazhuang, Hebei, China|Harbin Chest Hospital, Harbin, Heilongjiang, China|Infectious Disease Hospital of Hulunbuir, Hulunbuir, Inner Mongolia, China|Qingdao Chest Hospital, Qingdao, Shandong, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|The 8th Medical Center of Chinese Pla General Hospital, Beijing, China|Changsha Central Hospital, Changsha, China|Hunan Province Chest Hospital, Changsha, China|Chongqing Public Heath Treatment Center, Chongqing, China|Dalian Public Health Center, Dalian, China|Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China|Guangzhou Chest Hospital, Guangzhou, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, China|Second Affiliated Hospital of Hainan Medical University, Haikou, China|Hangzhou Red Cross Hospital, Hangzhou, China|Anhui Chest Hospital, Hefei, China|Second People's Hospital of Hohhot, Hohhot, China|Jiamusi Infectious Disease Hospital, Jiamusi, China|Jiamusi Tumor Hospital, Jiamusi, China|Jilin Tuberculosis Hospital, Jilin, China|People's Hospital of Linyi, Linyi, China|Second Hospital of Nanjing, Nanjing, China|Fourth People's Hospital of Nanning, Nanning, China|Guangxi Chest Hospital, Nanning, China|Shandong public health clinical center, Shandong, China|National Medical Center for Infectious Disease, Shanghai, China|Affiliated Hospital of Shaoxing University, Shaoxing, China|Shenyang Chest Hospital, Shenyang, China|Shijiazhuang Fifth Hospital, Shijiazhuang, China|Tianjin Haihe Hospital, Tianjin, China|Second People's Hospital of Weifang, Weifang, China|Wuhan Institute For Tuberculosis Control, Wuhan, China|Xi'an Chest Hospital, Xi'an, China|First Affiliated Hospital of Xiamen Medical University, Xiamen, China|The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China|Henan Provincial Chest Hospital, Zhengzhou, China|Affiliated Hospital of Zunyi Medical University, Zunyi, China|The 8th Affiliated Hospital of Xinjiang Medical University, Ürümqi, China",,"https://ClinicalTrials.gov/show/NCT06081361"
162,"NCT03057756","Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance","TB-MR","Unknown status","No Results Available","Multi-drug Resistant Tuberculosis","Combination Product: Km+ Mfx+ Pto + H + Cfz +E+Z","cure rate post treatment|TB-culture|Regimen tolorability|Adverse events","Centre de Recherche Médicale de Lambaréné|Institute of Tropical Medicine, University of Tuebingen|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","15 Years and older   (Child, Adult, Older Adult)",,"23","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TB-MR 001/2015","September 11, 2015","April 4, 2023","July 1, 2023","February 20, 2017",,"July 27, 2021","Centre de Recherches Médicales de Lambaréné, Lambarene, Please Select, Gabon",,"https://ClinicalTrials.gov/show/NCT03057756"
163,"NCT02581579","Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection",,"Completed","No Results Available","Tuberculosis","Dietary Supplement: Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Other: Placebo","Change from Baseline in Specific Treg memory cells at week 1|Proportion of patients presenting adverse events related to study treatment.|Proportion of participants presenting gastrointestinal adverse events related to study treatment.|Proportion of participants presenting systemic adverse events related to study treatment.","Manresana de Micobacteriologia, SL","All","2 Years to 17 Years   (Child)","Not Applicable","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","NYADAPETRICS","December 9, 2015","March 6, 2019","March 6, 2019","October 21, 2015",,"December 4, 2019","Germans Trias I Pujol Hospital, Badalona, Barcelona, Spain|Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain|Valle Hebron Hospital, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02581579"
164,"NCT06062238","Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults",,"Recruiting","No Results Available","Tuberculosis","Biological: M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine|Biological: Placebo","IGRA-Positive Cohort: Number of participants with laboratory-confirmed pulmonary tuberculosis (TB)|IGRA-Negative Cohort: Number of participants with sustained QuantiFERON®-TB Gold Plus assay conversion|IGRA-Negative Cohort: Number of participants with laboratory-confirmed pulmonary TB|HIV Cohort: Number of participants with laboratory-confirmed pulmonary TB|IGRA-Positive Cohort: Number of participants with laboratory-confirmed pulmonary TB (Less stringent laboratory-confirmed pulmonary TB case definition)|All Cohorts: Number of participants with solicited adverse events (AEs)|All Cohorts: Number of participants with unsolicited AEs|All Cohorts: Number of participants with serious adverse events (SAEs)|All Cohorts: Number of participants with potential immunemediated diseases (pIMDs)|All Cohorts: Number of participants with SAEs related to trial participation|All cohorts: Number of participants with geometric mean concentration (GMC) of M72-specific antibodies|All cohorts: Number of participants with seropositivity of M72-specific antibodies","Bill & Melinda Gates Medical Research Institute|Wellcome Trust|Bill and Melinda Gates Foundation","All","15 Years to 44 Years   (Child, Adult)","Phase 3","20000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gates MRI-TBV02-301","March 5, 2024","April 2028","April 2028","October 2, 2023",,"March 20, 2024","Gates MRI Investigational Site, Bandung, Indonesia|Gates MRI Investigational Site, Depok, Indonesia|Gates MRI Investigational Site, Jakarta, Indonesia|Gates MRI Investigational Site, Jakarta, Indonesia|Gates MRI Investigational Site, Jakarta, Indonesia|Gates MRI Investigational Site, Ahero, Kenya|Gates MRI Investigational Site, Eldoret, Kenya|Gates MRI Investigational Site, Kericho, Kenya|Gates MRI Investigational Site, Kilifi, Kenya|Gates MRI Investigational Site, Kisumu, Kenya|Gates MRI Investigational Site, Machakos, Kenya|Gates MRI Investigational Site, Mombasa, Kenya|Gates MRI Investigational Site, Nairobi, Kenya|Gates MRI Investigational Site, Nairobi, Kenya|Gates MRI Investigational Site, Chichiri, Malawi|Gates MRI Investigational Site, Lilongwe, Malawi|Gates MRI Investigational Site, Manhica, Mozambique|Gates MRI Investigational Site, Maputo, Mozambique|Wits RHI - Shandukani Research, Hillbrow, Gauteng, South Africa|Gates MRI Investigational Site, Bloemfontein, South Africa|Gates MRI Investigational Site, Brits, South Africa|Gates MRI Investigational Site, Cape Town, South Africa|Gates MRI Investigational Site, Cape Town, South Africa|Gates MRI Investigational Site, Cape Town, South Africa|Gates MRI Investigational Site, Cape Town, South Africa|Gates MRI Investigational Site, Cape Town, South Africa|Gates MRI Investigational Site, Cape Town, South Africa|Gates MRI Investigational Site, Cape Town, South Africa|Gates MRI Investigational Site, Durban, South Africa|Gates MRI Investigational Site, Durban, South Africa|Gates MRI Investigational Site, Durban, South Africa|Gates MRI Investigational Site, East London, South Africa|Gates MRI Investigational Site, Johannesburg, South Africa|Gates MRI Investigational Site, Johannesburg, South Africa|Gates MRI Investigational Site, Johannesburg, South Africa|Gates MRI Investigational Site, Johannesburg, South Africa|Gates MRI Investigational Site, Jouberton, South Africa|Gates MRI Investigational Site, Kimberley, South Africa|Gates MRI Investigational Site, Klerksdorp, South Africa|Gates MRI Investigational Site, Ladysmith, South Africa|Gates MRI Investigational Site, Middelburg, South Africa|Gates MRI Investigational Site, Mtubatuba, South Africa|Gates MRI Investigational Site, Paarl, South Africa|Gates MRI Investigational Site, Port Elizabeth, South Africa|Gates MRI Investigational Site, Pretoria, South Africa|Gates MRI Investigational Site, Rustenburg, South Africa|Gates MRI Investigational Site, Soweto, South Africa|Gates MRI Investigational Site, Soweto, South Africa|Gates MRI Investigational Site, Soweto, South Africa|Gates MRI Investigational Site #1, Tembisa, South Africa|Gates MRI Investigational Site, Tembisa, South Africa|Gates MRI Investigational Site, Vereeniging, South Africa|Gates MRI Investigational Site, Worcester, South Africa|Gates MRI Investigational Site, Hanoi, Vietnam|Gates MRI Investigational Site #1, Ho Chi Minh City, Vietnam|Gates MRI Investigational Site #2, Ho Chi Minh city, Vietnam|Gates MRI Investigational Site, Ho Chi Minh city, Vietnam|Gates MRI Investigational Site #1, Lusaka, Zambia|Gates MRI Investigational Site #2, Lusaka, Zambia|Gates MRI Investigational Site, Lusaka, Zambia|Gates MRI Investigational Site, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT06062238"
165,"NCT03080012","Salivary Therapeutic Drug Monitoring of Anti-Tuberculosis Drugs",,"Completed","No Results Available","Tuberculosis","Other: Saliva sampling|Other: Plasma/serum sampling","Saliva-plasma ratio or saliva-serum ratio|Salivary drug concentration|Plasma/serum drug concentration|Area under the time-concentration curve (AUC) in saliva and plasma/serum|Peak concentration (Cmax) in saliva and plasma/serum|Time of peak concentration (Tmax) in saliva and plasma/serum|Trough concentration (Cmin) in saliva and plasma/serum|Clearance (Cl) in saliva and plasma/serum|Half-life (t1/2) in saliva and plasma/serum|Elimination constant (Kel) in saliva and plasma/serum","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SALIV-01","March 7, 2017","May 2, 2018","May 2, 2018","March 15, 2017",,"November 21, 2018","University Medical Center Groningen (UMCG) Beatrixoord, Haren, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03080012"
166,"NCT00982969","The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis",,"Completed","No Results Available","Tuberculosis",,,"Armed Forces Capital Hospital, Republic of Korea","Male","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","QFTinROKmilitary","June 2008","October 2009","April 2010","September 23, 2009",,"July 20, 2010","Armed Forces Capital Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00982969"
167,"NCT01994460","Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis",,"Unknown status","No Results Available","Pulmonary Tuberculosis Without Resistance to Rifampicin","Drug: Linezolid|Drug: Ethambutol","Sputum culture conversion rate on liquid media|Sputum culture conversion rate on solid media|Time to sputum culture conversion (liquid and solid media)|Cure rate|Treatment success rate","Seoul National University Hospital|Ministry of Health & Welfare, Korea|SMG-SNU Boramae Medical Center|Seoul National University Bundang Hospital|Pfizer","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","429","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J-1310-026-523","January 2014","December 2015","June 2016","November 25, 2013",,"December 30, 2014","Seoul National University Bundang Hospital, Seongnam, Kyunggi, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01994460"
168,"NCT03787914","Effect of Community Mobile Outreach Approach Compared to Facility Based Directly Observed Treatment Short Course on Treatment Outcome Among Tuberculosis Patients in Jeddah: A Randomized Controlled Trial",,"Completed","No Results Available","Tuberculosis","Procedure: Mobile Outreach Approach","Treatment Success rate","Ministry of Health, Saudi Arabia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","H-02-J-002-00877","November 1, 2017","November 1, 2018","November 1, 2018","December 26, 2018",,"December 27, 2018","Ministry of Health, Jeddah, Makkah, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT03787914"
169,"NCT03074799","Nurse-Led, Symptom-Based Screening of Household Child Contacts of Tuberculosis Index Cases","SOAR","Completed","No Results Available","Tuberculosis","Other: Symptom -based Screening(Child Contacts)|Other: Clinical based Decisions","Percent of child contacts placed on IPT","Johns Hopkins University|United States Agency for International Development (USAID)","All","1 Day to 5 Years   (Child)","Not Applicable","4054","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00055079","October 1, 2015","September 15, 2018","September 15, 2018","March 9, 2017",,"March 4, 2020","PHRU, Klerksdorp, Matlosana, South Africa",,"https://ClinicalTrials.gov/show/NCT03074799"
170,"NCT00728507","Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis",,"Terminated","Has Results","Tuberculosis","Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol","To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.|To Compare the Safety and Tolerability of the 2 Intensive Phase Regimens.","Johns Hopkins University|Universidade Federal do Rio de Janeiro","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","121","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-0018","November 2009","April 2013","April 2013","August 5, 2008","April 20, 2017","April 20, 2017","Centro de Referência Professor Hélio Fraga - ENSP - FIOCRUZ, Curicica, Rio de Janeiro, Brazil|Posto de Saude Albert Sabin, Rio de Janeiro, RJ, Brazil|Hospital Universitario Clementio Fraga Filho, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00728507"
171,"NCT06192160","Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","RAD-TB","Not yet recruiting","No Results Available","Pulmonary Tuberculosis","Drug: Isoniazid|Drug: Rifampicin|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Bedaquiline|Drug: Pretomanid|Drug: Linezolid|Drug: TBI-223|Drug: Sutezolid","Difference in mean log10 (Time to positivity (TTP)) slope from longitudinal mycobacteria growth indicator tube (MGIT) liquid culture measurements over the first 6 weeks of treatment|Difference in the cumulative proportion of participants having at least one new Grade 3 or higher adverse event (AE) by week 8 of treatment|Cumulative proportion of participants with stable sputum culture conversion by week 8 as measured by culture-negative status via MGIT liquid culture at two consecutive measurements.|Mean log10 TTP slope from longitudinal MGIT liquid culture measurements over the first 8 weeks of treatment.|Cumulative proportion of participants with a new Grade 3 or higher AE by week 26 of treatment.|Cumulative proportion of participants with permanent discontinuation of study-provided anti-TB drugs due to any reason prior to Week 8 of treatment.|Cumulative proportion of participants with permanent discontinuation or temporary discontinuation for ≥3 days of at least one anti-TB drug due to any reason prior to week 8 of treatment.|Cumulative proportion of participants with permanent discontinuation of at least one anti-TB drug due to any reason prior to week 26 of treatment.|A composite of stable culture conversion at week 6 of treatment and no new Grade 3 or higher AE through week 8.|Proportion of participants with durable cure by 52 weeks after treatment initiation.","National Institute of Allergy and Infectious Diseases (NIAID)|TB Alliance","All","18 Years and older   (Adult, Older Adult)","Phase 2","315","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5409","April 15, 2024","June 10, 2025","April 14, 2026","January 5, 2024",,"January 25, 2024","12701, Gaborone CRS, Gaborone, Botswana|12201, Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil|12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio De Janeiro, Brazil|30022, Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|31730, GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince, Haiti|31441, Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, India|12601, Moi University Clinical Research Center (MUCRC) CRS, Eldoret, Kenya|12501, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS, Kericho, Kenya|30301, Blantyre CRS, Blantyre, Malawi|12001, Malawi CRS, Lilongwe, Malawi|32078, Nutrición-Mexico CRS, Mexico City, Mexico|11301, Barranco CRS, Lima, Peru|31981, De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC), Cavite, Philippines|31793, South African Tuberculosis Vaccine Initiative (SATVI) CRS, Cape Town, South Africa|31792, University of Cape Town Lung Institute (UCTLI) CRS, Cape Town, South Africa|31422, CAPRISA eThekwini CRS, Durban, South Africa|11201, Durban International CRS, Durban, South Africa|12301, Soweto ACTG CRS, Johannesburg, South Africa|11101, University of the Witwatersrand Helen Joseph (WITS HJH) CRS, Johannesburg, South Africa|31684, Rustenburg CRS, Rustenburg, South Africa|31784, Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|31802, Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Pathum Wan, Thailand|12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda|30313, Milton Park CRS, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT06192160"
172,"NCT00981071","The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure",,"Completed","No Results Available","Tuberculosis",,,"Armed Forces Capital Hospital, Republic of Korea","Male","Child, Adult, Older Adult",,"32","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","QFTconversion","May 2009","April 2010","April 2010","September 22, 2009",,"April 8, 2010",,,"https://ClinicalTrials.gov/show/NCT00981071"
173,"NCT00600782","Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region",,"Completed","No Results Available","Tuberculosis (TB)|Tuberculosis Vaccines","Biological: GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)","Occurrence, intensity and relationship to vaccination of solicited local and general symptoms|Occurrence, intensity and relationship to vaccination of unsolicited symptoms|Occurrence and relationship to vaccination of serious adverse events|Haematological and biochemical levels|Analysis of cytokine expression by M72-specific CD4+/CD8+ T cells by means of invitro flow cytometry|Antibody titres to M72 measured by ELISA","GlaxoSmithKline","All","21 Years to 40 Years   (Adult)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","110347","February 5, 2008","December 19, 2008","December 19, 2008","January 25, 2008",,"October 12, 2020","GSK Investigational Site, Worcester, Western Province, South Africa",,"https://ClinicalTrials.gov/show/NCT00600782"
174,"NCT02774993","Doxycycline in Human Pulmonary Tuberculosis","Doxy-TB","Completed","No Results Available","Tuberculosis","Drug: Doxycycline|Drug: placebo","Change of serum marker Procollagen III N-terminal peptide (PIIINP) from day 0 to day 14 in TB patients|Number of participants with treatment-related adverse events","National University Hospital, Singapore|Tan Tock Seng Hospital|National University of Singapore|A*Star","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Doxy_TB","September 2015","June 2017","June 2017","May 17, 2016",,"November 27, 2017","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02774993"
175,"NCT03026972","A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried","AEC/BC02","Completed","No Results Available","Tuberculosis","Biological: Placebo|Biological: Low dose adjuvant|Biological: High dose adjuvant|Biological: Low dose vaccine|Biological: High dose vaccine","The number of participants with Adverse Events after coxal muscle injection|Laboratory markers of immunity","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shanghai Public Health Clinical Center|Beijing Simoonrecord Pharmaceutical Information Consulting Co.,Ltd","All","18 Years to 45 Years   (Adult)","Phase 1","25","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","LTao-AEC/BC02-Ⅰ-healthy|LTao","April 16, 2018","September 4, 2018","October 30, 2019","January 20, 2017",,"March 24, 2022","Shanghai Public Health clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03026972"
176,"NCT05081401","Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","INSPIRE-TB","Recruiting","No Results Available","Multidrug Resistant Tuberculosis","Other: This is a non-intervention observational study.","End of treatment outcomes|The median time to Sputum Culture Conversion|Frequency of and time to relapse|frequency of recurrence-free survival|The frequency of and time to grade 3 or greater adverse events","Huashan Hospital","All","Child, Adult, Older Adult",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INSPIRE-TB","May 23, 2022","December 1, 2025","December 1, 2025","October 18, 2021",,"March 22, 2023","Guiyang Public Health Treatment Center, Guiyang, Guizhou, China|People's Hospital of Qiandongnan, Kaili, Guizhou, China|The Third People's Hospital of Liupanshui, Liupanshui, Guizhou, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China|Huashan Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05081401"
177,"NCT05568368","Time-to-Detection in Culture of Mycobacterium Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculoses","Other: No intervention","tuberculosis transmission|contact case tracking","Centre Hospitalier Universitaire de Nice","All","2 Years to 94 Years   (Child, Adult, Older Adult)",,"705","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","22Infectio01","March 15, 2022","September 15, 2022","September 15, 2022","October 5, 2022",,"October 5, 2022","Nice University Hospital, Nice, France",,"https://ClinicalTrials.gov/show/NCT05568368"
178,"NCT02175849","Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis","SNAP","Completed","No Results Available","Tuberculosis Infection",,"Yield of MDR-TB case detection through SNA|MDR-TB incidence among subgroups of contacts|MDR-TB incidence among rifampicin resistant TB cases|MDR-TB genotype|Cost-effectiveness ratio of SNA and passive case finding strategies","Oxford University Clinical Research Unit, Vietnam|National Tuberculosis Program, Vietnam","All","Child, Adult, Older Adult",,"596","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10TB","December 2013","September 2015","October 2015","June 26, 2014",,"November 15, 2016","National Lung Hospital, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT02175849"
179,"NCT03168945","Xpert Active Case-finding Trial 2: Community-based Active Case-finding for Tuberculosis in South Africa","XACT-2","Completed","No Results Available","Tuberculosis","Other: GeneXpert MTB/RIF|Other: Smear microscopy","The time-to-treatment of culture-positive TB cases initiating TB treatment in each study arm.|The proportion of culture-positive TB cases initiating TB treatment in each study arm.|The proportion of culture-positive TB cases completing 6-months of TB treatment in each study arm.|Accuracy of GeneXpert® Omni MTB/RIF at the point-of-care in a mobile unit.|Feasibility of performing GeneXpert® Omni MTB/RIF at the point-of-care in a mobile unit.|User adherence to methodology of GeneXpert® Omni MTB/RIF at the point-of-care in a mobile unit.|User acceptance to methodology of GeneXpert® Omni MTB/RIF at the point-of-care in a mobile unit.|Cost per TB case detected between study arms.|Cost per TB case successfully completing treatment between study arms.|To contribute data and samples as part of the RePORT consortium in order to achieve a better understanding of the prognosis of TB disease and the pathogenesis of progression from TB exposure to disease.","University of Cape Town|Medical Research Council, South Africa|National Institutes of Health (NIH)|University of Cape Town Lung Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","608","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","XACT-2|OISE-16-62105-1","November 2016","June 2020","August 2020","May 30, 2017",,"March 30, 2021","University of Cape Town, Cape Town, Western Province, South Africa",,"https://ClinicalTrials.gov/show/NCT03168945"
180,"NCT02744521","Training Inmate Peer Educators in Detecting Tuberculosis in a Developing Country Prison: A Cluster Randomized Trial",,"Unknown status","No Results Available","Tuberculosis","Other: Symptom-based screening intervention","Tuberculosis case detection rate (CDR)|Pre-treatment symptom duration|Treatment success rate (TSR)","Maastricht University|Mekelle University","All","18 Years and older   (Adult, Older Adult)","Not Applicable",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic","MaastrichtU","March 2016","April 2017",,"April 20, 2016",,"April 20, 2016",,,"https://ClinicalTrials.gov/show/NCT02744521"
181,"NCT01669096","Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342",,"Completed","Has Results","Tuberculosis","Biological: GSK Biologicals' investigational TB vaccine GSK 692342","Concentration of Specific Interferon Gamma (IFN-γ) Antibodies Secreted in Serum Samples|Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation CD4+/CD8+ T Cells Expressing at Least Two Different Immune Markers|Frequency of M72 Fusion Protein Specific Cluster of Differentiation CD4+/CD8+ T Cells Expressing at Least Two Different Immune Markers|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers (M1 to M 14)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers (M15 to M28)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers (M29 to M42)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers (M43 to M56)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers (M57 to M63)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M1 to M14)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M15 to M28)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M29 to M42)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers,Post Dose 2 (M43 to M56)|Frequency of M72 Specific Cluster of Differentiation CD4+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M57 to M63)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers (M1 to M14)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers (M15 to M28)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers (M29 to M42)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers (M43 to M56)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers (M57 to M63)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M1 to M14)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M15 to M28)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M29 to M42)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M43 to M56)|Frequency of M72 Specific Cluster of Differentiation CD8+ T Cells Expressing Any Combination of Immune Markers, Post Dose 2 (M57 to M63)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Any and Grade 3 Solicited Local Symptoms|Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Potential Immune-Mediated Disease(s) (pIMDs)","GlaxoSmithKline|Aeras","All","18 Years to 50 Years   (Adult)","Phase 2","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","116777|2012-002541-37","August 21, 2012","December 6, 2012","May 24, 2013","August 20, 2012","March 22, 2019","March 22, 2019","GSK Investigational Site, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT01669096"
182,"NCT06127641","Rehabilitation of People With Post-tuberculosis Lung Disease",,"Recruiting","No Results Available","Pulmonary Tuberculosis","Other: Standard care plus pulmonary rehabilitation|Other: Standard Care","Functional capacity using the ADL-Glittre test (TGlittre) incorporated into dynamic ventilation before and after the PR program|Clinical-functional assessment|Saint George's Respiratory Questionnaire (SGRQ)|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)|Pulmonary function measurements|Handgrip strength (HGS)|Quadriceps strength (QS)","Centro Universitário Augusto Motta|Rio de Janeiro State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","70493823.5.0000.5259","October 28, 2023","December 31, 2024","December 31, 2027","November 13, 2023",,"November 13, 2023","Agnaldo José Lopes, Rio de Janeiro, Brazil|Centro Universitario Augusto Motta, Rio De Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT06127641"
183,"NCT02875574","Improving the Management of Drug Resistant Tuberculosis in the UK","UK_DR-TB","Completed","No Results Available","Tuberculosis","Drug: Any treatment regimen|Other: Bacterial mutation","Treatment outcome","University College, London|National Institute for Health Research, United Kingdom","All","18 Years and older   (Adult, Older Adult)",,"630","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","16/0074","November 2016","December 2017","December 2017","August 23, 2016",,"December 20, 2017","Royal Free London NHS Foundation Trust, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02875574"
184,"NCT03851159","Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota",,"Recruiting","No Results Available","Tuberculosis","Dietary Supplement: Nyaditum resae®|Other: Mannitol","Gut microbiome composition in placebo versus experimental arm|Cytokine and cluster of differentiation (CD)4+ T-cell response in placebo versus experimental arm|Time to sputum conversion and reduction in bacillary load","University of Stellenbosch|Fundació Institut Germans Trias i Pujol","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","N14_10_136","May 10, 2019","December 31, 2024","December 31, 2024","February 22, 2019",,"March 28, 2024","Scottsdene Clinic, Cape Town, Western Cape, South Africa|Wallacedene Clinic, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT03851159"
185,"NCT02073669","Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults",,"Completed","No Results Available","Latent Tuberculosis","Procedure: Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)","Interferon gamma release assay ( IGRA)","Sheba Medical Center|Tel Aviv Lung Association","All","18 Years to 25 Years   (Adult)","Not Applicable","115","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","SHEBA-13-0668-DS-CTIL","March 2014","August 2018","November 2018","February 27, 2014",,"January 25, 2019","Sheba Medical Center, Ramat Gan, Israel|Israeli Defense Forces, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT02073669"
186,"NCT02684240","A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: Nitazoxanide|Other: Control","time to positivity (TTP)|Number of participants with treatment-related adverse events as determined by DAIDS toxicity tables|Maximum plasma concentration of NTZ|Most probable number of M tuberculosis in 1 ml of sputum|First-line drug susceptibility (DST) of Mycobacterium tuberculosis via Mycobacterial Growth Indicator System (MGIT)|Quantification of change in urine metabolites and correlation with change in TTP|Minimum plasma concentration of NTZ|Area under the curve of NTZ metabolites|Sputum concentration of NTZ|Change in Minimum inhibitory concentration (MIC) of NTZ against Tuberculosis over 14 days|Change in phylogeny of bacteria determined by sequencing of amplified 16S ribosomal DNA and/or metagenomic sequencing of bacterial DNA|Transcriptional signature of treatment response using whole blood transcriptional profiles","Weill Medical College of Cornell University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1302013616","February 2016","April 11, 2018","April 11, 2018","February 17, 2016",,"August 5, 2020","Les Centres GHESKIO, Port-au-Prince, Haiti",,"https://ClinicalTrials.gov/show/NCT02684240"
187,"NCT05586230","Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis",,"Recruiting","No Results Available","Tuberculosis|Rifampicin Resistant Tuberculosis","Drug: Pretomanid|Drug: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB","AUC0-∞|CL/F|AUC0-tlast|AUC0-48|Tmax|Cmax|Number of participants with an adverse event|Number of participants with a Grade 3 or higher adverse event assessed as related to study drug|Number of participants with a grade 2 or higher adverse event|Number of participants with a serious adverse event|Aggregated data on parent/guardian and/or participant (and/or study staff) reported palatability and acceptability of study drug given as single dose at entry","National Institute of Allergy and Infectious Diseases (NIAID)|Global Alliance for TB Drug Development|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","Female","up to 17 Years   (Child)","Phase 1","72","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT 2034|38754","October 3, 2023","January 31, 2026","January 31, 2026","October 19, 2022",,"February 7, 2024","Site 5071, Instituto de Puericultura e Pediatria Martagao Gesteira CRS, Rio De Janeiro, Brazil|Site 31441, BJMC CRS, Pune, India|Site 31976, PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa|Site 31790, Desmond Tutu TB Centre (DTTC) CRS, Cape Town, South Africa|Site 31929, Sizwe CRS, Johannesburg, South Africa|Site 5118, Kilimanjaro Christian Medical Center (KCMC), Moshi, Tanzania|Site 5115, Siriraj Hospital, Mahidol University NICHD CRS, Bangkok Noi, Thailand",,"https://ClinicalTrials.gov/show/NCT05586230"
188,"NCT05443178","Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy",,"Recruiting","No Results Available","Tuberculosis Infection","Drug: Nivaquine ® (Chloroquine)","Physicial examination 1.1|Physicial examination 1.2|Physicial examination 2.1|Physicial examination 2.2|Physicial examination 3.1|Physicial examination 3.2|Physicial examination 4.1|Physicial examination 4.2|Physicial examination 5.1|Physicial examination 5.2|Physicial examination 6.1|Physicial examination 6.2|Vital Signs 1.1|Vital Signs 1.2|Vital Signs 1.3|Vital Signs 1.4|Vital Signs 1.5|Vital Signs 2.1|Vital Signs 2.2|Vital Signs 2.3|Vital Signs 2.4|Vital Signs 2.5|Vital Signs 3.1|Vital Signs 3.2|Vital Signs 3.3|Vital Signs 3.4|Vital Signs 3.5|Safety Laboratory samples Panel 1.1|Safety Laboratory samples Panel 1.2|Safety Laboratory samples Panel 1.3|Safety Laboratory samples Panel 1.4|Safety Laboratory samples Panel 2.1|Safety Laboratory samples Panel 2.2|Safety Laboratory samples Panel 2.3|Safety Laboratory samples Panel 2.4|Safety Laboratory samples Panel 3.1|Safety Laboratory samples Panel 3.2|Safety Laboratory samples Panel 3.3|Safety Laboratory samples Panel 3.4|Safety Laboratory samples Panel 4.1|Safety Laboratory samples Panel 4.2|Safety Laboratory samples Panel 4.3|Safety Laboratory samples Panel 4.4|Safety Laboratory samples Panel 5.1|Safety Laboratory samples Panel 5.2|Safety Laboratory samples Panel 5.3|Safety Laboratory samples Panel 5.4|Safety Laboratory samples Panel 6.1|Safety Laboratory samples Panel 6.2|Safety Laboratory samples Panel 6.3|Safety Laboratory samples Panel 6.4|Safety Laboratory samples Panel 7.1|Safety Laboratory samples Panel 7.2|Safety Laboratory samples Panel 7.3|Safety Laboratory samples Panel 7.4|Safety Laboratory samples Panel 8.1|Safety Laboratory samples Panel 8.2|Safety Laboratory samples Panel 8.3|Safety Laboratory samples Panel 8.4|Safety Laboratory samples Panel 9.1|Safety Laboratory samples Panel 9.2|Safety Laboratory samples Panel 9.3|Safety Laboratory samples Panel 9.4|Safety Laboratory samples Panel 10.1|Safety Laboratory samples Panel 10.2|Safety Laboratory samples Panel 10.3|Safety Laboratory samples Panel 10.4|Safety Laboratory samples Panel 11.1|Safety Laboratory samples Panel 11.2|Safety Laboratory samples Panel 11.3|Safety Laboratory samples Panel 11.4|Safety Laboratory samples Panel 12.1|Safety Laboratory samples Panel 12.2|Urinanalysis 1.1|Urinanalysis 1.2|Urinanalysis 1.3|Urinanalysis 1.4|Urinanalysis 2.1|Urinanalysis 2.2|Urinanalysis 2.3|Urinanalysis 2.4|Urinanalysis 3.1|Urinanalysis 3.2|Urinanalysis 3.3|Urinanalysis 3.4|Urinanalysis 4.1|Urinanalysis 4.2|Urinanalysis 4.3|Urinanalysis 4.4|Safety 12 lead ECG 1.1|Safety 12 lead ECG 1.2|Safety 12 lead ECG 2.1|Safety 12 lead ECG 2.2|Safety 12 lead ECG 3.1|Safety 12 lead ECG 3.3|Safety 12 lead ECG 4.1|Safety 12 lead ECG 4.2|Safety 12 lead ECG 5.1|Safety 12 lead ECG 5.2|Safety ophtalmological examination 1.1|Safety ophtalmological examination 1.2|Safety ophtalmological examination 1.3|Safety ophtalmological examination 1.4|Safety ophtalmological examination 1.5|Occurence of adverse events and serious adverse events 1.1|Occurence of adverse events and serious adverse events 1.2|Occurence of adverse events and serious adverse events 1.3|Occurence of adverse events and serious adverse events 1.4|Occurence of adverse events and serious adverse events 1.5|Occurence of adverse events and serious adverse events 1.6|Drug concentration over time measured by the pharmacokinetics","University of Zurich","All","18 Years to 50 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Clear TB","January 4, 2022","July 4, 2024","December 1, 2024","July 5, 2022",,"December 14, 2023","Clinical Trial Center, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT05443178"
189,"NCT05640648","Human-centered Design and Communities of Practice to Improve Delivery of Home-based Tuberculosis Contact Investigation in Uganda","HCD CoP","Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary","Behavioral: User-Centered Implementation Strategy|Behavioral: Standard Implementation Strategy","Completion of TB Evaluation|TB Yield (symptomatic contacts)|Initiation of TB Preventative Therapy|Number of contacts diagnosed with active TB|Number of contacts initiating TB Preventative Therapy|TB Yield (all contacts)","Yale University|National Institute of Allergy and Infectious Diseases (NIAID)|National Heart, Lung, and Blood Institute (NHLBI)","All","Child, Adult, Older Adult","Not Applicable","10477","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Screening","R01AI104824|5R01AI104824|2000023199","March 7, 2022","October 26, 2023","October 26, 2023","December 7, 2022",,"March 4, 2024","Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT05640648/Prot_002.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT05640648/SAP_003.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT05640648/ICF_004.pdf","https://ClinicalTrials.gov/show/NCT05640648"
190,"NCT01424670","Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis",,"Completed","Has Results","Multidrug-resistant Tuberculosis","Drug: Delamanid + OBR|Drug: Placebo + OBR","Time To Sputum Culture Conversion (SCC) During 6-Month Intensive Period Using The Mycobacteria Growth Indicator Tube (MGIT) System|Proportion of Participants With SCC At 2 And 6 Months Using MGIT|Proportion of Participants With Sustained SCC At Month 18, Month 24, And Month 30 Using MGIT|Treatment Outcomes Assessed By Principal Investigators (PI)At The End Of Treatment With OBR|Number of Participants Who Developed Resistance To Delamanid|Mean (Time Averaged) Area Under The Curve (AUC) Of Change From Baseline In Time To Detection (TTD) To Month 6 Using MGIT|Mean Change From Baseline In TTD Using The MGIT System|Proportion of Participants With Final Outcome At Month 30 As A Treatment Success Or Failure (Including Relapse) Using MGIT","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 3","511","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","242-09-213","September 2, 2011","July 4, 2016","July 4, 2016","August 29, 2011","May 15, 2019","May 15, 2019","Tartu, Estonia|Riga, Latvia|Siauliai, Lithuania|Vilnius, Lithuania|Chisinau, Moldova, Republic of|Vorniceni, Moldova, Republic of|Alfonso Ugarte, Peru|Comas, Peru|El Agustino, Peru|Lima Cercado, Peru|Dasmariñas, Cavite, Philippines|Quezon City, Metro Manila, Philippines|Makati City, Philippines|Quezon City, Philippines|Cape Town, South Africa|Durban, South Africa|Klerksdorp, South Africa",,"https://ClinicalTrials.gov/show/NCT01424670"
191,"NCT05022862","Economic Incentives and vDOT for Latent Tuberculosis Infection",,"Recruiting","No Results Available","Latent Tuberculosis","Behavioral: Usual Care|Behavioral: Video Directly Observed Therapy alone|Behavioral: Video Directly Observed Therapy plus Financial Incentives","Treatment Completion|Adherence measurements|Treatment completion (alternative definition)|Costs of the incentive intervention|Cost-effectiveness of the incentive intervention","Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","399","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00183013|R01AI162888","February 7, 2022","April 15, 2026","October 15, 2026","August 26, 2021",,"January 5, 2024","Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05022862"
192,"NCT04694586","Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","HIGHSHORT-RP","Suspended","No Results Available","Tuberculosis, Pulmonary","Drug: rifampicin|Drug: pyrazinamide|Drug: HRZE|Drug: HR","Area under the plasma concentration-time curve (AUC) of 40 mg/kg PZA in a high-dose RIF regimen compared with standard-of-care|Safety of 35 mg/kg RIF and 40 mg/kg PZA compared with standard-of-care: AE and SAE|Peak Plasma Concentration (Cmax) of 40 mg/kg PZA in a high-dose RIF regimen compared with standard-of-care|Area under the plasma concentration-time curve (AUC) of high-dose RIF in combination with PZA 40 mg/kg compared with standard-of-care|Peak Plasma Concentration (Cmax) of high-dose RIF in combination with PZA 40 mg/kg compared with standard-of-care|Drug exposure of PZA 40 mg/kg in relation to Mtb drug-susceptibility level (MIC) compared with standard-of-care and literature-derived suggested PK/PD targets|Drug exposure of RIF 35 mg/kg in relation to Mtb drug-susceptibility level (MIC) compared with standard-of-care and literature-derived suggested PK/PD targets|Prediction of PZA pharmacokinetics at steady state (Day 14) based on drug concentration measurement at treatment Day 1|Prediction of RIF pharmacokinetics at steady state (Day 14) based on drug concentration measurement at treatment Day 1","University Hospital, Linkoeping|Linkoeping University","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-003721-25","November 30, 2022","May 31, 2024","May 31, 2026","January 5, 2021",,"January 5, 2024","Linköping University Hospital, Linköping, Sweden",,"https://ClinicalTrials.gov/show/NCT04694586"
193,"NCT02381470","Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Faropenem|Drug: Amoxicillin/clavulanic acid|Drug: Cefadroxil|Drug: Rifampicin","Rate of change of time to positivity (TTP) in liquid culture from day 0 to day 2|Rate of change of TTP in liquid culture from day 0 to day 7|Change in CFU/ml in solid culture from Day 0 to Day 2|Change in CFU/ml in solid culture from Day 0 to Day 7","National University Hospital, Singapore","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Faropenem_TB","February 11, 2019","September 28, 2019","October 2, 2019","March 6, 2015",,"March 23, 2020","De La Salle Health Institute, Cavite, Philippines|Tropical Disease Foundation, Makati City, Philippines|Lung Center Philippines, Quezon City, Philippines|National University Hospital, Singapore, Singapore, Singapore|Infectious Diseases Institute, Kampala, Uganda|Joint Clinical Research Centre, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT02381470"
194,"NCT04504851","Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct","ROSETTA","Unknown status","No Results Available","Pulmonary Tuberculosis","Drug: Rosuvastatin 10mg|Drug: Rifampicin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Ethambutol","Time to culture conversion in Liquid Media|Time to culture conversion in Solid media|Time to culture conversion in Liquid media|Sputum culture negative in Liquid media|Sputum culture negative in Solid media|Change in time to positivity (TTP)|Change in proportion of lung affected on CXR|Change in the aggregate cavity size on CXR|Change in score on St George's Respiratory Questionnaire (SGRQ)|Change in FEV1/FVC|One or more Grade 3 or Grade 4 adverse events|One of more Serious Adverse Events (SAEs)","National University Hospital, Singapore","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROSETTA","August 12, 2020","March 31, 2021","March 31, 2021","August 7, 2020",,"August 7, 2020","Tropical Disease Foundation, Makati City, Philippines|De La Salle Health Sciences Institute, Manila, Philippines|Lung Center Philippines, Quezon City, Philippines|National University Hospital, Singapore, Singapore, Singapore|Joint Clinical Research Centre, Kampala, Uganda|Vietnam Military Medical University, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04504851"
195,"NCT04098341","Screening for Tuberculosis in Pregnancy","STOP","Active, not recruiting","No Results Available","Latent Tuberculosis","Diagnostic Test: IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection","Uptake of screening for LTBI in antenatal care assessed by calculating the percentage of patients who accepted LTBI screening.|Offer of IGRA blood test screening by healthcare providers assessed by the percentage of eligible women who were offered a test.|Process outcomes for the feasibility study|Disease related outcomes|Acceptability outcomes|Knowledge of disease related outcomes|Cost effectiveness outcomes","Queen Mary University of London|University College, London|City, University of London|Imperial College London","Female","16 Years to 35 Years   (Child, Adult)","Not Applicable","310","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IRAS247388 REC19/LO/0557","July 3, 2019","October 31, 2020","May 31, 2023","September 23, 2019",,"January 13, 2023","Royal London Hospital, London, Essex, United Kingdom|Whipps Cross Hospital, London, Essex, United Kingdom|Newham University Hospital, London, Essex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04098341"
196,"NCT04232618","Point-of-care Triage Test for Active Tuberculosis","TriageTB","Unknown status","No Results Available","Tuberculosis|Tuberculosis, Pulmonary","Diagnostic Test: Multi-biomarker point-of-care test","Global diagnostic bio-signature for diagnosing active TB|Use of MBT for treatment response","University of Stellenbosch|London School of Hygiene and Tropical Medicine|Makerere University|Find|Leiden University Medical Center|Medical Research Council Unit, The Gambia|LINQ Management GMBH","All","15 Years to 70 Years   (Child, Adult, Older Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIA2018D-2499","November 5, 2020","September 2023","March 2024","January 18, 2020",,"January 25, 2022","Stellenbosch University, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04232618"
197,"NCT03027154","Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children",,"Completed","No Results Available","Tuberculosis Diagnosis","Biological: ESAT6-CFP10 in left arm and TB-PPD in right arm|Biological: ESAT6-CFP10 in right arm and TB-PPD in left arm","The diameter of induration or redness at the injection sites measured transversely to the long axis of the forearm 24 hours、48 hours and 72 hours after application of the agents|Number of participants with Adverse Events","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shanghai Public Health Clinical Center|Beijing Children's Hospital|Wuhan Institute for Tuberculosis Control|Wuhan Union Hospital, China","All","up to 17 Years   (Child)","Phase 3","96","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","LTao-EC III-children","October 2016","October 2017","March 2018","January 23, 2017",,"April 12, 2018","Wuhan Medical Treatment Center, Wuhan, Hubei, China|Beijing Children's Hospital, Beijing, China|Shanghai Public Health Clinical Center, Shanghai, China|Wuhan Institute for Tuberculosis Control, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT03027154"
198,"NCT00694629","TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: rifampin|Drug: rifapentine","The proportion of patients, by regimen, having negative sputum cultures at completion of eight weeks (40 doses) of treatment|The proportion of patients, by regimen, who permanently discontinue the assigned study treatment for any reason during the first eight weeks|time to culture-conversion|proportion of patients with any Grade 3 or 4 adverse reactions|correlation of the MGIT/BACTEC liquid culture growth index and other mycobacterial and clinical biomarkers with time to culture conversion and treatment failure|compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients|• To determine the tolerability and safety, and estimate the antimicrobial activity, of experimental regimens that include higher doses of rifapentine.","Centers for Disease Control and Prevention|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","865","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDC-NCHSTP-5399","December 2008","June 2013","December 2013","June 10, 2008",,"May 8, 2014","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of Southern California Medical Center, Los Angeles, California, United States|University of California at San Diego, San Diego, California, United States|University of California, San Francincisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital, Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|Veterans Administration Tennessee Valley Health Care System, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Veterans Administration Medical Center, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|Hopital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil|University of Manitoba, Winnepeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada|Nelson R Mandela School of Medicine, Durban, KwaZulu Natal, South Africa|Agencia de Salut Publica, Barcelona, Spain|Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00694629"
199,"NCT05428124","Poor In Vitro Fertilisation Outcomes in Genital Tuberculosis - Case Report",,"Completed","No Results Available","Tuberculosis, Female Genital|Fertility Disorders","Other: In vitro fertilisation","Live birth rate|Clinical pregnancy rate","Universitas Padjadjaran","Female","Child, Adult, Older Adult",,"7","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","OBGY-202206.01","January 1, 2014","June 30, 2021","July 31, 2021","June 22, 2022",,"June 22, 2022",,,"https://ClinicalTrials.gov/show/NCT05428124"
200,"NCT04052022","Paradoxical Tuberculosis Reactions in Patients Without HIV Infection",,"Recruiting","No Results Available","Tuberculosis",,"Immunologic and radiographic responses of TB patients with suspected paradoxical reactions.|Biomarkers and/or microbiologic burden correlate with paradoxical TB reactions.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"70","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","190133|19-I-0133","December 20, 2019","April 30, 2029","April 30, 2029","August 9, 2019",,"January 30, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04052022"
201,"NCT04397536","New Genomic Techniques and Management of Multidrug-resistant Tuberculosis","GENO-MDR","Unknown status","No Results Available","Multi-Drug Resistant Tuberculosis",,"Sensitivity for the detection of bedaquiline resistance|Performances (deadlines to obtain results, sensitivity, specificity) to identify the species within the tuberculosis complex, and to diagnose resistance to anti-tuberculosis drugs|Number of anti-tuberculosis days|Performances (sensitivity, specificity) of the WGS strategy by using different pipelines|Number of laboratory procedures|Costs of personal time and laboratory procedures","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"172","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP190613","August 29, 2020","September 1, 2022","December 1, 2022","May 21, 2020",,"March 29, 2022","Pitié Salpêtrière Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04397536"
202,"NCT02795260","Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)",,"Completed","No Results Available","Tuberculosis","Biological: Bacillus Calmette - Guerin|Biological: placebo of Bacillus Calmette - Guerin","Number of study population III Negative for Reaction at 24 hours After intradermal injection with EC or TB-PPD|Number of study population III Negative for Reaction at 48 hours After intradermal injection with EC or TB-PPD|the number of participants with Adverse Events after Intradermal injection","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Air Force Military Medical University, China|Proswell Medical Corporation|Jiangsu Province Centers for Disease Control and Prevention|Jurong Centers for Disease Control and Prevention","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1802","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","EC-III-healthy","May 2016","October 2016","October 2016","June 10, 2016",,"October 1, 2020",,,"https://ClinicalTrials.gov/show/NCT02795260"
203,"NCT03730181","Tuberculosis Clinical Trials Consortium Study 35",,"Recruiting","No Results Available","Latent Tuberculosis","Drug: Rifapentine|Drug: Isoniazid","Rifapentine exposure among participants by median area under the curve (AUC)|Number of participants with Grade 3 or 4 adverse events|Proportion of participants with Grade 3 or 4 adverse events|Number of participants who discontinue study drug due to an adverse event|Proportion of participants who discontinue study drug due to an adverse event|Estimation of rifapentine absorption rate constant (ka) from plasma drug levels|Estimation of rifapentine volume of distribution (Vd) from plasma drug levels|Estimation of rifapentine oral clearance (Cl/F) from plasma drug levels|Post-hoc Bayesian prediction of rifapentine and metabolite peak concentration (Cmax)|Post-hoc Bayesian prediction of rifapentine and metabolite time to peak concentration (Tmax)|Post-hoc Bayesian prediction of rifapentine and metabolite area-under-the-curve (AUC0-24)|Post-hoc Bayesian prediction of rifapentine and metabolite half life (t 1/2)|Palatability scores|Acceptability scores|Incidence of tuberculosis|Estimation of isoniazid absorption rate constant (ka) from plasma drug levels|Estimation of isoniazid volume of distribution (Vd) from plasma drug levels|Estimation of isoniazid oral clearance (Cl/F) from plasma drug levels|Post-hoc Bayesian prediction of isoniazid peak concentration (Cmax)|Post-hoc Bayesian prediction of isoniazid time to peak concentration (Tmax)|Post-hoc Bayesian prediction of isoniazid area-under-the-curve (AUC0-24)|Post-hoc Bayesian prediction of isoniazid half life (t 1/2)","Centers for Disease Control and Prevention|University of Stellenbosch|Johns Hopkins University|Sanofi|University of Cape Town|Chris Hani Baragwanath Academic Hospital|Washington D.C. Veterans Affairs Medical Center","All","0 Years to 12 Years   (Child)","Phase 1|Phase 2","72","U.S. Fed|Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","6993","October 12, 2019","July 2024","December 2024","November 5, 2018",,"September 1, 2023","Desmond Tutu TB Center, University of Stellenbosch, Stellenbosch, South Africa",,"https://ClinicalTrials.gov/show/NCT03730181"
204,"NCT04453293","Immunization With BCG Vaccine to Prevent Tuberculosis Infection","TIPI","Recruiting","No Results Available","Tuberculosis Infection","Biological: BCG (Tokyo 172) vaccine|Drug: Placebo","Change in TB IGRA blood test results from baseline pre-travel and post-travel return|Number of Participants with sustained conversion and reversion in the TB IGRA converters|Number of Participants with history of TB disease/symptoms while deployed|Identify potential risk factors for Mtb infection in the targeted study population collected on Post-Travel Questionnaire|Number of Participants with treatment-related adverse effects following intradermal administration of BCG vaccine|Number of Participants with self-reported symptoms of all-cause respiratory infections acquired while traveling abroad","Henry M. Jackson Foundation for the Advancement of Military Medicine|United States Department of Defense|Uniformed Services University of the Health Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2000","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2019-01|BAA 170090","December 1, 2021","May 14, 2025","May 14, 2025","July 1, 2020",,"April 28, 2023","The UAB Alabama Vaccine Research Clinic, Birmingham, Alabama, United States|Yale University, New Haven, Connecticut, United States|Hope Clinic of the Emory University Vaccine Center, Emory University, Decatur, Georgia, United States|The Brigham and Women's Hospital Center for Clinical Investigation, Boston, Massachusetts, United States|PENN Prevention Unit, University of Pennsylvania Division of Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|JBR Clinical Research, Salt Lake City, Utah, United States","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT04453293/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04453293"
205,"NCT00130247","Tuberculosis Treatment Shortening Trial",,"Completed","Has Results","Tuberculosis","Drug: Ethambutol|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Rifampin","Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat|Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol|Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Intention to Treat|Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Per Protocol|Relapses at 1 and 2 Years|Acquired Drug Resistance in Patients Who Relapsed|Immunologic: Changes in Cytokine Levels in Mycobacterium Tubercolosis (MTB) Antigen-stimulated Whole Blood Culture Supernatants - Results Are Pending|Immunologic: Store Peripheral Blood Mononuclear Cells (PBMC) - Results Are Pending|Immunologic: Changes in Sputum Cytokine Levels - Results Are Pending|Microbiologic: Changes in Sputum Mycobacterial mRNA - Results Are Pending|Microbiologic: Time After Inoculation Until Culture Positive in BACTEC 460 or MGIT 960 Enriched Liquid Media After 2 Months in Treatment - Results Are Pending","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 60 Years   (Adult)","Phase 3","394","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-009","April 8, 2002","September 2, 2008","November 28, 2008","August 15, 2005","January 27, 2010","November 8, 2018","Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil|Makati Medical Center, Makati, National Capital Region, Philippines|Mulago Hospital Complex, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00130247"
206,"NCT02512484","Improving the Detection of Active Tuberculosis in Accident and Emergency Departments","ACE","Unknown status","No Results Available","Latent Tuberculosis|Active Tuberculosis","Procedure: venepuncture, sputum collection, xray","xray diagnosis of active TB|diagnosis of latent TB","Public Health England","All","16 Years and older   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TB A&E study","May 2016","May 2017","December 2017","July 31, 2015",,"March 16, 2016","Barts NHS Trust, London, United Kingdom|Ealing Hospital, London, United Kingdom|West Middlesex Hospital NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02512484"
207,"NCT02602509","Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: Celecoxib|Drug: Rifampicin|Drug: Pyrazinamide","Log change CFU.day (cumulative over 8 hours) calculated from Mycobacteria Growth Indicator Tube (MGIT) Time to Positivity|Plasma concentrations of study drugs to determine the Area Under the Curve (AUC)|Plasma concentrations of study drugs to determine the Maximum Plasma Concentration (Cmax)","National University Hospital, Singapore","All","21 Years to 60 Years   (Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Celecoxib_WBA","November 2015","February 2016","February 2016","November 11, 2015",,"April 13, 2017","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02602509"
208,"NCT01782950","Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes","SOUTH","Unknown status","No Results Available","AIDS With Tuberculosis","Drug: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide","clinical outcome|Cmax|Number of adverse events|ART trough levels|Isoniazid Cmax","Makerere University","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDI","February 2013","March 2016","March 2016","February 4, 2013",,"April 13, 2015","Infectious Diseases Institute, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01782950"
209,"NCT05664568","The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis","BLAST","Recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: Cephalexin|Drug: Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Other: Standard of care treatment of tuberculosis","Time to positivity (TTP)|Adverse events|Area under the concentration versus time curve (AUC) of cephalexin|Cmax of cephalexin","Western Sydney Local Health District|Centre Of Research Excellence in Tuberculosis Control","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022/PID01942","March 15, 2023","July 2024","December 2024","December 23, 2022",,"June 26, 2023","Blacktown Hospital, Sydney, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Western Sydney Health District, Sydney, Australia",,"https://ClinicalTrials.gov/show/NCT05664568"
210,"NCT00797836","Quantiferon for Detection of Latent Tuberculosis in Healthcare Workers","QUANTIPS","Completed","No Results Available","Tuberculosis","Procedure: Quantiferon Gold","Therapeutic impact of tuberculosis screening using QFTG compared to TST. The impact is defined by the decision to treat of not a HCW with latent tuberculosis using QFTG, compared to the decision which would have been based on TST alone|Cost-effectiveness of replacing TST by QFTG|Prevalence and incidence of latent tuberculosis in exposed HCWs (Group 1)|Incidence of latent tuberculosis in HCWs exposed to an index case (Group 2)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 4","1024","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P070312|STIC AOM04013","November 2008","October 2010","November 2010","November 25, 2008",,"January 10, 2012","CHU Bichat Claude Bernard, Paris, Ile de France, France",,"https://ClinicalTrials.gov/show/NCT00797836"
211,"NCT02170441","Global Consortium for Drug-resistant Tuberculosis Diagnostics","GCDD","Completed","No Results Available","Tuberculosis|Tuberculosis, Multidrug-Resistant",,"Time to completion of rapid diagnostic assays","University of California, San Diego|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)","All","5 Years and older   (Child, Adult, Older Adult)",,"1128","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-0099|U01AI082229","April 2012","June 2014","June 2014","June 23, 2014",,"June 23, 2014","P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India|Phthisiopneumology Institute, Chisinau, Moldova, Republic of|Department of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT02170441"
212,"NCT02700347","Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: Pyrazinamide|Drug: Allopurinol","Cumulative whole blood bactericidal activity (WBA)|Plasma concentrations of study drugs to determine the Area Under the Curve (AUC)|Plasma concentrations of study drugs to determine the Maximum Plasma Concentration (Cmax)|Plasma concentrations of study drugs to determine the drug half-life (t1/2)","National University Hospital, Singapore","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PZA_WBA","February 2016","April 2016","April 2016","March 7, 2016",,"April 13, 2017","National University Hospital, Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02700347"
213,"NCT03910946","Prevalence of Latent Tuberculosis in High Risk Children",,"Unknown status","No Results Available","Latent Tuberculosis","Drug: Tuberculin, Purified Protein 5Unt/0.1 mL Solution","Prevalence of Latent Tuberculosis in High Risk Young Children Attending Pediatric Hospital of Assiut University","Assiut University","All","1 Year to 12 Years   (Child)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","latent tuberculosis","July 1, 2020","January 2021","February 2021","April 10, 2019",,"June 16, 2020",,,"https://ClinicalTrials.gov/show/NCT03910946"
214,"NCT04236765","Tuberculosis In Children Visiting Friends and Relatives",,"Unknown status","No Results Available","Tuberculosis Infection","Other: TB infection-screening benefiting group","change in health status: LTBI diagnosis after having traveled abroad|Sociodemographic characteristics of the patients|Epidemiological data (before travel abroad):|Epidemiological data (after travel abroad):|Clinical data: Bacillus Calmette-Guerin (BCG) vaccination|Clinical data: presence of BCG scar|Clinical data: height|Clinical data: weight","Hospital Mutua de Terrassa|Public Health Agency of Barcelona|Hospital Vall d'Hebron|Hospital Sant Joan de Deu|Institut Català de la Salut|Hospital Universitari Sant Joan de Reus|Hospital de Tortosa Verge de la Cinta","All","6 Months to 14 Years   (Child)","Not Applicable","492","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","P16/094","January 1, 2018","December 31, 2020","December 31, 2020","January 22, 2020",,"July 20, 2020","Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04236765"
215,"NCT02176772","Iron Absorption and Utilization During Tuberculosis and After Treatment",,"Completed","No Results Available","Tuberculosis","Other: Stable iron isotopes, non-drug intervention","Change from baseline in iron absorption of stable isotope tracers at week 8|Change from baseline in iron incorporation of stable isotope tracers at week 8|Change from baseline in iron absorption of stable isotope tracers at week 24|Change from baseline in iron incorporation of stable isotope tracers at week 24|Change from baseline in serum hepcidin at week 2|Change from baseline in serum hepcidin at week 4|Change from baseline in serum hepcidin at week 6|Change from baseline in serum hepcidin at week 8|Change from baseline in serum hepcidin at week 10|Change from baseline in serum hepcidin at week 12|Change from baseline in serum hepcidin at week 14|Change from baseline in serum hepcidin at week 16|Change from baseline in serum hepcidin at week 18|Change from baseline in serum hepcidin at week 20|Change from baseline in serum hepcidin at week 22|Change from baseline in serum hepcidin at week 24|Change from baseline in serum hepcidin at week 26","Swiss Federal Institute of Technology|Ifakara Health Institute|Swiss Tropical & Public Health Institute","All","18 Years to 45 Years   (Adult)",,"19","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","Fe_TB_Study_TZ","April 2015","January 2017","January 2017","June 27, 2014",,"June 5, 2017","Tb-clinic, Bagamoyo Research and Training Centre, Bagamoyo, Pwani, Tanzania",,"https://ClinicalTrials.gov/show/NCT02176772"
216,"NCT04721795","Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","ATORTUB","Completed","No Results Available","Tuberculosis, Pulmonary|Tuberculosis","Drug: Atorvastatin with standard anti tuberculosis drugs|Drug: Standard anti tuberculosis drugs only","Primary outcome measures Efficacy of atorvastatin treatment in combination with standard anti-TB chemotherapy|Time to sputum conversion|Early Bactericidal Activity|Incidence of treatment-emergent adverse events|Plasma level of atorvastatin in combination with standard anti TB chemotherapy","Obafemi Awolowo University Teaching Hospital|University Hospital Birmingham NHS Foundation Trust|Cures Within Reach","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ERC/2020/10/05|NHREC/27/02/2009a","January 19, 2021","March 31, 2022","June 30, 2022","January 25, 2021",,"December 8, 2023","Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, Osun, Nigeria|Birmingham Heartlands Hospital, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04721795"
217,"NCT04148053","Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis",,"Unknown status","No Results Available","Tuberculosis Infection","Diagnostic Test: TB-antigen responsive T cell markers","Positive rate and negative rate|Receiver operating characteristic curve","Tongji University","All","7 Years to 90 Years   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTB18001","November 1, 2018","December 31, 2019","March 1, 2020","November 1, 2019",,"November 1, 2019","Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04148053"
218,"NCT04434976","Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China",,"Completed","No Results Available","Tuberculosis; Pulmonary, Confirmed, Unspecified Means",,"The median time of pulmonary tuberculosis diagnosis confirmed|The correlation between the classification of the first-visit-institution and the diagnosis delay of the pulmonary tuberculosis|Bacteriology examination coverage rate: anti fast bacteria smear, tuberculosis culture, and GeneXpert.|The correlation between the use of fluoroquinolones as anti-infection treatment before tuberculosis diagnosis confirmed and the diagnosis delay of the pulmonary tuberculosis|The sociodemographic characteristics of patients with or without pulmonary tuberculosis diagnosis delay.|The rates of onset symptoms and its correlation to diagnosis delayed of pulmonary tuberculosis diagnosis confirmed patients.","Huashan Hospital","All","15 Years and older   (Child, Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","KY-2019TB-20","September 8, 2019","November 2, 2019","January 10, 2020","June 17, 2020",,"June 17, 2020","Anhui Province Hospital, Hefei, Anhui, China|The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China|Beihai Tuberculosis Hospital, Beihai, Guangxi, China|Guiyang Public Health Clinical Center, Guiyang, Guizhou, China|The 2th Hospital of Daqing, Daqing, Hei Longjiang, China|Henan Province Infectious Diseases Hospital, Zhengzhou, Henan, China|Wuhan Medical Treatment Center, Wuhan, Hubei, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Taicang, Taicang, Jiangsu, China|Xuzhou Infectious Diseases Hospital Huimei Liu, Xuzhou, Jiangsu, China|Jiangxi Province Chest Hospital, Nanchang, Jiangxi, China|Changchun Infectious Diseases Hospital, Changchun, Jilin, China|Shandong Province Chest hospital, Jinan, Shandong, China|905th Hospital of PLA Navy, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Xian Chest Hospital, Xian, Shanxi, China|Southwest Medical University Affiliated Hospital, Luzhou, Sichuan, China|Qiubei People's Hospital, Qiubei, Yunnan, China|Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China|Wenzhou Central Hospital, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04434976"
219,"NCT02933281","MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa","A-050","Completed","No Results Available","Tuberculosis","Biological: MTBVAC|Biological: BCG","Safety and reactogenicity of MTBVAC at escalating dose levels compared to BCG vaccine by assessing number of participants with AEs and SAEs|Difference in T cell response between MTBVAC dose levels across all post-immunization time points measured by percentage of MTBVAC-specific CD4 and CD8 T cells that produce any or a combination of relevant cytokines in ICS assay|Qualitative and quantitative results from QuantiFERON® TB (QFT) test summarized using participant count (percentage) summaries conversion and reversion rates in participants receiving escalating dose levels of MTBVAC|Qualitative and quantitative results from QFT test using percentage conversion and reversion rates of participants receiving escalating dose levels of MTBVAC compared to BCG dose levels of MTBVAC in comparison to BCG measured by QFT Gold Plus assay","International AIDS Vaccine Initiative|Biofabri, S.L|Universidad de Zaragoza|South African Tuberculosis Vaccine Initiative","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","144","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","A-050","May 14, 2018","September 5, 2021","September 5, 2021","October 14, 2016",,"February 27, 2023","SATVI: Worcester, Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT02933281"
220,"NCT04188041","Improving Rhode Island's Tuberculosis Preventive Services in Primary Care",,"Unknown status","No Results Available","Latent Tuberculosis","Other: TB Infection ECHO","Feasibility: Participant Attendance|Feasibility: Participant Retention|Impact: Procedural knowledge|Impact: Self- reported LTBI screening|Impact: Self- reported LTBI treatment|Reach: LTBI testing|Reach: LTBI treatment|Feasibility: Case Submission|Feasibility: ECHO session timing|Feasibility: Connectivity|Feasibility: Videoconferencing Equipment|Feasibility: Content expert facilitation|Feasibility: Communication with ECHO hub","Kent Hospital, Rhode Island|National Institute of General Medical Sciences (NIGMS)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","1370981-4|U54GM115677","October 2, 2019","March 24, 2021","July 31, 2022","December 5, 2019",,"March 29, 2022","Brown Family Medicine Department, Pawtucket, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04188041"
221,"NCT05899400","A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides",,"Completed","No Results Available","Tuberculosis, Pulmonary","Diagnostic Test: Diascopic iON Image Analysis System","Determined sensitivity and specificity of the iON device by comparing MTB slide results to their associated bacterial culture results from the same specimen(s).","Diascopic, LLC|National Institutes of Health (NIH)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)","All","Child, Adult, Older Adult",,"400","Industry|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Diascopic|1R43EB028736-01","September 15, 2019","October 31, 2022","December 31, 2022","June 12, 2023",,"June 12, 2023","Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05899400"
222,"NCT05454345","Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment",,"Not yet recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: Sitafloxacin|Drug: SMZ/TMP|Drug: Rifampin|Drug: Pyrazinamide|Drug: Rifapentine|Drug: Isoniazid|Drug: Ethambutol|Drug: Moxifloxacin","TB Disease-free Survival after the completion of the treatment cycle.|Percentage Participants With Grade 3 or Higher Adverse Events During Study Drug Treatment in Control Regimen|The rates of negative sputum conversion|TB disease-free survival at six and twelve months after study treatment assignment.","First Affiliated Hospital of Zhejiang University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","620","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","yzhang207","October 1, 2022","June 30, 2025","June 30, 2026","July 12, 2022",,"July 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05454345"
223,"NCT01162265","Prognostic Value of Interferon Gamma Release Assays in Predicting Active Tuberculosis Among Individuals With, or at Risk of, Latent Tuberculosis Infection","PREDICT","Completed","No Results Available","Tuberculosis|Latent Tuberculosis",,"Development of active TB. Prognostic values of tests quantified as incidence rate ratios (RR) among contacts and new entrants|Side effects from chemoprophylaxis","Public Health England|Imperial College London|Queen Mary University of London|University College, London|Brunel University|University of Birmingham","All","16 Years and older   (Child, Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PREDICT","August 2010","June 30, 2015","June 30, 2016","July 14, 2010",,"October 1, 2020","Ealing Hospital, Southall, London, United Kingdom|St George's Hospital, Tooting, London, United Kingdom|Homerton Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01162265"
224,"NCT03604848","NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB","GRACE-TB","Not yet recruiting","No Results Available","Multidrug Resistant Tuberculosis","Drug: WHO-approved MDR-TB regimen|Drug: NGS-guided regimen: Regimen A|Drug: NGS-guided regimen: Regimen B|Drug: NGS-guided regimen: Regimen C","Efficacy of NGS-guided treatment(the proportion of patients with a favorable efficacy outcome 18 months after the end of treatment)|Efficacy of shorter course regimen for simple MDR-TB patients(the proportion of patients with a favorable efficacy outcome between regimen A and regimen B)|Safety(the proportion of patients who experience grade 3 or greater adverse events)|The Median Time to Sputum Culture Conversion","Huashan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","488","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2018-291","August 5, 2018","August 4, 2024","August 4, 2024","July 30, 2018",,"July 30, 2018","The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China|the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China|Chest Hospitalof Xinjiang Uygur Autonomous Region of PRC, Urumqi, Xinjiang, China|Zhuji City People's Hospital, Zhuji, Zhejaing, China|Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China|Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China|The Second Hospital of Yinzhou of Ningbo, Ningbo, Zhejiang, China|Enze Medical Center of Taizhou CIty, Taizhou, Zhejiang, China|The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03604848"
225,"NCT04988984","Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)","New Assay TB","Unknown status","No Results Available","Tuberculosis Infection",,"Sensitivity and specificity when using Xpert TB/RIF tests with","Asan Medical Center","All","19 Years to 100 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-1745","November 17, 2020","November 17, 2020","December 31, 2023","August 4, 2021",,"August 4, 2021","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Songpa, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04988984"
226,"NCT00197704","Nutrition, Immunology and Epidemiology of Tuberculosis",,"Completed","No Results Available","Tuberculosis","Dietary Supplement: Multivitamins|Other: Placebo","To determine the efficacy of micronutrient supplements on sputum conversion, survival, and TB relapse and reinfection.|To examine the effect of micronutrient supplements on HIV viral load, CD4 counts, body weight and immunological parameters.","Harvard School of Public Health (HSPH)|Muhimbili University of Health and Allied Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","876","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AI45441","March 2000","May 2004","May 2004","September 20, 2005",,"November 11, 2010","Harvard School of Public Health, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00197704"
227,"NCT00904956","Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner","GRANLATHU","Unknown status","No Results Available","Tuberculosis",,,"Germans Trias i Pujol Hospital|CIBERES CRP-TB program","All","18 Years and older   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GRANLATHU","November 2009","June 2012","December 2012","May 20, 2009",,"July 11, 2011","Fundació Institut Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Teknon Foundation, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00904956"
228,"NCT00341601","Multi-Drug Resistant Tuberculosis in Korea",,"Completed","No Results Available","Tuberculosis",,"To compare the characteristics of subjects with relapsed tuberculosis verses the characteristics of subjects that do not experience relapse disease|To compare the frequencies of the Toll-like receptor 2 and 4 (TLR2 and TLR4) alleles in tuberculosis subjects and tuberculosis-exposed, healthy volunteers. Other putative susceptibility genes discussed in the background may also be examined.|To compare molecular characteristics, including the expression of the phenolic glycolipid, (PGL) of M. tuberculosis strains that occur in subjects with a prior history of disease, disease spread to nonpulmonary sites, or previously treated disea...","National Institute of Allergy and Infectious Diseases (NIAID)|International Tuberculosis Research Center|National Masan Tuberculosis Hospital|Korean Center for Disease Control and Prevention|National Institutes of Health Clinical Center (CC)","All","20 Years and older   (Adult, Older Adult)",,"777","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","999905069|05-I-N069","January 3, 2005",,"January 29, 2018","June 21, 2006",,"April 5, 2018","National Masan Tuberculosis Hospital &amp; Clinical Research Center, Masan, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00341601"
229,"NCT02174380","Effectiveness of Active Case Finding of Household Contacts in a Routine Tuberculosis (TB) Control Program",,"Unknown status","No Results Available","Tuberculosis","Other: Active Household Contact Evaluation","Active Tuberculosis","Lena Shah|Canadian Institutes of Health Research (CIHR)|McGill University|Universidad Peruana Cayetano Heredia","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","1900","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CIHR-235353","October 2012","December 2014","June 2015","June 25, 2014",,"July 9, 2014","Instituto de Medicina Tropicales ""Alexander von Humboldt"", Universidad Peruana Cayetano Heredia, San Martin de Porres, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT02174380"
230,"NCT02563327","Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","S31PK/PD","Unknown status","No Results Available","Tuberculosis","Drug: Rifapentine|Drug: Moxifloxacin|Drug: Rifampin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Ethambutol|Dietary Supplement: Pyridoxine","TB disease-free survival at twelve months after study treatment assignment|Proportion of participants with grade 3 or higher adverse events during study drug treatment","Centers for Disease Control and Prevention|AIDS Clinical Trials Group","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHHSTP-6719","May 30, 2016","March 2019","March 2020","September 30, 2015",,"March 1, 2017","Mulago Hospital, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT02563327"
231,"NCT00948077","Pharmacokinetic Study for Anti-tuberculosis Drugs","TBPK","Unknown status","No Results Available","Pulmonary Tuberculosis","Drug: Rifater and EMB","The maximum concentration (Cmax)of first-line TB drugs|N-acetyltransferase 1 and 2 (NAT 1 and 2), which effects the metabolism of anti-TB drugs, would be examined.","Taipei Medical University WanFang Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","2009WFCRC-08|98040","July 2009","June 2011","December 2011","July 29, 2009",,"April 12, 2011","Taipei Medical University- Wan Fang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00948077"
232,"NCT02503839","Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic","TBCOX2","Completed","No Results Available","Tuberculosis","Drug: etoricoxib|Biological: H56:IC31","Safety of etoricoxib (arm#1) assessed by the number of participants with adverse events|Safety of H56:IC31 vaccine (arm#2) assessed by the number of participants with adverse events|Safety of combined etoricoxib and H56:IC31 vaccine (arm#4) assessed by the number of participants with adverse events|Immunogenicity of etoricoxib (arm#1)|Immunogenicity of H56:IC31 vaccine (arm#2)|Immunogenicity of combined etoricoxib and H56:IC31 vaccine (arm#4)|Exploratory immune studies","Anne Margarita Dyrhol Riise|University of Oslo|Statens Serum Institut|Haukeland University Hospital|Oslo University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015/692|2014-004986-26","November 2015","September 2019","March 23, 2020","July 21, 2015",,"April 8, 2022","Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT02503839/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT02503839/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02503839"
233,"NCT01722396","Pharmacogenetics of Vitamin D Supplementation in Tuberculosis",,"Completed","No Results Available","Tuberculosis","Dietary Supplement: Vitamin D","Change in post supplementation vitamin D level|Ex vivo responses of monocytes to vitamin D|Ex vivo responses of T cells to vitamin D","University of Birmingham|Heart of England NHS Trust","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","62","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG-10-179","March 2011","November 2012","November 2012","November 6, 2012",,"January 16, 2013","Heart of England NHS Trust, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01722396"
234,"NCT00760149","Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis","High RIF","Completed","No Results Available","Tuberculosis","Drug: Rifampicin in higher doses","Pharmacokinetic parameters of rifampicin, desacetylrifampicin, isoniazid, pyrazinamide, ethambutol|Occurrence of adverse events|Bacteriological response of Mycobacterium tuberculosis|Compare accuracy of surrogate markers (SSCC, mRNA, cytokines) with standard two-month sputum conversion marker|Documenting the occurrence of mixed Mycobacterium tuberculosis strain infections","Radboud University Medical Center|European and Developing Countries Clinical Trials Partnership (EDCTP)|Sanofi|Kilimanjaro Christian Medical Centre, Tanzania|Kibong'oto National Tuberculosis Hospital, Sanya Juu, Tanzania|University Centre for Chronic Diseases Dekkerswald, Groesbeek, The Netherlands|National Institute for Public Health and the Environment (RIVM)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APRIORI 4.1|PACTR2009060001493909","July 2010","September 2013","September 2013","September 26, 2008",,"September 9, 2013","Kibong'oto National Tuberculosis Hospital, Sanya Juu, Kilimanjaro, Tanzania",,"https://ClinicalTrials.gov/show/NCT00760149"
235,"NCT02389322","Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65","IIb-healthy","Completed","No Results Available","Tuberculosis","Biological: 5μg/ml ESAT6-CFP10|Biological: 10μg/ml ESAT6-CFP10|Biological: BCG|Biological: placebo","immune response of ESAT6-CFP10 from the size of induration or redness in all population|immune response of TB-PPD from the size of induration or redness in all population|the results of specificity γ-IFN test in all subjects|the Number of Participants With Adverse Events|ESAT6-CFP10 cosistency with TB-PPD in all subjects|ESAT6-CFP10 cosistency with γ-IFN in all subjects|TB-PPD cosistency with γ-IFN in all subjects","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Air Force Military Medical University, China|Proswell Medical Corporation|Jiangsu Province Centers for Disease Control and Prevention|Jurong Province Centers for Disease Control and Prevention","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","1044","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","EC-IIb-healthy","March 2015","July 2015","September 2015","March 17, 2015",,"March 17, 2017","Jurong Province Centers for Disease Control and Prevention, Jurong, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02389322"
236,"NCT00412009","Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal",,"Completed","No Results Available","Tuberculosis","Procedure: Comprehensive package of activities","TB treatment success rate (cure + completed treatment)|Treatment defaulting rates|treatment failure rate|death rate","Institut de Recherche pour le Developpement","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PAL+ 2671","May 2003",,"January 2005","December 15, 2006",,"December 15, 2006","Programme National de Lutte Anti-tuberculeuse, Dakar, Senegal",,"https://ClinicalTrials.gov/show/NCT00412009"
237,"NCT01755598","Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults",,"Completed","Has Results","Tuberculosis|Tuberculosis Vaccines","Biological: GSK Biologicals' investigational TB vaccine (GSK692342)|Biological: Placebo","Incident Rates of Definite Pulmonary Tuberculosis (TB) Disease, Not Associated With HIV-infection, Meeting the Case Definition 1|Incident Rates of Definite Xpert MTB/Rif Positive Pulmonary TB Disease, Not Associated With HIV-infection, Meeting the Case Definition 2|Incident Rates of Definite Pulmonary TB Disease, Not Associated With HIV-infection Meeting the Case Definition 3|Incident Rates of Microbiological Pulmonary TB Disease, Meeting the Case Definition 4|Incidence Rates of Clinical TB Disease, Meeting the Case Definition 5|Number of Subjects With Serious Adverse Events (SAEs).|Number of Subjects With Any Unsolicited Adverse Events (AEs).|Number of Subjects With Any Solicited Local AEs in the Safety and Immune Sub-cohort|Number of Subjects With Any Solicited General AEs in the Safety and Immune Sub-cohort|Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)|Number of Subjects With Grade Equal or Greater Than 2 of Severity for Haematological and Biochemichal Abnormal Laboratory Values in the Safety and Immune Sub-cohort|Desciptive Statistics of the Frequency of M72-specific CD4+ T-cells Expressing Any Combination of Immune Markers in the Safety and Immune Sub-cohort|Desciptive Statistics of the Frequency of M72-specific CD8+ T-cells Expressing Any Combination of Immune Markers in the Safety and Immune Sub-cohort|M72-specific Antibody Concentrations as Measured by Enzyme Linked Immuno Sorbent Assay (ELISA) in the Safety and Immune Sub-cohort|Number of Seropositive Subjects for M72 Antibodies Measured by ELISA in the Safety and Immune Sub-cohort","GlaxoSmithKline|Aeras","All","18 Years to 50 Years   (Adult)","Phase 2","3575","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","115616","August 19, 2014","November 16, 2018","November 16, 2018","December 24, 2012","December 3, 2019","December 3, 2019","GSK Investigational Site, Kisumu, Kenya|GSK Investigational Site, Pretoria, Gauteng, South Africa|GSK Investigational Site, Soweto, Gauteng, South Africa|GSK Investigational Site, Klerksdorp, North-West, South Africa|GSK Investigational Site, Western Cape, Western Province, South Africa|GSK Investigational Site, Worcester, Western Province, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Lusaka, Zambia","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT01755598/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT01755598/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01755598"
238,"NCT01571739","Determining Risk in Latent Tuberculosis",,"Terminated","No Results Available","Latent Tuberculosis",,"To estimate the rate of PET plus CXR at baseline among all study participants.|To estimate the rate of PET+/CT- at baseline among all study participants.|To estimate the rate of regression of PET plus scans (to normal) at 3 and 12 months among the untreated subjects (n=30).","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","20 Years to 60 Years   (Adult)",,"18","NIH","Observational","Time Perspective: Prospective","999912036|12-I-N036","January 2, 2012",,"May 20, 2014","April 5, 2012",,"November 25, 2019","National Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01571739"
239,"NCT02454738","Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts",,"Completed","No Results Available","Latent Tuberculosis","Radiation: Ultralow dose chest CT scan","Interval change of CT abnormalities potentially suggesting active tuberculosis in the lung parenchyma during the follow-up.","Seoul National University Hospital","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SNUHchestradiology-001","June 2015","June 2016","June 2016","May 27, 2015",,"June 7, 2016","Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02454738"
240,"NCT01471977","Treatment Adherence of Tuberculosis Medicines","TBAD","Completed","No Results Available","Tuberculosis","Other: education,counseling, default tracers,quality of care","Proportion of patients cured|Proportion of patients completed treatment|Proportion of patients died|proportion of patients defaulted|proportion of patients with treatment failure|proportion of patients transferred out","Gambat Institute of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1280","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB","January 2004","December 2007","February 2010","November 16, 2011",,"November 16, 2011","Basic Medical Unit of Taluka Gambat, Khairpur, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT01471977"
241,"NCT05073965","Vitamin D Supplementation Effect In Children With Pulmonary Tuberculosis Treatment",,"Completed","No Results Available","Tuberculosis, Pulmonary","Dietary Supplement: Vitamin D|Other: Placebo","Change in Cough Symptom|Change in Fever Symptom|Change in Body weight|Change in Height|Change in Body Mass Index|Vitamin D level|Alanine Transaminase|Alkaline Phosphatase","Universitas Padjadjaran","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Paed-202108.01","December 1, 2020","July 30, 2021","July 30, 2021","October 12, 2021",,"October 12, 2021","RS Bethesda, Bengkayang, West Borneo, Indonesia","""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/65/NCT05073965/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05073965"
242,"NCT01979900","Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: Vaccae|Drug: placebo","The whole TB incidence after injection of Vaccae|Lesion degree (Bacteriology indicators, cavity) of patients|Systemic and local reactions and adverse events|The relation between skin test results and paroxysm of TB-PPD","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Guangxi Center for Disease Control and Prevention|Liuzhou Center for Disease Control and Prevention,China|Rongshui County Disease Control and Prevention,China|Liucheng County Disease Control and Prevention,China|Jin Chengjiang Center for Disease Control and Prevention,China|National Institutes for Food and Drug Control, China|Air Force Military Medical University, China|Simoon Record Pharma Information Consulting Co., Ltd.","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","10000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","LTao","October 2013","November 26, 2017","November 26, 2017","November 8, 2013",,"June 1, 2018","Jin Chengjiang Center for Diseases Control and Prevention, Hechi, Guangxi, Hechi, Guangxi, China|Liucheng County Diseases Control and Prevention, Liuzhou, Guangxi, Liuzhou, Guangxi, China|Liuzhou Center for Diseases Control and Prevention, Liuzhou, Guangxi, Liuzhou, Guangxi, China|Rongshui County Diseases Control and Prevention, Liuzhou, Guangxi, Liuzhou, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT01979900"
243,"NCT02410772","TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","S31/A5349","Completed","Has Results","Tuberculosis","Drug: rifapentine|Drug: rifapentine and moxifloxacin|Drug: control","TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Modified Intent to Treat [MITT] Population)|TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Assessable Population)|Percentage Participants With Grade 3 or Higher Adverse Events During Study Drug Treatment in Control Regimen (Regimen 1 2HRZE/4HR) Compared to Experimental Regimens, Regimen 3 (2HPZM/2HPM) and Regimen 2 (2HPZ/2HP) (Safety Analysis Population)|TB Disease-free Survival at Eighteen Months After Study Treatment Assignment|Proportion of Participants Who Are Culture Negative at Eight Weeks|Time to Stable Sputum Culture Conversion|Speed of Decline of Sputum Viable Bacilli by Automated MGIT Days to Detection|TB Disease-free Survival at Twelve and Eighteen Months After Study Treatment Assignment Assuming All Losses to Follow-up and Non-tuberculosis Deaths Have an Unfavorable Outcome|TB Disease-free Survival at Twelve and Eighteen Months After Study Treatment Assignment Assuming All Losses to Follow-up and Non-tuberculosis Deaths Have a Favorable Outcome|Discontinuation of Assigned Treatment for a Reason Other Than Microbiological Ineligibility|Efavirenz Maximum Concentration, Area Under the Time-concentration Curve, and Half Life","Centers for Disease Control and Prevention|AIDS Clinical Trials Group","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","2516","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6655","January 25, 2016","July 2020","May 2021","April 8, 2015","September 28, 2021","September 28, 2021","TBTC Site 82/ ACTG Site 801 USCF AIDS CRS, San Francisco, California, United States|TBTC Site 24 Columbia Unversity, New York, New York, United States|TBTC Site 20 UNTHSC (University of North Texas Health Science Center), Fort Worth, Texas, United States|TBTC Site 62 Baylor College of Medicine & Affiliated Hospitals/VA, Houston, Texas, United States|TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States|TBTC Site 94/ ACTG Site 12201 Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|TBTC Site 91/ ACTG Site 12101 Insituto Nacional de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil|TBTC Site 36 TB and Chest Service of Hong Kong, China, Hong Kong, China|TBTC Site 45/ ACTG Site 30022: Les Centres Gheskio (INLR), Port au Prince, Ouest, Haiti|TBTC Site 67/ ACTG Site 31730 GHESKIO centers IMIS, Port-au-Prince, Ouest, Haiti|TBTC Site 43/ ACTG Site 31441 BJ Medical College, Pune, Maharashtra, India|TBTC Site 44/ ACTG Site 11701 CART CRS, YRGCARE Medical Centre VHS, Chennai, Tamilnadu, India|TBTC Site 02/ ACTG 12501 Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS, Kericho, Kericho County, Kenya|TBTC Site 39/ ACTG Site 31460 Kisumu CRS, Kisumu, Nyanza Province, Kenya|TBTC Site 03/ ACTG Site 12601 Moi University Clinical Research Site, Eldoret, Kenya|TBTC Site 04/ ACTG Site 30301 Blantyre CRS (or College of Medicine - Johns Hopkins Research Project, COM-JHP), Blantyre, Malawi|TBTC Site 05/ ACTG Site 12001 UNC Project Tidziwe Centre, Lilongwe, Malawi|TBTC Site 90/ ACTG Site 11301 Asociacion Civil Impacta Salud y Educacion, Lima, Peru|TBTC Site 93/ ACTG Site 11302 CRS San Miguel, Lima, Peru|TBTC Site 10/ ACTG Site 31718 TASK Applied Science, Bellville, Cape Town, South Africa|TBTC Site 09/ ACTG Site 31792 University of Cape Town Lung Institute (Pty) Ltd, Mowbray, Cape Town, South Africa|TBTC Site 34 Wits Health Consortium Perinatal HIV Research Unit (PHRU), Soweto, Gauteng, South Africa|TBTC Site 49/ ACTG Site 12301 Soweto ACTG CRS, Soweto, Johannesburg, South Africa|TBTC Site 06/ ACTG Site 11201 Durban International Clinical Research Site, Durban, KwaZulu Natal, South Africa|TBTC Site 01/ACTG Site 8950 FAM CRU, Parow Valley, Western Cape, South Africa|TBTC Site 08/ ACTG Site 31793 South African Tuberculosis Vaccine Initiative (SATVI), Cape Town, Western Province, South Africa|TBTC Site 07/ ACTG Site 11101 Wits Helen Joseph CRS, Johannesburg, South Africa|TBTC Site 42/ ACTG Site 31802 The Thai Red Cross AIDS Research Centre, Pathumwan, Bangkok, Thailand|TBTC Site 69/ ACTG Site 31784 Thai-CTIU, CMU HIV Treatment CRS, Muang Chiang Mai, Chiang Mai, Thailand|TBTC Site 11/ ACTG Site 12401 Joint Clinical Research Centre, Kampala Clinical Research Site, Kampala, Uganda|TBTC Site 30 Uganda-Case Western Reserve Research Collaboration, Kampala, Uganda|TBTC Site 37 Vietnam NTP/UCSF Research Collaboration, Hanoi, Vietnam|TBTC Site 41/ ACTG Site 30313 Parirenyatwa Clinical Research Site, Harare, Zimbabwe","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/72/NCT02410772/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02410772"
244,"NCT06011915","A Retrospective Study of Treatment Patterns and Clinical Outcomes in Patients With Central Nervous System Tuberculosis",,"Completed","No Results Available","Central Nervous System Tuberculosis",,"2-year survival rate|2-year disability rate|Clinical features: age of onset, mode of onset|The presense of clinical symptoms of patients|Incidence of complications in patients with different treatment regimens|length of hospital stay|proportion of patients admitted to ICU","Tongji Hospital","All","Child, Adult, Older Adult",,"638","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RETUBO-N","August 22, 2017","July 26, 2023","July 26, 2023","August 25, 2023",,"August 28, 2023","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital(Wuhan Institute for Tuberculosis Control), Hubei, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT06011915"
245,"NCT04493918","Effectivity of Mesenchymal Stem Cell on Vertebral Bone Defect Due to Mycobaterium Tuberculosis Infection",,"Unknown status","No Results Available","Spinal Tuberculosis|Mesenchymal Stem Cell","Combination Product: Mesenchymal Stem cell + Nacl 0.9%|Combination Product: NaCl 0.9%","Vertebral bony fusion","Ahmad Jabir Rahyussalim|Indonesia University","All","15 Years to 64 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-04-0389","May 21, 2017","December 30, 2020","December 30, 2020","July 30, 2020",,"August 3, 2020","Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04493918"
246,"NCT01464762","Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis",,"Approved for marketing","No Results Available","Tuberculosis","Drug: TMC207",,"Janssen Infectious Diseases BVBA","All","18 Years to 99 Years   (Adult, Older Adult)",,,"Industry","Expanded Access",,"CR017233|TMC207TBC3001|2010-021125-12",,,,"November 4, 2011",,"November 27, 2017","Vilnius, Lithuania|Arkhangelsk, Russian Federation|Moscow, Russian Federation|Orel, Russian Federation|Saint-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01464762"
247,"NCT04848246","Effect of Smoking Cessation on Tuberculosis Treatment Outcomes",,"Completed","No Results Available","Tuberculosis, Pulmonary","Drug: Bupropion|Behavioral: Behavioural Change Communication","Percentage of patients completing anti-tuberculosis treatment|Percentage of participants achieving abstinence from smoking","Dow University of Health Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","292","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB-898/DUHS/Approval/2017/136","November 6, 2017","September 30, 2019","October 15, 2019","April 19, 2021",,"April 19, 2021","Dow University of Health Sciences, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT04848246"
248,"NCT03882177","StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis",,"Completed","Has Results","Tuberculosis|Pulmonary Tuberculosis","Drug: Pravastatin|Drug: Rifafour|Dietary Supplement: Vitamin B6","Frequency of Grade 3 or Higher Adverse Events|Number of Participants Who Permanently Discontinue Assigned Study Regimen for Any Reason","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","StAT-TB|38558","February 21, 2020","May 12, 2022","December 31, 2022","March 20, 2019","September 18, 2023","September 18, 2023","PHRU Non-Network CRS, Johannesburg, Gauteng, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/77/NCT03882177/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03882177"
249,"NCT02776150","Probe Melting Technology for Rapid Detection of Drug Resistant Tuberculosis","PMTforDR-TB","Unknown status","No Results Available","Tuberculosis, Pulmonary",,"the sensitivity and specificity of probe melting curves technology|Comparison of diagnostic efficacy|Evaluation of the application value of probe melting curve technology|analyze the cost-effect assessment of probe melting curve technology and other two kinds of detection methods","Beijing Hospital","All","18 Years and older   (Adult, Older Adult)",,"3100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BeijingH","May 2016","December 2018","June 2019","May 18, 2016",,"May 18, 2016",,,"https://ClinicalTrials.gov/show/NCT02776150"
250,"NCT05824871","Sudapyridine (WX-081) in RR/MDR/XDR-tuberculosis Patients","WISH","Enrolling by invitation","No Results Available","Rifampicin-resistant Tuberculosis","Drug: Sudapyridine|Drug: Bedaquiline","The percentage of participants with Sputum Culture Conversion|The Time to Sputum Culture Conversion|The percentage of participants with Sputum Culture Conversion and treatment success","Shanghai Jiatan Pharmatech Co., Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JYP0081M301","September 2, 2022","January 22, 2025","March 22, 2025","April 24, 2023",,"January 5, 2024","Beijing Chest Hospital affiliated to Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05824871"
251,"NCT05746611","Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein",,"Recruiting","No Results Available","Latent Tuberculosis Infection","Biological: Recombinant Mycobacterium tuberculosis fusion protein for injection|Biological: TB-PPD was injected","In Cohort 1, the diameter of redness or induration at the reaction site|In Cohort 2, the diameter of redness or induration at the reaction site|Number of cases in which all adverse events occurred.|Incidence of SAE","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","All","6 Months and older   (Child, Adult, Older Adult)","Phase 4","60500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","LKM-2022-EC02","April 17, 2023","May 31, 2024","June 30, 2025","February 28, 2023",,"June 8, 2023","Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Liuzhou, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT05746611"
252,"NCT05630872","Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis",,"Recruiting","No Results Available","HIV-associated Tuberculosis","Drug: Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC|Drug: DTG 50 mg orally QD plus TDF/3TC|Drug: 2HPZM|Drug: 2HPM","Model-simulated 5th percentile and corresponding 95% confidence interval of DTG minimum concentrations (Cmin) at 50 mg BID when co-administered with daily RPT 1200 mg plus HZM|DTG minimum concentration (Cmin)|DTG minimum concentration (Cmax)|DTG area under the concentration-time curve (AUC0-24)|Number of participants who experience Grade 3 or higher AEs|Number of participants who have a diagnosis of rifamycin hypersensitivity|Number of participants who experience ALT ≥3xULN with symptoms/jaundice or ALT ≥5xULN|Number of participants who prematurely discontinue study drugs DTG and/or RPT|Proportion of participants with HIV-1 viral load below 50 copies/mL","National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare|Mylan Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5406","February 13, 2024","October 31, 2024","May 31, 2025","November 30, 2022",,"March 4, 2024","University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792), Mowbray, Cape Town, Western Cape, South Africa|Durban International CRS (Site # 11201), Westridge, Durban RSA, South Africa|South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793), Worcester, Western Province, South Africa|Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site # 31802), Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT05630872"
253,"NCT01936831","High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)",,"Completed","Has Results","Tuberculosis","Drug: Isoniazid|Dietary Supplement: Vitamin B6","Daily Change in log10 Colony-forming Unit (CFU)|Daily Change in Time to Positivity (TTP)|INH PK Parameter Area Under the Concentration Time Curve (AUC 0-24 Hours)|Number of Participants With Grade 2 or Higher Drug-related Adverse Clinical or Laboratory Events|INH PK Parameter Minimum Plasma Concentration (Cmin)|INH PK Parameter Maximum Plasma Concentration (Cmax)|INH Minimum Inhibitory Concentration (MIC) Against M. Tuberculosis Isolates|Proportions of Participants Estimated to Have a Drop in log10 CFU/mL at or Above 0.65 log10 CFU/mL.|Daily Change in log10 CFU Measured by Early- (EBA0-2) and Late-phase (EBA2-7) Individual-based Parameter Estimates From Nonlinear Models|Daily Change in TTP Measured by Early- (EBA0-2) and Late-phase (EBA2-7) Individual-based Parameter Estimates From Nonlinear Models|EBA Measured by Individual-based Parameter Estimates From Linear or Nonlinear Models When the Number of Phases Differs Between Every Dosing Cohort|Mean EBA Measured by Ratio of the Following Areas: Numerator = AUC of Observed log10 CFU Over 7 Days and Denominator = Baseline log10 CFU for Every Dosing Cohort in Groups 1 and 2","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","282","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5312|UM1AI068636","August 13, 2014","September 22, 2021","October 6, 2021","September 6, 2013","February 17, 2023","February 17, 2023","GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (31730), Port Au Prince, Haiti|TASK Applied Science CRS (31718), Bellville, South Africa","""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT01936831/Prot_ICF_000.pdf|""Statistical Analysis Plan: Primary Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT01936831/SAP_001.pdf|""Statistical Analysis Plan: Pharmacology Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT01936831/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT01936831"
254,"NCT05258877","Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.",,"Completed","No Results Available","Tuberculosis, Pulmonary","Other: Plasma samples","To determine the Cmax of ethionamide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.|To determine the Cmax of ethionamide-sulfoxide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.|To determine the AUC of ethionamide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.|To determine the AUC of ethionamide-sulfoxide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.","BioVersys AG|TASK Applied Science","All","18 Years to 65 Years   (Adult, Older Adult)",,"30","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Eto-001","June 10, 2022","September 28, 2023","September 30, 2023","February 28, 2022",,"November 21, 2023","TASK Applied Sciences, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT05258877"
255,"NCT03137875","Evaluation of PCR Using DNA Extract From Slides and Filter Paper for the Detection of Tuberculosis and MDR-tuberculosis",,"Completed","No Results Available","Tuberculosis|Multi Drug Resistant Tuberculosis",,"proportion of positive samples for Mycobacterium tuberculosis detected by PCR from slides and filter papers among samples by microscopy|To assess the MTB extraction yield from smear-negative, low and high bacilli load specimens on slides, filter paper ( Genocardand FTA)","Epicentre|Medecins Sans Frontieres, Netherlands","All","16 Years to 80 Years   (Child, Adult, Older Adult)",,"122","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","HS 918","March 2011","December 2012","December 2012","May 3, 2017",,"May 3, 2017","Epicentre Mbarara Research Base, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT03137875"
256,"NCT02365623","An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)",,"Completed","No Results Available","Tuberculosis, Multidrug-Resistant","Drug: TMC207 (bedaquiline)|Drug: Background Regimen (BR)","Percentage of Participants With Sputum Culture Conversion|Number of Participants With Multidrug resistant (MDRTB) Outcome","Janssen Pharmaceutical K.K.","All","20 Years and older   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR105158|TMC207TBC2001","February 18, 2015","November 8, 2018","November 8, 2018","February 19, 2015",,"November 1, 2019","Kiyose, Japan|Sakai, Japan",,"https://ClinicalTrials.gov/show/NCT02365623"
257,"NCT04919239","Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)",,"Recruiting","No Results Available","Tuberculosis, Pulmonary","Biological: RUTI®|Biological: Placebo","Percentage of patients with Sputum Culture Negative|Proportion of patients with reduction of bacillary load|Proportion of patients with improvement of clinical signs and symptoms","Archivel Farma S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RUTIP2-2019-01","September 22, 2021","November 2025","November 2025","June 9, 2021",,"July 19, 2023","All India Institute of Medical Sciences (AIIMS), New Delhi, India|Agartala Government Medical College (AGMC), Tripura, India",,"https://ClinicalTrials.gov/show/NCT04919239"
258,"NCT00512330","Lipoarabinomannan (LAM) Enzyme-Linked Immunosorbent Assay (ELISA) in Diagnostics of Childhood Tuberculosis (TB)",,"Unknown status","No Results Available","Tuberculosis",,,"University Hospital, Bonn|Our Lady of Mount Carmel Community Hospital, Kapiri, Malawi|Ministry of Health and Population, Malawi|Mbeya Medical Research Programme, Mbeya, Tanzania|Unterstützerkreis Missionskrankenhaus Kapiri e.V., Munich, Germany|Foerderverein AIDS im Kindesalter in Bonn e.V., Bonn, Germany|Children's Medical Hospital, University of Bonn, Germany","All","up to 14 Years   (Child)",,"250","Other","Observational","Time Perspective: Prospective","LAM ELISA in childhood TB","August 2007",,"August 2008","August 7, 2007",,"August 6, 2008","Our Lady of Mount Carmel Hospital, Kapiri/Mchinji, Mchinji, Malawi",,"https://ClinicalTrials.gov/show/NCT00512330"
259,"NCT00800670","Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine",,"Terminated","No Results Available","Tuberculosis","Biological: Ad5Ag85A","Local and systemic signs and symptoms and laboratory toxicity|Immunogenicity will be compared among the groups by determining the level and quantity of antigen-specific T cells by human interferon ELISA and Elispot assay","McMaster University","All","18 Years to 55 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","REB 09-001","June 2009","December 2012","July 2013","December 2, 2008",,"September 8, 2017","McMaster University Medical Centre, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00800670"
260,"NCT03918226","Acute Presentation and Management of Abdominal Tuberculosis: A Ten-year Experience at a Tertiary Care Center in Pakistan",,"Completed","No Results Available","Tuberculosis; Abdomen","Procedure: exploratory laparotomy","Percentage of patients who develop complications after surgery|Percentage of patients who develop recurrence of abdominal tuberculosis (elevated ESR, CT scan findings of abdominal tuberculosis)|Mortality rate","Services Hospital, Lahore","All","12 Years to 90 Years   (Child, Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s16","May 1, 2008","April 30, 2018","April 30, 2018","April 17, 2019",,"April 17, 2019","Services hospital, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT03918226"
261,"NCT04055441","A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital",,"Unknown status","No Results Available","Pulmonary Tuberculosis",,"sputum smear conversion|sputum culture conversion","Assiut University","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","pulmonary tuberculosis","September 2019","September 2020","October 2020","August 13, 2019",,"August 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04055441"
262,"NCT06284187","Diagnosis Test of Real-time Polymerase Chain Reaction (RT-PCR) for Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis|Pulmonary",,"Number of participants with pulmonary TB by Allplex™ MTB/MDRe","Khon Kaen Hospital","All","15 Years and older   (Child, Adult, Older Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","KhonKaenH","January 1, 2023","October 31, 2023","December 31, 2023","February 28, 2024",,"February 28, 2024","Thananit Sangkomkamhang, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT06284187"
263,"NCT01154959","Latency in Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol","The immune response to crude antigens - PPD and CFA and defined antigens - ESAT-6 and CFP-10 as well as positive controls- SEB and anti-CD3.|Determining the correlation of increase in regulatory factors with the development of relapse in treated TB patients.","Tuberculosis Research Centre, India|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 3","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTB01","February 2010","December 2015","July 2016","July 1, 2010",,"April 19, 2021","Tuberculosis Research Centre, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT01154959"
264,"NCT01422798","An Open Cohort of Childhood Tuberculosis in Mbarara National Referral Hospital, Uganda",,"Completed","No Results Available","Tuberculosis",,"Number of confirmed, certain, probable and unlikely TB cases among TB suspects|Baseline clinical presentation of TB suspects|Baseline biological characteristics (smear microscopy, culture and XpertMTB/RIF® of sputum and other specimen for EPTB suspects) of TB suspects|XpertMTB/RIF® and culture results in stools of TB suspects|Number of children started on TB treatment among TB suspects|Number of TB suspect cases who were initially diagnosed as non TB who died or eventually received a TB diagnosis within the first 3 months of clinical follow-up|Treatment successes (cured and completed), failures, defaulters and deaths|TB recurrence 6 months after completion of TB treatment|Antiretroviral treatment (ART) regimen and time to initiation in co-infected children|Occurrence and clinical description of IRIS episodes|Type and frequency of grade 3 and 4 adverse events during TB treatment, with/without concomitant ART|Pill burden, adherence rate and drugs errors with the use of new paediatric dosages","Epicentre|Mbarara University of Science and Technology|Medecins Sans Frontieres, Netherlands","All","1 Month to 14 Years   (Child)",,"396","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Epicentre/MBA/2011/TBKidcohort","April 2012","December 2014","December 2014","August 24, 2011",,"March 2, 2016",,,"https://ClinicalTrials.gov/show/NCT01422798"
265,"NCT03862248","Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More","TriDoRe","Withdrawn","No Results Available","Tuberculosis, Pulmonary","Drug: 6EH³RZ|Drug: 6EHR³Z|Drug: 6EHRZLfx","Bacteriological effectiveness (proportion of relapse-free cure excluding deaths and lost-to-follow-up)|Frequency of resistance to the different drug components at screening.|Identify predictors of bacteriological effectiveness|Programmatic effectiveness (i.e proportion of participants with relapse-free cure)|Number of SAEs and study-specific adverse events of the different retreatment regimens|Negative predictive value of two-week FDA|Proportion of participants relapse-free cure|Difference (95% confidence interval) in bacteriological effectiveness (susceptible to both rifampicin and isoniazid vs heteroresistance to rifampicin and/or isoniazid).(heteroresistance), by regimen studied in the trial|Proportion of participants with acquired resistance|Identify predictors of programmatic effectiveness (including treatment regimen, resistance profile, presence of cavities, the grading of the smear, …)","Institute of Tropical Medicine, Belgium|Damien Foundation","All","Child, Adult, Older Adult","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TriDoRe","September 30, 2019","October 1, 2022","October 1, 2022","March 5, 2019",,"January 21, 2020","Damien Foundation, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT03862248"
266,"NCT03044158","GeneXpert Performance Evaluation for Linkage to Tuberculosis Care","XPEL-TB","Completed","No Results Available","Tuberculosis, Pulmonary|Rifampicin Resistant Tuberculosis","Device: GeneXpert I|Behavioral: Process re-design|Other: Performance Feedback","Number treated for microbiologically-confirmed TB within two weeks of referral for sputum-based testing|Number referred for TB testing|Number diagnosed with microbiologically-confirmed TB|Number suspected/diagnosed with RIF-resistant TB|Time to microbiologically-confirmed TB|Number treated for TB|Number of patients enrolled|Number diagnosed and treated for microbiologically-confirmed TB|Time-to-treatment of microbiologically-confirmed TB|Number diagnosed AND completing treatment|Number who died within 6 months","University of California, San Francisco|Makerere University|Johns Hopkins Bloomberg School of Public Health|London School of Hygiene and Tropical Medicine|Yale University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","10644","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R01HL130192|PACTR201610001763265","October 22, 2018","March 31, 2020","July 31, 2022","February 6, 2017",,"April 20, 2023","St Francis Njeru Health Center III, Buikwe, Uganda|Busana Health Center III, Busana, Uganda|Busesa Health Center IV, Busesa, Uganda|Buwama Health Center III, Buwama, Uganda|Iganga TC, Iganga, Uganda|Bukulula Health Center IV, Kalungu, Uganda|Nazigo Health Center III, Kayunga, Uganda|Kiganda Health Center IV, Kiganda, Uganda|Kira Health Center III, Kira, Uganda|Lugasa Health Center III, Lugala, Uganda|Bishop Asili Health Center, Luwero, Uganda|Kinoni Health Center III, Lwengo, Uganda|Kityerera Health Center IV, Mayuge, Uganda|Malongo Health Center III, Mayuge, Uganda|Mayuge Health Center III, Mayuge, Uganda|Wabulungu Health Center III, Mayuge, Uganda|Malangala Health Center III, Mityana, Uganda|Lwampanga Health Center III, Nakasongola, Uganda|Namungalwe Health Center III, Namungalwe, Uganda|Nankandulo Health Center IV, Nankandulo, Uganda",,"https://ClinicalTrials.gov/show/NCT03044158"
267,"NCT03303963","DIAgnostics for Multidrug Resistant Tuberculosis in Africa","DIAMA","Completed","No Results Available","Tuberculosis, Multidrug-Resistant","Diagnostic Test: Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line|Diagnostic Test: Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis","Validation of Deeplex test|Validation of GeneXpert 2nd line|Validation of MolBio TrueNat for INH, FQ and BDQ|Validation of FDA microscopy|Validation of GeneXpert Ct value|Estimation of proportion of additional resistance in patients resistant to Rifampicin|Measurement of the association of specific mutations against some drugs with programmatic treatment outcome|Evaluation of the add value of Connectivity system in the management of Multi Drug Resistant-Tuberculosis patients","Dissou AFFOLABI|Rwanda Biomedical Centre|The Tuberculosis Reference Laboratory Bamenda|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|Jimma University|Service de Pneumophtisiologie, Hôpital Ignace Deen|University of the Sciences, Techniques and Technologies of Bamako|Damien Foundation|Cheikh Anta Diop University, Senegal|Institute of Tropical Medicine, Belgium|World Health Organization|London School of Hygiene and Tropical Medicine|Genoscreen|Laboratoire de Référence des Mycobactéries","All","15 Years and older   (Child, Adult, Older Adult)",,"3356","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DRIA2014-326","May 4, 2017","June 30, 2022","November 30, 2022","October 6, 2017",,"March 14, 2023","Institute of Tropical Medecine, Antwerp, Belgium|Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou, Cotonou, Atlantique/Littoral, Benin|The Tuberculosis Reference Laboratory Bamenda, Bamenda, Cameroon|Institut National de Recherche Biomédicale (INRB), Kinshasa, Congo, The Democratic Republic of the|Jimma University, Jīma, Ethiopia|Service de Pneumophtisiologie, Hôpital Ignace Deen, Conakry, Conakry, Guinea|Université des Sciences, des Techniques et des Technologies de Bamako, SEREFO, Bamako, Mali|Damien Fundation, Ibadan, Nigeria|Rwanda Biomedical Center (RBC), Kigali, Rwanda|Université Cheick Anta Diop (UCAD), Dakar, Senegal","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/63/NCT03303963/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03303963"
268,"NCT02279875","A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Linezolid|Drug: HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)","Bactericidal Activity (Time to Positivity) Days 0 - 14 [BA(TTP)]|The Bactericidal Activity (Time to Positivity) Days 0 - 2 [BA(TTP)](0-2), and Bactericidal Activity (Time to Positivity) Days 7 - 14 [BA(TTP)](7-14)|The Bactericidal Activity Colony Forming Unit (BACFU)(0-14), BACFU(0-2) and BACFU(7-14)|Incidence of Treatment Emergent Adverse Events (TEAEs) presented by severity (DMID Grade), relatedness, and seriousness, leading to early withdrawal and leading to death.|Pharmacokinetic parameters for subjects (except in the HRZE treatment arm): Cmax, T1/2, AUC 0 - 12|Time over minimum inhibitory concentration (MIC) will be calculated for each subject in the linezolid arms individually and for each of the linezolid arms as a group, based on the MIC determined at baseline.|Time over concentration that inhibits 50% of mitochondrial protein synthesis (MPS IC50)|Correlation between AUC0-12 and AUC0-inf, Cmax and time over minimum inhibitory concentration and BA (0-2, 0-14 and 7-14) will be determined using both time to positivity and colony forming unit results, for all subjects combined.","Global Alliance for TB Drug Development","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","113","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LIN-CL001","November 2014","November 28, 2016","July 2017","October 31, 2014",,"January 11, 2019","TASK Clinical Research Centre, Bellville, Cape Town, South Africa|University of Cape Town Lung Institute (Pty) Ltd, Mowbray, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT02279875"
269,"NCT00811343","Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy","ETAT","Completed","No Results Available","Tuberculosis","Biological: QFTB-G and T-SPOT.TB tests","Therapeutic impact|medico-economic impact","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","430","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P070310|2008-A00744-51","December 2008","December 2010","June 2012","December 19, 2008",,"January 7, 2014","Bicêtre hospital, Le Kremlin Bicêtre, France",,"https://ClinicalTrials.gov/show/NCT00811343"
270,"NCT02810678","Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment","ACT4","Completed","No Results Available","Latent Tuberculosis Infection","Other: Latent Tuberculosis Infection program evaluation & diagnosis","The primary outcome will be the change in the number of household contacts (HHC) initiating treatment per newly diagnosed TB index patient within 3- 4 months from index patient diagnosis, between Phase 1 and Phase 2|Health system costs related to the implementation of the LTBI program evaluation and strengthening approach|Cross-over","McGill University|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FND-143350","July 2016","December 2018","April 2019","June 23, 2016",,"February 21, 2020","Centre de Pneumo-Phthysiologie, Cotonou, Benin|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Montreal Chest Institute, Montreal, Quebec, Canada|Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana|University Padjadjaran (UNPAD), Bandung, Indonesia|Vietnam national university, Hanoi, Vietnam","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/78/NCT02810678/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02810678"
271,"NCT02496572","Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan",,"Unknown status","No Results Available","Multidrug Resistant Tuberculosis","Drug: Short course MDR-TB treatment regimen","Rate of relapse-free success at 12 months follow-up (composite measure of the percentage of patients obtaining cure and treatment completion)|Predictive value of 1st and 2nd line drug resistance at baseline on treatment outcomes (proportion classified as sensitive amongst ethambutol, pyrazinamide, capreomycin and kanamycin)|Rate of adverse events (proportion of patients experiencing at least one adverse event)|Rate of treatment interruptions (proportion of patients missing treatment >1 day of complete regimen)|Rate of unfavorable outcomes whilst on treatment (composite of patients with default, death, failure) during study period|Agreement between smear microscopy and culture (expressed as a kappa coefficient)|Proportion of patients with amplification in drug resistance (defined as a patient previously testing sensitive to a drug who subsequently tests resistant) on follow-up drug susceptibility testing compared with baseline.|Rate of treatment modifications (composite measure of proportion of patients requiring cessation or replacement of a drug due to adverse events not described in the protocol)|Rate of successful outcomes at end of treatment (composite of patients with treatment outcomes cured and completed )|Rate of adverse events by organ group (categorised as cardiac, respiratory, gastrointestinal, auditory, systemic, dermatological, opthalmologic, neurological, other)|Severity of adverse events (proportion of adverse events classified as mild, moderate, severe and potentially life-threatening) as per DAID criteria|Number of missed days in patients missing >1 day of treatment","Medecins Sans Frontieres, Netherlands|Ministry of Health, Republic of Uzbekistan|Imperial College London","All","Child, Adult, Older Adult",,"110","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MSF MDRTB Uzbek","September 2013","March 2016","April 2016","July 14, 2015",,"July 14, 2015","Outpatient clinics in three districts, Nukus, Karakalpakstan, Uzbekistan",,"https://ClinicalTrials.gov/show/NCT02496572"
272,"NCT04147286","Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion","StatinTB","Recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: Atorvastatin 40mg|Drug: Placebo oral tablet","Total lung glycolysis (TLG) on PET/CT imaging","University of Cape Town|University of Zurich|University of Namibia|University of Bern|University of Stellenbosch","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HREC 675/2019|RIA2017T-2004","July 14, 2020","June 30, 2024","June 30, 2026","November 1, 2019",,"October 17, 2022","General Medicine & Global Health, Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Observatory, WC, South Africa",,"https://ClinicalTrials.gov/show/NCT04147286"
273,"NCT00214708","Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?",,"Unknown status","No Results Available","Tuberculosis","Procedure: Screening for Tuberculosis",,"Barts & The London NHS Trust|NHS Research and Development","All","0 Years and older   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","TB-02-04-CG","January 2002",,"September 2004","September 22, 2005",,"September 22, 2005","City and Hackney, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00214708"
274,"NCT01390987","Access to Care and Adherence Tuberculosis (TB) Survey","TBsurvey","Completed","No Results Available","Tuberculosis",,"Time to TB diagnosis","Azienda Ospedaliera San Gerardo di Monza","All","18 Years and older   (Adult, Older Adult)",,"137","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TBsurvey-001","June 2011","September 2012","December 2012","July 11, 2011",,"January 20, 2014","AO Fallacara, Triggiano, BA, Italy|Clinic of Infectious Diseases, AO San Gerardo, Monza, MB, Italy|Clinica di Malattie Infettive, Spedali Civili, Brescia, Italy|Clinica di Malattie Infettive, Ospedale San Martino, Genova, Italy|Clinica di Malattie Infettive, Ospedale Luigi Sacco, Milano, Italy|Clinica di Malattie Infettive, Policlinico Gemelli, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT01390987"
275,"NCT04074369","Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Diagnostic Test: CRISPR-based Test","Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay positive and/or MGIT culture positive for M.tuberculosis.|Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay negative and/or MGIT culture negative for M.tuberculosis.|Proportion of clinically diagnosed non-TB participants with CRISPR-based test MTB positive in sputum/BALF.","Huashan Hospital|Wenzhou Central Hospital|Red Cross Hospital, Hangzhou, China","All","18 Years to 80 Years   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20190601","May 1, 2019","October 30, 2019","October 30, 2019","August 30, 2019",,"August 30, 2019","Huashan Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04074369"
276,"NCT00216385","A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis","Drug: Gatifloxacin combined regimen","Efficacy: Percentage of relapses by 24 months following treatment cure|Safety: Percentage of adverse events|Efficacy: Time to relapse|Efficacy: Percentage of smear and culture conversion at 8 weeks|Efficacy: Percentage of patient cured at the end of treatment|Efficacy: Time to a composite ""unsatisfactory"" endpoint|Safety outcome: Distribution of type and grading of adverse events","Institut de Recherche pour le Developpement|World Health Organization|European Commission","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2070","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICA4-CT 2002-10057","January 2005",,"December 2008","September 22, 2005",,"September 22, 2005","Programme National de Lutte contre la Tuberculose, Cotonou, Benin|Service Pneumo-Phtisiologie, CHU Ignace Deen, Conakry, Guinea|Kenya Medical Research Institute, Nairobi, Kenya|Programme National de Lutte contre la Tuberculose, Dakar, Senegal|Medical Research Council, Durban, KwaZulu, South Africa",,"https://ClinicalTrials.gov/show/NCT00216385"
277,"NCT00922363","Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers",,"Completed","No Results Available","Tuberculosis","Biological: 50 µg Ag85B-ESAT-6 alone|Biological: 50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|Biological: 50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|Biological: 50 µg Ag85B-ESAT-6 + 625/125 µg CAF01","Adverse events|Immunogenicity","Statens Serum Institut","All","18 Years to 55 Years   (Adult)","Phase 1","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ACAF01-01","October 2009","October 2011","October 2011","June 17, 2009",,"January 21, 2013","Department of infectious diseases, C5-P, LUMC, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT00922363"
278,"NCT04242511","Tuberculosis Drug Levels in Diabetics",,"Unknown status","No Results Available","Tuberculosis|Diabetes Mellitus","Diagnostic Test: Measurement of tuberculosis medications level","TB medication levels","London North West Healthcare NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","v1.0 30/10/2019","May 2021","December 2021","May 2022","January 27, 2020",,"April 15, 2021",,,"https://ClinicalTrials.gov/show/NCT04242511"
279,"NCT03732014","Bronchial Washings in Sputum Scarce Cases of Pulmonary Tuberculosis",,"Withdrawn","No Results Available","Tuberculosis, Pulmonary",,"AFB Positivity","Faisal Faiyaz Zuberi|Dow University of Health Sciences","All","12 Years to 70 Years   (Child, Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","BrWash","January 2, 2019","September 1, 2019","November 30, 2019","November 6, 2018",,"August 23, 2021","Ojha Institute of Chest Diseases, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT03732014"
280,"NCT00293228","Treatment of Latent Tuberculosis Infection With Isoniazid",,"Completed","No Results Available","Tuberculosis","Drug: Isoniazid|Drug: isoniazid","Frequency of Mtb antigen-specific IFNγ-producing T cells measured by ELISPOT assay|Gene expression profiling","Instituto Nacional de Salud Publica, Mexico|Bill and Melinda Gates Foundation|Wellcome Trust","All","10 Years to 85 Years   (Child, Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","137","February 2007","March 2008","June 2009","February 17, 2006",,"May 26, 2010","Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico",,"https://ClinicalTrials.gov/show/NCT00293228"
281,"NCT01131351","Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis",,"Terminated","Has Results","Tuberculosis","Drug: Delamanid|Drug: Optimized Background Regimen (OBR)","Percentage of Participants With Potentially Clinically Significant Abnormalities in Vital Signs|Percentage of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Results|Percentage of Participants With Potentially Clinically Significant Laboratory Values|Percentage of Participants With Abnormal Audiometry Assessment Values|Percentage of Participants With Abnormal Visual Acuity Assessment Values|Percentage of Participants Taking Concomitant Anti-Tuberculosis (TB) Medication During the Trial|Percentage of Participants Taking Concomitant (Excluding Anti-TB) Medication During the Trial|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Immediately Reportable Events (IREs)|Cmax: Maximal Peak Plasma Concentration for Delamanid|Tmax: Time to Reach Maximal Peak Plasma Concentration for Delamanid|AUC0-24h: Area Under the Plasma Concentration-Time Curve From 0 To 24 Hours for Delamanid|Rac (Cmax): Ratio of Accumulation for Cmax of Delamanid|Rac (AUC): Ratio of Accumulation for AUC of Delamanid|Cmax: Maximal Peak Plasma Concentration for Delamanid Metabolites|Tmax: Time to Reach Maximal Peak Plasma Concentration for Delamanid Metabolites|AUC0-24h: Area Under the Plasma Concentration-Time Curve From 0 To 24 Hours for Delamanid Metabolites|Rac (Cmax): Ratios of Accumulation for Cmax for Delamanid Metabolites|Rac (AUC): Ratios of Accumulation for AUC for Delamanid Metabolites|Percentage of Participants With Sputum Culture Conversion by Mycobacteria Growth Indicator Tube (MGIT) at Day 168|Percentage of Participants With Sputum Culture Conversion on Solid Mycobacterial Culture Media at Day 168|Mean Change From Baseline in Time to Culture Positivity Using MGIT","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 64 Years   (Adult)","Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","242-08-210|2009-014944-13","February 19, 2010","May 12, 2011","May 12, 2011","May 26, 2010","November 11, 2021","November 11, 2021","Infectology Center of Latvia - Clinic of Tuberculosis and Lung Diseases, Ogre, Latvia|Hospital for Tuberculosis and Lung Diseases, Siauliai, Lithuania|National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania",,"https://ClinicalTrials.gov/show/NCT01131351"
282,"NCT03702738","Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis","NAC-TB","Unknown status","No Results Available","Tuberculosis, Pulmonary","Drug: N-acetyl cysteine","Median time to stable sputum culture conversion using liquid medium|Change from baseline in mean concentration of reduced glutathione (GSH) in blood cells, expressed as the AUC during days 1-28|GSH concentrations and the ratio of GSH to GSSG (oxidized glutathione) measured at discrete time points during treatment|Whole blood bactericidal activity (WBA) prior and at intervals post dosing","The Aurum Institute NPC|National Institute for Medical Research, Tanzania","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AUR1-1-219","March 1, 2019","December 31, 2021","December 31, 2021","October 11, 2018",,"January 22, 2021","NIMR-Mbeya Medical Research Centre, Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT03702738"
283,"NCT00341328","Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.",,"Completed","No Results Available","Tuberculosis","Biological: Intradermal injection of Mycobacterium w","The time of sputum conversion as well as the early sputum conversion between the two groups will be evaluated.|The cure rate will be evaluated as the primary parameter of efficacy.|The relapse in patients of category-I pulmonary TB will be compared in both the groups.|Recording of any clinical adverse reactions for assessment of safety.|An additional secondary efficacy endpoint is the patient's and physicians's global assessment of the clinical cure.","Ministry of Science and Technology, India","All","18 Years to 60 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-01C-1/2003-10|BT/PR7894/Med/14/1175/2006","March 2007","October 2011","March 2012","June 21, 2006",,"April 26, 2013","All India Institute of Medical Sciences, New Delhi, Delhi, India|Central JALMA Institute of Leprosy and Other Mycobacterial Diseases, Agra, India",,"https://ClinicalTrials.gov/show/NCT00341328"
284,"NCT02354014","Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB",,"Recruiting","No Results Available","Multidrug-Resistant Tuberculosis","Drug: Bedaquiline (TMC207)|Drug: Background Regimen (BR)","Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Maximum Plasma Concentration (Cmax)|Time to Reach Maximum Plasma Concentration (Tmax)|Minimum Plasma Concentration (Cmin)|Area Under the Plasma Concentration-time Curve From the Time of Dose Administration up to X Hours (AUCtime-h)|Elimination Half-life (t1/2)|Area Under the Plasma Concentration-time Curve From the Time of Dose Administration up to 168 Hours [AUC168h]|Volume of Distribution (Vd)|Apparent Clearance (CL)|Percentage of Participants with Favorable Treatment outcome (Sustained Positive Clinical Cure)|Time to First Confirmed Sputum Culture Conversion, to acid-fast bacilli (AFB) smear conversion, or Other Microbiology Specimen Sample","Janssen Research & Development, LLC","All","0 Months to 18 Years   (Child, Adult)","Phase 2","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR106371|TMC207-TIDP59-C211|2014-003372-23","May 2016","February 2025","February 2027","February 3, 2015",,"March 27, 2024","Hospital Geral da Polana Caniço, Maputo, Mozambique|De La Salle Health Sciences Institute- DLSUMC, Dasmarinas, Philippines|Lung Center Of The Philippines, Quezon City, Philippines|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|THINK: Tuberculosis & HIV Investigative Network, Durban, South Africa|Wits Health Consortium, Port Elizabeth, South Africa|Makerere University Lung Institute, Kampala, Uganda|State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine, Kiev, Ukraine",,"https://ClinicalTrials.gov/show/NCT02354014"
285,"NCT04152161","Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection",,"Active, not recruiting","No Results Available","Tuberculosis","Biological: BCG vaccine SSI|Biological: Placebo","Number of Participants With Sustained QuantiFERON®-TB Gold Plus Assay (QFT) Conversion From a Negative to Positive Test Based on positive QFT test results|Number of Participants with Sustained QFT Conversion From a Negative to Positive Test Based on positive QFT test results|Number of Participants With Solicited Adverse Events (AEs)|Number of Participants With Unsolicited AEs|Number of Participants With Serious Adverse Events|Number of Participants With AEs of Special Interest|Number of Participants With Serious Adverse Drug Reactions","Bill & Melinda Gates Medical Research Institute","All","10 Years to 18 Years   (Child, Adult)","Phase 2","1836","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Gates MRI-TBV01-201","October 16, 2019","September 1, 2025","September 1, 2025","November 5, 2019",,"October 5, 2023","Investigational Site, Klipfontein, Cape Town, South Africa|Investigational Site, Berea, Durban, South Africa|Investigational Site, Hillbrow, Johannesburg, South Africa|Investigational Site, Paarl, Western Cape, South Africa|Investigational Site, Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04152161"
286,"NCT01137370","The Impact of Vitamin D on Tuberculosis Among Koreans",,"Completed","Has Results","Tuberculosis",,"Prevalence of Vitamin D Deficiency|Median 25-OHD Level","Seoul National University Hospital","All","20 Years and older   (Adult, Older Adult)",,"203","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-0911-066-301","January 2010","March 2011","April 2011","June 4, 2010","February 24, 2014","February 24, 2014","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01137370"
287,"NCT04150367","Efficacy and Safety of Intravenous Treatment of Tuberculosis",,"Terminated","No Results Available","Tuberculosis, Pulmonary","Drug: Isoniazid|Drug: Rifampicin|Drug: Ethambutol","Percentage of patients with negative results of sputum analysis on Mycobacterium tuberculosis .|Time until the negative result of the Mycobacterium tuberculosis tests is obtained.|Combined percentage ratio of patients with negative results of Mycobacterium tuberculosis analysis and clinical improvement.|Combined percentage of patients with no response to treatment in 12 months.|Combined percentage ratio of patients with no response to treatment in 18 months.|Combined percentage ratio of patients with relapse of active tuberculosis in 18 months.|Combined percentage ratio of patients with death due to active tuberculosis in 18 months.|Combined percentage ratio of patients with relapse of active tuberculosis in 12 months.|Combined percentage ratio of patients with death due to active tuberculosis in 12 months.","Yuria-Pharm","All","18 Years to 65 Years   (Adult, Older Adult)",,"166","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","Invent-1","March 3, 2017","July 14, 2018","July 14, 2018","November 4, 2019",,"November 7, 2019","Regional Clinical Antituberculosis Dispensary, Chernivtsi, Ukraine|Regional phthisiopulmonary center, Ivano-Frankivs'k, Ukraine|Regional Antituberculosis Dispensary №1, Kharkiv, Ukraine|Regional Antituberculosis Dispensary, Kherson, Ukraine|National Yanovsky's Institute of Phthisiology and Pulmonology, Kyiv, Ukraine|Lviv Regional Phthisiopneumological Clinical Treatment and Diagnostic Center, L'viv, Ukraine|Regional territorial medical anti-tuberculosis association, Luts'k, Ukraine|Regional Clinical Antituberculosis Dispensary, Sumy, Ukraine|Ternopil Regional TB Dispensary, Ternopil', Ukraine",,"https://ClinicalTrials.gov/show/NCT04150367"
288,"NCT02736864","Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae",,"Completed","No Results Available","Pulmonary Tuberculosis",,"Correlation between extent of pulmonary disease by computed tomography and lung volumes by spirometry","Federal University of Uberlandia","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","FUUMGCD","September 28, 2016","October 2017","October 2017","April 13, 2016",,"February 14, 2018","Clinical Hospital of Federal University of Uberlândia (Av. Pará, 1720 - Umuarama), Uberlândia, Minas Gerais, Brazil",,"https://ClinicalTrials.gov/show/NCT02736864"
289,"NCT01181856","Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route",,"Completed","No Results Available","Tuberculosis","Biological: MVA 85A","Safety|Immunogenicity","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB022","January 2010","January 2011","January 2011","August 13, 2010",,"March 28, 2011","Centre of Clinical Vaccinology and Tropical Medicine (CCVTM) Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01181856"
290,"NCT01580007","Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Active Sodium Phenylbutyrate and active cholecalciferol|Drug: Placebo Sodium Phenylbutyrate plus active cholecalciferol|Drug: Active Sodium Phenylbutyrate and placebo cholecalciferol|Drug: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol","Proportion of pulmonary TB patients who are culture negative in sputum in week 4|Difference in improvement in clinical endpoints consisting of cough clearance, percentage chest x-ray clearance, fever remission and weight increase upto 8 weeks.|Sputum smear conversion time|Radiological improvement (percent lung involvement on CXR)|Cough clearance|Weight gain|Change in plasma PBA concentrations|Change in plasma 25(OH)D3 concentration|Clinical failure and default independently and 'death or clinical failure or default'|Hypercalcaemia (serum calcium > 2.6 mmol/L)|Gastrointestinal side effects|Immunological improvement (LL-37 in macrophages)|Functional immunological improvement (killing by macrophages)","International Centre for Diarrhoeal Disease Research, Bangladesh|Karolinska Institutet|National Institute of Diseases of the Chest and Hospital, Bangladesh|University of Iceland","All","18 Years to 60 Years   (Adult)","Phase 2","288","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PR-09068","December 2010","December 2014","December 2014","April 18, 2012",,"February 13, 2015","National Institute of Diseases of Chest and Hospital (NIDCH), Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT01580007"
291,"NCT05022238","Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia","H3TB","Recruiting","No Results Available","Tuberculosis, Multidrug-Resistant",,"Identification of drug-resistant tuberculosis transmission hotspots in Namibia|Feasibility study of three interventions to enhance drug-resistant TB case finding in Namibia, measured with a questionnaire|Transmission model","University of Namibia|UK Medical Research Council (MRC)|European and Developing Countries Clinical Trials Partnership (EDCTP)|Research Center Borstel|Imperial College London|University of Stellenbosch|National Taiwan University|Namibian National Tuberculosis and Leprosy Programme (NTLP)|UK Foreign, Commonwealth & Development Office (FCDO)","All","Child, Adult, Older Adult",,"2100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","HGC/611/2021","August 1, 2022","September 2025","September 2026","August 26, 2021",,"February 16, 2023","University of Namibia, Windhoek, Namibia",,"https://ClinicalTrials.gov/show/NCT05022238"
292,"NCT00216333","Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis","Drug: combined fixed dose combination","Efficacy : combined rate of failure at the end of treatment and relapse by 30 months.|Safety : occurrence of serious adverse events at any time during chemotherapy|Sputum culture results at two months of chemotherapy|Rate of completion of chemotherapy according to the protocol","International Union Against Tuberculosis and Lung Diseases|United States Agency for International Development (USAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","1500","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IUATLD CT Study C","December 2003",,"June 2007","September 22, 2005",,"September 13, 2006","Service de Pneumo-phtisiologie de Matiben, Algiers, Algeria|Program Nal. de Control de la Tuberculosis, Santa Cruz, Bolivia|Centro Internacional de Entrenamiento, Cali, Colombia|CHU Ignace Deen, Conakry, Guinea|Health Resesarch Center of Manhica, Manhica, Mozambique|Nepal Anti-Tuberculosis Association, Kathmandu, Nepal|Grupo Levir S.A., Lima, Peru|National Institute for Medical Research, Mwanza, Tanzania|National Hospital of TB and Respiratory Diseases, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT00216333"
293,"NCT02042261","The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study",,"Completed","No Results Available","Active Tuberculosis",,"Rifampicin concentration in relationship to MIC over 10|Cure rate on Clinical follow up (according to WHO criteria) in relation to rifampicin concentration at week 2|Sputum Culture conversion in relation to rifampicin, isoniazid and pyrazinamid concentration week 2|TB-score in relation to rifampicin, isoniazid and pyrazinamid concentration week 2|Time to positive Culture (TTP) in relation to isoniazid, ethambutol and pyrazinamid serum concentration and minimal inhibitory concentration (MIC)|Time to positive Culture (TTP) in relation to rifampicin serum concentration and minimal inhibitory concentration (MIC)","Thomas Schon|University Hospital, Linkoeping|Karolinska University Hospital|Linkoeping University","All","18 Years and older   (Adult, Older Adult)",,"38","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TB-TDM","January 2012","November 2015","March 2016","January 22, 2014",,"March 3, 2016","Dept of Infectious Diseases, Linköping, Sweden|Dept of Infectious Diseases, TB-unit, Karolinska Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02042261"
294,"NCT01571414","Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin",,"Completed","No Results Available","Tuberculosis","Drug: PA-824|Drug: Efavirenz (EFV)|Drug: Lopinavir/Ritonavir (LPV/r)|Drug: Rifampin (RIF)","Arm 1: PA-824 PK parameters area under the concentration-time curve (AUC) of 24 hours when dosed alone and when dosed together with EFV 600 mg daily|Arm 1: Grade 2 or higher signs and symptoms observed while on study and during the follow-up|Arm 2: PA-824 PK parameters AUC of 24 hours when dosed alone and when dosed together with LPV/r 400/100 mg twice daily|Arm 2: Grade 2 or higher signs and symptoms observed while on study and during the follow-up|Arm 3: PA-824 PK parameters AUC of 24 hours when dosed alone and when dosed together with RIF 600 mg once daily|Arm 3: Grade 2 or higher signs and symptoms observed while on study and during the follow-up|Arm 1: PA-824 PK parameters Cmax when dosed alone and when dosed together with EFV 600 mg daily|Arm 2: PA-824 PK parameters Cmax when dosed alone and when dosed together with LPV/r 400/100 mg twice daily|Arm 3: PA-824 PK parameters Cmax when dosed alone and when dosed together with RIF 600 mg once daily|Arm 1: PA-824 PK parameters Cmin when dosed alone and when dosed together with EFV 600 mg daily|Arm 1: EFV PK parameters AUC of 24 hours when EFV is dosed alone and when dosed together with PA-824 200 mg daily|Arm 2: PA-824 PK parameters Cmin when dosed alone and when dosed together with LPV/r 400/100 mg twice daily|Arm 2: LPV PK parameters AUC of 12 hours when LPV/r is dosed alone and when dosed together with PA-824 200 mg daily|Arm 3: PA-824 PK parameters Cmin when dosed alone and when dosed together with RIF 600 mg daily|Arm 1: PA-824 PK parameters T1/2 when dosed alone and when dosed together with EFV 600 mg daily|Arm 1: PA-824 PK parameters CL/F when dosed alone and when dosed together with EFV 600 mg daily|Arm 1: EFV PK parameters Cmax when EFV is dosed alone and when dosed together with PA-824 200 mg daily|Arm 1: EFV PK parameters Cmin when EFV is dosed alone and when dosed together with PA-824 200 mg daily|Arm 1: EFV PK parameters CL/F when EFV is dosed alone and when dosed together with PA-824 200 mg daily|Arm 1: EFV PK parameters T1/2 when EFV is dosed alone and when dosed together with PA-824 200 mg daily|Arm 2: PA-824 PK parameters T1/2 when dosed alone and when dosed together with LPV/r 400/100 mg twice daily|Arm 2: PA-824 PK parameters CL/F when dosed alone and when dosed together with LPV/r 400/100 mg twice daily|Arm 2: LPV PK parameters Cmax when LPV/r is dosed alone and when dosed together with PA-824 200 mg daily|Arm 2: LPV PK parameters Cmin when LPV/r is dosed alone and when dosed together with PA-824 200 mg daily|Arm 2: LPV PK parameters CL/F when LPV/r is dosed alone and when dosed together with PA-824 200 mg daily|Arm 2: LPV PK parameters T1/2 when LPV/r is dosed alone and when dosed together with PA-824 200 mg daily|Arm 3: PA-824 PK parameters T1/2 when dosed alone and when dosed together with RIF 600 mg daily|Arm 3: PA-824 PK parameters CL/F when dosed alone and when dosed together with RIF 600 mg daily","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","52","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5306|11829|ACTG5306","May 2012","May 2013","May 2013","April 5, 2012",,"November 5, 2021","Ucsf Hiv/Aids Crs, San Francisco, California, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Ohio State University CRS, Columbus, Ohio, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01571414"
295,"NCT01011543","Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Procedure: Diagnostic techniques in pulmonary tuberculosis","Sensibility of diagnosis of tuberculosis (positive culture and/or PCR)","Centre Hospitalier Universitaire Saint Pierre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","B07620096009","August 2009","December 2015","December 2015","November 11, 2009",,"August 3, 2018","CHU St Pierre; pulmonology department, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT01011543"
296,"NCT00201253","Expression of Tuberculosis in the Lung",,"Completed","No Results Available","Tuberculosis","Other: Bronchoalveolar lavages and venipunctures only","Pulmonary immune responses associated with resistance and susceptibility to Mycobacterium tuberculosis infection (measured at baseline)","University of Medicine and Dentistry of New Jersey|National Heart, Lung, and Blood Institute (NHLBI)|Rutgers, The State University of New Jersey","All","18 Years to 65 Years   (Adult, Older Adult)",,"40","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","286|R01HL051630","September 2000","June 2008","June 2008","September 20, 2005",,"January 26, 2015","UMDNJ-New Jersey Medical School, Newark, New Jersey, United States|Instituto Nacional de Enfermedades Respiratorias (INER), Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT00201253"
297,"NCT00134342","Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations",,"Completed","No Results Available","Tuberculosis","Other: T-SPOT TB ELISPOT test",,"University Health Network, Toronto|Oxford Immunotec","All","18 Years and older   (Adult, Older Adult)",,"203","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","04-0702-AE","January 2005","April 2005","April 2005","August 24, 2005",,"December 23, 2010","Mount Sinai Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00134342"
298,"NCT01642888","A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI",,"Completed","No Results Available","Tuberculosis","Biological: C-Tb|Biological: 2 T.U. Tuberculin PPD RT 23 SSI","To evaluate the diagnostic performance of C-Tb in relation to age, HIV and CD4 counts|To evaluate the clinical safety of C-Tb, with emphasis on children and HIV positive participants|To evaluate the difference in sensitivity between C-Tb and QuantiFERON®-TB Gold in-Tube in trial participants with confirmed TB diagnosis, overall, and according to age and HIV status.|To evaluate the difference in sensitivity between C-Tb and Tuberculin PPD RT23 SSI in trial participants with confirmed TB diagnosis overall, and according to age and HIV status.|To evaluate the difference in specificity between C-Tb and QuantiFERON®-TB Gold in-Tube in the control group of 100 children aged 5 - 11 years with no TB symptoms and no known exposure to MTb overall, and according to age.|To evaluate the difference in specificity between C-Tb and Tuberculin PPD RT23 SSI in the control group of 100 children aged 5 - 11 years with no TB symptoms and no known exposure to MTb overall, and according to age.|To compare the diagnostic outcome of C-Tb to that of QuantiFERON®-TB Gold in-Tube using a latent class approach|To compare the diagnostic outcome of C-Tb to that of Tuberculin PPD RT23 SSI using a latent class approach|To evaluate the diagnostic performance of Tuberculin PPD RT23 SSI in relation to age, HIV status and CD4 counts|To evaluate the clinical safety of Tuberculin PPD RT23 SSI|To evaluate the diagnostic performance of QuantiFERON®-TB Gold in-Tube in relation to age, HIV status and CD4 counts","Statens Serum Institut","All","28 Days to 65 Years   (Child, Adult, Older Adult)","Phase 3","1190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","TESEC-05|2011-005078-40","September 2012","September 2014","September 2014","July 17, 2012",,"April 14, 2016","Primecure Medicentre, Mercantile Hospital, Port Elizabeth, Eastern Cape, South Africa|Worthwhile Clinical Trials, Lakeview Hospital, Benoni 1501, Gauteng, South Africa|Synnyside Medi-Clinic, Pretoria, Gauteng, South Africa|Synexus Stanza Bopape Clinic, Pretoria, Gauteng, South Africa|Setshaba Research Centre, Pretoria, Gauteng, South Africa|M2 Karl Bremer Hospital, Bellville, Cape Town, Western Cape, South Africa|Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, Cape Town, Western Cape, South Africa|UCT Lung Institute, Groote Schuur Hospital, Cape Town, Western Cape, South Africa|Be Part Yoluntu Centre, Paarl, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT01642888"
299,"NCT00910871","To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.",,"Completed","Has Results","Tuberculosis","Drug: TMC207|Drug: Background Regimen (BR) for MDR-TB","The Median Time to Sputum Culture Conversion|The Percentage of Participants With Sputum Culture Conversion","Janssen Infectious Diseases BVBA","All","18 Years and older   (Adult, Older Adult)","Phase 2","241","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR012352|TMC207-TiDP13-C209|2008-008444-25","September 2009","March 2011","January 2013","June 1, 2009","May 16, 2013","April 24, 2015","Beijing, China|Fuzhou, China|Jinan, China|Nanjing, China|Shanghai, China|Talinn, Estonia|Tartu, Estonia|Nairobi, Kenya|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Stopinu Region, Latvia|Callao, Peru|Lima, Peru|Quezon City, Philippines|Arkhangelsk, Russian Federation|Moscow, Russian Federation|Orel, Russian Federation|Bellville West Cape, South Africa|Durban, South Africa|Sandringham, South Africa|Nakhon, Thailand|Nonthaburi, Thailand|Istanbul, Turkey|Kecioren, Turkey|Donetsk, Ukraine|Kiev, Ukraine|Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00910871"
300,"NCT00423566","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A (Tuberculosis vaccine)","Local and systemic reactions will be monitored 30 and 60 minutes after administration.|A photograph of the injection will be taken at 48 hours and this injection site will be reviewed 7 days after each immunisation.|Blood will be taken: 1 week after the first vaccination, 1 week after the second vaccination and then at 4, 8, 12 and 24 weeks. The blood is used for a full blood count and biochemical screen.|Immunological assays are performed at all time points to determine vaccine imunogenicity (T cell responses are measured using an interferon-gamma Elispot assay).","University of Oxford","All","18 Years to 45 Years   (Adult)","Phase 1","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB002","September 2002",,"July 2003","January 18, 2007",,"January 18, 2007","University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00423566"
301,"NCT04038632","Impact of an Innovative Childhood TB Diagnostic Approach Decentralized to District Hospital and Primary Health Care Levels on Childhood Tuberculosis Case Detection and Management in High Tuberculosis Incidence Countries (TB-Speed Decentralisation Study)",,"Unknown status","No Results Available","Tuberculosis in Children","Other: Decentralization of Childhood TB Diagnosis","Children diagnosed with TB|TB case detection|TB screening in outpatient children - 1|TB screening in outpatient children - 2|Feasibility of implementing the different diagnostic approach components - 1|Feasibility of implementing the different diagnostic approach components - 2|Feasibility of implementing the different diagnostic approach components - 3|TB treatment uptake and time to TB treatment initiation - 1|TB treatment uptake and time to TB treatment initiation - 2|Cost-effectiveness from the health services perspective|Acceptability by health care providers, NTPs and health authorities, and beneficiaries|Fidelity of the implementation of the diagnostic approach as compared to the protocol and study procedures - 1|Fidelity of the implementation of the diagnostic approach as compared to the protocol and study procedures - 2|Performance of the diagnostic approach at patient level|TB treatment outcome|Diagnostic performance of CXR reading by clinicians at DH and PHC levels|Added value of CXR in the diagnosis of TB in children as compared to microbiology and clinical evaluation only|Uptake of the quality control of the CXR reading","Institut National de la Santé Et de la Recherche Médicale, France|UNITAID","All","up to 14 Years   (Child)","Not Applicable","26000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","C18-25","March 7, 2020","March 2022","March 2022","July 31, 2019",,"September 5, 2021","Angroka Rh, Angroka, Cambodia|Taphem Hc, Angroka, Cambodia|Tropang Andert Hc, Angroka, Cambodia|Batheay Rh, Batheay, Cambodia|Choeung Chnok Hc, Batheay, Cambodia|Tumnub Hc, Batheay, Cambodia|KUS HC, KUS, Cambodia|Nhaeng Nhang Hc, Nhaeng Nhang, Cambodia|Sambour Hc, Sambour, Cambodia|Csi Messngssang, Bafia, Cameroon|HD BAFIA, Bafia, Cameroon|Csi Balamba Bafia, Balamba, Cameroon|Cma Batchenga, Batchenga, Cameroon|Cma Bokito Bafia, Bokito, Cameroon|Csi Essong, Essong, Cameroon|Cma Kiiki Bafia, Kiiki, Cameroon|Cma Fomakap, Obala, Cameroon|Csi Ngogo, Obala, Cameroon|Obala Hosp, Obala, Cameroon|Dr Banteapleu, Banteapleu, Côte D'Ivoire|Csu Dakpadou, Dakpadou, Côte D'Ivoire|Csr Daleu, Daleu, Côte D'Ivoire|H G de Danane, Danane, Côte D'Ivoire|Csu Kouan-Houle, Kouan-houle, Côte D'Ivoire|Csu Mahapleu, Mahapleu, Côte D'Ivoire|Csr Medon, Medon, Côte D'Ivoire|CMS SAGO, Sago, Côte D'Ivoire|Dr de Sahoua, Sahoua, Côte D'Ivoire|H G Sassandra, Sassandra, Côte D'Ivoire|Chiaquelane, Chiaquelane, Mozambique|Chibonzane, Chibonzane, Mozambique|Chidenguele, Chidenguele, Mozambique|Chalocuane, Chokwe, Mozambique|HOKWE, Chokwe, Mozambique|Hosp Rural Chokwe, Chokwe, Mozambique|MACUACUA, Macuacua, Mozambique|Hospital Rural de Manjacaze, Manjacaze, Mozambique|Laranjeira, Manjacaze, Mozambique|Babara Chc, Babara, Sierra Leone|Bo Govt Hosp, BO, Sierra Leone|New Police barracks, BO, Sierra Leone|Gbinti Chc, Gbinti, Sierra Leone|Gerihun Chc, Gerihun, Sierra Leone|Koribondo Chc, Koribondo, Sierra Leone|Mange Chc, Mange, Sierra Leone|Njala University Chc, Njala, Sierra Leone|Petifu Chc, Petifu, Sierra Leone|Port Loko Govt Hosp, Port Loko, Sierra Leone|Buyamba Hc Iii, Buyamba, Uganda|Kambuga Hospital, Kambuga, Uganda|Kanungu Hciv, Kanungu, Uganda|Kanyantorogo Hciii, Kanyantorogo, Uganda|Lwamaggwa Hc Iii, Lwamaggwa, Uganda|Lwanda Hc Iii, Lwanda, Uganda|St Bernards Manya Hc Iii, Manya, Uganda|Matanda Hciii, Matanda, Uganda|Rakai Hospital, Rakai, Uganda",,"https://ClinicalTrials.gov/show/NCT04038632"
302,"NCT03474198","Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis","TRUNCATE-TB","Completed","No Results Available","Tuberculosis, Pulmonary","Drug: Rifampicin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Linezolid|Drug: Clofazimine|Drug: Rifapentine|Drug: Levofloxacin|Drug: Bedaquiline","Unsatisfactory clinical outcome at week 96 after randomisation|Acceptability of the strategy using trial-specific questionnaire|Total days on TB drug treatment|Time off work or study due to illness/treatment|Total Quality of life using MOS-HIV questionnaire|Respiratory disability at week 96|Total Grade 3 or 4 clinical adverse events|Total serious adverse events|Death|Adherence to TB medication|Treatment default|Acquired drug resistance by week 96|Community transmission risk","University College, London|National University Hospital, Singapore|Singapore Clinical Research Institute (SCRI)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","675","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRUNCATE-TB","March 21, 2018","January 20, 2022","January 20, 2022","March 22, 2018",,"August 14, 2023","National Institute of TB and Respiratory Diseases, New Delhi, India|Universitas Padjadjaran, Bandung, Indonesia|Persahbahatan Hospital, Jakarta, Indonesia|Wahidin Sudirohusodo Hospital, Makassar, Indonesia|Saiful Anwar Hospital, Malang, Indonesia|Soetomo General Hospital, Surabaya, Indonesia|Perpetual Succour Hospital, Cebu, Philippines|De La Salle Health Sciences Institute, Manila, Philippines|Lung Center Philippines, Manila, Philippines|Philippines Tuberculosis Society Incorporated (PTSI), Manila, Philippines|Tropical Disease Foundation, Manila, Philippines|Quezon Institute, Quezon City, Philippines|National University Hospital, Singapore, Singapore|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Central Chest Institute of Thailand, Nonthaburi, Thailand|Infectious Diseases Institute, Kampala, Uganda|Joint Clinical Research Centre, Kampala, Uganda|Joint Clinical Research Centre, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT03474198"
303,"NCT03160638","Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis, Pulmonary","Drug: Azithromycin 250 mg","Systemic inflammation|Pulmonary inflammation|Pulmonary tissue degradation|Pulmonary tissue remodeling","University Medical Center Groningen","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZT_DSTB_BB","February 1, 2018","May 22, 2022","May 22, 2022","May 19, 2017",,"February 26, 2024","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03160638"
304,"NCT02066428","A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection",,"Completed","No Results Available","Tuberculosis","Biological: AERAS-404|Biological: Placebo","Evaluate the safety of one or two injections of two AERAS 404 antigen amounts administered with three different amounts of adjuvant|Evaluate the immunogenicity of one or two injections of two AERAS 404 antigen amounts administered with three different amounts of adjuvant.","Aeras|Statens Serum Institut","All","18 Years to 50 Years   (Adult)","Phase 1","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-005-404","November 2007","May 2009","May 2009","February 19, 2014",,"February 19, 2014","Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02066428"
305,"NCT02333799","A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Bedaquiline|Drug: PA-824|Drug: Linezolid","Incidence of bacteriologic failure or relapse or clinical failure through follow up until 6 months after the end of treatment.|Time to sputum culture conversion to negative status through the treatment period.|Proportion of subjects with sputum culture conversion to negative status at 4, 6, 8, 12, 16 and 26 or 39 weeks.|Incidence of Treatment Emergent Adverse Events (TEAEs) presented by incidence, and seriousness, leading to TB related or non-TB related death.|All Subjects- Pre-dose sampling at weeks 2, 8 and 16 to measure Ctrough levels of bedaquiline, bedaquiline metabolite M2, Linezolid and PA-824.|Time to sputum culture positivity","Global Alliance for TB Drug Development","All","14 Years and older   (Child, Adult, Older Adult)","Phase 3","109","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NiX-TB-(B-L-Pa)","March 2015","January 14, 2019","August 3, 2020","January 7, 2015",,"November 23, 2020","Task Applied Science - Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa|King DinuZulu Hospital Complex, Sydenham, Durban, South Africa|Sizwe Tropical Disease Hospital, Sandringham, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT02333799"
306,"NCT01587469","Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects",,"Completed","No Results Available","Tuberculosis",,"Proportion of all participants with Xpert MTB/RIF Assay MTB positive in sputum #1 who are AFB smear positive and MGIT culture positive for M.tuberculosis.|Proportion of all participants with Xpert MTB/RIF Assay MTB positive in sputum #1 who are AFB smear negative and MGIT culture positive for M.tuberculosis.|Proportion of US participants with Xpert MTB/RIF Assay MTB negative in sputum #1 who are MGIT culture negative for M.tuberculosis.","Cepheid|AIDS Clinical Trials Group|Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)",,"992","Industry|Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACTG A5295","May 2012","February 21, 2014","February 21, 2014","April 30, 2012",,"February 6, 2018","Ucsf Aids Ctu, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01587469"
307,"NCT03069807","Completion and Acceptability of Treatment Across Primary Care and the commUnity for Latent Tuberculosis","CATAPULT","Completed","No Results Available","Latent Tuberculosis","Other: Community/Primary Care|Other: Hospital/TB Clinic","Completion of Latent Tuberculosis Treatment|Complete of Latent Tuberculosis Treatment|Adherence to Treatment|Acceptability of Treatment|Adverse Effects of Treatment|Active Tuberculosis|Patient Satisfaction|Cost-effectiveness of Treatment|Patient Knowledge","Queen Mary University of London|University College, London|Public Health England","All","16 Years to 35 Years   (Child, Adult)","Not Applicable","362","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","4212301","January 2017","September 2019","March 2020","March 3, 2017",,"November 26, 2021","Shrewsbury Road Health Centre, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03069807"
308,"NCT01363765","Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil",,"Completed","Has Results","Tuberculosis","Other: Xpert MTB/Rif|Other: Smear microscopy","Notification Rate Ratio|Costs Per Detected Case|NRR of Non-laboratory Tested TB (Cluster-averaged).|NRR of Negative-laboratory TB (Cluster-averaged).","Ataulpho de Paiva Foundation|Bill and Melinda Gates Foundation","All","Child, Adult, Older Adult","Phase 4","34758","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OPPGH5254|GH5254","February 2012","October 2012","October 2012","June 2, 2011","March 12, 2014","March 12, 2014","Laboratories of Rio de Janeiro Health Department, Rio de Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT01363765"
309,"NCT01691534","Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)","NC-003","Completed","Has Results","Pulmonary Tuberculosis","Drug: TMC207 (J)|Drug: PA-824 (PA)|Drug: pyrazinamide (Z)|Drug: clofazimine (C)|Drug: Rifafour","Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14).|EBA Measured as the Daily Rate of Change in log10 CFUs of M. Tuberculosis in Sputum on Solid Media (Days 0-2)|EBA Measured as the Daily Rate of Change in log10 CFUs of M. Tuberculosis in Sputum on Solid Media (Days 7-14)|EBA Expressed as the Daily Percentage Change in Time to Positive (TTP) Signal in Liquid Culture for M. Tuberculosis (Days 0-14)|EBA Expressed as the Daily Percentage Change in TTP Signal in Liquid Culture for M. Tuberculosis (Day 0-2)|EBA Expressed as the Daily Percentage Change in TTP Signal in Liquid Culture for M. Tuberculosis (Days 7-14)","Global Alliance for TB Drug Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NC-003-(C-J-Pa-Z)","October 2012","April 2013","May 2013","September 24, 2012","December 13, 2016","December 13, 2016","Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa|Task Applied Science, Karl Bremer Hospita, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01691534"
310,"NCT00979290","Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs",,"Completed","No Results Available","Tuberculosis",,"To compare the frequency of occurrence of adverse reactions between using FDC and single drugs in pulmonary tuberculosis treatment|To compare the efficacy of anti-TB treatment between using FDC and single drugs","E-DA Hospital","All","18 Years and older   (Adult, Older Adult)",,"161","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","J120114933","October 2008","November 2009","November 2011","September 17, 2009",,"April 16, 2015","E-DA hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00979290"
311,"NCT05945498","Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years",,"Active, not recruiting","No Results Available","Tuberculosis Infection","Biological: TB/Flu-05E vaccine|Biological: Placebo","Number of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs)|Concentration of cytokines in nasal secrets after vaccination|Level of mucosal IgA antibody in nasal secret/saliva|Level of TB antigen-specific cytokine producing T-cells|Level of influenza specific cytokine producing T-cells|Level of TB antigen-specific cytokine release in whole blood assay|Level of А/H1N1pdm09 influenza specific cytokine release in whole blood assay|Level of TB antigen-specific IgG antibody|Influenza specific local antibody immune response|Influenza specific systemic antibody immune response","Tatyana Zubkova|Research Institute of Influenza, Russia","All","18 Years to 50 Years   (Adult)","Phase 1","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ВПТ-II-01/2022","May 10, 2023","June 16, 2023","September 17, 2023","July 14, 2023",,"July 14, 2023","Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05945498"
312,"NCT01517022","Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: nicotine replacement therapy","1. Change in TB Score at second month and sixth month|Sputum culture conversion|Sputum smear conversion|Mortality at sixth month|More than 10% weight gain at six months|Proportion of subjects in each group that have quit smoking at second month|Treatment completion|Cure, failure and default rate","All India Institute of Medical Sciences, New Delhi|University of Cape Town|Sri Venkateswara Institute of Medical Sciences University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","SKS/Med/NI1161","November 2010","September 2016","September 2016","January 25, 2012",,"October 13, 2017","All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT01517022"
313,"NCT02971644","Cobalt Alloy Pedicle Screw Implantation for Severe Kyphosis Deformity in Spinal Tuberculosis",,"Unknown status","No Results Available","Spinal Tuberculosis","Device: cobalt alloy pedicle screw implantation","Cobb angle|X-ray image|Frankel Grade","Affiliated Hospital of Hebei University","All","24 Years to 67 Years   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HebeiU_001","December 2014","June 2015","December 2016","November 23, 2016",,"November 23, 2016",,,"https://ClinicalTrials.gov/show/NCT02971644"
314,"NCT04813666","Lipoarabinomannan (LAM) in Urine for Diagnosis of Pulmonary Tuberculosis in HIV Patients",,"Completed","No Results Available","TB - Tuberculosis HIV","Diagnostic Test: Urinary LAM ELISA:","positive for TB","Mansoura University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","214","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MansouraU LAM","January 1, 2015","August 1, 2016","October 1, 2016","March 24, 2021",,"March 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04813666"
315,"NCT05007795","Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis","T3-RCT","Not yet recruiting","No Results Available","Tuberculosis, Multidrug-Resistant","Diagnostic Test: Targeted sequencing using the GenoScreen Deeplex assay","Impact of targeted genome sequencing to initiate more than or equal to five effective TB drugs within 14 days of diagnosis (reference standard phenotypic DST).|Feasibility of targeted sequencing to initiate more than or equal to five effective TB drugs within 14 days of diagnosis.","University of Cape Town|University of Stellenbosch|Ospedale San Raffaele|Stichting Katholieke Universiteit|University of Cape Town Lung Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","T3-RCT|743-2018","July 2023","August 2026","July 2027","August 16, 2021",,"July 27, 2023","University of Cape Town, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT05007795"
316,"NCT05306223","A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China","PROSPECT","Recruiting","No Results Available","Tuberculosis, Multidrug-Resistant","Drug: Bedaquiline|Drug: Levofloxacin|Drug: Linezolid|Drug: Cycloserine|Drug: Clofazimine|Drug: Pyrazinamide|Drug: Protionamide","Percentage of Participants with a Favorable Treatment Outcome at the End of Treatment|Percentage of Participants with a Favorable Treatment Outcome at 48 Weeks Post the End of Treatment|Percentage of Participants Achieving Treatment Success at the end of Treatment|Percentage of Participants with a Modified Favorable Treatment Outcome at the end of Treatment and at 48 Weeks Post end of Treatment|Percentage of Participants Experiencing All-cause Mortality|Percentage of Participants Experiencing Grade 3 or Greater Treatment-emergent Adverse Events (TEAEs) During Study Treatment and Follow-up|Percentage of Participants Experiencing TEAEs|Percentage of Participants with TB Relapses and Re-infections During the Treatment-free Follow-up Phase|Percentage of Participants Whose Isolates Develop Resistance to Bedaquiline and Other Drugs Used in the Regimen","Beijing Chest Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMC207TBC4006","May 10, 2022","August 8, 2025","August 8, 2025","April 1, 2022",,"January 18, 2023","Beijing Chest Hospital, Beijing, China|The Eighth Medical Center of PLA General Hospital, Beijing, China|Changsha Central Hospital, Changsha, China|Public health clinical medical center of Chengdu, Chengdu, China|Chongqing Public Health Medical Center, Chongqing, China|The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China|Guiyang Public Health Clinical Center, Guiyang, China|Anhui Chest Hospital, Hefei, China|Infectious Disease Hospital of Heilongjiang Province, Heilongjiang, China|Jiamusi Tumor Hospital, Jiamusi, China|Jiangxi Chest Hospital, Jiangxi, China|Shandong public health clinical center, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, China|Shenyang Chest Hospital, Shenyang, China|Wuhan Pulmonary Hospital, Wuhan, China|Xi'an Chest Hospital, Xi'an, China|The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China",,"https://ClinicalTrials.gov/show/NCT05306223"
317,"NCT02256696","Assessing PA-824 for Tuberculosis (the APT Trial)",,"Completed","Has Results","Pulmonary Tuberculosis","Drug: PA-824|Drug: Rifampin|Drug: Rifabutin|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Isoniazid","Time to Sputum Culture Conversion on Liquid Medium|Number of Participants With Grade 3 or Higher Adverse Events|Number of Participants With Permanent Discontinuation of Assigned Study Regimen|Time to Culture Conversion on Solid Medium|Percentage of Participants With Sputum Culture Conversion by 8 Weeks of Treatment|Steady State Pharmacokinetics (PK) (AUC) of PA-824 When Given With Rifampin or Rifabutin|PK (Cmax) of PA-824 at 200 mg Once Daily With Rifampin or Rifabutin-containing Treatment|Relationship Between PA-824 Exposure (AUC) and Rate of Change in Time to Positivity (TTP) Over 12 Weeks","Johns Hopkins University|University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Phase 2","157","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00093014|#FD-R-004794-01","April 29, 2015","May 1, 2022","May 1, 2022","October 6, 2014","July 18, 2023","July 18, 2023","University of Cape Town Lung Institute, Cape Town, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT02256696/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT02256696/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02256696"
318,"NCT00203762","Effect of Public Sector Antiretroviral Treatment Programme on Tuberculosis and Immunization Care",,"Unknown status","No Results Available","Tuberculosis","Behavioral: Public sector antiretroviral treatment programmes","TB case detection|TB treatment completion|Measles immunization completed by 18 months|TB cure rate|TB mortality rate|TB treatment failure rate|TB treatment interruption rate|Proportion of TB cases that smear positive","University of Cape Town|Free State Department of Health|Medical Research Council, South Africa|Knowledge Translation Programme, University of Toronto|Institute for Clinical Evaluative Sciences|London School of Hygiene and Tropical Medicine|University of the Western Cape","All","Child, Adult, Older Adult","Not Applicable","39","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDRC 102770-001","May 2003",,"December 2006","September 20, 2005",,"October 24, 2007","University of Cape Town Lung Institute, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00203762"
319,"NCT06191692","1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam",,"Not yet recruiting","No Results Available","Tuberculosis Infection","Drug: Isoniazid|Drug: Rifapentine|Drug: Rifampicin","1. % Adequate adherence in each arm|The incidence rate of severe adverse events among two arms.|Comparison of adherence measured as the proportion of treatment taken in the regimens (1HP vs 3HR).|The incidence rate of a targeted event of grade 3,4 or 5*** and one grade increase from the baseline among two arms.","Freundeskreis Für Internationale Tuberkulosehilfe e.V","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBIshort","April 1, 2024","December 1, 2024","December 1, 2026","January 5, 2024",,"February 20, 2024","Vietnam National Lung Hospital, Hà Nội, Ha Noi, Vietnam|Ha Noi Lung Hospital, Hà Nội, Vietnam",,"https://ClinicalTrials.gov/show/NCT06191692"
320,"NCT02371681","NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Treatment|Radiation: PET/CT Scan|Procedure: Sample Collection","To characterize, in the context of a standard EBA study, the effect of various antituberculosis drugs on radiographic and immunologic markers as measured by PET/CT and immunologic assays, in subjects with drug sensitive pulmonary tuberculosis wh...|PET/CT Changes|Rank order of drugs","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","262","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","999915070|15-I-N070","February 25, 2015","September 1, 2017","November 14, 2017","February 26, 2015",,"June 18, 2023","Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa|TASK Applied Sciences, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT02371681"
321,"NCT00265226","Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients",,"Completed","No Results Available","Tuberculosis","Biological: Intra-dermal administration of Mycobacterium w","The time of sputum conversion as well as the early sputum conversion between the 2 groups will be evaluated.|The cure rate will be evaluated as the primary parameter of efficacy.|The relapse in patients of category II tuberculosis will be compared in both the groups.|Recording of any clinical adverse reactions at anytime during the study for assessment of safety|An additional secondary efficacy endpoint is the patient's and physician's global assessment of the clinical cure.","Ministry of Science and Technology, India","All","18 Years to 60 Years   (Adult)","Phase 3","1020","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-01A/2003-10|NI-705","March 2005","December 2010","March 2011","December 14, 2005",,"January 6, 2014","Mahavir Hospital, Hyderabad, Andhra Pradesh, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Lala Ram Swarup Institute of Tuberculosis and Respiratory Diseases, New Delhi, Delhi, India|Smt NHL Municipal Medical College & B.J. Medical College, Ahmedabad, Gujarat, India|National Tuberculosis Institute, Bangalore, Karnataka, India|SMS Medical College, Jaipur, Rajasthan, India|Tuberculosis Research Centre, Chennai, Tamilnadu, India|Central JALMA Institute of Leprosy, Agra, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT00265226"
322,"NCT02464683","Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis","VitaminD","Unknown status","No Results Available","Pulmonary Tuberculosis","Dietary Supplement: VitaminD","Determination of cytokines","Instituto Nacional de Enfermedades Respiratorias","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INERC50-13","April 2014","December 2015","December 2016","June 8, 2015",,"June 8, 2015","Martha Torres Rojas, Mexico city, DF, Mexico",,"https://ClinicalTrials.gov/show/NCT02464683"
323,"NCT00427830","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A","The occurance and severity of local and systemic side effects will be monitored. Vital signs and local reactions will be monitored at 30 and 60 minutes after each immunisation (and after 7 days).|Immunogenicity will be measured: The induction of T cell responses (as measured by an interferon-gamma Elispot assay) will be performed on PBMCs from blood samples taken at the specified time points.|Proliferation assays and cytotoxic T cell assays will be performed on strong CD4+ and CD8+ responses respectively.|Antibody titres will be measured from frozen plasma samples.","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB005","May 2003",,"January 2005","January 29, 2007",,"January 29, 2007","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00427830"
324,"NCT00427453","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A","The occurance and severity of local and systemic side effects will be monitored. Vital signs and local reactions will be monitored at 30 and 60 minutes after each mmunisation (and after 7 days).|Blood will be taken at: the screening visit, prior to the BCG vaccination, 1 and 4 weeks after the BCG vaccination, and also at 1,4, 8, 12 and 24 weeks after the MVA85A vaccination.|Immunogenicity will be measured: The induction of T cell responses (as measured by an interferon-gamma Elispot assay) will be performed on PBMCs from blood samples taken at the specified time points.|Proliferation assays and cytotoxic T cell assays will be performed. Other serological measures of immune response, i.e. antibody titres will be analysed on frozen plasma samples.","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB004","June 2003",,"March 2005","January 29, 2007",,"January 29, 2007","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00427453"
325,"NCT02581527","A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis","RIFASHORT","Completed","No Results Available","Pulmonary Tuberculosis","Drug: Rifampicin|Drug: Isoniazid|Drug: Ethambutol|Drug: Pyrazinamide","The occurrence of grade 3 or 4 adverse events at any time during chemotherapy.|the primary outcome measure is the combined rate of failure at the end of treatment and relapse during the subsequent 12 months in smear positive patients in the modified intent to treat population.|Sputum cultures positive for M.tuberculosis at 8 and 12 weeks from randomisation.|Per protocol analysis of the primary efficacy outcome (the combined rate of failure at the end of treatment and relapse during the subsequent 12 months in smear positive patients)|Combined unfavourable endpoint (rate of failure at the end of treatment and relapse) measured 18 months from randomisation in the Xpert MTB/RIF positive (i) modified intent-to-treat and (ii) per protocol populations|Any adverse event, up to one month after completion of treatment, graded according to the DAIDS criteria|Time to unfavourable outcome in the modified intent-to-treat and per protocol sputum smear microscopy-positive population.","St George's, University of London|London School of Hygiene and Tropical Medicine|University of Botswana","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","672","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15.0190","February 1, 2017","January 1, 2022","July 31, 2022","October 21, 2015",,"April 27, 2023","University of Botswana, Gaborone, Botswana|Hopital National Ignace Deen, Conakry, Guinea|GENETUP, National Anti-TB Association, Kathmandu, Nepal|Aga Khan University Hospital, Karachi, Pakistan|Hospital Nacional Dos de Mayo, Lima, Peru|Epicentre, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT02581527"
326,"NCT02193776","A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.","NC-005","Completed","Has Results","Tuberculosis","Drug: PA-824|Drug: bedaquiline|Drug: moxifloxacin|Drug: pyrazinamide|Drug: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet","Rate of Change in Time to Sputum Culture Positivity (TTP) Over 8 Weeks in the Mycobacterial Growth Indicator Tube (MGIT) System|Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Global Alliance for TB Drug Development","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NC-005-(J-M-Pa-Z)","October 23, 2014","February 8, 2016","February 7, 2018","July 18, 2014","July 26, 2019","July 26, 2019","The Aurum Institute: Tembisa Hospital, Tembisa, Gauteng, South Africa|Klerksdorp Tshepong Hospital, Jouberton, Klerksdorp, South Africa|TASK Applied Science, Cape Town, South Africa|University of Cape Town Lung Institute (Pty) Ltd, Cape Town, South Africa|THINK: Tuberculosis & HIV Investigative Network of KwaZulu-Natal, Durban, South Africa|CHRU Themba Lethu Clinic, Johannesburg, South Africa|University of Witwatersrand, Clinical HIV Research Unit (CHRU), Helen Joseph Hospital, Johannesburg, South Africa|Ifakara Health Institute, Bagamoyo, Tanzania|NIMR-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania|Uganda Case Western Reserve University Research Collaboration, Kampala, Uganda","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/76/NCT02193776/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/76/NCT02193776/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02193776"
327,"NCT00944021","Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)",,"Completed","Has Results","Pulmonary Tuberculosis","Drug: PA-824|Drug: Rifafour e-275 mg","Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).|Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14).|Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2).|Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14).|Pharmacokinetics- Maximum Observed Plasma Concentration (Cmax) (Day 1).|Pharmacokinetics- Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC 0 to Infinity) (Day 1).|Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 1).|Pharmacokinetics-Maximum Observed Plasma Concentration (Cmax) (Day 14).|Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 14).","Global Alliance for TB Drug Development","All","18 Years to 64 Years   (Adult)","Phase 2","69","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PA-824-CL-010","August 2009","January 2010","May 2010","July 22, 2009","March 9, 2016","September 20, 2019",,,"https://ClinicalTrials.gov/show/NCT00944021"
328,"NCT01215851","Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)",,"Completed","Has Results","Pulmonary Tuberculosis","Drug: PA-824|Drug: Pyrazinamide|Drug: TMC207|Drug: Rifafour|Drug: Moxifloxacin","Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 7-14).|Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14)","Global Alliance for TB Drug Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NC-001-(J-M-Pa-Z)","October 2010","May 2011","August 2011","October 7, 2010","April 1, 2016","February 28, 2017","Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa|Task Applied Science, Karl Bremer Hospital, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01215851"
329,"NCT06199921","ATORvastatin in Pulmonary TUBerculosis","ATORTUB","Recruiting","No Results Available","Pulmonary Tuberculosis|Tuberculosis|Koch's Disease","Drug: Atorvastatin 20mg|Drug: Atorvastatin 40mg|Drug: Atorvastatin 60mg","Safety: Proportion of participants with grade 3 or higher adverse events during study drug treatment|Efficacy:Time to stable sputum culture conversion on solid and /liquid media|Efficacy: TB disease-free survival at six months post randomization|Efficacy: Proportion of participants who are culture negative|Efficacy: TB disease-free survival at twelve months post randomization|Efficacy: Proportion of participants who are symptom free at 12 months post randomization|Efficacy: Proportion of participants with improved chest x-ray severity|Efficacy: Proportion of participants with improvement in lung function post treatment","Obafemi Awolowo University Teaching Hospital|Open Philanthropy","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ERC/2023/11/15|IRB/IEC/0004553","January 3, 2024","November 30, 2024","May 30, 2025","January 10, 2024",,"January 10, 2024","National Tuberculosis Reference Laboratory, Zaria, Kaduna, Nigeria|Federal Medical Center, Keffi, Nasarawa, Nigeria|Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, Osun, Nigeria|Bowen University Teaching Hospital, Iwo, Osun, Nigeria|University College Hospital, Ibadan, Oyo, Nigeria|University of Abuja Teaching Hospital, Gwagwalada, Nigeria|Federal Teaching Hospital, Katsina, Nigeria|Usman Danfodio University, Sokoto, Nigeria",,"https://ClinicalTrials.gov/show/NCT06199921"
330,"NCT00507000","Pulmonary Tuberculosis and Vitamin D",,"Unknown status","No Results Available","Tuberculosis","Drug: Cholecalciferol|Drug: Lactose granules","Time to convert from sputum positivity to negativity|1 To study the relapse rate and safety assessment 2 To study the effect of Vitamin D supplementation on the pattern of effector immune function in patients suffering from pulmonary Tuberculosis.","Indian Council of Medical Research|Ministry of Science and Technology, India","All","18 Years to 60 Years   (Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","BT/pr7898/Med/14/1179/2006","May 2008","September 2010","September 2012","July 25, 2007",,"January 27, 2011","Depratment of Endocrinology;Medicine, All India Institute of Medical sciences, and DBT, Delhi, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00507000"
331,"NCT01215110","Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)",,"Completed","Has Results","Pulmonary Tuberculosis","Drug: TMC207|Drug: Rifafour e-275 mg","Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 7-14).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).|Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).|Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14)|Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2)|Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14)|Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 7-14)|Summary of Statistical Analysis of TMC207 Maximum Plasma Concentration Following Dosing (C(Max)) on Days 1 and 14|Summary of Statistical Analysis of TMC207 Time of Maximum Plasma Concentration (T(Max)) on Days 1 and 14|Summary of Statistical Analysis of TMC207 Area Under the Concentration-time Curve Over the Dose Interval of 0 to 24 h (AUC(0-24)) on Day 1 and Day 14","Global Alliance for TB Drug Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TMC207-CL001","April 2010","August 2010","September 2010","October 6, 2010","April 26, 2017","April 26, 2017","Karl Bremer Hospital, Belville, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01215110"
332,"NCT01043575","High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis","TBTC-29PK","Completed","No Results Available","Smear Positive, Pan-sensitive, Pulmonary Tuberculosis","Drug: Rifapentine|Drug: Rifampin","The primary objective of this study is to characterize rifapentine pharmacokinetic parameters (AUC0-24 and peak concentration) in patients with TB.|• To assess the pharmacodynamic effects of higher dose, daily rifapentine AUC0-24 on tolerability and safety during two months of treatment of tuberculosis.|• To assess the pharmacodynamic effect of rifapentine pharmacokinetic parameters (AUC0-24) on biomarkers of treatment activity in patients with tuberculosis.|• To assess in multivariate analyses the pharmacodynamic effect on biomarkers of treatment activity of the independent variables of rifapentine AUC0-24, HIV infection, isoniazid exposure (AUC0-12) and study site (African vs. non-African).|To determine if free (non-protein bound) rifapentine and free rifampin exposures are directly associated with anti-mycobacterial activity.|• To determine the effects of polymorphisms of transporter genes on rifampin and rifapentine pharmacokinetic parameters.","Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBTC Study 29PK","April 2009","May 2010","May 2010","January 7, 2010",,"August 17, 2012","Denver Public Health, Denver, Colorado, United States|University of North Texas, Denton, Texas, United States|TBTC site 40 / South Texas, Harlingen, Texas, United States|Audie L. Murphy VA Medical Center, San Antonio, Texas, United States|University of KwaZulu Natal, Durban, South Africa|Uganda / Case Western Reserve Research Collaboration, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01043575"
333,"NCT01269268","Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis",,"Completed","No Results Available","Active Tuberculosis",,"Characterization of antigens of Mycobacterium tuberculosis K strain for serodiagnosis of tuberculosis","Yonsei University","All","20 Years to 75 Years   (Adult, Older Adult)",,"270","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","4-2010-0213","June 2010","May 14, 2014","May 14, 2014","January 4, 2011",,"March 18, 2019","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01269268"
334,"NCT05766267","Short-course Regimens for the Treatment of Pulmonary Tuberculosis","CRUSH-TB","Recruiting","No Results Available","Tuberculosis, Pulmonary|Tuberculosis Infection","Drug: Rifabutin|Drug: Delamanid|Drug: Bedaquiline|Drug: Moxifloxacin|Drug: Pyrazinamide|Drug: Isoniazid|Drug: Rifampin|Drug: Ethambutol","Time to sputum culture negative in liquid media after study treatment among participants in Experimental Regimens (2 BZMRb/ 2 BMRb, Arm 1) and (2 BMZD/ 2 BMD, Arm 2) compared to Control (2HRZE/4HR, Arm 3) in modified intention-to-treat group (ITT)|The proportion of participants with a grade 3 or higher adverse event in Experimental Regimens (2 BZMRb/2 BMRb, Arm 1) and (2 BMZD/2 BMD, Arm 2) compared to Control Regimen (2HRZE/4HR, Arm 3) in the modified intention-to-treat group|The proportion of participants experiencing lack of sustained cure in each experimental regimens (2BZMRb/2BMRb, Arm 1) and (2BMZD/2BMD, Arm 2) compared to Control Regimen (2HRZE/4HR, Arm 3)|Time to sputum culture negative in solid media after study treatment assignment among participants in Experimental Regimens (2BZMRb/2BMRb, Arm 1) and (2BMZD/2BMD, Arm 2) compared to Control Regimen (2HRZE/4HR, Arm 3) in modified intention-to-treat group|Proportion of participants with sputum culture negative by 8 weeks and by 12 weeks (solid and liquid media) in all 3 regimens|All-cause study drug discontinuation among participants in experimental regimens compared to control regimen|The rate of change in time to sputum culture positivity (TTP) through 17 weeks in the Mycobacterial Growth Indicator Tube (Bactec MGIT960) among participants in all three regimens|Clearance of bedaquiline|Volume of Distribution of bedaquiline|Rate of absorption of bedaquiline","Centers for Disease Control and Prevention|Tuberculosis Trials Consortium","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","288","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7406","November 21, 2023","October 30, 2025","December 31, 2026","March 13, 2023",,"January 8, 2024","TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States|TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States|TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States|McGill University Health Centre, Montréal, Canada|Vancouver, British Columbia Centre for Disease Control, Vancouver, Canada|TBTC Site 45 Les Centres Gheskio (INLR), Port au Prince, Ouest, Haiti|TBTC Site 67 GHESKIO centers IMIS, Port-au-Prince, Ouest, Haiti|TBTC Site 09 University of Cape Town Lung Institute (Pty) Ltd, Mowbray, Cape Town, South Africa|TBTC Site 30 Uganda-Case Western Reserve Research Collaboration, Kampala, Uganda|TBTC Site 76 CAB-V. Can Tho Province, Vietnam - Thot Not District TB Unit, Cần Thơ, Can Tho, Vietnam|TBTC Site 74 CAB-V. Ho Chi Minh City, Vietnam - District 6 TB Unit, Ho Chi Minh City, Ho Chi Minh, Vietnam|TBTC Site 75 CAB-V. Ho Chi Minh City, Vietnam - Phoi Viet Respiratory Centre, Ho Chi Minh City, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT05766267"
335,"NCT01498419","Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)",,"Completed","Has Results","Pulmonary Tuberculosis","Drug: Moxifloxacin (M)|Drug: Pretomid (Pa)|Drug: Pyrazinamide (Z)|Drug: Rifafour","The Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) Over 8 Weeks of Treatment.|Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Liquid Media|Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Solid Media|The Rate of Change in Time to Sputum Culture Positivity (TTP) Through 8 Weeks in the MGIT System in Sputum Over 8 Weeks in Participants as Derived From a Non-linear Regression Model.|Percentage of Participants Who Discontinue Due to an Adverse Event in Each Experimental Arm.|Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Solid Media|Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Liquid Media","Global Alliance for TB Drug Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","207","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NC-002-(M-Pa-Z)","March 2012","April 2013","July 2013","December 23, 2011","December 12, 2016","June 28, 2018","Task Applied Science, Karl Bremer Hospital, Cape Town, South Africa|University of Cape Town Lung Institute (Pty) Ltd, Cape Town, South Africa|KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban, South Africa|CHRU Themba Lethu Clinic, Johannesburg, South Africa|Klerksdorp Tshepong Hospital, Klerksdorp, South Africa|The Aurum Institute: Tembisa Hospital, Tembisa, South Africa|Ifakara Health Institute, Bagamoyo, Tanzania|Mbeya Medical Research Programme, Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT01498419"
336,"NCT00803322","Improving Community Based Tuberculosis Care in Ethiopia","community","Completed","No Results Available","Pulmonary Tuberculosis",,"smear positive tuberculosis case notification rate|smear positive treatment success rate","University of Bergen|Centre for International Health, SNNP Regional health Bureau","All","Child, Adult, Older Adult",,"318","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0001|001","September 2006","September 2007","April 2008","December 5, 2008",,"December 5, 2008","Dale and Wonsho districts Sidama zone, Southern Ethiopia, Yirgalem, Snnpr, Ethiopia",,"https://ClinicalTrials.gov/show/NCT00803322"
337,"NCT06041919","Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis",,"Recruiting","No Results Available","Rifampicin Susceptible Pulmonary Tuberculosis","Drug: RESP301|Drug: HRZE","Early Bactericidal Activity (EBA) of inhaled RESP301 measured as time to positivity (TTP)|Early Bactericidal Activity (EBA) of inhaled RESP301 measured as colony forming units (CFU)|Safety and tolerability of inhaled RESP301 measured as incidence of Treatment Emergent Adverse Events (TEAEs)","Thirty Respiratory Limited","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RESP30X-EBA","September 27, 2023","April 30, 2024","July 31, 2025","September 18, 2023",,"October 10, 2023","TASK Clinical Research Centre, Cape Town, Bellville, South Africa",,"https://ClinicalTrials.gov/show/NCT06041919"
338,"NCT00317330","A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: Isoniazid|Drug: Pyrazinamide|Drug: Rifampin",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult","Phase 3","6400","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-581|ICIDR#1","December 2004",,"June 2005","April 24, 2006",,"August 27, 2010","Municipal Health Department, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00317330"
339,"NCT01252992","Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis","PARATB","Completed","No Results Available","Extrapulmonary Tuberculosis","Genetic: Genetic analysis|Radiation: Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|Other: Immunologic analysis|Other: QuantiferonTB Gold test","Risk factors of paradoxical reaction|Incidence and natural history of paradoxical reactions|Immune description of paradoxical reactions|Preliminary study of Diagnosis factors of paradoxical reaction","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"135","Other","Observational","Observational Model: Other|Time Perspective: Prospective","P081253|2010-A00375-34","March 14, 2011","February 21, 2018","February 21, 2018","December 3, 2010",,"May 28, 2021","Georges Pompidou Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT01252992"
340,"NCT00396084","Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis",,"Completed","Has Results","Tuberculosis","Drug: Gatifloxacin|Drug: Isoniazid|Drug: Levofloxacin|Drug: Linezolid|Drug: Moxifloxacin","Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)|Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Fluoroquinolones/Isoniazid (INH) Comparison|Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Fluoroquinolones/Isoniazid (INH) Comparison|Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Linezolid Once Daily/Linezolid Twice Daily/Isoniazid (INH) Comparison|Difference in Sputum Bacillary Loads: Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Linezolid Once Daily/Linezolid Twice Daily/INH Comparison|Sputum mRNA Clearance Rate - Results Are Pending.|Sputum Cytokine Proteins - Results Are Pending.|Maximum Plasma Drug Concentration (Cmax)|Time to Maximum Plasma Drug Concentration (Tmax) and Half-life|Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC)|Pharmacokinetic Parameters: Area Under the Curve (AUC) During First 12 and 24 Hours|Area Under the Curve During First 12 or 24 Hours / Minimum Inhibitory Concentration (AUC/MIC)|Pharmacokinetic Parameters: Area Under the Curve During First 12 and 24 Hours|Maximum Plasma Drug Concentrations (Cmax), Adjusted for Free Drug Concentration|Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC) Adjusted for Free Drug Concentrations|Area Under the Curve (AUC) During First 12 and 24 Hours Adjusted for Free Drug Concentrations|Area Under the Curve (AUC) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC)|Percent Dosing Interval Above Minimum Inhibitory Concentration (MIC)","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-553","February 10, 2004","November 23, 2007","December 28, 2007","November 6, 2006","June 25, 2009","November 8, 2018","San Francisco General Hospital - Pulmonary and Critical Care Medicine, San Francisco, California, United States|Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil",,"https://ClinicalTrials.gov/show/NCT00396084"
341,"NCT01600963","A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis",,"Withdrawn","No Results Available","Multi-drug Resistant Tuberculosis","Drug: Arm A Double-blind Phase: TMC207|Drug: Arm B Double-blind Phase: Placebo|Drug: Treatment Failure During Double-blind Phase: TMC207|Drug: Treatment Failure During Follow-up Phase: TMC207","Number of patients with favorable treatment outcome at Week 60|Number of patients with confirmed culture conversion at Week 84|Number of patients with confirmed culture conversion at Week 60 or at time of trial discontinuation|The number of patients with development of pre-extensively drug-resistant tuberculosis and extensively drug-resistant tuberculosis|Time to sputum culture conversion|Number of patients with negative culture and smear for tuberculosis|Time to positive signal in Mycobacteria Growth Indicator Tube (MGIT960)|Number of patients with confirmed culture conversion by lung cavity status|Number of patients with confirmed culture conversion by geographic region|Number of patients with confirmed culture conversion by human immunodeficiency virus status|Number of patients with confirmed culture conversion by baseline resistance to anti-tuberculosis therapy|Number of patients with Tuberculosis Symptom Profile symptoms at Week 36 and at the end of the treatment-free follow up|Number of tuberculosis-related deaths per investigator assessment|Number of patients with weight gain (greater than 5 percent) at Week 36 and at the end of the treatment-free follow up|Number of patients with improvements in laboratory assessments at Week 36 and at the end of the treatment-free follow up|Number of patients with improvements in chest radiograph assessments at Week 36 and at the end of the treatment-free follow up|Number of patients that received salvage regimen with favorable treatment outcome 24 weeks after the end of the individualized salvage regimen|Mean plasma concentrations of TMC207|Mean plasma concentrations of N-monodesmethyl metabolite of TMC207|Number of patients affected by an adverse event|Number of patients with confirmed culture conversion at Week 36|Number of patients who required lung surgeries (resection or pneumonectomy) during the study|Number of patients with confirmed culture conversion by baseline albumin grade|Number of patients with confirmed culture conversion by baseline TMC207 minimal inhibitory concentration|Number of patients with confirmed culture conversion at Week 132|Number of patients who experienced death|Number of patients will be qualified as cure based on the WHO outcome definition and the number of treatment failures, deaths, transfer out/defaults, and treatment completed","Janssen Infectious Diseases BVBA","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR100807|TMC207-TIDP13-C210|2011-000653-23|U1111-1135-7013","March 2014","July 2016","November 2022","May 17, 2012",,"December 2, 2015","Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|Phnom Penh, Cambodia|Beijing, China|Changsha, China|Chongqing, China|Fuzhou, China|Jinan, China|Nanjing, China|Shanghai, China|Kohtla-Järve, Estonia|Talinn, Estonia|Addis Ababa, Ethiopia|Gondar, Ethiopia|Tbilisi, Georgia|Busan, Korea, Republic of|Daegu, Korea, Republic of|Gwangju, Korea, Republic of|Gyeongsangnam-Do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Stopinu Region, Latvia|Monterrey, Mexico|Lima, Peru|Quezon City, Philippines|Arkhangelsk, Russian Federation|Ekaterinburg, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Orel, Russian Federation|Saint-Petersburg, Russian Federation|Paarl, South Africa|Sandringham, South Africa|Ysterplaat, South Africa|Changhua County, Taiwan|New Taipei City, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Nonthaburi, Thailand|Kecioren, Turkey|Donetsk, Ukraine|Kiev, Ukraine|Ternopil, Ukraine",,"https://ClinicalTrials.gov/show/NCT01600963"
342,"NCT04311502","Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study",,"Active, not recruiting","No Results Available","HIV|Tuberculosis","Drug: Clofazimine (CFZ)|Drug: Rifapentine (RPT)|Drug: Isoniazid (INH)|Drug: Pyrazinamide (PZA)|Drug: Ethambutol (EMB)|Drug: Rifampicin (RIF)|Dietary Supplement: Pyridoxine (vitamin B6)","Time to stable culture conversion in liquid media|Proportion of participants across study arms experiencing any Grade 3 or higher adverse event (AE) that is at least a one grade increase from baseline|Proportion of participants with favorable clinical/bacteriologic outcome|Proportion of participants with favorable composite outcome including treatment completion|Proportion of participants across study arms who prematurely discontinue their treatment regimen|Mean QTcF change from baseline|Occurrence of absolute QTcF ≥480 ms and ≤500 ms, and ≥500 ms at any time during study treatment|Occurrence of QTcF change from baseline of ≥30 ms and ≤60 ms, and ≥60 ms at any time during study treatment|Time to stable culture conversion in solid media|Proportion of participants with culture conversion across all study arms|Proportion of participants with one or more serious adverse events (SAEs)|Time (days) to positivity in liquid culture (MGIT) after start of treatment across study arms|Change in chest X-ray score from baseline to end of treatment in each Arm (week 13 in Arm 1, week 26 in Arm 2)|Proportion of participants who have a TB relapse, from end of treatment until Week 65|Proportion of participants who have a TB recurrence, from end of treatment until Week 65|Pharmacokinetic parameter for CFZ: Minimum concentration (Cmin)|Pharmacokinetic parameter for CFZ: Maximum concentration (Cmax)|Pharmacokinetic parameter for CFZ: Time of Cmax (Tmax)|Pharmacokinetic parameter for CFZ: Area under the concentration curve (AUC0-24h)","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","104","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5362|30148","June 16, 2021","June 23, 2024","June 23, 2024","March 17, 2020",,"September 11, 2023","Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, India|Malawi CRS, Lilongwe, Central, Malawi|Blantyre CRS, Blantyre, Malawi|CAPRISA eThekwini CRS, Durban, Kwa Zulu Natal, South Africa|Milton Park CRS, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT04311502"
343,"NCT05097638","Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.",,"Completed","No Results Available","Pulmonary Tuberculoses|Pulmonary Function; Newborn, Abnormal","Diagnostic Test: spirometry","Post tuberculosis lung functional impairment|post tuberculosis persistent clinical symptoms|Grading of obstruction function:","Assiut University","All","Child, Adult, Older Adult",,"210","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5884","January 20, 2018","November 1, 2019","February 4, 2020","October 28, 2021",,"October 28, 2021","Chest Department-faculty of medicine-Assuit university, Assuit, Egypt",,"https://ClinicalTrials.gov/show/NCT05097638"
344,"NCT03900858","Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)","TB","Unknown status","No Results Available","Silicosis Tuberculosis","Drug: Isoniazid；Rifapentine","Cumulative rate of culture-confirmed or clinically diagnosed TB disease in participants|Percentage of participants with drug discontinuation for any reason and due to adverse drug reactions associated with 1RPT/INH|Percentage of patients with Grade 3 or 4 drug toxicities and deaths associated with 1RPT/INH|Percentage of participants who complete the treatment regimen","Huashan Hospital|Wenling No.1 People's Hospital, China","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","566","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2017ZX10201302-004","December 1, 2018","January 1, 2022","June 1, 2022","April 3, 2019",,"April 5, 2019","Wenling No.1 People's Hospital, Zhejiang, Taizhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03900858"
345,"NCT02597621","Biomarkers for Therapy Response in Drug-resistant Tuberculosis",,"Completed","No Results Available","Tuberculosis, Multidrug-resistant","Other: no intervention","Identification of biomarkers for therapy response","Research Center Borstel","All","18 Years and older   (Adult, Older Adult)",,"192","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M/XDR_BIO_01","March 2013","December 2020","January 2021","November 5, 2015",,"April 11, 2024","Research Center Borstel, Borstel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT02597621"
346,"NCT05840809","Pharmacokinetics of Drugs Used to Treat Drug Sensitive Tuberculosis in Breastfeeding Mother-infant Pairs","MILK TB","Recruiting","No Results Available","Tuberculosis Active|Breastfeeding|Tuberculosis","Drug: First line tuberculosis treatment","Concentration of rifampicin in maternal plasma|Concentration of rifampicin in breastmilk|Concentration of rifampicin in infant plasma|Concentration of isoniazid in maternal plasma|Concentration of isoniazid in breastmilk|Concentration of isoniazid in infant plasma|Concentration of ethambutol in maternal plasma|Concentration of ethambutol in breastmilk|Concentration of ethambutol in infant plasma|Concentration of pyrazinamide in maternal plasma|Concentration of pyrazinamide in breastmilk|Concentration of pyrazinamide in infant plasma|Maximum concentration of rifampicin in maternal plasma|Maximum concentration of rifampicin in breastmilk|Maximum concentration of isoniazid in maternal plasma|Maximum concentration of isoniazid in breastmilk|Maximum concentration of ethambutol in maternal plasma|Maximum concentration of ethambutol in breastmilk|Maximum concentration of pyrazinamide in maternal plasma|Maximum concentration of pyrazinamide in breastmilk|Anxiety in mothers|Depression in mothers|Maternal beliefs about medicines","University of Liverpool|Infectious Diseases Institute, Makerere University College of Health Sciences","Female","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MILK TB","January 20, 2022","December 20, 2023","January 29, 2024","May 3, 2023",,"May 3, 2023","Infectious Diseases Institute, Kampala, Uganda","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT05840809/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05840809"
347,"NCT00172783","PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period",,"Unknown status","No Results Available","Tuberculosis",,,"National Taiwan University Hospital","All","3 Months to 15 Years   (Child)",,"460","Other","Observational","Time Perspective: Other","940201","June 2005",,"December 2005","September 15, 2005",,"September 15, 2005","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00172783"
348,"NCT00266383","The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population",,"Completed","No Results Available","Tuberculosis",,,"National Health Research Institutes, Taiwan","All","0 Years and older   (Child, Adult, Older Adult)",,"250","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","DOH94-DC-1009","January 2005",,"December 2005","December 16, 2005",,"December 19, 2005","National Health Research Institutes, Miaoli county, Taiwan",,"https://ClinicalTrials.gov/show/NCT00266383"
349,"NCT02727582","Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment","PODrtb","Completed","No Results Available","Multidrug-resistant Tuberculosis",,"To characterize the effects of 2nd-line drug exposures on treatment response in MDR-TB patients.|To identify drug exposures associated with the risk of treatment-related toxicities in patients on a standard 2nd-line regimen for MDR-TB.","University of Cape Town|Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)",,"142","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PODrtb","July 30, 2015","January 30, 2021","January 30, 2021","April 4, 2016",,"April 29, 2021","Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa|DP Marias Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02727582"
350,"NCT02349841","Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Meropenem|Drug: Faropenem|Drug: Amoxycillin/clavulanic acid|Drug: Rifafour e275","Primary Endpoint (The EBA CFU(0-14) as determined by the rate of change in logCFU per ml sputum)|Efficacy (The EBA CFU(0-2) and EBA CFU(2-14) as determined by the rate of change of logCFU in sputum)|Safety and Tolerability (Incidence of treatment emergent adverse events (TEAEs)|Pharmacokinetics (The maximum observed plasma concentration (Cmax), time to reach Cmax (Tmax), the minimum observed plasma concentration (Cmin)|Pharmacokinetics - Pharmacodynamics (descriptive analyses, and no inferential tests will be carried out, of EBA CFU(0-14), EBA CFU(0-2), and EBA CFU(2-14) vs. AUC(0-24) • Time over Minimum inhibitory concentrations (TMIC) (for meropenem; faropenem)","TASK Applied Science|Eduardo Mondlane University|GlaxoSmithKline|Barcelona Centre for International Health Research|Research Center Borstel","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TASK-001","September 2014","December 2014","December 2014","January 29, 2015",,"September 13, 2018","TASK Foundation NPC, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02349841"
351,"NCT03827811","Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis","PandrTB","Recruiting","No Results Available","Multi-drug Resistant Tuberculosis",,"Drug exposure (AUC)|Rate of decline of viable M.tubercolosis in sputum|Collecting adverse events as a measure of safety","University of Cape Town|Partners in Health|Epicentre|Medecins Sans Frontieres, Netherlands|Institute of Tropical Medicine, Belgium|Interactive Research and Development","All","15 Years to 99 Years   (Child, Adult, Older Adult)",,"625","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PandrTB","January 30, 2020","April 30, 2023","April 30, 2023","February 1, 2019",,"November 4, 2022","National Scientific Center of Phthisiopulmonology, Almaty, Kazakhstan|Partners in Health Lesotho House 233 Corner Lancers and Caldwell Roads, Maseru, Lesotho|Indus Hospital, Karachi, Pakistan|Peru-1, Lima, Peru|Peru_2, Lima, Peru|Khayelitsha Town 2 Clinic, Cape Town, Western Cape, South Africa|Hanoi Lung Hospital, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03827811"
352,"NCT01311999","Surveillance and Follow-up for Latent Tuberculosis Infection and Risk of Developing Active Tuberculosis in Patients Receiving Long-term Dialysis",,"Completed","No Results Available","To Predict the Potential of Development of Active Tuberculosis in Those Receiving Long-term Dialysis by Using Interferon-gamma Release Assy",,"Development of active tuberculosis","National Taiwan University Hospital","All","18 Years and older   (Adult, Older Adult)",,"234","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201009057R","February 2011","November 2013","November 2013","March 10, 2011",,"December 4, 2013","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01311999"
353,"NCT03830671","The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB",,"Completed","No Results Available","Multi-drug Resistant Tuberculosis","Drug: 18-month regimen containing 6 anti-TB drugs","the treatment success rate|death rate|sputum conversion rate at the end of month 2, month 3,intensive phase and treatment completion.|Frequency of adverse drug reaction occurring during treatment.|Radiological manifestation change of TB lesion or cavity at the end of month 2, month 3,intensive phase and treatment completion.","Beijing Chest Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","515","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018ZX10722301-001","March 8, 2019","June 8, 2022","June 8, 2022","February 5, 2019",,"October 12, 2022","Beijing Chest Hospital, Beijing, China|The 8th Medical Center of Chinese Pla General Hospital, Beijing, China|Changchun Infectious Disease Hospital, Changchun, China|Hunan Institute For Tuberculosis Control, Changsha, China|Public Health Clinical Center of Chengdu, Chengdu, China|Shenzhen Third Peple's Hospital, Guangzhou, China|Guangzhou Chest Hospital, Guanzhou, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, China|Infectious Disease Prevention Hospital in Heilongjiang Province, Harbin, China|Anhui Chest Hospital, Hefei, China|The Fourth People's Hospital of Inner Mongolia Autonomous region, Hohhot, China|Shandong Provincial Chest Hospital, Jinan, China|Shanghai Pulmonary Hospital, Shanghai, China|Shenyang Chest Hospital, Shenyang, China|Tianjin Haihe Hospital, Tianjin, China|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an, China|Xi'an Chest Hospital, Xi'an, China|The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan, China|The Infectious Disease Hospital of Wangkai Zaozhuang, Zaozhuang, China|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Ürümqi, China",,"https://ClinicalTrials.gov/show/NCT03830671"
354,"NCT00173433","Exogenous Reinfection of Tuberculosis in Taiwan",,"Completed","No Results Available","Tuberculosis",,"relapse due to reinfection","National Taiwan University Hospital","All","Child, Adult, Older Adult",,"150","Other","Observational",,"9461700627","August 2005","July 2006","July 2006","September 15, 2005",,"December 9, 2014","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00173433"
355,"NCT04342598","Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India",,"Completed","No Results Available","Multi-drug Resistant Tuberculosis","Other: Serum Vitamin D","Adult pulmonary multi-drug resistant tuberculosis|Latent TB infection among controls","Harvard School of Public Health (HSPH)|Foundation for Medical Research|Municipal Corporation of Greater Mumbai, India","All","18 Years to 60 Years   (Adult)",,"352","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","IRB19-0237","January 27, 2020","December 17, 2020","December 17, 2020","April 13, 2020",,"February 25, 2021","Foundations for Medical Research, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04342598"
356,"NCT06224036","Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis",,"Recruiting","No Results Available","Drug-resistant Tuberculosis","Drug: JDB0131|Drug: Delamanid|Drug: Ethylpyrazine rifampicide (II)","EBA|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Immediately Reportable Events (IREs)|ECG|Safe tolerance|Tmax|Cmax|AUC0-24h|T Tss,max|Css,max|Css,min|Css,avg|t1/2,ss|AUC0-12,ss|AUC0-t,ss|AUC0-∞,ss|Vd,ss|CL,ss|Rac（Cmax）|Rac（AUC）|Fluctuation coefficient","Beijing Chest Hospital|West China Hospital|Wuhan Pulmonary Hospital (Wuhan Institute For Tuberculosis Control)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JDB-131-201","October 31, 2023","March 31, 2024","March 31, 2024","January 25, 2024",,"January 25, 2024","Wuhan Chest Hospital (Wuhan Institute For Tuberculosis Control), Wuhan, Hubei, China|West China Hospital, Sichuan University, Chendu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT06224036"
357,"NCT01859923","A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)",,"Completed","Has Results","Multidrug Resistant Tuberculosis","Drug: Delamanid|Drug: Delamanid Pediatric Formulation (DPF)|Drug: Optimized Background Regimen (OBR)","Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE)|Number of Participants With Abnormal Physical Examination Values|Number of Participants With Clinically Significant Abnormal Vital Sign Values|Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Values|Number of Participants With Clinically Significant Laboratory Test Abnormalities|Population Pharmacokinetic (POPPK) Model Point Estimate for Central Clearance (L) and Inter-compartmental Clearance (Q) of Delamanid|POPPK Model Point Estimate for Central Volume of Distribution (Vc) and Peripheral Volume of Distribution (Vp) of Delamanid|POPPK Model Point Estimate for Absorption Rate Constant (Ka) of Delamanid|POPPK Model Point Estimate for Absorption Lag Time (ALAG1) of Delamanid|Baseline QT Interval (QTcB) Effect|PK/PD Relationship: POPPK Model Point Estimate for Slope of Linear Mixed Effects Model for Change in QTcB Interval Versus Delamanid Plasma Concentrations|Number of Participants With Treatment Outcome as Assessed by Principal Investigator|Number of Participants With Abnormal Chest X-ray|Number of Participants With Investigator-Assessed Signs and Symptoms of Tuberculosis|Sputum Culture Conversion (SCC)|Number of Participants With Palatability Score as Assessed by the Investigator|Number of Participants With Palatability Score as Assessed by the Parent or Participant","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","0 Years to 17 Years   (Child)","Phase 2","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","242-12-233|2012-004620-38","July 20, 2013","January 13, 2020","January 13, 2020","May 22, 2013","November 23, 2020","November 23, 2020","De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines|Lung Center of the Philippines, Quezon City, Metro Manila, Philippines|Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/23/NCT01859923/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/23/NCT01859923/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01859923"
358,"NCT01317654","Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone","ES","Completed","No Results Available","Tuberculosis Meningitis","Other: Observation","Survival|Neurological disability|Tuberculosis relapse rate","Oxford University Clinical Research Unit, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam","All","1 Year to 90 Years   (Child, Adult, Older Adult)",,"340","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ES","April 2006","April 2008","April 2008","March 17, 2011",,"September 15, 2011",,,"https://ClinicalTrials.gov/show/NCT01317654"
359,"NCT06141148","Clinical Presentation, and Treatment Outcomes in Tuberculous Patients in Sohag Governorate",,"Recruiting","No Results Available","Tuberculosis","Diagnostic Test: sputum analysis|Diagnostic Test: lymph node biobsy","percent of cured tuberculous patients|percent of treatment failure","Sohag University","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Soh-Med-23-10-012MS","November 1, 2023","December 30, 2024","December 30, 2024","November 21, 2023",,"November 21, 2023","Sohag university Hospital, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT06141148"
360,"NCT00082173","Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis",,"Completed","Has Results","Tuberculosis","Drug: Moxifloxacin","Proportion of Patients With Sterile Sputum Cultures|Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 2","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FD-R-002135-01","October 2004","September 2007","September 2008","May 4, 2004","May 22, 2013","May 22, 2013","Clementino Fraga Filho Hospital, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00082173"
361,"NCT00397709","Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection",,"Terminated","No Results Available","Tuberculosis","Drug: I ( isoniazid), II (isoniazid + rifampin )","to compare the compliance|to compare the side effects|Development of tuberculosis","Hospital Virgen de la Luz","All","16 Years to 89 Years   (Child, Adult, Older Adult)","Phase 4","228","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBQXCU2|TBQXPNCU1","March 1996",,"February 2006","November 9, 2006",,"December 31, 2008","Maria Paloma Geijo Martinez. Hospital Virgen de la Luz, Cuenca, Spain",,"https://ClinicalTrials.gov/show/NCT00397709"
362,"NCT05329415","Tuberculosis Drug Levels and Continuous Glucose Monitoring in Diabetic Patients",,"Active, not recruiting","No Results Available","Tuberculosis|Diabetes Mellitus","Diagnostic Test: TB Drug Levels","Rifampicin/Isoniazid/Pyrazinamide Cmax 2 hours post-dose|Antidiabetic medication Cmax at baseline and 2 hours post dose|Mean daily subcutaneous glucose measurement","London North West Healthcare NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","v1 20.07.2021","February 1, 2022","May 1, 2023","May 2024","April 15, 2022",,"June 7, 2023","London North West University NHS University Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05329415"
363,"NCT01301144","Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis|Urea Breath Test",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"113","NIH","Observational","Time Perspective: Prospective","999911106|11-I-N106","February 13, 2011",,"March 30, 2016","February 23, 2011",,"April 5, 2018","Unviersite de Bamako, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT01301144"
364,"NCT05398562","Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis|Skin Tests","Diagnostic Test: Mycobacterial recombinant allergens 0.1 μg|Diagnostic Test: Mycobacterial recombinant allergens 0.2 μg|Diagnostic Test: Placebo","Incidence of AEs and SAEs|Number of participants with abnormal changes in laboratory parameters - Complete blood count (CBC)|Number of participants with abnormal changes in laboratory parameters - Biochemical blood test (BBT)|Number of participants with abnormal changes in laboratory parameters - Immunologic blood test (IBT)|Number of participants with abnormal Changes in laboratory parameters - Urinalysis (UA)|Number of participants with abnormal ECG findings|Number of participants with abnormal changes in physical examination data|Number of participants with abnormal changes in the functions of vital organs and vital signs - Heart rate (HR)|Number of participants with abnormal changes in the functions of vital organs and vital signs - Respiratory rate (RR)|Number of participants with abnormal changes in the functions of vital organs and vital signs - Blood pressure (BP): Systolic blood pressure (SBP) and Diastolic blood pressure (DBP)|Number of participants with abnormal changes in the functions of vital organs and vital signs - Body temperature (BT)|Incidence and severity of immediate hypersensibility reactions in each group according to the four-point scale|Proportion of volunteers who have withdrawn from the trial early due to the AE/SAE|Incidence of systemic post-injection reactions|Incidence of local post-injection reactions","St. Petersburg Research Institute of Vaccines and Sera","All","18 Years to 50 Years   (Adult)","Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","ATR-I-004-2019","February 13, 2020","June 17, 2020","June 26, 2020","June 1, 2022",,"June 1, 2022","Limited Liability Company ""Scientific Research Center Eco-Safety"", Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05398562"
365,"NCT01242592","Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Anti-Tuberculosis Treatment","Sputum conversion|Quality of Life","NMP Medical Research Institute","All","18 Years to 60 Years   (Adult)","Phase 2","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NMP/H/01","February 2005",,"June 2008","November 17, 2010",,"November 17, 2010","NMP medical Research Institute, Jaipur, Rajastha, India",,"https://ClinicalTrials.gov/show/NCT01242592"
366,"NCT02115854","Labial Biopsy in Patients With Tuberculosis Disease",,"Completed","No Results Available","Tuberculosis|Sarcoidosis","Other: labial biopsy","presence of granuloma on labial biopsy","Hopital Lariboisière","All","18 Years and older   (Adult, Older Adult)",,"65","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","granuloma1","December 2010","April 2014",,"April 16, 2014",,"April 16, 2014","Unite de Recherche Thérapeutique, Paris, France",,"https://ClinicalTrials.gov/show/NCT02115854"
367,"NCT04241809","Bioaerosol Sampling in Suspected Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis Confirmation by Sputum Microscopy With or Without Culture","Diagnostic Test: Bioaerosol Sampling","Primary Aim|Secondary Aim (1)","Desmond Tutu HIV Foundation|National Institutes of Health (NIH)|University of Cape Town|Zeteo Tech Incorporated","All","13 Years to 100 Years   (Child, Adult, Older Adult)",,"102","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01AI147347-01","May 15, 2020","May 27, 2022","May 27, 2022","January 27, 2020",,"March 27, 2023","Aerobiology Research Centre, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04241809"
368,"NCT01967134","Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis",,"Completed","Has Results","Latent Tuberculosis|Latent Tuberculosis Bacteriology and Histology Unknown","Biological: H56:IC31","Number of Participants With at Least One Adverse Event (AE) Through Day 210|Median % Change in Response to Peptides From Vaccine Antigen Ag85B From Pre-vaccination to Day 70 in Participants Who Received Two Vaccinations|Median % Change in Response to Peptides From Vaccine Antigen ESAT-6 From Pre-vaccination to Day 70 in Participants Who Received Two Vaccinations|Number of Participants Who Received at Least Two Vaccinations and Tested Positive for Mtb Infection on Day 210|Median % Change in Response to Peptides From Vaccine Antigen Ag85AB From Pre-vacc to Day 210","Aeras|Statens Serum Institut","All","18 Years to 50 Years   (Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","C-032-456","November 2011","December 2012","June 2013","October 22, 2013","August 21, 2019","August 21, 2019","SATVI Project Office, Brewelskloof Hospital, Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT01967134"
369,"NCT00557765","Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area",,"Completed","No Results Available","Tuberculosis|Latent Tuberculosis Infection",,"Correlation between results of TST and IGRA tests and exposure scores","University Hospital, Geneva|Ligue Pulmonaire Genevoise","All","18 Years and older   (Adult, Older Adult)",,"295","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","04-184","October 2004",,"January 2006","November 14, 2007",,"November 14, 2007","Centre antituberculeux; Geneva University Hospital, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT00557765"
370,"NCT06153069","Subclinical TB With Innovative Modified Short-course Regimens","SWIFT","Active, not recruiting","No Results Available","Tuberculosis","Drug: Short-course regimen|Drug: Standard regimen","Treatment success rate of the short-course regimen|Relapse rate during follow-up|Culture conversion rate|Median time to Sputum Culture Conversion|The frequency of grade 3 or greater adverse events","Huashan Hospital","All","14 Years to 80 Years   (Child, Adult, Older Adult)","Phase 4","556","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2023-715","November 1, 2023","October 2025","November 2027","December 1, 2023",,"December 14, 2023","Huashan Hospital of Fudan University, Shanghai, Shanghai, China|Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT06153069"
371,"NCT01638520","Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Drug: Pascolizumab|Drug: Placebo","Efficacy - Time to detection on liquid culture of sputum on Week 8|Co-primary outcome measure - safety|Sputum culture status (positive or negative) on liquid culture at week 8|Rate of change (area under the curve) from baseline to week 8 in the time to positivity in liquid culture of sputum|Rate of change in serial sputum colony counts on solid cultures from baseline to week 8|Rate of change of RPF-dependent serial sputum colony counts from baseline to week 8|Sputum culture status (positive or negative) on solid culture at week 8|Rate of change of sputum smear lipid-body positive mycobacteria from baseline to week 8|Serum IL-4 levels (free and drug-bound)|Time to resolution of fever|Time to resolution of all TB symptoms|Resolution of chest X-ray changes at week 24|Resolution of PET/MRI changes at week 8 and week 24|TB relapse at any time up to week 96|Anti-pascolizumab antibodies","National University Hospital, Singapore|National University of Singapore","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DSRB 2012/02212","June 2012","February 2017","July 2017","July 11, 2012",,"April 4, 2017","Institute of Respiratory Medicine, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Lung Centre Philippines, Manila, Philippines|Philippines Tuberculosis Society Inc., Manila, Philippines|Changi General Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore, Singapore|Ng Teng Fong General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01638520"
372,"NCT01698476","Immune Reconstitution in Tuberculosis Disease","IRETB","Completed","No Results Available","Pulmonary Tuberculosis (TB)","Drug: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Drug: Placebo tablets","Composite clinical TB score|Clinical secondary endpoints|Laboratory secondary endpoints","Karolinska Institutet|Addis Ababa University|Armauer Hansen Research Institute, Ethiopia","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","390","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRETB-2012","September 2012","August 2015","August 2015","October 3, 2012",,"February 5, 2016","Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine, Addis Ababa, Lideta sub city, Ethiopia",,"https://ClinicalTrials.gov/show/NCT01698476"
373,"NCT01130311","Replacement of Vitamin D in Patients With Active Tuberculosis","SUCCINCT","Completed","No Results Available","Tuberculosis, Pulmonary","Drug: Cholecalciferol|Drug: Saline injection","To measure difference in Clinical RESPONSES between test and control groups after treatment with vitamin D|To assess the effects of vitamin D replacement on cytokine responses","Aga Khan University|Dow University of Health Sciences","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","259","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","AgaKhanU|091014MED|09014MED","October 2009","April 2010","December 2010","May 26, 2010",,"June 28, 2011","Aga Khan University, Karachi, Sind, Pakistan|Ojha Istitute of Chest Diseases, Karachi, Sind, Pakistan|Abbasi Shaheed Hospital, Karachi, Sind, Pakistan|Malir Chest Clinic, Karachi, Sind, Pakistan",,"https://ClinicalTrials.gov/show/NCT01130311"
374,"NCT00513396","High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis",,"Completed","No Results Available","Tuberculosis, Multidrug-Resistant","Drug: Isoniazid|Drug: Placebo","Time to sputum culture conversion|Extent of radiological improvement|Proportion with peripheral neuropathy|Proportion with hepatotoxicity","GSVM Medical College","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TB chest - 1/2005","January 2004",,"December 2006","August 8, 2007",,"August 8, 2007",,,"https://ClinicalTrials.gov/show/NCT00513396"
375,"NCT03173261","Role of Genexpert in Extra Pulmonary Tuberculosis",,"Unknown status","No Results Available","Extra Pulmonary Tuberculosis","Diagnostic Test: Genexpert","the percentage of positive patients for extra pulmonary tuberculosis","Assiut University","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PTB","June 2017","April 2018","September 2018","June 1, 2017",,"June 1, 2017",,,"https://ClinicalTrials.gov/show/NCT03173261"
376,"NCT02759848","The Role of Tuberculosis in Chronic Obstructive Lung Disease","TROTIC","Completed","No Results Available","The Role of Tuberculosis in COPD",,"all cause mortality","Istanbul Medeniyet University","All","40 Years and older   (Adult, Older Adult)",,"598","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TROTIC-1234-TROTIC","January 2012","December 2014","December 2014","May 3, 2016",,"May 3, 2016",,,"https://ClinicalTrials.gov/show/NCT02759848"
377,"NCT03220464","Early Diagnosis of Active Tuberculosis Using Ultra Low-dose Chest CT",,"Unknown status","No Results Available","Tuberculosis, Pulmonary|Latent Tuberculosis","Radiation: Ultra low dose chest computed tomography (ULDCT)|Radiation: Chest X-ray|Diagnostic Test: Interferon-gamma Release Assay (IGRA)","Incidence of active pulmonary tuberculosis|Prevalence of active pulmonary tuberculosis at enrollment|Prevalence of latent tuberculosis at enrollment|Change of ultra low dose chest CT findings in latent tuberculosis patients","Seoul National University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","116","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","1704-157-849","June 20, 2017","April 30, 2019","April 30, 2020","July 18, 2017",,"July 21, 2017","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03220464"
378,"NCT03312647","Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection",,"Unknown status","No Results Available","Latent Tuberculosis Infection",,"The numbers of adverse drug reactions (ADR) during LTBI treatment|The numbers of severe ADR during LTBI treatment","Hanyang University","All","19 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HYUMC_CM_002","June 19, 2017","May 2018","May 2018","October 18, 2017",,"October 18, 2017","Sang-Heon Kim, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03312647"
379,"NCT01635153","Effects of a Protein Calorie Supplement in HIV-infected Women With Tuberculosis","DarDar","Completed","Has Results","HIV|Tuberculosis","Dietary Supplement: Protein calorie supplement|Dietary Supplement: Micronutrient","Change in CD4 Count|BMI at 6 Months|Number of Subjects Who Achieve 100 Cell Increase in CD4","Dartmouth-Hitchcock Medical Center|National Institutes of Health (NIH)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","151","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DarDar 2-C CPHS 21592 D12221|RO1 503498","May 2012","July 2014","July 2014","July 9, 2012","August 18, 2020","August 18, 2020","Infectious Disease Centre, Dar es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT01635153"
380,"NCT00340990","Immune Responses to Mycobacterium Tuberculosis",,"Completed","No Results Available","Mycobacterium Tuberculosis",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"111","NIH","Observational",,"999904009|04-I-N009","October 6, 2003",,"November 27, 2015","June 21, 2006",,"December 5, 2019","University of Mali, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT00340990"
381,"NCT00567840","PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis",,"Completed","Has Results","Pulmonary Tuberculosis","Drug: PA-824","Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14).|Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-2).|Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 2-14).|EBA Expressed as the Change in Time to Positive (TTP) Signal in Liquid Culture for M. Tuberculosis (Days 0-14)|EBA Expressed as the Change in Time to Positive (TTP) Signal in Liquid Culture for M. Tuberculosis (Days 0-2)|EBA Expressed as the Change in Time to Positive (TTP) Signal in Liquid Culture for M. Tuberculosis (Days 2-14) Show Description: [Not Specified]","Global Alliance for TB Drug Development","All","18 Years to 64 Years   (Adult)","Phase 2","69","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PA-824-CL-007","August 2007","December 2007","December 2007","December 5, 2007","April 4, 2017","May 15, 2017","Tiervlei Trials Center, Stellenbosch University, Cape Town, Cape Province, South Africa|University of Cape Town Lung Institute, Cape Town, Cape Province, South Africa",,"https://ClinicalTrials.gov/show/NCT00567840"
382,"NCT03851588","Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis","RADIANT-TB","Completed","Has Results","HIV Infections|Tuberculosis","Other: Placebo|Drug: Dolutegravir 50 mg","Virological Suppression at 24 Weeks|Virological Suppression at 12 Weeks (Modified ITT)|Virological Suppression at 24 Weeks (Per Protocol)|Virological Suppression at 48 Weeks (Modified ITT)|Virological Suppression at 48 Weeks (Per Protocol)|CD4 Change at 24 and 48 Weeks|Dolutegravir Trough Concentrations|Grade 3 or 4 Adverse Events|Change in Sleep Assessment From Baseline|Change in Mental Health Assessment From Baseline|Serious Adverse Events|Adverse Events Requiring Discontinuation of an ART Drug|Antiretroviral Resistance Mutations Testing by Genotypic Resistance Assay in Participants With Virologic Failure|Primary Outcome Differences Among ART-naïve Versus First-line Interruption Status|Secondary Outcome Differences Among ART-naïve Versus First-line Interruption Status by Modified ITT Analysis|Secondary Outcome Differences Among ART-naïve Versus First-line Interruption Status by Per Protocol Analysis","University of Cape Town|Wellcome Trust|Medecins Sans Frontieres, Netherlands","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CIDRI003","December 19, 2019","January 20, 2022","June 28, 2022","February 22, 2019","September 18, 2023","September 18, 2023","Khayelitsha Site B/Ubuntu Clinic, Cape Town, Western Cape, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/88/NCT03851588/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03851588"
383,"NCT00865826","Observational Study of Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals",,"Completed","No Results Available","HIV Infections|Tuberculosis","Other: Standardized diagnostic evaluation","Effectiveness in creating a standard diagnostic evaluation for identification of participants with active pulmonary TB|Prevalence of TB in symptomatic and asymptomatic individuals|Rates of TB drug resistance|Feasibility and incremental benefits of diagnostic and screening evaluations over a range of CD4 cell counts|Value of oral candidiasis as a predictor of TB|Significance of investigational serologic assay when added to sputum acid-fast bacilli (AFB) smears when identifying participants with active TB compared to AFB smears alone|Storage of samples for future diagnostic and pathogenesis studies of mycobacterial, virologic, and immunologic factors","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Dental and Craniofacial Research (NIDCR)","All","13 Years and older   (Child, Adult, Older Adult)",,"801","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACTG A5253|1U01AI068636","December 2009","March 2011","March 2011","March 19, 2009",,"March 18, 2015","Gaborone Prevention/Treatment Trials CRS, Gaborone, Botswana|Molepolole Prevention/Treatment Trials CRS (Molepolole PTT CRS), Molepolole, Botswana|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Manguinhos, Rio de Janeiro, Brazil|BJ Medical College CRS, Pune, Maharashtra, India|NARI Pune CRS, Pune, Maharashtra, India|University of North Carolina Lilongwe CRS, Lilongwe, Malawi|San Miguel CRS, San Miguel, Lima, Peru|Asociacion Civil Impacta Salud y Educacion - Miraflores, CRS, Lima, Peru|Soweto ACTG CRS, Johannesburg, Gauteng, South Africa|Wits HIV CRS, Johannesburg, Gauteng, South Africa|CAPRISA eThekwini CRS, Durban, KwaZulu-Natal, South Africa|Durban Adult HIV CRS, Durban, KwaZulu-Natal, South Africa|UZ-Parirenyatwa CRS (30313), Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT00865826"
384,"NCT00374517","Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs",,"Withdrawn","No Results Available","Refractory Pulmonary Tuberculosis","Drug: Pimonidazole hydrochloride","Frequency of pimonidazole labeling in specific lesion types within resected lung specimens and the frequency of co-localization of AFB positive bacilli with pimonidazole regions in lesions.","National Institute of Allergy and Infectious Diseases (NIAID)|International Tuberculosis Research Center|National Institutes of Health Clinical Center (CC)","All","20 Years and older   (Adult, Older Adult)","Phase 2","0","NIH|Other","Interventional","Primary Purpose: Treatment","999906241|06-I-N241","September 5, 2006","February 2, 2010","February 2, 2010","September 11, 2006",,"July 2, 2017","International Tuberculosis Research Center, Masan, Korea, Republic of|National Masan Tuberculosis Hospital, Masan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00374517"
385,"NCT01865487","A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)",,"Completed","Has Results","Latent Tuberculosis Bacteriology and Histology Unknown|Latent Tuberculosis","Biological: H56ug/IC31nmol|Biological: Placebo","Number and Percentage of Unsolicited and Solicited Adverse Events Recorded Post Day 0 Vaccination.|Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - CD4+ ICS (LTBI-negative)|Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - CD4+ ICS (LTBI-positive)|Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - IFN-gamma ELISpot|Evaluate Kinetics of QuantiFERON®-TB Gold Test (QFT) Responses in LTBI-negative Participants","Aeras|Statens Serum Institut","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","98","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-035-456","August 2013","August 2015","November 2015","May 31, 2013","December 19, 2019","December 19, 2019","eKhayavac TB Vaccine Trial, Khayelitsha, Cape Town, South Africa|SATVI Project Office, Brewelskloof Hospital, Worcester, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/87/NCT01865487/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT01865487"
386,"NCT05397730","MTB cfDNA Levels in TBP",,"Recruiting","No Results Available","Tuberculosis, Pleural","Diagnostic Test: Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)","The MTB cfDNA level in TBP and non-TB pleural effusions|The diagnostic performance of MTB cfDNA and Xpert Ultra in diagnosing MTB culture-positive and MTB culture-negative TBP|Clinical factors that may affect the levels of MTB cfDNA in TBP|Association between the gut microbiota and the occurrence of TBP","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"62","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TBP_cfDNA_levels","October 1, 2022","September 30, 2024","September 30, 2025","May 31, 2022",,"March 15, 2023","Prince of Wales Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05397730"
387,"NCT00419068","Trial of Adjunctive Vitamin D in Tuberculosis Treatment",,"Completed","No Results Available","Tuberculosis, Pulmonary","Drug: Cholecalciferol|Drug: Migliol Placebo Oil","Time to sputum culture conversion|Rate of bacillary kill|2-month culture conversion rate|Time to sputum smear conversion|Weight change|Radiographic response","Barts & The London NHS Trust|British Lung Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","146","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","2005-003562-42|EudraCT no: 2005-003562-42|REC ref: 06/Q0605/83","January 2007","September 2009","September 2009","January 8, 2007",,"September 30, 2009","Whipps Cross University Hospital NHS Trust, London, United Kingdom|Newham University Hospital NHS Trust, London, United Kingdom|London Chest Hospital, London, United Kingdom|Homerton University Hospital NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00419068"
388,"NCT04151602","Transmission of Tuberculosis Among Illicit Drug Use Linkages","TOTAL","Enrolling by invitation","No Results Available","Tuberculosis|Illicit Drug Use","Behavioral: Smoked illicit drug use","TB disease prevalence|Incipient TB prevalence|Proportion of active TB cases resulting from recent transmission within this network of PWUD|Quantity of aerosolized Mtb in exhaled breath: amount of aerosolized Mtb exhaled in one hour","Boston Medical Center|University of Stellenbosch|Desmond Tutu HIV Foundation/ University of Cape Town|Boston University|Medical Research Council, South Africa|National Institute of Allergy and Infectious Diseases (NIAID)","All","15 Years and older   (Child, Adult, Older Adult)",,"800","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","H-38910|1R01AI147316-01","April 22, 2021","April 2024","April 2024","November 5, 2019",,"June 26, 2023","Privately Rented Facility, Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT04151602"
389,"NCT00698386","Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients",,"Unknown status","No Results Available","Pulmonary Tuberculosis","Dietary Supplement: Zinc supplement|Dietary Supplement: Placebo","The time of sputum conversion as well as the early sputum conversion from the baseline between the two groups will be evaluated.|The cure rate will be evaluated as the primary parameter of efficacy.|The relapse at an interval of 6,12,18 and 24 months after the completion of the therapy in patients of category-I pulmonary TB will be compared in both the groups.|Recording of any clinical adverse reactions at anytime during the study for assessment of safety.|An additional secondary efficacy endpoint is the patient's and physician's global assessment of the clinical cure.","Ministry of Science and Technology, India","All","18 Years to 60 Years   (Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","DTPR7885/Med/141166/06","February 2008","September 2009","September 2009","June 17, 2008",,"September 15, 2009","All India Institute of Medcial Sciences-, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00698386"
390,"NCT00677339","L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)","AVDAPT","Completed","No Results Available","Smear Positive Pulmonary Tuberculosis","Drug: L-arginine|Drug: Vitamin D|Drug: Placebo L-arginine|Drug: Placebo Vitamin D","Proportion of pulmonary TB patients who are culture negative at 1 month|Difference in improvement in composite clinical endpoint comprising weight, cough clearance and FEV1 at 2 months.|Change in plasma L-arginine concentration|Change in plasma 25(OH)D3 concentration|Death, clinical failure and default independently, and 'death or clinical failure or default'.|Hypercalcaemia|Gastrointestinal side effects|Sputum smear conversion time|Radiological improvement (percentage lung involvement on CXR at 2 months).|Cough clearance|Difference in improvement in percent predicted FEV1 at 2 and 6 months.|Weight gain|Immunological improvement (exhaled NO)|Immunological improvement (T cell CD3ζ expression and T cell function)|Functional improvement measured using six minute walk test|Quality of life assessment using modified St George Respiratory Questionnaire.|Primary end points stratified by HIV status.|Primary end points stratified by baseline vitamin D and L-arginine status.|Primary end points stratified by ethnicity (Papuan and non-Papuan patients).","Menzies School of Health Research|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Australian National University","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVDAPT 1","June 2008","February 2010","May 2010","May 14, 2008",,"January 18, 2012","Timika Tuberculosis Clinic and Community Hospital, Timika, Papua Province, Indonesia",,"https://ClinicalTrials.gov/show/NCT00677339"
391,"NCT04928378","Bone Resistant Tuberculosis","TboneR","Completed","No Results Available","Bone and Osteoarticular Infection Due to MDR M. Tuberculosis Strains","Other: Descriptive retrospective study","study of infected population with MDR TB IOATB|Drug susceptibility testing","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult",,"23","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP210051","May 17, 2021","July 1, 2021","January 21, 2022","June 16, 2021",,"May 10, 2022","Pitié Salpêtrière Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04928378"
392,"NCT00864383","Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","REMoxTB","Completed","Has Results","Pulmonary Tuberculosis","Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).|Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)|Combined Failure of Bacteriological Cure and Relapse as Defined by Culture Using Liquid Media (Mycobacteria Growth Indicator Tube-MGIT).|Number of Patients Who Are Culture Negative (Solid LJ Culture)|Number of Patients Who Are Culture Negative (Liquid MGIT Culture)|Time to First Culture Negative Sputum Sample (LJ Solid Media)|Time to First Culture Negative Sputum Sample (MGIT Liquid Media)|Sensitivity Analysis Assuming All Losses to Follow-up and Non-tuberculous Deaths Have an Unfavorable Outcome Using Solid (L-J) Media.|Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculous Deaths Have a Favourable Outcome Using Solid (L-J) Media.","Global Alliance for TB Drug Development|European and Developing Countries Clinical Trials Partnership (EDCTP)|University College, London|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","1931","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REMoxTB|ISRCTN85595810","January 2008","October 2013","February 2014","March 18, 2009","May 25, 2015","March 21, 2017","Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China|Shanghai Pulmonary Hospital, Shanghai, China|TB Institute, Tianjin, China|Nirmal Kumar Jain, Jaipur, Rajasthan, India|Mahatma Gandhi Medical College& Hospital, Jaipur, Rajsthan, India|Ram-Tej Hospital,, Agra, Uttar Pradesh, India|Siddharth Nursing Home,, Agra, Uttar pradesh, India|Rajul Nursing Home, Aligarh, Uttar Pradesh, India|Varshneya Chest Clinic & Eye Care Centre, Aligarh, Uttar Pradesh, India|Dr. Neeraj Gupta Clinic, Firozabad, Uttar Pradesh, India|S.P.S Chauhan Clinic, Firozabad, Uttar Pradesh, India|Dr. R. K. Garg's Clinic,, Gaziabad, Uttar Pradesh, India|Indra Nursing Home and Maternity Centre, Ghaziabad, Uttar Pradesh, India|Dr. AK Singh Clinic, Kanpur, Uttar Pradesh, India|Dr. S. K. Katiyar, Swaroop Nagar,, Kanpur, Uttar Pradesh, India|Guru Tej Bahadur Hospital, Kanpur, Uttar Pradesh, India|Dr. Komal Gupta, Lucknow, Uttar Pradesh, India|New City Hospital and Trauma Centre,, Lucknow, Uttar Pradesh, India|Surya Chest Foundation,, Lucknow, Uttar Pradesh, India|Surya Kant Clinic, Lucknow, Uttar Pradesh, India|Dr. Mahip Saluja Clinic, U.P., Meerut,, Uttar Pradesh, India|Arya Chest Clinic, UP,India, Meerut, Uttar Pradesh, India|Dr. S. P. Sondhi Clinic,, Meerut, Uttar Pradesh, India|Sri Ram Plaza, Meerut, Uttar Pradesh, India|Jigyasa Medical Center, Moradabad, Uttar Pradesh, India|Saanvi MultiSpeciality Clinic,, Moradabad, Uttar Pradesh, India|A-One Hospital, Delhi, India|Dr. D.K. Chauhan, New Delhi, India|Centre for advanced lung and sleep disorders, New Delhi, India|Dr. Mittal's clinic, New Delhi, India|Diligent Hospital, New Delhi, India|Ish Medical Centre and Respiratory Lab,, New Delhi, India|Smt Prakash Devi Memorial Medical Centre,, New Delhi, India|Centre for Respiratory Disease Research at KEMRI, Nairobi, Kenya|Institute of Respiratory Medicine (IPR) Jalan Pahang, Kuala Lumpur, Malaysia|Hospital General de Occidente de la secretaria, Guadalajara, Seattle, Mexico|Madibeng centre for Research, 40 Pienaar Street,, Madibeng, Brits, South Africa|Clinical HIV Research Unit (CHRU), Johannesburg, Westdene, South Africa|Centre for TB Research and Innovation, University of Cape Town Lung Institute, Cape Town, South Africa|Tiervlei Trial Center and University of Stellenbosch, Cape Town, South Africa|Unit for Clinical & Biomedical TB Research, MRC Durban, Durban, South Africa|NIMR Mbeya Medical Research Programme, Mbeya, Tanzania|Kilimanjaro Christian Medical Centre, Moshi, Tanzania|Srinagarind Hospital, Division of Pulmonary Medicine, Khon Kaen University, Khon Kaen, Mueang, Thailand|Chest Disease Institute (CDI), Ministry of Public,, Nonthaburi, Mueang, Thailand|Rajavithi Hospital, Division Of Pulmonary Medicine, Bangkok, Phayathai, Thailand|University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT00864383"
393,"NCT00401271","Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: OPC-67683|Drug: Rifafour e-275","TB bacterial load in sputum measured as colony forming units|Early Bactericidal Activity (EBA)|Slope 0-14|Tme to culture positivity","Otsuka Frankfurt Research Institute GmbH","All","18 Years to 64 Years   (Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","242-06-101","November 2006",,"March 2007","November 20, 2006",,"March 7, 2007","Tiervlei Trial Center, Karl Bremer Hospital, Bellville, W Cape, South Africa|University of Cape Town Lung Institute, Mowbray, W Cape, South Africa|Medical Research Council, Durban, South Africa",,"https://ClinicalTrials.gov/show/NCT00401271"
394,"NCT01223534","QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.","OPTIMIST","Completed","No Results Available","Latent Tuberculosis Infection","Drug: Preventive treatment with Isoniazid.|Drug: Preventive treatment with Isoniazid","Development of tuberculosis.|Prescription of treatment.","Hospital Universitari de Bellvitge|Cellestis","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","871","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","QFT-ECC-01|2009-017430-49|TRA-126","July 2010","February 2016","February 2016","October 19, 2010",,"May 27, 2016","Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01223534"
395,"NCT01136161","Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection",,"Completed","No Results Available","Latent Tuberculosis Infection|Tuberculosis","Biological: RUTI|Biological: RUTI Matching Placebo","Local tolerability|Focal Tolerability|Systemic tolerability|Vital Signs and physical examination|ECG|Laboratory Tests|Immunogenicity","Archivel Farma S.L.|Parexel","All","18 Years to 50 Years   (Adult)","Phase 2","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RUTISAPH2","June 2010","May 2011","May 2011","June 3, 2010",,"January 24, 2013","Parexel Int. Bloemfontein, Bloemfontein, South Africa|Parexel Int. George, George, South Africa|Parexel Int. Port Elizabeth, Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT01136161"
396,"NCT00495339","MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis, Pulmonary","Drug: Levofloxacin","Number of patients with bacterioexcretion|Dynamics of chest radiograph|Dynamics of Intoxication|All clinical and laboratory adverse events","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LEVOF_L_00972","June 2007","April 2008",,"July 3, 2007",,"March 4, 2009","Sanofi-Aventis, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00495339"
397,"NCT00425113","Metronidazole for Pulmonary Tuberculosis (South Korea)",,"Completed","Has Results","Tuberculosis|Multi-Drug Resistant Tuberculosis","Drug: Metronidazole|Procedure: Blood Draw|Procedure: CT Scan|Procedure: PET Scan","Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT).|Time to Sputum Culture Conversion to Negative on Solid Medium","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","20 Years and older   (Adult, Older Adult)","Phase 2","35","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","999907041|07-I-N041","December 2006","October 2012","February 2013","January 22, 2007","July 10, 2013","July 10, 2013","National Masan Tuberculosis Hospital, Masan, Korea, Republic of|Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00425113"
398,"NCT03927664","Clinico-radiological Classification of Peritoneal Tuberculosis",,"Completed","No Results Available","Tuberculosis|Tuberculosis; Abdomen (Etiology)|Tuberculosis, Peritoneal","Other: Radiological assessment","Correlation of radiological characterization of classification with clinical presentation","Post Graduate Institute of Medical Education and Research, Chandigarh|PGIMER","All","12 Years and older   (Child, Adult, Older Adult)",,"55","Other","Observational","Observational Model: Cohort|Time Perspective: Other","NK/5243/Study/019","May 1, 2019","April 30, 2020","July 30, 2020","April 25, 2019",,"August 31, 2020","Postgraduate Institute of Medical Education and Research, Chandigarh, India|Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT03927664"
399,"NCT04121026","Validation of a Tuberculosis Treatment Decision Algorithm in HIV-infected Children","TB-Speed HIV","Unknown status","No Results Available","Tuberculosis|HIV","Other: External validation of the PAANTHER TB treatment decision algorithm","Proportion of missed TB cases|Feasibility of the PAANTHER TB treatment decision algorithm (a): Proportion of children with presumptive TB having completed the algorithm.|Feasibility of the PAANTHER TB treatment decision algorithm (b): Time to final TB treatment decision|Proportion of HIV-infected children with unlikely TB among those initiated on treatment as per the PAANTHER TB treatment decision algorithm|Incidence of morbidity|Incidence of mortality|Time to ART initiation in ART-naïve children|CD4 (absolute count and %) gain|TB treatment outcomes (a): Weight gain at 6 months (absolute value and percentage of body weight)|TB treatment outcomes (b): TB symptoms resolution in children on TB treatment|Feasibility of IPT initiation (a): Time to IPT initiation|Feasibility of IPT initiation (b): Proportion of children initiated on IPT|Performance of the Monocyte-to-Lymphocyte Ratio and the C-reactive protein and their potential added value in the PAANTHER score and algorithm to detect TB|Proportion of NPAs (or sputum) and stool samples with mycobacterium tuberculosis (MTB) detected using Ultra|Proportion of children with NPA and stool samples collected as per study protocol|Proportion of NPA-related adverse events (AEs)|Discomfort/pain/distress experienced by the child during NPA as assessed by the child|Discomfort/pain/distress experienced by the child during NPA as assessed by the parents|Discomfort/pain/distress experienced by the child during NPA as assessed by the nurse","Institut National de la Santé Et de la Recherche Médicale, France|UNITAID","All","1 Month to 14 Years   (Child)","Not Applicable","550","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","C18-27","October 2, 2019","June 30, 2022","June 30, 2022","October 9, 2019",,"September 22, 2021","Cocody University Teaching Hospital, Abidjan, Côte D'Ivoire|Treichville University Teaching Hospital, Abidjan, Côte D'Ivoire|José Macamo General Hospital, Maputo, Mozambique|Maputo Central Hospital, Maputo, Mozambique|Mbarara Regional Hospital, Mbarara, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT04121026"
400,"NCT01433796","Screening for Tuberculosis in HIV-infected Patients Eligible for Antiretroviral Treatment",,"Completed","No Results Available","HIV Infection|Tuberculosis",,"Correlation between baseline clinical characteristics and presence of microbiologically confirmed active tuberculosis.|Comparison of ART outcome in patients taking concomitant anti-tuberculosis therapy and those only taking ART.|Comparison of diagnostic methods for detection of TB among HIV-infected subjects eligible to start ART.","Lund University|Swedish International Development Cooperation Agency (SIDA)","All","18 Years and older   (Adult, Older Adult)",,"812","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LU-2010/672|3120/215/03","October 2011","May 2013","December 2015","September 14, 2011",,"March 8, 2016","Adama Health Centre, Adama, Oromia, Ethiopia|Geda Health Centre, Adama, Oromia, Ethiopia|Dhera Health Center, Dhera, Oromia, Ethiopia|Mojo Health Centre, Mojo, Oromia, Ethiopia|Welenchiti Health Centre, Welenchiti, Oromia, Ethiopia",,"https://ClinicalTrials.gov/show/NCT01433796"
401,"NCT02558842","Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance",,"Completed","No Results Available","Pulmonary Tuberculosis|Extra Pulmonary Tuberculosis","Other: Education Strategy","cure rate|dropout rate","Hospital de Clinicas de Porto Alegre|Federal University of Rio Grande do Sul","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","13-0192","March 2013","September 2015","December 2015","September 24, 2015",,"August 3, 2016","Alice Mânica Müller, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT02558842"
402,"NCT04682990","DIAGNOSIS of PULMONARY TUBERCULOSIS Through HUMAN BREATH (TBENOSE)","TBENOSE","Completed","No Results Available","Tuberculosis, Pulmonary|HIV Seropositivity","Device: Tor Vergata Electronic Nose (TV eNose)|Other: Survey & Physical Exam|Diagnostic Test: TB LAMP test|Other: Sputum Samples|Other: Chest X-Ray|Other: Follow Up 5 days after beginning of Tx.|Other: Follow Up & 15 days after beginning of Tx.|Other: Follow Up & 30 days after beginning of Tx.","Diagnostic Accuracy value of the TV eNose signal value to differentiate patients with Pulmonary TB to control participants|Accuracy value of the diagnostic between Pulmonary TB, Pulmonary TB+ HIV patients and control patients with the TV eNose|Average Days needed to observed a negative result with the device after initiation of treatment.","University of Rome Tor Vergata","All","18 Years and older   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TB Project eNose-Cameroon","January 5, 2021","December 5, 2021","December 5, 2021","December 24, 2020",,"December 8, 2021","Centre des Maladies Respiratoire, Douala, Littoral, Cameroon",,"https://ClinicalTrials.gov/show/NCT04682990"
403,"NCT03544476","Mobile Health Intervention for Active Tuberculosis",,"Completed","No Results Available","Tuberculosis|Adherence, Medication","Behavioral: Mobile phone TB treatment support app plus usual care|Other: Usual care","Acceptability (perceived usefulness and ease of use)|Feasibility of implementation|Initial efficacy - Treatment outcome|Global Health Patient-Reported Outcomes Measurement Information System (PROMIS) short form|Tuberculosis Knowledge Assessment Questionnaire|Engagement","University of Washington|National Institute of Nursing Research (NINR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","STUDY00002080|K23NR017210","April 9, 2019","March 31, 2020","July 31, 2020","June 1, 2018",,"December 10, 2020","Hospital Dr. Antonio A. Cetrángolo, Vicente López, Province Of Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT03544476"
404,"NCT00291889","Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.",,"Completed","No Results Available","Tuberculosis (TB)","Biological: Mtb72F/AS02.","Occurrence of solicited symptoms during the 7-day follow-up period, unsolicited symptoms during the 30-day follow-up period, grade 3 vaccine related local and general symptoms during the 30-day follow-up and serious adverse events during the entire study|Immunogenicity as assessed by humoral and CMI response.","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","102039","July 2004","May 2005","May 2005","February 15, 2006",,"May 30, 2017","GSK Investigational Site, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT00291889"
405,"NCT00804713","Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits","LTBI","Completed","Has Results","Latent Tuberculosis Infection","Drug: BST|Drug: TST|Other: QFT|Other: T-spot","TST Induration Will be Interpreted Relative to Risk, in Accordance With Published CDC Guidelines.|Positive QFT-GIT Result","Henry M. Jackson Foundation for the Advancement of Military Medicine|Infectious Diseases Clinical Research Program","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2017","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","IDCRP-021","March 2009","June 2009","August 2022","December 9, 2008","October 15, 2014","March 29, 2023","Fort Jackson, SC, Columbia, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00804713"
406,"NCT01521364","Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients",,"Completed","Has Results","Multidrug-resistant Tuberculosis|Extensively Drug-resistant Tuberculosis","Drug: Addition of different doses of clarithromycin.","Area Under the Time Concentration Curve (AUC0-12h) of Linezolid in Plasma After Addition of 0mg, 250mg, or 500mg Clarithromycin (CLA).|Linezolid (LIN) and Clarithromycin (CLA) Pharmacokinetic Parameters, e.g. Tmax, Cmax, Cmin, T1/2, Cl.|Number of Patients With Adverse Events (AEs)|Pharmacokinetic Parameters, e.g. Tmax, T1/2, Cmax, Cmin, Cl, of Anti-TB Drugs That Are Co-administered as Part of the Continued Standard Care.|Area Under the Time Concentration Curve (AUC0-12h) of Linezolid in Saliva.","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 4","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL35534.042.11|2011-000513-39","December 2011","October 2012","November 2012","January 30, 2012","July 1, 2013","July 1, 2013","Tuberculosis Center Beatrixoord, Haren, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01521364"
407,"NCT03711721","Nutritional Support for HIV-Tuberculosis Co-infected Adults in Senegal, West Africa",,"Completed","No Results Available","HIV and Tuberculosis Co-infection","Dietary Supplement: Food basket|Dietary Supplement: Ready-to-Use Therapeutic Food","Uptake, as determined by percent of monthly nutritional support rations received, transported, stored, and utilized by subjects.|Acceptability, as determined by patient reported perceptions of nutritional support.|Costs of monthly nutritional support rations.|Tuberculosis treatment adherence as determined by Medication Possession Ratio|Tuberculosis treatment adherence as determined by patient reported number of missed doses in the previous 7 days and 4 weeks.|Tuberculosis treatment completion defined as completing full course of prescribed therapy|Adherence to antiretroviral therapy as determined by Medication Possession Ratio|Adherence to antiretroviral therapy as determined by patient reported number of missed doses in the previous 7 days and 4 weeks|CD4 cell count|Presence of acid fast bacteria using sputum smear microscopy|Results of GeneXpert|Nutritional status as determined by Body Mass Index|Nutritional status as determined by change in weight (kg)|Food security status measured using the Household Food Insecurity Access Scale (HFIAS)|Hemoglobin levels (g/dl)","University of Washington|La Clinique des Maladies Infectieuses, Centre Hospitalier National Universitaire de Fann","All","18 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20150056","June 2016","August 2017","August 2017","October 18, 2018",,"October 18, 2018",,,"https://ClinicalTrials.gov/show/NCT03711721"
408,"NCT00558480","Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis",,"Withdrawn","No Results Available","Latent Tuberculosis Infection","Drug: Vitamin A|Drug: Vitamin A placebo","Measurement of cytokine (IFN-gamma, IL-10, TNF-alpha, TGF-beta) levels produced in response to M. tb.|FoxP3 gene expression with RT-PCR on mRNA from PBMCs.|Incidence of probable/confirmed TB; change in weight (mean weight gain)|Qualitative (positive/negative) and quantitative (mean change in counts) reversion of the T-cell assay","Medical Research Council Unit, The Gambia|European and Developing Countries Clinical Trials Partnership (EDCTP)|Department of State for Health and Social Welfare, The Gambia","All","5 Years to 14 Years   (Child)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","SCC 1066","July 2009","July 2011","December 2012","November 15, 2007",,"April 9, 2015",,,"https://ClinicalTrials.gov/show/NCT00558480"
409,"NCT03492216","Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)","DIPT","Completed","No Results Available","HIV/AIDS|Tuberculosis","Behavioral: Incentives for negative EtG test|Behavioral: Incentives for positive IsoScreen test","Non-heavy drinking determined by self-report (Alcohol Use Disorders Identification Test - Consumption [AUDIT-C], prior 3 months, negative) and phosphatidylethanol (PEth) <35 ng/mL|INH Adherence determined by proportion of participants that achieve >90% MEMS adherence to INH during prescribed IPT|Hepatotoxicity|INH concentration in hair|HIV viral suppression|Active TB rates","University of California, San Francisco|Infectious Diseases Research Collaboration, Uganda|Mbarara University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Not Applicable","680","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention","17-22727","April 16, 2018","February 1, 2022","August 2, 2022","April 10, 2018",,"October 7, 2022","Infectious Disease Research Collaboration (IDRC), Mbarara, Uganda|Mbarara Regional Referral Hospital (MRRH): Immune Suppression Syndrome HIV, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT03492216"
410,"NCT04490746","Identifcation of Biomarkers for Active Pulmonary Tuberculosis",,"Unknown status","No Results Available","Tuberculosis|Diagnosis","Other: with no intervention, Collect samples","metabolic product","Second Affiliated Hospital, School of Medicine, Zhejiang University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","研2020-556","October 1, 2020","October 1, 2022","October 1, 2022","July 29, 2020",,"July 29, 2020","Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04490746"
411,"NCT03478033","Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis","RRHT","Unknown status","No Results Available","Tuberculosis, Pulmonary|AIDS","Drug: Rifampicin|Drug: Rifabutin","The rate of sputum negative conversion|Case fatality rate|Treatment completion status|The percentage of HIV viral load less than the detection limit|AE|Time of sputum negative conversion|Chest CT scans improvement","Shanghai Public Health Clinical Center|The Guangxi Zhuang Autonomous Region Longtan hospital|The Fourth People's Hospital of Nanning|Shenzhen Third People's Hospital|Yunnan Provincial Infectious Disease Hospital|Zhejiang University|Chongqing Public Health Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2017ZX10202101-002","April 15, 2018","June 1, 2020","December 31, 2020","March 27, 2018",,"April 24, 2018","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03478033"
412,"NCT00146744","Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults",,"Completed","No Results Available","Tuberculosis (TB)","Biological: Mtb72F/AS02A","Occurrence of solicited symptoms during the 7-day follow-up period, unsolicited symptoms during the 30-day follow-up period, grade 3 vaccine related local and general symptoms during the 30-day follow-up and serious adverse events during the entire study|Immunogenicity as assessed by humoral and CMI response.","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","102374","July 2005","May 2006","May 2006","September 7, 2005",,"May 30, 2017","GSK Investigational Site, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT00146744"
413,"NCT04518228","Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum",,"Recruiting","No Results Available","HIV Infections|Tuberculosis","Drug: Bictegravir (BIC)|Drug: Tenofovir alafenamide (TAF)|Drug: Cabotegravir (CAB)|Drug: Dolutegravir (DTG)|Drug: Atazanavir/ritonavir (ATV/r)|Drug: Darunavir/ritonavir (DRV/r)|Drug: Lopinavir/ritonavir (LPV/r)|Drug: Cobicistat|Drug: Ritonavir|Drug: First-Line TB Treatment|Drug: Second-Line TB Treatment|Drug: Doravirine (DOR)","Number of women who meet area under the curve (AUC) target in second trimester (2T)|Number of women who meet area under the curve (AUC) target in third trimester (3T)|Number of women who meet area under the curve (AUC) in postpartum (PP)|Area under the curve (AUC) in second trimester (2T)|Area under the curve (AUC) in third trimester (3T)|Area under the curve (AUC) postpartum (PP)|Tenofovir-diphosphate (TFV-DP) concentrations in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS) in second trimester (2T)|Tenofovir-diphosphate (TFV-DP) concentrations in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS) in third trimester (3T)|Tenofovir-diphosphate (TFV-DP) concentrations in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS) postpartum (PP)|Cord blood/maternal plasma concentration ratio at delivery|Infant washout half-life after delivery (if not breastfeeding)|Maternal breast milk/maternal plasma concentration ratio (if breast feeding)|Infant plasma concentration at breast milk PK visit (if breast feeding)|Area under the curve (AUC) at second trimester (2T)|Area under the curve (AUC) at third trimester (3T)|Maternal breast milk/maternal plasma concentration ratio|Infant plasma concentration|Ratio of cord blood concentration to maternal blood concentration|Infant washout half-life of drug after birth (if the infant is not breastfeeding, and if the half-life is estimable)|Efavirenz, lopinavir, atazanavir, darunavir, dolutegravir, and/or raltegravir: AUC at second trimester (2T), third trimester (3T), and postpartum (PP)|Frequency of grade 3 or higher maternal adverse events|Frequency of grade 2 or higher infant adverse events|Frequency of maternal and infant serious adverse events|Frequency of grade 3 or higher maternal adverse events assessed as related to the drug under study|Frequency of grade 2 or higher infant adverse events assessed as related to the drug under study|Pregnancy outcome: occurrence of live birth versus fetal loss/stillbirth.|Gestational age at birth|Birth weight|Occurrence of congenital anomaly|Occurrence of mitochondrial disorder|Number of infants with confirmed positive HIV nucleic acid test result|Maternal HIV-1 RNA","National Institute of Allergy and Infectious Diseases (NIAID)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|Gilead Sciences|ViiV Healthcare|Merck Sharp & Dohme LLC","Female","Child, Adult, Older Adult",,"325","NIH|Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMPAACT 2026|38609","September 1, 2021","March 11, 2026","March 11, 2026","August 19, 2020",,"January 29, 2024","Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, San Diego, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|University of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV NICHD CRS, Miami, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Rush University Cook County Hospital Chicago NICHD CRS, Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS (Site ID: 4001), Chicago, Illinois, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Baylor College of Medicine/ Texas Children's Hospital NICHD CRS (Site ID: 5128), Houston, Texas, United States|Molepolole CRS (Site ID: 12702), Molepolole, Kweneng District, Botswana|Gaborone CRS (Site ID: 12701), Gaborone, South-East District, Botswana|Univ. of Sao Paulo Brazil NICHD CRS (Site ID: 5074), Ribeirão Preto, São Paulo, Brazil|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio De Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio De Janeiro, Brazil|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS, Kericho, Kenya|Malawi CRS, Lilongwe, Malawi|IMPAACT/ Gamma Project/ UPR Pediatric HIV/AIDS Research CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, South Africa|Sizwe CRS, Johannesburg, South Africa|Famcru Crs, Tygerberg Hills, South Africa|Kilimanjaro Christian Medical Centre (KCMC) (Site ID: 5118), Moshi, Tanzania|Siriraj Hospital, Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS (Site ID: 5116), Chiang Rai, Thailand|Baylor-Uganda CRS, Kampala, Uganda|Seke North CRS (Site ID: 30306), Seke North, Chitungwiza, Zimbabwe|St Mary's CRS (Site ID: 30303), St. Mary's, Chitungwiza, Zimbabwe|Harare Family Care CRS (Site ID: 31890), Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT04518228"
414,"NCT02331823","Research on New Regimens for Retreatment Pulmonary Tuberculosis",,"Unknown status","No Results Available","Reinfection Pulmonary Tuberculosis","Drug: Isoniazid Aminosalicylate Tablets|Drug: Streptomycin injectable","success rate|adverse reaction rate","Shanghai Pulmonary Hospital, Shanghai, China|Shanghai Center for Disease Control and Prevention|Jiangsu Province Centers for Disease Control and Prevention|Zhejiang University|Centers for Disease Control and Prevention","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","864","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013ZX10003009","June 2013","December 2015","December 2016","January 6, 2015",,"January 6, 2015","Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02331823"
415,"NCT00023361","TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Rifabutin","Rate of confirmed treatment failure and relapse|Safety and tolerability|Response of HIV RNA to TB treatment|Paradoxical reactions","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Not Applicable","215","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-2174|TBTC STUDY 23","February 1999",,"February 2003","September 10, 2001",,"September 5, 2005","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023361"
416,"NCT02501421","Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine",,"Completed","No Results Available","Tuberculosis","Biological: tuberculosis vaccine|Biological: Placebo","Immediate reactions|Solicited local and systemic reactions|Unsolicited events and abnormal laboratory findings|Serious adverse events (SAEs), including abnormal laboratory findings","Research Institute for Biological Safety Problems|Ministry of Health, Kazakhstan|Research Institute of Influenza, Russia","All","18 Years to 50 Years   (Adult)","Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VPT-I-01/2013","October 2013","April 2014","February 2015","July 17, 2015",,"August 28, 2020",,,"https://ClinicalTrials.gov/show/NCT02501421"
417,"NCT05899179","Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above",,"Recruiting","No Results Available","Latent Tuberculosis Infection","Biological: Recombinant Mycobacterium Tuberculosis Fusion Protein|Biological: Purified Protein Derivative of Tuberculin","Measure the diameter of redness or induration at the reaction site|Evaluate the incidence of all adverse events|Evaluate the incidence of serious adverse event (SAE)|In subgroup, count the number of patients with changes in clinical significance of blood routine test before skin test compared with that 7 days after skin test|In subgroup, count the number of patients with changes in clinical significance of urine routine test before skin test compared with that 7 days after skin test|In subgroup, count the number of patients with changes in clinical significance of liver and kidney function test before skin test compared with that 7 days after skin test|In subgroup, count the number of patients with changes in clinical significance of electrocardiogram test before skin test compared with that 7 days after skin test|In subgroup, count the number of patients with changes in clinical significance of blood routine test 7 days after skin test compared with that before skin test|In subgroup, count the number of patients with changes in clinical significance of urine routine test 7 days after skin test compared with that before skin test|In subgroup, count the number of patients with changes in clinical significance of liver and kidney function test 7 days after skin test compared with that before skin test|In subgroup, count the number of patients with changes in clinical significance of electrocardiogram test 7 days after skin test compared with that before skin test","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shenzhen Third People's Hospital|Wuhan Institute for Tuberculosis Control","All","65 Years and older   (Older Adult)","Phase 3","780","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","LKM-2022-EC01","August 3, 2023","June 30, 2025","October 31, 2025","June 12, 2023",,"August 22, 2023","Guangzhou Municipal Hospital of Chest Medicine, Guangzhou, Guangdong, China|The Third People's Hospital Of Shenzhen, Shenzhen, Guangdong, China|Wuxi NO.5 People's Hospital, Wuxi, Jiangsu, China|Wuhan Institute for Tuberculosis Control, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT05899179"
418,"NCT02253537","Evaluation of the QuantiFERON-TB Test.",,"Completed","Has Results","Tuberculosis","Device: CST001","Number of Participants With Clinical Signs/Symptoms Indicating TB With a Positive CST001 Assay Result as an Indication of Clinical Sensitivity","QIAGEN Gaithersburg, Inc","All","18 Years to 70 Years   (Adult, Older Adult)",,"15","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CST001_USA5","February 2, 2015","April 26, 2016","April 26, 2016","October 1, 2014","June 6, 2019","June 18, 2019","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02253537"
419,"NCT02256839","Evaluation of the QuantiFERON-TB Test.",,"Completed","Has Results","Tuberculosis","Device: CST_001","Clinical Specificity of the CST001 Assay as Measured by the Number of Correctly Identified Actual Negatives","QIAGEN Gaithersburg, Inc","All","18 Years to 80 Years   (Adult, Older Adult)",,"268","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CST001_USA4","October 2014","October 2015","October 2015","October 6, 2014","August 1, 2019","August 1, 2019","Oregon Health & Sciences University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02256839"
420,"NCT00962793","Diagnosis of Latent Tuberculosis(TB) Infection in Health Care Workers Using TST and Whole Blood Interferon-γ Assay",,"Completed","No Results Available","Tuberculosis",,,"Yonsei University","All","20 Years and older   (Adult, Older Adult)",,,"Other","Observational","Time Perspective: Prospective","4-2009-0187",,,,"August 20, 2009",,"August 20, 2009",,,"https://ClinicalTrials.gov/show/NCT00962793"
421,"NCT02758236","Tuberculosis Research of INA-RESPOND On Drug Resistance","TRIPOD","Completed","No Results Available","Lung Tuberculosis|MDR TB","Other: No Intervention","Reporting the rate of MDR-TB amongst new and retreated TB cases.|Reporting the treatment outcomes (cured, failed, died, treatment completion, and lost to follow up)|Reporting the protective factors for treatment success.|Reporting the risk factors of treatment interruption (loss to follow up vs other treatment outcome).|Reporting how many percent clinically defined TB subjects compare to bacteriologically confirmed TB (AFB, X-pert, sputum culture).|Measuring the sensitivity and specificity of AFB and Xpert MTB/RIF relative to culture results.|Measuring sensitivity and specificity of Rif susceptibility results in Xpert MTB/RIF against result in DST as gold standard along with 97.5% confidence intervals.","Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|The National Institute of Allergy and Infectious Diseases, United States","All","18 Years and older   (Adult, Older Adult)",,"490","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INA102|U1111-1263-2311","February 13, 2017","November 30, 2018","April 26, 2021","May 2, 2016",,"November 19, 2021","Site 520: University of Udayana/Sanglah Hospital, Denpasar, Bali, Indonesia|Site 560: University of Diponegoro/ Dr. Kariadi Hospital, Semarang, Central Of Java, Indonesia|Site 590: Persahabatan Hospital, Jakarta, DKI Jakarta, Indonesia|Site 570: University of Airlangga/ Dr. Soetomo Hospital, Surabaya, East Of Java, Indonesia|Site 600 : Adam Malik Hospital, Medan, North Sumatra, Indonesia|Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia|Site 580: University of Gadjah Mada/ Dr. Sardjito Hospital, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT02758236"
422,"NCT02142894","Evaluation of the QuantiFERON-TB Test.",,"Completed","Has Results","Tuberculosis","Device: CST001","Number of Participants With Clinical Signs/Symptoms Indicating TB With a Positive CST001 Assay Result as an Indication of Clinical Sensitivity","QIAGEN Gaithersburg, Inc","All","18 Years to 70 Years   (Adult, Older Adult)",,"33","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CST001_USA1","May 27, 2014","March 28, 2016","March 28, 2016","May 20, 2014","June 6, 2019","June 18, 2019","University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02142894"
423,"NCT05413551","Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention",,"Recruiting","No Results Available","Tuberculosis Infection|Isoniazid Adverse Reaction","Drug: Low-dose isoniazid|Drug: Standard dose of isoniazid|Drug: High-dose isoniazid","Isoniazid plasma area-under-the-curve|Maximum isoniazid concentration (Cmax)|Isoniazid concentration at 24 hours","Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)|Federal University of Mato Grosso|Fiocruz Mato Grosso do Sul","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","65808|1R21AI172182-01","March 23, 2023","July 31, 2024","September 30, 2024","June 10, 2022",,"December 11, 2023","Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT05413551"
424,"NCT04629378","Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB","TB_COMBO_01","Completed","No Results Available","Tuberculosis","Drug: Meropenem Injection|Drug: Amoxicillin Clavulanate|Drug: Pyrazinamide|Drug: Bedaquiline|Drug: Rifafour","Early bactericidal activity (EBA) over 14 treatment days based on the rate of change in colony forming unit (CFU) count per treatment arm|EBA over 14 treatment days based on the rate of change in time to positive culture (TTP) per treatment arm|Safety and tolerability of study treatments administered over 14 consecutive days|Cmax: Maximum observed plasma drug concentration.|Tmax: Time at which Cmax is observed (obtained without interpolation).(interventional arms only) after 14 consecutive days - Analyte, Meropenem; amoxicillin; CA; bedaquiline|Cmin: Minimum observed plasma drug concentration 24 hours following the last dose.|AUC(0-24): Area under the drug concentration-time curve calculated using linear trapezoidal summation from time zero to time 24 hours.","TASK Applied Science","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TASK-005_TB_COMBO_01","August 17, 2020","June 4, 2021","June 4, 2021","November 16, 2020",,"January 25, 2022","TASK Clinical Research Centre, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04629378"
425,"NCT05236452","Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection",,"Recruiting","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Tuberculosis Infection","Other: Training for traditional and modern care providers","Tuberculosis case detection rate","Bahir Dar University","All","Child, Adult, Older Adult","Not Applicable","774","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","353/2021","July 1, 2022","December 30, 2023","December 30, 2023","February 11, 2022",,"April 21, 2023","Bahir Dar University, Bahir Dar, Amhara, Ethiopia",,"https://ClinicalTrials.gov/show/NCT05236452"
426,"NCT00756808","Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?",,"Completed","No Results Available","Tuberculosis",,"detection of latent TB","Northwell Health|Staten Island University Hospital","All","65 Years and older   (Older Adult)",,"135","Other","Observational","Time Perspective: Prospective","07-050","October 2007","July 2010","July 2010","September 22, 2008",,"February 7, 2014","Staten Island University Hospital, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT00756808"
427,"NCT02573623","Evaluation of an Innovative Tuberculosis Diagnostic Test","PROMISE-TB","Unknown status","No Results Available","Tuberculosis|HIV",,"Proportion of children with tuberculosis who are correctly identified by a immunoenzymatic test for tuberculosis as having the condition|Proportion of tuberculosis negative children who are correctly identified as such by a immunoenzymatic test for tuberculosis","ANRS, Emerging Infectious Diseases|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","up to 15 Years   (Child)",,"300","Other","Observational","Time Perspective: Prospective","ANRS12293 PROMISE-TB","July 2013","October 2015","December 2015","October 12, 2015",,"October 12, 2015","Department of Paediatrics and Child Health, University Teaching Hospital.UNZA-SOM, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT02573623"
428,"NCT00023335","TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Rifapentine|Drug: Isoniazid",,"Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-1427|TBTC Study 22","April 1995",,"March 2001","September 10, 2001",,"September 5, 2005","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023335"
429,"NCT04951986","Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis","NEW-STRAT TB","Recruiting","No Results Available","Disseminated Tuberculosis|HIV","Drug: Rifampin|Drug: Levofloxacin|Drug: Rifampicin, Pyrazinamide, Ethambutol and Isoniazid|Drug: Prednisone|Drug: Placebo","All-cause mortality|In-hospital mortality during index admission","University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Phase 3","732","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HREC REF: 001/2021","August 11, 2021","June 30, 2024","December 31, 2024","July 7, 2021",,"March 31, 2022","Khayelitsha Hospital, c/o Steve Biko and Walter Sisulu Drives, Khayelitsha, Cape Town, Western Cape, South Africa|Mitchells Plain Hospital, Mitchells PLain, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04951986"
430,"NCT00763295","Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?",,"Completed","No Results Available","Latent Tuberculosis|HIV Infections","Other: T-Spot.TB test",,"Northwell Health","All","18 Years to 75 Years   (Adult, Older Adult)",,"53","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","08-015","May 2008","January 2010","January 2010","September 30, 2008",,"October 26, 2012","Staten Island University Hospital, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT00763295"
431,"NCT01778062","Indacaterol EfectIveness In COPD Patients With Tuberculosis History","INFINITY","Completed","Has Results","Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis","Drug: Indacaterol|Drug: Control","Trough Forced Expiratory Volume in One Second Change|St. George Respiratory Questionnaire for COPD (SGRQ-C) Change After 8 Weeks of Treatment|Change From Baseline in Transition Dyspnea Index (TDI) After 8 Weeks of Treatment|Incidence of COPD Exacerbation","Novartis Pharmaceuticals|Novartis","All","19 Years and older   (Adult, Older Adult)","Phase 3","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CQAB149BKR01","February 2013","September 2014","September 2014","January 29, 2013","September 18, 2015","October 23, 2015","Novartis Investigative Site, Anyang-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Koyang-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Jeonju-si, Jeollabuk-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Koyang, Kyunggi, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01778062"
432,"NCT03519425","A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi","PROSPECT","Unknown status","No Results Available","Tuberculosis|Hiv|Tuberculosis, Pulmonary","Other: Optimised HIV screening and linkage to care|Other: Optimised tuberculosis screening and linkage to care","Time to tuberculosis treatment initiation|Same day TB treatment initiation|Undiagnosed/untreated microbiologically-confirmed pulmonary tuberculosis|Undiagnosed/untreated HIV|Time to antiretroviral therapy initiation|Mortality|TB treatment outcome|Quality of life (EQ5D utility score)|Quality of life (EQ5D visual analogue scale)|Cost-effectiveness","Liverpool School of Tropical Medicine|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|London School of Hygiene and Tropical Medicine|University of Liverpool|McGill University|Kamuzu University of Health Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1455","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","17-050","November 15, 2018","December 2019","June 2020","May 9, 2018",,"December 10, 2019","Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Chichiri, Malawi",,"https://ClinicalTrials.gov/show/NCT03519425"
433,"NCT04600167","Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus","PROTID","Recruiting","No Results Available","Diabetes Mellitus|Tuberculosis","Drug: Isoniazid and Rifapentine (INH-RPT)|Drug: Placebo","First diagnosis of TB|Occurrence of possible, probable or definite TB disease|Occurrence of an adverse event|Treatment completion|All-cause mortality|Occurrence of possible, probable, or definite TB, or death","Dr. Nyanda Elias Ntinginya|Stichting Katholieke Universiteit- Radboudumc (RUMC), Netherlands|Otago University, New Zealand|Makerere University|St George's, University of London, United Kingdom|Kilimanjaro Christian Medical University College (KCMUCo), Tanzania|Uganda Martyrs Hospital Lubaga, Uganda|King's College London|National Institute for Medical Research, Tanzania","All","18 Years and older   (Adult, Older Adult)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NIMR-MB-002","June 17, 2022","December 2025","December 2025","October 23, 2020",,"March 29, 2023","Mbeya zonal referral hospital, Mbeya, Tanzania|Kilimanjaro Christian Medical Center, Moshi, Tanzania|Makerere University, Kampala, Uganda|Martyrs Hospital Lubaga, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04600167"
434,"NCT01364324","Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Early Gastric Cancer","Drug: standard first line anti-TB drugs","The change in the maximum concentration (Cmax) of first-line TB drugs|The effects of pharmacokinetics on responses of pulmonary TB to anti-TB drug","National Cancer Center, Korea","All","18 Years to 80 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NCCCTS-10-493","September 2010","June 2020","June 2020","June 2, 2011",,"September 25, 2020","Respiratory Clinic, National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01364324"
435,"NCT04424264","The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants","EpiTAF","Completed","No Results Available","HIV-1-infection|Tuberculosis","Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz","IC TFV-DP concentrations during coadministration of TAF or TDF with RIF/INH in TB/HIV-1 coinfected participants|Maintenance of irological suppression (HIV-1 RNA < 50 copies/mL)|Comparison plasma concentrations of TAF with TDF|Comparison of IC TFV-DP concentrations of TDF","Professor Francois Venter|University of Cape Town|University of Witwatersrand, South Africa","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WRHI061","December 5, 2019","October 30, 2020","October 30, 2020","June 9, 2020",,"June 7, 2022","Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa|Wits RHI Yeoville Clinic, Johannesburg, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT04424264"
436,"NCT00962676","Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients",,"Completed","No Results Available","Tuberculosis",,,"Yonsei University","All","20 Years and older   (Adult, Older Adult)",,"140","Other","Observational",,"4-2009-0129","July 2009","December 2010","December 2010","August 20, 2009",,"February 2, 2012","Yonsei Univ., Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00962676"
437,"NCT01954563","Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A","Safety of 5 x 10^7 pfu dose of MVA85A administered by aerosol and compared to the same dose administered intradermally|Immunogenicity of 5 x 10^7 pfu dose of MVA85A administered by aerosol followed by the same dose administered intradermally, compared to the same dose of MVA85A given intradermally and boosted by aerosol","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB035","October 2013","January 2016","January 2016","October 1, 2013",,"January 28, 2016","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01954563"
438,"NCT01622140","Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis",,"Completed","No Results Available","Latent Tuberculosis Infection|Tuberculosis",,"Latent tuberculosis infection|Tuberculosis disease at 6 months|Tuberculosis disease at 12 months|Tuberculosis disease at 18 months|Tuberculosis disease at 24 months","Centers for Disease Control and Prevention","All","Child, Adult, Older Adult",,"21334","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDC-TBESC-TO1","October 2012","December 31, 2020","December 31, 2020","June 18, 2012",,"January 28, 2021","Maricopa County Department of Public Health, Phoenix, Arizona, United States|California Department of Public Health, Richmond, California, United States|Denver Health and Hospitals Authority, Denver, Colorado, United States|University of Florida Board of Trustees, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Hawaii Department of Health, Honolulu, Hawaii, United States|Maryland Department of Public Health, Baltimore, Maryland, United States|Duke University, Durham, North Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Public Health Seattle-King County, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01622140"
439,"NCT01398618","Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)",,"Unknown status","No Results Available","Latent Tuberculosis Infection","Drug: 4-month rifampin vs. 9-month isoniazid","Number of Participants developing active tuberculosis|the sensitivity and specificity of tuberculin-skin-testing and QuantiFERON TB-Gold assay for the development of active pulmonary tuberculosis","National Taiwan University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201010017M","May 2011","December 2013","December 2013","July 20, 2011",,"July 20, 2011","Chest Hospital, Department of Health, Executive Yuan, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01398618"
440,"NCT00023452","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection","PREVENT TB","Completed","Has Results","Tuberculosis","Drug: RPT + INH once weekly for 3 months given by DOT|Drug: Isoniazid (INH) daily for 9 months","Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants Less Than [<]18 Years of Age at 33 Months After Enrollment|Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants <18 Years of Age at 24 Months Following Completion of Study Therapy|Cumulative Rate of Culture-Confirmed or Probable (Clinical) TB Disease (Regardless of Age) At 33 Months After Enrollment|Percentage of Participants With Drug Discontinuation Due to Adverse Drug Reactions Associated With 3RPT/INH or 9INH|Percentage of Patients With Grade 3 or 4 Drug Toxicities Associated With 3RPT/INH or 9INH|Percentage of Participants With Death Due to Any Cause|Percentage of Participants With Methadone Withdrawal Associated With 3RPT/INH and 9INH Among Participants Receiving Concomitant Methadone|Percentage of Participants With Drug Discontinuation for Any Reason Associated With 3RPT/INH or 9INH|Percentage of Participants Who Completed the Treatment Regimen|Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture Confirmed or Probable (Clinical) TB Disease Among Participants <18 Years of Age Who Completed Study Phase Therapy Within 33 Months of Enrollment|Percentage of Participants With Resistance to Study Medications in Isolates of MTB From Participants Who Developed Active TB Disease Within 33 Months of Enrollment|Cumulative Rate of Culture-Confirmed or Probable TB Disease in HIV-Infected Participants Within 33 Months After Enrollment|Cumulative Rate of HIV-Infected Participants With Culture-Confirmed or Probable TB Disease at 24 Months After Completion of Study Therapy|Cumulative Rate of Participants <18 Years Old With Culture-Confirmed or Probable (Clinical) TB Disease Within 33 Months of Enrollment|Cumulative Rate of Participants <12 Years Old With Culture-Confirmed or Probable (Clinical) TB Disease Within 33 Months of Enrollment","Centers for Disease Control and Prevention|VA Office of Research and Development","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","8053","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCHSTP-3041|CDC TBTC Study 26","June 2001","October 2010","September 2013","September 10, 2001","September 27, 2012","April 10, 2018","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|UCSD Medical Center, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Emory University, Department of Medicine, Atlanta, Georgia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Michael Debakey Veterans Affairs Medical Center, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada|Agencia de Salut Publica, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00023452"
441,"NCT04208789","Artificial Inteligent for Diagnosing Drug-Resistant Tuberculosis",,"Completed","No Results Available","MDR Tuberculosis|Resistance to Tuberculostatic Drugs","Diagnostic Test: Rapid Molecular Drug-Resistant Tuberculosis Test|Other: Artificial Intelligent Model|Diagnostic Test: Drug Susceptibility Test","Accuracy of Artificial Intelligent Model to Drug Susceptibility Test Results|Accuracy of Rapid Molecular Drug Resistant Tuberculosis test to Drug Susceptibility Test Results","Hasanuddin University|Chulalongkorn University","All","Child, Adult, Older Adult",,"524","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","0111190912","June 15, 2020","September 30, 2020","October 2, 2020","December 23, 2019",,"October 27, 2020","Kanudjoso Djatiwibowo General Hospital, Balikpapan, East Kalimantan, Indonesia|Tarakan General Hospital, Tarakan, North Kalimantan, Indonesia|Labuang Baji General Hospital, Makasar, South Sulawesi, Indonesia|Balai Besar Kesehatan Paru Masyarakat, Makasar, South Sulawesi, Indonesia|Wahidin Sudirohusodo General Hospital, Makassar, South Sulawesi, Indonesia",,"https://ClinicalTrials.gov/show/NCT04208789"
442,"NCT02245347","Genome Sequencing of Multidrug Resistant Tuberculosis (MDR TB) in Sputum","MDRTB01","Unknown status","No Results Available","Tuberculosis",,"Identification and sequencing of mycobacterial DNA from sputum samples","St George's Healthcare NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","12.LO.1694","April 2013","April 2016",,"September 19, 2014",,"September 19, 2014","St George's NHS Healthcare Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02245347"
443,"NCT00691392","Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)","S30PK","Completed","No Results Available","Multi-Drug Resistant Tuberculosis|Extensively Drug Resistant Tuberculosis","Drug: Linezolid|Drug: Microcrystalline Methylcellulose - Placebo","Characterize linezolid pharmacokinetic parameters (AUC0-24 and linezolid time over MIC) in patients with MDR-TB and XDR-TB.|Assess the pharmacodynamic effects of linezolid AUC0-24 on tolerability (bone marrow toxicity, peripheral and ocular neuropathies) and safety during four months of treatment of tuberculosis|characterize the pharmacokinetics of ofloxacin and potentially other second line anti-tuberculous drugs utilized in the treatment of patients with MDR TB.|Assess the pharmacodynamic effect of linezolid pharmacokinetic parameters ( on biomarkers of treatment activity. Biomarkers to be evaluated are time to detection in liquid culture, sputum culture conversion at two and four months of study treatment.","Centers for Disease Control and Prevention|University of Texas|Columbia University|University of KwaZulu|University of Cape Town|Boston University|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TBTC Study 30PK","April 2009","May 2010","May 2010","June 5, 2008",,"August 17, 2012","King George V Hospital, Durban, KwaZulu Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT00691392"
444,"NCT03334734","Phase 2a Study of PBTZ169",,"Terminated","Has Results","Tuberculosis","Drug: PBTZ169|Drug: Isoniazid","Early Bactericidal Activity (0-14)|Early Bactericidal Activity (0-2)|Early Bactericidal Activity (0-7)|Peak Plasma Concentration (Сmax) of PBTZ169|Minimal Plasma Concentration (Сmin) of PBTZ169|Residual Concentration (Ctrough) of PBTZ169|Time to Reach Maximum Concentration (Tmax) of PBTZ169|AUC(0-24)|AUC (0-t)|AUC(0-∞) of PBTZ169|Accumulation Ratios for the PK Parameters AUC(0 -24)|Average Concentration (Css,av) of PBTZ169|Fluctuations (%) in the Dosing Interval|Total (Plasma) Clearance (Clt) of PBTZ169|Volume of Distribution (Vd) of PBTZ169|Plasma Half-life Time (T1/2) of PBTZ169|Elimination Constant (Kel) of PBTZ169","Nearmedic Plus LLC|OCT LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","16","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBTZ169-A15-C2A-1","December 16, 2016","September 10, 2017","February 22, 2018","November 7, 2017","March 9, 2020","March 9, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/34/NCT03334734/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03334734"
445,"NCT00000785","A Registry of Tuberculosis Cases in the CPCRA",,"Completed","No Results Available","HIV Infections|Tuberculosis",,,"National Institute of Allergy and Infectious Diseases (NIAID)","All","1 Day and older   (Child, Adult, Older Adult)",,"1509","NIH","Observational","Time Perspective: Cross-Sectional","CPCRA 017|11568","August 1992","June 1994","June 1994","August 31, 2001",,"October 1, 2013","Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States|Veterans Administration Med Ctr / Regional AIDS Program, Washington, District of Columbia, United States|AIDS Research Alliance - Chicago, Chicago, Illinois, United States|Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States|Comprehensive AIDS Alliance of Detroit, Detroit, Michigan, United States|Henry Ford Hosp, Detroit, Michigan, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Addiction Research and Treatment Corp, Brooklyn, New York, United States|Clinical Directors Network of Region II, New York, New York, United States|Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York, New York, United States|Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland, Oregon, United States|Richmond AIDS Consortium, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00000785"
446,"NCT02156882","Establishment of a Clinical Trial Unit in Mavalane, Maputo, in Mozambique","MaTuTU","Completed","No Results Available","Tuberculosis",,"Number of participants with clinical and microbiological cure at month 6 after treatment initiation","Michael Hoelscher|Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)",,"81","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MaTuTU-TB-01","June 2014","May 2016","September 2016","June 5, 2014",,"March 7, 2018","Centro de Investigação e Treino em Saúde da Polana Caniço, Maputo, Mozambique|Instituto Nacional de Saúde, Eduardo Mondlane Avenue nº 1008 MISAU, Maputo, Mozambique",,"https://ClinicalTrials.gov/show/NCT02156882"
447,"NCT02906007","Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV",,"Active, not recruiting","No Results Available","Tuberculosis|HIV","Drug: Bedaquiline","Frequency of participant termination from treatment due to a drug-related adverse event|Frequency of adverse events of ≥ Grade 3 severity|Frequency of adverse events of ≥ Grade 3 severity assessed by the Core Team to be at least possibly related to the study medication|Frequency of participants with absolute QTcF ≥ 500 msec|Frequency of unstable dysrhythmias requiring hospitalization and treatment|Incidence of death|Area Under the Curve (AUC0-24h or AUC0-168h)|Frequency of adverse events ≥ Grade 3 severity|Frequency of adverse events ≥ Grade 3 severity assessed by the Core Team to be at least possibly related to the study drug.|Frequency of participants with absolute QTcF greater than or equal to 500 msec|Pharmacokinetic parameter maximal concentration|Pharmacokinetic parameter trough concentration (concentration at the end of an dosing interval)|Pharmacokinetic parameter time of maximal concentration|Pharmacokinetic parameter oral clearance|Pharmacokinetic parameter theoretical steady state AUC|Quantitative post-treatment bedaquiline concentrations|Post-treatment bedaquiline concentrations below limit of quantifications","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","0 Months to 18 Years   (Child, Adult)","Phase 1|Phase 2","84","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1108|11884|IMPAACT P1108","September 21, 2017","February 28, 2024","August 15, 2025","September 19, 2016",,"February 20, 2024","Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Sizwe CRS, Johannesburg, Gauteng, South Africa|PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa",,"https://ClinicalTrials.gov/show/NCT02906007"
448,"NCT02169882","High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study","ReDEFINe","Completed","No Results Available","Tuberculosis, Meningeal","Drug: Placebo|Drug: Rifampicin|Drug: Other TB drugs|Drug: Adjuvant dexamethasone","Rifampicin concentrations in plasma and cerebrospinal fluid (CSF)|Rifampicin concentrations in plasma and CSF at steady-state|Grade 3 and 4 and serious adverse events|Mortality|Neurological response|Neuroradiological response|Resolution of blood and CSF inflammatory response|Sensitivity of GeneXpert for diagnosing TBM","Universitas Padjadjaran|United States Agency for International Development (USAID)|Radboud University Medical Center","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TB-201406.01|PGA-2000003601","December 1, 2014","November 5, 2016","May 5, 2017","June 23, 2014",,"June 1, 2017","Hasan Sadikin General Hospital, Bandung, Jawa Barat, Indonesia",,"https://ClinicalTrials.gov/show/NCT02169882"
449,"NCT02236078","Brief Bactericidal Activity of Anti-Tuberculosis Drugs","BBA","Completed","No Results Available","Tuberculosis|Drug-resistant Tuberculosis|Isoniazid Resistant Tuberculosis (Disorder)","Drug: High dose isoniazid","Delta CFU/ml/day|Time-to-detection (TTD)","Centers for Disease Control and Prevention|Kenya Medical Research Institute","All","8 Years to 99 Years   (Child, Adult, Older Adult)","Phase 1","18","U.S. Fed|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHHSTP-6435","November 2015","September 30, 2020","September 30, 2020","September 10, 2014",,"October 19, 2020","National Institute for Research on Tuberculosis, Chennai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT02236078"
450,"NCT00851630","Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)","THIRST","Completed","Has Results","HIV|Tuberculosis","Drug: Fixed dose combination zidovudine/lamivudine/abacavir","Number of Serious Adverse Events (SAEs)|Tuberculosis-immune Reconstitution Inflammatory Syndrome Events|Plasma HIV Ribonucleic Acid (RNA) Level < 400 Copies/ml|HIV RNA Level < 50 Copies/ml","Duke University|Kilimanjaro Christian Medical Centre, Tanzania|Kibongoto National Tuberculosis Hospital, Tanzania|GlaxoSmithKline","All","13 Years and older   (Child, Adult, Older Adult)","Phase 4","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00013131","June 2004","September 2007","September 2007","February 26, 2009","January 8, 2010","May 4, 2010","Kilimanjaro Christian Medical Centre, Moshi, Tanzania",,"https://ClinicalTrials.gov/show/NCT00851630"
451,"NCT01683773","Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A",,"Completed","No Results Available","Tuberculosis","Biological: AERAS-402|Biological: MVA85A","Safety of AERAS-402 followed by MVA85A|Immunogenicity of AERAS-402 followed by MVA85A","University of Oxford|Aeras|Crucell Holland BV|Emergent BioSolutions|University of Birmingham","All","18 Years to 55 Years   (Adult)","Phase 1","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB032","September 2012","August 2014","August 2014","September 12, 2012",,"September 17, 2014","Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford, Oxfordshire, United Kingdom|The Wellcome Trust Clinical Research Facility (WTCRF), University of Birmingham, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01683773"
452,"NCT05871489","Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens","STEM-TB","Recruiting","No Results Available","Tuberculosis, Multidrug-Resistant|HIV","Drug: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Drug: Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Drug: Bdq, Lzd, Lfx, Z, Dlm (9-12 months)","End-of-treatment outcome|Final tuberculosis treatment outcome|Adverse events of interest","Harvard Medical School (HMS and HSDM)|National Institute of Allergy and Infectious Diseases (NIAID)|Partners in Health|Socios En Salud Sucursal, Peru","All","0 Years to 120 Years   (Child, Adult, Older Adult)",,"800","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01AI146095","September 22, 2020","June 30, 2026","June 30, 2027","May 23, 2023",,"June 13, 2023","Partners In Health, Kazakhstan, Almaty, Kazakhstan|Partners In Health, Lesotho, Maseru, Lesotho|Socios En Salud, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT05871489"
453,"NCT05376189","Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis",,"Not yet recruiting","No Results Available","Spondylitis|Tuberculosis","Dietary Supplement: 400 IU|Dietary Supplement: 5000 IU|Dietary Supplement: 10000 IU|Drug: Fixed Drug Combination","The Oswestry Disability Index|The Visual Analogue Scale|Toll-Like Receptor 2 (TLR-2)|Toll-Like Receptor 4 (TLR-2)","Hasanuddin University","All","19 Years to 50 Years   (Adult)","Phase 2|Phase 3","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0204221709","July 1, 2022","December 30, 2022","February 1, 2023","May 17, 2022",,"May 17, 2022","Wahidin Sudirohusodo General Hospital, Makassar, South Sulawesi, Indonesia",,"https://ClinicalTrials.gov/show/NCT05376189"
454,"NCT04145258","Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","INTENSE-TBM","Recruiting","No Results Available","Tuberculous Meningitis","Drug: Aspirin|Drug: Placebo of aspirin|Drug: WHO TBM treatment|Drug: Intensified TBM treatment","Rate of all-cause death|Rate of all-cause death or loss to follow-up|Rate of new central neurological event or aggravation of a central neurological event existing at baseline|Rate of grade 3-4 adverse events (DAIDS adverse events grading table)|Rate of serious adverse events|Rate of solicited treatment related adverse events|Percentage of patients with disability|M. tuberculosis culture conversion rate|Time to culture positivity|Time to first hospital discharge|Cost-effectiveness incremental ratio of trial interventions|Prevalence of resistance to anti-TB drugs among patients with positive culture at inclusion|Subset of patients: In vitro bactericidal activity of anti-TBM treatment|Subset of patients: Maximum Plasma Concentration [Cmax] of rifampicin and linezolid|Subset of patients: Minimum Plasma Concentration [Cmin] of rifampicin and linezolid|Subset of patients: Area Under the Curve [AUC] of rifampicin and linezolid|Subset of patients: Time for maximal concentration [Tmax] of rifampicin and linezolid|Subset of patients: Half-life (t1/2) of rifampicin and linezolid|HIV-infected participants: Rate of new AIDS-defining illnesses|HIV-infected participants: Percentage of participants with virological success (plasma HIV-1 RNA <50 copies/ml)|HIV-infected participants: CD4 count change from baseline|HIV-infected participants, subset of patients: Maximum Plasma Concentration [Cmax] of of dolutegravir|HIV-infected participants, subset of patients: Minimum Plasma Concentration [Cmin] of dolutegravir|HIV-infected participants, subset of patients: Area Under the Curve [AUC] of dolutegravir|HIV-infected participants, subset of patients: Time for maximal concentration [Tmax] of dolutegravir|HIV-infected participants, subset of patients: Half-life (t1/2) of dolutegravir","ANRS, Emerging Infectious Diseases|European Union|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","768","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANRS 12398 INTENSE-TBM|EDCTP RIA2017T-2019","February 7, 2021","September 2025","April 2026","October 30, 2019",,"January 22, 2024","Cocody University Hospital, Abidjan, Côte D'Ivoire|Treichville University Hospital, Abidjan, Côte D'Ivoire|Yopougon University Hospital, Abidjan, Côte D'Ivoire|University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar|University Hospital Tambohobe, Fianarantsoa, Madagascar|Morafeno University Hospital, Toamasina, Madagascar|Kayelitsha District Hospital, Cape Town, South Africa|Mitchells Plain Hospital, Cape Town, South Africa|New Somerset Hospital, Cape Town, South Africa|Dora Nginza Hospital, Port Elizabeth, South Africa|Livingstone and PE Central Hospitals, Port Elizabeth, South Africa|Mbarara Regional Reference Hospital, Mbarara, Uganda|Regional Reference Hospital of Kabale, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT04145258"
455,"NCT00402610","A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment","Development of tuberculosis|Suspension of chemoprophylaxis due to adverse effects|Mortality","Sociedad Andaluza de Enfermedades Infecciosas","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","332","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","GAEI 94/0071a|FIS 94/0071A","January 1994",,"December 1998","November 22, 2006",,"October 24, 2008","Hospital Universitario Reina Sofía, Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT00402610"
456,"NCT03498534","Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis",,"Withdrawn","No Results Available","Latent Tuberculosis|Diabetes Mellitus","Drug: Isoniazid 300Mg Tab|Drug: Isoniazid 300 MG","Development of active TB","Instituto Nacional de Salud Publica, Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CI-543","September 2012","December 2012","December 2013","April 13, 2018",,"April 17, 2018",,,"https://ClinicalTrials.gov/show/NCT03498534"
457,"NCT01071603","Tuberculosis in China",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Multidrug-Resistant|Extensively Drug Resistant Tuberculosis",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"199","NIH","Observational","Time Perspective: Prospective","999910060|10-I-N060","February 2, 2010",,"January 29, 2018","February 19, 2010",,"April 5, 2018","Henan Provincial Chest Hospital, Zhengzhou, China",,"https://ClinicalTrials.gov/show/NCT01071603"
458,"NCT05073926","Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis",,"Recruiting","No Results Available","Latent Tuberculosis|Staphylococcus Aureus","Other: No intervention is part of the study protocol","Incidence of rifampicin resistant S. aureus in individuals treated with rifampicin versus isoniazide for latent tuberculosis infection|Frequency of mutations associated with rifampicin resistance in S.aureus during and after rifampicin treatment for latent tuberculosis infection","Region Skane","All","16 Years and older   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021-02312","September 30, 2021","June 2024","December 2024","October 12, 2021",,"November 18, 2023","Skåne University Hospital, Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT05073926"
459,"NCT01244204","Role of Vitamin D in Innate Immunity to Tuberculosis",,"Completed","No Results Available","Vitamin D Deficiency|Tuberculosis","Dietary Supplement: Vitamin D|Dietary Supplement: Placebo","Serum vitamin D levels|Tuberculin Skin Test conversion","Harvard School of Public Health (HSPH)","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","1K99HL089710-01A1","November 2009","May 2010","March 2011","November 19, 2010",,"August 3, 2012",,,"https://ClinicalTrials.gov/show/NCT01244204"
460,"NCT04021121","Adjunctive Linezolid for the Treatment of Tuberculous Meningitis","ALTER","Completed","No Results Available","Tuberculosis, Meningeal","Drug: LZD|Drug: High dose RIF|Drug: Standard dose RIF","Cerebrospinal Fluid (CSF) and Plasma LZD Pharmacokinetic Parameters|Proportion of participants with Grade 3 or higher adverse events (AE).|Proportion of participants who complete LZD treatment.|Modified Rankin Scale (MRS) performance.|Neurocognitive Battery Performance: Wechsler Adult Intelligence Scale-III Digit Symbol (WAIS-III).|Neurocognitive Battery Performance: Color Trails, Part 1|Neurocognitive Battery Performance: Color Trails, Part 2|Neurocognitive Battery Performance: Category Fluency|Neurocognitive Battery Performance: Hopkins Verbal Learning Test-Revised (HVLT-R)|Neurocognitive Battery Performance: World Health Organization-University of California-Los Angeles Auditory Verbal Learning Test (WHO-UCLA AVLT).|Neurocognitive Battery Performance: Grooved Pegboard Bilateral|Neurocognitive Battery Performance: Finger Tapping Bilateral|Montreal Cognitive Assessment performance (Conditional).","University of California, San Francisco|MRC/UVRI and LSHTM Uganda Research Unit|London School of Hygiene and Tropical Medicine|Fogarty International Center of the National Institute of Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-26068|R21TW011035","May 5, 2021","July 5, 2023","December 4, 2023","July 16, 2019",,"January 24, 2024","Masaka Regional Referral Hospital/MRC UVRI Uganda Research Unit on AIDS, Masaka, Uganda","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/21/NCT04021121/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04021121"
461,"NCT02583048","Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis",,"Completed","Has Results","Tuberculosis|HIV Infections","Drug: Bedaquiline|Drug: Delamanid|Drug: Dolutegravir|Drug: Multidrug Background Treatment (MBT) for TB","Mean Change From Baseline in QTcF|Post-Baseline QTcF|Percentage of Participants With an Occurrence of QTcF Greater Than 500 Milliseconds (ms)|Percentage of Participants With an Increase in QTcF From Baseline of Greater Than 60 Milliseconds (ms)|Changes in QTcF From Baseline|Percentage of Participants With an Occurrence of QTcF >480 and ≤500 Milliseconds (ms)|Percentage of Participants With an Occurrence of QTcF Increase From Baseline of >30 and ≤60 Milliseconds (ms)|BDQ PK Parameter Minimum Plasma Concentration (Cmin) Determined Based on BDQ Levels From Individual Participants Enrolled in Arms 1 and 3|BDQ PK Parameter Maxmum Plasma Concentration (Cmax) Determined Based on BDQ Levels From Individual Participants Enrolled in Arms 1 and 3|BDQ PK Parameter Area Under the Concentration Time Curve (AUC 0-22h) Calculated Based on Intensive PK Samples Obtained From Individual Participants Enrolled in Arms 1 and 3|N-monodesmethyl Metabolite of BDQ PK Parameter Cmin Determined Based on BDQ Metabolite Levels From Individual Participants Enrolled in Arms 1 and 3|N-monodesmethyl Metabolite of BDQ PK Parameter Cmax Determined Based on BDQ Metabolite Levels From Individual Participants Enrolled in Arms 1 and 3|N-monodesmethyl Metabolite of BDQ PK Parameter AUC 0-22h Calculated Based on Intensive PK Samples Obtained From Individual Participants Enrolled in Arms 1 and 3|DLM PK Parameter Cmin Determined Based on DLM Levels From Individual Participants Enrolled in Arms 2 and 3|DLM PK Parameter Cmax Determined Based on DLM Levels From Individual Participants Enrolled in Arms 2 and 3|DLM PK Area Under the Concentration Time Curve (AUC 0-11h) Determined Based on Intensive PK Samples Obtained From Individual Participants Enrolled in Arms 2 and 3|DLM Metabolite DM6705 PK Parameter Cmin Determined Based on DLM Metabolite Levels From Individual Participants Enrolled in Arms 2 and 3|DLM Metabolite DM6705 PK Parameter Cmax Determined Based on DLM Metabolite Levels From Individual Participants Enrolled in Arms 2 and 3|DLM Metabolite DM6705 PK AUC 0-11h Determined Based on Intensive PK Samples Obtained From Individual Participants Enrolled in Arms 2 and 3|Percentage of Participants With an Occurrence of Grade 3 or Higher Adverse Event|Percentage of Participants Who Discontinued Study TB Drug(s) For Any Reason|Percentage of Participants Who Died","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","84","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5343|12005","August 15, 2016","January 7, 2019","February 4, 2021","October 21, 2015","January 29, 2020","January 27, 2022","Barranco CRS, Lima, Peru|Task Applied Science (TASK) CRS, Cape Town, Western Cape Province, South Africa|South African Tuberculosis Vaccine Initiative (SATVI) CRS, Cape Town, Western Cape Province, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02583048/Prot_001.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02583048/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02583048"
462,"NCT01038830","QuantiFERON Change During Anti-tuberculosis Medication",,"Completed","No Results Available","Tuberculosis|Interferon-gamma Release Assay",,,"Armed Forces Capital Hospital, Republic of Korea","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","QFTchange","May 2008","April 2010","May 2010","December 24, 2009",,"June 14, 2010","Armed Forces Capital Hospital, Seongnam, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01038830"
463,"NCT05047315","Evaluating a New Stool Based qPCR for Diagnosis of Tuberculosis in Children and People Living With HIV","Stool4TB","Recruiting","No Results Available","Tuberculosis|Diagnoses Disease",,"Diagnostic performance qPCR test in stool samples|Comparison of diagnostic performance|Monitor response to TB treatment","Barcelona Institute for Global Health|Makerere University|Amsterdam Institute for Global Health and Development|Centro de Investigacao em Saude de Manhica|Baylor Eswatini Clinical Centre of Excellence (COE)|Research Center Borstel|Fundação Manhiça|Baylor College of Medicine","All","0 Years to 8 Years   (Child)",,"1945","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIA2018D-2511","December 1, 2021","April 1, 2025","September 30, 2025","September 17, 2021",,"October 18, 2023","Centro de investigação de Saúde de Manhiça, Manhiça, Maputo, Mozambique|Baylor Eswatini Clinical Centre of Excellence (COE), Mbabane, Swaziland|Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05047315"
464,"NCT02273765","Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis","REFLATE TB2","Completed","No Results Available","HIV-1 Infection|Tuberculosis","Drug: Tenofovir + lamivudine + raltegravir|Drug: Tenofovir + lamivudine + efavirenz","Proportion of patients in virologic success|Time to death|Frequency, type and time to new or recurrent AIDS-defining illnesses|Frequency, type and time to severe HIV-associated non-AIDS defining illnesses|Frequency, type and time to grade 3 or 4 adverse events|Frequency, type and time to drug-induced clinical or biological adverse reactions of grade 3 or 4 or leading to treatment interruption|Change in plasma HIV-1 RNA from baseline to week 48|Proportion of patients in virologic success at each time point (HIV-1 RNA<50 copies/mL)|Time to virologic failure during follow-up|Frequency and time to new antiretroviral genotypic resistance in plasma RNA in patients with virologic failure|Change in CD4 cell counts from baseline to week 48|Frequency, type and time to Immune Reconstitution Inflammatory Syndrome|Frequency of tuberculosis treatment outcomes","ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC|Ministry of Health, Brazil","All","18 Years and older   (Adult, Older Adult)","Phase 3","460","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 12300 REFLATE TB2","September 11, 2015","November 28, 2018","November 28, 2018","October 24, 2014",,"December 31, 2018","Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ, Rio de Janeiro, Brazil|PACCI / CePReF Centre de Prise en charge de Recherche et de Formation, Abidjan, Côte D'Ivoire|Hôpital Saint Louis, Paris, France|Instituto Nacional de Saude / Hospital Geral de Machava, Maputo, Mozambique|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02273765"
465,"NCT05571735","Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","CVTB","Enrolling by invitation","No Results Available","Covid-19 Pandemics|Tuberculosis","Biological: Pfizer-BioNTech COVID-19 vaccine|Biological: AstraZeneca vaccine|Biological: Janssen Ad26.COV2.S COVID-19 vaccine","Comparison of humoral and cellular responses to SARS-CoV-2 between bacteriologically confirmed TB patients under treatment vs healthy individuals at the end of the study|Comparison of humoral and cellular responses to SARS-CoV-2 between bacteriologically confirmed TB patients under treatment vs healthy individuals.|Occurrence and comparison of solicited local reactogenicity signs and symptoms for 7 days following each dose of vaccination|Occurrence and comparison of solicited systemic reactogenicity signs and symptoms for 7 days following each dose of vaccination|Occurrence and comparison of unsolicited adverse events (AEs) following each dose of vaccination|Comparison of changes from baseline for safety laboratory measures between bacteriologically confirmed TB patients under treatment vs healthy individuals.","University of Oxford","All","18 Years and older   (Adult, Older Adult)",,"108","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VIR21002","April 15, 2023","April 14, 2024","April 14, 2024","October 7, 2022",,"June 23, 2023","Shoklo Malaria Research Unit (SMRU), Mae Ramat, Tak, Thailand",,"https://ClinicalTrials.gov/show/NCT05571735"
466,"NCT03474029","Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI","ASTERoiD","Recruiting","No Results Available","Latent Tuberculosis","Drug: Rifapentine daily for 6 weeks|Drug: Rifapentine and Isoniazid weekly for 12 weeks|Drug: Rifampin and Isoniazid daily for 12 weeks|Drug: Rifampin daily for 16 weeks","Treatment discontinuation due to adverse drug reaction|Culture-confirmed tuberculosis (TB) in participants 18 years old and older and culture-confirmed or clinical TB in participants less then 18 years old.|Proportion who complete assigned treatment|Proportion with drug discontinuation for any reason|Proportion with any grade 3, 4, or 5 (i.e., death) adverse event associated with study drug|Proportion who have died for any reason|Proportion with hepatitis and non-hepatotoxic systemic drug reactions|Proportion with culture-confirmed or clinical TB regardless of age|Proportion with TB among those who complete assigned therapy|Safety (defined as treatment discontinuation due to adverse drug reaction) among participants with human immunodeficiency virus (HIV) infection.|Safety (defined as treatment discontinuation due to adverse drug reaction) among participants < 18 years old.|Tolerability (defined as proportion of with drug discontinuation for any reason) among participants with human immunodeficiency virus (HIV) infection.|Tolerability (defined as proportion of with drug discontinuation for any reason) among participants < 18 years old.|Effectiveness among participants with human immunodeficiency virus (HIV) infection.|Effectiveness among participants < 18 years old.","Centers for Disease Control and Prevention","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","3400","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-7024","August 1, 2019","December 2028","December 2028","March 22, 2018",,"July 12, 2023","Denver Health and Hospital Authority, Denver, Colorado, United States|George Washington University, Washington, District of Columbia, United States|Washington DC VA Medical Center, Washington, District of Columbia, United States|New York Harbor Healthcare System, Manhattan, New York, United States|New York City Bureau of TB Control, New York, New York, United States|San Antonio VA, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|Liverpool Hospital, Sydney, Australia|Paramatta Chest, Sydney, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Calgary TB Clinic, Calgary, Alberta, Canada|Edmonton TB Clinic, Edmonton, Alberta, Canada|British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Desmond Tutu TB Center, Stellenbosch, South Africa",,"https://ClinicalTrials.gov/show/NCT03474029"
467,"NCT01690754","Evaluating the Effectiveness of Interactive SMS Reminders on TB Treatment Outcomes",,"Completed","No Results Available","Tuberculosis","Other: Interactive Reminders","Treatment Outcomes|Physical fitness and mobility|Psychological Impacts|Self-reported medication adherence|Sputum conversion","Interactive Research and Development|Massachusetts Institute of Technology","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","2207","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRD_IRB_2011_03_002","March 2011","November 2014","November 2014","September 24, 2012",,"March 20, 2015","Civil Hospital, Karachi, Pakistan|Indus Hospital, Karachi, Pakistan|Jinnah Postgraduate Medical Center, Karachi, Pakistan|Landhi Medical Complex, Karachi, Pakistan|Private GP clinics and Private labs partnering with Interactive Research and Devellopment, Karachi, Pakistan|Sindh Government Hospital - Liaqatabad, Karachi, Pakistan|Sindh Government Hospital - New Karachi, Karachi, Pakistan|Sindh Government Hospital - Qatar, Karachi, Pakistan|Sindh Government Hospital New Karachi Kaali Market, Karachi, Pakistan|UHC-New Karachi, Karachi, Pakistan|Urban Health Center - Landhi, Karachi, Pakistan",,"https://ClinicalTrials.gov/show/NCT01690754"
468,"NCT03141060","Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB",,"Recruiting","No Results Available","Tuberculosis|HIV Infections","Drug: Delamanid|Drug: Optimized multidrug background regimen (OBR) for children with MDR-TB","Frequency of Grade 3 or 4 adverse events (AEs)|Frequency of Grade 3 or 4 AEs judged by the Clinical Management Committee (CMC) to be related to DLM|Frequency of permanent discontinuations of DLM due to a toxicity or AE|Frequency of QTcF interval greater than or equal to 500 ms|Frequency of participant deaths|Frequency of Grade 3 or 4 AEs|Frequency of Grade 3 or 4 AEs judged by the CMC to be related to DLM|Frequency of Grade 2, 3 or 4 AEs|Frequency of Grade 2, 3 or 4 AEs judged by the CMC to be related to DLM|Frequency of change in QTcF interval from baseline of greater than 60 ms","National Institute of Allergy and Infectious Diseases (NIAID)|Otsuka Pharmaceutical Development & Commercialization, Inc.","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","48","NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT 2005|20721","January 30, 2018","May 30, 2024","October 30, 2025","May 4, 2017",,"April 3, 2024","Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Sizwe CRS, Johannesburg, Gauteng, South Africa|PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania",,"https://ClinicalTrials.gov/show/NCT03141060"
469,"NCT02106039","Pulmonary Tuberculosis Patients With Diabetes Mellitus","TANDEM","Completed","No Results Available","Diabetes Mellitus|Pulmonary Tuberculosis","Procedure: intensive monitoring","Better diabetes control in diabetes patients with tuberculosis under treatment|Cost-effectiveness of different strategies for diabetes management during TB treatment|Measurement of long-term requirements for diabetes management in TB patients diagnosed with diabetes after TB treatment completed|Association between glycemic control and clinical-microbiological response to TB treatment","Universitas Padjadjaran|London School of Hygiene and Tropical Medicine|Radboud University Medical Center|Leiden University Medical Center|University of Stellenbosch|St George's, University of London|University of Otago|University of Medicine and Pharmacy Craiova|University Medical Center Groningen|Universidad Peruana Cayetano Heredia","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB-201403.01","April 28, 2014","February 21, 2017","December 21, 2017","April 7, 2014",,"April 18, 2019","Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia|Universidad Peruana Cayetano Heredia, Lima, San Martin De Porres, Peru|University of Medicine and Pharmacy Craiova, Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02106039"
470,"NCT04700579","Pre- and Post-treatment Lung Microbiota, Metabolome and Immune Signatures at the Site of Disease in Patients With Active Pulmonary Tuberculosis","TB-LUNG","Recruiting","No Results Available","TB - Tuberculosis|HIV/AIDS",,"Characterization of changes in microbiota in diseased vs. non-diseased lung segments, stratified by HIV status.|Association of specific microbial taxa in diseased segments with elevated SCFAs and impaired host inflammation and tissue repair biomarkers.|Evaluate the impact of treatment on the lung microbiome.","University of Stellenbosch|New York University","All","18 Years to 60 Years   (Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","N19/09/126","March 4, 2021","December 31, 2024","January 2026","January 8, 2021",,"March 28, 2024","Kraaifontein Community Health Centre, Cape Town, Western Cape, South Africa|Scottsdene Clinic, Cape Town, Western Cape, South Africa|Wallacedene Clinic, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04700579"
471,"NCT01138202","Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: LPV/r","plasma concentration level|identify toxicities|CD4|HIV RNA|genotypic resistant","The HIV Netherlands Australia Thailand Research Collaboration|Department of Disease Control, Ministry of Public Health Thailand","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other","HIV-NAT 104","November 2010","December 2015","December 2015","June 7, 2010",,"July 17, 2020","HIV-NAT Thai Red Cross AIDS Research Center, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01138202"
472,"NCT00947609","Improving Latent Tuberculosis (TB) Diagnosis in Thai Children","TB Px","Completed","No Results Available","Latent Tuberculosis|HIV Infections",,,"SEARCH Research Foundation|Columbia University|New York Blood Center|HIV Netherlands Australia Thailand Research Collaboration|Queen Sirikit National Institute of Child Health","All","2 Months to 16 Years   (Child)",,"158","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SEARCH TB Px","August 2009","December 2011","December 2011","July 28, 2009",,"June 6, 2012","HIV Netherlands Australia Thailand (HIV-NAT) Research Organization, Bangkok, Thailand|Queen Sirikit National Institute of Child Health, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00947609"
473,"NCT02712671","Testing for Tuberculosis in the United Kingdom HIV Infected Population",,"Active, not recruiting","No Results Available","HIV|Latent Tuberculosis","Radiation: Chest radiograph|Procedure: Blood interferon gamma release assay|Procedure: Tuberculin skin testing (TST)|Procedure: Sputum induction for mycobacterial microscopy and culture|Other: Mycobacterium tuberculosis polymerase chain reaction testing|Procedure: Spirometry","Number of cases of active tuberculosis disease|Number of cases of subclinical tuberculosis|Number of cases latent tuberculosis infection|Number with subsequent active TB disease|Time to subsequent active TB disease|Number of participants with a diagnosis of airways disease in an HIV infected cohort|Quality of life scores for those with HIV infection with or without TB infection.|Uptake of latent TB preventive treatment in an HIV clinic cohort|Cost of latent TB preventive treatment in an HIV clinic cohort|Number of adverse events for each participant taking latent TB preventive treatment","University College, London","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UCL 12/0212","June 2013","February 2016","September 2024","March 18, 2016",,"May 31, 2017","Ian Charleson Centre, Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02712671"
474,"NCT00474435","Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis","PETE","Unknown status","No Results Available","Tuberculosis|HIV Infections","Drug: Emtricitabine/tenofovir/efavirenz","Pharmacokinetic parameters of emtricitabine, tenofovir and efavirenz|Pharmacokinetic parameters of the tuberculostatic agents|Biochemistry and haematology samples for safety|Questioning about occurrence of adverse events|CD4 count and HIV-1 RNA|Sputum staining and culture","African Poverty Related Infection Oriented Research Initiative|Radboud University Medical Center|Kilimanjaro Christian Medical Centre, Tanzania","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCN-AKF 04.03","November 2008","December 2009","December 2009","May 17, 2007",,"December 17, 2010","Kibong'oto National Tuberculosis Hospital, Moshi, Kilimanjaro Region, Tanzania",,"https://ClinicalTrials.gov/show/NCT00474435"
475,"NCT00857402","Arginine as an Adjuvant Treatment Against Tuberculosis",,"Completed","No Results Available","Tuberculosis|HIV","Dietary Supplement: Peanuts|Dietary Supplement: Daboqolo","Final outcome according to WHO|Change in Chest X-ray pattern from baseline to 2 months|Levels of exhaled and urinary nitric oxide|Weight gain from baseline until 2 months|Sedimentation rate|Sputum smear conversion|Reduction of cough from baseline to 2 months","Linkoeping University|University of Gondar|Kalmar County Hospital","All","15 Years to 60 Years   (Child, Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","ArgII|HLF_20060246","February 2004","December 2006","December 2006","March 6, 2009",,"March 6, 2009","Gondar University, DOTS-center, Gondar, Region 3, Ethiopia, Gondar, Ethiopia",,"https://ClinicalTrials.gov/show/NCT00857402"
476,"NCT04677478","Impact of the Respiratory Isolation on the Quality of Life in Patients Hospitalized for Tuberculosis or COVID-19","ISO-BK","Unknown status","No Results Available","Tuberculosis|Covid19","Other: Impact of respiratory isolation on quality of life","Quality of life using semi-structured interview.|Quality of life using 36-Item Short Form Health Survey (SF-36)|Quality of life using State-Trait Anxiety Inventory (STAY) A+B scale|Quality of life using Beck Depressive Inventory (BDI) -13","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200227","December 2020","January 2022","January 2022","December 21, 2020",,"December 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04677478"
477,"NCT01379066","Tuberculosis Volatile Organic Compounds","TBVOC","Completed","No Results Available","Pulmonary Tuberculosis",,"Identification of tuberculosis from bacterial plates","Landon Pediatric Foundation","All","1 Year to 40 Years   (Child, Adult)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TB1","August 2009","December 2009","December 2010","June 23, 2011",,"August 13, 2014","Oxnard Specialty Clinic, Oxnard, California, United States|Pediatric Diagnostic Center, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT01379066"
478,"NCT04721080","Pulmonary Tuberculosis Sequelae in Patients With COPD",,"Unknown status","No Results Available","Copd|Tuberculosis|Quality of Life","Other: Functional Outcome Measurements","Exercise Capacity|Dyspnea Assessment|COPD Assessment|Quality of Life Assessment","Izmir Katip Celebi University","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","IKC145","May 1, 2020","May 1, 2021","May 1, 2021","January 22, 2021",,"March 3, 2021","İlknur Naz Gürşan, İzmir, Turkey",,"https://ClinicalTrials.gov/show/NCT04721080"
479,"NCT00822315","Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: efavirenz|Drug: raltegravir","Virologic success, using Time to Loss of Virologic Response (TLOVR) algorithm: -Plasma HIV RNA below 50 copies/ml at week 20, confirmed at week 24 -Absence of permanent treatment discontinuation -Absence of death -Still follow-up at week 24|Proportion of patients with virologic response with the following definitions: - Plasma HIV RNA <50 copies/ml at week 24 - Rate of strategy discontinuation and treatment changes - Proportion of death - Proportion of patients loss to follow-up|Proportion of patients with virologic response with the following definitions: o Plasma HIV RNA <50 copies/ml o Plasma HIV RNA <400 copies/ml|Evolution in HIV RNA and HIV DNA (total and 2 LTR circular) from baseline to week 48|Rate of viral resistance mutations in the plasma at the time of virologic failure and in comparison with HIV-RNA mutations at W0|Evolution of CD4 cell counts from baseline to week 48|Frequency, type and time to a new AIDS-defining event or death|Frequency, type, time to grade 3 or 4 adverse event|Rate of success of TB treatment|Anti-TB resistance rate|Evolution of raltegravir and efavirenz trough concentration","ANRS, Emerging Infectious Diseases|Gilead Sciences|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","155","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 12180 REFLATE TB","July 2009","November 2011","May 2012","January 14, 2009",,"July 17, 2013","Hospital Genral de Nova Iguaçu, Nova Iguaçu, Brazil|Hospital Nossa Senhora da Coceiçao, Porto alegre, Brazil|Hospital Sanatorio Pertenon, Porto Alegre, Brazil|Ipec/Fiocruz, Rio de Janeiro, Brazil|Hospitral Universitario Pr Edgar Santos, Salvador da Bahia, Brazil|STD/AIDS department, Sao Paulo, Brazil|Hôpital Lariboisière, Paris, France|Hôpital Saint-Louis, Paris, France|CHI Villeneuve Saint Georges, Villeneuve Saint Georges, France",,"https://ClinicalTrials.gov/show/NCT00822315"
480,"NCT00440544","A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)","TMUVA-01","Terminated","No Results Available","Tuberculosis","Biological: Ag85B-ESAT6 fusion protein H1","To evaluate the safety profile (medical examinations, adverse events and laboratory safety tests) of a nasal TB subunit vaccine with and without adjuvant given as two doses with 2 months interval.|To evaluate the cell mediated and humoral immunogenicity profile of a nasal TB subunit vaccine with and without adjuvant, given as two doses with 2 months interval.","St George's, University of London|Statens Serum Institut|Novartis Vaccines|European Union","All","18 Years to 55 Years   (Adult)","Phase 1","9","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TMUVA-01|EudraCT Number: 2005-005140-81|FP6-2002-LIFESCIHEA-2.3 503240","January 2007","November 2007","February 2008","February 27, 2007",,"November 2, 2008","St George's Vaccine Institute, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00440544"
481,"NCT04899076","Stool Processing Kit (SPK) Evaluation for Pediatric Tuberculosis (TB)",,"Completed","No Results Available","Tuberculosis","Device: Stool Processing Kit","Sensitivity and specificity of a single Ultra/SPK using microbiological confirmation on respiratory specimens as reference standard|Diagnostic accuracy of a single Ultra/SPK using the National Institutes of Health (NIH) consensus definition as reference standard|Diagnostic accuracy of a single Ultra/SPK for Rifampin resistance detection|Additional yield (increase in sensitivity) of a 2nd Ultra/SPK|Diagnostic accuracy of a single Ultra/SPK for TB detection per subgroup|Diagnostic accuracy of additional interventions: Simple One Step (SOS), Optimized Sucrose Flotation (OSF) and Fujifilm SILVAMP TB LAM|Feasibility and user appraisal of the different stool processing methods","Foundation for Innovative New Diagnostics, Switzerland|Mulago Hospital, Uganda|University of Cape Town Lung Institute|University of California, San Francisco|All India Institute of Medical Sciences, New Delhi|KEM Hospital Research Centre","All","up to 14 Years   (Child)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7210-07-2/1","June 19, 2019","March 31, 2021","October 31, 2021","May 24, 2021",,"November 24, 2023","All India Institute of Medical Sciences, New Delhi, India|KEM Hospital Research Centre, Pune, India|University of Cape Town Lung Institute, Cape Town, South Africa|Mulago Hospital, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04899076"
482,"NCT03135366","Self-verification and Support Via Mobile Phones Drastically Improves Tuberculosis Treatment Success in LMIC Settings",,"Completed","No Results Available","Tuberculosis","Behavioral: Keheala|Other: Standard of Care","Unsuccessful Treatment Outcomes","Yale University|United States Agency for International Development (USAID)|Keheala|MIT's Applied Cooperation Team|Kenya National Tuberculosis, Leprosy and Lung Disease Program","All","Child, Adult, Older Adult","Not Applicable","1190","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HarvardU","January 4, 2016","December 31, 2016","April 14, 2017","May 1, 2017",,"July 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03135366"
483,"NCT05964842","Using SMS Reminders, Phone Calls and Money Incentives to Enhance Linkage to Care of Presumptive TB Patients in Uganda","MILEAGE4TB","Recruiting","No Results Available","Tuberculosis","Behavioral: SMS|Behavioral: Phone call|Behavioral: Mobile money incentive","Completion of TB diagnosis|Median time to completing TB diagnosis|Initiation of TB treatment|Median time to initiating treatment|Acceptability of the intervention","Makerere University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1548","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Screening","MILEAGE4TB","August 14, 2023","March 31, 2024","April 30, 2024","July 28, 2023",,"February 9, 2024","Luwero General Hospital, Luwero, Kasana, Uganda|Kiruddu National Referral Hospital, Kampala, Makindye, Uganda|Mukono General Hospital, Mukono, Uganda|Entebbe Regional Referral Hospital, Wakiso, Uganda|Wakiso Health Center IV, Wakiso, Uganda",,"https://ClinicalTrials.gov/show/NCT05964842"
484,"NCT01601626","Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV",,"Terminated","Has Results","HIV Infection|Tuberculosis","Drug: Standard-dose Lopinavir/Ritonavir|Drug: Double-dose Lopinavir/Ritonavir|Drug: Raltegravir|Drug: Isoniazid|Drug: Pyridoxine|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Rifabutin|Drug: Rifampin","Percent of Participants Whose HIV Viral Load Was Less Than 400 Copies/mL at Week 48.|Percent of Participants Who Experienced Sputum Conversion at Week 8.|Percent of Participants Who Experienced TB Treatment Failure|Percent of Participants Who Experienced TB Relapse/Recurrence|Percent of Participants Who Experienced TB Relapse/Recurrence and Who Had TB Drug Resistance|Percent of Participants Whose HIV Viral Load Was Less Than 50 Copies/mL at Week 48|Number of Participants Reporting a Grade 3 or 4 Sign or Symptom|Number of Participants Reporting a Grade 3 or 4 Laboratory Abnormality|Percent of Participants Who Interrupted or Discontinued at Least One HIV Drug Due to Toxicity|Percent of Participants Who Interrupted or Discontinued at Least One TB Drug Due to Toxicity|Percent of Participants Who Experienced HIV Virologic Failure|Cumulative Probability of HIV Virologic Failure at Week 72|Number of Participants Who Experienced MTB IRIS|CD4 Count Change From Baseline to Week 8|CD4 Count Change From Baseline to Week 24|CD4 Count Change From Baseline to Week 48|CD4 Count Change From Baseline to Week 72|Percent of Participants Who Experienced a New AIDS-defining Illness|Percent of Participants Who Died|Percent of Participants Who Experienced a New AIDS-defining Illness or Died","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5290|1U01AI068636","July 13, 2013","January 19, 2017","June 28, 2017","May 18, 2012","February 13, 2018","February 13, 2018","Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, RS, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (31730), Port Au Prince, Haiti|Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti|Moi University Clinical Research Center CRS (12601), Eldoret, Kenya|Investigaciones Medicas en Salud (INMENSA) (11302), San Isidro, Lima, Peru|Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru|Wits HIV CRS (11101), Johannesburg, Gauteng, South Africa|Durban Adult HIV CRS (11201), Durban, South Africa","""Statistical Analysis Plan: Primary Analysis"", https://classic.clinicaltrials.gov/ProvidedDocs/26/NCT01601626/SAP_001.pdf|""Statistical Analysis Plan: PK and Safety Interim Analysis"", https://classic.clinicaltrials.gov/ProvidedDocs/26/NCT01601626/SAP_002.pdf|""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/26/NCT01601626/Prot_ICF_003.pdf","https://ClinicalTrials.gov/show/NCT01601626"
485,"NCT03497195","Achieving Tuberculosis (TB) Control In Zambia","TB","Completed","No Results Available","Tuberculosis","Diagnostic Test: Screening at community level","increase TB case detection","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18194","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-300001132","July 1, 2017","December 31, 2018","December 31, 2018","April 13, 2018",,"September 25, 2019","Center for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT03497195"
486,"NCT05005637","The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis With Positive IGRA",,"Enrolling by invitation","No Results Available","Tuberculous Uveitis","Drug: Anti Tuberculosis Drug|Drug: Prednisone tablet","Percentage of Treatment Failure","Fakultas Kedokteran Universitas Indonesia","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06/DIPI/2021","July 27, 2021","March 2024","June 2024","August 13, 2021",,"February 23, 2024","Cipto Mangunkusumo National Central General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT05005637"
487,"NCT01392365","Development of a Prediction Model for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease",,"Completed","No Results Available","Crohn's Disease|Intestinal Tuberculosis",,"Final diagnosis (Intestinal tuberculosis or Crohn's disease)","Asan Medical Center","All","16 Years and older   (Child, Adult, Older Adult)",,"117","Other","Observational","Time Perspective: Prospective","2011-0380","July 2011","February 2015","February 2015","July 12, 2011",,"June 14, 2016","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01392365"
488,"NCT01693224","Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa",,"Unknown status","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Tuberculosis, Miliary","Device: Alere ""Determine"" lateral-flow urine lipoarabinomannan assay|Device: Alere ""Clearview"" ELISA urine LAM assay|Device: Cepheid Xpert MTB/Rif assay","Sensitivity of the lateral-flow urine LAM assay (LF-LAM)|Failure rate of the lateral-flow urine LAM assay|Inter-reader variability of the lateral-flow urine LAM assay|Specificity of the lateral-flow urine LAM assay (LF-LAM)|Sensitivity of the ELISA-based urine LAM test|Diagnostic yield (expressed as number of TB cases detected) of various diagnostic strategies (see description)|Time to diagnosis (expressed in days) of various diagnostic strategies (see description)|Accuracy, efficiency, costs, and cost-effectiveness of various combinations of TB diagnostic tests|Satisfaction of lateral-flow urine LAM test operators|Specificity (Sp) of the ELISA-based urine LAM test|Sensitivity of the Xpert MTB/Rif test to detect MTB in blood","Tuberculosis Clinical Diagnostics Research Consortium|University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Not Applicable","512","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DMID 10-0051|NA_00043138","April 2011","February 2013","February 2013","September 26, 2012",,"September 26, 2012","G.F. Jooste Hospital, Cape Town, Western Cape, South Africa|Town Two Clinic, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT01693224"
489,"NCT00560521","Continuous Positive Airway Pressure on Tuberculosis Pleural Effusion",,"Completed","No Results Available","Tuberculosis|Pleural Effusion","Behavioral: CPAP","Evaluate of pleural effusion volume","Universidade Federal do Rio de Janeiro","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Oliveira-1","March 2005",,"March 2007","November 19, 2007",,"November 19, 2007","Clementino Fraga Filho University Hospital- Federal University of Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00560521"
490,"NCT01525134","Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis",,"Unknown status","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Tuberculosis, Miliary","Device: Alere ""Determine"" lateral-flow urine lipoarabinomannan assay|Device: Alere ""Clearview"" ELISA urine LAM assay","Sensitivity of the lateral-flow urine LAM assay (LF-LAM)|Failure rate of the lateral-flow urine LAM assay|Inter-reader variability of the lateral-flow urine LAM assay|Specificity of the lateral-flow urine LAM assay (LF-LAM)|Sensitivity of the ELISA-based urine LAM test|Diagnostic yield (expressed as number of TB cases detected) of various diagnostic strategies (see description)|Time to diagnosis (expressed in days) of various diagnostic strategies (see description)|Accuracy, efficiency, costs, and cost-effectiveness of various combinations of TB diagnostic tests|Satisfaction of lateral-flow urine LAM test operators|Specificity (Sp) of the ELISA-based urine LAM test","Tuberculosis Clinical Diagnostics Research Consortium|Makerere University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","504","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DMID10-0001|NA_00038297","January 2011","February 2012","April 2012","February 2, 2012",,"February 2, 2012","Infectious Diseases Institute, Makerere University, Kampala, Uganda|Mulago National Referral Hospital, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01525134"
491,"NCT00164281","Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana",,"Completed","No Results Available","Tuberculosis|HIV Infections","Drug: Isoniazid","Incident tuberculosis|Death|Adverse events","Centers for Disease Control and Prevention|Botswana Ministry of Health|United States Agency for International Development (USAID)","All","18 Years and older   (Adult, Older Adult)","Phase 4","2000","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CDC-NCHSTP-3441","November 2004","July 2009","May 2011","September 14, 2005",,"February 6, 2014","Gaborone and Francistown Health Clinics, Gaborone and Francistown, Botswana",,"https://ClinicalTrials.gov/show/NCT00164281"
492,"NCT05981495","Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection Kit for the Diagnosis of Tuberculosis Disease",,"Not yet recruiting","No Results Available","Tuberculosis, Pulmonary|Tuberculosis, Extrapulmonary|Tuberculosis Active","Device: NanoDetect-TB","NanoDetect-TB result compared to sputum culture|NanoDetect-TB result compared to AFB Smear and NAAT","NanoPin Technologies, Inc.|Fortrea","All","2 Years and older   (Child, Adult, Older Adult)",,"460","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NanoDetect-TB_01","August 2023","December 2024","December 2024","August 8, 2023",,"August 8, 2023",,,"https://ClinicalTrials.gov/show/NCT05981495"
493,"NCT01685086","Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis",,"Unknown status","No Results Available","To Determine the Prevalence of Latent Tuberculosis in Each Group|To Monitor the Occurrence of Active Tuberculosis",,"occurrence of active tuberculosis|Latent tuberculosis infection","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201110013RC","March 2012",,,"September 13, 2012",,"September 13, 2012","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01685086"
494,"NCT00164463","TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment",,"Completed","No Results Available","Tuberculosis","Drug: Moxifloxacin|Drug: Isoniazid","Compare in healthy volunteers the pharmacokinetics of moxifloxacin alone versus moxifloxacin administered with rifampin.|Compare the pharmacokinetics of moxifloxacin among patients with tuberculosis being treated with multidrug therapy (isoniazid or ethambutol, rifampin, and pyrazinamide) to those of healthy volunteers receiving moxifloxacin plus rifampin.|Determine variation of moxifloxacin pharmacokinetics (PK) among patients with pulmonary TB during treatment.|Compare serum concentrations of isoniazid rifampin and pyrazinamide among patients being treated with moxifloxacin versus patients being treated with ethambutol as the fourth drug in multidrug treatment.|Compare serum concentrations of rifampin, pyrazinamide and ethambutol among patients being treated with moxifloxacin versus patients being treated with isoniazid as the fourth drug|Determine the association between polymorphisms of MDR1 genotype (P-glycoprotein) and rifampin PK parameters.|Determine the effect of polymorphisms of MDR1 genotype and/or rifampin PK on isoniazid PK parameters adjusted for N-acetyltransferase genotype (NAT2).|Determine the effects of polymorphisms of MDR1 and UGT genotypes on moxifloxacin PK parameters.|Determine by multivariate regression analyses the associations between moxifloxacin or rifampin PK parameters and markers of disease severity.","Centers for Disease Control and Prevention|US Department of Veterans Affairs|Bayer|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","U.S. Fed|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDC-NCHSTP-4222","July 2004","August 2007","August 2007","September 14, 2005",,"June 8, 2011","University of Southern California Medical Center, Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Duke University Medical Center, Durham, North Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Veterans Administration Medical Center, Houston, Texas, United States|Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio, Texas, United States|University of British Columbia, Vancouver, British Columbia, Canada|Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00164463"
495,"NCT01007396","Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay",,"Completed","Has Results","Latent Tuberculosis Infection","Other: 1-step tuberculin skin test (TST) and blood sampling","Annual Incidence of Tuberculosis Infection Among Newly Employed Doctors and Nurses in Korea|Negative Conversion Rate in Follow-up QuantiFERON-TB Gold In-Tube Test (QFT-IT Test) After Treatment of Latent Tuberculosis Infection (LTBI)","Samsung Medical Center","All","Child, Adult, Older Adult","Not Applicable","322","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2007-09-019","January 2008","December 2009","December 2009","November 4, 2009","January 11, 2012","January 11, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01007396"
496,"NCT05280886","Multi-site Cohort Study for the Development of Personalized Pharmacotherapy in Patients With Tuberculosis (TB)",,"Recruiting","No Results Available","Tuberculosis|Latent Tuberculosis|Nontuberculous Mycobacterium Infection","Procedure: therapeutic drug monitoring(TDM)","The maximum plasma concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Development of population pharmacokinetic (PK) model of antibiotics|AUC/MIC|Cmax/MIC|Time above MIC (T > MIC)|N-acetyltransferase 2(NAT2) Pharmacogenetic analysis|Solute carrier organic anion transporter family member 1B1(SLCO1B1) Pharmacogenetic analysis|Biomarker exploration for adverse drug reaction","Inje University|Ministry of Science and ICT","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","cPMTb-001","July 24, 2018","December 31, 2024","February 28, 2025","March 15, 2022",,"April 19, 2023","General Hospital Dr. Soetomo, Surabaya, Jawa Timur, Indonesia|Ibnu Sina Hospital, Gresik, Perum Grand, Indonesia|Inje University Busan Paik Hoapital Clinical Trial Center, Busan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05280886"
497,"NCT01378312","A Study to Evaluate Safety and Immunogenicity of AERAS-402",,"Completed","No Results Available","Tuberculosis","Biological: AERAS 402|Biological: Placebo","Number and Percentage of Adverse Events by treatment group|Immune Response","Aeras","All","18 Years to 45 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-004-402","February 2011","October 2011","March 2012","June 22, 2011",,"March 17, 2014","Lotus Labs, Bangalore, India",,"https://ClinicalTrials.gov/show/NCT01378312"
498,"NCT04443283","The Effect of Latent Tuberculosis Infection on the Pregnancy Outcome of IVF-ET",,"Unknown status","No Results Available","Infertility|Tuberculosis","Other: No intervention","clinical pregnancy rate|miscarriage rate|live birth rate|tuberculosis reactivation","Peking University Third Hospital","Female","Child, Adult, Older Adult",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PCCMRP","January 1, 2019","December 30, 2022","December 30, 2022","June 23, 2020",,"June 29, 2020","Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04443283"
499,"NCT01613196","Positron Emission Tomography in Extrapulmonary Tuberculosis","TUBOGTEP","Completed","No Results Available","Extrapulmonary Tuberculosis|Lymph Node Tuberculosis|Bone Tuberculosis","Other: Positron Emission Tomography with 18F-Fluoro-deoxy-glucose","ΣSUVmax variations between the beginning and end of treatment and during follow-up post-treatment, in patients considered cured|Change in SUVmax differences in the lesions according to their location in cured patients.|Variations ΣSUVmax and SUVmax in individual lesions in patients not cured.|Frequency, type and consequences on the therapeutic management of lesions revealed by FDG-PET.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AOM 11080|2011-A01658-33","May 2012","September 2016","March 2018","June 7, 2012",,"March 29, 2018","BICHAT Claude Bernard, Paris, France",,"https://ClinicalTrials.gov/show/NCT01613196"
500,"NCT00647205","Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT",,"Completed","No Results Available","HIV Infections|Tuberculosis","Device: QuantiFERON TB Gold In-Tube|Device: T-SPOT.TB®","Intradermal Tuberculin Tests QuantiFERON TB Gold In-Tube® T-SPOT.TB®","French National Agency for Research on AIDS and Viral Hepatitis","All","18 Years and older   (Adult, Older Adult)","Phase 4","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ANRS EP 40 QUANTI SPOT","January 2008","May 2010","November 2010","March 31, 2008",,"August 9, 2011","Service des Maladies Infectieuses B Hopital Bichat, Paris, France",,"https://ClinicalTrials.gov/show/NCT00647205"
501,"NCT01225640","PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay",,"Completed","No Results Available","Tuberculosis","Drug: PNU-100480|Drug: RHZE","The primary endpoint is rate of change in sputum log CFU/mL count (EBA) from Days 0-2.|Rate of change in sputum log CFU/mL count (extended EBA).|Rate of change in culture time to positivity (TTP) measured by MGIT and in log transformed TTP|Cumulative whole blood bactericidal activity (measured as log reduction in CFU) against intracellular M. tuberculosis relative to administered dose and drug PK|Plasma concentrations of PNU-100480 and PNU-101603 will be used to determine PK parameters (AUCtau, AUC tau,ss, Cmax, Tmax, terminal half-life t1/2, Cavg, Rac) as data permit|Safety assessments including physical exams, AEs, laboratory tests, ECGs, and vital signs.","Sequella, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1171003","August 2011","December 2011","December 2011","October 21, 2010",,"January 14, 2016","Pfizer Investigational Site, Bellville, Cape Town, South Africa|Pfizer Investigational Site, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01225640"
502,"NCT01832987","Pharmacokinetic Parameters of Co-trimoxazole",,"Completed","No Results Available","Tuberculosis","Drug: co-trimoxazole","AUC|Determination of the AUC/MIC and T>MIC|Validating DBS analysis","University Medical Center Groningen","All","18 Years to 64 Years   (Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","SXT8469","October 2013","August 2014","August 2014","April 16, 2013",,"September 16, 2014","UMCG - Tuberculosis Center, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01832987"
503,"NCT01856634","Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis",,"Completed","No Results Available","Multidrug Resistant Tuberculosis|Pediatric","Drug: 100 mg Delamanid|Drug: 50 mg Delamanid|Drug: 25 mg Pediatric Formulation Delamanid|Drug: 10 mg Delamanid Pediatric Formulation|Drug: 5 mg Delamanid Pediatric Formulation|Drug: Optimized Background Regimen","Plasma Concentrations|Adverse Events|Safety Summary|Palatability of the Pediatric Formulation","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","up to 17 Years   (Child)","Phase 1","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","242-12-232","June 14, 2013","December 10, 2017","December 28, 2017","May 17, 2013",,"January 30, 2018","De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines|Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01856634"
504,"NCT00004736","Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Nelfinavir mesylate|Drug: Ethambutol hydrochloride|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Lamivudine|Drug: Rifabutin|Drug: Stavudine|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","NIH","Interventional","Primary Purpose: Treatment","ACTG A5062|AACTG A5062",,,,"August 31, 2001",,"September 11, 2008","Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Cook County Hosp, Chicago, Illinois, United States|Beth Israel Med Ctr, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States|Brown Univ / Miriam Hosp, Providence, Rhode Island, United States|Miriam Hosp / Brown Univ, Providence, Rhode Island, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00004736"
505,"NCT06338462","Cali Sin Tos Aim 2",,"Not yet recruiting","No Results Available","Tuberculosis","Device: Chatbot|Diagnostic Test: Oral testing","Implementation of the mHealth strategy to assess feasibility.|Oral specimen collection to assess feasibility.","Yale University|National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult","Not Applicable","120","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2000034128|R21AI174129","May 2024","May 2025","May 2025","March 29, 2024",,"March 29, 2024","Centro Internacional de Entrenamiento e Investigaciones Medicas (CIDIEM), Cali, Colombia",,"https://ClinicalTrials.gov/show/NCT06338462"
506,"NCT06058065","Sensitivity and Specificity of Xpert MTB/RIF Ultra",,"Not yet recruiting","No Results Available","Tuberculosis",,"Sensitivity and Specificity of Xpert MTB/RIF Ultra|Prevalence of rifampicin resistance among patients with TB active infection presented to Chest Department in Assiut University Hospital","Assiut University","All","18 Years to 70 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Ultra Xpert® MTB/RIF","December 11, 2023","November 28, 2024","December 25, 2024","September 28, 2023",,"October 4, 2023",,,"https://ClinicalTrials.gov/show/NCT06058065"
507,"NCT06318416","Precision Rifampin Trial for Personalized Dosing","P-RIF","Not yet recruiting","No Results Available","Tuberculosis","Diagnostic Test: urine spectrophotometry for rifampin absorbance","Rifampin serum area under the concentration time curve for the 24 hour dosing interval|Adverse events|Time to sputum culture conversion to negative|Weight change","University of Virginia|Haydom Lutheran Hospital|Rutgers University","All","3 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","HSR230382","July 1, 2024","January 30, 2027","January 30, 2028","March 19, 2024",,"March 21, 2024",,,"https://ClinicalTrials.gov/show/NCT06318416"
508,"NCT00905970","Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection","HYPDYN","Unknown status","No Results Available","Latent Tuberculosis Infection",,"QuantiFeron-Gold-In Tube method assay|Detection of M.tuberculosis DNA and RNA in the exhaled breath condensate","Germans Trias i Pujol Hospital|Fondo de Investigacion Sanitaria","All","18 Years and older   (Adult, Older Adult)",,"105","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HYPDYN|CEIC EO-07-033","May 2009","December 2011","December 2011","May 21, 2009",,"July 11, 2011","Fundació Institut Germans Trias i Pujol, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00905970"
509,"NCT00805272","Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients","IGRAVIH","Completed","No Results Available","HIV|Tuberculosis|Latent Tuberculosis Infection","Other: QTF-TB Gold and T-SPOT TB","To evaluate the theoretical therapeutic impact (in terms of CHIMIOPROPHYLAXIE antituberculous theoretically managed) of the tracking of tuberculosis-latent by QTF-TB Gold IT® or T-SPOT.TB among patients HIV.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","536","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P070311","February 2009","September 2011","February 2012","December 9, 2008",,"March 19, 2012","Service de médecine interne hôpital saint louis, Paris, France",,"https://ClinicalTrials.gov/show/NCT00805272"
510,"NCT01748357","Siemens VOC TB Pilot Study",,"Completed","No Results Available","Tuberculosis",,"Percentage of correctly identified patients with tuberculosis|Change in VOC pattern induced by storage for several days|Change in VOC pattern induced by storage temperature|Change in VOC pattern induced by tuberculosis therapy","Research Center Borstel|Siemens Corporate Technologies","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RCBorstel003","December 2012","December 2013","December 2013","December 12, 2012",,"November 6, 2014","Research Center Borstel, Borstel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT01748357"
511,"NCT00564642","Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity",,"Completed","No Results Available","Hepatitis|Tuberculosis","Drug: N Acetylcysteine","Hepatotoxicity","National Research Institute of Tuberculosis and Lung Disease, Iran","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5344-21-07-86","November 2007","January 2009","April 2009","November 28, 2007",,"April 22, 2009","National Research Institute of Tuberculosis and Lung Disease (NRITLD), Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00564642"
512,"NCT06171646","Effect of Breathing Exercise on Fatigue in Patients With Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis, Pulmonary|Fatigue","Behavioral: breathing exercise","Change in fatigue during the Follow-up","Sema Aytaç, PhD|Tuberculosis Network European Trialsgroup","All","18 Years and older   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","5122023","June 1, 2023","September 30, 2023","September 30, 2023","December 14, 2023",,"December 14, 2023","Gaziantep University, Gaziantep, Turkey",,"https://ClinicalTrials.gov/show/NCT06171646"
513,"NCT05017324","Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial","SMARTT","Recruiting","No Results Available","Rifampicin Resistant Tuberculosis|Drug-resistant Tuberculosis|Multidrug Resistant Tuberculosis|Pulmonary Tuberculoses","Device: WGS DST strategy","The Effectiveness of a WGS DST strategy for individualisation of RR-TB treatment|Health economic evaluation of a WGS DST strategy for individualization of RR-TB treatment|Impact of WGS strategy for individualisation of RR-TB treatment on Health related Quality of Life (HRQOL)","Universiteit Antwerpen|Aurum Institute|University of Stellenbosch|University of the Free State|Free State Department of Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","AUR1-11-248|T001018N|2020-004084-10","September 21, 2021","December 2022","January 2025","August 23, 2021",,"October 15, 2021","Free State Department of Health Clinics, Bloemfontein, Free State, South Africa",,"https://ClinicalTrials.gov/show/NCT05017324"
514,"NCT03982277","Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy","SAEFRIF","Completed","No Results Available","Tuberculosis","Drug: Rifampin 300 Mg Oral Capsule","Measures of model predicted exposure/pharmacokinetic (PK) parameters|Pharmacokinetics of high dose rifampicin on DTG and EFV|Safety of high dose rifampicin|Efficacy of high dose rifampicin","Makerere University","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ST/224/219","April 30, 2019","March 16, 2021","July 23, 2021","June 11, 2019",,"March 23, 2023","Infectious Diseases Institute, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT03982277"
515,"NCT04930744","Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","METHOD","Recruiting","No Results Available","Tuberculosis|Pulmonary Tuberculosis|HIV Coinfection","Drug: Isoniazid|Drug: Rifampicin|Drug: Ethambutol|Drug: Pyrazinamide|Drug: Metformin hydrochoride","Safety and tolerability of metformin as measured by the number of grade 3 or higher gastrointestinal (GI) adverse events|Metformin added to standard ATT improves respiratory health as measured by radiographic score|Metformin added to standard ATT improves respiratory health as measured by 6-minute Walk Test (6MWT) as assessed by distance x 02 saturation (2° endpoint)|Metformin added to standard ATT improves respiratory health as measured by spirometry: Forced Vital Capacity (FVC)|Metformin added to standard ATT improves respiratory health as measured by spirometry: Forced Expiratory Volume (FEV1%) (2° endpoint)|Metformin added to standard ATT improves respiratory health as measured by Saint George's Respiratory Questionnaire (SGRQ) assessed by 2° endpoint|Metformin added to standard ATT improves HIV outcomes as measured by HIV viral load|Metformin added to standard ATT improves HIV outcomes as measured by CD4|Metformin added to standard ATT improves HIV outcomes as measured by T cell count|Metformin added to standard ATT improves TB treatment outcomes","University of Massachusetts, Worcester|National Institute of Allergy and Infectious Diseases (NIAID)|Aurum Institute|A*STAR Infectious Diseases Labs|University of Cape Town|Wits Health Consortium (Pty) Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","112","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AUR1-1-199|5U01AI134585","August 26, 2021","November 1, 2025","November 1, 2025","June 18, 2021",,"March 12, 2024","Tembisa Clinical Research Centre-The Aurum Institute, Johannesburg, Gauteng, South Africa|Isango Lethemba TB Research Unit, Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT04930744"
516,"NCT01241188","A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)","TESEC-04","Completed","No Results Available","Tuberculosis","Biological: C-Tb|Biological: 2 TU Tuberculin PPD RT 23 SSI","The diameter of induration at the injection sites measured transversely to the long axis of the forearm 2-3 days after application of the agents|Injection site adverse reactions within 28 days after application of the agents|All adverse events occurring within 28 days after application of the agents|Laboratory safety parameters of haematology and biochemistry|In vitro IFN-γ response as measured by the QuantiFERON®-TB Gold In Tube assay","Statens Serum Institut","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","253","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","TESEC-04","April 2011","December 2011","December 2011","November 16, 2010",,"April 17, 2015","University of Cape Town Lung Institute (Pty) Ltd, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01241188"
517,"NCT01198366","Study of AERAS-402 in Healthy Infants",,"Completed","Has Results","Tuberculosis","Biological: AERAS-402 1.5 x 10^10 vp|Biological: AERAS-402 3.0 x 10^10 vp|Biological: AERAS-402 1.0 x 10^11 vp|Biological: Placebo","Adverse Events Collected Per Subject|Percentage of Cells Expressing Various Cytokines Will be Measured by Intracellular Cytokine Staining (ICS) in All Subjects|Interferon-gamma (IFN-gamma) Enzyme-linked Immunospot (ELISpot) Response: Spot Forming Units/10^6 PBMC According to ELISpot Assay|Antigen-specific Antibody Response - Mean Optical Density (Mean OD)|Percentage of Subjects Converting From a Negative QuantiFERON Test (QFT) to Positive QFT After Vaccination","Aeras|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","112 Days to 182 Days   (Child)","Phase 1|Phase 2","487","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-029-402","September 2010","January 2014","April 2014","September 10, 2010","August 4, 2015","May 8, 2017","Boro Heath Center, Boro, Kenya|KEMRI/CDC Research and Public Heath Collaboration, Kisumu, Kenya|Siaya District Hospital, Siaya, Kenya|CISM: Centro de Investigacao em Saude de Manhica, Manhica, Mozambique|Univeristy of Cape Town, Cape Town, South Africa|Perinatal HIV Research Unit (PHRU) Chris Hani Baragwanath Hospital, Soweto, South Africa|SATVI: Worcester, Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT01198366"
518,"NCT04216420","Electronic Pillbox-enabled SAT Versus DOT for TB Medication Adherence and Treatment Outcomes","SELFTB","Completed","No Results Available","Tuberculosis","Device: MERM-observed self-administered therapy","Level of adherence|Sputum conversion|Negative IsoScreen urine isoniazid test|Adverse treatment outcome|Self-reported adherence|Health-related quality of life (HRQoL)|Catastrophic costs|Post-diagnostic cost from an individual patient's perspective|Patient-reported treatment satisfaction|Patient-reported usability of the MERM device","Addis Ababa University|Addis Ababa University, College of Health Sciences, CDT-Africa, Ethiopia|Emory University School of Medicine, US|Armauer Hansen Research Institute, Ethiopia|Fogarty International Center of the National Institute of Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","114","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","077/19/CDT|D43TW009127","June 1, 2020","July 31, 2021","August 31, 2021","January 2, 2020",,"July 12, 2022","Addis Ababa University, College of Health Sciences, Addis Ababa, Ethiopia",,"https://ClinicalTrials.gov/show/NCT04216420"
519,"NCT01003093","A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine","THYB-01","Completed","No Results Available","Tuberculosis","Biological: 50 microgram antigen (Ag85B + ESAT-6)|Biological: 50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|Biological: 50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a","Physical examination. Local adverse events. Systemic adverse events. Laboratory safety tests including urine safety tests.|Detection by ELISPOT of IFN gamma spot-forming cells in PBMC. Detection by ELISA of IFN gamma production in supernatants of PBMC. Detection of humoral response (IgG) by ELISA.","Statens Serum Institut","Male","18 Years to 55 Years   (Adult)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","THYB-01|Eudract number: TEST-001599-14","November 2005","March 2008","June 2008","October 28, 2009",,"January 21, 2013","Leiden University Medical Centre, Leiden, RC Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01003093"
520,"NCT00000950","Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Ethambutol hydrochloride|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Pyridoxine hydrochloride|Drug: Rifampin",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","50","NIH","Interventional","Primary Purpose: Treatment","ACTG 309",,"May 2002",,"August 31, 2001",,"March 2, 2011","Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|Harbor UCLA Med Ctr, Torrance, California, United States|University of Miami (Pediatric), Miami, Florida, United States|Emory Univ, Atlanta, Georgia, United States|Queens Med Ctr, Honolulu, Hawaii, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Tulane Univ School of Medicine, New Orleans, Louisiana, United States|SUNY / Health Sciences Ctr at Brooklyn, Brooklyn, New York, United States|Beth Israel Med Ctr, New York, New York, United States|St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr, New York, New York, United States|Mount Sinai Med Ctr, New York, New York, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00000950"
521,"NCT05100758","Active Hexose Correlated Compound in Tuberculosis-HIV (Human Immunodeficiency Virus) Infection",,"Completed","No Results Available","Tuberculosis|Human Immunodeficiency Virus","Dietary Supplement: Active Hexoses Correlated Compound","Sputum Conversion Duration|Chest X-Ray Extension|Interleukin 6 Level|Interleukin 10 Level|Cluster Differentiation 4 (CD4) cells value|Cluster Differentiation 8 (CD8) cells value","Hasanuddin University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0307210724","October 1, 2018","October 1, 2020","December 1, 2020","October 29, 2021",,"October 29, 2021","Labuang Baji General Hospital, Makasar, South Sulawesi, Indonesia",,"https://ClinicalTrials.gov/show/NCT05100758"
522,"NCT00346476","Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa",,"Completed","Has Results","HIV Infections|Tuberculosis",,"Number of Participants With Microbiologically Confirmed Tuberculosis Infection|Number of Participants With HIV Infection|Changes in Clustering and Transmission of TB Among HIV Infected and Uninfected Participants|Changes in the Clustering and Transmission of TB Among HIV Infected and Uninfected Participants After the Introduction of HAART|Diversity of TB Strains Among HIV Infected Participants Receiving HAART, HIV Infected Participants Not Receiving HAART, and HIV Uninfected Participants|Number of Recurrent Cases of TB Attributable to Endogenous Reactivation Versus Exogenous Re-infection in Both HIV Infected and Uninfected Participants","CIPRA SA|National Institute of Allergy and Infectious Diseases (NIAID)|Comprehensive International Program of Research on AIDS","All","15 Years and older   (Child, Adult, Older Adult)",,"1250","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","CIPRA-SA Project 3B|U19AI053217","April 2006","December 2010","December 2010","June 30, 2006","February 9, 2011","February 11, 2011","Desmond Tutu HIV Centre Department of Medicine, Cape Town, Western Cape, South Africa|Desmond Tutu HIV Centre Department of Medicine, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT00346476"
523,"NCT04085133","Prevalence and Burden of Bronchiectasis in Tuberculous Patients",,"Completed","No Results Available","Pulmonary Tuberculoses","Diagnostic Test: Gene Xpert Chest x ray and MSCT chest","To study prevalence of bronchiectasis in TB patients by case per year.|To evaluate the burden of bronchiectasis in TB patients","Assiut University","All","18 Years to 50 Years   (Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","12345817","September 26, 2019","January 1, 2020","April 1, 2020","September 11, 2019",,"February 17, 2023","Assiut unviresty, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04085133"
524,"NCT01033929","A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis","TESEC-02","Completed","No Results Available","Tuberculosis","Biological: rdESAT-6 + rCFP-10 (C-Tb)","Local and systemic adverse reactions at the injection sites within 28 days after application of the tests (0.01/0.1 µg C-Tb).|Immune response of 2 doses (0.01 and 0.1 µg/0.1 mL) of C-Tb from the size of induration; the safety of unpreserved C-Tb and C-Tb preserved with 0.5% phenol and the pain associated with the injection of unpreserved C-Tb and preserved C-Tb","Statens Serum Institut","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","TESEC-02|2009-012984-33","January 2010","November 2010","November 2010","December 17, 2009",,"January 21, 2013","St George's University of London, London, London SW17 0RE, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01033929"
525,"NCT06058299","Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis",,"Recruiting","No Results Available","Pulmonary TB|Pulmonary Tuberculosis|Drug Sensitive Tuberculosis","Drug: TBAJ-876|Drug: Pretomanid|Drug: Linezolid|Drug: Bedaquiline|Drug: HRZE|Drug: HR","Time to stable sputum conversion|Favorable Outcome 26 Weeks after End of Treatment","Global Alliance for TB Drug Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NC-009","October 24, 2023","February 2025","June 2026","September 28, 2023",,"March 7, 2024","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines|Tropical Disease Foundation, Makati City, Philippines|Lung Center of the Philippines, Quezon City, Philippines|Madibeng Centre for Research, Brits, South Africa|TASK Brooklyn, Cape Town, South Africa|University of Cape Town Lung Institute (UCTLI), Cape Town, South Africa|Desmond Tutu Health Foundation, Cape Town, South Africa|Setshaba Research Centre, City Of Tshwane, South Africa|Enhancing Care Foundation, Durban, South Africa|Synergy Biomed Research Institute (SBRI), East London, South Africa|TB and HIV Investigative Network (THINK), Hillcrest, South Africa|WITS, Clinical HIV Research Unit (CHRU) Themba Lethu Clinic, Helen Joseph Hospital, Johannesburg, South Africa|Perinatal HIV Research Unit (PHRU), Klerksdorp, South Africa|Isango Lethemba TB Research Unit, Port Elizabeth, South Africa|The Aurum Institute, Rustenburg, South Africa|NIMR-MBEYA Medical Research Center, Mbeya, Tanzania|Kilimanjaro Christian Medical Centre, Moshi, Tanzania|National Institute for Medical Research (NIMR), Mwanza, Tanzania|Case Western Reserve University- Research collaboration Uganda, Kampala, Uganda|Joint Clinical Research Centre (JCRC), Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT06058299"
526,"NCT01329250","Pharmacokinetics and Safety of Moxifloxacin","MFX468","Terminated","No Results Available","Tuberculosis","Drug: Moxifloxacin","Bound area under the plasma concentration-time curve (AUC0-24h) relative to the minimal inhibitory concentration (MIC)|Unbound AUC0-24h/MIC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis|Bound AUC0-24h/Mutant Prevention Concentration (MPC) ratio|Unbound AUC0-24h/MPC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis and suppression of MFX resistance|% of patients having adverse effects, including QT interval prolongation, hypersensitive reactions, diarrhoea, vomiting and hepatic or renal injury|Evaluation of the predictive performance of the limited sampling strategies based on a pharmacokinetic population model to calculate AUC0-24h. Several limited sampling points will be evaluated.|Correlation between MFX concentration (mg/L) and QT interval (msec)|Correlation of drug exposure (AUC) and adverse effects|Correlation between the genetic risk score and MFX induced QT prolongation","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MFX468","May 2011","June 2015","August 2016","April 5, 2011",,"November 18, 2016","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01329250"
527,"NCT02840877","The Impact of Alcohol Consumption on Tuberculosis Treatment Outcomes",,"Completed","Has Results","Tuberculosis|Alcohol Consumption|Treatment Adverse Effect","Behavioral: DOT Adherence Monitoring","Time to Culture Conversion|Cmax|Area Under Curve (AUC)|Poor Treatment Outcome|Side Effects to TB Drugs","Boston Medical Center|Medical Research Council, South Africa|Boston University|University of Cape Town|National Institute of Allergy and Infectious Diseases (NIAID)|University of Stellenbosch","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","303","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-34970|1R01AI119037-01A1","May 16, 2017","June 28, 2022","October 12, 2023","July 21, 2016","August 14, 2023","November 2, 2023","Worcester Community Day Centre, Worcester, Western Cape Province, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/77/NCT02840877/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/77/NCT02840877/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02840877"
528,"NCT01798121","Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)","02","Unknown status","No Results Available","Tuberculosis Identification.","Biological: To compare new PPD to reference standard material|Biological: Reference standard","Compare new PPD to Reference Standard","JHP Pharmaceuticals LLC|Syneos Health","All","18 Years to 60 Years   (Adult)","Phase 2","90","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)","JHP-Aplisol-02","February 2013","March 2013","July 2013","February 25, 2013",,"February 25, 2013",,,"https://ClinicalTrials.gov/show/NCT01798121"
529,"NCT00816426","Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: Rifampicin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Kanamycin|Drug: Moxifloxacin","Comparison between the relative permeability coefficients of RIF and KM in pathologically defined large caseous necrotic nodules.|The comparison between the relative permeability coefficients of RIF, KM, INH, PZA and MXF in caseous necrotic nodules versus open cavities|The comparison between the absolute permeability coefficients of each of the five drugs in uninvolved lung and in closed necrotic lesions|The comparison between the exposure ratio or ratio between the Area Under the Curve (AUC0-24) in lesions (AUClesion), uninvolved lung (AUClung) and plasma (AUCplasma) for RIF and KM in large caseous necrotic nodules","National Institute of Allergy and Infectious Diseases (NIAID)|Korean Center for Disease Control and Prevention|International Tuberculosis Research Center|Novartis Institute for Tropical Medicine|Asian Medical Center|National Institutes of Health Clinical Center (CC)","All","20 Years to 100 Years   (Adult, Older Adult)","Phase 1","19","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","999909061|09-I-N061","December 29, 2008","August 26, 2014","December 29, 2017","January 1, 2009",,"December 9, 2019","Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00816426"
530,"NCT03819114","Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy",,"Completed","Has Results","HIV Infections|Tuberculosis","Drug: Levonorgestrel (LNG)","LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants|Number and Percentage of Participants Experiencing Either a Serious Adverse Event (SAE) or Adverse Event (AE) Potentially or Definitely Associated With Single Dose LNG Administration.|Maximum Concentration (Cmax) of LNG|Minimum Concentration (Cmin) of LNG|Oral Clearance (CL/F) of LNG|Volume of Distribution (Vd) of LNG|Half-life (T1/2) of LNG|Time of Minimum Concentration (Tmin) of LNG|LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants|LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants|LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 2","122","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5375|38493|UM1AI068636","May 6, 2019","November 2, 2020","November 30, 2020","January 28, 2019","November 30, 2021","December 27, 2021","2701 Northwestern University CRS, Chicago, Illinois, United States|Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago, Illinois, United States|Weill Cornell Upton CRS (7803), New York, New York, United States|Unc Aids Crs (3201), Chapel Hill, North Carolina, United States|Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia, Pennsylvania, United States|Pitt CRS (1001), Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS (31443), Dallas, Texas, United States|Gaborone CRS (12701), Gaborone, Botswana|12101 Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS (12501), Kericho, Kenya|Blantyre CRS (30301), Blantyre, Malawi|Malawi CRS (12001), Lilongwe, Malawi|University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101), Johannesburg, Gauteng, South Africa|Family Clinical Research Unit (FAM-CUR) CRS (8950), Cape Town, West Cape, South Africa|Durban Adult HIV CRS (11201), Durban, South Africa|Soweto ACTG CRS (12301), Johannesburg, South Africa|31802 Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Bangkok, Patumwan, Thailand|31784 Chiang Mai University HIV Treatment CRS, Chiang Mai, Thailand","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/14/NCT03819114/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/14/NCT03819114/SAP_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/14/NCT03819114/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03819114"
531,"NCT00929396","A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers","THYB-02","Completed","No Results Available","Tuberculosis","Biological: 50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)","Physical examination. Local adverse events.Systemic adverse events. Laboratory safety tests including urine safety tests.|Detection by ELISPOT of IFNgamma spot-forming cells in PBMCs. Detection by ELISA of IFNgamma production in supernatants of PBMC. Detection by ELISA of IgG antibodies in serum/plasma. Detection by Elisa of TNFalfa and IFNgamma in serum","Statens Serum Institut","All","18 Years to 55 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","THYB-02","September 2007","June 2009","June 2009","June 29, 2009",,"January 21, 2013","Leiden University Medical Centre, Leiden, RC Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT00929396"
532,"NCT02097095","Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)",,"Completed","No Results Available","Tuberculosis",,"Collect and store biological samples for future use to evaluate potential biological markers correlated to the risk for tuberculosis.|Collect and store biological samples for future use to evaluate immune correlates of protection from tuberculosis in subjects vaccinated with GSK 692342 (M72/AS01E).","Aeras|GlaxoSmithKline","All","18 Years to 50 Years   (Adult)",,"3253","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","C-041-972","August 2014","November 30, 2016","November 30, 2016","March 26, 2014",,"February 1, 2017",,,"https://ClinicalTrials.gov/show/NCT02097095"
533,"NCT01516203","Phase 2a EBA Trial of AZD5847",,"Completed","No Results Available","Tuberculosis","Drug: AZD5847|Drug: Ethambutol, isoniazid, pyrazinamide, rifampin","Early Bactericidal Activity: Rate of change in sputum colony forming unit (CFU) counts (bactericidal activity) during the entire 14 days of study drug administration (EBA0-14)|Adverse event collection: Complete blood count, coagulation panels, liver function tests, Creatine phosphokinase, urinalysis and 12-lead electrocardiograms as well as unsolicited events (adverse events, serious adverse events).|Change in Mycobacterium tuberculosis (MTB) mRNA in sputum by RT-PCR for fbpB, hspX, icl1, rrnA-p1 and other specific mycobacterial mRNA targets of interest over the periods (baseline and Days 2, 4, 8, 14)|Change in urine, sputum, and serum metabolomic biomarkers over the periods (baseline and Days 8, 14)|Pharmacokinetic and pharmacodynamic parameters Tmax, Cmax, half life, AUC, AUC/MIC, Cmax, Cmax/MIC, time > MIC using non-compartmental analysis, compartmental and population models|Rate of change in sputum CFU counts (bactericidal activity) during the first 2 days of study drug administration (traditional EBA; EBA0-2)|Rate of change in sputum CFU counts (bactericidal activity) during the first 2 to 14 days of study drug administration (traditional EBA; EBA2-14)|The change in time after inoculation until culture detection (time to detection; TTD) in MGIT enriched liquid culture media over the period Day 0 to Day 2|The change in time after inoculation until culture detection (time to detection; TTD) in MGIT enriched liquid culture media over the period Day 2 to Day 14|The change in time after inoculation until culture detection (time to detection; TTD) in Mycobacterial Growth Indicator Tube (MGIT) enriched liquid culture media over the period Day 0 to Day 14","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-0006","December 5, 2012","December 12, 2013","December 24, 2013","January 24, 2012",,"October 15, 2018","Task Clinical Research Centre, Ekurhuleni, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT01516203"
534,"NCT01582711","Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT","iAdhere","Completed","No Results Available","Latent Tuberculosis Infection","Behavioral: Self Administered Therapy (SAT)|Behavioral: SMS reminders|Drug: isoniazid and rifapentine","Treatment completion rate.|Treatment completion rates between the DOT arm and the SAT arm with SMS reminders|Treatment completion rates between the DOT arm and the SAT arm without SMS reminders.|Treatment completion rates between the SAT arm with SMS reminders and the SAT arm without SMS reminders.|Rates of treatment discontinuation by category.|Rates of SMS reminders utilization.|Rates of any drug-related grade 3, 4, or 5 adverse events between the DOT arm and the SAT arms (both combined and individually)|Rates and timing of treatment discontinuations between the DOT arm and the SAT arms (both combined and individually).|Cost of treatment (in USD or QALY) associated with adverse events between the DOT arm and the SAT arms (both combined and individually).|Rates of antituberculosis drug resistance among Mycobacterium tuberculosis strains cultured from patients who develop active TB between the DOT arm and the SAT arms (both combined and individually).","Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Phase 3","1002","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCHHSTP 6222|TBTC Study 33","September 2012","October 2014","October 2014","April 23, 2012",,"August 3, 2015","University of California, San Francisco, San Francisco, California, United States|Denver Public Health Department, Denver, Colorado, United States|Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, United States|Columbia University College of Physicians and Surgeons and New York City Department of Health, New York, New York, United States|Duke University, Durham, North Carolina, United States|Vanderbilt University Medical Center and Nashville Metro Public Health Department, Nashville, Tennessee, United States|University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas, United States|Audie L. Murphy VA Hospital, San Antonio, Texas, United States|South Texas - Department of State Health Services, San Antonio, Texas, United States|TB and Chest service of Hong Kong, Hong Kong, China|Wits Health Consortium, Soweto, South Africa|Agencia de Salut Publica - Barcelona, Spain and UNTHSC, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01582711"
535,"NCT00226434","Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA)",,"Completed","No Results Available","HIV Infection|Tuberculosis","Procedure: Early antiretroviral treatment|Procedure: Late antiretroviral treatment","Survival rate|Type, frequency and severity of Adverse Events that occur during the trial and to their potential relations with the drugs, HIV or TB infection|Frequency of Immune Reconstitution Inflammatory Syndrome|Frequency of TB paradoxical reaction, defined as worsening or emergence of signs or symptoms of TB (e.g. fever, cough, shortness of breath, adenopathy or exacerbation of disease at other extra pulmonary sites) during appropriate TB treatment|Occurrence of opportunistic infections|Evaluation of TB treatment success|Evaluation of ART treatment success|Resistance to ARV treatment determined by genotyping HIV-1 strains among patients with detectable viral load on Day 0 and Week 50|Patient's adherence to TB and ARV treatment evaluated based on interviews and pill counts at each study visit|Pharmacokinetic study to assess efavirenz plasma exposure will be assayed at regular time intervals|Survival Rate","French National Agency for Research on AIDS and Viral Hepatitis|National Institutes of Health (NIH)|ANRS, Emerging Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Phase 3","661","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 1295 CAMELIA|CIPRA KH 001","January 2006","May 2010","May 2010","September 27, 2005",,"March 16, 2012","Calmette Hospital, Phnom Penh, Cambodia|Khmero-Soviet Friendship Hospital, Phnom Penh, Cambodia|Siem Reap Referral Hospital, Siem Reap, Cambodia|Provincial hospital, Svay Rieng, Cambodia|Provincial hospital, Takeo, Cambodia",,"https://ClinicalTrials.gov/show/NCT00226434"
536,"NCT06239337","Evaluation of Xpert MTB/RIF Ultra in Stools and Urine to Improve Tuberculosis Diagnosis in Children",,"Completed","No Results Available","Tuberculosis|Pediatric Infectious Disease","Diagnostic Test: Xpert MTB/RIF Ultra in stools and urine","To determine the sensitivity and specificity of Xpert MTB/RIF Ultra in stool and urine samples in presumptive TB pediatric cases in comparison to Xpert MTB/RIF Ultra in respiratory/extrapulmonary sample|To determine sensitivity and specificity of Xpert MTB/RIF Ultra in stool and urine samples in subpopulations: HIV/not HIV, SAM/no SAM, <5 years old vs. 5 or more years old.|To determine the added diagnostic yield of Xpert MTB/RIF Ultra in stool and urine samples when gold standard is negative","Medecins Sans Frontieres, Spain|Ministry of Health, Guinea-Bissau|Ministry of Health, South Sudan|Institute of Tropical Medicine, University of Tuebingen","All","6 Months to 15 Years   (Child)",,"563","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MSF18115","June 26, 2019","June 1, 2023","December 15, 2023","February 2, 2024",,"February 2, 2024","Simao Mendes hospital, Bissau, Guinea-Bissau|Malakal hospital, Malakal, Upper Nile, South Sudan","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT06239337/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT06239337"
537,"NCT02430259","Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention",,"Completed","No Results Available","Silicosis|Tuberculosis","Drug: Weekly INH / RRT given by DOT","Cumulative rate of culture-confirmed or clinically diagnosed TB disease in participants|Percentage of participants with drug discontinuation for any reason and due to adverse drug reactions associated with 3RPT/INH|Percentage of patients with Grade 3 or 4 drug toxicities and deaths associated with 3RPT/INH|Percentage of participants who complete the treatment regimen|The proportion of rifampicin and/or isoniazid resistance of M. tuberculosis isolates in patients who develop TB in preventive treatment group.|Measure the quantitative and qualitative changes of the results of QuantiFERON Gold In-Tube before and after preventive treatment.","Huashan Hospital","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","566","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","81373064","March 2015","June 2018","June 2018","April 30, 2015",,"June 30, 2020","Wenling No.1 People's Hospital, Zhejiang, Taizhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02430259"
538,"NCT02413931","Nosocomial Transmission of MDR-TB in Bucharest, Romania",,"Completed","No Results Available","Tuberculosis, Multidrug-resistant","Other: Routine management practices applied","Number of patients with nosocomially transmitted MDR-TB|Concordance between phenotypic drug susceptibility testing and detected resistance mutations|Proportion of patients with changes in drug susceptibility pattern during treatment|Proportion of patients with mixed infections|Clustering within the MDR-TB patient population|Number of patients with different TB genotypes (e.g. Beijing, LAM, EAI, etc.)|Proportion of patients with cardio-pulmonary impairment at different time points|Proportion of patients with socio-economic and psychological adverse outcomes|Proportion of patients with co-morbidities and co-infections","Research Center Borstel|""Marius Nasta"" Pulmonology Institute|Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)",,"53","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RCBorstel_MNI_001","May 2015","January 2020","January 2020","April 10, 2015",,"April 11, 2024","Marius Nasta Pulmonology Institute, Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02413931"
539,"NCT00460590","Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town",,"Completed","No Results Available","Tuberculosis","Biological: MVA 85A","To assess the safety of a single intradermal injection of 5 x 107pfu MVA85A, when administered to healthy subjects. The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events (AEs).|To assess the immunogenicity of a single vaccination with MVA85A in healthy subjects. The specific endpoints for immunogenicity will be markers of cell-mediated immunity as outlined above","University of Oxford|University of Cape Town","All","12 Years to 50 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB008","October 2005","June 2008","June 2008","April 16, 2007",,"August 7, 2008","University Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT00460590"
540,"NCT05317247","Cough Audio Classification as a TB Triage Test","CAGE-TB","Recruiting","No Results Available","Tuberculosis","Diagnostic Test: Cough sounds","Develop and validate algorithms that can distinguish between TB and non-TB coughs|Finalised smartphone-based mHealth application|Avert unnecessary Ultra tests","University of Stellenbosch|Amsterdam Institute for Global Health and Development|University of Göttingen|Makerere University","All","12 Years and older   (Child, Adult, Older Adult)",,"1751","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","M21/10/022","April 19, 2022","June 2024","September 30, 2024","April 7, 2022",,"December 1, 2023","Stellenbosch University, Cape Town, Western Cape, South Africa|Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05317247"
541,"NCT01618422","Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou",,"Completed","Has Results","Pulmonary Tuberculosis","Other: Directly Observed Therapy (DOTS) plus|Other: Directly Observed Therapy (DOTS)","Number of Participants Suffering From Treatment Failure/ Relapse (Unfavourable Outcome) Among Rifampicin Resistant Group.","Chinese University of Hong Kong|Guangzhou Institute of Respiratory Disease","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRE-2008.286-T","March 2009","February 2013","February 2014","June 13, 2012","October 5, 2015","December 7, 2015","Guangzhou Chest Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01618422"
542,"NCT00170404","TB Nutrition, Immunology and Epidemiology",,"Completed","No Results Available","Mycobacterium Tuberculosis","Drug: Folic Acid|Drug: Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|Drug: Selenium|Drug: Vitamin A",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","887","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","00-032","June 2000",,"October 2005","September 15, 2005",,"August 27, 2010","Muhimbili University, College of Health Sciences, Dar Es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT00170404"
543,"NCT02053129","Evaluation of PTB Screening in ANC in Lusaka, Zambia",,"Completed","No Results Available","Pulmonary Tuberculosis","Other: TB screening Questionnaire|Other: Sputum smear and culture (only in HIV negative women who are symptomatic)","number of positive pulmonary tuberculosis (PTB) tests|Sensitivity and specificity of symptom-based TB screening","University of North Carolina, Chapel Hill|Centre for Infectious Disease Research in Zambia","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","5033","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CIDRZ 1217/IRB12-0417","November 2011","October 2012","December 2013","February 3, 2014",,"September 15, 2017","Centre for Infectious Disease Research in Zambia, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT02053129"
544,"NCT02613169","Infant TB Infection Prevention Study","iTIPS","Completed","Has Results","Tuberculosis","Drug: Isoniazid","Mycobacterium Tuberculosis (MTB) Infection|Mycobacterium Tuberculosis (MTB) Infection Cumulative Incidence|Severe Adverse Events (SAE)|Combined Outcome of MTB Infection, TB Disease, and Death|Combined Outcome of MTB Infection Including IGRA, TST, and Additional Interferon-gamma-independent Immune Markers in QFT-Plus Supernatants","University of Washington|Thrasher Research Fund","All","6 Weeks to 10 Weeks   (Child)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00000341","August 2016","October 2019","December 2020","November 24, 2015","June 10, 2021","April 28, 2023","Kisumu County Hospital, Kisumu, Kenya","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/69/NCT02613169/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/69/NCT02613169/SAP_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/69/NCT02613169/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02613169"
545,"NCT03271567","Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients",,"Completed","No Results Available","Active Tuberculosis|Tuberculosis, Extrapulmonary|Tuberculosis, Pulmonary","Diagnostic Test: Nanodisk-MS assay","Diagnostic test correlation","Chinese University of Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Alice Ho Miu Ling Nethersole Hospital","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TB Protocol ver.1","September 28, 2017","July 31, 2019","December 31, 2019","September 5, 2017",,"February 26, 2020","Prince of Wales Hospital, Sha Tin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03271567"
546,"NCT00078247","Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Abacavir|Drug: Lamivudine|Drug: Zidovudine|Drug: Tuberculosis treatment","CD4+ decline (slope)|Time to AIDS|Safety|Response to antituberculous therapy|Immune reconstitution|Viral drug resistance","National Institute of Allergy and Infectious Diseases (NIAID)|Makerere University","All","13 Years to 60 Years   (Child, Adult)","Phase 3","350","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R01AI051219-01A2","October 2004",,,"February 23, 2004",,"August 12, 2010","Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00078247"
547,"NCT02331732","Virtually Observed Treatment (VOT) for Tuberculosis Patients in Moldova",,"Unknown status","No Results Available","Tuberculosis","Behavioral: Virtually Observed Treatment|Other: Directly Observed Treatment","Adherence to medication|Adherence 80%|Patient wellbeing|Patient satisfaction|Travel and time cost of treatment borne by patient, self reported.|Employment, self reported|Treatment success|Body mass index (BMI)|Side effects reported during treatment","The Behavioural Insights Team","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201405*","October 2015","February 2017","March 2017","January 6, 2015",,"September 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02331732"
548,"NCT01380119","Tuberculosis (TB) Immunotherapy Phase 2 Study","imm02","Completed","No Results Available","Tuberculosis","Biological: V7|Other: placebo","sputum conversion|safety","Lisichansk Regional Tuberculosis Dispensary|National Medical University, Ukraine|Immunitor USA Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","imm02|LisichnskRTD","August 2011","August 2012","August 2012","June 27, 2011",,"October 29, 2013","Lisichansk TB Dispensary, Lisichansk, Luhansk, Ukraine",,"https://ClinicalTrials.gov/show/NCT01380119"
549,"NCT01040611","Effectiveness of Music Therapy","TMT","Unknown status","No Results Available","Tuberculosis","Behavioral: Music therapy","Effectiveness of music therapy on anxiety, depression and physiological responses","Taipei Medical University WanFang Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","EVA98-13","October 2009","September 2010","September 2010","December 29, 2009",,"November 19, 2010","Taipei Medical University -WanFang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01040611"
550,"NCT00096681","Prevalence of HIV and Tuberculosis in Masiphumelele Township, Cape Town, South Africa",,"Completed","Has Results","HIV Infections|Tuberculosis",,"Number of Participants With Microbiologically Confirmed Pulmonary Tuberculosis|Number of Participants With a Positive HIV Test","CIPRA SA|National Institute of Allergy and Infectious Diseases (NIAID)","All","15 Years and older   (Child, Adult, Older Adult)",,"762","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","CIPRA-SA Project 3A|U19AI053217|CIPRA|Project 3A","February 2005","August 2005","February 2006","November 15, 2004","February 17, 2011","March 14, 2011",,,"https://ClinicalTrials.gov/show/NCT00096681"
551,"NCT05388448","EBA, Safety and Tolerability of Sanfetrinem Cilexetil",,"Recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: Sanfetrinem Cilexetil|Drug: Amoxicillin/clavulanic acid|Drug: Rifampicin","Rate of change in mycobacterium tuberculosis (Mtb) load in sputum from pre-treatment to Day 14 on-treatment, based on colony forming unit (CFU) count on solid culture media (7H11 agar plates)|Rate of change in mycobacterium tuberculosis (Mtb) load in sputum from pre-treatment to Day 14 on-treatment, based on time to positive (TTP) culture in the BACTEC MGIT 960 liquid culture system|Number of patients with abnormal safety and tolerability findings following the study regimens, administered for 14 days","TASK Applied Science|GlaxoSmithKline|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","105","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TASK-009-SANF","April 21, 2022","September 1, 2023","December 1, 2023","May 24, 2022",,"May 24, 2022","TASK Clinical Research Centre, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT05388448"
552,"NCT00130325","A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts","IRS","Completed","No Results Available","Tuberculosis","Drug: Isoniazid|Drug: Placebo of Isoniazid tablets 300mg","Qualitative IFN-g ELISPOT reversion|Quantitative IFN-g ELISPOT reversion","Medical Research Council Unit, The Gambia","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","214","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRS SCC965","October 2004","October 2008","June 2009","August 15, 2005",,"January 13, 2010","MRC Laboratories, Banjul, Ksmd, Gambia",,"https://ClinicalTrials.gov/show/NCT00130325"
553,"NCT04484129","MDR-TB Close Contacts Tracing in China (TCCT Study)",,"Unknown status","No Results Available","Multidrug Resistant Tuberculosis",,"Confirmed cases of active tuberculosis|Clinical diagnosis of active tuberculosis|Incidence of latent tuberculosis infection|Risk factors associated with TB development|Compliance of follow-up|Comparison the Mycobacteria tuberculosis strains between index patients and their contacts","Huashan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KY2020-806","July 21, 2020","December 31, 2022","December 31, 2022","July 23, 2020",,"July 23, 2020","The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China|Guiyang Public Health Treatment Center, Guizhou, Guizhou, China|Henan Hospital of Infectious Diseases, Zhengzhou, Henan, China|Jiangxi Public Health Center, Nanchang, Jiangxi, China|Huashan Hospital of Fudan University, Shanghai, Shanghai, China|Chest Hospitalof Xinjiang Uygur Autonomous Region of PRC, Ürümqi, Xinjiang, China|Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China|The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04484129"
554,"NCT01350674","Role of EBUS-TBNA in Diagnosing TB in Mediastinal/Hilar Lymph Nodes",,"Suspended","No Results Available","Tuberculosis","Procedure: EBUS-TBNA","The ratio of tuberculosis in mediastinal lymph nodes","Centre Hospitalier Universitaire Saint Pierre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","B07620109427|AK/10-10-3949/67","December 2010","December 2017","March 2018","May 10, 2011",,"July 31, 2018","CHU St. Pierre; pulmonology department, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT01350674"
555,"NCT04703075","Ultra Curto (Ultra Short) TB Prevention Therapy",,"Active, not recruiting","No Results Available","Tuberculosis","Drug: Rifapentine 600 mg and INH 300 mg|Drug: Rifapentine 900 mg and INH 900 mg","Number of participants who complete treatment with >90% adherence","Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)","All","15 Years to 99 Years   (Child, Adult, Older Adult)","Phase 4","500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00284317|U01AI152961","March 24, 2022","July 31, 2024","December 31, 2024","January 11, 2021",,"March 29, 2024","Fundacao de Medicina Tropical Doutor Heitor, Manaus, AM, Brazil|NAPDOT, Rio De Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT04703075"
556,"NCT00004740","Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users",,"Unknown status","No Results Available","Tuberculosis","Drug: isoniazid",,"National Institute on Drug Abuse (NIDA)|Johns Hopkins University|Office of Rare Diseases (ORD)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","NIH|Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Prevention","199/11642|JHUSM-93090801","February 1995",,,"February 25, 2000",,"June 24, 2005",,,"https://ClinicalTrials.gov/show/NCT00004740"
557,"NCT00108862","Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis","STRIDE","Completed","Has Results","HIV Infection|Tuberculosis","Other: Strategy: Immediate ART|Other: Strategy: Deferred ART","Percent of Participants Who Survived Without AIDS Progression.|Percent of Participants Reporting a Grade 3 or 4 Adverse Event or Laboratory Abnormality|Time to First New AIDS-defining Illness or Death.|Percent of Participants With Culture-confirmed Tuberculosis (TB) Who Survived Without AIDS Progression.|Percent of Participants Who Interrupted or Discontinued at Least One Tuberculosis (TB) Medication Due to Toxicity.|Percent of Participants With Confirmed or Probable Tuberculosis (TB) Whose TB Resolved, or Who Required TB Treatment Through the End of Follow-up, or Died, or Were Lost to Follow-up.|Percent of Participants Whose CD4 Increased by at Least 100 Cells/mm^3 Between Baseline and Week 48.|Percent of Participants With MTB IRIS.|Percent of Participants With HIV IRIS.|Percent of Participants Whose HIV Viral Load Was Less Than 400 Copies/mL at Week 48.","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 4","809","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5221|1U01AI068636","August 2006","July 2010","July 2010","April 20, 2005","November 2, 2011","October 11, 2018","University of Southern California (1201), Los Angeles, California, United States|University of California, San Diego, AVRC CRS (701), San Diego, California, United States|University of California, San Francisco AIDS CRS (801), San Francisco, California, United States|NY Univ. HIV/AIDS CRS (401), New York, New York, United States|Gaborone Prevention/Treatment Trials CRS (12701), Gaborone, Botswana|Molepolole Prevention/Treatment Trials CRS (12702), Molepolole, Botswana|Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, RS, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil|Projecto Praca Onze/Hesfa CRS (30333), Rio de Janeiro, Brazil|Les Centres GHESKIO CRS (30022), Bicentenaire, Port-au-Prince, Haiti|National AIDS Research Institute Pune CRS (11601), Pune, Maharashtra, India|Y.R.G Ctr, for AIDS Research and Education (11701), Chennai, India|AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret, Kenya|Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho, Kenya|College of Med. JHU CRS (30301), Blantyre, Malawi|University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi|Investigaciones Medicas en Salud (INMENSA) (11302), San Isidro, Lima, Peru|Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru|CAPRISA eThekwini CRS (31422), Durban, KwaZulu-Natal, South Africa|Durban Adult HIV CRS (11201), Durban, South Africa|Soweto ACTG CRS (12301), Johannesburg, South Africa|Univ. of Witwatersrand CRS (11101), Johannesburg, South Africa|Chiang Mai University ACTG CRS (11501), Chiang Mai, Thailand|Joint Clinical Research Centre (JCRC) (12401), Kampala, Uganda|Kalingalinga Clinic CRS (12801), Lusaka, Zambia|UZ-Parirenyatwa CRS (30313), Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT00108862"
558,"NCT02169141","Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients",,"Completed","No Results Available","Tuberculosis","Other: Pharmacokinetics","AUC/MIC ratio of Levofloxacin|Cmax/MIC ratio of Capreomycin|Volume of Distribution|Clearance","University Medical Center Groningen|Republican Scientific and Practical Centre for Pulmonology and TB|National Institute for Public Health and the Environment (RIVM)","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Time Perspective: Prospective","LC-20","November 2012","February 2013","November 2013","June 23, 2014",,"June 23, 2014","Republican Scientific and Practical Center for TB and Pulmonology, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT02169141"
559,"NCT05044910","The Impact of Malnutrition on Immune Responses to Tuberculosis","TBMAM","Active, not recruiting","No Results Available","Malnutrition, Child|Tuberculosis","Dietary Supplement: Ready to Use supplementary food (RUSF)","IFNγ concentration","Tuberculosis Research Centre, India|Institute of Child Health, Madras Medical College, Chennai|Stanley Medical College|Kanchi Kamakoti Childs Trust Hospital, Chennai, India|Queen Mary University of London|London School of Hygiene and Tropical Medicine|DBT, India","All","12 Months to 60 Months   (Child)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019037","August 1, 2020","December 31, 2023","August 1, 2024","September 16, 2021",,"December 29, 2023","Institute of Child Health, Chennai, Tamil Nadu, India|Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT05044910"
560,"NCT04745897","Accessibility of the World Health Organization's eTB Catalogue of Recommendations",,"Completed","No Results Available","Tuberculosis","Other: eTB Catalogue of Recommendations (eTB)|Other: World Health Organization Tuberculosis Website (WHO TB)","Accessibility of Information on a Seven-Point Likert Scale|Satisfaction on a Seven-Point Likert Scale|Understanding with Multiple Choice Questions|Preference on a Seven-Point Likert-Scale","McMaster University","All","Child, Adult, Older Adult","Not Applicable","244","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","7908","February 26, 2021","August 29, 2021","August 29, 2021","February 9, 2021",,"December 13, 2021","McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04745897"
561,"NCT04187469","Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB",,"Unknown status","No Results Available","Pulmonary Tuberculosis","Drug: Moxifloxacin, Isoniazid, Rifampicin|Drug: Rifampicin,Isoniazid,Pyrazinamide,Ethambutol","The rate of adverse outcomes|The rate of Treatment success|The rate of sputum Mtb negative conversion|The time of sputum Mtb negative conversion|Number of Patients With Adverse Events","Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","286","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZDWY.GRK.004","March 1, 2020","February 1, 2023","February 1, 2024","December 5, 2019",,"December 5, 2019","The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04187469"
562,"NCT04975178","Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa","MTBVACN3","Recruiting","No Results Available","Tuberculosis","Biological: MTBVAC|Biological: BCG","To demonstrate efficacy in terms of incidence of MTBVAC against TB disease in healthy HU and HEU newborns compared to BCG|To assess the safety and reactogenicity of MTBVAC in healthy HU and HEU newborns compared to BCG.","Biofabri, S.L|TuBerculosis Vaccine Initiative|University of Cape Town|Institut Pasteur de Madagascar|Biomedical Research Center EPLS|Universidad de Zaragoza|University of Stellenbosch|University of KwaZulu|Wits Health Consortium (Pty) Ltd","All","5 Minutes to 7 Days   (Child)","Phase 3","7120","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MTBVACN3","September 23, 2022","June 2028","September 2029","July 23, 2021",,"October 10, 2023","South African Tuberculosis Initiative, Brewelskloof Hospital, Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04975178"
563,"NCT03867136","Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","TB-TRUST","Active, not recruiting","No Results Available","Multidrug Resistant Tuberculosis","Drug: PZA sensitivity guided ultra-short all Oral Regimen|Drug: Standardized Shorter Regimen","Treatment success rate of the ultra short regimen|The median time to Sputum Culture Conversion|The frequency of grade 3 or greater adverse events among patients treated with the ultra short regimen","Huashan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","354","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2018-331","June 1, 2020","May 1, 2023","November 1, 2023","March 7, 2019",,"April 7, 2023","The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China|Guiyang Public Health Treatment Center, Guizhou, Guizhou, China|The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, China|Hunan Chest Hospital, Changsha, Hunan, China|Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, China|Huashan Hospital of Fudan University, Shanghai, Shanghai, China|Shanxi Provincial Tuberculosis Control Institute, Xi'an, Shanxi, China|Southwest Medical University Affiliated Hospital, Luzhou, Sichuan, China|Chest Hospitalof Xinjiang Uygur Autonomous Region of PRC, Urumqi, Xinjiang, China|Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China|Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China|The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China|Jiangxi Chest Hospital, Nanchang, China",,"https://ClinicalTrials.gov/show/NCT03867136"
564,"NCT04525235","Phenotyping of High Dose Rifampicin","PHENORIF","Completed","No Results Available","Tuberculosis","Combination Product: phenotyping cocktail|Drug: rifampicin","area under the curve","Radboud University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","PHENORIF","January 7, 2021","August 12, 2021","August 12, 2021","August 25, 2020",,"August 17, 2021","TASK, Cape Town, South Africa|UCT lung institute, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT04525235"
565,"NCT04909385","TB PCR in BAL and EBUS-TBNA","TRiBE","Active, not recruiting","No Results Available","Tuberculosis",,"The diagnostic performance of Xpert Ultra in BAL and EBUS_TBNA","Imperial College Healthcare NHS Trust|Chelsea and Westminster NHS Foundation Trust|The Hillingdon Hospitals NHS Foundation Trust|Barts & The London NHS Trust|University Hospital Birmingham NHS Foundation Trust|University Hospitals, Leicester|Manchester University NHS Foundation Trust|Royal Free Hospital NHS Foundation Trust|London North West University Health Care NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"394","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","266798","January 15, 2021","February 29, 2024","February 29, 2024","June 1, 2021",,"November 30, 2023","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04909385"
566,"NCT04249531","Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™",,"Unknown status","No Results Available","Tuberculosis","Drug: Amikacin Inhalation Dry Powder|Drug: Amikacin Injectable Product","The actual dose will be calculated|The AUC0-24 will be calculated|The Cmax will be calculated|The Tmax will be calculated|Local tolerability of the inhalation of dry powder amikacin will be established.|The tolerability of the inhalation of dry powder amikacin will be established|The dPmax (maximum pressure drop) will be measured|The Vi (inhaled volume) will be measured|The Ti (total inhalation time) will be measured|The PIF (peak inspiratory flow rate) will be measured|The MIF (mean inspiratory flow rate) will be measured|The FIR (average flow increase rate between 20% and 80% of PIF) will be measured","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Amika-01","June 1, 2020","April 1, 2022","June 1, 2022","January 31, 2020",,"May 3, 2021","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04249531"
567,"NCT00548444","T-Cell Turnover Following Vaccination With MVA85A",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A|Other: Deuterated glucose infusion","Proliferation and disappearance rates of responding antigen-specific T-cells|Immunogenicity|Safety","University of Oxford|Wellcome Trust|St George's, University of London","All","18 Years to 50 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB018|EudraCT number: 2007-001293-8","October 2007","January 2010","January 2010","October 24, 2007",,"January 18, 2010","University of Oxford, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00548444"
568,"NCT00568854","Immunobiology of Diabetes and Tuberculosis",,"Terminated","Has Results","Tuberculosis|Diabetes Mellitus","Biological: BCG","Antigen-specific Immune Response Measured by Reaction to Tuberculin Skin Test|Kinetics of Mycobacterial-specific Immune Response After BCG Vaccination","Stanford University","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SU-10182007-744","April 2007","March 2008","March 2008","December 6, 2007","August 16, 2016","August 16, 2016","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00568854"
569,"NCT00057434","Vitamin A Therapy for Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis|HIV Infections","Drug: multivitamin","Mortality|Morbidity","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1140","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","5R01AI041956-05","September 1998",,,"April 3, 2003",,"September 18, 2007","Zomba Central Hospital, Zomba, Malawi",,"https://ClinicalTrials.gov/show/NCT00057434"
570,"NCT05148949","Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients",,"Unknown status","No Results Available","COVID-19|Pulmonary Tuberculosis","Biological: Standard dosage inactivated vaccine|Biological: Double dosage inactivated vaccine","Incidence of adverse reaction within 28 days after each dose|GMT of neutralizing antibodies against live SARS-CoV-2 virus on day 28 after the second dose.|Incidence of solicited adverse events within 7 days after each dose.|Incidence of adverse events within 28 days after each dose.|Incidence of unsolicited adverse events within 28 days after each dose.|Incidence of serious adverse events (SAE) till the 3 months after the last vaccination.|GMT of anti-S protein of SARS-CoV-2 binding antibodies on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients.|Fold increase of anti-S protein of SARS-CoV-2 binding antibodies on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients.|GMT of neutralizing antibodies against live SARS-CoV-2 virus on day 28 and month 3 after the last dose in pulmonary tuberculosis patients.|8. Fold increase of neutralizing antibodies against live SARS-CoV-2 virus on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients.","Jiangsu Province Centers for Disease Control and Prevention","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","JSVCT134","December 22, 2021","December 10, 2022","March 10, 2023","December 8, 2021",,"August 16, 2022","Huai'an No.4 People's Hospital, Huai'an, Jiangsu, China|Taizhou People's Hospital, Taizhou, Jiangsu, China|Wuxi No.5 People's Hospital, Wuxi, Jiangsu, China|Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, China|Binhai County Hospital of Chinese medicine, Yancheng, Jiangsu, China|Danyang Center for Disease Control and Prevention, Zhenjiang, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05148949"
571,"NCT05820594","Using BCG Vaccine to Understand Tuberculosis Infection","Pilot BCG CHIM","Recruiting","No Results Available","Tuberculosis","Biological: Intradermal BCG (bacillus calmette-guerin) vaccine AJV","To quantify BCG recovered from the intradermal BCG challenge site.|To monitor for adverse events and any serious adverse events in participants|Confirm agreement between BCG recovery between punch biopsy and minimally invasive skin biopsy.|Confirm agreement between BCG recovery between punch biopsy and minimally invasive skin scrape.|Longitudinal quantification of BCG recovery from the intradermal BCG challenge site.|Evaluate the immune response to BCG at intradermal injection site from skin biopsy|Assess cellular immune response to BCG in systemic circulation.|Measure antibody response to BCG injection in respiratory mucosa.|Measure cellular immune response to BCG injection in respiratory mucosa.|Assess antibody response to BCG injection in systemic circulation","Liverpool School of Tropical Medicine|University of Oxford","All","18 Years to 50 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","23-005|321376","June 30, 2023","March 1, 2024","March 1, 2024","April 19, 2023",,"July 7, 2023","Liverpool School of Tropical Medicine, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05820594"
572,"NCT00091936","Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Didanosine|Drug: Efavirenz|Drug: Lamivudine|Drug: Standard TB treatment","Diagnosis of an AIDS-defining illness|18-month mortality","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","592","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPRISA START|CAPRISA 001|START|CIPRA","August 2009",,,"September 21, 2004",,"March 29, 2010","King Edward VIII Hospital, Congella, Durban, South Africa|Prince Cyril Zulu CDC, Congella, Durban, South Africa",,"https://ClinicalTrials.gov/show/NCT00091936"
573,"NCT01497769","Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route",,"Completed","No Results Available","Tuberculosis","Biological: Aerosol inhaled MVA85A|Biological: Intradermal MVA85A","Safety of MVA85A vaccination by the aerosol inhaled route|Immunogenicity of MVA85A vaccination by the aerosol inhaled route compared with the intradermal route","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","TB026","September 2011","October 2012","April 2013","December 22, 2011",,"July 2, 2013","Centre of Clinical Vaccinology and Tropical Medicine (CCVTM) Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01497769"
574,"NCT00000778","A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Isoniazid|Drug: Pyridoxine hydrochloride|Drug: Levofloxacin",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","NIH","Interventional","Primary Purpose: Treatment","DATRI 008",,,,"August 31, 2001",,"August 8, 2008","Univ of Alabama at Birmingham, Birmingham, Alabama, United States|UCLA Med Ctr, Los Angeles, California, United States|Harbor - UCLA Med Ctr, Torrance, California, United States|Broward Gen Med Ctr, Fort Lauderdale, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Illinois, Chicago, Illinois, United States|Tulane Univ Med School, New Orleans, Louisiana, United States|Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States|Univ TX Galveston, Galveston, Texas, United States|Baylor College of Medicine / Houston Veterans Adm Med Ctr, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00000778"
575,"NCT03973970","Assessing the Ability of the T-SPOT®.TB Test (IQ)","IQ","Completed","No Results Available","Tuberculosis",,"NTBSLR|IGRA","Oxford Immunotec","All","18 Years and older   (Adult, Older Adult)",,"201","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","US TX 153","September 23, 2019","June 30, 2020","June 30, 2020","June 4, 2019",,"February 24, 2021","University of Texas Health, Brownsville, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03973970"
576,"NCT05621343","New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis","TB-LIVE","Recruiting","No Results Available","Latent Tuberculosis|Persistent Infection|Mycobacterium Tuberculosis",,"Cytokine levels|Gene expression|Activity of indoleamine 2, 3-dioxygenase (IDO)","Region Skane","All","15 Years to 100 Years   (Child, Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021-04885","December 21, 2021","June 2024","December 2024","November 18, 2022",,"November 18, 2022","Skåne University Hospital, Malmö, Skåne, Sweden",,"https://ClinicalTrials.gov/show/NCT05621343"
577,"NCT05330884","BCG Revaccination in Children and Adolescents","BRiC","Suspended","No Results Available","Tuberculosis Infection|Tuberculosis","Biological: BCG vaccine|Drug: Oral Chemoprophylaxis","Incidence of TB (all forms - PTB / EPTB) as per NTEP guidelines|Adverse events|MTB infection","Tuberculosis Research Centre, India|Institute of Child Health, Chennai|All India Institute of Medical Sciences, Guwahati|The Grant Medical College & Sir J.J. Group of Hospitals|All India Institute of Medical Sciences, Bhubaneswar|All India Institute of Medical Sciences, Patna|Rajendra Institute of Medical Sciences, Ranchi|National Institute of Tuberculosis and Respiratory Diseases, New Delhi|Rajiv Gandhi Hospital, Chennai|Madurai Medical College|Government Vellore Medical College, Vellore","All","6 Years to 18 Years   (Child, Adult)","Phase 3","9200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2022 005","July 15, 2024","June 2027","December 2027","April 15, 2022",,"December 18, 2023","Dr Aishwarya Venkataraman, Chennai, Tamil NADU, India",,"https://ClinicalTrials.gov/show/NCT05330884"
578,"NCT05383742","Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis",,"Recruiting","No Results Available","Tuberculous Meningitis","Drug: Rifampicin (RIF)|Drug: Isoniazid (INH)|Drug: Linezolid (LZD)|Drug: Pyrazinamide (PZA)|Drug: ethambutol (EMB)|Drug: Rifampicin|Drug: Isoniazid","Modified Rankin Scale (6-death, 5-severe disability, 4-moderately severe disability, 3-moderate disability, 2-slight disability, 1-no significant disability, 0-no symptoms)|Modified Rankin Scale (all 7 levels)|Modified Rankin Scale using collapsed categories at 12, 24, 36, 48 and 72 weeks: mRS (0 or 1), (2 or 3), (4 or 5), (6)|Modified Rankin Scale 5 or 6|Change in mRS from baseline to each of 12, 24, 36, 48, and 72 weeks|Time to death over 48 and 72 weeks|Proportion of participants with Grade 3 or higher AEs over 8 weeks|Proportion of participants with a serious adverse event (SAE) over 8 weeks|Proportion of participants who complete study treatments, which is defined as completing 168 doses within 185 days for Arm A and 252 doses in 278 days for Arm B|Proportion of participants with TBM IRIS (as defined in protocol) over 48 weeks|Wechsler Adult Intelligence Scale Digit Symbol or Symbol Digit Modalities|Color Trails 1, 2|Category Fluency|Hopkins Verbal Learning Test-Revised|Grooved Pegboard Bilateral|Finger-tapping Bilateral|Patient Health Questionnaire (PHQ-9) total score|WHO DAS score|Change in BMRC TBM grade at week 1. BMRC TBM grade is defined as:|Time to coma clearance, which is defined as Glasgow Coma Score of 15 for ≥48 hours for hospitalized participants, over 4 weeks.|Time to new neurological event, which is defined as fall in Glasgow Coma Score of ≥2 points for ≥48 hours for hospitalized participants or since last visit for non-hospitalized participants, new onset seizures, new focal neurologic deficit|CSF to plasma ratio|Rate of CSF uptake|Plasma absorption rate constant (ka)|Drug clearance (Cl/F)|Volume of distribution (Vd)|Post-hoc Bayesian predictions of secondary parameters Cmax|Time to Cmax|Time to AUC0-24|Time to plasma elimination half-life|Time to CSF elimination half-life","National Institute of Allergy and Infectious Diseases (NIAID)","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2","330","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5384","December 7, 2023","May 10, 2027","May 10, 2027","May 20, 2022",,"March 6, 2024","Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (12101), Rio De Janeiro, Brazil|Byramjee Jeejeebhoy Government Medical College (BJMC) CRS (31441), Pune, India|Moi University Clinical Research Center (MUCRC) CRS (12601), Eldoret, Kenya|Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS (12501), Kericho, Kenya|Malawi CRS, Lilongwe, Malawi|Nutrición-Mexico CRS, Mexico City, Mexico|Barranco CRS, Lima, Peru|De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981), Cavite, Philippines|Durban International CRS, Durban, South Africa|University of the Witwatersrand Helen Joseph (WITS HJH) CRS, Johannesburg, South Africa|Kilimanjaro Christian Medical Centre (KCMC) (Site ID: 5118), Moshi, Tanzania|Siriraj Hospital, Mahidol University NICHD CRS (Site ID: 5115), Bangkok, Bangkoknoi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|National Lung Hospital CRS (Site ID: 32483), Vĩnh Phúc, Hanoi, Vietnam|Milton Park CRS, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT05383742"
579,"NCT00212498","Tuberculosis Research Blood Bank",,"Withdrawn","No Results Available","Tuberculosis","Procedure: Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies","Develop TB Blood Bank","NYU Langone Health","All","21 Years to 75 Years   (Adult, Older Adult)",,"0","Other","Observational","Time Perspective: Prospective","11354 (previously 4424)","November 2006","January 2012",,"September 21, 2005",,"December 9, 2015","NYU School of Medicine Division of Pulmonary and Critical Care Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00212498"
580,"NCT03536117","Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates","MTBVAC-03","Completed","No Results Available","Tuberculosis","Biological: MTBVAC|Biological: BCG","Number of participants with treatment-related adverse events as defined in protocol.|Immunogenicity analysis in infants|MTBVAC-induced QFT conversion and reversion kinetics","Biofabri, S.L|South African Tuberculosis Vaccine Initiative|Universidad de Zaragoza|TuBerculosis Vaccine Initiative","All","up to 96 Hours   (Child)","Phase 2","99","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MTBVAC-03","February 12, 2019","May 19, 2022","May 19, 2022","May 24, 2018",,"June 18, 2023","SATVI: Worcester, Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT03536117"
581,"NCT00018083","Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen",,"Unknown status","No Results Available","Tuberculosis|HIV Infections","Drug: rifabutin|Drug: isoniazid|Drug: efavirenz",,"National Center for Research Resources (NCRR)|Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Not Applicable",,"NIH|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCRR-M01RR00030-0162",,,,"July 4, 2001",,"June 24, 2005","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00018083"
582,"NCT05575518","A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis","OptiRiMoxTB","Recruiting","No Results Available","Tuberculosis|Human Immunodeficiency Virus","Drug: Optimised rifamycin","Bacteriological cure, absence of either TB treatment failure or relapse|Proportional of adverse events (AE) of grade 3 severity or higher|Proportional of clinically significant adverse events related to the intervention|Clinical improvement of TB symptoms|Clinical improvement of body mass index (BMI)|Clinical improvement of participant reported health status","Stellah Mpagama|University of St Andrews|Radboud University Medical Center|Kibong'oto Infectious Diseases Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","414","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OptiRiMoxTB-01","August 11, 2023","December 31, 2025","March 31, 2026","October 12, 2022",,"August 25, 2023","Kibong'oto Infectious Diseases Hospital, Moshi, Kilimanjaro, Tanzania",,"https://ClinicalTrials.gov/show/NCT05575518"
583,"NCT04240990","Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition","TB-Speed SAM","Unknown status","No Results Available","Tuberculosis|Severe Acute Malnutrition","Other: Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.","Sensitivity of the score obtained|Specificity of the score obtained|Prevalence of TB among hospitalized children with SAM|Clinical characteristics of TB disease in hospitalized children with SAM|Bacteriological characteristics of TB disease in hospitalized children with SAM|Biological characteristics of TB disease in hospitalized children with SAM|Radiological characteristics of TB disease in hospitalized children with SAM|Estimated time to TB treatment decision in hospitalized children with SAM|Diagnostic accuracy measures: 1/ Sensitivity of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 2/ Specificity of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 3/ Negative predictive value of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 4/ Positive predictive value of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 5/ AUROC of diagnostic prediction models with and without the different tests results|Diagnostic accuracy of Ultra performed on one NPA and one stool sample against mycobacterial culture performed on gastric aspirates|Proportion of children with NPA and stool samples collected as per study protocol|Proportion of NPA-related adverse events (AEs)|Tolerability of NPA collection: 1/ Discomfort/pain/distress experienced by the child as assessed by the child|Tolerability of NPA collection: 2/ Discomfort/pain/distress experienced by the child as assessed by the parents|Tolerability of NPA collection: 3/ Discomfort/pain/distress experienced by the child as assessed by the nurse|Mortality at 6 months|Percentage weight gain 6 months|TB treatment outcomes","Institut National de la Santé Et de la Recherche Médicale, France|UNITAID","All","up to 59 Months   (Child)","Not Applicable","720","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","C18-28","November 4, 2019","November 4, 2020","November 4, 2020","January 27, 2020",,"January 27, 2020","Mulago National Referral Hospital, Kampala, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT04240990"
584,"NCT05311423","The Prevalence and Reproductive Outcome of Infertile Women With Genital Tuberculosis","TB-PRIME","Unknown status","No Results Available","Infertility, Female|Genital Tuberculoses, Female","Diagnostic Test: QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra","Clinical pregnancy rate of ART|Continued pregnancy rate of ART|Prevalence of SGTB among infertile women|Prevalence of FGTB/LTBI among infertile women|Abortion rate|Ectopic pregnancy rate|Preterm birth rate|Live birth rate|Maternal mortality rate|Neonatal mortality rate|Spontaneous pregnancy rate|The incidence of grade 3-4 adverse events|The rate of drug discontinuation due to adverse drug reactions|Treatment completion rate|Incidence of active tuberculosis of LTBI group during 1 year after enrollment","Huashan Hospital|Shanghai First Maternity and Infant Hospital|General Hospital of Ningxia Medical University|Tang-Du Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The First Affiliated Hospital of Zhengzhou University|The 924th Hospital of Joint Logistics Support Force of Chinese People's Liberation|Shenzhen Zhongshan Urology Hospita|Northwest Women's and Children's Hospital, Xi'an, Shaanxi|Jiangxi Maternal and Child Health Hospital|The First People's Hospital of Yunnan|Tongji Hospital|The Second Hospital of Hebei Medical University|First Affiliated Hospital of Wenzhou Medical University","Female","20 Years to 43 Years   (Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KY2021-840","December 1, 2021","June 1, 2023","August 1, 2023","April 5, 2022",,"April 5, 2022","Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05311423"
585,"NCT06236152","Steroids vs Placebo in Treatment of Tuberculous Lymphadenitis",,"Completed","No Results Available","Tuberculous Lymphadenitis, Cervical","Drug: Ferrous sulfate|Drug: Deltacortril","Regression of size of cervical lymph nodes was measured using ultrasound neck","Fahad Javed Awan|Pak Emirates Military Hospital","All","Child, Adult, Older Adult","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PakEmiratesMH1023Fahad","July 1, 2022","June 30, 2023","August 15, 2023","February 1, 2024",,"February 1, 2024","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT06236152"
586,"NCT01222338","Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients",,"Completed","No Results Available","Tuberculosis","Biological: V-5 immunitor","primary endpoint: sputum smear conversion|liver function|quality of life|hematology parameters|weight gain","Lisichansk Regional Tuberculosis Dispensary|National Medical University, Ukraine|Immunitor USA Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","123","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","imm01","January 2010","December 2010","January 2011","October 18, 2010",,"August 3, 2012","Lisichansk TB Dispensary, Lisichansk, Luhansk, Ukraine",,"https://ClinicalTrials.gov/show/NCT01222338"
587,"NCT00000796","A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Cycloserine|Drug: Ethionamide|Drug: Capreomycin sulfate|Drug: Aminosalicylic acid|Drug: Streptomycin sulfate|Drug: Ethambutol hydrochloride|Drug: Amikacin sulfate|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Pyridoxine hydrochloride|Drug: Levofloxacin|Drug: Rifampin|Drug: Clofazimine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","525","NIH","Interventional","Primary Purpose: Treatment","ACTG 238|CPCRA 026|11215",,,"October 1998","August 31, 2001",,"November 3, 2021","Cook County Hosp, Chicago, Illinois, United States|Henry Ford Hosp, Detroit, Michigan, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|Comprehensive Health Care Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Interfaith Med Ctr, Brooklyn, New York, United States|SUNY / Health Sciences Ctr at Brooklyn, Brooklyn, New York, United States|Beth Israel Med Ctr, New York, New York, United States|Clinical Directors Network of Region II, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Saint Clare's Hosp and Health Ctr, New York, New York, United States|Cornell Univ Med Ctr, New York, New York, United States|Mount Sinai Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00000796"
588,"NCT05781646","Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital",,"Completed","No Results Available","Tuberculous Meningitis","Diagnostic Test: Xpert MTB/RIF","Detection of M. tuberculosis from CSF specimen","Chiang Mai University","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CMUXpertTBM","January 1, 2015","March 30, 2016","December 31, 2016","March 23, 2023",,"March 23, 2023",,,"https://ClinicalTrials.gov/show/NCT05781646"
589,"NCT00164450","TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection",,"Completed","No Results Available","Tuberculosis","Drug: Rifapentine + isoniazid once weekly for 3 months","Determine whether rifapentine exposure (level 24 hours after drug ingestion) is equivalent in young children receiving weight-based dosing to adults receiving 900 mg.|Correlate estimated rifapentine exposure with toxicity in young children receiving rifapentine and isoniazid for latent tuberculosis infection.|Validate the accuracy of estimated rifapentine exposure with pediatric rifapentine dose based on weight.|Determine estimated drug bioavailability in pediatric subjects (ages 2 to < 12 years) given higher mg/kg doses of rifapentine.|Determine the association in adults between polymorphisms of MDR1 genotype (P-glycoprotein) and rifapentine estimated exposure.|Determine the frequency of lower antitubercular drug concentrations in adults with acetylator status determined by N-acetyltransferase genotypes and of rifapentine by C24 and by MDR1 genotypes.","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","230","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-4679","September 2005","August 2008","August 2008","September 14, 2005",,"August 25, 2008","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|University of Southern California Medical Center, Los Angeles, California, United States|University of California at San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Public Health Department, Denver, Colorado, United States|Washington DC Veterans Administration Medical Center, Washington, District of Columbia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern University School of Medicine, Chicago, Illinois, United States|Hines Veterans Administration Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|New Jersey School of Medicine, Newark, New Jersey, United States|Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Veterans Administration Tennessee Valley Health Care System, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Veterans Administration Medical Center, Houston, Texas, United States|Audie L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle-King County Health Department, Seattle, Washington, United States|Hopital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnepeg, Manitoba, Canada|Montreal Chest Institute, Montreal, Quebec, Canada|Agencia de Salut Publica, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00164450"
590,"NCT02953847","The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)","BIO3FDC","Completed","No Results Available","Tuberculosis","Drug: Rimactane|Drug: Rifafour e-275|Drug: Rimactazid 150/75","Cmax","University of Cape Town","All","18 Years to 55 Years   (Adult)","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","BIO3FDC","November 2016","February 2017","February 2017","November 3, 2016",,"May 10, 2017","Clinical Research Centre, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02953847"
591,"NCT02225158","Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection",,"Terminated","No Results Available","Latent Tuberculosis Infection",,"Define the immunologic differences in CD4+ T cell responses between helminth-infected and uninfected subjects with concomitant latent TB at the time of diagnosis and on serial follow-up.|Evaluate the immune phenotype and functionality of tissue resident immune cells obtained by bronchoalveolar lavage in subjects with LTBI and either: 1) structural lung damage from prior treated/healed pulmonary tuberculosis or 2) recent prolonge...|Define the role of stable long lasting antigen-specific IL-2 producing CD4+ central memory T cells in identifying subsets of patients with LTBI","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)",,"1","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140178|14-I-0178","August 15, 2014","May 11, 2017","May 11, 2017","August 26, 2014",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Montgomery County Public Health Services, TB, Refugee and Migrant Health, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02225158"
592,"NCT05861440","Applying Shear Wave Elastography for Adjunct Steroid on Tuberculous Lymphadenitis",,"Recruiting","No Results Available","Tuberculous Lymphadenitis","Drug: Prednisolone|Drug: standard anti-tuberculosis agents","reduction rate of paradoxical upgrading reaction|hospital-anxiety scale|hospital- depression scale|tuberculosis relapse rate|treatment duration|adverse events during corticosteroid therapy|paradoxical upgrading reaction rate in low elasticity group","National Taiwan University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202301222MINA","May 2023","July 2025","December 2025","May 16, 2023",,"May 19, 2023","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05861440"
593,"NCT00472316","Innovative Approaches to Tuberculosis Control",,"Completed","No Results Available","Tuberculosis","Behavioral: Active Case Finding for Tuberculosis","To compare TB incidence in communities randomized to DOTS+ACF and DOTS alone over the 18-month period following ACF campaign.|To compare case notification rates of TB in the 2 arms of the study during the ACF campaign.","Johns Hopkins University|Universidade Federal do Rio de Janeiro","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2U19AI045432-06","May 2007","October 2009","May 2011","May 11, 2007",,"August 18, 2017","The Health Department of Rio de Janeiro, Brazil, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00472316"
594,"NCT04926922","PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia",,"Active, not recruiting","No Results Available","Tuberculosis|HIV",,"Frequency of positive results using the IGRA and TST.|Proportion of each test type successfully completed and the result determined.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"200","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","10000231|000231-I","July 27, 2021","June 7, 2024","June 7, 2024","June 15, 2021",,"April 1, 2024","National Institutes of Health Cinical Center, Bethesda, Maryland, United States|C.H. Rennie Hospital, Kakata, Liberia|Duport Road Clinic, Monrovia, Liberia|JFK Medical Center, Monrovia, Liberia|Redemption Hospital, Monrovia, Liberia",,"https://ClinicalTrials.gov/show/NCT04926922"
595,"NCT00242047","Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination.",,"Unknown status","No Results Available","Tuberculosis","Biological: Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).","Prevention of tuberculosis with bacteriological or histological confirmation, or meeting strict clinical criteria,in the first 2 years of life.|Comparison of Rate of Adverse Events.|Comparison of Mortality Rates.|Microbiological diagnosis of tuberculosis in a primary care setting.|Rating of diagnostic scoring systems.|Case definition of tuberculosis.","University of Cape Town|Aeras|Japan BCG Laboratory 4-2-6 Kohinata,Tokyo 112-0006, Japan.","All","0 Years to 24 Hours   (Child)","Phase 4","12000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UCT REC 271/2000","March 2001",,"August 2006","October 19, 2005",,"October 19, 2005","South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town., Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00242047"
596,"NCT00978510","Study of Health Personnel and the Assistance to Patients With Tuberculosis in Hospital Environment",,"Completed","No Results Available","Tuberculosis|Health Care Professionals|Hospital Environment",,,"Sociedade Cearense de Infectologia","All","Child, Adult, Older Adult",,"159","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","TB HGWA 2","January 2004",,"December 2006","September 17, 2009",,"September 17, 2009","Hospital Geral Dr. Waldemar Alcântara, Fortaleza, Ceará, Brazil",,"https://ClinicalTrials.gov/show/NCT00978510"
597,"NCT02638272","Early Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures",,"Completed","No Results Available","Spinal Tuberculosis","Procedure: no debridement","The operative time in minutes|blood loss in milliliter|erythrocyte sedimentation rate (ESR) in mm/h|kyphotic angle in degree","The Second Hospital of Anhui Medical University","All","14 Years to 67 Years   (Child, Adult, Older Adult)","Not Applicable","74","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1898","January 2009","February 2014","September 2015","December 23, 2015",,"December 23, 2015",,,"https://ClinicalTrials.gov/show/NCT02638272"
598,"NCT05738681","Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial",,"Recruiting","No Results Available","Tuberculosis|Drug Induced Liver Injury|Hepatitis","Drug: N acetyl cysteine","Prevalence of hepatitis at 8 weeks|Prevalence of hepatitis among NAT2 slow acetylator patients","Mahidol University","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Si 1052/2020","September 9, 2022","March 31, 2023","May 31, 2023","February 22, 2023",,"February 22, 2023","Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT05738681"
599,"NCT00201123","Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs",,"Completed","Has Results","Tuberculosis|AIDS-related Complex","Drug: Aerosol Interferon-Gamma|Drug: Subcutaneous interferon-gamma|Other: Placebo","Sputum Conversion|Chest Cavity Size|Bronchoalveolar Lavage (BAL) to Measure Flow of Cytometry and Cytokine Levels","NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","89","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","264|R01HL059832-06","April 2005","January 2007","August 2007","September 20, 2005","June 10, 2014","December 16, 2016","NYU School of Medicine, New York, New York, United States|The Lung Institute at University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT00201123"
600,"NCT01099098","Prevalence of Latent Tuberculosis (TB) Infection Diagnosed by Interferon-gamma Release Assay and Tuberculin Skin Tests in Patients With Old Healed TB",,"Completed","No Results Available","Tuberculosis",,"Prevalence of latent TB infection","Seoul National University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"480","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","H-0909-054-295","January 2010","January 2011","March 2011","April 6, 2010",,"May 12, 2011","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01099098"
601,"NCT01121068","Monthly Follow up of Interferon Gamma Releasing Assay (IGRA) Among Health-care Workers Treating Tuberculosis (TB) Patients",,"Completed","No Results Available","Tuberculosis","Other: Blood samplings","Results of interferon-gamma releasing assay","Seoul National University Hospital","All","20 Years and older   (Adult, Older Adult)",,"49","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","monthly IGRA","May 2010","May 2011","December 2011","May 12, 2010",,"January 6, 2014","Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01121068"
602,"NCT02701439","SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting","PTB","Completed","No Results Available","Tuberculosis","Device: Small membrane filtration","Sensitivity and specificity of SMF method and Xpert MTB/RIF assay","Epicentre|Boston University|University of Florida","All","18 Years and older   (Adult, Older Adult)",,"1050","Other","Observational","Time Perspective: Cross-Sectional","SMF-01","September 2012","June 2014","June 2014","March 8, 2016",,"March 8, 2016","Epicentre Mbarara Research Base, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT02701439"
603,"NCT00023426","TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis",,"Completed","No Results Available","Tuberculosis","Drug: rifapentine","Proportion of patients who fail to complete therapy in each of the dosing groups|1. Rate of serious adverse events in each of the dosing groups|2. Rate of total adverse events in each of the groups|3. Rate of relapse in patients with positive sputum culture at 2 months, in each of the groups","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CDC-NCHSTP-2404|HCK45|25","July 1999",,"February 2003","September 10, 2001",,"September 13, 2005","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023426"
604,"NCT02712424","DAR-901 TB Booster Vaccine to Prevent TB in Adolescents","DAR-PIA","Completed","Has Results","Tuberculosis","Biological: DAR-901|Biological: Sterile saline placebo","New Infection With Mycobacterium Tuberculosis|Persistent New Infection With M. Tuberculosis","Dartmouth-Hitchcock Medical Center|Muhimbili University of Health and Allied Sciences","All","13 Years to 15 Years   (Child)","Phase 2","625","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","29001","March 2016","February 1, 2020","February 1, 2020","March 18, 2016","May 11, 2021","May 11, 2021","Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/24/NCT02712424/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/24/NCT02712424/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02712424"
605,"NCT02520973","Screening for TB in Pregnancy. on HIV-Infected Pregnant Women",,"Completed","No Results Available","Tuberculosis","Other: Sputum sample","Proportion of women diagnosed with TB","Johns Hopkins University|University of Witwatersrand, South Africa","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","00039194","May 2015","June 30, 2017","June 30, 2017","August 13, 2015",,"August 18, 2017","Perinatal HIV Research Unit, Klerksdorp, Northwest, South Africa",,"https://ClinicalTrials.gov/show/NCT02520973"
606,"NCT02169570","Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis","EVIDENT","Unknown status","No Results Available","Type 2 Diabetes Mellitus|Pulmonary Tuberculosis","Dietary Supplement: Vitamin D|Dietary Supplement: Calcium|Dietary Supplement: Placebo Vit D|Dietary Supplement: Placebo Calcium","Change in Weight|Change in TB score|Change Acid Fast Bacilli (AFB) smear (Sputum)|Change in chest X-ray|Change Heamoglobin A1c (HbA1c)|Change in Fasting Blood Test (FBS)|Change in Random Blood Sugar (RBS)","Dow University of Health Sciences","All","30 Years to 60 Years   (Adult)","Phase 4","435","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","SPH-P02","December 2014","December 2016","December 2017","June 23, 2014",,"June 23, 2014","School of Public Health, Dow university of Health Sciences, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT02169570"
607,"NCT02735590","The Correlate of Risk Targeted Intervention Study","CORTIS","Unknown status","No Results Available","Tuberculosis","Drug: Isoniazid|Drug: Rifapentine","Treatment Efficacy|Performance of COR","University of Cape Town|South African Tuberculosis Vaccine Initiative|Aurum Institute|Centre for the AIDS Programme of Research in South Africa|University of Stellenbosch|London School of Hygiene and Tropical Medicine|Fred Hutchinson Cancer Center","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","2927","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CORTIS-01","September 20, 2016","December 31, 2019","December 31, 2019","April 12, 2016",,"December 24, 2018","Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, KwaZulu-Natal, South Africa|Aurum Institute, Klerksdorp, North West Province, South Africa|Aurum Institute, Rustenburg, North West, South Africa|Stellenbosch Immunology Research Group, Cape Town, Western Cape, South Africa|South African Tuberculosis Vaccine Initiative (SATVI), Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02735590"
608,"NCT05249699","The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation","PTTKT","Unknown status","No Results Available","Kidney Transplant Infection|Tuberculosis|Isoniazid Toxicity","Drug: Isoniazid|Other: without any additional anti-tuberculosis treatment","The primary outcome is the incidence of tuberculosis in these groups.|The secondary outcome is subject incidence of adverse events","West China Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","303","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","WestChinaH-PTTKT","April 1, 2022","July 1, 2023","August 1, 2023","February 22, 2022",,"April 4, 2022",,,"https://ClinicalTrials.gov/show/NCT05249699"
609,"NCT00517231","Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment",,"Withdrawn","No Results Available","Pulmonary Tuberculosis",,,"UPECLIN HC FM Botucatu Unesp|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.","All","18 Years to 80 Years   (Adult, Older Adult)",,"0","Other","Observational","Time Perspective: Prospective","upeclin/HC/FMB-Unesp-pre02","June 2005","June 2015","June 2015","August 16, 2007",,"July 7, 2015",,,"https://ClinicalTrials.gov/show/NCT00517231"
610,"NCT02729571","Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults","MTBVAC-Ph1b","Completed","No Results Available","Tuberculosis","Biological: MTBVAC|Biological: BCG","Safety and reactogenicity in infants and adults: includes injection site and systemic and regional adverse events, solicited and unsolicited. A diary card will be for solicited local, regional, and systemic adverse event data.|Primary immunogenicity analysis (in infants only): Measure of frequencies and co-expression patterns of CD4 and CD8 T cells expressing specific cytokines in whole blood.","Biofabri, S.L|South African Tuberculosis Vaccine Initiative|TuBerculosis Vaccine Initiative|Triclinium Clinical Trial Project Management (Pty) Ltd.|Universidad de Zaragoza","All","1 Day to 50 Years   (Child, Adult)","Phase 1|Phase 2","54","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MTBVAC-02","September 2015","September 2016","March 2018","April 6, 2016",,"May 1, 2018","South African Tuberculosis Vaccine Initiative, Brewelskloof Hospital, Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02729571"
611,"NCT00456183","Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.",,"Completed","No Results Available","Tuberculosis","Biological: MVA 85A","Safety of a single intradermal injection of 5 x 107pfu MVA85A|Efficacy|latently infected with MVA85A on the immune response, both to antigen 85A (the antigen in|the vaccine) and to ESAT6/CFP10 antigens (M.tb specific).|Endpoints:|The specific endpoints for safety and reactogenicity will be actively and passively collected|data on adverse events (AEs). The specific endpoints for immunogenicity will be markers of|cell-mediated immunity as described below.","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB007","August 2005",,"April 2007","April 4, 2007",,"May 31, 2007","Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00456183"
612,"NCT04545164","Computer Aided Screening for Tuberculosis in Low Resource Environments","CASTLE","Completed","No Results Available","Tuberculosis Infection|HIV Infections","Diagnostic Test: CAD4TB|Diagnostic Test: FujiLAM","TB treatment initiation|Mortality|Undiagnosed TB|Same day TB treatment","London School of Hygiene and Tropical Medicine|Liverpool School of Tropical Medicine|Kamuzu University of Health Sciences|Malawi-Liverpool-Wellcome Trust Clinical Research Programme","All","18 Years and older   (Adult, Older Adult)","Not Applicable","498","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17799","September 2, 2020","March 31, 2022","May 26, 2022","September 10, 2020",,"January 26, 2023","Zomba Central Hospital, Zomba, Malawi","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/64/NCT04545164/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04545164"
613,"NCT01589497","Essentiality of INH in TB Therapy",,"Completed","Has Results","Tuberculosis","Drug: Rifampicin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Moxifloxacin","Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14|Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 14|Daily Change in log10 Transformed Colony-forming Unit (CFU) Counts Per mL Sputum From Baseline (Study Treatment Initiation) to Day 2|Daily Change in log10 Colony-forming Unit (CFU) Counts Per mL Sputum From Day 2 to Day 14|Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 2|Daily Change in Time to Positivity (TTP) From Day 2 to Day 14|Log10 Transformed Colony-forming Unit (CFU) Count Per mL From Sputum Samples at Baseline and Day 14|Correlation Between Time to Positivity (TTP) and log10 Transformed Colony-forming Unit (CFU) Counts Per mL|Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-24hour) for Rifampicin (RIF)|Rifampicin PK Parameter Clearance (CL/F)|Rifampicin PK Parameter Maximum Plasma Concentration (Cmax)|Rifampicin PK Parameter Last Concentration (CLast)|AUC0-24hour for Isoniazid (INH) at Day 1|Isoniazid PK Parameter CL/F at Day 1|Isoniazid PK Parameter Cmax at Day 1|Isoniazid PK Parameter CLast at Day 1|AUC0-24hour for Isoniazid at Day 14|Isoniazid PK Parameter CL/F at Day 14|Isoniazid PK Parameter Cmax at Day 14|Isoniazid PK Parameter CLast at Day 14|AUC0-24hour for Pyrazinamide (PZA)|Pyrazinamide PK Parameter CL/F|Pyrazinamide PK Parameter Cmax|Pyrazinamide PK Parameter CLast|AUC0-24hour for Ethambutol (EMB)|Ethambutol PK Parameter CL/F|Ethambutol PK Parameter Cmax|Ethambutol PK Parameter CLast|AUC0-24hour for Moxifloxacin (Mox) at Day 14|Moxifloxacin PK Parameter CL/F at Day 14|Moxifloxacin PK Parameter Cmax at Day 14|Moxifloxacin PK Parameter CLast at Day 14","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","69","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5307|1U01AI068636","June 30, 2015","January 28, 2016","February 10, 2016","May 2, 2012","April 4, 2017","April 6, 2018","University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town, Western Cape, South Africa|TASK Applied Science CRS (31718), Bellville, South Africa",,"https://ClinicalTrials.gov/show/NCT01589497"
614,"NCT02651259","Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women",,"Completed","Has Results","Tuberculosis","Drug: Rifapentine (RPT)|Drug: Isoniazid (INH)|Dietary Supplement: Pyridoxine (vitamin B6)","Clearance Relative to Bioavailability (CL/F) for Rifapentine (RPT) for Intensive and Sparse PK|Clearance Relative to Bioavailability (CLmet/F) for Desacetyl Rifapentine (Des-RPT)|Absorption Rate Constant (ka) for Rifapentine (RPT)|Volume of Distribution Relative to Bioavailability (Vc/F) for Rifapentine (RPT)|Incidence of Related Serious Adverse Events (SAEs) in Pregnant and Postpartum Women Taking Once-weekly RPT + INH|Percentage of Participants With Grade 2 Adverse Events (AEs) Judged to be Related to Study Drug Regimen|Percentage of Participants With All Grade 3 and 4 AEs|Percentage of Participants With All Serious AEs|Percentage of Participants With All AEs Leading to Permanent Discontinuation of Study Drug Regimen (i.e., RPT, INH, and Pyridoxine)|Percentage of Participants With Related Serious Adverse Events (AEs) in Infants Born to Women Taking Once-weekly RPT + INH|Clearance Relative to Bioavailability (CL/F) for Rifapentine (RPT)|Area Under the Curve From 0 to 24 Hours (AUC0-24) for RPT and Area Under the Curve From 0 to 24 Hours (AUC0-24) for Des-RPT Pregnant Women in 2nd and 3rd Trimester|Maximum Concentration (Cmax) for RPT Maximum Concentration (Cmax) for Des-RPT Pregnant Women in 2nd and 3rd Trimester|Maximum Concentration (Cmin) for RPT and Maximum Concentration (Cmin) for Des-RPT Pregnant Women in 2nd and 3rd Trimester|Cord Blood Concentrations of Rifapentine (RPT) Among Infants|Plasma Concentrations of Rifapentine (RPT) Among Infants|Cord Blood Concentrations of Desacetyl Rifapentine (Des-RPT) Among Infants|Plasma Concentrations of Desacetyl Rifapentine (Des-RPT) Among Infants|Number of Participants With Discontinuation of Study Drug Due to Intolerance (Tolerability of Study Drug Regimen - i.e., RPT, INH, and Pyridoxine)|Number of Mothers With Active TB up to 24 Weeks Postpartum|Number of Infants With Active TB up to 24 Weeks of Life|Clearance (CL/F) of INH|Absorption (ka) of INH|Volume of Distribution of INH","National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT 2001|12026","March 13, 2017","April 10, 2019","April 10, 2019","January 8, 2016","May 6, 2020","November 4, 2021","Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS, Kericho, Kenya|Malawi CRS, Lilongwe, Central Malawi, Malawi|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Harare Family Care CRS, Harare, Zimbabwe","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/59/NCT02651259/Prot_002.pdf|""Statistical Analysis Plan: Final Safety Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/59/NCT02651259/SAP_000.pdf|""Statistical Analysis Plan: Final PK Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/59/NCT02651259/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02651259"
615,"NCT00731471","A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A","Safety of MVA85A|Immunogenicity of MVA85A","University of Oxford|Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal","All","18 Years to 50 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB019","August 2008","January 2011","January 2011","August 11, 2008",,"March 28, 2011","Centre Hospitalier Le Dantec, Dakar, Senegal",,"https://ClinicalTrials.gov/show/NCT00731471"
616,"NCT02414828","A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB","C-010-402","Completed","Has Results","Tuberculosis","Biological: Placebo|Biological: AERAS-402 3 x 10^8 vp|Biological: AERAS-402 3 x 10^9 vp|Biological: AERAS-402 3 x 10^10 vp","Number of Participants With Solicited and Unsolicited AEs|Forced Expiratory Volume in One Second (FEV1)|Forced Vital Capacity (FVC)|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the ""on TB Treatment"" Stratum|Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the ""on TB Treatment"" Stratum|Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the ""Post TB Treatment"" Stratum|Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the ""Post TB Treatment"" Stratum","Aeras|Crucell Holland BV","All","18 Years to 45 Years   (Adult)","Phase 2","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-010-402","October 2008","July 2010","November 2010","April 13, 2015","May 4, 2016","May 4, 2016","University of Cape Town Lung Institute Pty (Ltd), Cape Town, Mowbray, South Africa",,"https://ClinicalTrials.gov/show/NCT02414828"
617,"NCT02457208","PK Study of Anti-TB Drugs",,"Completed","No Results Available","Tuberculosis","Drug: Isoniazid (H)|Drug: Rifampicin (R)|Drug: Pyrazinamide (Z)|Drug: Ethambutol (E)","Plasma drug levels of Rifampicin|Plasma drug levels of Isoniazid|Plasma drug levels of Pyrazinamide|Plasma drug levels of Ethambutol|Time to negativity of M. tuberculosis|Genotyping MTB strains","University of Oxford","All","18 Years and older   (Adult, Older Adult)","Phase 1","61","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMRU1407","July 7, 2015","January 14, 2018","January 14, 2018","May 29, 2015",,"October 3, 2018","Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand",,"https://ClinicalTrials.gov/show/NCT02457208"
618,"NCT02251327","Feasibility and Accuracy of a Novel Xpert Cartridge","(XpertDST)","Completed","No Results Available","Tuberculosis","Device: Investigational Xpert DST test","Sensitivity and specificity|Diagnostic yield (for tuberculosis) of the investigational Xpert test and of the conventional Xpert MTB/RIF test|the proportion of specimens with a result of 'invalid' and the proportion of specimens with a result of 'error'|Proportion of study participants with TB and DRTB","Johns Hopkins University|Boston Medical Center","All","18 Years and older   (Adult, Older Adult)",,"401","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NA_0008420","June 4, 2014","June 15, 2015","December 2015","September 29, 2014",,"August 22, 2018",,,"https://ClinicalTrials.gov/show/NCT02251327"
619,"NCT05118490","Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients","1 to 3","Recruiting","No Results Available","HIV Seropositivity|Tuberculosis|Household Contact","Drug: Daily rifapentine and isoniazid for 4 weeks|Drug: Weekly rifapentine and isoniazid for 12 weeks","Treatment adherence- self-report|Treatment adherence- pill count|Treatment adherence- electronic monitoring device (EMD)|Adverse Events|Early treatment discontinuation|Cost-effectiveness","The Aurum Institute NPC|Johns Hopkins University","All","13 Years and older   (Child, Adult, Older Adult)","Phase 4","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00298999","July 19, 2023","October 28, 2024","December 31, 2024","November 12, 2021",,"March 18, 2024","The Byramjee Jeejeebhoy Medical Centre (BJGMC-JHU) CRS, Pune, Maharashtra, India|Yayasan KNCV - The Persahabatan Hospital, Jakarta, Jakarta, Jaya, Indonesia|Fundação Aurum (The Aurum Institute Mozambique), Chokwé, Gaza, Mozambique|The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp, North West Province, South Africa",,"https://ClinicalTrials.gov/show/NCT05118490"
620,"NCT00144417","TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment",,"Completed","No Results Available","Tuberculosis","Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Drug: isoniazid","• To compare the culture-conversion rate at the end of the intensive phase of therapy of the moxifloxacin regimen vs. that of the isoniazid regimen|To compare the safety and tolerability of the moxifloxacin regimen to that of the isoniazid regimen|To determine the time to culture-conversion of the moxifloxacin regimen and the isoniazid regimen using data from 2-, 4-, 6-, and 8-week cultures|To compare the proportion of patients with any Grade 3 or 4 adverse reactions|To compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients|To compare the rates of treatment failure of the moxifloxacin regimen and the isoniazid regimen|To determine whether there is delayed toxicity attributable to moxifloxacin (toxicity that becomes evident after the 8 weeks of moxifloxacin therapy)","Centers for Disease Control and Prevention|Global Alliance for TB Drug Development|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","433","U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CDC-NCHSTP-4448","February 2006","June 2007","December 2007","September 5, 2005",,"August 3, 2011","Veterans Administration Medical Center of Arkansas, Little Rock, Arkansas, United States|University of Southern California Medical Center, Los Angeles, California, United States|University of California at San Diego, San Diego, California, United States|University of California, San Francincisco, San Francisco, California, United States|Denver Public Health Department, Denver, Colorado, United States|Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Hines Veterans Administration Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|New Jersey School of Medicine, Newark, New Jersey, United States|Columbia University, New York, New York, United States|Harlem Hospital, Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Veterans Administration Tennessee Valley Health Care System, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Veterans Administration Medical Center, Houston, Texas, United States|Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio, Texas, United States|Seattle-King County Health Department, Seattle, Washington, United States|Hopital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil|University of Manitoba, Winnepeg, Manitoba, Canada|Montreal Chest Institute, Montreal, Quebec, Canada|Nelson R. Mandela School of Medicine, Durban, KwaZulu Natal, South Africa|Agencia de Salut Publica, Barcelona, Spain|Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00144417"
621,"NCT05202548","Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021",,"Completed","No Results Available","Lymphadenitis, Tuberculous|Immune Defect","Other: Immuno-histochemical staining","IHC slides","Universitas Katolik Widya Mandala Surabaya|Indonesia's Ministry of Research and Technology (Ristekdikti/BRIN)","All","Child, Adult, Older Adult",,"45","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","002/AMD-SP2H/LT-MULTIPDPK/LL7","May 1, 2021","June 25, 2021","June 25, 2021","January 21, 2022",,"January 21, 2022","Vincentius A Paulo Surabaya Hospital, Surabaya, East Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT05202548"
622,"NCT02252198","Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests","FIND","Completed","No Results Available","Tuberculosis","Other: Epistem Genedrive® and MolBio Truenat™","Non-inferiority of tests|Sensitivity and specificity of Epistem Genedrive® MTB iD|Sensitivity and specificity of MolBio Truenat™ TB Assay|Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay|Training needs for each assay|Operational feasibility|Cost-comparison between assays","Johns Hopkins University|Boston Medical Center","All","18 Years and older   (Adult, Older Adult)",,"504","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NA_00085221","February 2014","January 2015","January 2015","September 30, 2014",,"December 12, 2017","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02252198"
623,"NCT02375698","A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB","C-037-456","Completed","Has Results","Tuberculosis","Biological: H56:IC31|Biological: Placebo","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Mean Percent Change From Baseline of Participants' Responses to TB Antigens Ag85A and ESAT-6","Aeras|Statens Serum Institut","All","18 Years to 60 Years   (Adult)","Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","C-037-456","November 21, 2014","June 24, 2016","October 24, 2016","March 3, 2015","November 18, 2019","November 18, 2019","Task Clinical Research Centre, Bellville 7530, Cape Town, South Africa|University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa|The Aurum Institue, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT02375698"
624,"NCT02430506","A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB","C-012-402","Completed","No Results Available","Tuberculosis","Biological: Placebo|Biological: AERAS-402","Safety of AERAS-402 in healthy, HIV-negative, BCG-vaccinated, QuantiFERON®-TB Gold In-Tube test (QFT-G)(+) and QFT-G(-) adults without evidence of tuberculosis disease in Kenya.|Immunogenicity profile of AERAS-402 in healthy, HIV-negative, BCG-vaccinated, QFT-G(+) and QFT-G(-) adults without evidence of tuberculosis disease in Kenya.","Aeras","All","18 Years to 45 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-012-402","September 2008","June 2009","July 2010","April 30, 2015",,"April 27, 2016","Kenya Medical Research Institute, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT02430506"
625,"NCT00653770","A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A",,"Completed","No Results Available","Tuberculosis","Biological: FP85A|Biological: MVA85A","To assess the safety of a new tuberculosis vaccine, FP85A, when administered individually and sequentially with MVA85A in a prime-boost regime, to healthy volunteers, who have previously been vaccinated with BCG|To assess the cellular immune response generated by FP85A, when administered individually and sequentially with MVA85A in a prime-boost regime to healthy volunteers, who have previously been vaccinated with BCG.","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB017","September 2007","January 2010","January 2010","April 7, 2008",,"February 9, 2010","CCVTM, University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00653770"
626,"NCT00330304","Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children",,"Completed","No Results Available","Tuberculosis","Drug: Isoniazid|Drug: Cotrimoxazole|Drug: isoniazid|Other: placebo","TB incidence|Mortality|intercurrent infections|adherence|adverse events|antimicrobial resistance","University of Cape Town|University of Stellenbosch|Medical Research Council|Rockefeller Foundation","All","8 Weeks to 15 Years   (Child)","Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Prevention","299/2005","January 2003","November 15, 2011","November 15, 2011","May 26, 2006",,"April 22, 2019","Red Cross Childrens Hospital, Cape Town, Western Cape, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00330304"
627,"NCT03712709","Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test",,"Completed","No Results Available","Tuberculosis, Pulmonary","Diagnostic Test: Truenat MTB","Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB assay|Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB-RIF Dx assay|Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB assay compared to Xpert MTB/RIF|Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB-RIF Dx assay compared to Xpert MTB/RIF|Time to TB detection and RIF resistance detection.","Foundation for Innovative New Diagnostics, Switzerland|Burnet Institute|National Institute for Research in Tuberculosis, Chennai, India|Universidad Peruana Cayetano Heredia|Ethiopian Public Health Institute|PD Hinduja Hospital and Medical Research Centre, Mumbai, India","All","18 Years and older   (Adult, Older Adult)",,"1926","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","7212-03/2","March 12, 2019","July 9, 2020","July 9, 2020","October 19, 2018",,"August 6, 2020","EPHI, Addis Ababa, Ethiopia|State TB and Demonstration Center, Ahmedabad, India|NIRT, Chennai, India|PD Hinduja Hospital, Mumbai, India","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT03712709/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT03712709/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03712709"
628,"NCT06114628","Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","PARADIGM4TB","Recruiting","No Results Available","Pulmonary Tuberculosis","Drug: GSK3036656|Drug: BTZ-043|Drug: Bedaquiline (B)|Drug: Delamanid (D)|Drug: Pretomanid (Pa)|Drug: Moxifloxacin (M)|Drug: Linezolid (L)|Drug: Pyrazinamide (Z)|Drug: Rifampicin (R)|Drug: Isoniazid (H)|Drug: Ethambutol (E)","Rate of change in log10(Time to Positivity of MGIT culture) (Phase 2B)|Favourable/Unfavourable outcome (Phase 2C)|Grade 3/4/5 adverse events (Phase 2B)|Grade 3/4/5 adverse events (Phase 2C)|Serious adverse events (Phase 2B)|Serious adverse events (Phase 2C)|Adverse events of special interest (Phase 2B)|Adverse events of special interest (Phase 2C)|Regimen-related adverse events (Phase 2B)|Regimen-related adverse events (Phase 2C)|Adverse events leading to withdrawal from the study (Phase 2B)|Adverse events leading to withdrawal from the study (Phase 2C)|Adverse events leading to discontinuation of the regimen (AESI) (Phase 2B)|Adverse events leading to discontinuation of the regimen (Phase 2C)|Favourable/unfavourable status (Phase 2B)|Favourable/unfavourable status (Phase 2C)|Time to culture negative status (Phase 2B)|Time to culture negative status (Phase 2C)|Culture conversion measured from Mycobacterial Growth Indicator Tube system (MGIT) liquid culture results (Phase 2B)|Culture conversion measured from Mycobacterial Growth Indicator Tube system (MGIT) liquid culture results (Phase 2C)|PK parameters; Area under the plasma concentration versus time curve (AUC) over 0 to 24 hours|PK parameters; Peak Plasma Concentration (CMax)","University College, London|Radboud University Medical Center|London School of Hygiene and Tropical Medicine|University of Oxford|Research Center Borstel|Lygature|TASK Applied Science|Vita-Salute San Raffaele University|Helmholtz Zentrum Munchen|KNCV Tuberculosis Foundation|Critical Path Institute|European Lung Foundation|Instituto de Saude Publica da Universidade do Porto|University of Liverpool|Institut de Recherche Pour le Developpment|University of Hamburg-Eppendorf|University of California, San Francisco|TB Alliance|Find|University of Milano|University of St Andrews|Uppsala University|European Respiratory Society|Tuberculosis Network European Trialsgroup|Janssen, LP|Otsuka Pharmaceutical Development & Commercialization, Inc.|German Center for Infection Research|LMU University Hospital Munich|University of Cambridge|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","2500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UNITE4TB-01","January 9, 2024","February 24, 2027","August 11, 2027","November 2, 2023",,"January 12, 2024","TASK, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT06114628"
629,"NCT05818059","Active Close Contact Investigation of Tuberculosis Through Computer-aided Detection and Stool Xpert MTB/RIF Among People Living in Ethiopia","CADOOL","Not yet recruiting","No Results Available","Diagnosis|Tuberculosis|geneXpert","Diagnostic Test: Diagnosis of Tuberculosis with computer-aided detection (CAD) software","CAD4TB and Stool GeneXpert Accurancy rate for Diagnosis of TB|Stool GeneXpert and Sputum GeneXpert concordance|Concordance beetwen CAD4TB and Sputum MTB/RIF|TB incidence rate","Doctors with Africa - CUAMM|University of Bari|Armauer Hansen Research Institute, Ethiopia","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","231","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","University of Bari","May 2023","December 31, 2023","December 31, 2024","April 18, 2023",,"April 18, 2023","St Luke Hospital, Wolisso, Oromia, Ethiopia",,"https://ClinicalTrials.gov/show/NCT05818059"
630,"NCT01861730","Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants","C-015-404","Completed","No Results Available","Tuberculosis","Biological: AERAS-404|Biological: Placebo","Investigate the safety of AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants.|Investigate the safety of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants","Aeras|Statens Serum Institut|Sanofi Pasteur, a Sanofi Company|National Institute of Allergy and Infectious Diseases (NIAID)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group","All","64 Days to 196 Days   (Child)","Phase 1|Phase 2","243","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-015-404/ IMPAACT P1113|U01AI068632|C-015-404","July 1, 2013","December 22, 2017","December 22, 2017","May 24, 2013",,"April 9, 2018","PHRU, Chris Hani Baragwanath Hospital, Johannesburg, Guateng, South Africa|Shandukani Research, Johannesburg, Hillbrow, South Africa|KID-CRU, Tygerberg Hospital, Cape Town, Tygerberg, South Africa|South African TB Vaccine Initiative (SATVI), Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT01861730"
631,"NCT02043314","A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: Isoniazida","Average bioequivalence based on the 90% CI","Oswaldo Cruz Foundation","All","18 Years to 50 Years   (Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03.ISZ18-08BE.02","October 2008","October 2008","March 2009","January 23, 2014",,"January 23, 2014","Synchrophar - Ass. e Desenv. de Projetos Clínicos Ltda., Campinas, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02043314"
632,"NCT05021731","Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease",,"Not yet recruiting","No Results Available","Latent Tuberculosis|Kidney Failure","Drug: Rifampicin plus Isoniazid|Drug: Rifapentine plus Isoniazid|Drug: Rifampicin alone","Treatment completion|Permanent discontinuation because of adverse events|Permanent discontinuation because of adverse events related to the treatment|Death","Miguel Santín|Institut d'Investigació Biomèdica de Bellvitge|Instituto de Salud Carlos III|Hospital Universitari de Bellvitge","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PI21/00444","April 20, 2024","April 30, 2025","April 30, 2025","August 25, 2021",,"March 15, 2024",,,"https://ClinicalTrials.gov/show/NCT05021731"
633,"NCT02060006","TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial",,"Unknown status","No Results Available","Tuberculosis","Drug: Meloxicam 7.5mg daily for 8 weeks","Incidence of TB IRIS|Proportion discontinuing Meloxicam due to adverse event|The proportion of patients in each arm with the following indicators of TB-IRIS severity/quality of life (QOL) (degree of pain or discomfort >III|The proportion of patients with local or disseminated suppuration/abscess of any site, unscheduled clinic visits, hospitalizations, missed more than a day at work, etc","University of Stellenbosch|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO13060453","April 2014","April 2015","April 2015","February 11, 2014",,"April 3, 2014","Stellenbosch University Tygerberg Hospital, Cape Town, Western Cape Province, South Africa",,"https://ClinicalTrials.gov/show/NCT02060006"
634,"NCT02075203","Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents",,"Completed","Has Results","Tuberculosis","Biological: AERAS-404|Drug: Placebo|Biological: Bacillus Calmette-Guérin (BCG)","Safety Profile of H4:IC31 and BCG Revaccination in HIV-uninfected, Remotely BCG Vaccinated Adolescents.|Number of Participants Testing Positive for Mtb at Day 84|Rates of Sustained Conversion to Mtb-positive|Percentage of Participants With Immune Response to Vaccine in HIV-uninfected, Remotely BCG-vaccinated Adolescents: o H4:IC31 o BCG Revaccination","Aeras|Sanofi Pasteur, a Sanofi Company","All","12 Years to 17 Years   (Child)","Phase 2","989","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-040-404","February 2014","August 28, 2017","October 6, 2017","March 3, 2014","July 29, 2019","September 4, 2019","South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester, Cape Town, Western Cape, South Africa|Desmond Tutu HIV Foundation (DTHF), Nyanga, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT02075203/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT02075203/SAP_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT02075203/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02075203"
635,"NCT01450085","Chepetsa TB - Reducing TB Among HIV-Infected Malawians",,"Completed","No Results Available","Tuberculosis","Other: GeneXpert|Other: LED Microscopy","Survival of newly-diagnosed HIV-infected patients at 1 year","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1R01AI093316-01A1","September 2012","December 2016","December 30, 2016","October 12, 2011",,"August 18, 2017","Blantyre, Thyolo District, Malawi|Blantyre, Malawi",,"https://ClinicalTrials.gov/show/NCT01450085"
636,"NCT00617643","Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Nevirapine without dose escalation|Drug: Nevirapine initiation with dose escalation","To compare the pharmacokinetics of nevirapine with dose escalation and without dose escalation of nevirapine on day 7, 14 and 21 in patients who are on rifampicin therapy.|Safety and tolerability of nevirapine when administered in HIV-TB coinfected patients receiving rifampicin","Makerere University|University of Liverpool","All","18 Years to 60 Years   (Adult)","Phase 4","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPR 004","May 2008","June 2009","December 2010","February 18, 2008",,"December 6, 2010","Infectious Diseases Institute, Faculty of Medicine, Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00617643"
637,"NCT04089423","FujiLAM Prospective Evaluation Trial",,"Completed","No Results Available","Diagnosis of Tuberculosis in People Living With HIV","Device: Fujifilm SILVAMP TB LAM","Point estimates of sensitivity and specificity of FujiLAM, with 95% confidence intervals, using the defined eMRS.|Point estimates of sensitivity and specificity of FujiLAM, with 95% confidence intervals, using the defined CRS.|Diagnostic yield, with 95% confidence interval, of FujiLAM test among eMRS positive patients and AlereLAM, Smear and Ultra (sputum, urine) as comparators (on Day 1 specimens).","Foundation for Innovative New Diagnostics, Switzerland|Centre for Infectious Disease Research in Zambia|Infectious Diseases Institute, Uganda|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|Swiss Tropical & Public Health Institute|Ifakara Health Institute|University of Cape Town|Viet-Tiep Hospital|National Tuberculosis Control Programme|Fujifilm|Omega Diagnostics|Tuberculosis and Lung Disease Hospital in Hai Phong|The HIV Netherlands Australia Thailand Research Collaboration","All","18 Years and older   (Adult, Older Adult)",,"1731","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","7430-2/1","December 13, 2019","December 31, 2021","December 31, 2021","September 13, 2019",,"January 25, 2022","Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi|CIDRI-Africa University of Cape Town, Cape Town, South Africa|Ifakara Health Institute, Dar es Salaam, Tanzania|The HIV Netherlands Australia Thailand Research collaboration, Bangkok, Bankok, Thailand|Infectious Diseases Institute, Kampala, Uganda|Viet Tiep Hospital, Hải Phòng, Le Chan, Vietnam|Centre for Infectious Disease Research in Zambia, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT04089423"
638,"NCT05807399","PanACEA - STEP2C -01",,"Recruiting","No Results Available","Pulmonary Tuberculosis|Other Specified Pulmonary Tuberculosis","Drug: BTZ-043|Drug: Rifampicin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Moxifloxacin","Time to stable culture conversion to negative in liquid media|Relapse - free survival at 12 months after randomization|Frequency of all adverse events (serious and non-serious)|Frequency of adverse events of Grade 3 severity (severe) or higher|Frequency of adverse events possibly, probably or definitely related to study drug|Frequency of treatment discontinuations or interruptions related to adverse events/serious adverse event|Changes in ECG intervals of PR, RR, QRS, QT, Fridericia-corrected QT [QTcF]|Area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0-24) predicted from limited pharmacokinetic sampling.|The observed maximum concentration (Cmax)|Time to reach Cmax (Tmax)|Minimum observed plasma concentration 24 hours following the last dose (Cmin)|DTG and TFD concentration|Identification of M. tuberculosis complex and Rifampicin (RIF) resistance by PCR (GeneXpert Ultra MTB/RIF®/GeneXpert XDR/HAIN MTBDRplus or similar)|Identification of M. tuberculosis complex and Isoniazid (INH) resistance by PCR (GeneXpert Ultra MTB/RIF®/GeneXpert XDR/HAIN MTBDRplus or similar)|Minimum inhibitory concentrations (MIC) of study drugs the patient was receiving","Michael Hoelscher|Radboud University Medical Center|University of California, San Francisco|University College, London|Ludwig-Maximilians - University of Munich","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PanACEA - STEP2C -01","April 14, 2023","February 23, 2025","February 23, 2025","April 11, 2023",,"March 22, 2024","Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon|Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi|Instituto Nacional de Saúde (INS), Maputo, Mozambique|TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa|Ifakara Health Institute (IHI), Bagamoyo, Tanzania|National Institute for Medical Research (NIMR-MMRC), Mbeya, Tanzania|Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania|Makerere University Lung Institute Limited, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05807399"
639,"NCT02109874","A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)","C-011-404","Completed","No Results Available","Tuberculosis","Biological: AERAS-404 (mcg H4/nmol IC31)|Biological: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl","Evaluate the safety of two injections of AERAS 404 prepared with four escalating amounts of antigen in healthy adult subjects. Safety will be measured by number (percentage) and severity of SAEs.|Evaluate the immunogenicity of two injections of AERAS 404 prepared with four escalating amounts of antigen in healthy adult subjects. Immune response will be based on percentage of CD4+ and CD8+ cells.","Aeras|Statens Serum Institut","All","18 Years to 50 Years   (Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","C-011-404","December 2008","December 2010","September 2012","April 10, 2014",,"April 27, 2016","South African Tuberculosis Vaccine Institute; Brewelskloof Hospital, Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT02109874"
640,"NCT02337270","Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol",,"Completed","No Results Available","Tuberculosis","Biological: Ad5Ag85A","Number of participants reporting adverse events|Immunogenicity of one of two doses of Ad5Ag85A administered by aerosol|Immunogenicity of inhaled administration of Ad5Ag85A compared with intramuscular administration|Number of participants reporting adverse events with inhaled administration of Ad5Ag85A compared with intramuscular administration|Immune responses measured from induced sputum compared with bronchoalveolar lavage|immune responses measured from induced sputum compared with bronchoalveolar lavage|Number of participants developing a positive interferon release assay for TB after vaccination with Ad5Ag85A|Number of participants reporting adverse events correlated with level of pre-existing anti-adenoviral antibodies|Immune response to vaccination correlated with pre-existing anti-adenoviral antibodies|Number of participants reporting adverse effects correlated with dose of vaccine received by inhalation|Immune response to vaccine correlated with dose of vaccine received by inhalation","McMaster University|Canadian Institutes of Health Research (CIHR)","All","18 Years to 55 Years   (Adult)","Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","M002","September 5, 2017","September 7, 2021","September 7, 2021","January 13, 2015",,"November 1, 2021","McMaster University Medical Centre, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02337270"
641,"NCT03881228","Patient Centered Intervention to Prevent Tuberculosis Among Children Under Five Years Old",,"Recruiting","No Results Available","Tuberculosis|Pediatric ALL|Behavior, Health","Behavioral: Increasing the completion of IPT","Isoniazid preventive treatment completion at week 24 recorded in treatment card|Isoniazid preventive treatment completion at week 20 recorded in treatment card|Questionnaire on self reported adherence to daily treatment","Universidad Peruana Cayetano Heredia","All","1 Day to 100 Years   (Child, Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","103161","December 1, 2019","December 2022","December 15, 2023","March 19, 2019",,"May 23, 2022","Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT03881228"
642,"NCT00571753","Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)",,"Terminated","No Results Available","Pulmonary Tuberculosis","Drug: isoniazid","Incidence of early treatment failure, defined as continuous or recurrently positive sputum cultures|Further adverse events of isoniazid|Time course of sputum conversion|Duration of hospitalization","University of Cologne","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IDANAT2|EUDRACT Number:2007-000224-41","June 2008","December 2011","February 2012","December 12, 2007",,"February 28, 2011","Specialized Hospital for Active Treatment of Pulmonary Diseases ""Sveta Sofia"", Sofia, Bulgaria|Zentralkrankenhaus Bad Berka GmbH, Bad Berka, Germany|Karl-Hansen-Klinik, Bad Lippspringe, Germany|Helios Klinikum Emil von Behring GmbH, Berlin, Germany|Medizinische Klinik I, Abteilung Pneumologie/Allergologie, Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Germany|Abteilung Innere Medizin/ Pneumologie, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Lungenfachklinik Immenhausen, Immenhausen, Germany|Department I of Internal Medicine, University Hospital, University of Cologne, Köln, Germany|Diakoniekrankenhaus Rotenburg, Rotenburg, Germany|Division of Infectious Diseases and Clinical Immunology, Department of Internal Medicine, Ulm, Germany|Specialized Hospital of Lung Diseases and Tuberculosis in Wielkopolska in Chodzież, Chodzież, Poland|Department of Pulmonal Diseases, K. Marcinkowski University of Medical Sciences, Poznan, Poland",,"https://ClinicalTrials.gov/show/NCT00571753"
643,"NCT05412212","Brief Educational Video for Patients Prescribed LTBI Treatment",,"Active, not recruiting","No Results Available","Latent Tuberculosis","Other: LTBI video intervention","Treatment completion|Treatment initiation|Treatment initiation by treatment regimen|Treatment completion by treatment regimen|Video Watch Completion|Video Accessibility|Understanding of Treatment Importance","Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1902","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","12324","June 3, 2022","December 30, 2024","February 28, 2025","June 9, 2022",,"January 18, 2024","Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena, California, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/12/NCT05412212/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT05412212"
644,"NCT02074956","A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults",,"Completed","No Results Available","Tuberculosis","Biological: AERAS-404|Biological: Placebo","Safety profile of two injections of AERAS 404 at different dose levels of antigen and adjuvant.|Immunogenicity of two injections of AERAS 404 at different dose levels of antigen and adjuvant.","Aeras|Statens Serum Institut","All","18 Years to 45 Years   (Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C 006 404|C-006-404","May 2008","October 2009","October 2009","February 28, 2014",,"March 17, 2014","University of Tampere Vaccine Research Clinic, Biokatu, Tampere, Finland",,"https://ClinicalTrials.gov/show/NCT02074956"
645,"NCT00541294","Diagnosis of Tuberculosis Infection in HIV Co-infected Children","ThrasherIGRA","Completed","No Results Available","Latent Tuberculosis Infection|Tuberculosis|HIV Infections",,,"Case Western Reserve University|Thrasher Research Fund","All","3 Months to 15 Years   (Child)",,"250","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RES104272","January 15, 2008","February 22, 2011","February 22, 2011","October 10, 2007",,"January 18, 2022","Despond TuTu TB Centre, Stellenbosch University, Tygerberg, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00541294"
646,"NCT00810849","A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis","IMPI","Completed","No Results Available","Tuberculous Pericarditis","Drug: Prednisolone|Biological: Mycobacterium w immunotherapy","Composite end-point of death, constriction, or cardiac tamponade requiring pericardial drainage.|Safety of immunomodulatory treatment|The secondary efficacy outcomes are the individual components of the composite primary outcome (i.e., death, constriction, and cardiac tamponade requiring pericardiocentesis), and all-cause hospitalization.","University of Cape Town|Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","1400","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IMPI-TRIAL1","December 2008","February 2014","August 2014","December 18, 2008",,"September 3, 2014","Groote Schuur Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00810849"
647,"NCT02021747","Biologic Basis Of Increased Susceptibility Of Smokers To Pulmonary Infection With Mycobacterium Tuberculosis",,"Withdrawn","No Results Available","Tuberculosis|Chronic Obstructive Pulmonary Disease",,"Alveolar Macrophage","Weill Medical College of Cornell University|Hamad Medical Corporation|Weill Cornell Medical College in Qatar","All","18 Years to 60 Years   (Adult)",,"0","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-00055 [JIRB]|NPRP 5-400-3-107|11262/11","January 2014","October 2016","October 2016","December 27, 2013",,"May 24, 2017","Hamad Medical Corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT02021747"
648,"NCT04552015","Microneedles for Diagnosis of LTBI",,"Terminated","No Results Available","Latent Tuberculosis","Diagnostic Test: TST vs PPD microneedle test","size of induration at 48 hours post-PPD injection","The HIV Netherlands Australia Thailand Research Collaboration|National Nanotechnology Center (NANOTEC), The National Science and Technology Development Agency (NSTDA)","All","20 Years to 60 Years   (Adult)","Not Applicable","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HIV-NAT 276","April 8, 2021","October 1, 2022","October 1, 2022","September 17, 2020",,"March 1, 2023","Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT04552015"
649,"NCT04260477","Novel Triple-dose Tuberculosis Retreatment Regimen","Tri-Do-Re","Active, not recruiting","No Results Available","Multidrug-resistant Tuberculosis|Pulmonary Tuberculosis|Tuberculosis|Resistance to Tuberculostatic Drugs","Drug: 6EH³R³Z|Drug: 6EHRZ","number of patients with any grade 3-5 Adverse Event (AE) during treatment, assessed as probably or definitely related to TB treatment|Describe bacterial effectiveness specific|Describe acquired resistance specific|number of previously treated patients with H-monoresistance and H-polyresistance, rifampicin (RMP) resistance missed by Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF)|Programmatical effectiveness:number of participants with treatment success divided by number of participants with failure, death, or Lost to follow-up (LTFU)|Clinical effectiveness: number of participants with treatment success, divided by number of participants with failure or death|Bacteriological effectiveness : number of participants with treatment success, divided by number of participants with failure|number of participants with acquired resistance, to Isoniazid (INH) and/or RMP|number of participants with stable (without reversion) SSM conversion|number of participants with drug-induced hepatotoxicity|number of participants with any TB treatment change due to drug-induced hepatoxicity|number of participants with any TB treatment change due to AE|number of participants with any grade 3-5 AE|number of participants with any Serious Adverse Event (SAE)","Institute of Tropical Medicine, Belgium|Damien Foundation","All","Child, Adult, Older Adult","Phase 3","370","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ITM202001","March 1, 2021","June 2025","September 2025","February 7, 2020",,"February 15, 2024","Damien Foundation, Niamey, Niger",,"https://ClinicalTrials.gov/show/NCT04260477"
650,"NCT04620772","Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis",,"Not yet recruiting","No Results Available","Tuberculosis|Tubercular Meningitis|Arachnoiditis; Tuberculous (Etiology)","Drug: Cyclophosphamide injection","Functional independece at 6 months|Independent ambulation|Improvement in modified Rankin scale|Improvement in visual acuity (1)|Improvement in visual acuity (2)|Improvement in visual acuity (3)|Improvement in sphincter function|Change in mRS|Patient well being|Life threatening infections|Infections needing hospitalization|Flare up of TB|Cytopenias|Transaminitis|Hemorrhagic cystitis|Adverse effects","All India Institute of Medical Sciences, New Delhi","All","14 Years to 60 Years   (Child, Adult)","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IEC-975/03.10.2020","January 1, 2021","December 31, 2023","December 31, 2024","November 9, 2020",,"December 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04620772"
651,"NCT00414882","A Cluster-Randomized Trial of DOTS vs DOTS Plus Active Case Finding",,"Completed","No Results Available","Mycobacterium Tuberculosis",,,"National Institute of Allergy and Infectious Diseases (NIAID)","All","up to 99 Years   (Child, Adult, Older Adult)",,"200000","NIH","Observational","Time Perspective: Prospective","06-0017","July 10, 2007","June 28, 2009","June 2012","December 22, 2006",,"January 31, 2019","Municipal Health Department, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00414882"
652,"NCT06057519","Pragmatic Optimized Rifampicin Trial","PORT","Recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: Optimised dose rifampicin|Drug: Standard dose rifampicin","Incidence of hepatotoxicity|Adverse events|Treatment outcome|Culture conversion rate|PK parameter, AUC0-24|PK parameter, Cmax|PK parameter, Tmax|PK parameter, Clearance|PK parameter, Volume of distribution|PK parameter, T1/2","Radboud University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","164","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PORT- 01","January 16, 2024","December 31, 2025","December 31, 2025","September 28, 2023",,"February 13, 2024","Radboud University Medical Centre, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT06057519"
653,"NCT03736278","Characteristics of Tuberculosis Infection in Rheumatic Disease",,"Completed","No Results Available","Tuberculosis|Autoimmune Diseases","Other: No intervention","Mortality","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","201805069RIND","November 10, 2018","November 30, 2018","September 24, 2019","November 9, 2018",,"December 11, 2019","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03736278"
654,"NCT05926466","BTZ-043 Dose Evaluation in Combination and Selection","DECISION","Recruiting","No Results Available","Tuberculosis, Pulmonary|Other Specified Pulmonary Tuberculosis","Drug: BTZ-043|Drug: Bedaquiline|Drug: Delamanid|Drug: Moxifloxacin","Time to positivity in BD MGIT liquid culture|Time to stable culture conversion to negative in liquid media|Proportion of participants converting to negative sputum culture in liquid media|Frequency of all adverse events (serious and non-serious)|Frequency of adverse events of Grade 3 severity (severe) or higher|Frequency of adverse events possibly, probably or definitely related to study drug|Frequency of treatment discontinuations or interruptions related to adverse events/serious adverse event|Changes in ECG intervals of PR, RR, QRS, QT, Fridericia-corrected QT [QTcF]|Area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0-24)|The observed maximum concentration (Cmax)|Time to reach Cmax (Tmax)|Minimum observed plasma concentration 24 hours following the last dose (Cmin)|Apparent oral clearance (Cl/F)|Terminal half-life (t 1/2)|Identification of M. tuberculosis complex and Isoniazid (INH) resistance by PCR (GeneXpert Ultra MTB/RIF®/ GeneXpert XDR/HAIN MTBDRplus or similar)|Minimum inhibitory concentrations (MIC) of study drugs the patient was receiving","Michael Hoelscher|Radboud University Medical Center|University of California, San Francisco|University College, London|Ludwig-Maximilians - University of Munich","All","18 Years to 64 Years   (Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMU-IMPH-BTZ-043-04|UNITE4TB-02","September 21, 2023","August 2024","August 2024","July 3, 2023",,"December 22, 2023","TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa|TASK Applied Science Eden, George, South Africa|National Institute for Medical Research (NIMR-MMRC), Mbeya, Tanzania|National Institute for Medical Research (NIMR-Mwanza),, Mwanza, Tanzania",,"https://ClinicalTrials.gov/show/NCT05926466"
655,"NCT05325125","Childhood TB Sequel",,"Recruiting","No Results Available","Tuberculosis, Pulmonary",,"Change in self- or parent-reported respiratory symptoms|Lung function measured by spirometry","London School of Hygiene and Tropical Medicine|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","up to 19 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","22613","March 29, 2022","June 2024","June 2024","April 13, 2022",,"September 13, 2023","MRCG at LSHTM, Fajara, Gambia",,"https://ClinicalTrials.gov/show/NCT05325125"
656,"NCT00115609","Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: efavirenz|Drug: tenofovir DF|Drug: emtricitabine","treatment success rate at week 48 (W48)|course of plasma HIV-1 RNA between W0 and W48|tuberculosis cure rate|safety of trial treatments (number of events, description, time to onset, metabolic disorders, immune restoration syndrome)|frequency of treatment changes or discontinuations|clinical progression of HIV infection|course of CD4 and CD8 T lymphocytes|study of resistance in the case of virological failure|study of compliance and quality of life|pharmacokinetic study of tuberculostatic agents|effect of treatment on hepatitis B viral replication","French National Agency for Research on AIDS and Viral Hepatitis","All","18 Years and older   (Adult, Older Adult)","Phase 3","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-002470-30|ANRS129 BKVIR","January 2006","November 2009","November 2009","June 24, 2005",,"December 22, 2011","Service des maladies Infectieuses et tropicales Hopital Necker-Enfants Malades, Paris, France",,"https://ClinicalTrials.gov/show/NCT00115609"
657,"NCT01761201","""Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients"".","FLISH-ILT","Terminated","No Results Available","Latent Tuberculosis Infection|Infection in Solid Organ Transplant Recipients","Drug: Levofloxacin|Drug: Isoniazid","Difference in incidence of tuberculosis disease|Mortality|Toxicity|Retransplantation|Graft dysfunction|Transplant rejection","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Phase 3","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FLISH-ILT|2010-022302-41","January 2012","February 2014","February 2014","January 4, 2013",,"August 6, 2014","Complejo Hospitalario de Albacete, Albacete, Spain|Hospital Infanta Cristina,, Badajoz, Spain|Hospital Clinic, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Cruces, Bilbao, Spain|Complejo Hospitalario Universitario, Coruña, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital universitario Virgen de las Nieves, Granada, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Carlos Haya, Málaga, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Marqués de Valdecillas, Santander, Spain|Hospital Virgen del Rocío, Seville, Spain|Hospital Universitario La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01761201"
658,"NCT00257907","Immune Response to Mycobacterium Tuberculosis Infection",,"Completed","No Results Available","Latent Tuberculosis",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"157","NIH","Observational",,"060030|06-I-0030","November 18, 2005",,"February 24, 2016","November 23, 2005",,"April 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Mali-NIAID HIV Research Initiative FMPOS, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT00257907"
659,"NCT01503099","Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease",,"Unknown status","No Results Available","Intestinal Tuberculosis|Pulmonary Tuberculosis|Crohn's Disease",,"Calprotectin levels in patients with active intestinal tuberculosis|Levels of calprotectin in patients with intestinal tuberculosis after antituberculous therapy.","Lovisenberg Diakonale Hospital|Helse Sor-Ost|The Unger-Vetlesen Medical Fund, Jersey, C.I|Odd Fellow Medical Fund, Norway","All","18 Years and older   (Adult, Older Adult)",,"550","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","LDS 150","October 2009","December 2011","December 2012","January 2, 2012",,"January 2, 2012","Population Health & Research Institiute, Medical College, Trivandrum, Kerala, India|Lovisenberg Diakonal Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01503099"
660,"NCT01611402","Gene Expression in HIV and Tuberculosis Co-infection",,"Completed","No Results Available","Tuberculosis",,"Identify blood mRNA expression profiles distinguishing TB onoinfectedfrom TB/HIV co-infected patients (ART-naive and ART-treated with and without TB-IRIS).|Correlate gene expression levels with clinical and laboratory variablesincluding flow cytometry and soluble biomarkers.|Quantify the tuberculosis antigen load at the beginning of anti-TB therapy by lateral flow lipo-arabinomannan assay (TB-LAM LFA) and study how the antigen burden affects the disease presentation (including radiographic findings), or transcriptio...|Study separated cell populations (monocytes, dendritic cells, NK, T cell subsets or neurtrophils) to validate any identified transcriptional signature or to further investigate pathogen-specific responses.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"96","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","120142|12-I-0142","May 29, 2012",,"April 6, 2016","June 5, 2012",,"April 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01611402"
661,"NCT01315301","Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis","TB-HAART","Unknown status","No Results Available","Acquired Immunodeficiency Syndrome|Tuberculosis","Other: Comparison of different treatment strategies","mortality|Tuberculosis-Immune Reconstitution Inflammatory Syndrome|New AIDS defining clinical events|Drug Induced Liver toxicity|Virologic success","Karolinska Institutet|Addis Ababa University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SWE-2007-270","August 2008","January 2012","March 2012","March 15, 2011",,"March 15, 2011","Tikur Anbessa (Black Lion) Hospital, Addis Ababa, Ethiopia",,"https://ClinicalTrials.gov/show/NCT01315301"
662,"NCT06159023","Conventional Bronchoscope With BAL vs. Thin Bronchoscope With BW to Diagnose Pulmonary TB",,"Not yet recruiting","No Results Available","Tuberculosis, Pulmonary","Device: bronchial washing using a thin bronchoscope","TB detection rate|Mycobacterium tuberculosis culture|AFB(acid-fast bacilli) smear|Adverse event|Time to treatment","Pusan National University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","TBBR trial","December 15, 2023","December 31, 2024","December 31, 2025","December 6, 2023",,"December 6, 2023","Pusan National University Hospital, Busan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT06159023"
663,"NCT01986543","Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection","RIFAVIRENZ","Unknown status","No Results Available","Tuberculosis|HIV","Drug: drug administration","Efavirenz through concentration before drug intake (Cmin); maximal concentration (Cmax); time to achieve the Cmax (Tmax) and area under the curve of concentrations vs time at steady state during a 24-hour dosing interval (AUC0-24)|Efavirenz Cmin; Cmax; Tmax; AUC0-24|Pharmacokinetic parameters of R and H (Cmin, Cmax and AUC0-24)|Mycobacterium tuberculosis culture of sputum|Plasma HIV-1 RNA|Grade 3 and 4 adverse events","ANRS, Emerging Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 12292 RIFAVIRENZ","December 2013","December 2017","December 2017","November 18, 2013",,"July 11, 2017","Mbarara Research Base, Mbarara PO box 1956, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT01986543"
664,"NCT04930978","Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis","COVID-19-TB","Recruiting","No Results Available","COVID-19 Respiratory Infection|Pulmonary Tuberculoses",,"Number of participants with active TB|Number of participants with COVID-19 infection|Number of participants with SARS-CoV-2 antibodies|Differences in immune responses between the groups","Tuberculosis Research Centre, India","All","18 Years to 65 Years   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020 041","June 21, 2021","June 20, 2024","June 20, 2024","June 18, 2021",,"November 22, 2023","National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT04930978"
665,"NCT06272812","A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.",,"Not yet recruiting","No Results Available","Tuberculosis (TB)","Biological: MTBVAC|Biological: Placebo","To evaluate the protective efficacy of of MTBVAC against bacteriologically confirmed pulmonary TB disease, diagnosed by more than one diagnostic test with sputum obtained before initiation of TB treatment as compared to placebo.|To evaluate the protective efficacy of one dose of MTBVAC against bacteriologically confirmed pulmonary TB disease, not associated with HIV infection, diagnosed with sputum obtained before initiation of TB treatment, as compared to placebo.|To evaluate the protective efficacy of MTBVAC candidate vaccine against definite Xpert MTB/RIF Ultra positive pulmonary TB disease diagnosed with sputum obtained before initiation of TB treatment, as compared to placebo.|To evaluate the protective efficacy of one dose of MTBVAC candidate vaccine against clinical TB, as compared to placebo|To assess the safety and reactogenicity of one dose of MTBVAC candidate vaccine.|To assess the immunogenicity of one dose of the MTBVAC candidate vaccine via assessment of humoral and cell-mediated immune (CMI) responses in a subset of the enrolled participants.","International AIDS Vaccine Initiative|Biofabri, SLU|Universidad de Zaragoza","All","14 Years to 45 Years   (Child, Adult)","Phase 2","4300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IAVI C113","September 2024","March 2028","March 2028","February 22, 2024",,"February 22, 2024",,,"https://ClinicalTrials.gov/show/NCT06272812"
666,"NCT00727844","Linezolid to Treat Extensively-Drug Resistant Tuberculosis",,"Completed","Has Results","Pulmonary Tuberculosis|Multidrug Resistant Tuberculosis|Extensively Drug Resistant Tuberculosis","Drug: Immediate Start Linezolid|Drug: Delayed Start Linezolid","Number of Patients Converted to Sputum Culture Negative in Each Arm, With Data Censored at 4 Months.","National Institute of Allergy and Infectious Diseases (NIAID)","All","20 Years and older   (Adult, Older Adult)","Phase 2","41","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-I-N167","July 2008","October 2012","November 2014","August 4, 2008","February 24, 2014","March 14, 2016","National Masan Tuberculosis Hospital, Changwon, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00727844"
667,"NCT00931736","Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness",,"Completed","No Results Available","Latent Tuberculosis Infection","Drug: Isoniazid|Drug: Rifampin","Confirmed active TB during 28 months after randomization|Confirmed active TB in compliant participants|Probable and confirmed active TB|Rate of Grade 3 & 4 adverse events|Comparative cost-effectiveness of regimens|Occurrence of drug resistance in confirmed cases of active TB","McGill University|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 3","6031","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCT-94831|ISRCTN05675547","August 2009","April 2017","April 2017","July 2, 2009",,"December 19, 2017","Woolcock Institute of Medical Research, Sydney, New South Wales, Australia|Centre de Pneumophthysiologie, Cotonou, Benin|Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde, Rio de Janeiro, Brazil|University of Alberta, Edmonton, Alberta, Canada|British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada|Montreal Chest Institute, Montreal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Research and Development Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana|Service de Phtisiologie, Hopital National Ignace Deen, Conakry, Guinea|Health Research Unit, Faculty of Medicine, Bandung, West Java, Indonesia|Korean Institute of Tuberculosis, Seoul, Korea, Republic of|King Fahad National Guard Hospital, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT00931736"
668,"NCT01331811","Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)",,"Completed","No Results Available","HIV|Tuberculosis|Pediatrics","Other: Development of a diagnosis algorithm","Tuberculosis diagnostic algorithm|Evaluation of the QuantiFERON(R)-TB Gold In-Tube|Comparison of two in-vitro IGRAs|Percentage of TB diagnosis sampling procedures actually performed|Evaluation of the morbidity (IRIS, drug toxicity and other opportunistic infections) and mortality in TB-HIV co-infected children|Specificity and sensibility of TB diagnosis sampling procedures compared to TB diagnosis gold standard (sputum or gastric aspirate culture)|Evaluation of the Xpert MTB/RIF assay|Comparison of the Xpert MTB/RIF test to the gold standard (culture of gastric aspirates or sputum)|Comparison of the performance Xpert MTB/RIF assay on sampling methods other than the reference method (gastric aspirate and sputum)","ANRS, Emerging Infectious Diseases|Institut Pasteur, Cambodia|National Pediatric Hospital, Cambodia|Angkor Hospital for Children|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam|Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam|Number 2 Children's Hospital, Ho Chi Minh City|Hôpital Necker-Enfants Malades, Paris, France|Groupe Hospitalier Pitie-Salpetriere|CHRU Arnaud de Villeveuve, Montpellier, France|IRD, Yaounde, Cameroon|Fondation Chantal Biya,Yaounde, Cameroon|CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso|Centre Muraz|Centre Pasteur du Cameroun|Centre Hospitalier D'essos","All","up to 13 Years   (Child)","Not Applicable","441","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ANRS12229 PAANTHER 01","April 2011","March 2014","May 2014","April 8, 2011",,"August 5, 2015","CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso|National Pediatric Hospital, Phnom Penh, Cambodia|Angkor Hospital for Children, Siem Reap, Cambodia|Centre Hospitalier d'Essos, Yaounde, Cameroon|Centre Mère Enfant Chantal Biya, Yaounde, Cameroon|Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam|Pediatric Hospital Nhi Dong 2, Ho Chi Minh City, Vietnam|Pham Ngoc Thach Hospital, Ho chi Minh ville, Vietnam",,"https://ClinicalTrials.gov/show/NCT01331811"
669,"NCT05122624","A Clinical Risk Score for Early Management of TB in Uganda","PredicTB","Completed","No Results Available","Tuberculosis, Pulmonary","Other: PredicTB score","Difference in 7-day treatment initiation (pre-post)|Implementation: proportion of encounters in which PredicTB is used as indicated|Incremental cost-effectiveness of PredicTB|Difference in TB mortality (pre- post)|Difference in loss to care (pre- post)|Difference in differences of 7- day treatment initiation (pre- post)|Reach: proportion of same-day treatment initiation|Adoption: proportion of providers adopting PredicTB|Maintenance: change in effectiveness over time|Modeled changes in 5-year mortality with PredicTB","Johns Hopkins Bloomberg School of Public Health|National Institute of Allergy and Infectious Diseases (NIAID)","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","1206","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R21AI161301|IRB00015699","November 10, 2021","July 15, 2023","February 29, 2024","November 17, 2021",,"April 4, 2024","Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05122624"
670,"NCT01811823","Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","TIV_HIV_TB","Completed","No Results Available","Influenza|HIV|Tuberculosis","Biological: Trivalent Inactivated Influenza Vaccine","humoral antibody responses, measured by hemagglutinin inhibition assay (HAI), to each of three strains included in the seasonal non-adjuvanted trivalent influenza vaccine.|• To compare the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on vaccine-strain specific cell mediated immune responses, evaluated by ELISPOT assay, following non-adjuvanted TIV vaccination.","University of Witwatersrand, South Africa","All","18 Years to 55 Years   (Adult)","Phase 4","301","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","TIV_HIV_TB","March 31, 2014","November 20, 2014","November 20, 2014","March 15, 2013",,"September 5, 2018","Respiratory and Meningeal Pathogens research unit, Johannesburg, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT01811823"
671,"NCT01252537","Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia",,"Completed","No Results Available","HIV Infection|Tuberculosis|Immunosuppression",,"Correlation between degree of immunosuppression measured by clinical scoring and CD4 cell count at baseline|Correlation between degree of immunosuppression measured by clinical scoring and CD4 cell count at baseline and outcome of tuberculosis treatment|Correlation between plasma immune activation markers and degree of immunosuppression","Lund University|Swedish International Development Cooperation Agency (SIDA)|Swedish Agency for Civil Contingencies","All","18 Years and older   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LU 2010/14","September 2010","March 2012","January 2014","December 3, 2010",,"April 23, 2014","Adama Health Centre, Adama, Oromia, Ethiopia|Bishoftu hospital, Bishoftu, Oromia, Ethiopia|Dukem Health Centre, Dukem, Oromia, Ethiopia|Mojo Health Centre, Mojo, Oromia, Ethiopia|Welenchiti Health Centre, Welenchiti, Oromia, Ethiopia",,"https://ClinicalTrials.gov/show/NCT01252537"
672,"NCT04044001","BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)",,"Completed","No Results Available","Pulmonary Tuberculoses|Other Specified Pulmonary Tuberculosis","Drug: BTZ-043|Drug: Rifafour e-275®|Drug: Probe Drug Cocktail|Drug: Dolutegravir 50mg Tab","Safety and tolerability of BTZ-043|Bactericidal Activity Endpoint - MGIT|Bactericidal Activity Endpoint - CFU|Bactericidal Activity Endpoint - LAM|Bactericidal Activity Endpoint - MBLA|Pharmacokinetic Endpoint - BTZ-043 - AUC|Pharmacokinetic Endpoint - BTZ-043 - Cmax|Pharmacokinetic Endpoint - BTZ-043 - Tmax|Pharmacokinetic Endpoint - BTZ-043 - Cmin|Pharmacokinetic Endpoint - BTZ-043 - Cl|Pharmacokinetic Endpoint - BTZ-043 - Vd|Pharmacokinetic Endpoint - BTZ-043 - T1/2|Pharmacokinetic Endpoint - BTZ-043 - pharmacodynamics (PD)|Pharmacokinetic Endpoint - Population PK AUC|Pharmacokinetic Endpoint - Population PK Cmax|Pharmacokinetic Endpoint - Food Effect PK AUC|Pharmacokinetic Endpoint - Food Effect PK Cmax|Pharmacokinetic Endpoint - Probe Drugs PK AUC|Pharmacokinetic Endpoint - Probe Drugs PK Cmax","Michael Hoelscher|European and Developing Countries Clinical Trials Partnership (EDCTP)|Radboud University Medical Center|German Federal Ministry of Education and Research|Ludwig-Maximilians - University of Munich","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","77","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PanACEA-BTZ-043-02","November 15, 2019","March 3, 2022","May 31, 2022","August 2, 2019",,"August 10, 2022","TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa|University of Cape Town Lung Institute (UCTLI), Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT04044001"
673,"NCT00057421","Tuberculosis in HIV Infected Patients in Uganda",,"Completed","No Results Available","Tuberculosis|HIV Infections","Drug: prednisolone",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 60 Years   (Adult)","Phase 2","190","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","R01AI032414","November 1998",,"September 2002","April 3, 2003",,"September 18, 2007","Mulago Hospital Tuberculosis Clinic, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00057421"
674,"NCT00685360","A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)",,"Completed","Has Results","Tuberculosis, Pulmonary|Tuberculosis, Multidrug Resistant|Extensively Drug-Resistant Tuberculosis","Drug: Delamanid|Drug: Optimized Background Regimen (OBR)|Drug: Placebo","Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) Using the Mycobacteria Growth Indicator Tube (MGIT) System|Tmax 1 and 2: Time to Maximal Peak Concentration (Tmax) for Delamanid Following First and Second Daily Dose|Cmax 1 and 2: Maximal Peak Concentration (Cmax) for Delamanid Following First and Second Daily Dose|Area Under the Plasma Concentration Curve From 0 to 24 Hours (AUC0-24h) for Delamanid|Accumulation Ratio for Cmax (Rac[Cmax]) for Delamanid|Accumulation Ratio for AUC From Time 0 to 24 Hours (Rac[AUC0-24h]) for Delamanid|Time to Maximal Peak Concentration (Tmax) for Delamanid Metabolite (DM)-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722|Maximal Peak Concentration (Cmax) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722|Area Under the Plasma Concentration Curve From 0 to 24 Hours (AUC0-24h) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722|Accumulation Ratio for Cmax (Rac[Cmax]) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722|Accumulation Ratio for AUC (Rac[AUC]) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722|Elimination Half-life (t1/2) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722|Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) Using Solid Culture Media|Change From Baseline in Time to Culture Positivity Using the MGIT System|Area Under the Curve (AUC) of Change From Baseline in Time to Culture Positivity in the MGIT System|Percentage of Participants With Sputum Culture Negative at Day 57 Using the MGIT System Without Consideration of Subsequent Culture Results|Percentage of Participants With Sputum Culture Negative at Day 57 and Day 84 Using the MGIT System Without Respect to Interim Culture Results|Percentage of Participants With Sputum Culture Negative at Day 57 Using Solid Culture Media Without Respect to Subsequent Culture Results|Percentage of Participants With Sputum Culture Negative at Day 57 and Day 84 Using Solid Culture Media Without Respect to Interim Culture Results|Percentage of Participants Who Achieved SCC From the MGIT System Analyzed by Cochran-Armitage Linear Trend Test for Dose-response Relationship|Percentage of Participants Who Achieved Initial SCC Using the MGIT System|Percentage of Participants Who Achieved Initial SCC Using the Solid Culture Media|Percentage of Participants Who Achieved Final SCC Using MGIT|Percentage of Participants Who Achieved Final SCC Using Solid Culture Media|Percentage of Participants With Clinically Significant Physical Examination Findings, Including Vision and Neuropsychiatric Assessments|Percentage of Participants With Clinically Significant Vital Sign Abnormalities|Percentage of Participants With Categorical Changes in 12-lead Electrocardiogram Results at Day 56|Percentage of Participants With Clinically Significant Laboratory Test Abnormalities|Percentage of Participants With Clinically Significant Audiometry Findings|Percentage of Participants Using Concomitant Medications|Percentage of Participants With At Least One Treatment-Emergent Adverse Events (TEAEs)|Time-matched Change From Baseline (Day -1) in QTcF at Day 56|Mean Change From Baseline in QTcF|Mean Change From Baseline in QTcB|Mean Change From Baseline in Ventricular Rate|Mean Change From Baseline in PR Interval|Mean Change From Baseline in QRS Interval|Mean Change From Baseline in QT Interval|Percentage of Participants With Change in ECG Morphological Patterns From Baseline","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 64 Years   (Adult)","Phase 2","481","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","242-07-204|2007-005229-31","May 8, 2008","June 11, 2010","June 11, 2010","May 28, 2008","December 1, 2021","December 1, 2021","University of Texas Health Center at Tyler / Heartland National TB Center / Texas Center for Infectious Disease, San Antonio, Texas, United States|Beijing Chest Hospital, Beijing, China|Shanghai Pulmonary Hospital, Shanghai, China|Abbassia Chest Hospital, Cairo, Egypt|North Estonian Medical Centre Foundation, Tallinn, Estonia|Tartu University Lung Hospital, Tartu, Estonia|Kinki Chuo Chest Hospital, Osaka, Japan|Fukujuji Hospital, Tokyo, Japan|Masan Medical Center, Changwon, Korea, Republic of|National Masan Hospital, Masan, Korea, Republic of|Younsei University Medical Center (YUMC), Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clinic of Tuberculosis and Lung Diseases, Riga, Latvia|Hospital Nacional Daniel Alcides Carrión, Carrion, Peru|Hospital Nacional Sergio E. Bernales, Lima, Peru|Hospital Nacional Hipolito Unanue, Unanue, Peru|Tropical Disease Foundation, Manila, Philippines",,"https://ClinicalTrials.gov/show/NCT00685360"
675,"NCT00953927","A Study of MVA85A in Healthy Infants",,"Completed","Has Results","Tuberculosis","Biological: MVA85A/AERAS-485|Biological: Candida Skin Test Antigen","To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants.|To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants.|To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells.|To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials.|To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay.|To Discover Correlates of Protection From Tuberculosis in Infants Vaccinated With MVA85A/AERAS-485.|To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial.","Aeras|University of Oxford|University of Cape Town","All","126 Days to 182 Days   (Child)","Phase 2","2797","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-020-485|Oxford TB020","July 2009","October 2012",,"August 6, 2009","December 12, 2013","May 24, 2016","South African Tuberculosis Vaccine Initiative (Satellite), Ceres, South Africa|South African Tuberculosis Vaccine Initiative (Satellite), Robertson, South Africa|South African Tuberculosis Vaccine Initiative (Headquarters), Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT00953927"
676,"NCT02898623","Serological Test for the Diagnosis of TB","MycoTB","Terminated","No Results Available","Active Tuberculosis","Other: No intervention","Positive and negative predictive values for the diagnosis of active TB","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","9179","December 20, 2013","December 20, 2014","June 20, 2015","September 13, 2016",,"December 10, 2021","University Hospital Montpellier Department of microbiology, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02898623"
677,"NCT03787940","Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis",,"Unknown status","No Results Available","Tuberculous Meningitis","Drug: Isoniazid","Number of Participants with death or severe disability|days for coma-clearance time|days for fever-clearance time|difference of CSF protein concentration|difference of CSF glucose concentration|difference of CSF white cell counts|difference of CSF chloride concentration","Beijing Chest Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","676","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2018ZX10302302-004","March 4, 2019","December 31, 2021","December 31, 2021","December 27, 2018",,"February 1, 2021","Beijing Chest Hospital affiliated to Capital Medical University, Beijing, China|Jiamusi Infectious Disease Hospital, Jiamusi, China|Jiangxi Provincial Chest Hospital, Nanchang, China|Zunyi Medical College affiliated Hospital, Zunyi, China",,"https://ClinicalTrials.gov/show/NCT03787940"
678,"NCT03959566","PanACEA Sutezolid Dose-finding and Combination Evaluation","SUDOCU","Completed","No Results Available","Pulmonary Tuberculosis|Other Specified Pulmonary Tuberculosis","Drug: Sutezolid|Drug: Bedaquiline, Delamanid, Moxifloxacin|Drug: Midazolam oral solution","Primary Efficacy Endpoint: Change in sputum mycobacterial load over time|Primary safety endpoint: proportion of patients experiencing adverse events as defined below|Secondary Efficacy Endpoint 1: Time to stable culture conversion|Secondary Efficacy Endpoint 2: Culture conversion in liquid media|Secondary Efficacy Endpoint 3: Culture conversion on solid media|Secondary Efficacy Endpoint 4: No conversion to negative culture|Pharmacokinetics Endpoint Sutezolid 1: AUC 0-24|Pharmacokinetics Endpoint Sutezolid 2: Cmax|Pharmacokinetics Endpoint Sutezolid 3: Tmax|Pharmacokinetics Endpoint Sutezolid 4: Cmin|Pharmacokinetics Endpoint Sutezolid 5: Cl/F|Pharmacokinetics Endpoint Sutezolid 6: Vd/F|Pharmacokinetics Endpoint Sutezolid 7: t1/2|Pharmacokinetics Endpoint Midazolam|Pharmacokinetics Endpoint Bedaquiline|Exploratory endpoint 1: rate of change in MBLA|Exploratory endpoint 2: time to negative MBLA|Exploratory endpoint 3: time to stable culture conversion in MBLA|Exploratory endpoint 4: rate of change in bacterial load|Mycobacterial Identification and Characterization Endpoint 1: MIC|Mycobacterial Identification and Characterization Endpoint 2: mutations","Michael Hoelscher|European and Developing Countries Clinical Trials Partnership (EDCTP)|Sequella, Inc.|Radboud University Medical Center|University of California, San Francisco|German Federal Ministry of Education and Research|Ludwig-Maximilians - University of Munich","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PanACEA-SUDOCU-01","May 6, 2021","September 30, 2022","September 30, 2022","May 22, 2019",,"May 1, 2023","The Aurum Institute for Health Research, Johannesburg, South Africa|Kilimanjaro Clinical Research Institute, Moshi, Arusha, Tanzania|Ifakara Health Institute, Bagamoyo, Tanzania|National Institute for Medical Research (NIMR - MMRC), Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT03959566"
679,"NCT00170209","Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)",,"Completed","No Results Available","Latent Tuberculosis Infection","Drug: Isoniazid|Drug: Rifampin","Adverse events of all grades|Rates of drug completion (compliance)|Confirmed active TB during 16 months after randomization (efficacy)|Occurrence of drug resistance in confirmed cases of active TB","McGill University|Canadian Institutes of Health Research (CIHR)","All","up to 18 Years   (Child, Adult)","Phase 3","844","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCT-44154","August 2011","November 2014","May 2015","September 15, 2005",,"December 19, 2017","Woolcock Institute of Medical Research, Sydney, New South Wales, Australia|Centre de Pneumophthysiologie, Cotonou, Benin|Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde, Rio de Janeiro, Brazil|University of Alberta, Edmonton, Alberta, Canada|British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada|Montreal Children's Hospital, Montreal, Quebec, Canada|Research and Development Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana|Service de Pneumo-Phtisiologie, Hopital National Ignace Deen, Conakry, Africa, Guinea|Health Research Unit, Faculty of Medicine, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT00170209"
680,"NCT00298870","Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: Isoniazid|Drug: isoniazed","The incidences of unfavorable events in two different treatment regimens based on the NAT2 gene polymorphism|Other adversed events during the 8 weeks of the intensive phase of the anti-tuberculosis therapy","Osaka University","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 4","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PG-MRT-TB-01","June 2005",,,"March 3, 2006",,"October 18, 2012","Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Osaka, Japan|Osaka Hospital, Anti-Tuberculosis Association, Osaka Branch, Neyagawa, Osaka, Japan|National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan|National Hospital Organization Toneyama, Toyonaka, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT00298870"
681,"NCT05190146","Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden",,"Active, not recruiting","No Results Available","Tuberculosis, Pulmonary",,"IGRA status per site|IGRA status by age group per site|Suspected pulmonary TB during follow-up period|Laboratory-confirmed pulmonary TB during follow-up period","Bill & Melinda Gates Medical Research Institute","All","15 Years to 34 Years   (Child, Adult)",,"8000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Gates MRI TBV02-E01","December 20, 2021","September 11, 2023","September 30, 2024","January 13, 2022",,"March 29, 2024","Investigational Site, Dhaka, Bangladesh|Investigational Site, Porto Alegre, Brazil|Investigational Site, Rio De Janeiro, Brazil|Investigational Site, Kinshasa, Congo, The Democratic Republic of the|Investigational Site, Banjul, Gambia|Investigational Site, Pune, India|Investigational Site, Bandung, West Java, Indonesia|Investigational Site, Bakti, Indonesia|Investigational Site, Persabahan, Indonesia|Investigational Site, Kisumu, Kenya|Investigational Site, Mombasa, Kenya|Investigational Site, Nairobi, Kenya|Investigational Site, Manica, Mozambique|Investigational Site, Maputo, Mozambique|Investigational Site, Comas, Peru|Investigational Site, Lima, Peru|Investigational Site, Dasmariñas, Philippines|Investigational Site, Iloilo City, Philippines|Investigational Site, Makati City, Philippines|Investigational Site, Mandaluyong City, Philippines|Investigational Site, Quezon City, Philippines|Investigational Site, Bloemfontein, South Africa|Investigational Site, Durban, South Africa|Investigational Site, Germiston, South Africa|Investigational Site, Kimberley, South Africa|Investigational Site, Mtubatuba, South Africa|Investigational Site, Soshanguve, South Africa|Investigational Site, Soweto, South Africa|Investigational Site, Three Rivers, South Africa|Investigational Site, Entebbe, Uganda|Investigational Site, Mulago, Uganda|Investigational Site, Ho Chi Minh City, Vietnam|Investigational Site, Hà Nội, Vietnam|Investigational Site, Emmasdale, Zambia|Investigational Site, Lusaka, Zambia|Investigational Site, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT05190146"
682,"NCT04844502","Cardiopulmonary Function and Quality of Life in Pulmonary Tuberculosis",,"Recruiting","No Results Available","Tuberculosis, Pulmonary|Physical Disability|Quality of Life","Other: Physical rehabilitation","Physical Capacity|Quality of Life reported","Universidade Federal do Rio de Janeiro","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","10481219.9.0000.5257","April 7, 2021","December 1, 2023","December 1, 2023","April 14, 2021",,"November 28, 2023","University Hospital, Rio de Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT04844502"
683,"NCT00311207","Development of Tuberculosis Diagnostic Kit",,"Unknown status","No Results Available","Tuberculosis|Lung Cancer|Pneumonia",,,"Taichung Veterans General Hospital","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","940601/C05098","December 2005",,"November 2006","April 5, 2006",,"April 5, 2006","Taichung Veterans General Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00311207"
684,"NCT00140309","TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment",,"Completed","No Results Available","Tuberculosis, Pulmonary","Drug: moxifloxacin (with isoniazid, rifampin, pyrazinamide)","Two-month culture conversion|Serious Adverse Event","Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Phase 2","350","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","CDC-NCHSTP-3716","July 2003",,"December 2005","September 1, 2005",,"March 19, 2007","University of Southern California Medical Center, Los Angeles, California, United States|University of California at San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Public Health Department, Denver, Colorado, United States|Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Hines Vetrans Administration Medical Center, Hines, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|New Jersey School of Medicine, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Veterans Administration Tennessee Valley Health Care System, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Veterans Administration Medical Center, Houston, Texas, United States|Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio, Texas, United States|Seattle-King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute, Montreal, Quebec, Canada|Nelson R Mandela School of Medicine, Durban, KwaZulu Natal, South Africa|Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00140309"
685,"NCT04856644","Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","ESCAPE-TB","Not yet recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: 4-month rifapentine-based regimen","Treatment Efficacy|Safety and tolerability|Early sterilizing activity|Sputum culture conversion|Speed of decline of sputum viable bacilli|TB disease-free survival at 12 months sensitivity analysis (unfavorable outcome)|TB disease-free survival at 12 months sensitivity analysis (favorable outcome)|Rate of treatment discontinuation|All-cause mortality|Attributable mortality|Changes in interferon-gamma levels|Changes in tumor necrosis factor-alpha levels|Changes in interleukin-12 and interleukin-6 levels|Changes in triggering receptor expressed on myeloid cells-1 (TREM-1) levels","Kaohsiung Veterans General Hospital.|National Taiwan University|Taipei Veterans General Hospital, Taiwan|Chang Gung Memorial Hospital|Centers for Disease Control, Taiwan","All","20 Years and older   (Adult, Older Adult)","Phase 3","366","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSVGH-20561","May 1, 2021","December 31, 2023","December 31, 2024","April 23, 2021",,"April 23, 2021","Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04856644"
686,"NCT03929705","Assessing the Ability of the T-SPOT®.TB Test","IQ","Completed","No Results Available","Tuberculosis (TB)",,"T-Spot","Oxford Immunotec","All","18 Years and older   (Adult, Older Adult)",,"676","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AF SA 148","May 2, 2019","January 23, 2020","January 23, 2020","April 29, 2019",,"October 23, 2020","University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT03929705"
687,"NCT03409315","Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients","PERFECT","Unknown status","No Results Available","Tuberculosis, Multidrug-Resistant","Procedure: Centralized Therapeutic Drug Monitoring","Feasibility of centralized TDM|Impact of centralized TDM","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"360","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTDM/FQ1","February 10, 2018","November 2020","December 2020","January 24, 2018",,"October 10, 2019","The Prince Charles and Caboolture Hospitals, Brisbane, Australia|Republican Scientific and Practical Centre of Pulmonology and Tuberculosis, Minsk, Belarus|Hélio Fraga Reference Center, Rio De Janeiro, Brazil|Athens Chest Hospital ""Sotiria"", Athens, Greece|Alma Mater Studiorum University of Bologna, Bologna, Italy|Reuh Tldc, Upeslejas, Latvia|Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico|University Medical Center Groningen Beatrixoord, Haren, Netherlands|Vila Nova Gaia/Espinho Medical School, Vila Nova De Gaia, Portugal|University of Cape Town, Lung Insitute, Cape Town, South Africa|Karolinska University Hospital, Stockholm, Sweden|Kibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania|Royal London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03409315"
688,"NCT01218217","Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB","SQ109EBA","Completed","No Results Available","Tuberculosis, Pulmonary","Drug: SQ109|Drug: Rifampicin","The extended early bactericidal activity (EBA)of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.|The standard EBA (EBA 0-2) of each treatment group, as determined by the rate of change of log Colony Forming Units (logCFU) in sputum over the period Day 0-2 (linear, bi-linear or non-linear regression of logCFU over time).|Extended EBA (EBA 2-14) of each treatment group, as determined by the rate of change of logCFU in sputum over the periods Day 2-14 (linear, bi-linear or non-linear regression of logCFU over time).|The change in time to positivity (TTP) in the Mycobacterium Growth Indicator Tube (Bactec MGIT 960 system).|Pharmacokinetics|Proportion of subjects with serious adverse events and proportion of subjects who discontinue due to an adverse event in each experimental arm.","Michael Hoelscher|Sequella, Inc.|European and Developing Countries Clinical Trials Partnership (EDCTP)|German Federal Ministry of Education and Research|Quintiles, Inc.|CMed Technologies Inc.|PathCare|Parexel|Ludwig-Maximilians - University of Munich","All","18 Years to 64 Years   (Adult)","Phase 2","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMU-IMPH-SQ109-01","November 2010","September 2011","May 2012","October 11, 2010",,"January 14, 2013","TASK Applied Sciences, Cape Town, South Africa|University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01218217"
689,"NCT03819374","Improving HIV/Tuberculosis Outcomes in Irkutsk",,"Completed","No Results Available","Tuberculosis|HIV Infections|Substance Use",,"Nonadherence as measured by clinic attendance, pharmacy refill and daily adherence response to the mHealth app will be more frequent in participants with ongoing substance use.|Correlation of serum mass spectrometry to urine colorimetry for AUC of anti-tuberculosis drugs|Correlation of serum mass spectrometry to urine colorimetry for peak concentration of anti-tuberculosis drugs","University of Virginia|National Institute on Drug Abuse (NIDA)|Scientific Center for Family Health and Human Reproduction Problems, Russia","All","18 Years to 64 Years   (Adult)",,"53","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","20451|R01DA044137","April 15, 2018","May 30, 2020","April 30, 2021","January 28, 2019",,"March 9, 2022","Irkutsk Regional Clinical Tuberculosis Hospital, Irkutsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03819374"
690,"NCT00023374","TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance",,"Completed","No Results Available","Tuberculosis","Drug: Rifampin|Drug: Pyrazinamide|Drug: Ethambutol|Drug: REZ","Combined endpoint of bacteriologic plus clinical failure and relapse within 2 years of completing treatment among patients with isoniazid-resistant tuberculosis and among patients enrolled with intolerance to isoniazid|Occurrence and timing of toxicities and drug intolerances|Time to completion and the frequency of successful completion|Occurrence of acquired resistance|Proportion with documented conversion of 8-week sputum cultures|Bacteriologic failure or relapse in patients with resistance to streptomycin|Bacteriologic failure or relapse among patient with history of prior treatment|Bacteriologic failure or relapse by duration of isoniazid received|Bacteriologic failure or relapse among patients with positive 8-week sputum cultures","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Not Applicable","98","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-2340|24","August 2000","December 2006","December 2010","September 10, 2001",,"August 3, 2011","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023374"
691,"NCT00351702","Preventive Therapy for Tuberculosis in HIV Infected Persons",,"Completed","No Results Available","Human Immunodeficiency Virus|Tuberculosis","Drug: Isoniazid with Ethambutol","Primary outcome measure is the development of tuberculosis.|Secondary outcome measures include adverse drug reactions and mortality rate.","Tuberculosis Research Centre, India|United States Agency for International Development (USAID)","All","15 Years to 60 Years   (Child, Adult)","Phase 3","650","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","trc20B","February 2001","September 2008","June 2011","July 13, 2006",,"June 7, 2016","Tuberculosis Research Centre, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00351702"
692,"NCT00772408","Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis",,"Completed","No Results Available","Pulmonary Tuberculosis|Genetic Variants of Host|Immune Response of Host",,"susceptibility of pulmonary tuberculosis|clinical presentation of pulmonary TB","Chang Gung Memorial Hospital","All","20 Years to 90 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NSC 95-2314-B-182A-030","August 2006","November 2009","November 2009","October 15, 2008",,"February 28, 2013","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Hsien, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00772408"
693,"NCT04738812","Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","DATURA","Recruiting","No Results Available","Tuberculosis|HIV-1-infection|Immuno-Deficiency","Drug: Intensified TB treatment (initial phase)|Drug: WHO standard TB treatment (initial phase)","Rate of all causes death|Rate of adverse events|Rate of AIDS-defining illnesses|Rate of paradoxical TB-associated IRIS|Rate of TB treatment success|Rate of TB recurrence|Rate of virological success|Adherence to TB and ART treatment|Immunological response|Plasma concentrations of rifampicin and isoniazid|Plasma concentrations of efavirenz and dolutegravir","ANRS, Emerging Infectious Diseases|European Union|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","1330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 12424 DATURA","April 21, 2022","March 2025","March 2025","February 4, 2021",,"September 21, 2022","National Center for HIV/AIDS, Dermatology and STD (NCHADS), Phnom Penh, Cambodia|Jamot Hospital, Yaoundé, Cameroon|Ignace Deen Hospital, Conakry, Guinea|Mbarara Regional Referral hospital, Mbarara, Uganda|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam|University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT04738812"
694,"NCT00001407","Interferon Gamma for Drug Resistant Tuberculosis",,"Completed","No Results Available","Pneumonia|Pulmonary Tuberculosis","Drug: Interferon Gamma",,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","30","NIH","Interventional","Primary Purpose: Treatment","940149|94-I-0149","May 1994",,"May 2003","November 4, 1999",,"March 4, 2008","National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001407"
695,"NCT01785186","Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design",,"Completed","Has Results","Tuberculosis, Pulmonary","Drug: SQ109|Drug: Rifampicin|Drug: Moxifloxacin|Drug: isoniazid|Drug: pyrazinamide|Drug: ethambutol|Dietary Supplement: pyridoxine","Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media|Frequency of Adverse Events|Mycobacteriology Identification and Characterization by PCR and MIC|Pharmacokinetics Including AUC, Cl, t1/2, Vd, and Protein Binding|Pharmacodynamics Including AUC0-24/MIC (h*ng/mL) and Cmax/MIC (ng/mL)|Time to First Negative Culture on Liquid and Solid Media|Proportion of Negative Sputum Cultures|Rate of Change in Time to Positivity|Rate of Change in Quantitative PCR During Therapy|Occurence of Treatment Failure (Relapse or Emergence of Drug-resistance)|Changes in Baseline Laboratory Safety Parameters During Treatment and Follow-up","Michael Hoelscher|Sequella, Inc.|European and Developing Countries Clinical Trials Partnership (EDCTP)|German Federal Ministry of Education and Research|Medical Research Council|Radboud University Medical Center|Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)","Phase 2","365","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PanACEA-MAMS-TB-01","April 2013","September 2014","March 2015","February 7, 2013","September 20, 2017","September 20, 2017","TASK Applied Science, Bellville, South Africa|University of Cape Town, Centre for Tuberculosis Research Innovation, Cape Town, South Africa|Wits Health Consortium, Johannesburg, South Africa|The Aurum Institute for Health Research, Johannesburg, South Africa|Ifakara Health Institute, Bagamoyo, Tanzania|NIMR - Mbeya Medical Research Programme, Mbeya, Tanzania|Kilimanjaro Christian Medical Centre (KCMC) / Kilimanjaro Clinical Research Institute (KCRI) (with affiliated field sites such as Kibong'oto National Tuberculosis Hospital Same, Mererani, Chekereni and Mawenzi Regional Hospital), Moshi, Tanzania",,"https://ClinicalTrials.gov/show/NCT01785186"
696,"NCT01322841","Universal Screening for Tuberculosis and Anemia With the CHICA System",,"Completed","Has Results","Tuberculosis|Iron Deficiency Anemia","Other: CHICA Diagnosis Module|Other: CHICA Placebo","Percentage of Patients Screened Positive for One of the Disorders|Percentage of Patients Diagnosed With One of the Disorders","Indiana University|National Library of Medicine (NLM)","All","3 Years to 11 Years   (Child)","Not Applicable","2239","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","CHICA_Screening|5K22LM009160","October 2007","July 2009","September 2010","March 25, 2011","December 18, 2015","December 2, 2016","Children's Health Services Research, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01322841"
697,"NCT02836483","A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: LCB01-0371 800mg, QD|Drug: LCB01-0371 400mg, BID|Drug: LCB01-0371 800mg, BID|Drug: Tubes 3~5Tablet, QD|Drug: Zyvox 600mg, BID|Drug: LCB01-0371 1200mg, QD","EBA0-14|EBA0-2|EBA2-14|EBA2-7","LigaChem Biosciences, Inc.","All","19 Years to 75 Years   (Adult, Older Adult)","Phase 2","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCB01-0371-15-2-01","December 10, 2016","July 1, 2019","July 1, 2019","July 19, 2016",,"February 6, 2020","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02836483"
698,"NCT00376012","Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis",,"Unknown status","No Results Available","Tuberculosis|Human Immunodeficiency Virus Infections","Drug: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)","Primary outcome measures are TB cure and relapse rates|Secondary Outcome measure is mortality rates.","Tuberculosis Research Centre, India","All","15 Years to 60 Years   (Child, Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","trc20A","February 2001","September 2007","September 2008","September 14, 2006",,"June 11, 2008","Tuberculosis Research Centre, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00376012"
699,"NCT03011580","Vitamin D to Resolve Inflammation After Tuberculosis (ResolveD-TB)","ResolveD-TB","Completed","No Results Available","Recurrent Tuberculosis","Dietary Supplement: Fultium-D3|Dietary Supplement: Placebo","Mean maximum standardised uptake value (SUVmax) on PET-CT scanning at 8-week follow-up.|Inflammation Score on PET-CT at 8-week follow-up.|Proportion of PET-hot lesions resolving over the course of the study|Total and differential white cell counts|Concentrations of inflammatory mediators in serum at 8-week follow-up.|Concentrations of inflammatory mediators in plasma at 8-week follow-up.|Concentrations of inflammatory mediators in induced sputum supernatants at 8-week follow-up.|Concentrations of inflammatory mediators in supernatants of antigen-stimulated whole blood at 8-week follow-up.|Induced sputum transcriptional profiles at 8-week follow-up.|Whole blood transcriptional profiles at 8-week follow-up.|Sputum microbiology at 8-week follow-up.","Queen Mary University of London","All","20 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","011410","March 14, 2017","April 1, 2019","August 1, 2019","January 5, 2017",,"September 16, 2019","Barts Health NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03011580"
700,"NCT05590455","Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","TIMPANI","Recruiting","No Results Available","Tuberculous Meningitis|HIV I Infection","Drug: Adalimumab Injection","3-month all-cause mortality|3-month incidence of severe/life threatening bacterial infections and opportunistic infections|3-month incidence of grade 3 and 4 adverse reactions and those leading to ART or anti tuberculosis treatment (ATT) interruption|3-month incidence of all grade 3 and 4 adverse events|9-month all-cause mortality|9-month disability free survival (using Rankin score)|3-month and 9-month incidence of all grade infectious diseases and opportunistic infections|9-month neurological disability score (Rankin score)|Time to and severity of TB-associated paradoxical immune reconstitution inflammatory syndrome (IRIS) between D0 and 9 months|Time to discharge|Cerebrospinal fluid (CSF) pleocytosis/protein/glucose levels at W0, W1 and W4|CSF mycobacterial cultures negativation (culture conversion), time to culture positivity and cycle threshold (GeneXpert Mycobacterium tuberculosis/Rifampicin Ultra) at W1, W4,|Proportion of patients with HIV RNA<50 copies/mL at 9 months|CD4 counts at 9 months (and gain from baseline)|Inflammatory biomarkers and cytokines profiles in CSF at W0, W1, W4|Inflammatory biomarkers in blood at W0, W4, W10, M6 and M9|Cytokines profiles in blood at W0, W4, W10, M6 and M9","ANRS, Emerging Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 12404 TIMPANI","April 11, 2023","June 2025","December 2025","October 21, 2022",,"September 22, 2023","Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ, Rio De Janeiro, Brazil|Instituto Nacional de Saude, Maputo, Mozambique|Adult Infectious Diseases Centre, University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT05590455"
701,"NCT02114684","Improving Retreatment Success (IMPRESS)","IMPRESS","Completed","Has Results","Recurrent Tuberculosis","Drug: moxifloxacin","Sputum Culture Conversion Rates at Week 8 and Month 6 Post Tuberculosis Treatment Initiation|Time to Culture-conversion of the Moxifloxacin Regimen and the Ethambutol Regimen|Proportion of Patients With Any Grade 3 or 4 Adverse Reactions in the Two Study Arms|Number of Participants With Adverse Events and 8-week Culture Conversion Rates Among HIV-infected Patients vs. HIV-uninfected Patients|Proportion of Patients With Unfavourable Outcomes or Tuberculosis Recurrence in the Moxifloxacin and Control Arm.","Centre for the AIDS Programme of Research in South Africa","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","197","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CAP 011","November 2013","July 2017","July 17, 2017","April 15, 2014","August 5, 2019","August 5, 2019","CAPRISA eThekwini Clinical Research Site (eCRS), Durban, KwaZulu Natal, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/84/NCT02114684/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/84/NCT02114684/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02114684"
702,"NCT04563273","Clinical Study of BCG Vaccine for Intradermal Injection",,"Completed","No Results Available","Tuberculosis","Biological: BCG vaccine 1（0.025mg/0.1ml/person）|Biological: BCG vaccine 2 （0.05mg/0.1ml/person）|Biological: BCG vaccine 3（0.075mg/0.1ml/person）|Biological: BCG vaccine 4 （0.075mg/0.1ml/person）|Biological: Placebo of BCG vaccine （0.1ml/person）","Incidence of adverse events after vaccination|Positive conversion rate of BCG-PPD skin test 12 weeks and 6 months after vaccination|Positive conversion rate of EC skin test 12 weeks and 6 months after vaccination","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","All","6 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","BCG-I-healthy","October 21, 2020","October 30, 2022","October 30, 2022","September 24, 2020",,"May 9, 2023","Sichuan Center for Disease Control and Prevention, Chendu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04563273"
703,"NCT00449345","Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis",,"Unknown status","No Results Available","Latent Tuberculosis Infection","Procedure: Blood test for Quantiferon-GOLD assay",,"Assuta Hospital Systems|Maccabi Healthcare Services, Israel","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","2006055","May 2007",,,"March 20, 2007",,"May 30, 2007","Community Tuberculosis service, Rehovot, Israel",,"https://ClinicalTrials.gov/show/NCT00449345"
704,"NCT01371916","Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF",,"Completed","No Results Available","Tuberculous Meningitis",,"the positive percentage of total macrophages","Xijing Hospital","All","14 Years to 75 Years   (Child, Adult, Older Adult)",,"316","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","xijing004","September 2010","November 2013","January 2014","June 13, 2011",,"August 20, 2014","Xijing Hospital, Xi'an, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT01371916"
705,"NCT03174184","Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB",,"Completed","Has Results","Tuberculosis, Pulmonary","Drug: Rifampin|Drug: MEROPENEM 2 grams TID|Drug: MEROPENEM 1 gram TID|Drug: MEROPENEM 3 grams QD|Drug: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Drug: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet","Estimate of the 14-day Early Bactericidal Activity (EBA), Based on Colony Forming Unit Counts, of the Combination of Meropenem and Amoxicillin/Clavulanate, Without Versus With Rifampin|AUC for Rifampin|Frequency of Grade 2 or Higher Adverse Events|Distribution of Minimum Inhibitory Concentration (MIC) of Rifampin|Estimate the Antimycobacterial Activity Based on Liquid Culture Time-to-positivity","Johns Hopkins University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00119017|FD-R-05724","August 23, 2017","May 13, 2022","May 13, 2022","June 2, 2017","July 19, 2023","July 19, 2023","Task Applied Science and Stellenbosch University, Stellenbosch, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/84/NCT03174184/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03174184"
706,"NCT00332306","Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment",,"Unknown status","No Results Available","Tuberculosis|Human Immunodeficiency Virus Infections","Drug: Didanosine, Lamivudine, Efavirenz|Drug: Didanosine, Lamivudine, Nevirapine","Suppression of Viral load to < 400 copies/ml or a two log reduction in viral load from the baseline value at the end of 6 months and a viral load <400 copies/ml at 24 months of antiretroviral therapy|To compare the response to treatment between partially supervised drug administration and unsupervised drug administration.|To compare the tolerability and toxicity attributable to study drugs.","Tuberculosis Research Centre, India|National AIDS Control Organisation|Indian Council of Medical Research","All","18 Years to 61 Years   (Adult)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","trc23","June 2006","June 2009","December 2011","June 1, 2006",,"October 8, 2009","Tuberculosis Research Centre, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00332306"
707,"NCT00463086","Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons","HAART-IPT","Completed","No Results Available","Tuberculosis|Latent Tuberculosis Infection|HIV Infections","Drug: isoniazid|Drug: Placebo","Rate of development of TB (microbiologically confirmed TB or highly probable TB) during the 36 month risk period|Rate of drug toxicity (specifically, peripheral neuropathy, hepatitis +/-raised ALT grade III or worse and allergic rashes grade III or worse|Proportions adhering to study drug and HAART at the end of each study year as measured by pharmacy refills|Rate of development of INH monoresistance during the 36 month risk period.|Death|Worsening ART outcomes (virological and immunological failure)","University of Cape Town|Medecins Sans Frontieres, Netherlands|Imperial College London|Johns Hopkins University|London School of Hygiene and Tropical Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1368","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HAARTIPT07","November 2007","November 2011","November 2011","April 20, 2007",,"July 17, 2012","Ubuntu Clinic,Site B Khayelitsha, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00463086"
708,"NCT06352970","Effects of Tuberculosis Infection on Development and Function of the Placenta",,"Not yet recruiting","No Results Available","Pregnancy Related|Tuberculosis Infection|Placenta Diseases","Other: TB infection","Proportion of women with pathological placental findings according to the Amsterdam consensus criteria|Proportions of women with placental RNA and protein expression patterns linked to pregnancy- related disorders|Proportions of infants (born to participating women) with adverse outcome","Lund University|Addis Ababa University|Armauer Hansen Research Institute, Ethiopia","Female","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LundU-2024","May 1, 2024","December 31, 2025","December 31, 2027","April 8, 2024",,"April 8, 2024",,,"https://ClinicalTrials.gov/show/NCT06352970"
709,"NCT00004444","Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis",,"Completed","No Results Available","Tuberculosis, Pulmonary","Drug: paromomycin|Drug: streptomycin",,"FDA Office of Orphan Products Development|University of Illinois at Chicago","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","U.S. Fed|Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","199/13445|UIC-FDR001167","November 1994",,"January 2001","October 19, 1999",,"March 25, 2015",,,"https://ClinicalTrials.gov/show/NCT00004444"
710,"NCT02897180","Efficacy of Nyaditum Resae(R) Against Active TB in Georgia",,"Unknown status","No Results Available","Close Contacts of Active Tuberculosis","Biological: Nyaditum resae(R)|Biological: Placebo","Efficacy, incidence of confirmed cases of active TB|Efficacy, incidence of all cases of active TB and mortality (all causes)|Incidence of adverse events during the administration of the NR","Fundació Institut Germans Trias i Pujol|National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","3300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NYADAGEORG","March 10, 2017","October 2020","March 2021","September 13, 2016",,"September 7, 2017","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia",,"https://ClinicalTrials.gov/show/NCT02897180"
711,"NCT04421495","Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China",,"Active, not recruiting","No Results Available","Multidrug Resistant Tuberculosis","Drug: Delamanid","Proportion of participants experiencing all-cause mortality|Proportion of participants experiencing treatment-emergent AEs|The Percentage of Participants With Sputum Culture Conversion|The Median Time to Sputum Culture Conversion","Beijing Chest Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","608","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCSY-TB-2020-002","July 16, 2020","June 16, 2022","July 16, 2024","June 9, 2020",,"July 7, 2022","Beijing Chest Hospital, Capital Medical University, Beijing, China|Changsha Central Hospital, Changsha, China|Public Health Clinical Center of Chengdu, Chengdu, China|Chongqing Infectious Disease Medical Center, Chongqing, China|Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China|Guangzhou Chest Hospital, Guangzhou, China|Guiyang Public Health Clinical Center, Guiyang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, China|Hangzhou Red Cross Hospital, Hangzhou, China|Jiamusi Tumor Hospital, Jiamusi, China|Tuberculosis Hospital in Jilin Province, Jilin, China|Shandong Provincial Chest Hospital, Jinan, China|The Third People's Hospital of Kunming City, Kunming, China|Lanzhou Pulmonary Hospital, Lanzhou, China|Longtan Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China|Jiangxi Chest (Third People) Hospital, Nanchang, China|Shanghai Pulmonary Hospital, Shanghai, China|Hebei Chest Hospital, Shijiangzhuang, China|The Fifth People Hospital of Suzhou, Suzhou, China|The Fourth People's Hospital of Taiyuan, Taiyuan, China|Wuhan Institute For Tuberculosis Control, Wuhan, China|Wuhan Jinyintan Hospital, Wuhan, China|Xi'an Chest Hospital, Xi'an, China|Shanxi Provincial Tuberculosis Institute, Xian, China|Henan Provincial Chest Hospital, Zhengzhou, China",,"https://ClinicalTrials.gov/show/NCT04421495"
712,"NCT00052195","Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People",,"Completed","No Results Available","Tuberculosis|HIV Infections","Biological: SRL-172","safety and efficacy of a prime-boost immunization strategy for the prevention of HIV-associated dTB and pTB|Risk factors for HIV-associated dTB and relative contributions of primary infection, reinfection, and reactivation in its pathogenesis","Dartmouth-Hitchcock Medical Center|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1975","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1R01AI045407-01A2|3R01AI045407-02S1|5R01AI045407-03|U01AI045407-06|U01AI045407-07|U01AI045407-08","September 2001","December 2008","May 2009","January 27, 2003",,"February 19, 2016","Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT00052195"
713,"NCT00366470","A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: A. 100,000 IU Cholecalciferol per dose of 3.3ml|Other: B. Migliol Oil without Cholecalciferol","Time to sputum culture conversion|Percent of Patients Culture Positive|Performance Status|Time To Sputum Smear Conversion|Proportion of Patients Smear Positive|Time To Growth In Liquid Media|RNTCP Treatment Outcomes|Weight Gain","Peter Daley|Dalhousie University|Christian Medical College, Vellore, India","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TB-VitaminD|CTRI/2007/091/000008","November 2009","May 2012","May 2012","August 21, 2006",,"July 6, 2012","Christian Medical College, Vellore, Tamil Nadu, India|Bethesda Hospital, Ambur, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00366470"
714,"NCT00023387","TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine",,"Completed","No Results Available","Tuberculosis","Drug: Rifapentine|Drug: 25-desacetyl Rifapentine|Drug: Isoniazid","Compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three difference doses: 600 mg, 900 mg, and 1200 mg|Describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of isoniazid and the occurrence of toxicity attributed to anti-tuberculosis treatment.","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CDC-NCHSTP-2558|TBTC Study 25PK","March 2000",,"May 2001","September 10, 2001",,"September 13, 2005","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023387"
715,"NCT03036163","Phase 1 Study of PBTZ169",,"Completed","Has Results","Tuberculosis","Drug: PBTZ169 - 40 mg|Drug: PBTZ169 - 80 mg|Drug: PBTZ169 - 160 mg|Drug: PBTZ169 - 320 mg|Drug: PBTZ169 - 640 mg|Drug: PBTZ169 - 320 mg (multiple administration)|Drug: PBTZ169 - 640 mg (multiple administration)","Incidence of Drug-related Adverse Events [Safety and Tolerability]|Peak Plasma Concentration (Сmax) of PBTZ169|Time to Reach Maximum Concentration (Tmax) of PBTZ169|Area Under the Concentration-time Curve (AUC0-∞)|Plasma Half-life Time (T1/2) of PBTZ169|Mean Plasma Retention Time (MRT) of PBTZ169|Total (Plasma) Clearance (Cl) of PBTZ169|Volume of Distribution (Vd) of PBTZ169|Elimination Constant (Kel) of PBTZ169|Renal Clearance (Clren) of PBTZ169|Peak Steady State Plasma Concentration (Cmax,ss) of PBTZ169|Time to Reach Maximum Steady State Concentration (Tmax,ss) of PBTZ169|Area Under the Plasma Concentration Versus Time Curve in Steady State (AUCss) of PBTZ169|Volume of Steady State Distribution (Vd,ss) of PBTZ169|Area Under the Concentration-time Curve (AUC0-t)|AUC0-t/AUC0-∞","Nearmedic Plus LLC|OCT LLC","Male","18 Years to 45 Years   (Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PBTZ169-Z00-C01-1","January 2016","September 2016","November 2016","January 30, 2017","April 13, 2020","April 13, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/63/NCT03036163/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03036163"
716,"NCT01608685","Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients",,"Completed","No Results Available","Latent Tuberculosis Infection",,"Agreement between results of QuantiFERON-Gold-in-tube and probability of latent tuberculosis infection|Agreement between results of T-SPOT.TB and probability of latent tuberculosis infection|Agreement between results of IGRA tests and TST in renal transplant recipients","Ligue Pulmonaire Genevoise","All","18 Years and older   (Adult, Older Adult)",,"205","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","KH-2010","January 2010","December 2011","December 2011","May 31, 2012",,"May 31, 2012","Geneva University Hospital/Division of Nephrology, Geneva 11, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT01608685"
717,"NCT01549457","TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment",,"Unknown status","No Results Available","Latent Tuberculosis Infection","Other: Cell phone text messages","Successful completion of LTBI treatment regimens.","University of British Columbia|British Columbia Cancer Agency","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","350","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","H11-02216","April 2012","October 2016","October 2016","March 9, 2012",,"October 12, 2015","New Westminster TB Control Clinic, New Westminster, British Columbia, Canada|Vancouver Downtown TB Control Clinic, Vancouver, British Columbia, Canada|Vancouver TB Control Clinic (VTC),, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01549457"
718,"NCT03305991","Tuberculosis Infection in Women of Reproductive Age and Their Infants",,"Completed","No Results Available","Tuberculosis|Pregnancy Complications",,"Incidence of adverse pregnancy outcomes|Incidence of active tuberculosis in participants during pregnancy, post-partum period and periods outside pregnancy, respectively|Pattern of child growth with regard to maternal tuberculosis infection status during pregnancy|Incidence of tuberculosis infection in Ethiopian infants during the first four years of life","Lund University","Female","Child, Adult, Older Adult",,"2120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LundU-2015","December 1, 2015","March 12, 2024","March 12, 2024","October 10, 2017",,"March 13, 2024","Adama Health Center, Adama, Ethiopia|Adama Regional Hospital, Adama, Ethiopia|Gheda Health Center, Adama, Ethiopia",,"https://ClinicalTrials.gov/show/NCT03305991"
719,"NCT04593771","Phase I Clinical Protocol of BCG-PPD in Healthy People",,"Completed","No Results Available","Tuberculosis","Drug: BCG-PPD","Evaluate the incidence of all adverse event and results of laboratory tests|Evaluate the effectiveness of the product by measuring the size of the skin response","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Sichuan Center for Disease Control and Prevention|Neijiang Center for Disease Control and Prevention|Beijing Kangterike Statistical Technology Co., Ltd.","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 1","80","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","LKM-2020-PPD01","October 21, 2020","May 24, 2021","May 24, 2021","October 20, 2020",,"February 22, 2022","Sichuan Center for Disease Control and Prevention, Chendu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04593771"
720,"NCT02958709","Optimizing Treatment to Improve TBM Outcomes in Children","TBM-KIDS","Completed","No Results Available","Tuberculosis, Meningeal","Drug: High-dose: RIF, INH, PZA, EMB|Drug: High dose: RIF, INH, PZA, LEVO|Drug: Standard of care: RIF, INH, PZA, EMB","Characterize the Volume of Distribution (Vd) in plasma of rifampicin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Characterize the Oral Clearance (CL/F) in plasma of rifampicin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Characterize the Rate of Absorption (ka) in plasma of rifampicin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Characterize the Penetration Coefficient in CSF of rifampicin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Characterize the Volume of Distribution (Vd) in plasma of levofloxacin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Characterize the Oral Clearance (CL/F) in plasma of levofloxacin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Characterize the Rate of Absorption (ka) in plasma of levofloxacin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Characterize the Penetration Coefficient in CSF of levofloxacin given at model-derived optimal daily doses in children ages 6 months to 12 years of age with TBM.|Assess the relationship between RIF concentrations and longitudinal functional outcomes as measured by longitudinal Modified Rankin Score (MRS) for children|To evaluate the safety of TBM treatment over eight weeks, by treatment Arm, as measured by Grade 3 or higher adverse events|Describe neurocognitive outcomes among children ages 6 months to 6 years of age who are treated for TBM, longitudinally over 18 months, by treatmentArm, as measured by the Mullen Gross Motor Scale|Describe neurocognitive outcomes among children ages 6 months to 6 years of age who are treated for TBM, longitudinally over 18 months, by treatmentArm, as measured by the Mullen Visual Reception Scale|Describe neurocognitive outcomes among children ages 6 months to 6 years of age who are treated for TBM, longitudinally over 18 months, by treatmentArm, as measured by the Mullen Fine Motor Scale|Describe neurocognitive outcomes among children ages 6 months to 6 years of age who are treated for TBM, longitudinally over 18 months, by treatmentArm, as measured by the Mullen Receptive Language Scale|Describe neurocognitive outcomes among children ages 6 months to 6 years of age who are treated for TBM, longitudinally over 18 months, by treatmentArm, as measured by the Mullen Expressive Language Scale|Describe TBM treatment outcomes at 12 months which will be classified as favorable (cured or treatment completed) or unfavorable (death, lost to follow up, treatment failure, transferred out) at 48 weeks.","Johns Hopkins University|National Institute for Research in Tuberculosis, Chennai, India|University of North Carolina|B. J. Medical College, Pune|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 12 Years   (Child)","Phase 1|Phase 2","38","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00051196|1R01HD074944-01A1","February 22, 2017","November 15, 2020","November 15, 2020","November 8, 2016",,"October 28, 2021","Byramji Jeejeebhoy Government Medical College and Sassoon Hospital, Pune, Maharashtra, India|National Institute of Research in TB and Institute of Child Health, Chennai, Tamil Nadu, India|UNC Project- Malawi, Lilongwe, Lilongwe District, Malawi",,"https://ClinicalTrials.gov/show/NCT02958709"
721,"NCT00939419","The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis",,"Completed","No Results Available","Tuberculosis, Pulmonary|Quality of Health Care|Community Health Care|Volunteer Health Workers|Tuberculosis Treatment Effectiveness","Other: Health workers TB care group|Other: Community health workers TB care group|Other: Self-administered treatment group","Cured and successful completion of treatment of smear positive and smear negative pulmonary tuberculosis cases.","University of Leeds|The Regional Government of Tigray,Ethiopia|University of Nottingham|World Health Organization","All","15 Years and older   (Child, Adult, Older Adult)","Phase 4","924","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","3140-ET","January 2005","December 2006","February 2007","July 15, 2009",,"July 16, 2009","Tigray Regional Health Bureau, Department for Diseases Prevention and Control, Mekelle, Tigray, Ethiopia",,"https://ClinicalTrials.gov/show/NCT00939419"
722,"NCT01395654","Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment",,"Unknown status","No Results Available","Hepatitis|Tuberculosis, Pulmonary","Drug: isoniazid, rifampin, pyrazinamide","The duration needed for successfully rechallenge anti-tuberculosis treatment|Number of participants with recurrence of hepatitis","National Taiwan University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201010025M","July 2011","December 2013","December 2015","July 15, 2011",,"December 27, 2012","Chest Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01395654"
723,"NCT02175134","IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis",,"Terminated","No Results Available","Suspected Tuberculous Peritonitis","Other: Blood and Ascites ELISPOT","the frequency of laparoscopic biopsy|the frequency of correct or wrong diagnosis","Asan Medical Center","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2014-0616","July 2014","June 2018","June 2018","June 26, 2014",,"August 29, 2018","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02175134"
724,"NCT04966052","COPD Co-infection With Tuberculosis on Th17 Cell Differentiation",,"Completed","No Results Available","Tuberculosis Infection|Chronic Obstructive Pulmonary Disease","Other: No intervention","Differentiation of Th17 cells","Peking University Third Hospital|Beijing Geriatric Hospital","All","40 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M2017390","April 1, 2018","April 1, 2020","June 1, 2020","July 19, 2021",,"July 19, 2021","Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04966052"
725,"NCT03739736","TB Reduction Through ART and TB Screening Project","TREATS","Unknown status","No Results Available","Tuberculosis|HIV/AIDS","Other: Combination of TB/HIV prevention activities (arm A)|Other: Combination of TB/HIV prevention activities (arm B)|Other: Standard of care (arm C)","The incidence rate of TB infection|The prevalence of TB disease|Notified bacteriologically confirmed pulmonary TB incidence rate in the parent HPTN071 trial Population Cohort|Notified bacteriologically confirmed pulmonary TB incidence rate among adults in the community","London School of Hygiene and Tropical Medicine|Zambart|Health Systems Trust, South Africa|International Union Against Tuberculosis and Lung Diseases|KNCV Tuberculosis Foundation|Imperial College London|University of Sheffield|QIAGEN GmbH, Germany|Delft Imaging Systems BV (Delft), Netherlands|London School of Economics and Political Science","All","15 Years and older   (Child, Adult, Older Adult)",,"4200","Other","Observational","Observational Model: Other|Time Perspective: Other","14905|RIA2016S-1632","June 12, 2018","April 30, 2021","April 30, 2021","November 14, 2018",,"February 25, 2021","Health Systems Trust, Cape Town, Western Cape, South Africa|Zambart, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT03739736"
726,"NCT00604617","Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children",,"Completed","No Results Available","Tuberculosis|HIV","Procedure: Interferon-Gamma Release Assay|Drug: RT-23",,"Case Western Reserve University|National Institute of Allergy and Infectious Diseases (NIAID)","All","3 Months to 5 Years   (Child)",,"564","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","07-0061|R01AI076199","January 26, 2009","August 21, 2012","August 21, 2012","January 30, 2008",,"January 18, 2022","University of Stellenbosch, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00604617"
727,"NCT03202693","A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.","CL-004","Completed","No Results Available","Tuberculosis","Drug: PA-824","Characterize the plasma pharmacokinetic variable area under the curve of a single oral-suspension dose of PA-824.|Characterize the plasma pharmacokinetic variable maximum concentration of a single oral-suspension dose of PA-824.|Characterize the plasma pharmacokinetic variable time to peak plasma concentration of a single oral-suspension dose of PA-824.|The frequency and severity of treatment related adverse events throughout the study.","Global Alliance for TB Drug Development","Male","19 Years to 50 Years   (Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PA 824-CL-004","March 2006","May 2006","May 2006","June 28, 2017",,"August 2, 2018","Covance Clinical Research Unit, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03202693"
728,"NCT03806699","Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent",,"Unknown status","No Results Available","Tuberculosis","Biological: Placebo|Biological: ID93+GLA-SE","Adverse events|Humoral and cellular immunogenicity assays","Quratis Inc.","All","14 Years to 18 Years   (Child, Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CT-QTP101-002","April 2, 2019","September 2020","December 2020","January 16, 2019",,"July 23, 2019","HALLYM UNIV. Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03806699"
729,"NCT03806686","Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers",,"Unknown status","No Results Available","Tuberculosis","Biological: Placebo|Biological: ID93+GLA-SE","Adverse events|Humoral and cellular immunogenicity assays|Efficacy at prevention of latent Mtb infection (QFT conversion)","Quratis Inc.|Access to Advanced Health Institute (AAHI)","All","19 Years to 64 Years   (Adult)","Phase 2","107","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CT-QTP101-001","May 31, 2018","March 2020","June 2020","January 16, 2019",,"May 31, 2019","Ajou University Hospital, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03806686"
730,"NCT00001033","The Treatment of Tuberculosis in HIV-Infected Patients",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Ethambutol hydrochloride|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Pyridoxine hydrochloride|Drug: Levofloxacin|Drug: Rifampin",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 3","650","NIH","Interventional","Primary Purpose: Treatment","ACTG 222|CPCRA 019|11199",,,"July 1997","August 31, 2001",,"November 4, 2021","USC CRS, Los Angeles, California, United States|Howard University Hosp., Div. of Infectious Diseases, ACTU, Washington, District of Columbia, United States|Univ. of Miami AIDS CRS, Miami, Florida, United States|Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States|Cook County Hosp. CORE Ctr., Chicago, Illinois, United States|Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States|SUNY - Buffalo, Erie County Medical Ctr, Buffalo, New York, United States|NY Univ. HIV/AIDS CRS, New York, New York, United States|Cornell University A2201, New York, New York, United States|Beth Israel Med. Ctr. (Mt. Sinai), New York, New York, United States|Univ. of Cincinnati CRS, Cincinnati, Ohio, United States|Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00001033"
731,"NCT00338793","Corticosteroids in the Treatment of Tuberculous Pleurisy",,"Completed","No Results Available","Tuberculous Pleurisy","Drug: prednisolone","Death|Presence of pleural thickening|Pulmonary function at completion of treatment|Adverse drug effects|Improvement in clinical symptoms and signs (such as pleuritic chest pain, temperature)|Reabsorption of pleural effusion|Failure rate at the end of treatment","Guangxi Medical University|National Natural Science Foundation of China|Ministry of Education, China|Bureau of Science and Technology of Guangxi Province, China","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","Shi-TB-01","July 2006",,"August 2008","June 20, 2006",,"August 26, 2008","Huan-Zhong Shi, Nanning, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT00338793"
732,"NCT02816931","Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory Concentrations","TDM-MDR-TB","Completed","No Results Available","Tuberculosis, Multidrug Resistant",,"Free area under the curve (fAUC) for second-line TB drugs, separate and in relation to minimum inhibitory concentration (MIC)|Free maximal concentration (fCmax) for second-line TB drugs, separate and in relation to minimum inhibitory concentration (MIC)|Sputum culture conversion|Time to sputum culture positivity (TTP)|Change in TB score 2 during the first 3 months of treatment|Changes in drug resistance - WGS (whole genome sequencing) or MIC|Time to sputum culture conversion|Treatment outcome|EQ-5D Quality of life","Karolinska Institutet|Fudan University|University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"37","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","540-2013-8797|D0879701","March 2016","September 1, 2018","June 1, 2020","June 29, 2016",,"October 14, 2020","Xiamen Designated TB hospital, Xiamen, Fujian, China",,"https://ClinicalTrials.gov/show/NCT02816931"
733,"NCT03598842","Tuberculosis - Learning the Impact of Nutrition","TB-LION","Active, not recruiting","No Results Available","Tuberculosis|Malnutrition|Helminth Infection","Dietary Supplement: Nutritional Supplementation Meal|Dietary Supplement: Multivitamin|Drug: Anti-parasitic medications","Immune response|Immune Response|Anthropometric measurement|Anthropometric measurements","Boston Medical Center|Rutgers, The State University of New Jersey|Jawaharlal Institute of Postgraduate Medical Education & Research","All","18 Years to 60 Years   (Adult)","Not Applicable","123","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-37473|6005415","July 12, 2019","December 2025","December 2025","July 26, 2018",,"September 14, 2023","Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT03598842"
734,"NCT03831906","Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia)",,"Completed","No Results Available","Tuberculosis|Severe Pneumonia|Covid19","Diagnostic Test: Xpert MTB/RIF Ultra (Ultra)","All-cause mortality 12 weeks after inclusion|Number of children diagnosed with TB at 12 weeks|• Proportion of children with TB treatment initiated at any time during follow-up|• Time to TB treatment initiation|• Duration of TB treatment at end of trial|• Number of inpatient deaths|• Duration of initial hospitalization|• Number of readmissions following discharge|• Weight gain at 12 weeks|• Proportion of NPA and stool samples with positive TB detection using Ultra•|• Proportion of Ultra-confirmed and clinically-diagnosed TB cases|• Feasibility of NPA and stool samples collection (1)|• Feasibility of NPA and stool samples collection (2)|• Safety of NPA collection|• Tolerability of NPA specimen collection procedures assessed by the child|• Tolerability of NPA specimen collection procedures assessed by the parents|• Tolerability of NPA specimen collection procedures assessed by the nurses|• Acceptability of NPA and stool specimen collection procedures|To assess the prevalence of Covid-19 (confirmed and probable cases) in children below 5 years admitted with WHO-defined severe pneumonia|Number of inpatients death in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Duration of initial hospitalization in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Number of readmissions following discharge in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Weight gain in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Inability to breastfeed or drink in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Lethargy or reduced level of consciousness in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Convulsions in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Stridor in calm child in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Oxygen saturation < 90% in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Central cyanosis in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Grunting in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Nasal flaring in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Chest in-drawing in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|To describe the laboratory characteristics (CRP) of Covid-19 cases|To describe the laboratory characteristics (full blood count) of Covid-19 cases|Description by type and frequency of the signs of viral pneumonia on CXR with interstitial changes of Covid-19 cases|To assess the yield of stool as compared to nasal swab for the detection of the SARS-CoV-2 by real time reverse transcription-polymerase chain reaction (RT-PCR)|Number of children having a PCR positive for respiratory syncytial virus|To assess seroprevalence and seroconversion (immunoglobulin M and immunoglobulin G to SARS-CoV-2) at Day 0 and Month 3","Institut National de la Santé Et de la Recherche Médicale, France|UNITAID","All","2 Months to 59 Months   (Child)","Not Applicable","2570","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","C18-26","March 20, 2019","June 30, 2021","June 30, 2021","February 6, 2019",,"November 1, 2021","Kampong Cham Provincial Referral Hospital, Kampong Cham, Cambodia|National Pediatric Hospital, Phnom Penh, Cambodia|Takeo Provincial Referral Hospital, Takeo, Cambodia|Biyem Assi District Hospital, Yaoundé, Cameroon|Chantal Biya Foundation, Yaoundé, Cameroon|Cocody University Teaching Hospital, Abidjan, Côte D'Ivoire|Treichville University Teaching Hospital, Abidjan, Côte D'Ivoire|Yopougon University Teaching Hospital, Abidjan, Côte D'Ivoire|José Macamo General Hospital, Maputo, Mozambique|Maputo Central Hospital, Maputo, Mozambique|Jinja Regional Reference Hospital, Jinja, Uganda|Mulago National Referral Hospital, Kampala, Uganda|Holy Innocents Children's Hospital, Mbarara, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT03831906"
735,"NCT01895582","Performance of IGRAs for TB Infection Diagnosis in Elderly","IGRage","Terminated","No Results Available","Ageing|Tuberculosis","Other: Blood samples","Number of positive, indeterminate, negative tests in each group|Test results in clinical LTBI patients|Correlation with TB-infection date|Blood samples collection in order to test new hypothesis in patients with non-concordant results|Performance comparison between tests (T-SPOT.TB®, Quantiferon-Gold-IT®)","Assistance Publique - Hôpitaux de Paris","All","75 Years and older   (Older Adult)",,"160","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P110131|2012-A00326-37","July 17, 2013","March 17, 2019","March 17, 2019","July 10, 2013",,"May 28, 2021","Service de médecine interne, Bondy, France|Servive de Médecine Interne (Pr S. Herson), Paris, France|Service de Médecine Interne, Diabete et Maladies Métaboliques, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT01895582"
736,"NCT02975570","Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","DAZZLE","Withdrawn","No Results Available","Tuberculosis Multi Drug Resistant Active","Drug: Delamanid|Drug: Linezolid|Drug: Levofloxacin|Drug: Pyrazinamide|Drug: WHO MDR-TB regimen","Successful outcome at 18 months after randomization using culture results, follow up visits,|Secondary - Adverse Events","Boston University|Westat|University of Florida","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-36160","August 2017","August 2021","August 2022","November 29, 2016",,"September 11, 2017",,,"https://ClinicalTrials.gov/show/NCT02975570"
737,"NCT03575299","Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells","MDR-TB","Unknown status","No Results Available","Multi-drug Resistant Tuberculosis","Biological: The adoptive treatment of allogeneic γδT cells|Other: Control|Drug: Conventional treatment","sputum smear|Sputum tubercle bacillus culture|Fecal microbiome analysis|Assessment of immune function","Zhinan Yin, Ph.D.|Shenzhen Third People's Hospital|Jinan University Guangzhou","All","18 Years to 50 Years   (Adult)","Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GDT-MDR-TB-069","June 1, 2018","June 30, 2021","December 31, 2021","July 2, 2018",,"July 2, 2018","Shenzhen Third People's Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03575299"
738,"NCT04094012","Risk of SDRs Under 3HP and 1HP Regimen for LTBI",,"Completed","No Results Available","Latent Tuberculosis Infection","Drug: isoniazid and rifapentine","number of participants with systemic drug reactions|number of participants with any flu-like symptoms|number of participants with hepatotoxicity|Treatment completion rate|Plasma level of isoniazid, rifapentine, acetyl-isoniazid, and Desacetyl-rifapentine|Characteristics associated with the development of systemic drug reactions","National Taiwan University Hospital","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","490","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201812127MINB","September 24, 2019","October 8, 2023","December 15, 2023","September 18, 2019",,"December 26, 2023","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04094012"
739,"NCT02573350","A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683",,"Completed","Has Results","Tuberculosis, Multidrug-Resistant","Drug: Delamanid|Drug: OBR","Number of Participants With Clinically Significant Abnormality in Vital Signs|Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Values|Number of Participants With Clinical Significant Abnormality in Laboratory Test|Number of Participants With Abnormality in Audiometry at Baseline|Number of Participants With Abnormality in Visual Acuity|Number of Participants With Abnormality in Neurological and Psychiatric Assessment Reported as Treatment-emergent Adverse Event (TEAE)|Number of Participants With Clinical Significant Abnormality in Thyroid Function Test Reported as TEAE|Number of Participants With Any Concomitant Medication Usage|Percentage of Participants With At Least One TEAEs and Serious Adverse Events (SAEs)|Number of Participants With Clinical Significant Abnormality in Coagulation (PT and aPTT) Reported as TEAE|Number of Participants With Clinical Significant Abnormality in Cortisol|Percentage of Treatment Responders Using the Mycobacterial Growth Indicator Tube (MGIT) Culture System|Percentage of Treatment Responders Using Solid Culture Medium|Percentage of Treatment Non-responders Using the MGIT Culture System|Percentage of Treatment Non-responders Using Solid Culture Medium|Percentage of Sustained Converters Using the MGIT Culture System|Percentage of Sustained Converters Using Solid Culture Medium|Percentage of New Converters Using the MGIT Culture System|Percentage of New Converters Using Solid Culture Medium|Percentage of Non-converters Using the MGIT Culture System|Percentage of Non-converters Using Solid Culture Medium|Percentage of Reverters Using the MGIT Culture System|Percentage of Reverters Using Solid Culture Medium|Percentage of Participants Who Developed Resistance to Delamanid While on Treatment","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 64 Years   (Adult)","Phase 2","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","242-07-208|2008-005107-26","March 26, 2009","October 27, 2011","October 27, 2011","October 9, 2015","November 1, 2021","November 1, 2021","Beijing Chest Hospital, Beijing, China|North Estonian Medical Centre Foundation Center of Pulmonology, Tallinn, Estonia|Tartu University Lung Hospital, Tartu, Estonia|Younsei University Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|State Agency of Tuberculosis and Lung Disease, Riga, Latvia|Hospital Nacional Sergio E. Bernales, Lima, Peru|Tropical Disease Foundation, Makati City, Philippines",,"https://ClinicalTrials.gov/show/NCT02573350"
740,"NCT02237365","A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis","AspirinTBM","Completed","No Results Available","Tuberculous Meningitis","Drug: 81mg aspirin|Drug: 1000mg aspirin|Drug: Placebo","Number of episodes of either cerebral bleeding or clinically significant upper-gastro-intestinal bleeding (composite endpoint)|Number of episodes of MRI-proven brain infarction or death (composite endpoint)|Time to death|Number of grade 3&4 and serious adverse events|Duration of hospital stay|Neurological disability score|Resolution of cerebrospinal fluid (CSF) inflammation|Antimicrobial activity of peripheral blood monocyte/macrophages|Proportion of patients with MRI-proven brain infarction","Oxford University Clinical Research Unit, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","23TB","October 17, 2014","June 24, 2016","December 22, 2016","September 11, 2014",,"March 7, 2017","Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02237365"
741,"NCT00737724","Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment",,"Terminated","No Results Available","HIV|AIDS|Tuberculosis","Drug: Simultaneous ARV and antiMTB|Drug: Deferred RV and antiMTB treatment","Time to remission of signs and symptoms of active tuberculosis as well as general symptoms.|Time to negative measurement of mycobacterial load in body fluids or affected tissues|CD4+ cell count increase|Lymphoproliferative response to specific antigens against Mtb|Time to undetectable HIV plasma load; HIV genotype","Instituto Nacional de Enfermedades Respiratorias|Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT).","All","18 Years to 60 Years   (Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C43-06","March 2008","February 2011","February 2011","August 20, 2008",,"March 26, 2015","Centro de Investigaciones en Enfermedades Infecciosas, Mexico city, DF, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico",,"https://ClinicalTrials.gov/show/NCT00737724"
742,"NCT05539989","Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa",,"Not yet recruiting","No Results Available","Tuberculosis|HIV Infections","Biological: VPM1002 Vaccine|Biological: BCG Vaccine|Drug: Placebo","All adverse events|Solicited adverse events|Grade 3 or higher adverse events|Serious adverse events|Adverse pregnancy outcomes|Frequency and response of VPM1002-specific and BCG-specific CD4+ and CD8+ T cells expressing Th1 and/or Th17 cytokines|Mycobacteria-specific IgA, IgG, and IgM binding antibodies|Association of HIV and IGRA with primary safety outcomes (All AEs, solicitated AEs, grade 3 or higher AEs, serious adverse events, adverse pregnancy outcomes).|Cellular immunogenicity outcome measures associated with HIV and IGRA status|Humoral immunogenicity outcome measures associated with HIV and IGRA status|Gene expression profiles|Differential leukocyte count and immunophenotype|Measurement of soluble proinflammatory mediators|Acceptability of the study products","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","8 Years to 14 Years   (Child)","Phase 1|Phase 2","480","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IMPAACT 2035/HVTN 604|UM1AI068632|UM1AI068616|UM1AI106716|HHSN275201800001I","December 31, 2024","July 31, 2027","July 31, 2027","September 14, 2022",,"March 26, 2024","Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa|Isipingo CRS, Soshanguve, Kwa Zulu Natal, South Africa|Klerksdorp CRS, Klerksdorp, North West Province, South Africa|Desmond Tutu TB Centre - Stellenbosch University (SU) CRS, Cape Town, Western Cape, South Africa|Emavundleni CRS, Cape Town, Western Cape, South Africa|Umlazi CRS, Durban, South Africa|Wits RHI Shandukani Research CRS, Johannesburg, South Africa|Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg Hills, South Africa",,"https://ClinicalTrials.gov/show/NCT05539989"
743,"NCT05643781","Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection","Co-TB","Completed","No Results Available","COVID-19|Tuberculosis|Post-acute COVID-19 Syndrome",,"Covid-19 recovery and course and the impact of tuberculosis (TB) or no tuberculosis infection.|Hospitalisation and Covid-19 severity|Cardiac outcomes post-Covid-19.|Lung function assessment post-Covid-19.","The Aurum Institute NPC|Chris Hani Baragwanath Academic Hospital|Ludwig-Maximilians - University of Munich","All","18 Years to 70 Years   (Adult, Older Adult)",,"157","Other","Observational","Observational Model: Cohort|Time Perspective: Other","AUR2-8-296","March 23, 2021","November 30, 2022","November 30, 2022","December 9, 2022",,"January 11, 2023","The Aurum Institute, Johannesburg, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT05643781"
744,"NCT01392911","Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB","HR1","Completed","No Results Available","Pulmonary Tuberculosis (TB)","Drug: Rifampicin","The incidence and severity of adverse events associated with increasing doses of rifampicin when administered as a single drug.|The incidence and severity of adverse events associated with increasing doses of rifampicin when combined with isoniazid, pyrazinamide and ethambutol.|The Early Bactericidal Activity (EBA) expressed as the fall of colony forming units per mL of sputum per day at the intervals: Baseline to Day 2, Baseline to Day 7, Baseline to Day 14, and Day 8 to Day 14.|The change in Time to Positivity (TTP) as measured in the Mycobacterium Growth Indicator Tube (Bactec MGIT960 system) at the intervals: Baseline to Day 2, Baseline to Day 7, Baseline to Day 14, and Day 8 to Day 14.|The area under the plasma concentration versus time curve (AUC) of rifampicin, and if possible also the AUC of pyrazinamide, isoniazid and ethambutol after 7 days of monotherapy with rifampicin and after 7 days of combination therapy|Pharmacodynamic endpoints for single dose rifampicin (assessed at Day 7) and or rifampicin, isoniazid, pyrazinamide and ethambutol when administered together (assessed at Day 14).","Radboud University Medical Center|European and Developing Countries Clinical Trials Partnership (EDCTP)|Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.|University Centre for Chronic Diseases Dekkerswald, Groesbeek, NL","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","128","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PanACEA - RUNMC - HR1|2007.23011.01","June 2011","July 2018","November 2018","July 13, 2011",,"November 26, 2018","TASK Applied Science, Bellville, South Africa|University of Cape Town Lung Institute, Mowbray, South Africa",,"https://ClinicalTrials.gov/show/NCT01392911"
745,"NCT04308928","Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis","TBMBIOMARKER","Recruiting","No Results Available","Tuberculous Meningitis",,"Identify CSF or blood-based biosignatures for the diagnosis of TBM in children|Develop a prototype POC diagnostic test platform based on the biosignatures.|Evaluate the newly developed test in a new patient cohort.","University of Stellenbosch","All","3 Months to 13 Years   (Child)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UStellenboschTBM","April 1, 2020","July 30, 2024","October 31, 2024","March 16, 2020",,"May 23, 2022","Stellenbosch University Immunology Research Group, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04308928"
746,"NCT03898635","Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis",,"Unknown status","No Results Available","Tuberculous Meningitis","Drug: Linezolid","Survival|Number of participants with Medical Research Council grade deterioration","Huashan Hospital","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2017-44","January 1, 2018","May 1, 2019","June 1, 2019","April 2, 2019",,"April 2, 2019","Infectious department of Huashan Hospital, Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03898635"
747,"NCT01358162","Phase IC Study of Safety and PK of SQ109 300mg Daily",,"Completed","No Results Available","Tuberculosis","Other: Placebo|Drug: SQ109","Safety & tolerability via: physical exams, color and visual acuity tests, funduscopic exams, neurological exams, vital signs, electrocardiograms, routine clinical labs (includes chemistry, hematology, coagulation and urinalysis data), and adverse events.|Pharmacokinetics of SQ109: Serial blood samples prior to and following single/multiple doses: AUC(0-t): area under the concentration time curve to the last time with concentration greater than or equal to the validated limit of quantitation of the assay|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: AUC(0-infinity): area under the concentration time curve to infinity|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: AUC(0-24): area under the concentration time curve to 24 hours|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: t1/2: apparent terminal half-life|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: CL/F: apparent oral clearance|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Vz/F: apparent volume of distribution|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Cmin: observed minimum concentration|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Cavg: calculated average concentration during the dosing interval|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Tmax: Time of maximum concentration (Cmax)|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: AUC(0-tau) Area under the concentration time curve to the end of the dosing interval, 24 hours|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: RCmax: Accumulation ratio for Cmax estimated as Cmax (Day 14) / Cmax (Day 1)|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Tmin: Time to minimum concentration (Cmin)|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Linearity Index: AUC(0-tau) (Day 14) / AUC(0-infinity)(Day 1)|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: RAUC : Accumulation ratio for AUC estimated as AUC0-tau (Day 14)/ AUC(0-24)(Day 1)|Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Cmax: observed maximum concentration","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","10","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09-0111|N01AI80024C","November 2010","February 2011","April 2011","May 23, 2011",,"May 14, 2013","Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01358162"
748,"NCT03470233","Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB",,"Completed","No Results Available","Multi-drug Resistant Tuberculosis",,"Dose of Deltyba|Administration duration of Deltyba|Compliance of Deltyba|Incidences of AEs|Incidences of ADRs|Incidences of AEs in special populations|Incidences of ADRs in special populations|Observed cases of resistance to Deltyba after completing the administration (Week 24) or premature discontinuation of Deltyba, Observed cases of resistance to Deltyba after 6 months of administration or discontinuation of administration|Response rate","Korea Otsuka Pharmaceutical Co., Ltd.","All","Child, Adult, Older Adult",,"149","Industry","Observational","Observational Model: Case-Only|Time Perspective: Other","242-402-00005","May 25, 2017","June 21, 2021","June 21, 2021","March 19, 2018",,"September 17, 2021","Ulsan University Hospital, Ulsan, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03470233"
749,"NCT03028129","Prevention of Tuberculosis in Prisons",,"Terminated","Has Results","Tuberculosis, Pulmonary|Antibiotic Prophylaxis","Drug: Isoniazid 900 milligrams|Drug: Placebo","Quantiferon TB Gold Plus (QIAGEN®) Conversion at the Premature Exclusion Visit.","Federal University of Mato Grosso|Oswaldo Cruz Foundation","Male","18 Years to 45 Years   (Adult)","Phase 4","467","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","U1111-1189-0829","September 4, 2017","August 10, 2019","August 10, 2019","January 23, 2017","October 25, 2019","October 25, 2019","Roberto Oliveira, Dourados, Mato Grosso Do Sul, Brazil","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/29/NCT03028129/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/29/NCT03028129/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03028129"
750,"NCT03302949","Treating Tuberculosis Wasting With a High-protein Supplement","NUTRIATO","Terminated","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Undernutrition|Malnutrition","Dietary Supplement: Lacprodan® DI-8090","Anthropometry|Treatment Outcome|Treatment outcome|Diet|Health-related quality of life","University of Aarhus|Bandim Health Project|Arla Foods","All","18 Years and older   (Adult, Older Adult)","Not Applicable","232","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1004","August 1, 2017","November 1, 2022","January 30, 2023","October 5, 2017",,"September 11, 2023","The Bandim Health Project, Bissau, Denmark, Guinea-Bissau",,"https://ClinicalTrials.gov/show/NCT03302949"
751,"NCT03265977","A Phase II Study of H56:IC31 in Healthy Adolescents","A-043","Withdrawn","No Results Available","Tuberculosis Infection","Biological: H56:IC31|Other: Placebo","Frequency and severity of adverse events|ESAT-6 free IGRA conversion from a negative to positive test at any time point after Day 84 and through end of follow-up for the primary endpoint.|Primary ESAT-6 free IGRA conversion from a negative to a positive test|Initial ESAT-6 free IGRA reversion from a positive to a negative test at any time point after primary ESAT-6 free IGRA conversion through the end of follow up.|Percentage of CD4+ and CD8+ T cells that express IFN-γ, TNF, and/or IL-2 alone or in combination in response to stimulation with peptide pools representing the entire amino acid sequence of the vaccine antigens.","Aeras|Statens Serum Institut|Aurum Institute|South African Tuberculosis Vaccine Initiative|Oslo University Hospital|University of Copenhagen|University of Bergen|National Institute for Medical Research, Tanzania","All","12 Years to 17 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","A-043","June 2018","April 30, 2021","June 30, 2021","August 29, 2017",,"April 10, 2018","Aurum Institute - Klerksdorp, Klerksdorp, South Africa|Aurum Institute - Rustenburg, Rustenburg, South Africa|Aurum Institute - Tembisa, Tembisa, South Africa|National Institute for Medical Research, Mwanza, Isamilo Area, Tanzania",,"https://ClinicalTrials.gov/show/NCT03265977"
752,"NCT02822014","PET/CT in Extrapulmonary TB in HIV Patients: a Clinical Trial",,"Completed","No Results Available","Extrapulmonary Tuberculosis in HIV Patients","Other: FDG-PET/CT","clinical evolution of TB/HIV patients: cure or relapse within 36 months of follow-up with relapse documented microbiologically","Centre Hospitalier Universitaire Saint Pierre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AK/09-09-52/3810","February 2010","January 2013","June 2015","July 4, 2016",,"July 4, 2016",,,"https://ClinicalTrials.gov/show/NCT02822014"
753,"NCT05556746","Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB","PRESCIENT","Recruiting","No Results Available","Tuberculosis, Pulmonary|HIV","Drug: Bedaquiline|Drug: Clofazimine|Drug: Pyrazinamide|Drug: Delamanid|Drug: Rifampin|Drug: Isoniazid|Drug: Ethambutol","Time to stable liquid culture conversion|Proportion experiencing any Grade 3 or higher AE|Proportion with favorable composite outcome|Proportion who prematurely discontinue treatment|Change in skin coloration|Distress related to skin coloration|Mean change in QTcF from baseline to week 2, 8, 12, 16 and 20|Mean change in QTcF from baseline to end of treatment|Occurrence of absolute QTcF ≥480 ms and <500 ms, and ≥500 ms|Occurrence of QTcF change from baseline of ≥30 ms and <60 ms, and ≥60 ms|Proportion of participants with one or more serious adverse events (SAEs)|Proportion with culture conversion in liquid and solid media (separately) at weeks 4, 8 and 12 after randomization|Proportion with TB relapse (by M. tuberculosis genotyping) from end of treatment to 60 weeks|Proportion of treatment-emergent genotypic and phenotypic resistance to BCZD|Time (days) to positivity in liquid culture (MGIT) after start of treatment across study arms","Brigham and Women's Hospital|University of Cape Town|Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic|University of Stellenbosch|University of California, Los Angeles|Harvard School of Public Health (HSPH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022p003075|U01AI170426","November 24, 2023","June 2025","January 2027","September 27, 2022",,"January 29, 2024","GHESKIO, Port-au-Prince, Haiti|University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT05556746"
754,"NCT01802502","Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation","REMOVER","Completed","No Results Available","Tuberculous Meningitis","Drug: Rifampicin intravenous|Drug: Oral rifampicin","Pharmacokinetic profile of several rifampicin dose|mortality","Universitas Padjadjaran|Radboud University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB-201302.01","June 2013","October 2013","April 2014","March 1, 2013",,"June 17, 2014","Hasan Sadikin Hospital, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT01802502"
755,"NCT03211208","Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients","ALISTER","Unknown status","No Results Available","Drug-Induced Liver Injury|Anti-Tuberculous Drug Reaction|Tuberculosis",,"Anti-tuberculosis drug-induced liver injury","University of Edinburgh|NHS Lothian","All","16 Years to 85 Years   (Child, Adult, Older Adult)",,"540","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AC16145","May 22, 2017","April 2020","April 2020","July 7, 2017",,"October 16, 2018","Royal Infirmary Edinburgh, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03211208"
756,"NCT05680415","Clinical Trial of Mica",,"Recruiting","No Results Available","Latent Tuberculosis Infection","Biological: Mycobacterium Vaccae for Injection","End point of efficacy|End point of safety|End point of immunogenicity","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","All","15 Years and older   (Child, Adult, Older Adult)","Phase 4","6800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","LKM-2022-BWK01","April 19, 2023","September 30, 2026","August 31, 2027","January 11, 2023",,"June 8, 2023","Liujiang district Prevention and Control center, Liuzhou, Guangxi, China|Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT05680415"
757,"NCT01874314","Effects of SQ109 on QTc Interval in Healthy Subjects",,"Withdrawn","No Results Available","Tuberculosis","Drug: SQ109|Other: SQ109 Placebo|Drug: Moxifloxacin","Solicited and unsolicited adverse events, including symptoms, physical findings, laboratory testing, holter monitor and ECG changes for 300mg/day SQ109|Electrocardiogram and holter monitor data (QTc, T wave forms, QRS, RR and PR intervals) for 300mg/day SQ109|Solicited and unsolicited adverse events, including symptoms, physical findings, laboratory testing, holter monitor and ECG changes for 450mg/day SQ109|Pharmacokinetics of SQ109 at doses of 300 or 450mg/day; AUC0-, (Cmax), time to maximum concentration (Tmax), elimination rate constant, elimination half-life, clearance, volume of distribution, and urinary excretion|Electrocardiogram and holter monitor data (QTc, T wave forms, QRS, RR and PR intervals) for 450mg/day SQ109","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-0079|HHSN272200800026C",,"December 2015","December 2015","June 11, 2013",,"March 24, 2014","Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01874314"
758,"NCT01674218","Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: Moxifloxacin|Drug: PA-824|Other: Placebo","Effect of PA-824 on cardiac ventricular repolarization (CVR) as measured by QT interval corrected for heart rate using individual-specific formula (QTcI) during the first 24 hours following dosing of PA-824 in healthy volunteers as compared to placebo.|Effect of PA-824 on CVR measured by QT interval corrected for heart rate by group-specific formula (QTcN), Fridericia (QTcF) and Bazett (QTcB) formulae during the first 24 hours following dosing in healthy volunteers compared to placebo.|Effect of PA-824 plus moxifloxacin on CVR as measured by QT and QT corrected for heart rate (QTcI, QTcN, QTcF, and QTcB) during the first 24 hours following dosing of PA-824 in healthy volunteers as compared to placebo.|The effect of Moxifloxacin on CVR as measured by QTcI, QTcN, QTcF, and QTcB, HR and non-QTc ECG intervals (HR, and PR, QRS, and RR intervals) during the first 24 hours following dosing of PA-824 in healthy volunteers as compared to placebo.|Safety and tolerability evaluated by ophthalmology exam.|Analysis of the QTcI, QTcN, QTcF, QTcB, PR, QRS, and RR intervals and heart rate matched to PK sampling times to allow determination of any PK / pharmacodynamic effect of PA-824 alone and in combination with moxifloxacin.|Safety and tolerability evaluated by standard 12-lead ECGs obtained pre-dose and 2, 4, 7 and 10 hrs post-dose on treatment days.|Safety and tolerability evaluated by continuous AE monitoring throughout the study; physical exams, and laboratory evaluations|Serum pharmacokinetics (PK) of 400 mg and 1000 mg of PA-824 and of 400 mg of PA-824 plus 400 mg of moxifloxacin for up to 5 days following dosing.","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","74","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-0058|N01AI80024C","September 2012","December 2012","December 2012","August 28, 2012",,"November 14, 2014","Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01674218"
759,"NCT05048485","Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets","TB-LEOPARD","Enrolling by invitation","No Results Available","Tuberculosis, Pulmonary|Helminthiasis|Malnutrition",,"Percent of participants who successfully complete TB treatment|Body Mass Index (BMI) at the end of treatment|Detection of parasites in stool specimen","Boston Medical Center|Jawaharlal Institute of Postgraduate Medical Education & Research","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-41912","April 9, 2022","December 2024","December 2024","September 17, 2021",,"May 1, 2023","Boston Medical Center, Boston, Massachusetts, United States|Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India",,"https://ClinicalTrials.gov/show/NCT05048485"
760,"NCT00023348","TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Isoniazid|Drug: Rifabutin","To determine the proportion of patients with HIV-related tuberculosis who have abnormal pharmacokinetics of isoniazid and rifabutin.|1) To determine risk factors for abnormal pharmacokinetics of isoniazid and rifabutin|2) To evaluate the correlation between pharmacokinetic parameters of isoniazid and rifabutin and the occurrence of toxicity attributed to antituberculous therapy.|3) To evaluate the correlation between pharmacokinetic parameters of isoniazid and rifabutin and the efficacy of TB therapy.|4) To define and correlate phenotypic INH acetylator status with the results of genotypic acetylator data obtained in the parent trial.","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","150","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-2173|23A","July 1999",,"November 2002","September 10, 2001",,"September 13, 2005","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023348"
761,"NCT00023400","TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Nelfinavir|Drug: Rifabutin","Impact of nelfinavir (given at 1250mg bid as part of a combination antiretroviral regimen) on area under the curve for rifabutin and 25-O-desacetyl rifabutin when rifabutin is given 300 mg bi-weekly as part of tuberculosis chemotherapy.|To compare the pharmacokinetics of nelfinavir given twice daily at 1250 mg bid with twice-weekly isoniazid and rifabutin to the pharmacokinetics of nelfinavir 1250 mg twice-daily in historical HIV-infected patients not receiving isoniazid and rifabutin.","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","0 Years and older   (Child, Adult, Older Adult)","Phase 4","20","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-2587|23B","February 2000",,"February 2002","September 10, 2001",,"September 5, 2005","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023400"
762,"NCT01376843","Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers",,"Completed","No Results Available","Tuberculosis",,"conversion rate of latent tuberculosis infection in hospital workers","Yonsei University","All","20 Years to 75 Years   (Adult, Older Adult)",,"53","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","4-2011-0161","June 2011","May 2012","May 2012","June 20, 2011",,"March 6, 2013","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01376843"
763,"NCT03512249","Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence",,"Active, not recruiting","No Results Available","Tuberculosis, Pulmonary","Biological: H56:IC31|Biological: Placebo","• Rate of TB disease recurrence (relapse or reinfection), defined as TB diagnosed by confirmation of Mtb by culture of sputum.|Solicited adverse events and all adverse events occurring the first 14 days after each of the 1st and 2nd vaccinations|Serious adverse events including medically important events occurring after the 1st vaccination through the end of the trial|Efficacy of H56:IC31 compared to placebo in reducing the rate of TB disease relapse|Efficacy of H56:IC31 compared to placebo in reducing the rate of TB disease reinfection|Antigen-specific cell-mediated immune responses to H56:IC31|Humoral immune responses to H56:IC31","International AIDS Vaccine Initiative|Statens Serum Institut|South African Tuberculosis Vaccine Initiative|University of Cape Town Lung Institute|TASK Applied Science|The Aurum Institute NPC|National Institute for Medical Research, Tanzania|Ospedale San Raffaele|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","18 Years to 60 Years   (Adult)","Phase 2","831","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","A-055","January 31, 2019","March 20, 2023","March 30, 2024","April 30, 2018",,"February 22, 2024","Task Clinical Research Centre, Bellville, Cape Town, South Africa|University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa|The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa|The Aurum Institute, Klerksdorp, North-West, South Africa|South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester, Cape Town, Western Cape, South Africa|NIMR Mbeya Medical Research Centre, Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT03512249"
764,"NCT04923958","Rapid Research in Diagnostics Development for TB Network","R2D2TB Network","Recruiting","No Results Available","Tuberculosis","Diagnostic Test: Novel mycobacterial culture techniques|Diagnostic Test: Novel sputum smear microscopy techniques|Diagnostic Test: Sputum-based molecular assays|Diagnostic Test: Tongue swab-based molecular assays|Diagnostic Test: Urine LAM assays|Diagnostic Test: Blood-based host immune response assays|Diagnostic Test: Breath-based assays|Diagnostic Test: Artificial intelligence-based digital health tools|Diagnostic Test: Phage-based assays|Diagnostic Test: Cartridge-based molecular assays for detecting drug resistance|Diagnostic Test: Sequencing-based assays for detecting drug resistance","Sensitivity|Specificity","University of California, San Francisco|University Hospital Heidelberg|Christian Medical College, Vellore, India|Vietnam National Lung Hospital|De La Salle University Medical Center|University of Stellenbosch|Makerere University|Johns Hopkins Bloomberg School of Public Health|Harvard Medical School (HMS and HSDM)|Stanford University|Foundation for Innovative New Diagnostics, Switzerland|Socios En Salud Sucursal, Peru|Federal University of Mato Grosso|Medical Research Council|National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia|Centre for Infectious Disease Research in Zambia|National Institute of Allergy and Infectious Diseases (NIAID)","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","6050","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","U01AI152087","April 14, 2021","May 31, 2025","May 31, 2025","June 11, 2021",,"June 29, 2023","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Chitoor (Christian Medical College satellite campus), Vellore, India|Christian Medical College CMC Pulmonary Outpatient Department, Vellore, India|Primary care clinics (Shalom/LCC, CHAD), Vellore, India|De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines|Brooklyn Chest Hospital, Cape Town, South Africa|Khayelitsha District Health Center, Cape Town, South Africa|Kraaifontein Community Health Clinic, Cape Town, South Africa|Scottsdene primary care clinic, Cape Town, South Africa|Wallacedene primary care clinic, Cape Town, South Africa|Kisenyi Health Center, Kampala, Uganda|Mulago Outpatient Department, Kampala, Uganda|Hanoi Lung Hospital, Outpatient departments, Hanoi, Vietnam|National Lung Hospital, Outpatient departments, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04923958"
765,"NCT04618198","Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa","ATLAS","Recruiting","No Results Available","Tuberculosis|HIV I Infection|Sepsis","Other: Immediate anti-TB therapy|Other: Sepsis-specific dose anti-TB therapy","28-day mortality|In-hospital mortality|6-month mortality|Time to death|Duration of hospitalization|Time to anti-TB therapy|Adverse events|Sepsis etiology|Time to ambulation|Time to temperature normalization|Karnofsky score|Peak drug concentration isoniazid|Peak drug concentration rifampin|Total drug exposure isoniazid|Total drug exposure rifampin","University of Virginia|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 3","436","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","22611|U01AI150508-01A1","December 10, 2021","March 25, 2025","June 25, 2025","November 5, 2020",,"March 14, 2023","Kibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania|Mbarara University Science Technology, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT04618198"
766,"NCT02497079","Diagnostic Accuracy of Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples",,"Unknown status","No Results Available","Lymphadenopathy|Tuberculosis|Sarcoidosis","Device: Nested PCR for formalin-fixed tissues|Device: Nested PCR for fresh tissues|Device: Real-time PCR for fresh tissues","Number of participants who detected each polymerase chain reactions for Mycobacterium tuberculosis","Pusan National University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PNUH-P-1","July 2015","December 2018","December 2018","July 14, 2015",,"July 20, 2015","Pusan National University Hospital, Busan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02497079"
767,"NCT05473195","A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098","BETO","Recruiting","No Results Available","Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)","Drug: BVL-GSK098 9mg|Drug: Ethionamide 250mg|Drug: Ethionamide 250 mg|Drug: Isoniazid 300 MG","EBA CFU|EBA TTP","TASK Applied Science","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TASK-010-BETO","December 6, 2022","October 2023","October 2023","July 25, 2022",,"January 19, 2023","TASK Clinical Research Centre, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT05473195"
768,"NCT00341042","Collection of Tissue Specimens in Mali, West Africa, for HIV and Tuberculosis Research",,"Terminated","No Results Available","Tuberculosis|HIV",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"253","NIH","Observational",,"999905028|05-I-N028","January 4, 2005",,"May 1, 2013","June 21, 2006",,"April 5, 2018","Universite of Bamako, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT00341042"
769,"NCT01585636","Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: SQ109","Safety|Pharmacokinetics of SQ109 in fasted subjects and effect of high-fat, high calorie meal on pharmacokinetics","Sequella, Inc.|Quintiles, Inc.","Male","18 Years to 55 Years   (Adult)","Phase 1","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SQ109-CP001","September 2006","February 2007","February 2007","April 26, 2012",,"August 19, 2013","Quintiles Phaes 1 Clinical Study Unit, Lenexa, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01585636"
770,"NCT05411744","One-month Latent Tuberculosis Treatment for Renal Transplant Candidates",,"Recruiting","No Results Available","Latent Tuberculosis|End Stage Renal Disease|Renal Transplant Candidate for Right Kidney|Renal Transplant Candidate for Left Kidney","Drug: 1 month Rifapentine, Isoniazid and Vitamin B6","Rate of adverse events with 1-m INH/RPT/Vit B6|Rate of treatment compliance|Rate of treatment completion","Rutgers, The State University of New Jersey","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2018001735","July 1, 2022","June 30, 2025","June 30, 2029","June 9, 2022",,"March 8, 2024","Pinki J Bhatt, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05411744"
771,"NCT00000638","Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Isoniazid|Drug: Pyrazinamide|Drug: Pyridoxine hydrochloride|Drug: Rifampin",,"National Institute of Allergy and Infectious Diseases (NIAID)|Hoechst Marion Roussel|Lederle Laboratories","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","2000","NIH|Industry","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Prevention","ACTG 177|CPCRA 004|TB/PPD+|11152",,,"September 1999","August 31, 2001",,"November 2, 2021","Univ of Alabama at Birmingham, Birmingham, Alabama, United States|Children's Hosp of Los Angeles, Los Angeles, California, United States|Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|Highland Gen Hosp / San Francisco Gen Hosp, Oakland, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium, San Jose, California, United States|San Mateo AIDS Program / Stanford Univ, Stanford, California, United States|Stanford Univ Med Ctr, Stanford, California, United States|Olive View Med Ctr, Sylmar, California, United States|Harbor UCLA Med Ctr, Torrance, California, United States|Yale Univ / New Haven, New Haven, Connecticut, United States|HIV Ctr - District of Columbia Gen Hosp, Washington, District of Columbia, United States|Whitman - Walker Clinic / Georgetown Univ Med Ctr, Washington, District of Columbia, United States|Georgetown Univ Med Ctr, Washington, District of Columbia, United States|Howard Univ, Washington, District of Columbia, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Queens Med Ctr, Honolulu, Hawaii, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Children's Mem Hosp Family Cln / Northwestern Univ Med Schl, Chicago, Illinois, United States|Northwestern Univ Med School, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|Louis A Weiss Memorial Hosp, Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|St Louis Regional Hosp / St Louis Regional Med Ctr, Saint Louis, Missouri, United States|Univ of Nebraska Med Ctr, Omaha, Nebraska, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Adirondack Med Ctr at Saranac Lake, Albany, New York, United States|Albany Med College / Division of HIV Medicine A158, Albany, New York, United States|Mid - Hudson Care Ctr, Albany, New York, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|Comprehensive Health Care Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Interfaith Med Ctr, Brooklyn, New York, United States|SUNY / Health Sciences Ctr at Brooklyn, Brooklyn, New York, United States|SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States|Nassau County Med Ctr, East Meadow, New York, United States|City Hosp Ctr at Elmhurst / Mount Sinai Hosp, Elmhurst, New York, United States|North Shore Univ Hosp, Manhasset, New York, United States|Beth Israel Med Ctr, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Saint Clare's Hosp and Health Ctr, New York, New York, United States|Cornell Univ Med Ctr, New York, New York, United States|Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States|Mount Sinai Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|SUNY - Stony Brook, Stony Brook, New York, United States|SUNY / State Univ of New York, Syracuse, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Moses H Cone Memorial Hosp, Greensboro, North Carolina, United States|Wake County Dept of Health, Raleigh, North Carolina, United States|Univ of Cincinnati, Cincinnati, Ohio, United States|Univ of Kentucky Lexington, Cincinnati, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Ohio State Univ Hosp Clinic, Columbus, Ohio, United States|Girard Med Ctr, Philadelphia, Pennsylvania, United States|Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina / UNC, Charleston, South Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Meharry Med College, Nashville, Tennessee, United States|Univ of Texas Galveston, Galveston, Texas, United States|Houston Clinical Research Network, Houston, Texas, United States|Univ of Puerto Rico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000638"
772,"NCT00000959","Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Isoniazid|Drug: Pyridoxine hydrochloride",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","600","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","CPCRA 005|11557",,,"June 1996","August 31, 2001",,"November 4, 2021","UCLA Med Ctr, Los Angeles, California, United States|Community Consortium of San Francisco, San Francisco, California, United States|Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States|Hill Health Corp, New Haven, Connecticut, United States|Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States|Veterans Administration Med Ctr / Regional AIDS Program, Washington, District of Columbia, United States|AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States|Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States|Comprehensive AIDS Alliance of Detroit, Detroit, Michigan, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Addiction Research and Treatment Corp, Brooklyn, New York, United States|Clinical Directors Network of Region II, New York, New York, United States|Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00000959"
773,"NCT00000636","Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Isoniazid|Drug: Pyrazinamide|Drug: Pyridoxine hydrochloride|Drug: Rifampin",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","2000","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","CPCRA 004|TB/PPD+|ACTG 177|11556",,,"October 1997","August 31, 2001",,"November 2, 2021","Community Consortium / UCSF, San Francisco, California, United States|Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States|Hill Health Corp, New Haven, Connecticut, United States|Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States|Veterans Administration Med Ctr / Regional AIDS Program, Washington, District of Columbia, United States|AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States|Chicago Dept of Health / Speciality STD Clinic, Chicago, Illinois, United States|AIDS Research Alliance - Chicago, Chicago, Illinois, United States|Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States|Johns Hopkins Univ / Brazil, Baltimore, Maryland, United States|Johns Hopkins Univ / School of Hygiene & Public Health, Baltimore, Maryland, United States|Boston Dept of Health and Hosps, Boston, Massachusetts, United States|Comprehensive AIDS Alliance of Detroit, Detroit, Michigan, United States|Henry Ford Hosp, Detroit, Michigan, United States|Southern New Jersey AIDS Cln Trials / Dept of Med, Camden, New Jersey, United States|Saint Michael's Med Ctr, Newark, New Jersey, United States|Lattimore Comprehensive Pulmonary Disease Clinic, Newark, New Jersey, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Addiction Research and Treatment Corp, Brooklyn, New York, United States|Clinical Directors Network of Region II, New York, New York, United States|Beth Israel Med Ctr, New York, New York, United States|Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York, New York, United States|Philadelphia FIGHT, Philadelphia, Pennsylvania, United States|Richmond AIDS Consortium, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00000636"
774,"NCT03100786","Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis",,"Active, not recruiting","No Results Available","Tuberculosis|Tuberculous Meningitis|Drug-Induced Liver Injury","Drug: Dexamethasone|Other: Placebo","All-cause mortality or new neurological event|Overall survival until 12 months after randomization|Neurological disability at 12 months (modified Rankin score)|Severe (grade 3 and 4) and serious adverse events by 12 months|Requirement for 'rescue' corticosteroids","Oxford University Clinical Research Unit, Vietnam|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam","All","18 Years and older   (Adult, Older Adult)","Phase 3","720","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","27TB","February 8, 2018","June 30, 2024","June 30, 2024","April 4, 2017",,"March 22, 2024","Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT03100786"
775,"NCT01014481","Appropriate Timing of HAART in Co-infected HIV/TB Patients","TIME","Terminated","No Results Available","HIV Infections|Tuberculosis","Drug: tenofovir, lamivudine, efavirenz","death rate|hospitalization|adverse events|composite endpoint of a. death b. hospitalization and c. adverse event|TB IRIS|Risk of death","Bamrasnaradura Infectious Diseases Institute|Mahidol University|Thai Red Cross AIDS Research Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0435.3/1551","October 2009","May 2011","May 2011","November 17, 2009",,"November 17, 2011","Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand",,"https://ClinicalTrials.gov/show/NCT01014481"
776,"NCT01875952","Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)","HIV/TB","Unknown status","No Results Available","Human Immunodeficiency Virus (HIV)|Tuberculosis (TB)|Latent Tuberculosis Infection (LTI)","Drug: Isoniazid","Production of interferon gamma, in response to treatment of latent infection","Instituto Nacional de Salud Publica, Mexico|Instituto Nacional de Enfermedades Respiratorias|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years to 60 Years   (Adult)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Informed Consent:552 / 306|000000000014520","May 2010","June 2012","June 2013","June 12, 2013",,"June 12, 2013","Instituto Nacional de Salud Publica, Mexico, Cuernavaca Morelos, Mexico|Clínica Especializada CONDESA, Mexico City, D.F, Mexico",,"https://ClinicalTrials.gov/show/NCT01875952"
777,"NCT00524147","Drainage of Tuberculous Pleural Effusions",,"Completed","No Results Available","Tuberculous Pleurisy","Procedure: Pigtail drainage","Chest radiography, daily monitoring of the volume of fluid drained, the time needed for resolution of fever and dyspnea, and total amounts of fluid drained, and the length of chest drainage and hospitalization|Chest radiography and pulmonary function testing with spirometry","Taipei Medical University Hospital","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TMU92-AE1-B36","October 2003","October 2005","December 2006","September 3, 2007",,"December 30, 2010","Taipei Medical University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00524147"
778,"NCT00157066","Effects of Vitamin D Supplementation on Antimycobacterial Immunity",,"Completed","No Results Available","Tuberculosis","Drug: Ergocalciferol","Bacillus Calmette-Guerin (BCG) lux whole blood assay|Antigen-stimulated whole blood interferon gamma production","Barts & The London NHS Trust|Imperial College London|University of Cape Town|Newham Chest Clinic, London E7 8QP, UK|Northwick Park Hospital, Harrow, UK|Department of Clinical Biochemistry, Homerton Hospital, London E9 6SR, UK|Environmental Health Department, London Borough of Newham, London E15 4SF, UK|Wellcome Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double","AM1","December 2002",,"September 2006","September 12, 2005",,"January 8, 2007","Tuberculosis Clinic, Newham Chest Clinic, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00157066"
779,"NCT00309673","Local Anesthesia and Tuberculin Skin Test in Infants and Children",,"Unknown status","No Results Available","Tuberculosis","Drug: lidocaine / Prilocaine","Measurement of tuberculin skin tests reaction performed with and without|local anaesthesia, in a child (intra subject reproducibility)|influence of local anaesthesia use, on tuberculin skin test interpretation|between observer reproducibility|pain evaluation in child over 5 years of age between tuberculin skin tests performed with and without local anaesthesia|relationship between local anaesthesia use and failure to perform a correct intradermal injection|local tolerance to lidocaine / prilocaine","Assistance Publique - Hôpitaux de Paris","All","1 Month to 15 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","CRC05001",,,,"April 3, 2006",,"April 3, 2006","Robert Debré Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT00309673"
780,"NCT01685099","Evaluating the Diagnostic Validity of Inflammation-associated Markers for Tuberculous Pleurisy",,"Unknown status","No Results Available","To Investigate Diagnostic Aid of the Inflammation and Apoptosis-associated Markers and Apoptosis Pattern of PE Neutrophil for Tuberculous Pleurisy",,"diagnosis of tuberculous pleurisy|mortality","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","201207061RIC","August 2012",,,"September 13, 2012",,"September 13, 2012","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01685099"
781,"NCT04179500","A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers","PaSEM","Active, not recruiting","No Results Available","Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Tuberculosis, MDR|Tuberculosis|Drug-Resistant Tuberculosis","Drug: Pretomanid|Drug: Bedaquiline|Drug: moxifloxacin|Drug: pyrazinamide","Total Sperm Number - Week 26|Total Sperm Number - Week 13 and Week 44|Change in Male Reproductive Hormones","Global Alliance for TB Drug Development","Male","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pa-824-CL-012","September 16, 2021","June 19, 2023","August 30, 2024","November 27, 2019",,"September 13, 2023","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|CHRU, Sizwe Tropical Diseases Hospital, Johannesburg, South Africa|Isango Lethemba TB Research Unit Empilweni TB Hospital, Port Elizabeth, South Africa|The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa",,"https://ClinicalTrials.gov/show/NCT04179500"
782,"NCT04062201","Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care",,"Active, not recruiting","No Results Available","Tuberculosis|Pre-XDR-TB|Extensively Drug-Resistant Tuberculosis|Multi Drug Resistant Tuberculosis|Rifampicin Resistant Tuberculosis","Drug: Bedaquiline Oral Tablet|Drug: Linezolid Oral Tablet|Drug: Delamanid in Oral Dosage Form|Drug: Clofazimine Oral Product|Drug: Levofloxacin Oral Tablet|Drug: Isoniazid Oral Product|Drug: Ethambutol Oral Product|Drug: Pyrazinamide Oral Product","The proportion of participants with a successful outcome at the end of treatment|The proportion of participants with a successful outcome at the end of follow up at 76 weeks post treatment initiation|The proportion of participants who experience grade 3 or greater adverse events during treatment and up to 30 days following the end of treatment|The proportion of participants with a successful composite outcome at 76 weeks post treatment initiation|PK/PD model of clofazimine exposure|PK/PD model of bedaquiline, delamanid, levofloxacin and linezolid exposure|PK/PD model drug exposures of drugs/metabolites known to cause QT prolongation (clofazimine, bedaquiline M2 metabolite, delamanid DM6705 metabolite, and levofloxacin)|PK/PD model drug exposures of linezolid","Wits Health Consortium (Pty) Ltd|Regents of the University of California|University of Cape Town|Perinatal HIV Research Unit of the University of the Witswatersrand","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","402","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BEAT Tuberculosis|72067418CA00006","August 22, 2019","June 2023","June 2023","August 20, 2019",,"October 24, 2022","Jose Pearson TB Hospital, Port Elizabeth, Eastern Cape, South Africa|King DinuZulu Hospital Complex, Durban, KwaZulu Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT04062201"
783,"NCT01456845","Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity",,"Completed","No Results Available","Hepatitis|Tuberculosis",,"Evaluation of plasma levels of isoniazid, rifampicin, pyrazinamide among cases and controls|Evaluation of plasma drug levels and its correlation among cases and controls and to assess the ability of these drug levels to predict subsequent development of drug induced hepatoxicity","All India Institute of Medical Sciences, New Delhi","All","18 Years to 65 Years   (Adult, Older Adult)",,"110","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SKS/DIH/2011","August 2010","June 2012","June 2012","October 21, 2011",,"August 31, 2012","All India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT01456845"
784,"NCT02238405","A Controlled Smoking Cessation Trial and Prospective Cohort Study of Tuberculosis (TB) Treatment Outcomes",,"Completed","No Results Available","Smoking Cessation|Tuberculosis","Other: Intensive anti-smoking counseling","Smoking cessation rate|negative TB treatment outcome (death, treatment failure, relapse, required prolongation of TB therapy","Johns Hopkins University|Global Fund|National Tuberculosis Control Program, Pakistan","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00037636","May 25, 2015","December 2017","January 2018","September 12, 2014",,"August 9, 2018","Indus Hospital, Karachi, Pakistan",,"https://ClinicalTrials.gov/show/NCT02238405"
785,"NCT01616264","Reproducibility of Computed Tomography",,"Completed","No Results Available","Tuberculosis|Pleural Effusion",,,"Universidade Federal do Rio de Janeiro","All","20 Years to 70 Years   (Adult, Older Adult)",,"20","Other","Observational","Time Perspective: Prospective","JUL 200456","January 2006","October 2009","December 2009","June 11, 2012",,"June 11, 2012",,,"https://ClinicalTrials.gov/show/NCT01616264"
786,"NCT00128206","Treatment of Latent TB Infection for Jailed Persons",,"Completed","Has Results","Tuberculosis","Drug: Isoniazid|Drug: Rifampin","Number of Participants With Laboratory Test or Clinical Judgment Resulting in the Need to Stop Study Medication|Completion of Therapy|Cost Effectiveness","University of California, San Francisco|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","364","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03-135|U01AI051315","November 2004","October 2008","September 2009","August 9, 2005","December 6, 2010","July 21, 2020","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00128206"
787,"NCT02729532","Effect of Xpert MTB/RIF on Patient Outcomes",,"Completed","No Results Available","Tuberculosis","Device: Xpert","Culture-positive patient drop-out before accessing treatment|Time to TB treatment|Percentage of participants who receive TB treatment within 14 days of enrolment (effect of Xpert on the accuracy of TB diagnosis)|Percentage of participants who did not receive TB treatment 14 days post-enrolment (effect of Xpert on the accuracy of TB diagnosis)|Time to TB Diagnosis|Number of TB patients lost to follow-up","University of North Carolina, Chapel Hill|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"776","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-1697|US NIH Grant P30 AI50410-17","June 22, 2016","February 9, 2018","February 9, 2018","April 6, 2016",,"April 22, 2019","Chelstone and Chilenje Health Centres, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT02729532"
788,"NCT02355223","Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission","FAST","Unknown status","No Results Available","Tuberculosis","Other: FAST","Reduction of time to TB diagnosis and treatment for patients and TB infection rates in health care workers.|Sensitivity and specificity of a novel exhaled breath test (EBT) and digital chest X-ray with computer assisted detection (dCXR/CAD4TB) as ""rule-out"" screening tests for tuberculosis in coughing patients|Costs and cost-effectiveness of FAST|Acceptability of FAST, novel screening strategies, and health care worker testing for latent tuberculosis.","Brigham and Women's Hospital|Hospital Nacional Hipólito Unanue|Socios En Salud Sucursal, Peru|Hospital Nacional Arzobispo Loayza|Hospital Nacional Sergio Bernales","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11060","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2014P002396","August 2016","February 2020","February 2020","February 4, 2015",,"January 12, 2018","Hospital Nacional Hipolito Unanue, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT02355223"
789,"NCT00929786","Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity",,"Completed","No Results Available","Hepatitis|Tuberculosis",,"Evaluation of plasma levels of isoniazid, rifampicin, pyrazinamide among cases and controls|Evaluation of plasma levels of any significant metabolites among cases and controls","All India Institute of Medical Sciences, New Delhi","All","16 Years to 65 Years   (Child, Adult, Older Adult)",,"72","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SKS/DIH/01|sksharma@aiims.ac.in","November 2007","April 2009","June 2009","June 30, 2009",,"November 10, 2009","All India Institute of Medical Sciences, New Delhi, Delhi, India|All India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00929786"
790,"NCT03537495","Pharmacokinetic Study of Linezolid for TB Meningitis","SIMPLE","Completed","No Results Available","Tuberculosis, Meningeal|Linezolid","Drug: Linezolid","Linezolid exposure in blood and CSF|Serious adverse event|Clinical response|Neurological response|Mortality|Blood inflammatory response|CSF inflammatory response","Universitas Padjadjaran|Radboud University Medical Center|Global Alliance for TB Drug Development","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB-201805.01","June 21, 2021","March 1, 2023","July 20, 2023","May 25, 2018",,"September 6, 2023","Hasan Sadikin General Hospital, Bandung, Jawa Barat, Indonesia",,"https://ClinicalTrials.gov/show/NCT03537495"
791,"NCT04777721","Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers",,"Active, not recruiting","No Results Available","Tuberculosis","Biological: BCG Danish","To quantify BCG recoverable from bronchial sample|Adverse Events","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","TB044","May 17, 2022","September 2023","September 2023","March 2, 2021",,"March 7, 2023","Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04777721"
792,"NCT05916638","MoMa Signature During Granulomatosis","MOSAR","Recruiting","No Results Available","Sarcoidosis|Tuberculosis","Other: blood sample","macrophage activation in sarcoidosis measured by epigenomic|monocyte activation in sarcoidosis measured by epigenomic|macrophage activation in sarcoidosis measured by flow cytometry|monocyte activation in sarcoidosis measured by flow cytometry|monocyte activation in sarcoidosis measured by transcriptomic|macrophage activation in sarcoidosis measured by transcriptomic|macrophage activation in sarcoidosis measured by cytokine measurement|monocyte activation in sarcoidosis measured by cytokine measurement|monocyte activation in tuberculosis measured by epigenomic|Identification of a pathogen that triggers sarcoidosis development by metagenomic study|identification of epigenetic modifications of monocytes by CUT&Tag method|Identification of a diagnostic test to discriminate sarcoidosis and tuberculosis","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP230273|2022-A02637-36","January 15, 2024","October 2025","October 2025","June 23, 2023",,"March 5, 2024","Hôpital Bichat, Paris, France",,"https://ClinicalTrials.gov/show/NCT05916638"
793,"NCT05122767","Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","DOLPHIN KIDS","Recruiting","No Results Available","Tuberculosis|HIV","Drug: Dolutegravir|Drug: 3HP","PK sampling of Dolutegravir - ka parameter|PK sampling of Dolutegravir - Vd parameter|PK sampling of Dolutegravir - Cl/F parameter|PK sampling of Dolutegravir - AUC parameter|PK sampling of Dolutegravir - Ctau parameter|Adverse Events|HIV-1 RNA viral load|PK sampling of RPT - AUC parameter|PK sampling of RPT - Cmax parameter|PK sampling of RPT - Ctau parameter|DTG Dose selection","The Aurum Institute NPC|Johns Hopkins University","All","3 Months to 17 Years   (Child)","Phase 1|Phase 2","92","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00280272","May 24, 2023","December 2024","December 2025","November 17, 2021",,"March 18, 2024","The Aurum Institute: Pretoria Clinical Research Centre, Pretoria, Gauteng, South Africa|Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital, Klerksdorp, North-West, South Africa",,"https://ClinicalTrials.gov/show/NCT05122767"
794,"NCT02606214","A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects",,"Terminated","No Results Available","Tuberculosis","Drug: TBA-354|Drug: TBA-354 Placebo","The comparison of the percentage of subjects per dose cohort with treatment emergent adverse events (TEAEs) from Days 1 to 28 compared to placebo|The percent of subjects per cohort with safety electrocardiogram change-from-baseline QTcF intervals of >30 milliseconds and =>60 milliseconds.|The mean Tmax of TBA-354 per dose cohort in plasma following dosing|The mean Cmax of TBA-354 per dose cohort in plasma following dosing|The mean AUC0-24 of TBA-354 per dose cohort in plasma following dosing","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TBA-354-CL-002","November 2015","December 2015","December 2016","November 17, 2015",,"September 18, 2019",,,"https://ClinicalTrials.gov/show/NCT02606214"
795,"NCT02342886","Shortening Treatment by Advancing Novel Drugs","STAND","Completed","Has Results","Tuberculosis, Pulmonary, Drug Sensitive|Tuberculosis, Pulmonary, Multi Drug-resistant","Drug: Moxifloxacin|Drug: PA-824|Drug: Pyrazinamide|Drug: HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|Drug: HR (rifampicin plus isoniazid combination tablets)","Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population)|Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population)","Global Alliance for TB Drug Development","All","18 Years and older   (Adult, Older Adult)","Phase 3","284","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NC-006-(M-PA-Z)","February 2015","January 2018","May 2018","January 21, 2015","March 26, 2019","March 26, 2019","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Centre for Respiratory Disease Research (CRDR) Keny Medical Research Institute (KEMRI), Nairobi, Kenya|Centre for Respiratory Disease Research (CRDR) Kenya Medical Research Institute (KEMRI), Nairobi, Kenya|Pusat Perubatan Universiti Kebangsaan, Cheras, Kuala Lumpur, Malaysia|Universiti Teknologi MARA, Batu Caves, Selangor, Malaysia|Institute of Respiratory Medicine (IPR), Kuala Lumpur, Malaysia|Philippine General Hospital, Ermita, Manila, Philippines|Vincent Balang, Pio del Pilar, Manila, Philippines|Lung Center of Philippines, Manila, Philippines|TASK, Bellville, Cape Town, South Africa|University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa|Setshaba Research Centre, Pretoria, Gauteng, South Africa|The Aurum Institute: Tembisa Hospital Cnr, Tembisa, Gauteng, South Africa|CHRU Themba Lethu Clinic, Westdene, Johannesburg, South Africa|Durban International Clinical Trials Unit (DbnlCTU), Durban, KwaZulu-Natal, South Africa|Klerksdorp Tshepong Hospital, Klerksdorp, North West Province, South Africa|Synexus SA, Mamelodi East, Pretoria, South Africa|Madibeng Centre for Research (MCR), Brits, South Africa|THINK: Tuberculosis & HIV Investigative Network of Kwazulu Natal, Durban, South Africa|The Aurum Institute, Klerksdorp, South Africa|The Aurum Institute: Rustenberg, Rustenburg, South Africa|Ifakara Health Institute (IHI), Dar es Salaam, Tanzania|NIMR - Mbeya Medical Research Programme (MMRP), Mbeya, Tanzania|Kilimanjaro National Institute for Medical Research, Mwanza, Tanzania|Uganda CWRU Research Collaboration, Kampala, Uganda|Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT02342886/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT02342886/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02342886"
796,"NCT01700790","Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin",,"Terminated","No Results Available","AIDS|Tuberculosis","Drug: Lopinavir/ritonavir and ritonavir","Proportion of patients with expected pre dose concentration of lopinavir.|Proportion of patients with successful treatment of HIV therapy.|Proportion of patients with expected AUC of rifampin|Proportion of patient with success of tuberculosis therapy|Proportion of patients with expected Cmax and AUC of lopinavir|Proportion of patients with expected Cmax of rifampin.","University of Miami|Oswaldo Cruz Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20100325","February 2016","November 17, 2018","December 31, 2018","October 4, 2012",,"May 16, 2019","Instituto Nacional de Infectologia Evandro Chagas - Fiocruz(INI), Laboratorio de Pesquisa Clinica em Micobacterioses(LAPCLINTB), Rio de Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT01700790"
797,"NCT04783727","PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis",,"Terminated","No Results Available","Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Bacterial Infections|Mycobacterial Infection","Diagnostic Test: Individualised treatment duration based on RNA transcriptomic model","Proportion of patients with favourable study outcome 12 months after treatment end|Proportion of patients who was lost to follow-up during treatment|Proportion of patients who had a treatment failure|Proportion of patients who died from TB|Proportion of patients who died of any cause","Research Center Borstel|Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PredictEndTBSignature","April 1, 2021","November 1, 2022","November 1, 2022","March 5, 2021",,"December 13, 2023","Research Center Borstel, Borstel, Schleswig-Holstein, Germany|Phthisiopneumology Institute Chiril Draganiuc, Chisinau, Moldova, Republic of|Marius Nasta Pulmonology Institute, Bucharest, Romania|Kharkiv National Medical University, Kharkiv, Ukraine|National Pirogov Memorial Medical University, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT04783727"
798,"NCT01417988","Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment","PrOMPT","Terminated","No Results Available","HIV Infection|Tuberculosis","Drug: Experimental: Empiric TB treatment|Drug: ART only arm","All-cause mortality in the first 24 weeks after initiation of ART|CD4 T cell absolute increase|Causes of death|Safety and tolerability of anti-tuberculous medications|HIV viral suppression|TB incidence rates after ART initiation","Prof JMA Lange|European and Developing Countries Clinical Trials Partnership (EDCTP)|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years and older   (Adult, Older Adult)","Phase 4","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIGHD_001","August 2011","June 2013","June 2013","August 16, 2011",,"February 17, 2014","Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon|Ministry of Health -Provincial Heatlh Directorate of the Sofala Province (Direcção Provincial de Saúde de Sofala DPSS), Beira, Mozambique|Infectious Diseases Institute University Makarere, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01417988"
799,"NCT02288481","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects",,"Completed","No Results Available","Tuberculosis","Drug: TBA-354|Other: Placebo","The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of TBA-354 and placebo.|Pharmacokinetics of TBA-354 in plasma following single oral doses. Cmax, AUC0-24|Effect of food on the Pharmacokinetics parameters of TBA-354 in plasma following an intermediate single oral dose. Cmax, AUC0-24|Number of subjects/time points with abnormal findings in safety electrocardiogram|Placebo-corrected safety electrocardiogram Change-from-baseline heart rate","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TBA-354-CL-001","January 2015","June 2015","June 2015","November 11, 2014",,"September 6, 2019","Celerion, Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02288481"
800,"NCT00926601","Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis",,"Unknown status","No Results Available","Mycoplasma Pneumonia|Pulmonary Tuberculosis",,,"Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-0906-006-281","June 2009",,,"June 23, 2009",,"June 14, 2012","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00926601"
801,"NCT04568954","TB-CAPT CORE Truenat Trial",,"Active, not recruiting","No Results Available","Tuberculosis|Diagnoses Disease","Diagnostic Test: Truenat TB platform/TB assays","Proportion of participants with microbiological confirmation starting TB treatment within 7 days of their first visit among enrolled participants|Time to bacteriological confirmation of TB|Proportion of patients treated for TB up to 60 days from enrolment|Proportion of participants with signs and symptoms suggestive of pulmonary TB starting TB treatment with microbiological confirmation within 60 days from enrolment|Cost and productivity related endpoints","Foundation for Innovative New Diagnostics, Switzerland|Ludwig-Maximilians - University of Munich|National Institute for Medical Research, Tanzania|Centro de Investigação em Saúde de Manhiça|Instituto Nacional de Saúde, Mozambique|Ifakara Health Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","TB041-3/1","August 28, 2022","January 28, 2024","April 30, 2024","September 29, 2020",,"January 18, 2024","Centro de Investigação em Saúde de Manhiça-Fundação, Manhiça, Vila Da Manhiça, Mozambique|Instituto Nacional de Saúde (INS), Maputo, Mozambique|Ifakara Health Institute, Dar es Salaam, Tanzania|National Institute of Medical Research (NIMR), Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT04568954"
802,"NCT05553236","Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis","TSELiOT","Not yet recruiting","No Results Available","Drug-resistant Tuberculosis|HIV Coinfection|Cost-Benefit Analysis","Diagnostic Test: Targeted next-generation sequencing","Number of participants with prespecified end of treatment outcomes|12-month relapse-free survival|Exposure time to ineffective drugs|Number of participants with acquired drug resistance|Time to effective treatment initiation with three drugs|Time to effective treatment initiation with four drugs|Time to culture conversion","University of California, San Francisco|University of Stellenbosch|National Health Laboratory Service (NHLS), South Africa|National Institute for Communicable Diseases, South Africa|National Institute of Allergy and Infectious Diseases (NIAID)|Find|Translational Genomics Research Institute|University Hospital Heidelberg","All","Child, Adult, Older Adult","Not Applicable","2500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AI153213|R01AI153213","February 28, 2024","January 2027","January 2027","September 23, 2022",,"January 23, 2024","South African National Health Laboratory Service, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT05553236"
803,"NCT06214910","ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa","ThiPhiSA","Recruiting","No Results Available","Tuberculosis","Drug: TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)","Completion of a course of TB preventive therapy (TPT)","University of Washington|Human Sciences Research Council|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 4","525","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","STUDY00018448|1R21AI179276-01","February 20, 2024","February 10, 2026","December 31, 2026","January 22, 2024",,"February 26, 2024","Human Sciences Research Council, Sweetwaters, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT06214910"
804,"NCT01800487","The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs",,"Completed","No Results Available","Tuberculosis","Drug: silymarin|Drug: Placebo","The number of patients who develop drug-induced liver injury (DILI) at 4 weeks","Ramathibodi Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ramathibodi_silymarin","January 2012","June 2013","July 2013","February 27, 2013",,"December 24, 2013","Gastroenterology and Hepatology, Ramathibodi hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01800487"
805,"NCT03912207","Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults",,"Active, not recruiting","No Results Available","Tuberculosis","Biological: BCG Danish|Other: Saline placebo","Identification of markers of innate immunity-cytokines|Identification of markers of innate immunity-antigen presenting cells|Identification of markers of innate immunity-inflammation in tissue|Identification of markers of adaptive immunity-antibodies|Identification of markers of adaptive immunity-T cells|Mycobacterial growth inhibition assay","University of Oxford|Wellcome Trust|National Institute for Health Research, United Kingdom|University of Leicester","All","18 Years to 50 Years   (Adult)","Phase 1","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other","TB043","April 19, 2019","June 2024","June 2024","April 11, 2019",,"January 3, 2024","Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Oxford University Hospitals- John Warin Ward, University of Oxford, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03912207"
806,"NCT01770730","A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients","LAMRCT","Completed","No Results Available","Tuberculosis","Device: Urine LAM strip test","All-cause mortality|Change in TB-related morbidity score|Change in Karnofsky performance index|Hospital length of stay|Diagnostic accuracy of urine LAM strip test","University of Cape Town|University of Zimbabwe|University of Zambia|NIMR - Mbeya Medical Research Programme","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2618","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LAMRCT","January 2013","December 2014","January 2015","January 18, 2013",,"June 3, 2015","University of Cape Town, Cape Town, Western Cape, South Africa|Mbeya Medical Research Programme, Mbeya, Tanzania|University Teaching Hospital, Lusaka, Zambia|University of Zimbabwe, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT01770730"
807,"NCT02382107","A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania",,"Completed","No Results Available","Tuberculosis","Other: Observational","The main objective is the evaluation of the diagnostic characteristics (sensitivity, specificity) of several new rapid diagnostic tests for TB compared to culture (both liquid and solid) as the reference standard in patients","Michael Hoelscher|""Marius Nasta"" Pulmonology Institute|Clinical Infectious Diseases Research Center Borstel, Germany|Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","LMU-IMPH-Bucharest-01","March 2015","May 2016","August 2017","March 6, 2015",,"March 7, 2018","Marius Nasta Pulmonology Institute, Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02382107"
808,"NCT01059422","Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients",,"Unknown status","No Results Available","HIV Infections|Tuberculosis","Drug: Raltegravir; Abacavir/Lamivudine","Proportion of subjects with plasma HIV-1 RNA <50 copies/ml by the Time to Loss of Virologic Response (TLOVR) algorithm","Central Institute of Epidemiology, Moscow, Russia|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAL/ABC/3TC - HIV/TB","October 2010","October 2011",,"January 29, 2010",,"May 6, 2011","Central Research Institute of Epidemiology, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01059422"
809,"NCT06022146","TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts","TB-YOUTH","Recruiting","No Results Available","Tuberculosis|Latent Tuberculosis","Drug: Rifampin and Isoniazid|Drug: isoniazid and rifapentine","Number of participants with culture or GeneXpert MTB/RIF confirmed TB or clinically highly suggested TB|Number of participants permanently withdrawal from medication for any reason.|N Number of participants complete the treatment.|All-cause mortality.|Number of participants with drug resistance result.","Huashan Hospital","All","13 Years and older   (Child, Adult, Older Adult)","Phase 3","3520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KY-2023-020","September 1, 2023","September 1, 2026","September 1, 2026","September 1, 2023",,"November 13, 2023","People's Hospital of Liping Town, Autonomous Region, Guizhou, China|Central Hospital of Jingan District, Shanghai, Shanghai, China|3rd People's Hospital of Bijie, Bijie, China|People's Hospital of Dafang Town, Bijie, China|People's Hospital of Nayong, Bijie, China|Chinese Medicine Hospital of Qingzhen, Guiyang, China",,"https://ClinicalTrials.gov/show/NCT06022146"
810,"NCT00567151","Co-Infection of NTM in Patients With Smear Positive Pulmonary TB",,"Completed","No Results Available","Tuberculosis, Pulmonary",,,"Seoul National University Hospital","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-0711-022-225|Non-applicable","December 2007","December 2008","December 2008","December 4, 2007",,"June 23, 2009","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00567151"
811,"NCT00802802","Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Efavirenz (EFV)|Drug: Rifampin-containing anti-TB therapy","Any treatment-related Grade 2B rash or Grade 3 or 4 toxicity requiring permanent discontinuation of efavirenz (EFV)|Death|A safety event as defined as a Grade 4 life-threatening toxicity or Grade 4 toxicity accompanying a serious adverse event (SAE) (e.g., hospitalization) or death that is judged to be at least possibly related to EFV|Failure to achieve the area under the curve (AUC) target range despite dose adjustment|A confirmed decrease (less than 1 log) from entry quantitative HIV RNA and RNA greater than 400 copies/mL","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 35 Months   (Child)","Phase 1","67","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1070|10633|IMPAACT P1070","February 10, 2010","March 18, 2016","February 16, 2018","December 5, 2008",,"November 1, 2021","Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Shandukani Research CRS, Johannesburg, Gauteng, South Africa|Durban Paediatric HIV CRS, Durban, KwaZulu-Natal, South Africa|Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg Hills, Western Cape Province, South Africa|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda|Harare Family Care CRS, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT00802802"
812,"NCT04871230","Dried Blood Spot Test to Assess TB in Pregnancy","DROPTB2","Completed","No Results Available","Tuberculosis","Diagnostic Test: 3G DBS|Diagnostic Test: Sputum Test|Diagnostic Test: 3G Veinous Blood","diagnostic feature of test 3 G q-PCR capillary blood compared to gold stantard test|diagnostic feature of test 3 G q-PCR capillary blood compared to 3 G q-PCR veinous blood","Institut Pasteur de Madagascar|National Tuberculosis Program, Madagascar|Analakely Hospital University Care and Public Health, Madagascar|Virginia-Maryland College Veterinary Medecine, Blacksburg|Johns Hopkins Bloomberg School of Public Health","Female","15 Years and older   (Child, Adult, Older Adult)",,"1424","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2021-01|TTS-2008-25933","October 27, 2021","September 30, 2022","September 30, 2022","May 4, 2021",,"September 28, 2023","CHRR Ambositra, CDT Ivato, Ambositra, Amoron'i Mania, Madagascar|CSBII Ivato, AMIT Behoririka, OSTIE Behoririka, CSB II Tanjombato, CSB II Analamahitsy, Antananarivo, Analamanga, Madagascar|CSB II Isotry Central, Dispensaire SALFA 67 ha, Centre Hospitalier d'Ambohidroa, Antananarivo, Analamanga, Madagascar|CSBII Ambohimanarina, CSB II Anosipatrana, CSB II Ambohipo, CHRD Itaosy, Antananarivo, Analamanga, Madagascar|Dispensaire SALFA Ambohibao, Centre Hospitalier de Soavinandriana, Dispensaire ECAR Anatihazo Isotry,, Antananarivo, Analamanga, Madagascar|Service de Pneumo-phtisio CHU Befelatanana, CHU de Soins et Santé Publique Analakely (CHUSSPA), Antananarivo, Analamanga, Madagascar|CHU Fenoarivo, Fenoarivo, Analamanga, Madagascar|DAT Toliara, SALFA Betela Toliara, Service Pneumo du CHU Toliara, Clinique Saint Luc, Tulear, Atsimo Andrefana, Madagascar|DAT Toamasina, CHU PPH Toamasina, SALFA Toamasina, CSBII Foulpointe, Toamasina, Atsinanana, Madagascar|DAT Mahabibo, SALFA Antanimalandy, Service de Pneumologie CHU Androva, Mahajanga, Boeny, Madagascar|Service Pneumo du CHU Fianarantsoa, SALFA Ivory Atsimo, CHRD1 Ambohimahasoa, CHRD1 Ambalavao, Fianarantsoa, Haute Matsiatra, Madagascar|CHRR Antsirabe, SALFA Andranomadio, CSB II Mandoto, CSB II Ambohibary , CSB II Ambohibary, Antsirabe, Vakinankaratra, Madagascar",,"https://ClinicalTrials.gov/show/NCT04871230"
813,"NCT00057122","Tuberculosis Prevention for HIV Infected Adults",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Isoniazid|Drug: Rifapentine|Drug: Rifampin","Development of confirmed, probable, or possible active pulmonary or extrapulmonary tuberculosis (TB)|Risk of TB and death|rates of adherence, adverse reactions and treatment discontinuation|patterns of antibiotic resistance|clinical and epidemiological factors associated with developing TB","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 3","1148","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01AI048526-01A1|5R01AI048526-02","September 2002","November 2008","June 2009","March 28, 2003",,"October 22, 2012","Chris Hani Baragwanath Hospital, Soweto, South Africa",,"https://ClinicalTrials.gov/show/NCT00057122"
814,"NCT04575519","Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis","SMA-TB","Recruiting","No Results Available","Tuberculosis, Pulmonary|Tuberculosis, MDR|Tuberculosis Infection","Drug: Control group|Drug: ASA group|Drug: IBU group|Drug: SoC TB","Time to ≥ 67% sustained reduction in the TB score|Hazard ratio for time to stable culture conversion (SCC)|Hazard ratio for stable culture conversion (SCC) at week 8 and week 16 after treatment start.|Proportion of patients with improvement or resolution of clinical signs and symptoms at end of treatment (TB score).|Proportion of patients with improvement of lung function impairment as change from baseline at week 8, 24 and end of treatment in the 1-second forced expiratory volume (FEV1) expressed as FEV1.|Changes in the BCN-SA Radiological Score Value.|Number of patients with improvement of Health-related Quality of Life comparing baseline measure with that over the course of therapy.","Fundació Institut Germans Trias i Pujol|National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia|Perinatal HIV Research Unit of the University of the Witswatersrand","All","18 Years to 60 Years   (Adult)","Phase 2","354","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SMA-TB-001","March 4, 2021","October 2024","June 2025","October 5, 2020",,"March 25, 2024","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Perinatal HIV Unit (PHRU)- Chris Hani Baragwanath Hospital, Soweto, Johannesburg, South Africa|PHRU- Matlosana, Tshepong Hospital MDR Unit, Klerksdorp, Matlosana, South Africa",,"https://ClinicalTrials.gov/show/NCT04575519"
815,"NCT02709278","Aerosol BCG Challenge Trial in Healthy UK Adults",,"Completed","No Results Available","Tuberculosis","Biological: BCG|Other: Saline placebo","Adverse Events (AE)|Quantification of BCG","University of Oxford|University of Birmingham","All","18 Years to 50 Years   (Adult)","Phase 1","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","TB041","March 7, 2016","May 9, 2019","May 9, 2019","March 16, 2016",,"November 18, 2023","Centre for Clinical Vaccinology and Tropical Medicine , University of Oxford, Oxford, Oxfordshire, United Kingdom|Oxford University Hospitals- John Warin Ward, University of Oxford, Oxford, Oxfordshire, United Kingdom|NIHR Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02709278"
816,"NCT01194180","A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A",,"Completed","No Results Available","Tuberculosis","Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu|Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu","Culture and RT-PCR quantification of BCG in challenge site biopsy|Established and exploratory markers of cell mediated immunity in blood samples and biopsied tissue","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB023","May 2010","January 2012","January 2012","September 2, 2010",,"August 30, 2012","Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01194180"
817,"NCT00023439","TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment",,"Completed","No Results Available","Tuberculosis","Other: Nucleic Acid Amplification Methods for diagnosis",,"Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)",,"300","U.S. Fed","Observational","Time Perspective: Prospective","CDC-NCHSTP-2530|NAA TBTC","May 2000",,,"September 10, 2001",,"August 3, 2011","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Chicago-Lakeside VAMC, Chicago, Illinois, United States|Harlem Hospital Center, New York, New York, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Nelson R. Mandela School of Medicine, Durban, KwaZulu Natal, South Africa|Makerere University Medical School, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00023439"
818,"NCT00107887","TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)",,"Completed","No Results Available","Tuberculosis|HIV Infections","Drug: INH preventive therapy|Drug: TST (tuberculin skin test)","Measured incidence of active TB in HIV clinic population before and following implementation of IPT policy|Comparative impact of IPT (Isoniazid Preventive Therapy) and ARVs (antiretrovirals) on TB incidence in the HIV clinic population|Characteristics of TST+ vs. TST+ HIV-infected patients|Clinical, demographic and laboratory predictors of developing active TB|Lessons learned related to training and implementation","Johns Hopkins University|Consortium to Respond Effectively to the AIDS/Tuberculosis Epidemic|Communicable Disease Program, Brazil|Bill and Melinda Gates Foundation","All","16 Years and older   (Child, Adult, Older Adult)","Phase 4","17415","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19790.01","June 2005","December 2010","December 2010","April 12, 2005",,"June 15, 2011","City of Rio De Janeiro Health Department Clinics, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00107887"
819,"NCT04781257","Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries","ERASE-TB","Active, not recruiting","No Results Available","Tuberculosis","Diagnostic Test: New test candidates","Sensitivity and specificity of new diagnostics to diagnose co-prevalent TB against a clinica/microbiological reference standard case definition|Evaluation of novel diagnostics for detection of developing, minimal TB against a clinica/microbiological reference standard case definition|Enhancement of diagnostic performance by simulating testing algorithms coupled with a risk estimate from a mathematical model|M.tb infection status as measured by an immunological assay|Classification of cases of co-prevalent or incident TB; through M.tb isolate sequencing and comparison with the source case isolate|Assessment of the proportion of HHC (without co-prevalent TB) with abnormal pulmonary function at baseline","Michael Hoelscher|European and Developing Countries Clinical Trials Partnership (EDCTP)|Ludwig-Maximilians - University of Munich","All","10 Years and older   (Child, Adult, Older Adult)",,"2100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LMU-IMPH-AIDA-03","March 1, 2021","April 30, 2024","April 30, 2024","March 4, 2021",,"November 28, 2023","Instituto Nacional de Saúde (INS) Centro de Investigação e Treino em Saúde da Polana Caniço, Maputo, Mozambique|NIMR - Mbeya Medical Research Centre, Mbeya, Tanzania|Biomedical Research & Training Institute (BRTI), Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT04781257"
820,"NCT02119130","Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa",,"Completed","No Results Available","Latent Tuberculosis|HIV","Device: QGIT","Impact of linking QGIT with CD4 blood collection and the current standard of care process of TST in HIV clinics in South Africa on operational metrics|Time to known latent TB infection status in clinics integrating QGIT with CD4 blood draw versus clinics with current standard of care (TST only)|Time to provision of IPT for eligible patients in QGIT versus TST-only clinics|Proportion of patients with known LTBI status in QGIT and TST-only clinics|Proportion of eligible patients receiving IPT between QGIT and TST-only clinics|Proportion of eligible patients receiving a second TST or QGIT following an initial negative test|Patient-, provider-, and clinic-level factors that impact outcomes within and between arms|Cost effectiveness of implementing QGIT versus TST-only|Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of key clinic personnel|Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients|Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of clinic personnel","Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|University of Witwatersrand, South Africa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3506","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NA_00085133|R01AI095041","November 1, 2014","June 2018","May 2019","April 21, 2014",,"October 3, 2019","Bothabelo CHC, Klerksdorp, North West, South Africa|Grace Mokhomo, Klerksdorp, North West, South Africa|Jouberton, Klerksdorp, North West, South Africa|Marcus Zenzile, Klerksdorp, North West, South Africa|NM Pretorious Gateway, Klerksdorp, North West, South Africa|Orkney, Klerksdorp, North West, South Africa|Park Street, Klerksdorp, North West, South Africa|Stilfontein, Klerksdorp, North West, South Africa|Tshepong Wellness Clinic, Klerksdorp, North West, South Africa|Tsholofelo, Klerksdorp, North West, South Africa|Boiki Tihapi, Potchefstroom, North West, South Africa|Potchefstroom Gateway, Potchefstroom, North West, South Africa|Potchefstroom, Potchefstroom, North West, South Africa|Steve Tshwete, Potchefstroom, North West, South Africa",,"https://ClinicalTrials.gov/show/NCT02119130"
821,"NCT00698334","Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis",,"Completed","No Results Available","HIV Infections|Acquired Immunodeficiency Syndrome|Tuberculosis","Drug: INH, Rifampicin, Ethambutol and Pyrazinamide","Cure rate|Treatment failure|Death|Relapse|Adverse drug reactions","All India Institute of Medical Sciences, New Delhi|Ministry of Health & Family Welfare, India","All","18 Years to 60 Years   (Adult)","Phase 3","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKS/NACO/2006","April 2006","September 2010","April 2011","June 17, 2008",,"November 8, 2011","All India Institute of Medcial Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00698334"
822,"NCT04528277","Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis","SCRIPT-LGTB","Unknown status","No Results Available","Infertility, Female|Recurrent Implantation Failure|Genital Tuberculoses, Female|Genital Tuberculosis, Latent","Drug: rifapentine plus isoniazid","Clinical pregnancy rates|Ongoing Pregnancy Rate|Miscarriage rate|Implantation rate|Incidence of LGTB|Incidence of FGTB|Incidence of grade 3 or greater adverse events|Completion rate of preventive treatment|Discontinuation of treatment|Discontinuation of treatment due to side effect of study drugs","Huashan Hospital|Shanghai First Maternity and Infant Hospital","Female","25 Years to 40 Years   (Adult)","Phase 3","1050","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KS20232","September 1, 2020","September 1, 2021","September 1, 2022","August 27, 2020",,"August 27, 2020","Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04528277"
823,"NCT00533390","Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg","IPEC-EFV","Terminated","No Results Available","Tuberculosis|HIV Infections","Drug: efavirenz","proportion of patients with viral load < 80 at the end of tuberculosis therapy proportion of adverse events in each group|Immunologic reconstitution Genotyping resistance","Oswaldo Cruz Foundation|Ministry of Health, Brazil","All","18 Years and older   (Adult, Older Adult)","Phase 4","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAAE-0017.1.009.000-03","January 2007","October 2012","October 2012","September 21, 2007",,"November 10, 2015","Universidade Federal do Espirito Santo, Vitoria, Espirito Santo, Brazil|FIOCRUZ Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT00533390"
824,"NCT02178748","Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents","TB036","Completed","No Results Available","Tuberculosis","Biological: MVA85A","T cell immunogenicity by gamma-interferon ELISPOT of Ag85A response.|Evaluation of cytokines in supernatant of stimulated cells using Luminex and flow cytometry of Ag85A response.","University of Oxford|MRC/UVRI and LSHTM Uganda Research Unit","All","12 Years to 17 Years   (Child)","Phase 2","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB036","June 2014","January 2015","January 2015","July 1, 2014",,"January 30, 2015","MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda",,"https://ClinicalTrials.gov/show/NCT02178748"
825,"NCT00023413","TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Rifabutin|Drug: Efavirenz","Compare PK of rifabutin 600mg twice weekly with efavirenz 600mg daily to PK of rifabutin 300mg twice weekly without efavirenz|*Describe PK of rifabutin 600mg twice weekly in combination with efavirenz 600mg daily with 2 NRTI's|*Describe PK of efavirenz in this regimen|*Assess safety of concomitant rifabutin and efavirenz in HIV-TB","Centers for Disease Control and Prevention|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHSTP-2588|23C","November 1999","February 2004","February 2004","September 10, 2001",,"June 5, 2012","Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00023413"
826,"NCT02063555","Phase I Trial of DAR-901",,"Completed","No Results Available","Tuberculosis","Biological: DAR-901|Biological: BCG|Biological: Sterile saline","Safety|Immunogenicity","Dartmouth-Hitchcock Medical Center|Aeras","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DAR-901-MDES","February 2014","March 2016","June 2016","February 14, 2014",,"August 2, 2016","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT02063555"
827,"NCT04865536","Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary","Drug: 1800 mg TBI-223|Drug: 2400mg TBI-223|Drug: 3000mg TBI-223|Drug: TBI-223 Placebo","Safety assessment Vital Signs - Blood pressure|Safety assessment Vital Signs - Pulse rate|Safety assessment Vital Signs - Respiration rate|Safety assessment Vital Signs - Temperature|Safety assessment Vital Signs - Pulse oximetry|Safety assessment - Cardiac monitoring|Safety assessment - Adverse Events (AEs)|Safety assessment Clinical Laboratory Tests - Hematology|Safety assessment Clinical Laboratory Tests - Serology|Safety assessment Clinical Laboratory Tests - Serum Chemistry|Safety assessment Clinical Laboratory Tests - Coagulation|Safety assessment Clinical Laboratory Tests - Urinalysis|Safety assessment - Serum Pregnancy Testing|Safety assessment - Follicle-stimulating hormone (FSH) Levels|Pharmacokinetics, non-food-effect cohorts - AUCtau|Pharmacokinetics, non-food-effect cohorts - Cmax|Pharmacokinetics, non-food-effect cohorts - C24|Pharmacokinetics, non-food-effect cohorts - Cavg|Pharmacokinetics, non-food-effect cohorts - Tmax|Pharmacokinetics, non-food-effect cohorts - AUCinf|Pharmacokinetics, non-food-effect cohorts - AUCextrap|Pharmacokinetics, non-food-effect cohorts - CL/F|Pharmacokinetics, non-food-effect cohorts - Vz/F|Pharmacokinetics, non-food-effect cohorts - lambaZ|Pharmacokinetics, non-food-effect cohorts - t1/2|Pharmacokinetics, non-food-effect cohorts - Cmin|Pharmacokinetics, non-food-effect cohorts - Ctrough|Pharmacokinetics, non-food-effect cohorts - RAUC|Pharmacokinetics, non-food-effect cohorts - RCmax measured.|Pharmacokinetics, food-effect cohorts - AUCtau|Pharmacokinetics, food-effect cohorts - AUCextrap|Pharmacokinetics, food-effect cohorts - AUCinf|Pharmacokinetics, food-effect cohorts - Cmax|Pharmacokinetics, food-effect cohorts - C24|Pharmacokinetics, food-effect cohorts - Clast|Pharmacokinetics, food-effect cohorts - Tmax|Pharmacokinetics, food-effect cohorts - Tlast|Pharmacokinetics, food-effect cohorts - CL/F|Pharmacokinetics, food-effect cohorts - Vz/F|Pharmacokinetics, food-effect cohorts - lambaZ|Pharmacokinetics, food-effect cohorts - t1/2|Pharmacokinetics, food-effect cohorts - Cavg|Pharmacokinetics, food-effect cohorts - Cmin|Pharmacokinetics, food-effect cohorts - Ctrough|Pharmacokinetics, food-effect cohorts - RAUC|Pharmacokinetics, food-effect cohorts - RCmax","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TBI-223-CL-002","February 16, 2021","May 15, 2021","March 25, 2022","April 29, 2021",,"April 15, 2022","TKL Research, Inc., Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04865536"
828,"NCT04666311","Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis","TB TRIAGE+","Completed","No Results Available","Pulmonary Tuberculosis|Tuberculosis Diagnosis|Covid-19|HIV","Diagnostic Test: Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|Diagnostic Test: CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection","Determine CAD4TB cut-off value|Determine Afinion CRP assay cut-off value|Evaluate CAD4TB ROC against reference standard|Evaluate Afinion CRP assay ROC against reference standard|Evaluate CAD4COVID and COVID-19 RDT ROC against reference standard","Klaus Reither|SolidarMed|Human Sciences Research Council|Institute of Tropical Medicine, Belgium|Radboud University Medical Center|Charite University, Berlin, Germany|University Hospital, Basel, Switzerland|Foundation for Innovative New Diagnostics, Switzerland|European and Developing Countries Clinical Trials Partnership (EDCTP)|Ministry of Health, Lesotho|Swiss Tropical & Public Health Institute","All","18 Years and older   (Adult, Older Adult)",,"1400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P1685-20A","February 15, 2021","April 5, 2022","August 11, 2022","December 14, 2020",,"September 9, 2022","Butha-Buthe District Hospital, Butha-Buthe, Lesotho|Caluza Clinic, Pietermaritzburg, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT04666311"
829,"NCT02554318","Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia","FSS","Completed","Has Results","Pulmonary Tuberculosis|Body Weight Changes|Motor Activity","Drug: Rifampicin|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Ethambutol|Dietary Supplement: Fermented soybean","Change in Bodyweight on a Digital Weight Scale From Baseline at 2 Months|Change in Hand-grip Strength on a Digital Dynamometer Scale From Baseline at 2 Months|Change in Distance on 6-minute Walk Test (6MWT) From Baseline at 2 Months|Change in Body Mass Index (BMI) From Baseline at 2 Months","University of Giessen|Indonesian Directorate General of Higher Education","All","18 Years to 55 Years   (Adult)","Not Applicable","147","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DGHE 626/E4.4/K/2011","November 2013","February 2015","February 2015","September 18, 2015","June 21, 2022","June 21, 2022",,,"https://ClinicalTrials.gov/show/NCT02554318"
830,"NCT00495651","Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)","TEMPRANO","Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Antiretroviral medications|Drug: Antiretroviral medications+Isoniazid prophylaxis","Death (all-cause), or severe HIV-related disease (AIDS-defining diseases, non-AIDS-defining malignancies, and non-AIDS-defining invasive bacterial diseases)|prevalence of HIV resistance (ANRS12253 associated study)|Grade 3 or 4 clinical events (including cardiovascular, renal and bone disease) and laboratory test results, as defined by the ANRS classification system of drug-related adverse events|Tuberculosis disease or tuberculosis-related death|Changes in CD4 counts|Resistance to antiretroviral medications|Adherence to treatment|Individual socio-economic factors|Quality of life|Conversions and reversions of repeated QuantiFERON® TB Gold tests between inclusion and month 12 (M12)(ANRS12224 associated study)|Cost-effectiveness of each trial arm in the short- and long-term|Death","French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Merck Sharp & Dohme LLC|ANRS, Emerging Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Phase 3","2073","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 12136 TEMPRANO","March 2008","January 2015","January 2015","July 3, 2007",,"June 3, 2015","Centre de prise en charge de personnes vivant avec le VIH la pierre angulaire, Abidjan, Côte D'Ivoire|Centre de Prise en Charge et de Formation ACONDA, Abidjan, Côte D'Ivoire|Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine, Abidjan, Côte D'Ivoire|Centre Intégré de Recherches Biocliniques d'Abidjan, Abidjan, Côte D'Ivoire|Centre médico-social El Rapha, Abidjan, Côte D'Ivoire|Formation Sanitaire Urbaine Anonkoua Kouté, Abidjan, Côte D'Ivoire|Hopital Général Felix Houphouet Boigny, Abidjan, Côte D'Ivoire|Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte D'Ivoire|Unité de Soins Ambulatoires et de Conseil, CHU de Treichville, Abidjan, Côte D'Ivoire",,"https://ClinicalTrials.gov/show/NCT00495651"
831,"NCT00850915","Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya","IPT","Completed","No Results Available","Tuberculosis","Other: community IPT","incidence of TB in household contacts|incidence of adverse events in household contacts|incidence of TB-related symptoms in household contacts|proportion of household contacts starting IPT|proportion of household contacts discontinuing IPT|proportion of household contacts adhering to IPT treatment","KNCV Tuberculosis Foundation|Stichting Mondiale Tuberculose (SMT)|Kenya Medical Research Institute|Division of Leprosy Tuberculosis and Lung Disease, MOPHS, Kenya|Centres for Disease Control and Prevention, Kenya.|Ministry of Public Health and Sanitation, Kenya|Kenya National AIDS & STI Control Programme","All","15 Years and older   (Child, Adult, Older Adult)","Phase 4","1259","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UR-01-2009-IPT-KENYA","April 2009","November 2012","November 2012","February 25, 2009",,"May 20, 2013","Makuyu H/C, Makuyu-Muranga, Central, Kenya|Huruma Lions -Central district, Nairobi, Nairobi North, Kenya|Kangemi HC, Nairobi, Nairobi North, Kenya|Blue House, Mathare, Nairobi, Nairobi South, Kenya|Jericho HC, Nairobi, Nairobi South, Kenya|Kibera AMREF, Nairobi, Nairobi South, Kenya|MMM, Mukuru, Embakasi, Nairobi, Nairobi South, Kenya|Pumwani Majengo H/C, Nairobi, Nairobi South, Kenya|Remand H/C, Nairobi, Nairobi South, Kenya|Soweto Kayole, Embakasi, Nairobi, Nairobi South, Kenya|KAPSABET District Hospital, Kapsabet-Nandi, North Rift, Kenya|NYALENDA, Kisumu district, Nyanza North, Kenya|Kadem leprosy, Migori, Migori District, Nyanza South, Kenya|Muhuru Health centre, Migori, Migori District, Nyanza South, Kenya|Awendo SDH, Rongo district, Nyanza South, Kenya|Lanet, Nakuru, RVS, Kenya|Nakuru West, Nakuru, RVS, Kenya|Narok District Hosp, Narok, RVS, Kenya",,"https://ClinicalTrials.gov/show/NCT00850915"
832,"NCT03942354","Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial","PRACTECAL-PRO","Unknown status","No Results Available","Multidrug Resistant Tuberculosis","Drug: Bedaquiline|Drug: Pretomanid|Drug: Moxifloxacin|Drug: Linezolid|Drug: Clofazimine|Drug: Directly observed therapy (DOT)","Change in St George's respiratory questionnaire SGRQ survey questionnaire from baseline to 12 months|Changes in Short form 12 survey questionnaire (patient satisfaction and experience) from baseline to 12 months","Medecins Sans Frontieres, Netherlands|University of Sussex|London School of Hygiene and Tropical Medicine|THINK TB & HIV Investigative Network|Wits Health Consortium (Pty) Ltd|Ministry of Public Health, Republic of Belarus|Ministry of Health, Republic of Uzbekistan","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRACTECAL-PRO","September 1, 2019","September 30, 2022","October 31, 2022","May 8, 2019",,"May 13, 2021","Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus|Doris Goodwin Hospital, Pietermaritzburg, KwaZulu Natal, South Africa|THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa|Helen Jospeh Hospital, Johannesburg, South Africa|Republican TB Hospital No. 2, Nukus, Karakalpakstan, Uzbekistan|Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital, Tashkent, Uzbekistan",,"https://ClinicalTrials.gov/show/NCT03942354"
833,"NCT02412436","PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB","PRIDE-HT","Completed","Has Results","HIV-1 Infection|Tuberculosis","Drug: Depot medroxyprogesterone acetate","Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Week 12|Percent of Participants With Progesterone Levels Above 1 ng/mL at Week 12|Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Weeks 2, 4, 6, 8, and 10|Cumulative Percentage of Participants With DMPA < 0.1 ng/mL|DMPA AUC|DMPA Cmin|DMPA Cmax|DMPA CL/F|Percent of Participants Who Experienced a Grade 3 or Higher Sign/Symptom or Laboratory Abnormality|DMPA Half-life|Time at Which Participant-specific Estimated Elimination Slopes for DMPA Level Cross the Threshold of 0.1 ng/mL","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 46 Years   (Adult)","Phase 2","62","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5338|UM1AI068636","November 3, 2015","June 15, 2017","June 15, 2017","April 9, 2015","September 25, 2018","July 1, 2019","Gaborone Prevention/Treatment Trials CRS (12701), Gaborone, Botswana|Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460), Kisumu, Kenya|Durban Adult HIV CRS (11201), Durban, South Africa|Univ. of Witwatersrand CRS (11101), Johannesburg, South Africa|UZ-Parirenyatwa CRS (30313), Harare, Zimbabwe","""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/36/NCT02412436/Prot_ICF_000.pdf|""Statistical Analysis Plan: Primary Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/36/NCT02412436/SAP_001.pdf|""Statistical Analysis Plan: PK Modeling Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/36/NCT02412436/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02412436"
834,"NCT00396370","BCG Vaccination Delivered Intradermally, Orally and by Combined Routes",,"Completed","No Results Available","Tuberculosis","Biological: BCG strain Connaught|Biological: BCG strain Danish|Other: Placebo","Immunogenicity: post-vaccination increases in mycobacteria-specific Th1 responses measured by both 7 day whole blood interferon (IFN)-gamma secretion and overnight IFN-gamma enzyme linked immunospot (ELISPOT) assays.|Immunogenicity: post-vaccination mycobacteria-specific secretory immunoglobulin A (IgA) responses measured by enzyme-linked immunosorbent assay (ELISA).|Microbiologic: variability of Bacillus Calmette-Guérin (BCG) replication in intradermal (ID) ulcerative lesions in Group G.|Safety: incidence of adverse events.|Immunogenicity: presence or absence of cutaneous T cell trafficking, as indicated by purified protein derivative (PPD) skin test responses as an indication of cutaneous T cell trafficking after vaccination with SSI BCG.|Immunogenicity: proportion of subjects in each treatment group achieving an immunologically significant increase in primary endpoint Mtb-specific immune responses (i.e., at least 2 standard deviations above mean for negative controls for above assays).","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 40 Years   (Adult)","Phase 1","69","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","01-351","December 2, 2008","July 23, 2012","July 23, 2012","November 6, 2006",,"November 12, 2019","Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00396370"
835,"NCT04472897","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants",,"Recruiting","No Results Available","Tuberculosis","Drug: GSK2556286|Drug: Placebo","Part A: Number of participants with any serious adverse events (SAEs) and non-SAEs|Part B: Number of participants with any SAEs and non-SAEs|Part A: Number of participants with AEs (SAEs and non-SAEs) by severity|Part B: Number of participants with AEs (SAEs and non-SAEs) by severity|Part A: Plasma concentrations of GSK2556286|Part A: Area under the plasma drug concentration versus time curve from time zero to last time of quantifiable concentration (AUC[0-t]) of GSK2556286|Part A: AUC from time zero extrapolated to infinity (AUC[0-inf]) of GSK2556286|Part A: Maximum observed plasma drug concentration (Cmax) of GSK2556286|Part A: Time to maximum observed plasma drug concentration (Tmax) of GSK2556286|Part A: Apparent terminal half-life (T1/2) of GSK2556286|Part B: Plasma concentrations of GSK2556286|Part B: AUC(0-t) of GSK2556286|Part B: AUC(0-inf) of GSK2556286|Part B: Area under the plasma drug concentration versus time curve from time zero during a dosage interval of time tau (AUC[0-tau)] of GSK2556286|Part B: Cmax of GSK2556286|Part B: Tmax of GSK2556286|Part B: Trough plasma concentration (Ctau) of GSK2556286|Part B: T1/2 of GSK2556286|Part A: AUC(0-t) of GSK2556286 under fasted and fed conditions|Part A: AUC(0-inf) of GSK2556286 under fasted and fed conditions|Part A: Cmax of GSK2556286 under fasted and fed conditions|Part A: Tmax of GSK2556286 under fasted and fed conditions|Part A: T1/2 of GSK2556286 under fasted and fed conditions|Part A: Dose proportionality of GSK2556286 based on AUC(0-inf)|Part A: Dose proportionality of GSK2556286 based on AUC(0-t)|Part A: Dose proportionality of GSK2556286 based on Cmax|Part B: Dose proportionality of GSK2556286 based on AUC(0-tau)|Part B: Dose proportionality of GSK2556286 based on Cmax|Part B: Observed accumulation ratio of GSK2556286 based on AUC (AUC[Ro])|Part B: Observed accumulation ratio of GSK2556286 based on Cmax (RCmax)|Part B: Steady state ratio (Rss) of GSK2556286|Part B: Ctau at the end of the dosing interval to assess steady state of GSK2556286","GlaxoSmithKline","All","18 Years to 60 Years   (Adult)","Phase 1","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","210035","October 30, 2020","July 4, 2024","July 4, 2024","July 16, 2020",,"December 12, 2023","GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04472897"
836,"NCT01545661","Utility of Sputum Induction and Novel Technologies to Improve TB Diagnosis in a High HIV Prevalence Primary Care Setting","SINET","Completed","No Results Available","Tuberculosis","Procedure: Sputum induction|Procedure: standard routine expectorated sputum","Time-to-treatment initiation|Diagnostic yield of sputum culture|Diagnostic yield and accuracy of sputum smear microscopy|Feasibility of sputum induction in primary care clinics|Safety and tolerability of sputum induction performed in primary care clinics|Diagnostic yield and accuracy of additional diagnostics including Xpert MTB/RIF assay, MODS and Genotype MTBDRplus|Cost-analysis of sputum induction for primary care clinics","University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Not Applicable","517","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SINET study","August 2009","May 2012","May 2012","March 7, 2012",,"December 24, 2012","University of Cape Town, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT01545661"
837,"NCT00423839","A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A (Tuberculosis vaccine)","Safety of the Vaccine. This will be determined by the degree and number of adverse events reported.|Immunogenicity of this vaccine. It is expected that the vaccine will stimulate T cell responses, which will be measured by interferon -gamma Elispot assays.","University of Oxford","Male","18 Years to 45 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AFTBVAC","March 2003",,"July 2005","January 18, 2007",,"January 18, 2007","MRC Labs, Fajara, Gambia",,"https://ClinicalTrials.gov/show/NCT00423839"
838,"NCT01479972","Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa",,"Completed","No Results Available","Tuberculosis","Biological: VPM1002|Biological: BCG","Safety|Immunogenicity","Vakzine Projekt Management GmbH|Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa|Triclinium Johannesburg, South Africa|University of Stellenbosch|HJ-CTC George, South Africa","All","up to 8 Days   (Child)","Phase 2","48","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VPM1002-ZA-2.12TB|DOH-27-0911-3677","November 2011","November 2012","November 2012","November 28, 2011",,"October 29, 2013","Children's Infectious Diseases Clinical Research Unit, Tygerberg Hospital, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01479972"
839,"NCT03758612","A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary","Drug: TBI-223 50mg|Drug: Placebo for TBI-223 50mg|Drug: TBI-223 100, 300, 600, 1200, 2000, 2600 mg|Drug: Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg|Drug: TBI-223 300 mg capsule|Drug: Placebo for TBI-223 300 mg capsule|Drug: TBI-223 Prototype 1 SR Tablet|Drug: TBI-223 Prototype 2 SR Tablet|Drug: TBI-223 Prototype 3 SR Tablet|Drug: TBI-223 IR Tablet","Number of participants with treatment-related and other adverse events as assessed by the Division of Microbiology and Infectious Disease (DMID) Toxicity Table|Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using AUClast|Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using AUCinf|Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using Cmax|Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using Tmax|Noncompartmental pharmacokinetic parameters of TBI-223 after single doses of TBI-223 using CL/F|Noncompartmental pharmacokinetic parameters of TBI-223 after single doses of TBI-223 using Vz/F|Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using λz|Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using T1/2|Compare the rate and extent of absorption of a single dose of TBI-223 using AUClast, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects|Compare the rate and extent of absorption of a single dose of TBI-223 using AUCinf, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects|Compare the rate and extent of absorption of a single dose of TBI-223 using Cmax, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects|Compare the rate and extent of absorption of a single dose of TBI-223 using Tmax, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects|Compare the rate and extent of absorption of a single dose of TBI-223 using CL/F, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects|Compare the rate and extent of absorption of a single dose of TBI-223 using Vz/F, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects|Compare the rate and extent of absorption of a single dose of TBI-223 using λz, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects|Compare the rate and extent of absorption of a single dose of TBI-223 using T1/2, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TBI-223-CL-001","January 16, 2019","February 22, 2020","March 14, 2020","November 29, 2018",,"September 5, 2021","Worldwide Clinical Trials (WCT), San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03758612"
840,"NCT01356095","A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi",,"Completed","No Results Available","Tuberculosis","Other: Knowledge translation intervention|Other: Palm-Plus","Proportion of patients classified as successfully treated.|Proportion of patients defaulting from treatment.|Proportion of successfully treated and default cases among patients treated for tuberculosis only and those on both tuberculosis and antiretroviral treatment|Weight change.","Dignitas International|University of Toronto|Ministry of Health and Population, Malawi","All","Child, Adult, Older Adult","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DI807","March 2011","March 2012","May 2012","May 19, 2011",,"August 29, 2012","Zomba District Health Centers, Dignitas International, Zomba, Malawi",,"https://ClinicalTrials.gov/show/NCT01356095"
841,"NCT00433719","Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis",,"Unknown status","No Results Available","HIV Infections|Tuberculous Meningitis","Drug: Combivir and efavirenz","Mortality|Fever clearance time|Coma clearance time|CD4 count|plasma HIV RNA|Grade 3 or 4 adverse event|Neurological disability","University of Oxford|Wellcome Trust","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","253","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OXTREC 023-04|ISRCTN63659091","September 2005","December 2008","December 2008","February 12, 2007",,"August 7, 2008","Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT00433719"
842,"NCT02219945","ENOSE in Pulmonary Tuberculosis in Yogyakarta","YOGYATBNOSE","Completed","No Results Available","Pulmonary Tuberculosis Suspected|Other Specified Chronic Obstructive Pulmonary Disease|Pulmonary Tuberculosis TB (+) Histology, (-) Bacteriology","Other: 5 min exhaled breath sampling with soft nose clamp","diagnostic precision of electronic nose signal in pulmonary TB|measuring response to TB treatment over time with the electronic nose","Tjip van der Werf|Gadjah Mada University|The Enose Company, Zutphen the Netherlands|University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","389","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TBDIAGNOSE|KE/FK/859/EC","November 2013","December 2014","April 2017","August 19, 2014",,"June 1, 2017","patients - at 5 lung clinics (Minggiran, Kalasan, Kotagede, Bantul, Kuonprogo) connected with Sudjarto Teachnig Hospital; healthy controls among students and staff of Hospital and Gadjah Mada Universitas, Yogyakarta, Jalan Kesehatan no.1, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT02219945"
843,"NCT01053598","Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting","NRA RETA","Completed","No Results Available","Tuberculosis|HIV|AIDS|HIV Infections",,"To evaluate the performance of NRA, NRA-p and REMA-p for the detection of M. tuberculosis complex from sputum samples from adult pulmonary TB suspects in a high TB and HIV prevalence setting, using LJ and MGIT culture as gold standard|-To measure the performance of each assay (NRA, NRA-p, REMA-p) in sputum smear-negative patients -To describe the results of the colorimetric methods in HIV-positive and HIV-negative patients","Epicentre|Mbarara University of Science and Technology|Medecins Sans Frontieres, Netherlands","All","14 Years and older   (Child, Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","821183","September 2011","September 2012","December 2012","January 21, 2010",,"February 20, 2013","Epicentre, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT01053598"
844,"NCT03988933","2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.","2R2","Active, not recruiting","No Results Available","Latent Tuberculosis","Drug: Rifampin double dose|Drug: Rifampin triple dose|Drug: Rifampin standard dose","Treatment completion (taking 80% of doses within 120% of allowed time)|Safety measured by Grade 3 to 5 adverse events|Safety measured by Grade 1 to 2 adverse events|Efficacy measured during follow-up visits and telephone calls","McGill University Health Centre/Research Institute of the McGill University Health Centre|Canadian Institutes of Health Research (CIHR)","All","10 Years and older   (Child, Adult, Older Adult)","Phase 2","1368","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","FND-143350-1","September 20, 2019","January 31, 2023","December 2024","June 18, 2019",,"March 28, 2023","Unviversity of Calgary, Calgary, Alberta, Canada|The Governors of the University of Alberta, Edmonton, Alberta, Canada|BCCDC TB clinic, Vancouver, British Columbia, Canada|MUHC, Montreal, Quebec, Canada|Universitas Padjadjaran, Klinik Penelitian Tuberculosis (TB research clinic), Bandung, Indonesia|Phoi Viet TB and Respiratory Diseases Clinic., Ho Chi Minh City, Vietnam|Hai Ba Trung District Health Center, No. 16B, Hà Nội, Vietnam|Hanoi Lung Hospital, Hà Nội, Vietnam|Nam Tu Liem District Health Center, No. 3, Hà Nội, Vietnam",,"https://ClinicalTrials.gov/show/NCT03988933"
845,"NCT01341184","TMC207 +/- Rifabutin/Rifampin",,"Completed","No Results Available","Tuberculosis","Drug: Rifabutin|Drug: Rifampin|Drug: TMC207","Pharmacokinetic profiles determined for Rifabutin + desacetyl rifabutin|Pharmacokinetic profiles determined for Rifampin + desacetyl rifampin|Pharmacokinetic profiles for TMC207 and M2|Pharmacokinetic profiles for TMC207 and M2 in combination with steady-state rifabutin (Group 1)|Pharmacokinetic profiles for TMC207 and M2 in combination with steady-state rifampin (Group 2)|Safety of TMC207|Tolerability of TMC207","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","33","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-0043|HHSN272201500007I","October 21, 2011","May 23, 2012","May 23, 2012","April 25, 2011",,"April 21, 2017","Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01341184"
846,"NCT03199313","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary","Drug: Sutezolid|Drug: Placebo","Safety and tolerability of single oral doses of sutezolid in healthy adult subjects evaluated by Treatment Emergent Adverse Events (TEAEs)|Pharmacokinetics (PK) of single oral doses of sutezolid using Cmax|Pharmacokinetics (PK) of single oral doses of sutezolid using AUC|Pharmacokinetics (PK) of single oral doses of sutezolid using Tmax","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Sutezolid - CL001","September 26, 2017","December 16, 2017","December 16, 2017","June 26, 2017",,"February 8, 2018","Worldwide Clinical Trials, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03199313"
847,"NCT02383849","IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants",,"Completed","No Results Available","Low-Birth-Weight Infant|Tuberculosis|HIV",,"Clearance of NVP, INH, RIF, and LPV/r after oral dose|Primary safety endpoints","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Days to 84 Days   (Child)",,"124","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMPAACT P1106|11882","August 4, 2015","February 14, 2020","February 14, 2020","March 9, 2015",,"August 6, 2021","Soweto IMPAACT CRS (8052), Johannesburg, Gauteng, South Africa|Family Clinical Research Unit (FAM-CRU) CRS (8950), Cape Town, Western Cape Province, South Africa",,"https://ClinicalTrials.gov/show/NCT02383849"
848,"NCT01288950","Vitamin D Supplementation Enhances Immune Response to Bacille-Calmette-Guerin (BCG) Vaccination in Infants","BCG-25-D","Completed","No Results Available","Tuberculosis","Dietary Supplement: Vitamin D3 (cholecalciferol)","Bacille-Calmette-Guerin (BCG) vaccine efficacy|Effect of a single dose of 50,000 IU vitamin D3 on serum vitamin D levels","University of California, San Diego|Thrasher Research Fund","All","up to 3 Days   (Child)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NR-0138","February 2011","July 2012","July 2012","February 3, 2011",,"August 22, 2012","Tijuana General Hospital, Tijuana, Baja California, Mexico",,"https://ClinicalTrials.gov/show/NCT01288950"
849,"NCT01113281","Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa",,"Completed","No Results Available","Tuberculosis","Biological: VPM1002 live vaccine|Biological: commercially available live vaccine BCG","Safety: physical examination, vital signs, electrocardiogram, liver sonography, laboratory safety parameters, tolerability, recording of concomitant medication and adverse events|Immunogenicity: Interferon-gamma-ELISA (IFN-g-ELISA) in supernatants of peripheral blood mononuclear cells (PBMC) restimulated with tuberculin (PPD from Staten Serum Institute, Denmark)|Immunogenicity: ELISPOT for the number of IFN-g-secreting PBMC after restimulation with PPD|Immunogenicity: Whole Blood Assays (WBA): IFN-g-ELISA of supernatants of whole blood restimulated with PPD|Immunogenicity: Intracellular Cytokine Staining (ICS) for IFN-g, TNF-a and IL-2 in CD4+ and CD8+ lymphocytes upon stimulation with PPD|Immunogenicity: ICS with other triple combinations of markers in CD4+ and CD8+ lymphocytes upon stimulation with PPD|Immunogenicity: Antigen-85B (Ag85B) and BCG as recall antigens for ELISA, ELISPOT, WBA and ICS|Immunogenicity: serum antibodies against PPD or Ag85B","Vakzine Projekt Management GmbH|Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site)|Triclinium Johannesburg, RSA (Monitoring and Overall Management of the study)|University of Stellenbosch|HJ-CTC George, RSA (Statistics & Report)","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VPM1002-ZA-1.10TB|DOH-27-0210-3083","April 2010","December 2010","March 2011","April 29, 2010",,"November 21, 2011","Farmovs-Parexel, Bloemfontein, South Africa",,"https://ClinicalTrials.gov/show/NCT01113281"
850,"NCT03561753","Pilot Clinical Trial of PRS TB Regimen I - Phase II",,"Completed","No Results Available","Pulmonary Tuberculosis TB in Sputum: (+) Microscopy","Drug: Group A (the standard 2HRZE/4HR regimen）|Drug: Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)","The rate of sputum smear/culture negative conversion|Radiological manifestation change of lung TB lesions or cavity|Number of Patients with Grade 3 or 4 Adverse Events|Number of Patients with TB recurrence/relapse","Shanghai Pulmonary Hospital, Shanghai, China|Shanghai Center for Disease Control and Prevention|No.85 Hospital, Changning, Shanghai, China|Shanghai Public Health Clinical Center|Bill and Melinda Gates Foundation|University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K18-103","December 1, 2017","December 31, 2019","January 31, 2020","June 19, 2018",,"November 9, 2020","Eighty-fifth Hospital of PLA, Shanghai, China|Shanghai Public Health Clinical Center Shanghai, China, Shanghai, China|Shanghai Center for Disease Control and Prevention, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03561753"
851,"NCT01990274","The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa","XACT","Completed","No Results Available","Tuberculosis","Procedure: GeneXpert MTB/RIF assay|Procedure: Smear microscopy","Comparison of novel intensive-case finding diagnostic tools to standard intensive-case finding strategy|The proportion of culture-positive TB cases completing TB treatment in each study arm|Feasibility of performing Xpert MTB/RIF at the point-of-care in a mobile unit using an alternative power supply|Cost per TB case detected between study arms|Cost per TB case successfully completing treatment between study arms|Determining whether LAM is present at sub-ELISA concentrations using mass spectroscopy of urine samples from TB patients|Validating the electronic chest X-ray scoring system for Computer Aided Diagnostics (CAD) of TB","University of Cape Town|University of Zimbabwe|Università degli Studi di Sassari|Radboud University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","875","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","XACT.2011.10800.003","October 2013","April 2015","April 2015","November 21, 2013",,"November 25, 2015","University of Sassari, Sassari, Italy|Radboud University, Nijmegen, Netherlands|University of Cape Town, Cape Town, Western Province, South Africa|University of Zimbabwe, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT01990274"
852,"NCT01494038","Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women",,"Completed","Has Results","HIV Infections|Tuberculosis","Drug: Isoniazid (INH)|Drug: Placebo for isoniazid (INH)","Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment|Number of Mothers With a Fetal Death|Number of Mothers With a Fetus Small for Gestational Age|Number of Mothers With an Infant Born Prematurely|Number of Mothers With a Low Birth-weight Infant|Number of Mothers With an Infant With a Congenital Anomaly|Number of Mothers With an Adverse Pregnancy Outcome: Spontaneous Abortion, Stillbirth, Premature Birth, Low Birth Weight, or Congenital Anomaly|Number of Infants With Grade 3 or Higher Clinical or Laboratory AE|Number of Infants With Grade 3 or Higher Clinical or Laboratory AE Related to Treatment|Number of Infants Which Are HIV-infected|Number of Infants Hospitalized|Incidence Rate of TB Infection Among Mothers|Incidence Rate of Tuberculosis (TB) Among Infants|Incidence Rate of Infant Death|Incidence Rate of Maternal Deaths|Incidence Rate of Combined Endpoints: Maternal TB or Maternal Death|Incidence Rate of Combined Endpoints: Infant TB or Infant Death|Incidence Rate of Combined Endpoints: Maternal TB, Maternal Death, Infant TB, or Infant Death|Incidence Rate of Combined Endpoint, Antepartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE|Incidence Rate of Combined Endpoint, up to 12 Weeks Postpartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE|Incidence Rate, Antepartum, of Grade 3 or Higher AE|Incidence Rate, up to 12 Weeks Postpartum, of Grade 3 or Higher AE|Incidence Rate, Antepartum, of Hepatotoxicity, Defined by Protocol-specific Definition of Hepatotoxicity, Related to Treatment|Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Related to Treatment|Incidence Rate, Antepartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause|Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause|Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment|Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment|Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Any Cause|Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Any Cause|Number of Mothers With Tuberculosis Resistant to INH|Number of Infants With Tuberculosis Resistant to INH|Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve of Plasma Concentration Versus Time (AUC24h), for INH|Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve (AUC24h), for EFV|Agreement Between Interferon-gamma Release Assay (IGRA) TB Test and Tuberculin Skin Test (TST) Results, Women at Delivery|Agreement Between IGRA and TST TB Test Results, Infant|Agreement Between IGRA and TST TB Tests, Women at 44 Weeks Postpartum|Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Self-report|Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Pill Count","National Institute of Allergy and Infectious Diseases (NIAID)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 4","956","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","P1078|10732|IMPAACT P1078","August 19, 2014","September 6, 2017","September 6, 2017","December 16, 2011","November 20, 2018","November 5, 2021","Gaborone CRS, Gaborone, Botswana|Molepolole CRS, Gaborone, Botswana|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Fam-Cru Crs, Cape Town, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda|Seke North CRS, Chitungwiza, Zimbabwe|St Mary's CRS, Chitungwiza, Zimbabwe|Harare Family Care CRS, Harare, Zimbabwe","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT01494038/Prot_001.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT01494038/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01494038"
853,"NCT01657656","Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia",,"Completed","No Results Available","Vitamin D Supplements|Tuberculosis|Sputum|Cytokines|Immunity","Dietary Supplement: Vitamin D","The primary endpoint will be time to sputum culture conversion from positive to negative.","Harvard School of Public Health (HSPH)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R00HL089710","October 2012","May 2014","July 2014","August 6, 2012",,"July 30, 2014","National Center for Communicable Dieases, Ulaanbaatar, Mongolia",,"https://ClinicalTrials.gov/show/NCT01657656"
854,"NCT01868464","Challenge Model for Assessment of Human TB Immunity",,"Completed","No Results Available","Tuberculosis","Biological: BCG TICE strain","Serious adverse events related to Tice® BCG administration|Summary of distribution, in terms of its precision, of BCG shedding from intradermal challenge sites using subjects' peak shedding, as detected by each of 3 assays (quantitative PCR, quantitative CFU plating and quantitative MGIT BACTEC culture).|Summary of distribution, terms of its central tendency (mean or GM), of BCG shedding from intradermal challenge sites at 3 time points, as detected by each of 3 assays (quantitative PCR, quantitative CFU plating and quantitative MGIT BACTEC culture).|The number of subjects experiencing Grade 3 (severe) clinical safety laboratory adverse events|The number of subjects experiencing Grade 3 (severe) injection site reactions following Tice® BCG administration.|The number of subjects experiencing Grade 3 (severe) solicited systemic reactions following Tice® BCG administration|The number of subjects in groups 3 and 4 experiencing Grade 3 (severe) injection site reactions.|The number of subjects spontaneously reporting Grade 3 (severe) adverse events related to Tice® BCG administration following Tice® BCG administration.|Summary of distribution of the area under the curve for repeated measures of shedding over time from 3 assays (quantitative PCR, quantitative CFU plating and quantitative MGIT BACTEC culture). Summarized in terms of its central tendency (mean or GM)|Summary of distribution of the area under the curve, in terms of its precision, for repeated measures of shedding over time from 3 assays (quantitative PCR, quantitative CFU plating and quantitative MGIT BACTEC culture).","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","92","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11-0033","May 28, 2014","December 18, 2017","December 18, 2017","June 4, 2013",,"January 27, 2020","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01868464"
855,"NCT00080119","Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV",,"Terminated","Has Results","HIV Infection|Tuberculosis|Pneumocystis Jiroveci Pneumonia","Drug: Isoniazid (INH)|Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX)|Drug: Isoniazid Placebo (PL)","Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children|Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children|Time From Randomization to Development of TB Infection or Death Among HIV-infected Children|Time From Randomization to HIV Disease Progression or Death Among HIV-infected Children|Time From Randomization to Development of TB Disease or Death Among Perinatally Exposed, HIV-uninfected Children|Time From Randomization to Development of TB Disease Among HIV Infected and Perinatally Exposed, HIV-uninfected Children|Time From Randomization to Development of TB Infection Among HIV-infected and Perinatally Exposed, HIV-uninfected Children|Time From Randomization to Death Among HIV-infected and Perinatally Exposed, HIV-uninfected Children|Time From Randomization to First New Grade 3 or Worse Adverse Event Among HIV-infected and Perinatally Exposed, HIV-uninfected Children","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Comprehensive International Program of Research on AIDS|Secure the Future Foundation","All","91 Days to 120 Days   (Child)","Phase 2|Phase 3","1354","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","PACTG P1041|U01AI068632","February 2004","May 2009","May 2009","March 25, 2004","October 19, 2010","February 5, 2019","Princess Marina Hospital, Gaborone, Botswana|University of Cape Town, Red Cross Children's Hospital, Cape Town, South Africa|University of Stellenbosch, Tygerberg Hospital, Cape Town, South Africa|Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, Durban, South Africa|Perinatal HIV Research Unit at Chris Hani Baragwanath Hospital, Johannesburg, South Africa|Chris Hani Baragwanath Hospital, Harriet Shezi Clinic, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT00080119"
856,"NCT00664313","TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB","LiMiT","Completed","No Results Available","Multi-drug Resistant Tuberculosis|Extensively Drug Resistant Tuberculosis","Drug: Linezolid|Drug: Placebo","Cumulative rate of serious adverse events - SAEs (measured as the number of SAEs per person days) during the period of study therapy and the four weeks of post-study therapy follow-up.|Proportion of patients in each arm who complete 80% of the proposed regimen (90 doses) within 18 weeks of treatment initiation.|The number of days required to convert to culture negative status in sputum of those in each treatment arm on solid and liquid media, respectively.|The proportion of culture-negative patients during the first 16 weeks of therapy (at two week intervals) of linezolid with OBT vs. that of OBT with placebo on solid and liquid media, respectively|Time to detection of M. tuberculosis on MGIT for each positive culture for sputum specimens collected every 2 weeks during the first 16 weeks of therapy|The occurrence of treatment failure in the first 12 month following initiation of study therapy|Changes from baseline in assessments for peripheral neuropathy|Changes from baselines in Snellen or Jaeger visual acuity test and Ishihara color plate test results to assess for optic neuropathy","Centers for Disease Control and Prevention|University of KwaZulu|Columbia University|Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDC-NCHHSTP-5356","April 2009","September 2010","September 2010","April 22, 2008",,"October 2, 2012","King George V Hospital, Durban, South Africa",,"https://ClinicalTrials.gov/show/NCT00664313"
857,"NCT01365702","Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung",,"Unknown status","No Results Available","Lung Disease, Obstructive|Tuberculosis",,"St-George respiratory questionnaire(SGRQ)|lung function|cough VAS|adverse reaction of tiotropium","Seoul National University Bundang Hospital","All","18 Years and older   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SNUBH_TLD and spiriva","June 2011","December 2012","December 2012","June 3, 2011",,"June 7, 2011","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01365702"
858,"NCT05542511","Host Blood RNA Signatures for Diagnosis of TB","RADIANT","Recruiting","No Results Available","Tuberculosis|Lower Respiratory Infection","Diagnostic Test: NanoString nCounter assay","Validate concise host transcriptional signatures for active TB|Characterization of respiratory microorganisms|Detection of Incident active TB","University of Stellenbosch","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M22/02/004_Sub StudyM20/06/017","June 23, 2022","May 31, 2024","September 2024","September 15, 2022",,"February 22, 2024","Stellenbosch University, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT05542511"
859,"NCT05935696","A Prospective Observational Study on the Role of Transthoracic Ultrasound in Differentiating Tuberculous From Malignant Pleural Effusion","TUS-TBE","Recruiting","No Results Available","Pleural Effusion|Tuberculosis, Pleural|Malignant Pleural Effusion",,"Transthoracic ultrasound","Sarawak General Hospital|Hospital Queen Elizabeth, Kota Kinabalu, Sabah|Institute of Respiratory Medicine Malaysia, Kuala Lumpur|Hospital Serdang, Selangor|University Malaya Medical Center, Selangor|Hospital Melaka, Melaka","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TUS-TBE v4.0","April 1, 2023","March 31, 2024","March 31, 2024","July 7, 2023",,"July 7, 2023","Sarawak General Hospital, Kuching, Sarawak, Malaysia",,"https://ClinicalTrials.gov/show/NCT05935696"
860,"NCT01554384","Trial of Point-of-treatment Xpert MTB/RIF Assay","TBNEATXpert","Completed","No Results Available","Tuberculosis","Procedure: Xpert MTB/RIF assay|Procedure: Smear microscopy","Difference in TB-related Morbidity|Time-to-diagnosis|Drop-out and lost-to-follow up rates|Feasibility of clinic-based performance of Xpert MTB/RIF assay performed by nursing staff without formal research training|Individual patient-level cost analysis, cost-effectiveness evaluation and quality of health indices evaluation|Time-to-treatment initiation","University of Cape Town|Biomedical Research and Training Institute|University of Zimbabwe|University of Zambia|Medical Research Council, South Africa|Mbeya medical research program|McGill University|Radboud University Medical Center|University of Cape Town Lung Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1472","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TBNEATXpertRCT|IP.09.32040.009","October 2010","July 2012","July 2012","March 15, 2012",,"June 6, 2013","Medical Research Council, Durban, Kwazulu-Natal, South Africa|University of Cape Town, Cape Town, Western Cape, South Africa|University Teaching Hospital of Zambia, Lusaka, Zambia|University of Zimbabwe, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT01554384"
861,"NCT04521803","High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis","IMPI-3","Recruiting","No Results Available","Tuberculous Pericarditis|HIV Status","Drug: high dose Rifampicin (RIF)","Drug exposure in PCF and mediates in Mtb load|Mortality between study arms|re-accumulation of pericardial effusion between study arms|TB-IRIS between study arms|Constrictive pericarditis between the study arms|CMR evidence","University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","IMPI-3 DMID 20-0007","January 10, 2022","September 15, 2025","February 28, 2026","August 21, 2020",,"March 1, 2024","Nelson Mandela Academic Hospital, Mthatha, Eastern Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04521803"
862,"NCT02508376","Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects",,"Completed","No Results Available","Tuberculosis","Other: AP10-602|Biological: GLA-SE|Biological: ID93","The number of serious adverse events considered related to the study injection reported at any point during the study period.|The number of subjects experiencing solicited injection site reactions within 7 days following study injection.|The number of subjects experiencing solicited systemic reactions within 7 days following study injection.|The number of subjects spontaneously reporting adverse events considered related to the study injection at any point during the study period.|Mean fold change from baseline (Day 1) in IgG antibody responses to ID93 on Day 85.|Percentage of CD4 and CD8 T cells producing 1 or more cytokines (IFN-gamma, TNF and IL-2) simultaneously in response to stimulation with the ID93 antigen as measured by intracellular cytokine staining at Day 71 relative to baseline (Day 1).|The magnitude of Th1 and Th2 cytokine production in PBMCs in response to the ID93 antigen relative to baseline (Day 1) at Day 71, as assayed by Luminex.|The proportion of subjects with at least a 4-fold increase in IgG antibody responses to ID93 on Day 85 relative to baseline (Day 1).","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 1","70","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","12-0109|HHSN272201300020I","October 22, 2015","August 31, 2017","August 31, 2017","July 24, 2015",,"September 15, 2017","University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT02508376"
863,"NCT05426720","Risk Factors and Biomarkers for Post-tuberculosis Lung Damage",,"Recruiting","No Results Available","Pulmonary TB","Other: no intervention","lung function|Absorption of TB lesions on lung CT scans after TB treatment","Peking University Third Hospital|Beijing Geriatric Hospital","Male","25 Years to 60 Years   (Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","M2022296","January 1, 2022","December 31, 2024","December 31, 2027","June 22, 2022",,"June 22, 2022","Peking University Third Hospital, Beijing, China|Beijing Geriatric Hospital, Beijing, China","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT05426720/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05426720"
864,"NCT02454205","An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","NEXT","Completed","No Results Available","Tuberculosis|Multidrug Resistant Tuberculosis|Extensively-drug Resistant Tuberculosis","Drug: Linezolid|Drug: Bedaquiline|Drug: Levofloxacin|Drug: Pyrazinamide|Drug: Isoniazid|Drug: Ethionamide|Drug: Terizidone|Drug: Moxifloxacin|Drug: Kanamycin","Treatment success|Favourable outcome rate|Time specific rate of treatment failure.|Time specific culture conversion proportions and rates.|Time specific relapse rate.|Rate of re-infection.|All cause mortality|Composite measure of QT interval on ECG, grade 3 and 4 adverse events, stopping drugs Safety and tolerability end-points.|Default rate|Rate of loss of follow-up.","University of Cape Town|University of Limpopo|Walter Sisulu University|University of Stellenbosch|University of Cape Town Lung Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NExT-5001","November 12, 2015","December 31, 2020","August 30, 2021","May 27, 2015",,"September 29, 2021","Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02454205"
865,"NCT00465465","A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG",,"Completed","No Results Available","Tuberculosis","Biological: MVA 85A","To assess the safety and immunogenicity of 2 different doses of intradermal vaccination of MVA85A, 10^7pfu and 10^8pfu, when administered to healthy subjects who have previously been vaccinated with BCG","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB009","October 2005","September 2007","September 2007","April 25, 2007",,"April 4, 2008","University of Oxford, CCVTM, Churchill Hospital, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00465465"
866,"NCT04528823","GXT - GeneXpert or Chest-X-ray or Tuberculin Skin Testing for Household Contact Assessment",,"Completed","No Results Available","Latent Tuberculosis","Other: Strategy 2: Symptom screen, Genexpert and TST|Other: Strategy 3:Symptom screen, CXR but NO TST","proportion starting therapy within 3 months of the index TB patient starting active TB treatment|Societal costs (health system and patient costs) of the full cascade of care|Prevalence of microbiologically confirmed and clinically diagnosed active TB|Prevalence of positive TST (>5 mm or >10 mm)|Incidence of grade 1-4 adverse events related to LTBI therapy.|Proportion of participants who complete LTBI therapy|Sensitivity and specificity of CXR|Prevalence of active TB diagnosed using CXR in participants who cannot produce a sputum sample.|The outcome measure of performance is the percentage of patients with valid specimens obtained by the induction of sputum over all patients with indication for this technique.","McGill University Health Centre/Research Institute of the McGill University Health Centre|Canadian Institutes of Health Research (CIHR)","All","5 Years to 50 Years   (Child, Adult)","Not Applicable","1589","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FND-143350-2","January 31, 2020","November 30, 2022","June 30, 2023","August 27, 2020",,"July 17, 2023","Centre National Hospitalier Universitaire de Pneumo Phtisiologie de Cotonou (CNHU-PPC), Cotonou, Benin|Manaus, Manaus, Brazil|Porto Alegre, Porto Alegre, Brazil|Centro de Estudos, Pesquisa e Desenvolvimento Tecnológico em Saúde Coletiva - CEPESC, Rio de Janeiro, Brazil","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/23/NCT04528823/Prot_002.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/23/NCT04528823/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04528823"
867,"NCT02422524","Pretomanid in Adults With Hepatic Impairment",,"Terminated","No Results Available","Tuberculosis","Drug: PA-824","AUC(0-infinity): Area under the concentration time-curve extrapolated to infinity at specified pre-dose and post-dose time points|AUC(0-last): Area under the concentration time-curve to the last concentration above the lower limit of quantitation at specified pre-dose and post-dose time points|CL/F: Apparent oral clearance calculated from Dose/AUC(0-infinifty) at specified pre-dose and post-dose time points|Cmax: Maximum Pretomanid concentration at specified pre-dose and post-dose time points|t(1/2): Apparent terminal elimination half-life at specified pre-dose and post-dose time points|Tmax: Time of maximum Pretomanid concentration at specified pre-dose and post-dose time points|Vd/F: Apparent Volume of Distribution at specified pre-dose and post-dose time points|Incidence of related adverse events|Incidence of serious adverse events|Severity of related adverse events|Severity of serious adverse events|Summary of ECG data|Summary of physical examination findings (height at baseline, and weight at serial time points)|Summary of safety laboratory parameters|Summary of vital signs at serial time points","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","14","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-0053","December 11, 2017","November 17, 2023","November 17, 2023","April 21, 2015",,"December 28, 2023","Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States|Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02422524"
868,"NCT06354257","A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age",,"Not yet recruiting","No Results Available","Tuberculosis","Drug: EE/LNG|Drug: GSK3036656 Dose Level 1|Drug: GSK3036656 Dose Level 2","Area under the plasma drug concentration (AUC)-time curve from time zero to extrapolated to infinity (AUC[0-inf]) of EE after being administered with 14 days of GSK3036656 at DL 2|Maximum observed concentration (Cmax) of EE after being administered with 14 days of GSK3036656 at DL 2|AUC(0-inf) of LNG after being administered with 14 days of GSK3036656 at DL 2|Cmax of LNG after being administered with 14 days of GSK3036656 at DL 2|AUC over the dosing interval (0-tau) of GSK3036656 after being administered with a single dose of EE/LNG|Cmax of GSK3036656 after being administered with a single dose of EE/LNG|Steady state assessment using trough plasma concentration (Ctau) of GSK3036656 after being administered with a single dose of EE/LNG|Tmax of GSK3036656 after being administered with a single dose of EE/LNG|AUC versus time curve (AUC[0-t]) of EE/LNG after being administered with a single dose of EE/LNG|AUC(0-t) of EE/LNG after being administered with 14 days of treatment with GSK3036656 at DL 2|Tmax of EE/LNG after being administered with a single dose of EE/LNG|Tmax of EE/LNG after being administered with 14 days of GSK3036656 DL 2|Apparent terminal half-life (t1/2) of EE and LNG after a single dose of EE/LNG|t1/2 of EE and LNG after a single dose of EE/LNG in combination with 14 days of treatment with GSK3036656 at DL 2|Number of participants with serious adverse events (SAEs)|Number of participants with Grade 3 or higher severity adverse events (AEs)|Number of participants with drug-related AEs|Number of participants with drug-related AEs following the administration of GSK3036656|Number of participants withdrawn from the treatment/study due to AEs|Percentage of participants with ECG values of Potential Clinical Importance (PCI)|Percentage of participants with clinical chemistry laboratory values of PCI|Percentage of participants with haematology laboratory values of PCI|Percentage of participants with vital signs parameters of PCI","GlaxoSmithKline","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","220104","April 5, 2024","October 30, 2024","October 30, 2024","April 9, 2024",,"April 9, 2024","GSK Investigational Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT06354257"
869,"NCT06305104","Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.",,"Recruiting","No Results Available","Tuberculosis","Biological: 2.5μg/ml EEC|Biological: 5μg/ml EEC|Biological: 5 unit（U） EC","Sensitivity of different doses of EEC and control EC in pulmonary tuberculosis patients aged 18 to 65 years ;|specificity of different doses of EEC and control EC in healthy subjects aged 18 to 65 years and patients with non-tuberculous lung disease ;|The skin test site specific reaction at 4h,8h (only for stage 2);24h, 48h, 72h, 96h, and 7 days after skin test. Those with average diameter of induration/redness is ≥5 mm will be considered to positive.|Receiver operator characteristic curve(ROC) of different doses of EEC to evaluate the optimal diagnostic test cut-off value of the test drug.|Area under the curve(AUC) of different doses of EEC to evaluate the optimal diagnostic test cut-off value of the test drug.|In healthy people, patients with tuberculosis and patients with non-tuberculous lung diseases, the consistency rates of the three detection reagents EEC , EC and IGRA were evaluated respectively.|Incidence of adverse events and serious adverse events at injection and non-injection sites，abnormal incidence of laboratory indicators and vital signs during the study period.","Chengdu CoenBiotech Co., Ltd|Beijing Chest Hospital, Capital Medical University|Wuhan Institute for Tuberculosis Control|The Public Health Clinical Center of Chengdu|Xuzhou Infectious Disease Hospital|Jiangsu Province Centers for Disease Control and Prevention|Changde First People's Hospital","All","3 Years to 75 Years   (Child, Adult, Older Adult)","Phase 2","420","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","KN-EEC-II","July 18, 2023","May 30, 2024","June 30, 2024","March 12, 2024",,"March 12, 2024","Beijing Chest Hospital, Beijing, Beijing, China|Wuhan Institute for Tuberculosis Control, Wuhan, Hubei, China|Changde First People's Hospital, Changde, Hunan, China|Jiangsu Province Centers for Disease Control and Prevention, Nanjing, Jiangsu, China|Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, China|Public health clinical center of chengdu, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT06305104"
870,"NCT01685905","The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection",,"Unknown status","No Results Available","Rheumatic Disease|Rheumatoid Arthritis|Ankylosing Spondylitis|Tuberculosis",,"The agreement between QuantiFERON-TB Gold(QFT-G) and tuberculin skin test(TST) as a screening test for latent tuberculosis infection(LTBI)|The correlation of the occurrence of active Tuberculosis and two tests (QuantiFERON-TB Gold (QFT-G) and tuberculosis skin test(TST))","Hanyang University|Bristol-Myers Squibb","All","Child, Adult, Older Adult",,"2000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TST_IGRA","April 2012","September 2013","September 2013","September 14, 2012",,"September 18, 2012","Hanyang University Hospital for rheumatic disease, Seoul, Sung-dong Gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01685905"
871,"NCT06246851","BCG Revaccination Study in Diabetic and Non-Diabetic Adults",,"Recruiting","No Results Available","Tuberculosis","Biological: BCG Danish","Intradermal vs. aerosol BCG in non-type 2 diabetics|Intradermal (in type 2 diabetics) vs intradermal (in non-type 2 diabetics)|Intradermal or aerosol BCG re-vaccination safety in healthy volunteers","University of Oxford","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TB046","February 2024","November 2027","November 2027","February 7, 2024",,"February 7, 2024","Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT06246851"
872,"NCT00771498","An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin","A06-295","Completed","No Results Available","HIV Infection|Tuberculosis","Drug: Lopinavir","Plasma levels of rifampin and lopinavir-ritonavir (pharmacokinetics).|HIV response to treatment|Adverse events","Oswaldo Cruz Foundation|Abbott","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","A06-295","November 2008","December 2012","December 2012","October 13, 2008",,"May 19, 2015","University of Espirito Santo, Vitoria, ES, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC), Rio de Janeiro, RJ, Brazil|Instituto Oswaldo Cruz (IOC), Rio de Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT00771498"
873,"NCT06178666","A Controlled Human Infection Model (CHIM) With Intradermal BCG in Malawi","MLWBCGCHIM","Not yet recruiting","No Results Available","Tuberculosis","Biological: BCG","Culture and PCR ascertainment of BCG load|Immunological response to BCG","Liverpool School of Tropical Medicine|Liverpool School of Tropical Medicine, United Kingdom|Fred Hutchinson Cancer Center|University of Liverpool|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|University of Oxford","All","18 Years to 50 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","23-Marvels-003|23-083","March 1, 2024","March 1, 2025","March 1, 2026","December 21, 2023",,"December 21, 2023","Queen Elizabeth Central Hospital, Blantyre, Malawi",,"https://ClinicalTrials.gov/show/NCT06178666"
874,"NCT01242475","A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG","TESEC-03","Completed","No Results Available","Tuberculosis","Biological: C-Tb|Biological: 2 TU Tuberculin PPD RT 23 SSI","The diameter of induration at the injection sites measured transversely to the long axis of the forearm 2-3 days after application of the agents|Injection site adverse reactions within 28 days after application of the agents|All adverse events occurring within 28 days after application of the agents|Laboratory safety parameters of haematology and biochemistry|In vitro IFN-γ response as measured by the QuantiFERON®-TB Gold In-Tube assay from blood samples taken at screening and 28 days after the injections of the skin test agents","Statens Serum Institut","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","151","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","TESEC-03|2009-017296-17","April 2011","November 2011","November 2011","November 17, 2010",,"January 21, 2013","Surrey Clinical Research Centre, University of Surrey, Surrey, Guildford, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01242475"
875,"NCT06019052","Evaluating Next Generation LAM Assays and Molecular Diagnostics (POC and Near POC) for the Diagnosis of TB Among People With Presumptive TB: a Prospective Multicentre Diagnostic Accuracy Study","DriveDx4TB","Not yet recruiting","No Results Available","Tuberculosis",,"1.1|1.2|1.3|2.1|2.2|2.3","Foundation for Innovative New Diagnostics, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"1890","Other","Observational","Observational Model: Other|Time Perspective: Prospective","TB051","February 2024","August 2025","November 2025","August 31, 2023",,"September 13, 2023",,,"https://ClinicalTrials.gov/show/NCT06019052"
876,"NCT06017843","Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding","SPOT-TB","Not yet recruiting","No Results Available","Tuberculosis","Other: Camps site selection for active case finding for TB using MATCH-AI","Camp positivity yield|Camp positivity rate|Camp All-Forms yield|Camp All-Forms TB rate","Centre for Global Public Health Pakistan|Mercy Corps Pakistan","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","180000","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","CGPH-TB2023-24","September 2023","August 2024","December 2024","August 30, 2023",,"September 6, 2023",,,"https://ClinicalTrials.gov/show/NCT06017843"
877,"NCT01934309","Clinical Decision-support Reminders to Improve IPT Initiation Among HIV Positive Adults in Western Kenya","TBTech","Completed","No Results Available","Tuberculosis","Behavioral: TB reminders","Prescription of Isoniazid|Time to isoniazid prophylactic therapy (IPT) initiation","Indiana University|Moi University|Academic Model Providing Access to Healthcare (AMPATH)|Regenstrief Institute, Inc.|Innovative Support to Emergencies, Diseases and Disasters (InSTEDD)|Kijani Consulting","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","3782","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","AID-OAA-TO-11-00060","September 2013","August 2014","August 2014","September 4, 2013",,"March 27, 2023","AMPATH, Eldoret, Kenya",,"https://ClinicalTrials.gov/show/NCT01934309"
878,"NCT05824091","Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults",,"Recruiting","No Results Available","Tuberculosis","Drug: MK-7762 (TBD09)|Other: Placebo","Safety: To characterize safety and tolerability of MK-7762 (TBD09) after administration of single doses or multiple doses in healthy adult participants.|Safety: To characterize laboratory results after administration of single doses or multiple doses of MK-7762 (TBD09).|Safety: To characterize electrocardiogram (ECG) parameters after administration of single doses or multiple doses of MK-7762 (TBD09).|Safety: To characterize vital signs after administration of single doses or multiple doses of MK-7762 (TBD09).|Oral Pharmacokinetics (PK) of MK-7762 (TBD09) following a single dose and multiple doses|Oral PK of MK-7762 (TBD09) following a single dose and multiple doses|Oral PK of MK-7762 (TBD09) following single dose|Oral PK of MK-7762 (TBD09) following multiple doses|Oral PK of MK-7762 (TBD09) following a single dose in a fasted state and fed state","Bill & Melinda Gates Medical Research Institute|Merck Sharp & Dohme LLC","All","19 Years to 55 Years   (Adult)","Phase 1","96","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gates MRI-TBD09-101","February 23, 2023","April 1, 2024","April 6, 2024","April 21, 2023",,"April 21, 2023","Investigational Site, Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT05824091"
879,"NCT01212003","Training Protocol on the Natural History of Tuberculosis",,"Recruiting","No Results Available","Mycobacterium Infections|Tuberculosis, Multidrug-Resistant|Latent Tuberculosis|Tuberculosis|Extensively Drug-Resistant Tuberculosis",,"Increase in the number of TB patients being actively followed at the NIH CC to provide information on TB patients with DS and drug-resistant disease for hypothesis generation and hands-on experience in the management of TB|Determination of subsets of lymphoid populations during various points in the treatment of TB|Description of whole genome sequences and their possible relationship to TB infection|Collection of MTB specimens for studies of the organism and its pathogenesis","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","2 Years to 100 Years   (Child, Adult, Older Adult)",,"150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","100195|10-I-0195","June 30, 2011",,,"September 30, 2010",,"April 11, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01212003"
880,"NCT01830439","Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)","CL-009","Completed","No Results Available","Tuberculosis","Drug: PA-824 200mg|Drug: PA-824 50mg","Time of the maximum drug concentration in hours [Tmax]|Maximum observed drug concentration in ng/mL [Cmax]|Area under the drug concentration-time curve in ng*hr/mL [AUC(0-t)]|Area under the drug concentration-time curve from time zero to infinity in ng*hr/mL [AUC(0-inf)]|Ratio of AUC(0-t) to AUC(0-inf) [AUC(0-t)/ AUC(0-inf)]|Number of participants with adverse events|Elimination half-life in hours [t1/2]|Terminal elimination rate constant in 1/hour [Kel]|Oral clearance in L/hour [Cl/F]|Volume of distribution following oral administration in L [Vd/F]","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PA-824-CL-009","September 2009","January 2010","January 2010","April 12, 2013",,"September 6, 2019","MDS Pharma Services (Celerion), Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01830439"
881,"NCT05686356","A Pan-TB Regimen Targeting Host and Microbe","panTB-HM","Recruiting","No Results Available","Tuberculosis","Drug: Sutezolid|Drug: N-acetyl cysteine|Drug: Pretomanid|Drug: Bedaquiline|Combination Product: Rifafour","The proportion of patients achieving durable (non-relapsing) cure|The proportion of subjects with TE ALT increases, graded according to severity|The proportion of subjects with TE increases in transaminases and bilirubin meeting Hy's criteria for serious liver injury|The proportion of subjects with TE AEs, according to seriousness|The number of TE AEs per treatment arm, according to seriousness|The proportion of subjects requiring temporary or permanent treatment discontinuation due to safety or tolerability concerns|FEV1 and FVC at 1, 2, 6, and 18 months after initiation of treatment|FEV1 and FVC slope during 6 and 18 months after initiation of treatment|FEV1/FVC ratio at 1, 2, 6, and 18 months after initiation of treatment|The proportion of subjects with sputum cultures showing growth of MTB at 1, 2, 3, and 4 months after initiation of treatment|The hazard ratio for stable culture conversion through the 4th month of treatment|The proportion of subjects with treatment failure|The proportion of subjects with relapse","The Aurum Institute NPC|Ludwig-Maximilians - University of Munich|Stichting Katholieke Universiteit|Wits Health Consortium (Pty) Ltd|Instituto Nacional de Saúde, Mozambique|National Institute for Medical Research, Tanzania|University of Stellenbosch|Sequella, Inc.|Global Alliance for TB Drug Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","352","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AUR1-1-312|24206|6986|RIA2019AMR-2647","July 28, 2023","September 30, 2025","September 30, 2025","January 17, 2023",,"November 30, 2023","Instituto Nacional de Saúde, Maputo, Mozambique|Clinical HIV Research Unit, Johannesburg, Gauteng, South Africa|The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa|Clinical HIV Research Unit, Durban, South Africa|NIMR-Mbeya Medical Research Centre, Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT05686356"
882,"NCT05756582","Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students","CROSSWORD","Recruiting","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Tuberculosis Infection|Latent Tuberculosis|Health Care Associated Infection","Diagnostic Test: Prevalence of Latent Tuberculosis Infection","The prevalence of Latent Tuberculosis Infection|Age|Sex|Vaccination history|Previous work or stay in other at risk countries|Recent exposure|Smoking|Co-morbidities / medical history|QuantiFERON-TB|Occupation|Working / training Unit|Years working as HCW","Eleonora Nucera|Catholic University of the Sacred Heart","All","18 Years to 72 Years   (Adult, Older Adult)",,"2040","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ID3528","November 17, 2021","June 30, 2026","December 15, 2026","March 6, 2023",,"February 13, 2024","UOSD Allergologia e Immunologia Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT05756582"
883,"NCT02216331","PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)",,"Completed","No Results Available","Tuberculosis","Drug: TMC207|Drug: rifapentine|Drug: rifampicin","Maximum observed TMC207 concentration in ng/mL [Cmax] between Groups 1 and 2|Area under the TMC207 concentration-time curve in ng*hr/mL [AUC0-t] between Groups 1 and 2|Area under the TMC207 concentration cuve from time zero to infinity in ng*hr/mL [AUC0-inf] between Groups 1 and 2|Maximum observed TMC207 concentration in ng/mL [Cmax] within treatment groups between Periods 1 and 2|Area under the TMC207 concentration-time curve in ng*hr/mL [AUC0-t] within treatment groups between Periods 1 and 2|Area under the TMC207 concentration cuve from time zero to infinity in ng*hr/mL [AUC0-inf] within treatment groups between Periods 1 and 2","Global Alliance for TB Drug Development","All","19 Years to 55 Years   (Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMC207-CL002","March 2010","May 2010","May 2010","August 13, 2014",,"September 6, 2019","Celerion (MDS Pharma Services), Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02216331"
884,"NCT05592223","Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines",,"Completed","No Results Available","Tuberculosis","Drug: BCG Vaccine USP|Drug: Isoniazid|Drug: Rifampin","Assess viable BCG bacteria from intradermal challenge site from culture.|The rate of AE's/SAE's|Assess quantitative bacterial 16S ribosomal DNA PCR|Quantification of IgG in the blood after BCG immunization and INH or RIF dosing.|Quantification of IgA in the blood after BCG immunization and INH or RIF dosing.","Fred Hutchinson Cancer Center|Merck Sharp & Dohme LLC","All","18 Years to 45 Years   (Adult)","Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","10903|RG1122457","December 6, 2022","August 23, 2023","December 1, 2023","October 24, 2022",,"January 5, 2024","Fred Hutchinson Cancer Center, Seattle, Washington, United States","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/23/NCT05592223/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05592223"
885,"NCT05581212","TB Case-Finding, Treatment and Prevention Intervention in Thailand","CaPThai","Not yet recruiting","No Results Available","Tuberculosis","Other: Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack","Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall|Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by age group (<15, ≥15 years)|Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by gender|Proportion of participants initiated on TPT who completed TPT|Proportion of participants who initiate TPT for whom treatment is discontinued due to adverse events or intolerance in the Intervention phase|Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - overall|Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by age group (<15, ≥15 years)|Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by gender","Institut de Recherche pour le Developpement|Division of Tuberculosis, Department of Disease Control, Ministry of Public Health, Thailand|London School of Hygiene and Tropical Medicine|Tuberculosis and HIV Research Foundation","All","Child, Adult, Older Adult","Not Applicable","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRD-1-001|21SANIN207","April 1, 2024","October 31, 2025","July 31, 2026","October 14, 2022",,"April 4, 2024",,,"https://ClinicalTrials.gov/show/NCT05581212"
886,"NCT00411996","The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: indinavir/ritonavir","pharmacokinetics of ritonavir-boosted indinavir 600/100mg bid in combination with rifampicin-containing anti-TB therapy.|safety of ritonavir-boosted indinavir 600/100mg bid in combination with rifampicin-containing anti-TB therapy|efficacy of ritonavir-boosted indinavir 600/100mg bid in combination with rifampicin-containing anti-TB therapy|the prevalence of immune recovery syndrome of TB and other HIV-related conditions after ritonavir-boosted indinavir 600/100mg bid","The HIV Netherlands Australia Thailand Research Collaboration","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIV-NAT 044","December 2006","October 2008","December 2009","December 15, 2006",,"July 17, 2020","HIV-NAT Thai Red Cross AIDS Research Center, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00411996"
887,"NCT01742364","Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe",,"Completed","Has Results","Tuberculosis","Device: Bioject ID Pen|Device: Needle and syringe","Injection Site Adverse Events (Following Injection)|Systemic Adverse Events|Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 (Cluster of Differentiation 4) T-cells|Short Term Whole Blood Intracellular Cytokine Staining Assay for BCG-specific CD4 T-cells","PATH|World Health Organization|University of Cape Town","All","up to 50 Years   (Child, Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","HS 645","December 2012","December 2013","December 2013","December 5, 2012","February 8, 2017","February 8, 2017","SATVI, University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01742364"
888,"NCT00054769","Diagnosing Tuberculosis in HIV Infected Children in Peru",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|HIV Infections",,,"National Institute of Allergy and Infectious Diseases (NIAID)","All","up to 12 Years   (Child)",,"760","NIH","Observational","Time Perspective: Prospective","1R01AI049139-01A1","March 2002","February 2007","February 2007","February 11, 2003",,"September 17, 2008","Instituto de Salud del Nino, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT00054769"
889,"NCT05139940","Validation of Artificial Intelligence Enabled TB Screening and Diagnosis in Zambia",,"Unknown status","No Results Available","Tuberculosis",,"Pilot Group to calibrate the operating points for AI algorithms|Main Cross Sectional Group|Main Cross Sectional Group:","Centre for Infectious Disease Research in Zambia","All","18 Years and older   (Adult, Older Adult)",,"2432","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Google AI","November 22, 2021","September 30, 2022","November 30, 2022","December 1, 2021",,"March 8, 2022","Chainda South Health Facility, Lusaka, Zambia|Chawama first level hospital, Lusaka, Zambia|Kanyama level 1, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT05139940"
890,"NCT05136833","Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients","CONSTAN","Withdrawn","No Results Available","Tuberculosis","Biological: RUTI® vaccine|Biological: Placebo","Early Bactericidal Activity (EBA) from day 0 to day 14|Early Bactericidal Activity (EBA) from 2 to 14 days|Early Bactericidal Activity (EBA) from 7 to 14 days|Early Bactericidal Activity (EBA) from 4 to 24 week|Hazard ratio for stable culture conversion (SCC).|Rate of Change in Time to Sputum Culture Positivity (TTP) in Liquid Culture Media (Days 0-14).|Rate of Change in Time to Sputum Culture Positivity (TTP) in Liquid Culture Media (week 4, 8, 16 and 24 )|The proportion of patients with AEs between each intervention arm and the control group.|The proportion of patients with SAEs between each intervention arm and the control group|Proportion of patients with CLINICAL, X-ray or LABORATORY worsening|Proportion of patients with improvement of clinical signs and symptoms, Bandim TB score|Number of patients with improvement of Health-related Quality of Life (HRQoL) comparing baseline measure with that over the course of therapy.","Archivel Farma S.L.|Fundació Institut Germans Trias i Pujol","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-R6|2021-003301-22","December 1, 2021","June 30, 2022","December 31, 2022","November 29, 2021",,"July 13, 2022",,,"https://ClinicalTrials.gov/show/NCT05136833"
891,"NCT05124678","Pharmacogenetics-guided Isoniazid Dosing in TB-HIV","PHINX","Unknown status","No Results Available","Tuberculosis","Drug: Isoniazid Tablets","Estimate the maximum concentrations of isoniazid stratified by NAT2 group|Estimate the area under the concentration-time curve of isoniazid stratified by NAT2 group|Estimate the of Clearance isoniazid stratified by NAT2 group|Estimate the Volume of distribution of isoniazid stratified by NAT2 group|Drug-induced hepatotoxicity|Other drug-related adverse events|Peripheral neuropathy|Sputum culture conversion at week 8","Makerere University","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDI SRC Ref:16/2020","December 7, 2021","March 30, 2022","June 30, 2022","November 18, 2021",,"January 25, 2022","Infectious Diseases Institute, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05124678"
892,"NCT05045391","Pulmonary Aspergillosis in Tuberculosis Patients",,"Active, not recruiting","No Results Available","Pulmonary Tuberculoses|Aspergillosis|Old Tuberculosis|Active Tuberculosis|Chronic Pulmonary Aspergillosis","Diagnostic Test: Aspergillus IgG detection","Aspergillus IgG|Aspergillus sp.|Antimicrobial resistance","Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","All","19 Years to 90 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1/2021","January 1, 2020","December 31, 2025","December 31, 2030","September 16, 2021",,"March 3, 2023","Research institute of epidemiology, microbiology and infectious diseases, Tashkent, Uchtepa, Uzbekistan",,"https://ClinicalTrials.gov/show/NCT05045391"
893,"NCT00546273","Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers",,"Completed","Has Results","Latent Tuberculosis Infection|Tuberculosis","Biological: RUTI|Biological: placebo of the vaccine RUTI","VAS Pain Score (Visual Analogic Scale, That Ranges From 0 to 100) to Evaluate Each Volunteer Subjective Pain Intensity at the Inoculation Point|Occurrence, Intensity and Relationship to Vaccination of Local and Systemic Events|Number of Clinically Relevant Abnormalities in the Laboratory Tests According to the Doctors' Impression|Evaluation of the Immunogenicity of the Different Doses of the Vaccine Tested","Germans Trias i Pujol Hospital|Archivel Farma S.L.","Male","18 Years to 40 Years   (Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FA/MI/01|EudraCT Number: 2006-000690-29","April 2007","June 2008","June 2008","October 18, 2007","March 25, 2009","May 27, 2009","Experimental Tuberculosis Unit. Fundació Institut per la Investigació Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Pharmacology Department. Hospital Universitari Germans Trias i Pujol., Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00546273"
894,"NCT01992263","Vitamin D Supplementation and TB",,"Unknown status","No Results Available","Tuberculosis|Vitamin D|Immunity","Dietary Supplement: Vitamin D (600 IU)|Dietary Supplement: Vitamin D (2000 IU)|Dietary Supplement: Vitamin D (4000 IU)|Other: Placebo","Immune function|Cell-mediated immunological markers|Vitamin D status|TB treatment outcomes|HIV disease progression","Cornell University|Arogyavaram Medical Centre","All","18 Years to 60 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","IRB #: 1304003801","June 2021","September 2022","February 2023","November 25, 2013",,"September 9, 2020","Cornell University, Ithaca, New York, United States|Arogyavaram Medical Centre (AMC), Madanapalle, India",,"https://ClinicalTrials.gov/show/NCT01992263"
895,"NCT03350048","Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB","ScreenTB","Completed","No Results Available","Pulmonary Tuberculosis","Diagnostic Test: Trans-Dot point-of-care test","Diagnostic performance of the TransDot finger-prick test|POC TransDOT test versus lab-based tests|TransDOT as treatment response marker|Identification of additional host marker signatures|Evaluation of the serum signature's underlying biological processes|Optimisation of ultra-sensitive TB culture techniques|Biomarker Biorepository Samples","Prof Gerhard Walzl|Armauer Hansen Research Institute, Ethiopia|Medical Research Council Unit, The Gambia|Leiden University Medical Center|Makerere University|London School of Hygiene and Tropical Medicine|European and Developing Countries Clinical Trials Partnership (EDCTP)|LINQ Management GMBH|University of Stellenbosch","All","18 Years to 70 Years   (Adult, Older Adult)",,"969","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","N16/05/070","April 1, 2016","April 30, 2019","July 31, 2020","November 22, 2017",,"February 1, 2023","Armauer Hansen Research Institute, Addis Ababa, Ethiopia|Medical Research Council The Gambia, Banjul, Gambia|European Research and Project Office GmbH, Saarbrücken, Saarland, Germany|LINQ Management GmbH, Berlin, Germany|University of Namibia, Windhoek, Namibia|The European & Developing Countries Clinical Trials Partnership Association (EDCTP), The Hague, South Holland, Netherlands|Leiden University Medical Center (Academisch Ziekenhuis Leiden, LUMC), Leiden, Netherlands|Stellenbosch University, Cape Town, Western Cape, South Africa|Makerere University, Kampala, Uganda|London School of Hygiene and Tropical Medicine, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT03350048/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03350048"
896,"NCT01945905","Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia","DOTS","Completed","No Results Available","Tuberculosis, Pulmonary","Other: Intramural|Other: Extramural","Compliance with treatment|Cured patients","Fundación FES|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)|Instituto Nacional de Salud Publica, Mexico","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","FES02013","December 2009","August 2014","September 2014","September 19, 2013",,"August 11, 2015","Secretaria de Salud Publica Municipal de Cali, Cali, Valle, Colombia",,"https://ClinicalTrials.gov/show/NCT01945905"
897,"NCT02782494","Comparing Consistency of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold for Latent Tuberculosis in Dialysis Population",,"Unknown status","No Results Available","Patients on Dialysis","Other: Examination of latent TB by QuantiFERON-TB","percentage of positive QFT|percentage of positive QFT change|percentage of occurrence of active TB","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201603066DIPB","May 2016","May 2018","May 2018","May 25, 2016",,"December 15, 2016","National Taiwan University Hospital, Taipei, Select..., Taiwan",,"https://ClinicalTrials.gov/show/NCT02782494"
898,"NCT01828827","Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects","CL-003","Completed","No Results Available","Tuberculosis","Drug: PA-824 1000 mg","Time of maximum drug concentration in hours [Tmax]|Maximum observed drug concentration in ng/mL [Cmax]|Area under the drug concentration-time curve in ng*hour/mL [AUC0-t]|Area under the drug concentration-time curve from time zero to infinity in ng*hour/mL [AUC(0-inf)]|Ratio of AUC(0-t) to AUC(0-inf) [AUC(0-t)/ AUC(0-inf)]|Number of participants with adverse events|Elimination half-life in hours [t1/2]|Terminal elimination rate constant in 1/hour [Kel]|Oral clearance in L/hour (Cl/F)|Volume of distribution in L (Vd/F)","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PA-824 CL-003","March 2007","March 2007","March 2007","April 11, 2013",,"January 14, 2016","MDS Pharma Services, Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01828827"
899,"NCT04890535","Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults",,"Completed","No Results Available","Tuberculosis","Drug: TBAJ-587|Drug: Placebo","Number of Participants with Treatment-Related Adverse Events in the Single Ascending Dose (SAD) population|Number of Participants with Treatment-Related Adverse Events in the Multiple Ascending Dose (MAD) population|Pharmacokinetics, Maximum concentration (Cmax), of TBAJ-587 and metabolites|Pharmacokinetics, Time of maximum concentration (Tmax), of TBAJ-587 and metabolites|Pharmacokinetics, Area under the concentration-time curve (AUC), of TBAJ-587 and metabolites|Effect of a high-calorie, high-fat meal on the pharmacokinetics of TBAJ-587","Global Alliance for TB Drug Development|QPS Holdings LLC","All","18 Years to 64 Years   (Adult)","Phase 1","106","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TBAJ-587-CL001","December 1, 2020","February 27, 2023","February 27, 2023","May 18, 2021",,"May 19, 2023","QPS Netherlands B.V., Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04890535"
900,"NCT00793702","Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration",,"Completed","No Results Available","Tuberculosis","Biological: rdESAT-6 + rCFP-10","Local and systemic adverse events with onset after the FIRST (0.01, 0.1 and 1.0 µg) or SECOND (0.01 and 0.1 µg) injection|The diameter of induration at the second injection site measured transversely to the long axis of the forearm","Statens Serum Institut","All","18 Years to 55 Years   (Adult)","Phase 1","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TESEC-01|EUDRACT No.: 2008-001489-96","November 2008","July 2009","July 2009","November 19, 2008",,"January 21, 2013","Rigshospitalet, Epidemiklinikken, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00793702"
901,"NCT05268380","Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia","Core-NB","Recruiting","No Results Available","COVID-19|HIV Seropositivity|Tuberculosis, Pulmonary|Tuberculosis Infection","Diagnostic Test: Covid-19, TB and HIV diagnosis","Covid-19 active infection in households|Covid-19 active infection in healthcare facilities|TB infection and disease in households|TB infection and disease in healthcare facilities|HIV seropositivity in households|HIV seropositivity in healthcare facilities","University of Namibia|European and Developing Countries Clinical Trials Partnership (EDCTP)|Research Center Borstel|Victus Global Botswana Organization","All","Child, Adult, Older Adult",,"2100","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","RIA2020EF-2963","August 1, 2022","May 31, 2023","December 31, 2023","March 7, 2022",,"February 15, 2023","University of Namibia, Windhoek, Namibia",,"https://ClinicalTrials.gov/show/NCT05268380"
902,"NCT03794284","Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium",,"Completed","No Results Available","Tuberculosis|Non-Tuberculous Mycobacterial Pneumonia","Diagnostic Test: VereMTB","diagnostic test correlation","Chinese University of Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"46","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VereMTB_v2_24_10_2018","February 28, 2019","July 31, 2022","July 31, 2022","January 7, 2019",,"August 9, 2022","Prince of Wales Hospital, Sha Tin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03794284"
903,"NCT02120638","Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide",,"Unknown status","No Results Available","Multidrug Resistant Tuberculosis","Drug: Pyrazinamide containing regimen|Drug: Regimen without Pyrazinamide","The Median Time to Sputum Culture Conversion|The Percentage of treatment success","Huashan Hospital","All","18 Years to 60 Years   (Adult)","Phase 3","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2013-260|2013ZX10003008-003","April 2014","April 2016","April 2016","April 23, 2014",,"April 23, 2014","Chongqing Pulmonary Hospital, Chongqing, Chongqing, China|The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Fifth People's Hospital of Wuxi, Wuxi, Jiangsu, China|Xinjiang Chest Hospital, Urumqi, Xinjiang, China|Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China|The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China|The Affiliated Hospital of Luzhou Medical College, Huzhou, Zhejiang, China|Wenling No.1 People's Hospital, Taizhou, Zhejiang, China|Ruian People's Hospital, Wenzhou, Zhejiang, China|Zhuji People's Hospital of Zhejiang Province, Zhuji, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02120638"
904,"NCT00675961","Effectiveness of Alcohol Interventions Among Tuberculosis (TB) Patients in Tomsk Oblast, Russia","IMPACT","Completed","No Results Available","Tuberculosis|Alcohol Use Disorders","Behavioral: Brief Counseling Intervention (BCI)|Drug: Naltrexone|Other: BCI + Naltrexone|Behavioral: Treatment as Usual","Alcohol: change in mean number of heavy drinking days in last month of study period compared with baseline|TB: successful treatment vs. non-successful treatment as defined by the WHO|Time to death|Nonadherence to TB therapy, defined as having taken less than 80% of indicated doses|Acquisition of drug resistance, defined as new resistance confirmed by DST performed during the study period (compared with baseline DST) to any TB drug to which the subject was exposed during the study|Change in the mean number of heavy drinking days (defined as 4 drinks per drinking day for women and 5 drinks per drinking day for men) in the last month of the study compared with baseline|Change in mean Addiction Severity Index (ASI) alcohol scores at the end of the study period, compared with baseline","Brigham and Women's Hospital|Mclean Hospital|Harvard School of Public Health (HSPH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005P-002539|NIH 1 RO1 AA016318-01","January 2007","June 2011","June 2011","May 12, 2008",,"October 25, 2017","Tomsk Oblast TB Services, Tomsk, Tomsk Oblast, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00675961"
905,"NCT04369326","Community Initiated Preventive Therapy for TB","CHIP-TB","Completed","No Results Available","Tuberculosis","Other: Community-Based TPT Initiation","The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy (TPT) per index patient, comparing the intervention to the control arm|The cluster-level ratio of the number of household child contacts less than 15 years of age identified per index patient, comparing the intervention to the control arm|The cluster-level proportions of estimated child contacts under 15 years who are identified|The cluster-level proportions of estimated child contacts under 15 years who are screened|The cluster-level proportions of estimated child contacts under 15 years who are initiated on TB preventive therapy|The cluster-level proportions of estimated child contacts under 15 years who complete TB preventive therapy|The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm in South Africa|The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm in Ethiopia|The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm among those less than 5 years of age|The proportion of child contacts, by study arm, who discontinued TPT due to incident TB|The proportion of child contacts, by study arm, who discontinued TPT due to pregnancy|The proportion of child contacts, by study arm, who discontinued TPT due to severe malaria|The proportion of child contacts, by study arm, who discontinued TPT due to a side effect|The proportion of child contacts, by study arm, who were lost to follow up|The proportion of children, by study arm, who were HIV-tested|The proportion of newly diagnosed HIV-positive children, by study arm, who are referred for initiation of antiretroviral therapy by the community health team|The proportion of newly diagnosed HIV-positive children, by study arm, who are initiated on antiretroviral therapy|The proportion of identified child contacts in the intervention arm whose caregiver agrees for them to be screened by community-based healthcare workers in their home|Mean number of attempted household visits per household|Mean duration of time per household visit|The proportion of TB contacts initiated on the correct TPT regimen by age and HIV status|The proportion of TPT initiations with the correct dose for weight|Proportion of TB index patient households in the intervention arm who refused a household visit due to stigma|Proportion of TB index patient households in the intervention arm who refused a household visit due to lack of time|Proportion of TB index patient households in the intervention arm who refused a household visit due to well status of the child|Proportion of TB index patient households in the intervention arm who do not receive a home visit because the family and/or child was not home on three separate attempts|Proportion of TB index patient households in the intervention arm who refused a household visit due to fear of disclosure","Johns Hopkins University|UNITAID|Aurum Institute|KNCV Tuberculosis Foundation","All","0 Days to 14 Years   (Child)","Not Applicable","1168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00249787","September 7, 2021","March 31, 2023","June 30, 2023","April 30, 2020",,"August 14, 2023","KNCV-Ethiopia, Oromia Region, Oromia, Ethiopia",,"https://ClinicalTrials.gov/show/NCT04369326"
906,"NCT05007821","Linezolid Dosing Strategies in Drug-Resistant TB",,"Recruiting","No Results Available","Tuberculosis, Multidrug-Resistant|Tuberculosis|Tuberculosis, Pulmonary","Drug: Linezolid 600 mg|Drug: Linezolid 1200 mg (QD)|Drug: Linezolid 1200 mg (TIW)|Drug: Bedaquiline 200 mg|Drug: Bedaquiline 100 mg|Drug: Delamanid 300 mg|Drug: Clofazimine 300 mg|Drug: Clofazimine 100 mg","Cumulative probability of sputum culture conversion|Cumulative probability of permanent discontinuation of at least one anti-TB drug due to adverse events, intolerance, or death|Cumulative probability of permanent discontinuation of LZD due to AEs, intolerance, or death; temporary discontinuation of LZD for any reason; and dose reduction of LZD|Cumulative probability of treatment-related adverse events|Cumulative probability of unfavorable TB treatment outcome|Delamanid minimum plasma concentration (Cmin)|Delamanid maximum plasma concentration (Cmax)|Delamanid time to reach maximum plasma concentration (Tmax)|Delamanid area under the concentration-time curve (AUC)|Delamanid apparent oral clearance (CL/F)|Linezolid minimum plasma concentration (Cmin)|Linezolid maximum plasma concentration (Cmax)|Linezolid time to reach maximum plasma concentration (Tmax)|Linezolid area under the concentration-time curve (AUC)|Linezolid apparent oral clearance (CL/F)|Proportion of doses taken during the treatment period","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","132","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5356","August 11, 2022","December 27, 2024","November 14, 2025","August 16, 2021",,"April 3, 2024","Gaborone CRS (Site ID: 12701), Gaborone, South-East District, Botswana|Hospital Nossa Senhora da Conceicao CRS (Site ID: 12201), Porto Alegre, Rio Grande Do Sul, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101), Rio De Janeiro, Brazil|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (Site ID: 31730), Port-au-Prince, Haiti|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS (Site ID: 30022), Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS (Site ID: 31441), Pune, Maharashtra, India|Moi University Clinical Research Center (MUCRC) CRS (Site ID: 12601), Eldoret, Rift Valley, Kenya|Barranco CRS (Site ID: 11301), Lima, Peru|De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981), Cavite, Philippines|Wits Helen Joseph Hospital CRS (Wits HJH CRS) (Site ID: 11101), Johannesburg, Gauteng, South Africa|Durban International CRS (Site ID: 11201), Durban, Kwa Zulu Natal, South Africa|Rustenburg CRS (Site ID: 31684), Rustenburg, North West Province, South Africa|University of Cape Town Lung Institute (UCTLI) CRS (Site ID: 31792), Cape Town, Western Cape Province, South Africa|South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site ID: 31793), Cape Town, Western Cape Province, South Africa|Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802), Pathum Wan, Bangkok, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784), Chiang Mai, Thailand|Milton Park CRS (Site ID: 30313), Milton Park, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT05007821"
907,"NCT01002170","Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament","CSPK","Completed","No Results Available","Pulmonary Tuberculosis",,"Setting up a suggested treating concentration fitting for Asian (Taiwanese) and developing the therapeutic drug monitoring protocols in Taiwan|Figuring out that factors causing different pharmacokinetics and the clinical outcomes in different Cycloserine level","Taipei Medical University WanFang Hospital|Centers for Disease Control, Taiwan","All","Child, Adult, Older Adult",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TB2NDCSTDMTW","May 2009","June 2009","May 2010","October 27, 2009",,"November 3, 2010","Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01002170"
908,"NCT04303104","Xpert Active Case-finding Trial 3 (XACT-3)","XACT-3","Recruiting","No Results Available","Tuberculosis","Other: GeneXpert Edge|Other: GeneXpert Ultra","Proportion with PTLF (defined as test positive patients failing to initiate treatment by 60 days) and/ or the proportion of infectious TB patients (smear positive and/ or with cavitatory disease) not initiating treatment within 14 days of diagnosis.|Proportion of culture-positive patients failing to initiate treatment in each study arm within 14 days of diagnosis.|Time to TB treatment initiation|Time-specific proportion of patients initiated on TB treatment up to 60 days.|Feasibility of Xpert being performed by minimally trained health care workers at point-of-care using.|Cost effectiveness analysis in each of the four countries.|Turn-around-time for Xpert testing in both arms.|Transmission impact using modelling based on exposure scores, imaging and CASS.|Household contact tracing yield from TB positive patients (active TB and QFT conversion).|The time-specific proportion of culture-positive TB cases initiating TB treatment in each study arm.|The proportion of culture-positive TB cases completing 6-months of TB treatment in each study arm.","University of Cape Town|Zambart (University of Zambia), Zambia|Instituto Nacional de Saúde, Mozambique|Biomedical Research and Training Institute, Zimbabwe|Radboud University Medical Center|London School of Hygiene and Tropical Medicine|University of Cape Town Lung Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","3375","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","XACT-3","March 26, 2021","July 1, 2023","December 1, 2024","March 10, 2020",,"July 14, 2022","Khosa Celso, Maputo, Mozambique|University of Cape Town, Cape Town, Western Cape, South Africa|Helen Ayles, Lusaka, Zambia|Junior Mutsvangwa, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT04303104"
909,"NCT02690818","Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging","TXT4MED","Completed","No Results Available","Latent Tuberculosis","Behavioral: Regularly scheduled LTBI medication reminder text messages","Recruitment|Retention|Perceptions of Intervention through a questionnaire","University of Arizona|Pima County Health Department|American Lung Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","TXT4MED","April 2016","September 26, 2018","September 26, 2018","February 24, 2016",,"April 23, 2019","Pima County Health Department, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02690818"
910,"NCT04203628","Evaluation of Four Stool Processing Methods Combined With Xpert MTB/RIF Ultra for Diagnosis of Intrathoracic Paediatric TB (TB-Speed - Stool Processing)",,"Unknown status","No Results Available","Tuberculosis","Diagnostic Test: Xpert MTB/Rif Ultra on stool samples|Diagnostic Test: Xpert MTB/Rif Ultra on respiratory sample","Sensitivity and sensibility of Ultra on stool|Per-protocol analysis of diagnostic accuracy of Ultra on stool using TB culture reference standard|Sensitivities and specificities of each sampling method|Proportion of Ultra ""trace"" results in stools out of the number of stools tested with Ultra|Proportion of Ultra semi-quantitative results ""very low""; ""low""; ""medium"" and ""high"" in stool|Proportion of invalid Ultra results from stool out of the number of stools tested with Ultra|Proportion of Rifampicin resistant results on Ultra (stool and respiratory), LPA and DST|Proportion of children successfully providing a stool sample|Relative gain of the 2nd stool sample as compared to the 1st one|Feasibility assessment of the stool processing methods","Institut National de la Santé Et de la Recherche Médicale, France|UNITAID","All","up to 14 Years   (Child)","Not Applicable","274","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","C19-34","January 13, 2020","February 2022","February 2022","December 18, 2019",,"September 5, 2021","Mbarara Regional Hospital, Mbarara, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT04203628"
911,"NCT05633056","An Adaptive Randomized Controlled Trial","ADAP-TIV","Not yet recruiting","No Results Available","Multi Drug Resistant Tuberculosis|HIV Infections","Behavioral: Adherence support intevention","Biological outcome|Clinical outcome","Columbia University|Centre for the AIDS Programme of Research in South Africa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CAP262","February 2023","February 2025","February 2027","December 1, 2022",,"December 1, 2022","King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa","""Study Protocol and Informed Consent Form: Informed Consent Form-English"", https://classic.clinicaltrials.gov/ProvidedDocs/56/NCT05633056/Prot_ICF_000.pdf|""Informed Consent Form: English version"", https://classic.clinicaltrials.gov/ProvidedDocs/56/NCT05633056/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05633056"
912,"NCT04141982","Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study)",,"Completed","No Results Available","Tuberculosis","Diagnostic Test: T-Cell SelectTM Kit","Achieving positive and negative clinical concordance between results of the T-SPOT.TB assay between 0-55hours after venipuncture","Oxford Immunotec","All","18 Years and older   (Adult, Older Adult)",,"680","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OI-18-01-IP-0001","November 4, 2019","March 18, 2020","March 18, 2020","October 28, 2019",,"March 3, 2022","NECCR Primacare Research, LLC, Fall River, Massachusetts, United States|Ohio State University, Columbus, Ohio, United States|University of Texas Health Science Center at Houston, School of Public Health in Brownsville, Brownsville, Texas, United States|Rapitrade, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT04141982"
913,"NCT04015713","Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset","LILAC-TB","Unknown status","No Results Available","Tuberculosis",,"Evolution of the plasma concentration of IL-1Ra between baseline (initiation of TB treatment) and Week 2|Evolution of the plasma concentration of IL-1Ra between baseline (initation of TB treatment) and weeks 1, 2, 4 and 8|Evolution of the concentration of sCD163 between baseline (initiation of TB treatment) and weeks 1, 2, 4 and 8|Evolution of the plasma concentration of IP-10 between baseline (initiation of TB treatment) and weeks 1, 2, 4 and 8|Impact of the occurrence of events on the evolution of biomarkers from baseline (initiation of TB treatment) to the end of treatment (Week 24)","ANRS, Emerging Infectious Diseases|Institut Pasteur, Cambodia|Institut National de la Santé Et de la Recherche Médicale, France|European Georges Pompidou Hospital","All","18 Years to 99 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ANRS 12394 LILAC-TB","January 21, 2020","March 2021","March 2021","July 11, 2019",,"February 6, 2020","Institut Pasteur Cambodge, Phon Phen, Cambodia|CEPREF/Programme PACCI, Abidjan, Côte D'Ivoire",,"https://ClinicalTrials.gov/show/NCT04015713"
914,"NCT04351685","Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants","VPM1002","Active, not recruiting","No Results Available","Mycobacterium Tuberculosis Infection","Biological: VPM1002|Biological: BCG SII","Incident cases of QFT conversion, indicating Mtb infection|The rate of TB disease in children receiving VPM1002 compared to BCG SII. Incident cases of sustained QFT conversion, indicating sustained Mtb infection.","Serum Institute of India Pvt. Ltd.|Vakzine Projekt Management GmbH","All","0 Days to 14 Days   (Child)","Phase 3","6940","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VPM1002-MN-3.05TB","November 9, 2020","August 30, 2023","November 30, 2025","April 17, 2020",,"December 20, 2022","Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon|Kenya Medical Research Institute / Center for Respiratory Disease Research, Nairobi, Kenya|Kenya Medical Research Institute - Center for Respiratory Disease Research, Siaya, Kenya|Empilweni Services and Research Unit (ESRU), Johannesburg, Coronation Ville, South Africa|Family Center for Research with Ubuntu, Cape Town, South Africa|Mecru Clinical Research Unit, Medunsa, South Africa|Respiratory and Meningeal Pathogens Research Unit, Soweto, South Africa|South African Tuberculosis Vaccine Initiative, Worcester, South Africa|Ifakara Health Institute, Dar Es Salaam, Tanzania|The national institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC), Mbeya, Tanzania|Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda|Makerere University/CISMAC, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04351685"
915,"NCT03891901","A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin","IMPACT-TB","Completed","Has Results","Tuberculosis","Drug: Imatinib|Drug: Isoniazid|Drug: Rifabutin","Number of Myelomonocytic Cells in the Blood|Frequency of Grade 3 or 4 Adverse Events (AEs)|Frequency of Serious Adverse Events (SAEs)|White Blood Cell Count|Maximum Concentration (Cmax) of Imatinib|Half-life (T1/2) of Imatinib|Area Under the Curve (AUC) for Imatinib|Elimination Rate Constant (Ke) of Imatinib|Maximum Concentration (Cmax) of Isoniazid|Half-life (T1/2) of Isoniazid|Area Under the Curve (AUC) for Isoniazid|Elimination Rate Constant (Ke) of Isoniazid|Maximum Concentration (Cmax) of Rifabutin|Half-life (T1/2) of Rifabutin|Area Under the Curve (AUC) for Rifabutin|Elimination Rate Constant (Ke) of Rifabutin","National Institute of Allergy and Infectious Diseases (NIAID)|Emory University|University of Pennsylvania|Aurum Institute|University of Florida","All","18 Years to 55 Years   (Adult)","Phase 2","24","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Aim 1|38518","October 27, 2020","August 30, 2022","August 30, 2022","March 27, 2019","September 28, 2023","October 23, 2023","Emory University DAIDS TB Non-Network CRS, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/01/NCT03891901/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/01/NCT03891901/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03891901"
916,"NCT01676155","The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis",,"Unknown status","No Results Available","To Compare the Serum Apoptosis-associated Markers Between Patients With Active TB and Patients With LTBI|To Evaluate the Efficiency of Apoptosis-associated Markers to Differentiate Potential of Active TB From LTBI",,"getting active tuberculosis|mortality","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20110822RC","September 2011",,,"August 30, 2012",,"August 30, 2012","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01676155"
917,"NCT03559582","Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)",,"Completed","No Results Available","Tuberculosis",,"Measure area under the concentration curve (AUC) to anti-tuberculosis (TB) medications relative to TB treatment outcome in severe TB syndromes|Collect stool in patients undergoing pharmacokinetic testing to measure the environmental enteropathy index|Collect stool in patients undergoing pharmacokinetic testing to measure the quantitative burden and species distribution of enteric pathogens by the enteric TAC assay- 35 bacterial, viral, parasitic species)","University of Virginia|National Institute of Allergy and Infectious Diseases (NIAID)|Scientific Center for Family Health and Human Reproduction Problems, Russia|Kilimanjaro Christian Medical Centre, Tanzania|Haydom Lutheran Hospital|Mbarara University of Science and Technology|International Centre for Diarrhoeal Disease Research, Bangladesh|University of Florida","All","Child, Adult, Older Adult",,"478","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","18452|U01AI115594","April 28, 2016","July 31, 2020","January 31, 2021","June 18, 2018",,"March 9, 2022",,,"https://ClinicalTrials.gov/show/NCT03559582"
918,"NCT00192556","Food Incentives for TB Treatment Compliance in East Timor (FITTCET)",,"Completed","No Results Available","Tuberculosis","Behavioral: food","proportion of patients who successfully complete TB treatment and achieve cure.|proportion of clinic visits compared with expected|response to treatment measures: symptoms (cough, sputum, fever);|changes in weight;sputum clearance;|micronutrient measurements.","Menzies School of Health Research|World Health Organization|Universidade da Paz","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","270","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FITTCET_1|WHO-TDR ID A30746","March 2005",,"August 2006","September 19, 2005",,"February 12, 2007","Menzies School of Health Research, Darwin, Northern Territory, Australia",,"https://ClinicalTrials.gov/show/NCT00192556"
919,"NCT01724723","Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment","HBV","Unknown status","No Results Available","Hepatitis|Tuberculosis|hepatitisB","Drug: entecavir (BARACLUDE®)","incidence of hepatitis|HBV viral load","National Taiwan University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NTUH-IRB-201109046MB","December 2012","June 2014","June 2014","November 12, 2012",,"November 12, 2012","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01724723"
920,"NCT05077813","Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19",,"Unknown status","No Results Available","Tuberculosis","Combination Product: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|Combination Product: 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|Combination Product: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Combination Product: All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|Combination Product: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|Other: The standard therapy","Time to first negative SARS-CoV-2 PCR in NP swap and Mycobacterium tuberculosis sputum culture|Sputum culture result (positive or negative)& COVID-19 PCR (positive or negative)|Serum levels of CRP and ESR|All cause mortality rate|Absolute lymphocyte counts (CD4,CD8 and CD25+FOXP3+ Regulatory T)|Measurement of cytokine (IFN-gamma and alpha , IL-6, IL-10, TNF-alpha, TGF-beta) levels produced in response to M. tb.|Vitamin D status|Retinoic acid status|Minocycline status|Serum indoleamine 2,3-dioxygenase (IDO) enzyme status|Chicoric Acid status","Kafrelsheikh University|Ministry of Health, Saudi Arabia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","How to kill Tuberculosis","December 2021","February 2022","February 2022","October 14, 2021",,"October 14, 2021","Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Ministry of health. First health cluster, Riyadh, Riaydh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT05077813"
921,"NCT03456102","Statin Adjunctive Therapy for TB","StAT-TB","Completed","Has Results","Tuberculosis","Drug: Pravastatin","Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events","Johns Hopkins University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00145353","March 9, 2020","August 31, 2022","August 31, 2022","March 7, 2018","June 28, 2023","June 28, 2023","Chris Hani Baragwanath Hospital, Johannesburg, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/02/NCT03456102/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03456102"
922,"NCT03363178","Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults",,"Unknown status","No Results Available","Tuberculosis","Biological: GC3107","Adverse Event|Whether the maximum Induration diameter greater than 5mm after TST.|Whether the maximum Erythema/Redness diameter greater than 5mm after TST.|Maximum diameter of Induration after TST.|Maximum diameter of Erythema/Redness after TST.|Maximum diameter variation of Induration after TST.|Maximum diameter variation of Erythema/Redness after TST.","Green Cross Corporation|GC Biopharma Corp","All","19 Years to 64 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","GC3107_P1","December 14, 2017","March 31, 2018","March 31, 2018","December 6, 2017",,"December 18, 2017","Korea University Guro Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03363178"
923,"NCT03356925","Improving TB Diagnosis and Treatment Through Basic, Applied and Health Systems Research","BAR","Completed","No Results Available","Tuberculosis","Diagnostic Test: Xpert Ultra Point of Care testing","Treatment time|TB diagnosis time|Time specific yield of Xpert Ultra|Airway and gut microbiome composition before, during, and after TB treatment","University of Stellenbosch","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1549","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Diagnostic","N14/10/13","February 6, 2018","June 30, 2022","June 30, 2022","November 29, 2017",,"November 2, 2022","Scottsdene Clinic, Cape Town, Western Cape, South Africa|Wallacedene Clinic, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT03356925"
924,"NCT03199339","A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary","Drug: TBA-7371|Drug: Placebo","Safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects by number and severity of treatment emergent adverse events (TEAEs)|Pharmacokinetics (PK) of single and multiple doses of TBA-7371 AUC(0-t)|Pharmacokinetics (PK) of single and multiple doses of TBA-7371 using Cmax|Pharmacokinetics (PK) of single and multiple doses of TBA-7371 using Tmax|Compare the rate and extent of absorption of a single oral dose of TBA-7371 using AUC, when administered after a high-calorie, high-fat meal versus when it's administered fasting in healthy adult subjects|Compare the rate and extent of absorption of a single oral dose of TBA-7371 using Cmax, when administered after a high-calorie, high-fat meal versus when it's administered fasting in healthy adult subjects|Compare the rate and extent of absorption of a single oral dose of TBA-7371 using Tmax, when administered after a high-calorie, high-fat meal versus when it's administered fasting in healthy adult subjects|Effects of multiple-dose administration of TBA-7371 on the pharmacokinetics of midazolam and bupropion using AUC|Effects of multiple-dose administration of TBA-7371 on the pharmacokinetics of midazolam and bupropion using Cmax|Effects of multiple-dose administration of TBA-7371 on the pharmacokinetics of midazolam and bupropion using Tmax|Safety and tolerability of the combination of TBA7371 with midazolam and bupropion by the number and severity of treatment emergent adverse events (TEAEs)","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","74","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TBA-7371-CL001","August 29, 2017","July 8, 2018","July 8, 2018","June 26, 2017",,"October 17, 2018","Worldwide Clinical Trials, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03199339"
925,"NCT03175380","Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US","(A-051)","Completed","No Results Available","Tuberculosis","Biological: bacillus Calmette-Guérin","Biological samples","Aeras","All","18 Years to 55 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A-051","August 8, 2017","January 10, 2019","January 10, 2019","June 5, 2017",,"September 4, 2019","Saint Louis University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03175380"
926,"NCT03075410","First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects",,"Completed","Has Results","Tuberculosis","Drug: GSK3036656|Drug: Placebo","Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A|Number of Participants With nSAE and SAEs for Part B|Number of Participants With Abnormal Electrocardiogram (ECG) Findings for Part A|Number of Subjects With Clinically Relevant Changes in ECG in Part B|Number of Participants With Abnormal Cardiac Telemetry Findings for Part A|Number of Participants With Abnormal Cardiac Telemetry Findings for Part B|Number of Participants With Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance (PCI) for Part A|Number of Participants With Vital Sign Parameters SBP and DBP of PCI for Part B|Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part A|Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part B|Number of Participants With Vital Sign Parameter Temperature of PCI for Part A|Number of Participants With Vital Sign Parameter Temperature of PCI for Part B|Number of Participants With Clinical Chemistry Parameters of PCI for Part A|Number of Participants With Clinical Chemistry Parameters of PCI for Part B|Number of Participants With Hematology Parameters of PCI for Part A|Number of Participants With Hematology Parameters of PCI for Part B|Number of Participants With Abnormal Urinalysis Parameters for Part A|Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part A|Number of Participants With Abnormal Urinalysis Parameters for Part B|Urine pH Analysis by Dipstick Method for Part B|Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A|AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A|Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A|Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A|Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A|AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B|AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B|Cmax of GSK3036656 Following Repeated Dose Administration for Part B|Tmax of GSK3036656 Following Repeat Dose Administration for Part B|t1/2 of GSK3036656 Following Repeated Dose Administration for Part B|AUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|AUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|Cmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|t1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|Tmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|Observed Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B|Observed Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B|Steady State Ratio (Rss) of GSK3036656 in Part B|Trough Plasma Concentrations at the End of the Dosing Interval (Ctau) of GSK3036656 Following Repeat Dose Administrations in Part B|AUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A|AUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A|Cmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A|AUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B|Cmax as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201040|2015-003654-41","April 2, 2017","August 4, 2017","August 4, 2017","March 9, 2017","April 19, 2019","April 19, 2019","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/10/NCT03075410/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/10/NCT03075410/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03075410"
927,"NCT03032367","TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)",,"Completed","No Results Available","Tuberculosis","Drug: bedaquiline","Bioequivalence of bedaquiline 4 x 100mg given to healthy adult males and females orally in tablet form compared to crushed form","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|US National Institute of Allergy and Infectious Diseases|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Early Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","TASK-002","November 10, 2016","December 9, 2016","January 11, 2017","January 26, 2017",,"July 28, 2017","TASK Clinical Research Centre, Bellville, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT03032367"
928,"NCT02968927","TB Host Directed Therapy","TBHDT","Unknown status","No Results Available","Tuberculosis","Drug: Everolimus 0.5 MG|Drug: Auranofin 6 MG|Drug: Vitamin D3|Drug: CC-11050|Drug: 2HRbZE/4HRb","SAEs and SUSARs|TEAEs other than SAEs and SUSARs|Sputum culture status on day 56","The Aurum Institute NPC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBHDT-AUR1-8-178","November 2016","September 2018","December 2020","November 21, 2016",,"January 10, 2019","The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT02968927"
929,"NCT02808507","Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa","Kharitode TB","Completed","Has Results","Tuberculosis","Other: Active TB case finding","Treatment Initiation Ratio in Facility Versus Contact Investigation Clinics|Comparative Treatment Initiation Ratio in the Incentive-based Versus Household-based Contact Investigation Arms|Comparative Costs and Cost-effectiveness of Active TB Case Finding Strategies|Comparative Number of Secondary TB Cases Identified in Incentive-based Versus Household-based Contact Tracing","Johns Hopkins Bloomberg School of Public Health|National Institute of Allergy and Infectious Diseases (NIAID)|Perinatal HIV Research Unit of the University of the Witswatersrand","All","0 Years to 99 Years   (Child, Adult, Older Adult)","Not Applicable","4852","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-0005|R01AI116787-02","July 18, 2016","January 17, 2018","January 30, 2020","June 21, 2016","December 2, 2022","June 22, 2023","Vhembe health subdistrict, Louis Trichardt, Limpopo, South Africa|Waterberg health subdistrict, Mokopane, Limpopo, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/07/NCT02808507/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02808507"
930,"NCT00005737","Tuberculosis Prophylaxis in the Homeless--A Controlled Trial",,"Completed","No Results Available","Lung Diseases|Tuberculosis",,,"National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"NIH","Observational",,"4946|R01HL055729","September 1995",,"August 1999","May 26, 2000",,"March 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00005737"
931,"NCT02689089","Taima TB: 3HP Study",,"Completed","No Results Available","Tuberculosis","Drug: 3HP","Completion of treatment","Ottawa Hospital Research Institute|Government of Nunavut|Government of Canada","All","2 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","182","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20160044-01H","November 28, 2016","August 15, 2019","August 15, 2019","February 23, 2016",,"March 24, 2020","The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02689089"
932,"NCT02681445","Non-invasive TB Triage and Patient Mapping Platform Using Breath Via Low-Cost Titanium Dioxide Nanotube Sensor",,"Completed","No Results Available","Tuberculosis","Device: Breath Collection","Correlation of sensor ability to detect breath biomarkers for TB","University of Utah","All","18 Years to 70 Years   (Adult, Older Adult)",,"810","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","00088349","February 2016","November 2017","November 2017","February 12, 2016",,"February 1, 2018","Mahatma Gandhi Institute of Health Science, Navi Mumbai, India",,"https://ClinicalTrials.gov/show/NCT02681445"
933,"NCT02619240","Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB",,"Completed","No Results Available","Tuberculosis","Procedure: bronchoscopy","The number of true positive BAL PCR using GeneXpert on BAL for rapid diagnosis of TB in few hours compare to the conventional TB PCR which usually take up few days to perform","Chinese University of Hong Kong","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CREC 2014.556","October 2015","April 30, 2017","August 30, 2017","December 2, 2015",,"April 17, 2019","Department of Medicine and Therapeutics, Prince of Wales Hospital, CUHK, Shatin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT02619240"
934,"NCT01599897","Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers",,"Completed","No Results Available","Pulmonary Tuberculosis","Biological: ID93 + GLA-SE|Biological: ID93 alone","Number of patients experiencing adverse events.|Immunogenicity","Access to Advanced Health Institute (AAHI)|Aeras|Paul G. Allen Family Foundation","All","18 Years to 45 Years   (Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IDRI-TBVPX-113","August 2012","May 2014","May 2014","May 16, 2012",,"September 15, 2017","Johnson County Clin-Trials, Lenexa, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01599897"
935,"NCT02533089","Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi",,"Completed","Has Results","Tuberculosis","Other: KT intervention","Proportion of Cases Successfully Treated, Defined as the Total Number of Cases Cured and Completing Treatment.|Proportion of Default Cases (Treatment Interrupted >= 2 Consecutive Months)|Proportion of Successes Among HIV Co-infected Cases","Dignitas International|Unity Health Toronto","All","Child, Adult, Older Adult","Not Applicable","1153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research","TB KT intervention","May 2016","February 2018","February 2018","August 26, 2015","March 24, 2020","March 24, 2020","4 Districts, SE zone of Malawi (Balaka, Machinga, Mangochi, Mulanje), Malawi, Malawi","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/89/NCT02533089/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02533089"
936,"NCT00233168","Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents",,"Completed","No Results Available","Lung Diseases|Tuberculosis","Behavioral: Adherence Program|Behavioral: Life Skills and Self-Esteem Training Program (Attention Control Arm)","Number of INH pills taken","San Diego State University|National Heart, Lung, and Blood Institute (NHLBI)","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","263","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","323|R01HL068595","September 2003","August 2007","August 2008","October 5, 2005",,"June 25, 2014","San Diego State University, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00233168"
937,"NCT02481726","68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT",,"Completed","No Results Available","Lung Cancer|Lung Tuberculosis","Radiation: 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG","Quantitative measurement of standardized uptake values (SUVs) of lesions.|Number of participants with adverse events as a measure of safety after 68Ga-NEB injection and PET/CT scanning.","Xijing Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","XijingH","March 2014","October 2014",,"June 25, 2015",,"June 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02481726"
938,"NCT04121494","ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)","TB039","Completed","No Results Available","Mycobacterium Tuberculosis, Protection Against|Tuberculosis","Biological: ChadOx1 85A - aerosol|Biological: ChadOx1 85A - IM","Safety - (serious) adverse events|Immunogenicity","François Spertini|University of Oxford|Centre Hospitalier Universitaire Vaudois","All","18 Years to 55 Years   (Adult)","Early Phase 1","39","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CHADOX","January 22, 2019","August 24, 2020","August 24, 2020","October 10, 2019",,"September 25, 2020","Centre hospitalier universitaire vaudois, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT04121494"
939,"NCT00460759","Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine",,"Terminated","No Results Available","Mycobacterium Tuberculosis","Drug: Moxifloxacin|Drug: Rifapentine",,"Johns Hopkins University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00007322","June 2007","August 24, 2008","August 24, 2008","April 16, 2007",,"December 7, 2017","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00460759"
940,"NCT02420444","A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults","C-013-404","Completed","No Results Available","Tuberculosis","Biological: BCG SSI|Biological: Placebo|Biological: AERAS-404","Number of unsolicited, solicited, and serious adverse events (SAEs).|Immunogenicity of BCG and a 2- or 3-dose regimen of AERAS-404 measured by intracellular staining assay (ICS).","Aeras|Sanofi Pasteur, a Sanofi Company","All","18 Years to 50 Years   (Adult)","Phase 1","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-013-404","January 2011","May 2012","November 2013","April 17, 2015",,"January 24, 2017","Centre Hosptialier Universitaire Vaudois (CHUV), Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT02420444"
941,"NCT02413502","Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US",,"Completed","No Results Available","Tuberculosis","Biological: BCG","Immune response measured by Intracellular cytokine staining (ICS)","Aeras|University of Rochester","All","18 Years to 55 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A-046","May 2015","September 2015","October 2015","April 10, 2015",,"October 9, 2015",,,"https://ClinicalTrials.gov/show/NCT02413502"
942,"NCT02391415","Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa",,"Completed","No Results Available","Tuberculosis","Biological: VPM1002|Biological: BCG|Biological: VPM1002(Hyg+)","The difference between the VPM1002 and BCG vaccination groups in the incidence of grade 3 and 4 adverse drug reactions and IMP-related ipsilateral or generalised lymphadenopathy of 10mm or greater (diameter).","Serum Institute of India Pvt. Ltd.|Vakzine Projekt Management GmbH|Triclinium Clinical Trial Project Management|Children's Infectious Diseases Clinical Research Unit (KID-CRU)|Desmond Tutu TB Centre|The Respiratory and Meningeal Pathogens Research Unit (RMPRU)|South African Tuberculosis Vaccine Initiative|University of Stellenbosch","All","up to 12 Days   (Child)","Phase 2","416","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","VPM1002-ZA-2.13TB|DOH-27-1114-4798","June 2015","November 2017","November 2017","March 18, 2015",,"April 18, 2018","Children's Infectious Diseases Clinical Research Unit, Tygerberg Hospital, Cape Town, South Africa|Desmond Tutu TB Centre, Cape Town, South Africa|South African Tuberculosis Vaccine Initiative, Cape Town, South Africa|The Respiratory and Meningeal Pathogens Reserach Unit, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT02391415"
943,"NCT02380508","Heterologous Effects of BCG in Healthy UK Adults",,"Completed","No Results Available","Tuberculosis","Drug: BCG SSI|Other: No vaccination|Drug: BCG Sii","Growth inhibition assays|Immune response markers","University of Oxford","All","18 Years to 45 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","TB038","February 2015","November 2016","November 2016","March 5, 2015",,"November 30, 2016","Centre for Clinical Vaccinology and Tropical Medicine , University of Oxford, Oxford, Oxfordshire, United Kingdom|Oxford University Hospitals- John Warin Ward, University of Oxford, Oxford, Oxfordshire, United Kingdom|NIHR Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02380508"
944,"NCT02378207","Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents",,"Completed","Has Results","Tuberculosis","Biological: H4:IC31|Biological: H56:IC31|Biological: BCG|Biological: Control Sodium Chloride 0.9%","Number of Participants With Adverse Events|Percentage of Participants With Response Rates to TB Antigens as Compared to Baseline|Evaluate Humoral Responses Elicited by the Different Vaccine Regimens.|* Evaluate Immune Response From Vaccine Regimens by Measuring Early (Innate) Vaccine-induced Peripheral Blood Transcription Profiles; Determine Which Responses Are Associated With Antigen-specific Adaptive Responses * Evaluate Adaptive Immune Response.|Evaluate Changes in Innate Cells in Response to the Vaccine Regimens|Measure Non-classical Major Histocompatibility Complex (MHC)-Restricted T-cell Vaccine-induced Responses, Such as to Mycobacterial Lipids (CD1-restricted) and Metabolites (MR1-restricted).|Evaluate QFT-GIT and ESAT-6 Free IGRA Discordance and Conversion/Reversion Rate During the Course of the Trial.","Aeras|HIV Vaccine Trials Network|Sanofi Pasteur, a Sanofi Company|Statens Serum Institut","All","12 Years to 17 Years   (Child)","Phase 1","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HVTN 602 / AERAS A-042","May 2015","October 31, 2016","December 9, 2016","March 4, 2015","November 18, 2019","November 18, 2019","Desmond Tutu HIV Foundation, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT02378207"
945,"NCT02375256","A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402","C-021-402","Completed","No Results Available","Tuberculosis","Biological: AERAS-402|Biological: Placebo|Biological: BCG (1-8 x105 cfu ID)","Cellular immune responses to AERAS-402 in healthy adult volunteers who received two booster doses of AERAS-402 administered 84 and 112 days after BCG vaccination, through leukapheresis and cryopreservation of cells followed by in vitro assay.|Evaluation of adverse events (AEs) and serious adverse events (SAEs).","Aeras","All","18 Years to 45 Years   (Adult)","Phase 1","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-021-402","October 2009","December 2010","December 2013","March 2, 2015",,"March 3, 2015",,,"https://ClinicalTrials.gov/show/NCT02375256"
946,"NCT04887740","Osteoarticular Infections on Material in Children",,"Completed","No Results Available","Osteoarticular Tuberculoses",,"Number of Participants with incidence of osteoarticular infections|Number of Participants with Epidemiology of osteoarticular infections|Number of Participants with bacterial ecology of osteoarticular infections","University Hospital, Montpellier","All","up to 16 Years   (Child)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL21_0183","January 1, 2021","April 1, 2021","April 1, 2021","May 14, 2021",,"May 21, 2021","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04887740"
947,"NCT00421798","Rapid Characterization of Paucibacillary TB Along Tex/Mex Border",,"Completed","No Results Available","Mycobacterium Tuberculosis",,,"The University of Texas Health Science Center, Houston|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 85 Years   (Adult, Older Adult)",,"780","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","06-0042 transfer from DMID","January 2007","January 2009","May 2009","January 12, 2007",,"July 9, 2009","The University of Texas at Brownsville, Brownsville, Texas, United States|Corporacion para Investigaciones Biologicas de Medellin, Medellin, Colombia|Jurisdicción Sanitaria III Matamoros, Matamoros, Mexico",,"https://ClinicalTrials.gov/show/NCT00421798"
948,"NCT02298309","Test and Treat TB: A Proof of Concept Trial in South Africa","Siyasiza","Completed","No Results Available","Tuberculosis","Other: Test-and-Treat TB","Number of patients who complete tuberculosis treatment|Proportion of mobile testers screened for tuberculosis|Proportion of eligible participants able to produce sputum samples|Prevalence of TB among those tested|Prevalence of tuberculosis and rifampin resistance|Distribution of TB symptoms ascertained from TB symptom screen questionnaire|Proportion returning to the mobile tester for TB test result|Linkage to TB care (first visit to a local TB treatment site ascertained from clinic record)|ART initiation date as documented by clinic record for those HIV co-infected","Massachusetts General Hospital|National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Healthcare Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4815","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","2014P001173/MGH|R21AI110264","April 2015","November 2017","November 2017","November 21, 2014",,"April 4, 2018","iThembalabantu Clinic/AIDS Healthcare Foundation, Durban, KwaZulu-Natal, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT02298309/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02298309"
949,"NCT00398996","A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients","SAPIT","Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Early versus intermediate versus late initiation of ART","To measure the incidence of progression to AIDS defining illness or mortality|A comparison of CD4+ cell count, viral load, opportunistic infections across the 3 study arms","Centre for the AIDS Programme of Research in South Africa","All","18 Years and older   (Adult, Older Adult)","Phase 3","642","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPRISA 003","June 2005","July 2010","July 2010","November 14, 2006",,"March 24, 2011","CAPRISA eThekwini Clinical Research Site, Durban, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT00398996"
950,"NCT02121314","HRZE Fasted/Fed in Newly Diagnosed TB","FASTFOOD","Completed","No Results Available","Tuberculosis","Drug: intravenous administration of 1st line TB drugs, day 1","pharmacokinetics|pharmacokinetics (AUC0-8, Cmax, and Tmax) of HRZE|To evaluate adverse events of HRZE, week 1 and 8 - while taking food or not","University Medical Center Groningen|University of Groningen|Gadjah Mada University","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UGM-RuG-UMCG-TB-001","July 2013","April 2014","June 2014","April 23, 2014",,"April 8, 2015","Sardjito Central Hospital, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT02121314"
951,"NCT02088892","A Clinical Challenge Study of BCG in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: BCG SSI|Drug: BCG Tice","Quantity of BCG at challenge site|Immune response markers","University of Oxford|Aeras|University of Birmingham","All","18 Years to 55 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","TB031","March 2014","January 2015","January 2015","March 17, 2014",,"January 22, 2015","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom|The Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02088892"
952,"NCT00682045","Latent Tuberculosis Infection in Renal Transplant Recipients",,"Completed","No Results Available","Renal Transplant",,"development of tuberculosis|all cause mortality","Asan Medical Center","All","16 Years and older   (Child, Adult, Older Adult)",,"240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC-20080169","June 2008","May 2010","May 2010","May 21, 2008",,"June 2, 2010","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00682045"
953,"NCT02043067","Enhanced TB Screening to Determine the Prevalence and Incidence of TB in Patients With HIV",,"Completed","No Results Available","Tuberculosis","Other: Comprehensive TB screening","Prevalence of undiagnosed TB in those with HIV.|Incidence of TB in a cohort of HIV clinic patients screened as 'TB negative'.","University of North Carolina, Chapel Hill|Centre for Infectious Disease Research in Zambia|Centers for Disease Control and Prevention","All","16 Years to 99 Years   (Child, Adult, Older Adult)",,"400","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIDRZ 1226/IRB12-0416","October 2011","September 2012","May 2013","January 23, 2014",,"September 15, 2017","Kalingalinga HIV Care and Treatment Clinic, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT02043067"
954,"NCT03915366","Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","EMPIRICAL","Active, not recruiting","No Results Available","Pneumonia|HIV/AIDS|Tuberculosis|Cytomegalovirus Infections","Drug: Valganciclovir Oral Solution [Valcyte]|Drug: Tuberculostatic Agents","Mortality|Days with oxygen therapy|Days of hospitalization|Serious Adverse Events|Adverse Reactions|Notable Adverse Events|Immune-reconstitution inflammatory syndrome|Baseline cytomegalovirus prevalence|Baseline tuberculosis prevalence|Tuberculosis incidence|Deaths attributable to tuberculosis|CMV prevalence in died participants|CMV Molecular response to treatment|TB-lipoarabinomannan (LAM) sensitivity and specificity|Quality-adjusted life expectancy|Per-patient cost","Hospital Universitario 12 de Octubre|University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France|PENTA Foundation|Centre Hospitalier Cocody|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|Eduardo Mondlane University|Centro de Investigação em Saúde de Manhiça|Stichting Katholieke Universiteit|Barcelona Institute for Global Health|University of Lincoln|Makerere University|University Teaching Hospital, Lusaka, Zambia|University of Zimbabwe|Kamuzu Central Hospital|Servicio Madrileño de Salud, Madrid, Spain","All","28 Days to 365 Days   (Child)","Phase 2|Phase 3","563","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19/096|2019-001749-42|EDCTP RIA2017MC-2013EMPIRICAL|U1111-1231-4736|PACTR201904797961340","March 1, 2020","January 31, 2025","July 31, 2025","April 16, 2019",,"February 9, 2024","Programme PACCI. Centre Hospitalier Cocody., Abidjan, Côte D'Ivoire|Université de Bourdeaux, Bourdeaux, France|INSERM, Toulouse, France|PENTA Foundation, Padova, Italy|Malawi Liverpool Welcome Trust. Queen Elizabeth Central Hospital College of Medicine, Blantyre, Malawi|Cemtro de Investigaçao em Saúde da Manhiça, Manhiça, Mozambique|Hospital Central Maputo, Maputo, Mozambique|Stichting Katholieke Universiteit Radboudumc, Nimega, Netherlands|Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Madrid, Spain|Makerere University - Mulago Hospital, Kampala, Uganda|University of Lincoln, Lincoln, United Kingdom|Lusaka Teaching Hospital, Lusaka, Zambia|University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT03915366"
955,"NCT01977768","TB Immunotherapy Trial With Heat-killed M. Vaccae","imm03","Completed","No Results Available","Tuberculosis","Biological: V7|Biological: Placebo","bacillary sputum smear clearance|changes in body weight|changes in body mass index (BMI)|changes in inflammation markers|changes in liver function test","Immunitor LLC|National Medical University, Ukraine|Immunitor USA Inc.|University of Stellenbosch|Lisichansk Regional Tuberculosis Dispensary","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","152","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","imm03","March 2014","October 2018","December 2018","November 7, 2013",,"July 25, 2019","Misheel Lung surgery hospital,, Ulaanbaatar, Ulaanbaatar Region, Mongolia|Lisichansk Regional TB Dispensary, Lisichansk, Ukraine",,"https://ClinicalTrials.gov/show/NCT01977768"
956,"NCT02465216","Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion",,"Completed","Has Results","Pulmonary Tuberculosis","Other: Placebo|Biological: ID93 + GLA-SE","Number of Adverse Events|Immunogenicity Responder Rate","Access to Advanced Health Institute (AAHI)|Wellcome Trust|South African Tuberculosis Vaccine Initiative","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IDRI-TBVPX-203","June 2015","January 2017","January 2017","June 8, 2015","November 9, 2018","March 12, 2019","TASK Applied Sciences, Cape Town, South Africa|Desmond Tutu HIV Centre (DTHC), Cape Town, South Africa|South African Tuberculosis Vaccine Initiative (SATVI), Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT02465216"
957,"NCT00005742","Behavioral Interventions for Control of Tuberculosis",,"Completed","No Results Available","Lung Diseases|Tuberculosis",,,"National Heart, Lung, and Blood Institute (NHLBI)","All","11 Years to 19 Years   (Child, Adult)",,,"NIH","Observational",,"4951|R01HL055770","September 1995",,"August 2001","May 26, 2000",,"February 29, 2016",,,"https://ClinicalTrials.gov/show/NCT00005742"
958,"NCT02845570","Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TB",,"Unknown status","No Results Available","Tuberculosis","Other: 68Ga-DOTANOC PET/MRI|Other: 18F-FDG PET/MRI","Standard uptake value (SUV) of 68Ga-DOTANOC in pulmonary TB lesions using PET/MRI|Comparison of uptake of 68Ga-DOTANOC with that of 18F-FDG in pulmonary TB.|Establishment of optimal timing for a 68Ga-DOTANOC PET scan to evaluate TB lung pathology","National University Hospital, Singapore|Tan Tock Seng Hospital","All","21 Years and older   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","DOTANOC TB","July 2016","August 2017",,"July 27, 2016",,"April 13, 2017","National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02845570"
959,"NCT01829490","Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults",,"Completed","No Results Available","Tuberculosis","Biological: ChAdOx1 85A|Biological: MVA85A","Safety of ChAdOx1 85A vaccination with, and without, MVA85A boost vaccination in healthy, BCG vaccinated adults.|To investigate the T-cell immune response of ChAdOx1 85A vaccination compared with ChAdOx1 85A vaccination with MVA85A boost vaccination.","University of Oxford|University of Birmingham","All","18 Years to 55 Years   (Adult)","Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB034","July 2013","April 2016","April 2016","April 11, 2013",,"May 12, 2016","Centre for Clinical Vaccinology and Tropical Medicine , University of Oxford, Oxford, Oxfordshire, United Kingdom|The NIHR/ Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01829490"
960,"NCT03096379","MRI Differentiating Gut TB and Crohn's",,"Completed","No Results Available","Crohn Disease|Intestinal Tuberculosis","Diagnostic Test: Magnetic resonance imaging","Small / large bowel transmural enhancement|Skip lesions in small / large bowel|Vascular engorgement|Mesenteric combing","The University of Hong Kong|The University of Hong Kong-Shenzhen Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MRE-TB-CD","December 30, 2014","December 30, 2018","March 30, 2019","March 30, 2017",,"April 17, 2019","The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03096379"
961,"NCT01779102","Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses","TESEC-07","Completed","No Results Available","Tuberculosis","Biological: C-Tb|Biological: Tuberculin PPD RT 23 SSI|Biological: C-Tb / Tuberculin PPD RT 23 SSI","To compare the size of induration of C-Tb and PPD RT 23 if injected alone or concomitantly in Tuberculosis infected patients (HIV positives and HIV negatives)|To assess if concomitant injections of C-Tb and PPD RT 23 influence the tests abilities to identify positive results of Tuberculosis in Tuberculosis infected patients|To compare the C-Tb test's ability to identify positive results in Tuberculosis infected patients with the in vitro QuantiFERON®TB Gold In Tube assay in blood collected immediately before application of the C-Tb skin test|To compare the C-Tb test's ability to identify positive results in Tuberculosis infected patients with the PPD RT 23 test|To assess the safety of C-Tb skin test by investigating laboratory safety parameters and assessing all adverse events (local and systemic) occurring within 28 days after administration of the C-Tb and/or PPD RT 23 tests","Statens Serum Institut","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","456","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","TESEC-07","October 2013","September 2014","September 2014","January 30, 2013",,"April 17, 2015","Be Part Yoluntu Centre, Paarl, Western Cape, South Africa|TASK, M2, Karl Bremer Hospital,, Cape Town, South Africa|Tiervlei Trial Centre, Karl Bremer Hospital, Cape Town, South Africa|UCT Lung Institute, Cape Town, South Africa|Primecure Medicentre, Port Elizabeth, South Africa|Synexus Stanza Bopape Clinic, Pretoria, South Africa|Setshaba Research Centre, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT01779102"
962,"NCT01768273","Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam",,"Completed","No Results Available","Tuberculosis","Drug: Midazolam|Drug: PA-824","Evaluate the effects of multiple-dose administration of PA-824 on the pharmacokinetics of midazolam, a sensitive probe substrate and representative compound for drugs metabolized by CYP3A enzymes.|To evaluate the safety and tolerability of PA-824 when given with midazolam.","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PA-824-CL-006","December 2009","January 2010","April 2010","January 15, 2013",,"September 12, 2019","MDS Pharma Services, Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01768273"
963,"NCT04407325","Tuberculosis Screening in Paraguayan Prisons","Prinose","Recruiting","No Results Available","Volatile Organic Compounds|Radiography","Device: electronic nose device|Device: dig chest Xray with automated readings","Volatile organic compound signal as measured with the AeoNose™|Tuberculosis probablity score using Computed Automated detection software CAD4TB® on chest Xrays|Positive mycobacterial sputum test|Comparison of predictive value of volatile organic compound signal with Tuberculosis Probability Score|added value of the use of AeoNose and Cad4TB as a TB screening algorithm in vulnerable populations","Radboud University Medical Center|European Union|Instituto de Saude Publica da Universidade do Porto|VHIR|University Medical Center Groningen|Laboratorio central de salud publica, Paraguay|Instituto Nacional de Enfermedades Respiratorias y del Ambiente Juan Max Boetner|National TB program Paraguay|IICS Paraguay","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","5000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","823890-EUSAT-RCS","October 18, 2021","July 1, 2023","December 1, 2023","May 29, 2020",,"April 3, 2023","Buen Pastor, Asuncion, Central, Paraguay|UPI, Asuncion, Central, Paraguay","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT04407325/Prot_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT04407325/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04407325"
964,"NCT04752592","Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB","SeroSelectTB","Recruiting","No Results Available","Tuberculosis, Pulmonary","Diagnostic Test: SeroSelectTB rapid TB test","To determine the impact of SeroSelectTB on health systems' diagnostic delay in Ethiopia, Tanzania and South Africa.|To describe SeroSelectTB performance in field conditions, including sensitivity and specificity, and positive and negative predictive values, in the study populations.|Evaluate cost-effectiveness of SeroSelectTB.","Norwegian Institute of Public Health|European and Developing Countries Clinical Trials Partnership (EDCTP)|University of Stellenbosch|Kilimanjaro Christian Medical University College|Armauer Hansen Research Institute, Ethiopia|Lateral Flow Laboratories (Pty) Ltd|InVivo BioTech Services GmbH|Aether Dynamics Consulting & Trading GmbH|E-MEDDIA|KNCV Tuberculosis Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","16682","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","19/10773","September 21, 2021","January 31, 2024","December 31, 2025","February 12, 2021",,"April 3, 2023","Amhara region, Bahir Dar, Ethiopia|Stellenbosch University Clinics, Cape Town, Western Cape, South Africa|Kilimanjaro region, Tanzania, Moshi, Tanzania",,"https://ClinicalTrials.gov/show/NCT04752592"
965,"NCT01404312","Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)",,"Completed","Has Results","Tuberculosis|HIV Infections","Drug: Rifapentine (RPT)|Drug: Isoniazid (INH)|Dietary Supplement: Pyridoxine (Vitamin B6)","Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause|Number of Participants With Occurrence of One or More Serious Adverse Events (SAEs) Versus no SAEs|Number of Participants With a Targeted Adverse Event|Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period|Cumulative Incidence of Death From Any Cause|Cumulative Incidence of Death Due to a Non-TB Event|Number of Participants With Antibiotic Resistance Among Mycobacterium Tuberculosis (MTB) Isolates in Participants Who Develop Active Tuberculosis|Efavirenz (EFV) Plasma Concentrations in Arm A|Nevirapine (NVP) Plasma Concentrations in Arm A|EFV Plasma Concentrations in Arm B","National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 3","3000","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A5279|10848|ACTG A5279","May 23, 2012","November 14, 2017","November 14, 2017","July 28, 2011","December 6, 2018","November 4, 2021","University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|University of Southern California CRS, Los Angeles, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Denver Public Health CRS, Denver, Colorado, United States|The University of Miami AIDS Clinical Research Unit (ACRU) CRS, Miami, Florida, United States|Northwestern University CRS, Chicago, Illinois, United States|Boston Medical Center CRS, Boston, Massachusetts, United States|Henry Ford Hosp. CRS, Detroit, Michigan, United States|Cooper Univ. Hosp. CRS, Camden, New Jersey, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Duke University Medical Center CRS, Durham, North Carolina, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|Houston AIDS Research Team CRS, Houston, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Gaborone CRS, Gaborone, Botswana|Molepolole CRS, Gaborone, Botswana|Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, São Paulo, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Inst de Infectologia Emilio Ribas Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince, Haiti|Kisumu Crs, Kisumu, Nyanza, Kenya|Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS, Kericho, Rift Valley, Kenya|Moi University Clinical Research Center (MUCRC) CRS, Eldoret, Kenya|Malawi CRS, Lilongwe, Central, Malawi|Blantyre CRS, Blantyre, Malawi|Barranco CRS, Lima, Peru|San Miguel CRS, Lima, Peru|Soweto ACTG CRS, Johannesburg, Gauteng, South Africa|Wits Helen Joseph Hospital CRS (Wits HJH CRS), Johannesburg, Gauteng, South Africa|Durban International Clinical Research Site CRS, Durban, KwaZulu-Natal, South Africa|Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Bangkok, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chon Buri, Thailand|Parirenyatwa CRS, Harare, Zimbabwe","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/12/NCT01404312/Prot_001.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/12/NCT01404312/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01404312"
966,"NCT01690403","Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients",,"Completed","No Results Available","Tuberculosis","Drug: rifapentine (M000473)|Drug: EFZ EMT TDF","To determine PK parameters Cmax, Cmin and AUC0-24 for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)|To determine PK parameters t1/2z, tmax for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)|To determine PK parameters tlag, CL/F for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)|To determine PK parameter for AUC0-10 for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)|To determine PK parameters Ctrough for rifapentine and 25-desacetyl- rifapentine (25-DR)|To determine PK parameters C8h for rifapentine and 25-desacetyl- rifapentine (25-DR)","Sanofi","All","18 Years to 55 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","INT12291|U1111-1131-1992","December 2012","March 2014","March 2014","September 21, 2012",,"February 27, 2015","Investigational Site Number 840001, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01690403"
967,"NCT06084715","The INSTITUT Study","INSTITUT","Recruiting","No Results Available","Tuberculosis, Pulmonary|Undernutrition","Other: Nutritional support","Percent of participants with an unfavorable outcome|Number of participants with failure of sputum conversion","Boston Medical Center|The International Union Against Tuberculosis and Lung Disease","All","18 Years and older   (Adult, Older Adult)",,"1050","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-43096","September 7, 2023","December 2025","December 2025","October 16, 2023",,"October 16, 2023","Centre Hospitalier et Universitaire de Pneumo-phtisiologie, Porto-Novo, Benin|National Tuberculosis Programme, Lomé, Togo",,"https://ClinicalTrials.gov/show/NCT06084715"
968,"NCT01631266","Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI",,"Completed","No Results Available","Tuberculosis","Biological: C-Tb|Biological: 2 T.U. Tuberculin PPD RT 23 SSI","To demonstrate an increasing trend in C-Tb test positivity across the four study groups, with 'positivity' defined as an induration ≥ 5 mm|To demonstrate a significantly lower response rate of C-Tb as compared to that of PPD RT23 SSI in the BCG vaccinated participants in the negative control group, with response defined as any induration (> 1mm) for both agents|To evaluate a possible trend in C-Tb induration diameters across the four pre-specified MTb infection risk sub-groups|To evaluate a possible trend in PPD RT23 SSI induration diameters across the four pre-specified MTb infection risk sub-groups|To evaluate a possible trend in QuantiFERON Gold In-Tube results across four pre-specified MTb infection risk sub-groups|To evaluate a possible trend in PPD RT23 SSI test positivity across four pre-specified MTb infection risk sub-groups|To evaluate a possible trend in QuantiFERON Gold In-Tube test positivity across four pre-specified MTb infection risk sub-groups|To evaluate the difference in sensitivity between C-Tb and QuantiFERON Gold In-Tube in the positive control group|To evaluate the difference in specificity between C-Tb and QuantiFERON Gold In-Tube in the negative control group|To evaluate the difference in sensitivity between C-Tb and PPD RT23 SSI in positive control group|To evaluate the difference in specificity between C-Tb and PPD RT23 SSI in the negative control group|To compare the size of induration of C-Tb if injected alone or concomitantly with PPD RT23 SSI in negative control group|To compare the specificity of C-Tb if injected alone or concomitantly with PPD RT23 SSI, in the negative control group|To compare the diagnostic outcome of C-Tb to that of QuantiFERON Gold In-Tube using a latent class approach|To compare the diagnostic outcome of C-Tb to that of PPD RT23 SSI using a latent class approach|To evaluate the secondary analyses above (1-14) of C-Tb and PPD RT23 SSI using alternative cut-off values|To compare the diagnostic outcome of C-Tb and QuantiFERON Gold In-Tube stratified on the four study groups|To compare the diagnostic outcome of C-Tb and PPD RT23 SSI stratified on the four study groups|To evaluate the clinical safety of C-Tb|To evaluate the clinical safety of PPD RT23 SSI","Statens Serum Institut","All","6 Weeks to 65 Years   (Child, Adult, Older Adult)","Phase 3","979","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","TESEC-06|2011-005617-36","July 2012","October 2014","October 2014","June 29, 2012",,"April 17, 2015","Hospital Universitario de Cruces, Barakaldo, Basque Country, Spain|CAP Drassanes, Unitat de Prevenció i Control de Tuberculosi, Barcelona, Catalonia, Spain|Hospital del Mar, Barcelona, Catalonia, Spain|Public Health Agency of Barcelona, Barcelona, Catalonia, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain|Hospital Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Catalonia, Spain|Hospital Mutua de Terrassa, Barcelona, Catalonia, Spain|Hospital San Joan De Deu, Barcelona, Catalonia, Spain|Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain|Complexo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Galicia, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain",,"https://ClinicalTrials.gov/show/NCT01631266"
969,"NCT01574638","Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults",,"Completed","No Results Available","Tuberculosis","Drug: Rifapentine (RPT)","RPT PK parameter: area under the curve over 24 hours (AUC 0 to 24h)|RPT PK parameter: AUC 0 to 24h|Grade 2 or higher signs and symptoms observed while on study beginning with the first dose of study drug and continuing through the follow-up period|RPT PK parameter: maximum observed plasma concentrations (Cmax)|Cmin (trough) values|Metabolizer status of human genetic variants/polymorphisms in gene SLCO1B1 and possibly other genes that are thought to affect PK of RIF|RPT PK parameter: minimum observed plasma concentration (Cmin)|RPT PK parameter: oral clearance (CL/F)|RPT PK parameter: elimination half-life (T 1/2)|RPT metabolite desacetyl-rifapentine (desRPT) PK parameter: AUC 0 to 24h|RPT metabolite desRPT PK parameter: Cmax|RPT metabolite desRPT PK parameter: Cmin|RPT metabolite desRPT PK parameter: CL/F|RPT metabolite desRPT PK parameter: T1/2|RPT PK parameter: Cmax|RPT PK parameter: Cmin|RPT PK parameter: CL/F|RPT PK parameter: T1/2|RPT metabolite desRPT PK parameter: AUC 0 to 24h|RPT and its metabolite desRPT PK parameter AUC 0 to 24h at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )|RPT and its metabolite desRPT PK parameter Cmax at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )|RPT and its metabolite desRPT PK parameter Cmin at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )|RPT and its metabolite desRPT PK parameter CL/F at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )|RPT and its metabolite desRPT PK parameter T1/2 at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 )|RPT and its metabolite desRPT PK parameter area under the curve extrapolated to infinity (AUC 0 to inf)|RPT and its metabolite desRPT PK parameter CL/F|RPT and its metabolite desRPT PK parameter T1/2|RPT and its metabolite desRPT PK parameter AUC 0 to 24h","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","44","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5311|11859|ACTG5311|ACTG 5311","June 2012","June 2013","June 2013","April 10, 2012",,"November 5, 2021","UCSD Antiviral Research Center CRS, San Diego, California, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01574638"
970,"NCT04717908","Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","TB-TRUSTplus","Active, not recruiting","No Results Available","Multidrug Resistant Tuberculosis","Drug: Bedaquiline|Drug: Pyrazinamide|Drug: Linezolid|Drug: Cycloserine|Drug: Clofazimine","Treatment success rate|The median time to Sputum Culture Conversion|The frequency of grade 3 or greater adverse events among patients","Huashan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","89","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY1214","January 20, 2021","April 30, 2023","November 30, 2023","January 22, 2021",,"April 6, 2023","The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China|Guiyang Public Health Treatment Center, Guizhou, Guizhou, China|The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan, China|Hunan Chest Hospital, Changsha, Hunan, China|Huaihua first people's Hospital, Huaihua, Hunan, China|Huashan Hospital of Fudan University, Shanghai, Shanghai, China|Shanxi Provincial Tuberculosis Control Institute, Xi'an, Shanxi, China|Chest Hospitalof Xinjiang Uygur Autonomous Region of PRC, Urumqi, Xinjiang, China|Baoshan People's Hospital, Baoshan, Yunnan, China|Yunnan Provincial Infectious Disease Hospital, Kunming, Yunnan, China|Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China|Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital), Ningbo, Zhejiang, China|Taizhou Enze medical center Enze Hospital, Taizhou, Zhejiang, China|The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China|Jiangxi Chest Hospital, Nanchang, China",,"https://ClinicalTrials.gov/show/NCT04717908"
971,"NCT01530568","Gene Xpert Diagnosis of TB Using Tracheal Aspirates From Intensive Care Unit (ICU) Patients",,"Completed","No Results Available","Tuberculosis","Other: Xpert|Other: Smear","Rates of TB treatment initiation|Mortality in ICU|Duration of mechanical ventilation|ICU length of stay","University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Not Applicable","341","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Diagnostic","TB Xpert ICU","August 2010","July 2013","July 2013","February 10, 2012",,"January 7, 2015","Groote Schuur Hospital, which operates within the Cape Town Central Health District of the Metro Region, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT01530568"
972,"NCT01927159","Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers",,"Completed","No Results Available","Pulmonary Tuberculosis","Biological: ID93 + GLA-SE|Other: Placebo","Number of Adverse Events|Immunogenicity","Access to Advanced Health Institute (AAHI)|Aeras|South African Tuberculosis Vaccine Initiative","All","18 Years to 50 Years   (Adult)","Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IDRI-TBVPX-114","September 2013","July 2015","July 2015","August 22, 2013",,"February 1, 2018","SATVI, Worcester, Western Cape, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/59/NCT01927159/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT01927159"
973,"NCT01492595","Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda","TBcontact","Completed","No Results Available","Tuberculosis",,"Proportion of <5 year-old child contacts classified as active TB disease, LTBI or no infection|Number of children <5 years exposed to TB in the household of adult index cases|Number of contacts identified as active TB basing on a symptom-based approach compared with those based on chest radiography|Proportion of contacts with HIV co-infection classified as non infected, LTBI or active TB|Median duration of exposure to symptomatic source case among the contacts in the various classes|Association of various risk factors with the final classification of contacts after assessment|Proportion of children with LTBI successfully treated (prevented from developing active TB disease) among HIV-infected and uninfected children|Proportion of children with no TB infection or disease successfully treated (prevented from developing active TB disease or LTBI)|Proportion of adverse events on treatment of TB disease, LTBI and TB exposure|Adherence to IPT regimens","Epicentre|Mbarara University of Science and Technology|Medecins Sans Frontieres, Netherlands","All","1 Month to 5 Years   (Child)",,"281","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Epicentre/MBA/2011/TBcontact","April 2012","April 2014","April 2014","December 15, 2011",,"March 2, 2016",,,"https://ClinicalTrials.gov/show/NCT01492595"
974,"NCT01408914","Trial of High-Dose Rifampin in Patients With TB","HIRIF","Completed","Has Results","Tuberculosis","Drug: Higher-Dose Rifampin","Steady State Pharmacokinetic Exposure of RIF|Sputum Culture Sterilization During the Initial 8 Weeks of Treatment|Incidence of Rifampin-related Grade 2 or Higher Adverse Events","Harvard University Faculty of Medicine|National Institute of Allergy and Infectious Diseases (NIAID)|Sanofi|Harvard School of Public Health (HSPH)|Brigham and Women's Hospital|University of Liverpool|St George's, University of London|University of Florida|Socios en Salud","All","18 Years to 60 Years   (Adult)","Phase 2","180","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","11-0050|5U01AI091429-03","September 2013","April 2016","April 2016","August 3, 2011","July 13, 2017","November 20, 2017","University of Florida, Gainesville, Florida, United States|Socios En Salud Sucursal Perú, Lima 6, Peru|School of Clinical Sciences at University of Liverpool, Liverpool, United Kingdom|St. George's University of London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01408914"
975,"NCT01547884","Effect of Filarial Infection on Immune Responses in Latent Tuberculosis",,"Completed","No Results Available","Mycobacterium Infections|Tuberculosis|Filariasis|Latent Tuberculosis",,"To compare the immune responses to mycobacterial antigens, including PPD and Mycobacterium tuberculosis culture filtrate protein, in individuals who are LTBI+ Hel- versus those who are LTBI+Hel+|To compare immune responses to mycobacterial antigens in LTBI+ Hel+ co- infected individuals, before and after treatment for filarialinfection.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"4268","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","999912073|12-I-N073","January 1, 2013","November 14, 2019","August 7, 2020","March 8, 2012",,"April 20, 2021","National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States|Nih-Nirt Icer, Chennai, India",,"https://ClinicalTrials.gov/show/NCT01547884"
976,"NCT02641106","VDOT for Monitoring Adherence to LTBI Treatment","VMALT","Completed","No Results Available","Tuberculosis|Latent Tuberculosis Infection","Other: Video Directly Observed Therapy|Other: In-Person DOT","Proportion of participants completing LTBI treatment|Participant satisfaction with method of monitoring LTBI treatment|cost-effectiveness of VDOT compared to in-person DOT for administering 3HP|Proportion of participants completing LTBI treatment in 12 weeks|Proportion of participants who took all 12 LTBI treatment doses on-schedule","University of California, San Diego","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","129","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","150155","March 8, 2016","June 30, 2020","June 30, 2020","December 29, 2015",,"February 5, 2021","San Diego County Health and Human Services Agency, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02641106"
977,"NCT01340820","Study of AERAS 422 in Healthy Adults",,"Completed","No Results Available","Tuberculosis","Drug: AERAS-422|Drug: BCG Tice","Safety|Immunogenicity","Aeras","All","18 Years to 45 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-007-422","December 2010","February 2012","May 2012","April 25, 2011",,"August 16, 2012","St. Louis University Hospital, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01340820"
978,"NCT04079400","Microbiome in Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases, Lung Cancer and Hemoptysis",,"Completed","No Results Available","Tuberculosis, Pulmonary|Non-Tuberculous Mycobacterial Pneumonia|Lung Cancer|Hemoptysis",,"16S rRNA sequencing","Gachon University Gil Medical Center","All","19 Years and older   (Adult, Older Adult)",,"43","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2016-5205","December 1, 2016","October 30, 2018","April 11, 2019","September 6, 2019",,"September 6, 2019",,,"https://ClinicalTrials.gov/show/NCT04079400"
979,"NCT01311505","Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)",,"Completed","Has Results","Tuberculosis","Drug: Myrin© 2 (Rifampicin + Isoniazid)|Drug: Rimactane® (Rifampicin)","Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])|Plasma Decay Half-life (t1/2)|Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)","Pfizer","Male","18 Years to 55 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B3801001","April 2011","May 2011","May 2011","March 9, 2011","July 30, 2012","July 30, 2012","Pfizer Investigational Site, Dasmariñas City, Philippines",,"https://ClinicalTrials.gov/show/NCT01311505"
980,"NCT01182259","The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study",,"Unknown status","No Results Available","Tuberculosis",,,"E-DA Hospital","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","JTWu002","October 2009",,,"August 16, 2010",,"August 16, 2010","E-DA hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01182259"
981,"NCT01049282","A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)","THYB-03","Completed","No Results Available","Tuberculosis","Biological: Antigen (Ag85B-ESAT-6)|Biological: Antigen (Ag85B-ESAT-6) with adjuvant (IC31)","Safety on Physical examination , and Laboratory safety tests of hematology clinical chemistry|Immunogenicity assessment by: A.Detection of IFN gama production after stimulation with Ag85B, ESAT-6 and H1. B.Detection of IgG antibodies to recombinant proteins Ag85B, ESAT-6 and H1 in serum/plasma.","Statens Serum Institut","Male","18 Years to 40 Years   (Adult)","Phase 1","39","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","THYB-03","December 2008","April 2010","April 2010","January 14, 2010",,"April 17, 2015",,,"https://ClinicalTrials.gov/show/NCT01049282"
982,"NCT02765087","E-Nose: Diagnostic Tool for Pleural TB",,"Unknown status","No Results Available","Tuberculosis, Pleural","Other: Medical History|Device: E-Nose|Other: Chest CT|Other: Pleural Fluid Analysis","Sensitivity and Specificity of the device for the diagnosis of Tuberculosis Pleural effusion|Adverse Effects related to the use of the device, according to the CTCEA","Universidad Central de Venezuela|The ENose Company, Zutphen, Netherlands|Foundation for Research in Mycobacteria (FUNDAIM)","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EN002","January 2015","December 2017","December 2017","May 6, 2016",,"November 14, 2017","Instituto de Biomedicina, Caracas, DC, Venezuela",,"https://ClinicalTrials.gov/show/NCT02765087"
983,"NCT00990990","Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers",,"Completed","No Results Available","Tuberculosis","Drug: PNU-100480|Drug: Placebo|Drug: Linezolid","To evaluate the safety and tolerability of ascending oral doses of PNU-100480 administered as extemporaneously prepared suspension (EPS) over 14 and 28 days in healthy adult volunteers.|To characterize the single dose and steady state pharmacokinetics of ascending oral doses of PNU-100480 administered over 14 and 28 days in healthy adult volunteers with regard to the parent drug and its metabolites.|To characterize the bactericidal activity in blood of orally administered PNU-100480 against intracellular M. tuberculosis in relation to blood concentrations ofPNU-100480 and its metabolites.|To characterize the effect of once a day administration of pyrazinamide for 2 days on the pharmacokinetics and bactericidal activity in blood of orally administered PNU-100480 against intracellular M. tuberculosis (Cohorts 5 and 6, Days 27-28 only).|To characterize pharmacokinetics and bactericidal activity in blood of orally administered linezolid against intracellular M. tuberculosis following 4 days of QD dosing.","Sequella, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","B1171002","October 2009","May 2010","May 2010","October 7, 2009",,"August 28, 2013","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00990990"
984,"NCT00871949","Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults",,"Completed","No Results Available","Tuberculosis","Drug: PNU-100480|Drug: Placebo","Evaluation of safety and tolerability of escalating single oral doses of PNU-100480.|Characterize pharmacokinetics of single oral doses PNU-100480.|Characterize the effect of food on the pharmacokinetics of a single oral dose of PNU-100480.|Characterize the bactericidal activity in blood of orally administered PNU-100480 against intracellular Mycobacterium tuberculosis in relation to blood concentrations of PNU-100480 (and its metabolites) (some periods only)","Sequella, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","B1171001","April 2009","August 2009","August 2009","March 30, 2009",,"August 27, 2013","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00871949"
985,"NCT02782416","Screening Latent Tuberculosis Infection and Observing Preventive Therapy in Kidney Transplantation",,"Unknown status","No Results Available","Kidney Transplantation","Other: Examination of latent tuberculosis","percentage of active TB","National Taiwan University Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","201309056RINC","January 2014","December 2017","December 2017","May 25, 2016",,"December 15, 2016","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02782416"
986,"NCT06074042","The Clinical Characteristics, Treatment and Prognosis of Tuberculosis-associated COPD",,"Recruiting","No Results Available","COPD","Other: previous pulmonary tuberculosis","the frequency of moderate/severe acute exacerbation of COPD during the follow-up of 12 months","Peking University Third Hospital|Peking University Shougang Hospital|The First Affiliated Hospital of Guangzhou Medical University|First Hospital of China Medical University|West China Hospital|Shanxi Bethune Hospital|Tibet Autonomous Region People's Hospital","All","35 Years and older   (Adult, Older Adult)",,"540","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M2023573","May 1, 2024","December 31, 2025","December 31, 2025","October 10, 2023",,"April 3, 2024","Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT06074042"
987,"NCT00767975","Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison","LTBI_prison","Completed","No Results Available","Tuberculosis","Drug: isoniazid , randomized, open label|Drug: rifampin, randomized, open label","COMPLETE RATE OF LTBI TREATMENT|Efficacy","National Taiwan University Hospital","Male","Child, Adult, Older Adult","Phase 3","2384","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200707047M|DOH-97-DC-1502","January 2008","November 2010","November 2010","October 7, 2008",,"November 29, 2010","Taipei Prison, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00767975"
988,"NCT02978131","Histopathological Techniques and PCR on Tissues Included in Paraffin for the Diagnosis of Tuberculosis",,"Completed","No Results Available","Tuberculosis|Diagnostic Techniques and Procedures|Sensitivity and Specificity|Polymerase Chain Reaction|Immunohistochemistry|Histochemistry","Other: Histopathological study|Other: Molecular study (Polymerase chain reaction)","Number of positive TB cases with different techniques","Lille Catholic University","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","OBS-032","May 2015","June 2016","June 2017","November 30, 2016",,"March 20, 2019",,,"https://ClinicalTrials.gov/show/NCT02978131"
989,"NCT00679159","A Study of MVA85A in Healthy Children and Infants",,"Completed","No Results Available","Tuberculosis","Biological: MVA85A|Biological: Prevenar","Safety of MVA85A. Both local and systemic adverse events will be monitored, including a daily diary card for the first week. Blood will be taken at day 7 and day 28 for biochemistry and haematology.|Immunogenicity of MVA85A","University of Oxford|University of Cape Town","All","6 Months to 11 Years   (Child)","Phase 2","168","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB014|MCC: 20070156","February 2008","December 2009","December 2009","May 16, 2008",,"February 9, 2010","University Cape Town, Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00679159"
990,"NCT06314386","Systems Analysis and Improvement Approach to Prevent TB","SAIA-TB","Not yet recruiting","No Results Available","Tuberculosis|TPT|TB - Tuberculosis","Other: Systems Analysis and Improvement Approach for TB (SAIA-TB)","TB Screening|Linkage to care for TB disease treatment|TB Evaluation|TB Diagnosis|Successful TB Prevention Treatment (TPT) Outcome|Successful TB Outcome","Boston College|National Institutes of Health (NIH)|Boston University|University of Washington|Medical Research Council, South Africa|National Institute of Nursing Research (NINR)","All","0 Years and older   (Child, Adult, Older Adult)","Not Applicable","19560","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","23.139.01|R01NR020866","January 6, 2025","February 29, 2028","February 28, 2029","March 18, 2024",,"March 18, 2024","Addo Clinic, Addo, South Africa|Lukhanyiso Clinic, Addo, South Africa|Kwa-Nonqubela Clinic, Alexandria, South Africa|Marselle Clinic, Boesmansriviermond, South Africa|Masakhane Clinic, Hankey, South Africa|Humansdorp Clinic, Humansdorp, South Africa|Pellsrus Clinic, Jeffrey's Bay, South Africa|Joubertina CHC, Joubertina, South Africa|Louterwater Clinic, Joubertina, South Africa|Twee Riviere Clinic, Joubertina, South Africa|Kareedouw Clinic, Kareedouw, South Africa|Kenton On Sea Clinic, Kenton on Sea, South Africa|Kirkwood Clinic, Kirkwood, South Africa|Moses Mabida Clinic, Kirkwood, South Africa|Imizamo Yetho Clinic, Patensie, South Africa|Nkwenkwezi Clinic, Port Alfred, South Africa",,"https://ClinicalTrials.gov/show/NCT06314386"
991,"NCT01121432","Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)",,"Unknown status","No Results Available","Mediastinal Lymphadenopathy|Tuberculous Mediastinal Lymphadenopathy","Procedure: endobronchial ultrasound-guided transbronchial needle aspiration","The ratio of tuberculous mediastinal lymphadenopathy","National Taiwan University Hospital","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201003061R","April 2010","April 2012","April 2012","May 12, 2010",,"May 12, 2010","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01121432"
992,"NCT00653627","A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination",,"Completed","No Results Available","Tuberculosis","Biological: BCG","Quantification of BCG after BCG vaccination|Immunogenicity of BCG vaccination","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","TB015|COREC Number: 07/Q1604/3","August 2007","April 2010","April 2010","April 7, 2008",,"July 1, 2010","CCVTM, University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00653627"
993,"NCT05671718","Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment",,"Recruiting","No Results Available","Drug Resistant Tuberculosis","Other: Nurse-Led Treatment in Primary Care","RR-TB treatment outcome|Severe Adverse Events as assessed by the Division of AIDS (DAIDS) AE grading table|Patient associated catastrophic costs|Time to RR-TB treatment initiation|Time to smear/culture conversion|Time to HIV treatment initiation|Time to HIV viral suppression|Time to adverse (AE) and severe (SAE) treatment related adverse event resolution|Provider adherence to dosing requirements, treatment initiation|RR-TB dosing changes based on AE and SAE events|AE and SAE adjuvant medication management strategy|Programmatic cost effectiveness evaluation","Johns Hopkins University|University of Witwatersrand, South Africa|University of Cape Town|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2944","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","IRB00234475|R01AI177135-01","September 4, 2023","June 30, 2028","December 31, 2030","January 5, 2023",,"January 30, 2024","King Dinuzulu TB Hospital, East London, South Africa|Nkquebela TB Hospital, East London, South Africa|Jose Pearson Hospital, Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT05671718"
994,"NCT03927313","Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM","LASER-TBM","Completed","No Results Available","Tuberculosis Meningitis|HIV-1-infection","Drug: Linezolid|Drug: High dose rifampicin|Drug: Aspirin|Drug: Standard of Care anti-tuberculous therapy|Drug: Dexamethasone","Number of participants in each arm who develop treatment related adverse events (AEs).|Death and disability after 56 days on treatment.|Death at day 56 and day 180.|Number of participants who are disabled.|Number of participants who develop Grade 3 or Grade 4 adverse events (AEs).|Number of participants in whom experimental drugs had to be stopped.|Linezolid toxicity|Major bleeding events.|Cerebrospinal fluid culture conversion.|The occurrence of TBM-immune reconstitution inflammatory syndrome|Changes on brain imaging","University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LASER-TBM","June 12, 2019","March 30, 2021","March 31, 2021","April 25, 2019",,"September 28, 2021","Livingstone Hospital, Port Elizabeth, Eastern Cape, South Africa|Mitchells Plain Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|New Somerset Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT03927313"
995,"NCT04064554","Clinical Study to Evaluate Safety and Immunogenicity of Bacillus Calmette-Guerin (BCG) Delivery Via Novel Micronjet600 Device Compared to Those Via Conventional Needle",,"Completed","No Results Available","Tuberculosis|BCG Vaccination","Device: BCG vaccination with MicronJet600|Device: BCG vaccination with conventional needle","Adverse Events|Average of usability VAS for medical device user|Spot Forming Unit (SFU) per PBMC(Peripheral Blood Mononuclear Cells)|Spot Forming Unit (SFU) per PBMC|Delta log10 CFU|Mycobacterial antigen specific T-cell|PPD test result (positive or negative) after application of medical device for clinical trial|Diameter of induration (mm) or presence or absence of blister|The diameter of the wheal|Fraction of subjects eligible for each grade in the injection fluid leakage assessment at the injection site|Progress of normal reaction after BCG injection|Diameter of the scar after BCG injection","Yonsei University","All","19 Years to 35 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1-2017-0073","December 1, 2017","September 11, 2019","September 11, 2019","August 22, 2019",,"December 5, 2019","Department of Internal Medicine, Yonsei University College of Medicine Division of Pulmonology, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04064554"
996,"NCT06135818","Same Day Diagnosis of Extrapulmonary TB (TB Serositis and TB Meningitis).","Epi-TB","Recruiting","No Results Available","Tuberculosis, Extrapulmonary","Diagnostic Test: IRISA-TB","Test-specific performance outcomes|Empiric treatment rates for extrapulmonary TB|Cost effectiveness","University of Cape Town|European Union|Zambart|Biomedical Research and Training Institute|Leiden University Medical Center|University of Cape Town Lung Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2160","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Epi-TB","March 16, 2021","May 31, 2025","May 31, 2026","November 18, 2023",,"November 18, 2023","University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa|University of Cape Town Lung Institute, Cape Town, Western Cape, South Africa|Zambart, Lusaka, Zambia|Biomedical Research and Training Institute, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT06135818"
997,"NCT00149448","Effectiveness of the TB Contact Priority Model",,"Completed","No Results Available","Tuberculosis","Behavioral: TB Contact Priority Model",,"National Heart, Lung, and Blood Institute (NHLBI)","Male","Child, Adult, Older Adult",,,"NIH","Observational",,"1304","May 2004","March 2009","March 2009","September 8, 2005",,"April 14, 2009",,,"https://ClinicalTrials.gov/show/NCT00149448"
998,"NCT04309656","A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid",,"Completed","No Results Available","Multi-drug Resistant Tuberculosis","Drug: Pretomanid","Relative bioavailability - Cmax|Relative bioavailability - AUC 0-t|Relative bioavailability - AUC 0-inf|Food effect - Cmax|Food effect - AUC 0-t|Food effect - AUC 0-inf|Dose effect - Cmax|Dose effect - AUC 0-t|Dose effect - AUC 0-inf|Taste perception of pediatric formulations by questionnaire|Adverse Events - relatedness using Adverse Event Attribution/Causality Ratings|Adverse events - severity|Adverse events - overall incidence|Adverse events - AE leading to withdrawal|Adverse events - Serious Adverse Events|Vital signs - blood pressure|Vital signs - pulse rate|Vital signs - body temperature|Vital signs - respiration rate|Vital signs - pulse oximetry|Vital signs - body weight|Electrocardiogram (ECG) - Heart rate|Electrocardiogram (ECG) - PR interval|Electrocardiogram (ECG) - RR interval|Electrocardiogram (ECG) - QRS complex|Electrocardiogram (ECG) - QT interval|Electrocardiogram (ECG) - QTc interval (corrected by Bazett's formula)|Electrocardiogram (ECG) - QTc interval (corrected by Fridericia's formula)|Hematology - hemoglobin|Hematocrit- hematocrit|Hematology- Total and differential leukocyte count|Hematology- Red blood cell count|Hematology- Platelet count|Serum chemistry - albumin|Serum chemistry - blood urea nitrogen|Serum chemistry - creatinine|Serum chemistry - total bilirubin|Serum chemistry - alkaline phosphatase|Serum chemistry - aspartate transaminase|Serum chemistry - alanine transaminase|Serum chemistry - sodium|Serum chemistry - potassium|Serum chemistry - chloride|Serum chemistry - lactate dehydrogenase|Serum chemistry - calcium|Serum chemistry - uric acid|Serum chemistry - glucose|Serum chemistry - gamma-glutamyl transferase|Serum chemistry - magnesium","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pa-824-CL-011","January 14, 2020","February 28, 2020","February 28, 2020","March 16, 2020",,"March 16, 2020","Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04309656"
999,"NCT00005739","Behavioral Interventions for Control of TB",,"Completed","No Results Available","Lung Diseases|Tuberculosis","Behavioral: Community-based directly observed therapy (DOT)|Behavioral: Clinic directly observed therapy (DOT)","Visit adherence rate|Treatment completion rate","Columbia University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)",,"145","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CUMC ID unknown (4948)|R01HL055751","September 1995","December 2004","December 2015","May 26, 2000",,"December 23, 2015","Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00005739"
1000,"NCT06205589","Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB",,"Not yet recruiting","No Results Available","Tuberculosis, Pulmonary","Biological: ID93 + GLA-SE vaccine|Biological: Placebo vaccine","Safety (Phase 2a and Phase 2b): Vaccine-related serious adverse event (SAE)|Safety (Phase 2a and Phase 2b): Grade ≥3 vaccine-related unsolicited adverse event (AE)|Safety (Phase 2a and Phase 2b): Grade ≥3 local or systemic reactogenicity AE|Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response relative to the negative control stimulation|Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response relative to the negative control stimulation and relative to the pre-vaccine response|Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response magnitude relative to the negative control stimulation|Efficacy (Phase 2b): Bacteriologically confirmed TB-related unfavorable outcome (treatment failure, TB recurrence, or death due to TB)|Efficacy (Phase 2a and 2b): Proportion of participants with quantifiable RS ratio|Cellular immunogenicity (Phase 2a): ID93-specific CD4+ T cell response through 12 months post second dose of vaccination|Humoral immunogenicity (Phase 2a): ID93-specific IgG response rate|Immunogenicity (Phase 2a): Differential leukocyte count and immunophenotype|Immunogenicity (Phase 2a): Measurement of soluble proinflammatory mediators","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","1500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ACTG A5397|UM1AI068636","April 10, 2024","December 1, 2028","December 1, 2028","January 16, 2024",,"January 16, 2024",,,"https://ClinicalTrials.gov/show/NCT06205589"
1001,"NCT04147676","Evaluation of Centralised TB Assay Solutions",,"Completed","No Results Available","Tuberculosis|Drug-resistant Tuberculosis",,"Diagnostic accuracy for MTB detection|Diagnostic accuracy for RIF/INH detection|Operational characteristics:","Foundation for Innovative New Diagnostics, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"1050","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7213-2/1","May 20, 2019","April 17, 2023","September 1, 2023","November 1, 2019",,"November 18, 2023","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Forschungszentrum Borstel. Leibniz Lungenzentrum (Borstel), Borstel, Germany|Indian Council of Medical Research (ICMR) Regional Medical Research Centre, Bhubaneswar, India|National Institute for Research in Tuberculosis, Chennai, India|Institute of Phthisiopneumology ""Ch. Draganiuc"" (PPI NRL), Moldova, Chisinau, Moldova, Republic of|Division of Wits Health Consortium (DMMH), Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT04147676"
1002,"NCT03783728","Video Based Directly Observed Therapy for Latent TB",,"Withdrawn","No Results Available","Latent Tuberculosis","Drug: Rifapentine 600 mg orally|Drug: Isoniazid 900 mg orally|Drug: Pyridoxine 50 mg orally","Percentage of patients completing treatment","St. Louis University","All","18 Years to 80 Years   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","29312","June 30, 2019","January 31, 2020","January 31, 2020","December 21, 2018",,"July 1, 2019","Saint Louis University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03783728"
1003,"NCT03423030","Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary","Drug: PBTZ169 Formulation|Drug: Placebo|Drug: PBTZ169 NCP","Safety and tolerability of increasing single oral doses of PBTZ169 Formulation in healthy male adult subjects evaluated by Treatment Emergent Adverse Events (TEAEs).|Relative oral bioavailability assessment of the PBTZ169 Formulation in comparison to NCP in healthy male subjects|Pharmacokinetics (PK) of single oral doses of PBTZ169 using Cmax|Pharmacokinetics (PK) of single oral doses of PBTZ169 using Tmax|Pharmacodynamics (PD) exploration after single oral doses of PBTZ169 Formulation and NCP|Broncho-alveolar passage exploration after single oral doses of PBTZ169 Formulation and NCP (tentative)","Innovative Medicines for Tuberculosis|Bill and Melinda Gates Foundation","Male","18 Years to 48 Years   (Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IM-006-11","December 5, 2017","March 28, 2018","March 28, 2018","February 6, 2018",,"July 13, 2018","Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT03423030"
1004,"NCT03281226","RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection","RIPENACTB","Unknown status","No Results Available","Tuberculosis, Pulmonary|HIV/AIDS","Drug: RIPE (2m) and RI (4m)|Drug: RIPE+NAC (2m) and RI (4m)","Number of participants with any biological intolerability or adverse event|Number of patients in the NAC treatment arm with shorter sputum smear conversion time and culture|Number of patients presenting tuberculostatic drug-related hepatotoxicity|Dosage of inflammatory cytokines","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAAE: 60219916.5.0000.0005","December 7, 2016","June 2019","December 2019","September 13, 2017",,"February 15, 2019","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil",,"https://ClinicalTrials.gov/show/NCT03281226"
1005,"NCT05588492","The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study",,"Recruiting","No Results Available","Pulmonology","Drug: Rifamycin-containing regimen|Drug: Rifamycin-free regimen","Primary Outcome Measure|Secondary Outcome Measure","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 4","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202110073MIND","January 1, 2022","December 31, 2026","December 31, 2026","October 20, 2022",,"October 20, 2022","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05588492"
1006,"NCT03878004","Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac",,"Completed","No Results Available","Healthy","Biological: GamTBvac vaccine|Biological: placebo","level of IFN-y secretion in whole blood or PBMC fraction|Number of Participants With Adverse Events|CD4+ and CD8+ T cells|titer of antibodies of the IgG class|QuantiFERON TB","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|contract research organization Cromos Pharma|contract research organization K-Research","All","18 Years to 49 Years   (Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","01-GamTBvac-2018","December 1, 2018","December 31, 2019","May 31, 2020","March 18, 2019",,"June 17, 2020","""City polyclinic № 2 Of the Department of health of the city of Moscow"", Выделите текст, чтобы посмотреть примеры, Moscow, Russian Federation|Sechenov University, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03878004"
1007,"NCT03086486","Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","ZeNix","Completed","Has Results","Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Tuberculosis, MDR|Tuberculosis|Extensively Drug-Resistant Tuberculosis|Pre-XDR-TB|XDR-TB","Drug: Pretomanid|Drug: Linezolid|Drug: Bedaquiline|Drug: Placebo Linezolid","Incidence of Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) Through Follow up Until 26 Weeks After the End of Treatment|Incidence of Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) Through Follow up Until 78 Weeks After the End of Treatment.|Time to Sputum Culture Conversion to Negative Status Through the Treatment Period|Sputum Culture Conversion to Negative Status at End of Treatment for Those Positive at Baseline","Global Alliance for TB Drug Development","All","14 Years and older   (Child, Adult, Older Adult)","Phase 3","181","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ZeNix (B-Pa-L) NC-007","November 21, 2017","February 15, 2021","February 8, 2022","March 22, 2017","June 29, 2023","June 29, 2023","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova, Republic of|Moscow City Research and Practice Tuberculosis Treatment Centre, Moscow, Russian Federation|Central TB Research Institute of the Federal Agency of Scientific Organizations Moscow, Moscow, Russian Federation|National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russian Federation|FSBI ""Saint-Petersburg Research Institute of Phthisiopulmonology"", Saint Petersburg, Russian Federation|Ural Research Institute of Phthisiopulmonology, Yekaterinburg, Russian Federation|Empilweni TB Hospital, Port Elizabeth, Eastern Cape, South Africa|Tshepong Hospital, Klerksdorp, North - West, South Africa|King DinuZulu Hospital Complex, Durban, South Africa|Clinical HIV Research Unit (CHRU) Sizwe Tropical Diseases Hospital, Johannesburg, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT03086486/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT03086486/SAP_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT03086486/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03086486"
1008,"NCT06050356","First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","nTB-01","Recruiting","No Results Available","Healthy","Biological: H107e|Biological: CAF®10b|Biological: H107e/CAF®10b - low adjuvant dose|Biological: H107e/CAF®10b - full adjuvant dose|Biological: Low dose intranasal H107e|Biological: Full dose intranasal H107e|Biological: H107e/CAF®10b|Biological: i.m. placebo|Biological: BCG|Biological: i.d. placebo|Biological: Intranasal H107e","Percentage of participants with solicited injection site reactions recorded up to seven days after each i.m. vaccination (phase 1a)|Percentage of participants with solicited systemic reactions recorded up to seven days after each i.m. vaccination (phase 1a)|Percentage of participants with unsolicited adverse events occurring up to 28 days after last i.m. vaccination (phase 1a)|Percentage of participants with adverse events of special interest occurring up to last visit (phase 1a)|Percentage of participants with serious adverse events (SAEs) occurring up to last visit (phase 1a)|Percentage of participants with solicited adverse events occurring up to seven days after i.n. mucosal recall (phase 1a)|Percentage of participants with unsolicited adverse events occurring up to 28 days after i.n. mucosal recall (phase 1a)|Percentage of participants with solicited injection site reactions recorded up to seven days after each vaccination (i.m. or i.d.) (phase 1b)|Percentage of participants with solicited systemic reactions recorded up to seven days after each vaccination (i.m. or i.d.) (phase 1b)|Percentage of participants with unsolicited adverse events occurring up to 28 days after last vaccination (phase 1b)|Percentage of participants with adverse events of special interest occurring up to last visit (phase 1b)|Percentage of participants with SAEs occurring up to last visit (phase 1b)|Percentage of participants with solicited adverse events occurring up to seven days after i.n. mucosal recall (phase 1b)|Percentage of participants with unsolicited adverse events occurring up to 28 days after i.n. mucosal recall (phase 1b)|Frequencies of H107e-specific T-cells producing IFN-γ and/or IL-17 induced by H107e/CAF®10b vs. placebo and vs. H107e/CAF®10b + BCG before first i.m. vaccination and two weeks after the second i.m. vaccination (phase 1b)|Frequencies of H107e-specific IFN-γ producing T-cells before first i.m. vaccination and two weeks after the second i.m. vaccination (phase 1a)|Frequencies of BCG-specific T-cells producing IFN-γ and/or IL-17 induced by H107e/CAF®10b + BCG vs. BCG alone (phase 1b)","Statens Serum Institut|Aurum Institute|Bill and Melinda Gates Foundation|Leiden University Medical Center|South African Tuberculosis Vaccine Initiative","All","18 Years to 45 Years   (Adult)","Phase 1","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","nTB-01|INV-042397|DOH-27-102023-7355","March 14, 2024","May 2026","May 2026","September 22, 2023",,"March 18, 2024","Aurum Institute, Pretoria, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT06050356"
1009,"NCT01135043","Simple Verbal Intervention for Adequately Collecting Sputum",,"Unknown status","No Results Available","Suspicious for Pulmonary Tuberculosis","Behavioral: education by brochure|Behavioral: control","culture result of Mycobacteria in sputum","Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","acceptable_sputa","July 2009","June 2010","September 2010","June 2, 2010",,"June 2, 2010","Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01135043"
1010,"NCT04243031","QuantiFERON Access Clinical Performance Study Protocol",,"Withdrawn","No Results Available","Tuberculosis (TB)","Device: QFT Access","TB Result","QIAGEN Gaithersburg, Inc","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TMF-17-1056-1","April 1, 2020","August 1, 2020","November 1, 2020","January 27, 2020",,"September 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04243031"
1011,"NCT02880982","Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren","ViDiKids","Completed","No Results Available","Latent Tuberculosis","Dietary Supplement: Cholecalciferol|Other: Placebo","Acquisition of latent tuberculosis infection|Incidence of active tuberculosis (TB)|Incidence of acute respiratory infection|Incidence of acute asthma exacerbation|Incidence and control of asthma, allergic rhinitis and atopic dermatitis|Incidence of bone fracture|Anthropometric outcomes (weight, height, body mass index, waist circumference)|Mathematics examination result|Stage of pubertal development, self-assessed using the Tanner scale|Bone mineral content, lumbar spine and whole body minus head|Body composition including fat mass and fat-free soft tissue mass|Muscle strength (grip strength, elastic leg strength)|Estimated maximal oxygen uptake, derived from 20 meter shuttle test performance|Bronchial hyper-responsiveness to exercise|Sensitisation to aeroallergens|Concentrations of antigen-stimulated inflammatory mediators|Vitamin D status, parathyroid hormone and circulating markers of bone formation and modelling|Attention Deficit Hyperactivity Disorder Rating Scale-IV score|Cost-effectiveness of vitamin D3 for prevention of LTBI and active TB|Incidence of potential adverse reactions to vitamin D3|Incidence of serious adverse events due to any cause|Incidence of fatal or life-threatening serious adverse events due to any cause|Proportion of participants sero-positive for SARS-CoV-2 at follow-up|Proportion of participants sero-positive for seasonal coronaviruses HKU1, 229E, OC43 and NL63 at follow-up|Proportion of participants sero-positive for influenza A and B at follow-up","Queen Mary University of London|University of Cape Town","All","6 Years to 11 Years   (Child)","Phase 3","1743","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","9408","March 14, 2017","November 17, 2021","June 30, 2022","August 26, 2016",,"September 8, 2022","Desmond Tutu HIV Foundation, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02880982"
1012,"NCT01611844","Optimization of Tuberculosis Intradermal Skin Test","TB Dermatest","Completed","No Results Available","Healthy Volunteers","Device: Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|Device: medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)","hypersensitivity reaction to tuberculin measured in millimeters of skin induration by comparing two methods of intradermal injection (Mantoux and BD micro-needle). [Phase 1]|spectroscopy instrumentation(non-invasive and objective method)to measure the PPD reaction|define changes in the cutaneous immune system at various times (7h, 24h and 48 h), induced by intradermal microinjection of tuberculin, by histological, immunohistochemical and molecular analysis","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","2009.591","September 2011","June 2012","April 2013","June 5, 2012",,"July 31, 2013","Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie-Centre Hospitalier Lyon Sud -Hospices Civils de Lyon, Pierre-Bénite, France",,"https://ClinicalTrials.gov/show/NCT01611844"
1013,"NCT05989802","Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)",,"Recruiting","No Results Available","Tuberculosis|Diagnostics|Global Health","Diagnostic Test: Oral swab molecular testing|Diagnostic Test: Automated Cough Sound Analysis|Diagnostic Test: Automated Lung Sound Analysis|Other: Chest X Ray Computer Aided Detection","Proportion with positive index test result among participants with tuberculosis (TB)|Proportion with negative index test result among participants without tuberculosis (TB)","University of California, San Francisco|Instituto Nacional de Saúde, Mozambique|National Referral Hospital|University of Cape Town|Johns Hopkins University|Elizabeth Glaser Pediatric AIDS Foundation|National Institute of Allergy and Infectious Diseases (NIAID)|University of California, Irvine","All","up to 65 Years   (Child, Adult, Older Adult)","Not Applicable","2100","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R01HL169449|U01AI152087|7200AA22RFA00004","January 26, 2024","September 1, 2026","September 1, 2026","August 14, 2023",,"January 31, 2024","Instituto Nacional de Saúde, Maputo, Mozambique|Dora Nginza Hospital, Cape Town, South Africa|Mulago National Referral Hospital, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05989802"
1014,"NCT04494516","Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial",,"Completed","No Results Available","Tuberculosis Infection|Tuberculosis Prevention",,"Perception of intervention adaptations as assessed by an in-depth interview|Perception of implementation strategies as assessed by an in-depth interview|Perception of the social context of the community-based health teams as assessed by an in-depth interview|Perception of the lessons learned as assessed by an in-depth interview","Johns Hopkins University|UNITAID|Aurum Institute|KNCV Tuberculosis Foundation","All","18 Years and older   (Adult, Older Adult)",,"183","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00237243","June 4, 2021","June 30, 2023","June 30, 2023","July 31, 2020",,"July 12, 2023","KNCV Tuberculosis Foundation, Addis Ababa, Ethiopia|The Aurum Institute, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT04494516"
1015,"NCT02912832","Prospective Assessment of TBDx Feasibility",,"Completed","No Results Available","Pulmonary Tuberculosis","Device: TBDx","Performance of TBDx compared to culture|Training needs through questionnaire assessment|Comparison of performance of TBDx on direct vs concentrated smear|Performance of TBDx in combination with Xpert MTB/RIF through analysis of two different algorithms|User appraisal regarding ease of use, hands-on-time and perceived benefit through appraisal questionnaire|Identify potential difficulties for implementation through observation and user appraisal","Foundation for Innovative New Diagnostics, Switzerland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","572","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","7012-05-3/1","October 2014","March 2015","August 2015","September 23, 2016",,"September 23, 2016","Instituto de Medicina Tropical Alexander von Humboldt - Universidad Peruana Cayetano Heredia, Lima, Peru|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02912832"
1016,"NCT01850043","The Epidemiology of TST Change in Korea",,"Completed","No Results Available","Tuberculosis|Latent Tuberculosis",,"TST positivity TST rate|BCG scar rates","Asan Medical Center","Male","18 Years to 29 Years   (Adult)",,"5552","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","KoreanTSTtrends","May 2005","May 2012","May 2012","May 9, 2013",,"December 12, 2013","The Korean Institute of Tuberculosis, Osong, Chungcheongbuk-Do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01850043"
1017,"NCT02821832","Using Biomarkers to Predict TB Treatment Duration",,"Active, not recruiting","Has Results","Pulmonary Tuberculosis","Procedure: Saliva collection|Procedure: Urine collection|Procedure: Sputum collection|Procedure: Blood Collection|Radiation: PET/CT Scan|Drug: Isoniazid, Rifampicin, Pyrazinamide and Ethambutol","Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C|Radiologic, Immunologic and Microbiologic Measures","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","946","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","999916133|16-I-N133","June 21, 2017","October 9, 2021","September 30, 2023","July 4, 2016","December 20, 2022","April 10, 2023","Clinical Infectious Diseases Research Initiative (Khayelitsha site), Cape Town, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/32/NCT02821832/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/32/NCT02821832/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02821832"
1018,"NCT04055584","PCR Techniques of Dried Sputum Using a Spotcard",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Diagnostic Test: Sputum","Is it possible to perform a diversity of molecular diagnostic TB tests and in addition new next generation sequencing approaches, with the DNA from the dried sputum spots?|Can we use DNA detection of the sputum from the dried card to certify that in the final utilisation format both the sputum and blood (not collected or tested in this study) are from the same patient?","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PCR techniques of dried sputum","July 2, 2019","November 30, 2021","December 31, 2021","August 14, 2019",,"May 3, 2021","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04055584"
1019,"NCT02276755","Vitamin D Supplementation in TB Prevention",,"Completed","No Results Available","Latent Tuberculosis","Dietary Supplement: Cholecalciferol (vitamin D3)|Other: Placebo","Acquisition of latent tuberculosis infection|Incidence of active TB disease|Incidence of self-reported acute respiratory infection (upper, lower and both combined)|Incidence of acute respiratory infection requiring hospitalization|Incidence of acute respiratory infections requiring antibiotic treatment|Number of days off school (total number and number due to acute respiratory infection)|Incidence of acute asthma exacerbation requiring hospitalization|Incidence of new asthma, allergic rhinitis and atopic dermatitis|Control of asthma, allergic rhinitis and atopic dermatitis|Incidence of bone fracture|Anthropometric outcomes (z-scores for height-for-age, weight-for-age, weight-for-height, body mass index-for-age, and waist circumference and waist-to-height ratio)|Body composition: impedance, impedance%, fat mass fat %, and fat-free mass|Muscle strength: grip strength and long jump distance from standing|Serum 25-hydroxyvitamin D concentration|Bone mineral density at the radius|Physical fitness (maximal oxygen consumption estimated from 20m shuttle run)|Attention-related behavior scores (Connors III)|Incidence of dental caries|Circulating and antigen-stimulated concentrations of cytokines, chemokines and other inflammatory mediators|Exam performance|Self-reported pubertal development|Spirometric lung volumes (FEV1 and FVC)|Urinary metabolome profile|Gut microbiome profile","Harvard School of Public Health (HSPH)","All","6 Years to 13 Years   (Child)","Phase 3","8851","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","140513","September 2015","June 2019","June 2020","October 28, 2014",,"July 16, 2020","Mongolian Health Initiative, Ulaanbaatar, Mongolia","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/55/NCT02276755/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02276755"
1020,"NCT00173264","Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis",,"Unknown status","No Results Available","Monoclonal Gammopathy|Tuberculosis",,,"National Taiwan University Hospital","All","0 Years and older   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Defined Population|Time Perspective: Retrospective","9461700601","June 2005",,"June 2005","September 15, 2005",,"September 15, 2005","Department of Laboratory Medicine, National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00173264"
1021,"NCT01798095","Equivalence Study of Specificity of PPD","03","Unknown status","No Results Available","Tuberculosis Infection","Biological: Aplisol@ PPD material|Biological: Reference Standard","Determination of similarity in responses|Determine equivalent specificity","JHP Pharmaceuticals LLC|Syneos Health","All","18 Years to 60 Years   (Adult)","Phase 2","152","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Diagnostic","JHP-03","February 2013","May 2013","July 2013","February 25, 2013",,"February 25, 2013","The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01798095"
1022,"NCT05477966","A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress",,"Not yet recruiting","No Results Available","Pulmonary Tuberculoses|Tuberculosis, Pulmonary","Other: Medical records review","Negative culture conversion until 8 weeks after initiation of treatment|Time to negative culture conversion|Treatment outcome including 1) Cure 2) Treatment completion 3) Treatment failure 4) Death 5) Loss of follow-up 6) Unknown","Jae-Joon Yim|Seoul National University Hospital","All","Child, Adult, Older Adult",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","H-2206-179-1336","July 18, 2022","July 18, 2023","July 18, 2023","July 28, 2022",,"July 28, 2022","Seoul National University, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05477966"
1023,"NCT03776500","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing",,"Completed","No Results Available","Tuberculosis, Pulmonary","Drug: PBTZ169|Drug: Placebo","Safety and tolerability of increasing multiple oral doses of PBTZ169 in healthy male adult subjects evaluated by Treatment Emergent Adverse Events (TEAEs).|Relative oral bioavailability assessment of PBTZ169 in healthy male subjects after multiple dosing|Pharmacokinetics (PK) of multiple oral doses of PBTZ169 using Cmax|Pharmacokinetics (PK) of multiple oral doses of PBTZ169 using Tmax|Metabolism interaction of multiple oral doses of PBTZ169 by measuring ratios of 7 probe substrates before the first and and after the last dose","Innovative Medicines for Tuberculosis|Bill and Melinda Gates Foundation","Male","18 Years to 48 Years   (Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IM-006-13","February 21, 2019","March 20, 2020","March 20, 2020","December 14, 2018",,"October 22, 2020","Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT03776500"
1024,"NCT01689831","Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)",,"Unknown status","No Results Available","Tuberculosis Infection","Biological: To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Biological: Reactivity of Aplisol compared to reference standard PPD-S2.","Confirm the potency of Aplisol equipotent to PPD-S2.|Assess tolerability of Aplisol with new tuberculin PPD","JHP Pharmaceuticals LLC|Syneos Health","All","18 Years to 60 Years   (Adult)","Phase 2","168","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Diagnostic","JHP - 42023","May 2012","October 2012","December 2012","September 21, 2012",,"September 21, 2012","The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01689831"
1025,"NCT02588196","The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis",,"Unknown status","No Results Available","Tuberculous Meningitis","Drug: Dexamethasone acetate","MRI|changes of cerebrospinal fluid|changes of clinical symptoms","Hui Bu|Hebei Medical University","All","14 Years and older   (Child, Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BH 002","November 2015","October 2018",,"October 27, 2015",,"October 29, 2015",,,"https://ClinicalTrials.gov/show/NCT02588196"
1026,"NCT03547479","VDOT and Mobile Payments in Cambodia",,"Withdrawn","No Results Available","Tuberculosis, Pulmonary","Behavioral: VDOT|Behavioral: VDOT + mobile money","Feasibility: % patients correctly using the system|Missed treatment|Compliance|Treatment default|Cure","University of Southern California|Operation ASHA|National University of Singapore|London School of Hygiene and Tropical Medicine","All","21 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","TW010592-01","May 2019","December 2019","December 2019","June 6, 2018",,"April 5, 2024",,,"https://ClinicalTrials.gov/show/NCT03547479"
1027,"NCT02619994","Treatment Shortening of MDR-TB Using Existing and New Drugs","MDR-END","Unknown status","No Results Available","Tuberculosis, Multidrug-Resistant","Drug: Linezolid|Drug: Delamanid|Drug: Levofloxacin|Drug: Pyrazinamide|Drug: Locally-used WHO-approved MDR-TB regimen in Korea","Treatment success rate|Time to sputum culture conversion after treatment start|Sputum culture conversion proportion|Treatment success|proportion of reverting to positive sputum culture after the end of treatment|Treatment success according to pyrazinamide resistance|proportion of death between the control and investigational arms","Seoul National University Hospital|Asan Medical Center|Dankook University|International Tuberculosis Research Center|Pusan National University Yangsan Hospital|Pusan National University Hospital|Samsung Medical Center|Severance Hospital|SMG-SNU Boramae Medical Center|Incheon St.Mary's Hospital|Ulsan University Hospital|Korean Institute of Tuberculosis|National Medical Center, Seoul|Korean Center for Disease Control and Prevention|Korea University","All","19 Years to 85 Years   (Adult, Older Adult)","Phase 2","238","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDR-END","January 2016","June 2021","June 2021","December 2, 2015",,"February 4, 2019","Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02619994"
1028,"NCT03416309","Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response","PAT","Unknown status","No Results Available","Tuberculosis, Pulmonary",,"Correlation between AUC of RHZE and TTP|Correlation between AUC of RHZE and toxicity|Correlation between PG and AUC of RHZE|Assess the consistency of results using of DPS for measuring the plasma drug concentrations|Correlate AUC of RHZE with antiTB response|Correlate PG with antiTB response","University of Turin, Italy|Research Center Borstel","All","18 Years and older   (Adult, Older Adult)",,"257","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PAT_Study","May 25, 2017","February 28, 2021","February 28, 2022","January 31, 2018",,"April 17, 2019","Ospedale Amedeo di Savoia, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT03416309"
1029,"NCT03089983","Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings","HARAPAN II","Active, not recruiting","No Results Available","Opioid Dependence|Addiction|HIV/AIDS|Tuberculosis|Hepatitis","Drug: Buprenorphine Naloxone|Drug: Methadone|Drug: Isoniazid|Drug: Rifapentine","TB treatment completion rates in prison using a visual analog scale (VAS)|TB treatment completion rates after release from prison using a visual analog scale (VAS)|Self-reported opioid agonist treatment (MMT or no OAT) adherence using a visual analog scale (VAS)|Self-reported ART adherence (for HIV+ participants) using a visual analog scale (VAS)|Percentage of opioid negative urine tests|Time to opioid relapse using urine drug tests|Drug craving using a craving scale|Addiction severity, employment, legal, and social functioning using the ASI-Lite|Health-related quality of life using the SF-12v2|Overdose or death reported from members of social network|Re-incarceration reports from Ministry of Justice and self-reported arrests|Self-reported patient satisfaction using a questionnaire","Yale University|University of Malaya|National Institute on Drug Abuse (NIDA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1331","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2000020053|1R01DA041271","August 21, 2017","March 2024","March 2024","March 24, 2017",,"March 1, 2024","Kajang Prison, Kajang, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT03089983"
1030,"NCT03072576","Accuracy and Feasibility of Xpert Ultra",,"Completed","No Results Available","Tuberculosis, Pulmonary","Device: Xpert MTB/RIF Ultra","Difference in sensitivity and specificity (ability to correctly identify those with TB and those without TB) between Xpert Ultra and Xpert MTB/ for Mycobacterium tuberculosis (MTB) detection (non-inferiority endpoint)|Sensitivity of Xpert Ultra for MTB detection (ability to correctly identify those with TB i.e. true positives), stratified by smear status|Sensitivity and specificity (ability to correctly identify those with TB resistant to Rifampin and those with TB susceptible to Rifampin) of Xpert Ultra for detection of Rifampin (RIF) resistance|Difference in sensitivity and specificity (ability to correctly identify those with TB resistant to Rifampin and those with TB susceptible to Rifampin) of Xpert Ultra and Xpert MTB/RIF for detection of RIF resistance|Proportion of test attempts that do not yield a determinate result for Xpert Ultra and for Xpert MTB/RIF","Foundation for Innovative New Diagnostics, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"1400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7210-04-2/1","March 2016","March 2017","October 2017","March 7, 2017",,"February 8, 2018","Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus|Clinical Research Unit, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|National Institute for Research in Tuberculosis, Madras, India|Dept of Microbiology, Hinduja Hospital, Mumbai, India|New Delhi Tuberculosis Centre, New Delhi, India|Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Science, University of the Witwatersrand, and The National Priority Program of the National Health Laboratory Service, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT03072576"
1031,"NCT02972697","Evaluation of 11C-acetate PET Imaging as a Novel Approach to Detecting Pathology in Pulmonary TB",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Radiation: 11C-acetate ligand|Radiation: FDG ligand","Standard uptake value (SUV) of 11C-acetate PET in pulmonary TB lesions","National University Hospital, Singapore","All","21 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11C_acetate","November 2016","September 2017",,"November 23, 2016",,"April 13, 2017","National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02972697"
1032,"NCT02967666","Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts",,"Unknown status","No Results Available","Tuberculosis, Pulmonary","Radiation: FDG ligand|Radiation: DOTANOC ligand","Standard uptake value (SUV) of 68Ga-DOTANOC in subclinical TB using PET/MRI","National University Hospital, Singapore","All","21 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DOTANOC_contacts","November 2016","May 2017",,"November 18, 2016",,"November 18, 2016","National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02967666"
1033,"NCT01322685","Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens",,"Unknown status","No Results Available","Tuberculosis|Lung Cancer",,,"Taipei Medical University WanFang Hospital","All","17 Years to 90 Years   (Child, Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","99042","July 2010",,"June 2011","March 24, 2011",,"March 24, 2011","Taipei Medical University - WanFang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01322685"
1034,"NCT04567368","TB-CAPT MTB/XDR Study",,"Active, not recruiting","No Results Available","Tuberculosis|Resistance Bacterial|Diagnoses Disease","Diagnostic Test: Xpert MTB/XDR","Sensitivity and specificity of Xpert MTB/XDR assay|Sensitivity and specificity of Xpert MTB/XDR assay compared to phenotypic anti-tuberculosis drug susceptibility testing and WGS separately","Foundation for Innovative New Diagnostics, Switzerland|University of Cape Town|Wits Health Consortium (Pty) Ltd|Ludwig-Maximilians - University of Munich|Ospedale San Raffaele|Swiss Tropical & Public Health Institute|Heidelberg University|African Society for Laboratory Medicine","All","Child, Adult, Older Adult",,"753","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","TB042","May 14, 2021","June 30, 2024","June 30, 2024","September 28, 2020",,"November 27, 2023","University of Cape Town, Cape Town, South Africa|University of the Witwatersrand, Johannesburg, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT04567368/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT04567368/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04567368"
1035,"NCT05065905","Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis","MSPB_TB","Completed","Has Results","HIV Coinfection|Aids/Hiv Problem|Tuberculosis, Pulmonary|Human Immunodeficiency Virus|Lentivirus Infections|RNA Virus Infections","Drug: Interferon-Gamma","Sputum Culture|Average Hemoglobin Level|Leucocytes Level|CD3|CD4|CD8|CD4/CD8","SPP Pharmaclon Ltd.|North-Western State Medical University named after I.I.Mechnikov","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","78","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSPB_TB","January 19, 2006","March 29, 2006","April 6, 2006","October 4, 2021","January 25, 2024","January 25, 2024","Saint-Petersburg State Medical Academy n.a. I.I.Mechnikov of Ministry of Health, Saint Petersburg, Saint-Petersburg, Russian Federation|City Tuberculosis Hospital #2 of Saint-Petersburg, Saint Petersburg, Saint-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05065905"
1036,"NCT01162486","Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers","TBTC S29B","Completed","Has Results","Tuberculosis|Tuberculosis, Pulmonary","Drug: Rifampin & midazolam|Drug: rifapentine & midazolam|Drug: rifapentine and midazolam","Number of Participants With Grade 2 or Higher Adverse Events Over the Course of the 26 Day Trial|Pharmacokinetics (AUC of RPT Over 24 Hours Post-dose)|Midazolam, AUC Over 12 Hours Post-dose|Transporter Genes|Rifapentine Concentrations From Dried Blood Spots","Johns Hopkins University|Sanofi|Centers for Disease Control and Prevention","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","37","Other|Industry|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDC-NCHHSTP-5779","April 2010","February 2011","March 2011","July 14, 2010","May 7, 2019","May 7, 2019","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01162486"
1037,"NCT00743470","A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects",,"Terminated","No Results Available","HIV|Tuberculosis","Drug: lopinavir/ritonavir|Drug: rifabutin","Analysis of pharmacokinetic variables will be computed for each sampling time and each parameter.|Analysis of safety measures including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.","Abbott","All","18 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-457","August 2008","October 2008",,"August 28, 2008",,"November 2, 2010","Site Reference ID/Investigator# 11441, Waukegan, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00743470"
1038,"NCT03266003","An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment",,"Completed","No Results Available","Tuberculosis|Drug-resistant Tuberculosis|Adherence, Medication|Adherence, Patient","Other: Electronic DOT|Other: In-person DOT","Proportion of medication doses directly observed|Proportion of medication doses not directly observed|Medication side effects","Centers for Disease Control and Prevention|New York City Department of Health and Mental Hygiene|Columbia University","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","216","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CDC-6995.0","July 19, 2017","January 10, 2020","December 31, 2020","August 29, 2017",,"July 28, 2021","Morrisania Chest Center, Bronx, New York, United States|Fort Greene Chest Center, Brooklyn, New York, United States|Corona Chest Center, Jackson Heights, New York, United States|Washington Heights Chest Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03266003"
1039,"NCT01879163","Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults",,"Completed","No Results Available","Tuberculosis (TB)","Biological: MVA85A-IMX313|Biological: MVA85A","Safety evaluation through actively and passively collected data on adverse events|Evaluation of immune response of MVA85A-IMX313 vaccination compared with MVA85A vaccination in healthy, BCG vaccinated adults.","University of Oxford|Imaxio","All","18 Years to 55 Years   (Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","TB028","July 2013","December 2014","December 2014","June 17, 2013",,"December 16, 2014","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom|Wellcome Trust Clinical Research Facility, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01879163"
1040,"NCT02153528","Optimization of the TB Treatment Regimen Cascade","OneRIF","Completed","Has Results","Tuberculosis, Pulmonary","Drug: double rimfampicin|Drug: Standard TB treatment","Tuberculose Treatment Outcome|Number of Participants Who Develop Liver Toxicity|High-level Rifampicin Resistant TB Adverse Treatment Outcomes|Number of Initial Resistant TB Cases Who Switched to MDR-TB Treatment or Were Cured|the Negative Predictive Value of Conversion at 2 Weeks for Relapse.|Proportion of Acquired Rifampicin Resistance Among Failures and Relapses|Area Under the Curve of Auramine Resp. FDA at 2 Weeks to Predict Adverse Treatment Outcome at 1 Year After Treatment Completion|Weight Gain|Fever Resolution","Damien Foundation|National TB control Programme Bangladesh|Institute of Tropical Medicine, Belgium","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","701","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OneRIF","November 2014","August 1, 2017","August 1, 2017","June 3, 2014","February 13, 2020","February 13, 2020","Damien Foundation Bangladesh TB project in Greater Mymensingh district (8 selected clinics), Dhaka, Greater Mymensingh District, Bangladesh","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/28/NCT02153528/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/28/NCT02153528/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02153528"
1041,"NCT06221488","Testing Health Workers At Risk to Advance Our Understanding of TB Infection","THWART-TB","Recruiting","No Results Available","Tuberculosis|Tuberculosis Infection","Diagnostic Test: TB infection testing","Interferon gamma release assay conversion|TB disease","Beth Israel Deaconess Medical Center|University of Stellenbosch","All","18 Years to 100 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DP2AI176896","January 15, 2024","December 31, 2028","December 31, 2029","January 24, 2024",,"February 5, 2024","Stellenbosch University, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT06221488"
1042,"NCT05117788","Bioneer IRONqPCR ™ RFIA Kit Kit Clinical Evaluation",,"Active, not recruiting","No Results Available","Tuberculosis, Multidrug-Resistant",,"Diagnostic accuracy for MTB detection|diagnostic accuracy for isoniazid (INH), rifampicin (RIF), fluoroquinolone (FQ) and aminoglycoside (AMG) resistance detection|The diagnostic accuracy for MTB detection by subgroup (smear status, sample type, site, HIV status and TB history).|Compare the diagnostic accuracy of the Bioneer IRONqPCR ™ RFIA kit for MTB detection to Xpert Ultra|Diagnostic accuracy for resistance detection of the Bioneer IRONqPCR ™ RFIA Kit by subgroup (smear status, sample type, site, smear status, by gene target)|Compare the diagnostic accuracy of the Bioneer IRONqPCR ™ RFIA Kit|Compare the diagnostic accuracy of the Bioneer IRONqPCR ™ RFIA Kit for resistance detection to the GenoType MTBDRplus and MTBDRsl assays|Compare the diagnostic accuracy of the Bioneer IRONqPCR ™ RFIA Kit for resistance detection to Xpert MTB/XDR|Assess Bioneer IRONqPCR ™ RFIA Kit technical performance, including non-determinant rates, ease of use and other systems operational characteristics.","Foundation for Innovative New Diagnostics, Switzerland|V. N. Karazin Kharkiv National University|Kenya Medical Research Institute|Universidad Peruana Cayetano Heredia|Bioneer Corporation","All","18 Years and older   (Adult, Older Adult)",,"1372","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","7217-2/1_TB040","February 23, 2022","May 30, 2024","June 1, 2024","November 11, 2021",,"October 10, 2023","KEMRI, Nairobi, Kenya|Instituto de Medicina Tropical Alexander von Humboldt - Universidad Peruana Cayetano Heredia, Lima, Peru|V.N Karazin Kharkiv National University, Kharkiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT05117788"
1043,"NCT00285441","Identification of Cytokine Profiles and T Cell Subsets Among Immunosuppressed Patients at Risk of Developing Active Tuberculosis",,"Unknown status","No Results Available","Tuberculosis|HIV Infections|Rheumatoid Arthritis",,,"Hvidovre University Hospital|Copenhagen Hospital Corporation|The Danish Rheumatism Association|Danish Lung Association","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","KF-01-278477","November 2005",,"September 2008","February 2, 2006",,"February 28, 2006","Infectious disease department University Hospital Hvidovre, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00285441"
1044,"NCT00507754","Latent Tuberculosis Infection in Cancer Patients",,"Completed","No Results Available","Advanced Cancer","Other: T-SPOT TB test","Rate of Positive Results of T-SPOT.TB (%)","M.D. Anderson Cancer Center","All","Child, Adult, Older Adult",,"24","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2006-1095","June 2007","May 2011","May 2011","July 27, 2007",,"September 26, 2011","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00507754"
1045,"NCT04088019","Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive",,"Recruiting","No Results Available","Tuberculosis; Uveitis (Manifestation)|Anti-Tuberculous Drug Reaction|Tuberculous Uveitis","Drug: Fixed drug combination (FDC) of ATT and Oral steroid","Proportion of clinical improvement|The changes of type 1 interferon scoring in selected gene expression","Fakultas Kedokteran Universitas Indonesia","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19-06-0769","October 30, 2019","July 2024","July 2024","September 12, 2019",,"February 28, 2024","RSUPN dr. Cipto Mangunkusumo (Cipto Mangunkusumo Hospital), Jakarta Pusat, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04088019"
1046,"NCT00834353","Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis",,"Completed","No Results Available","Pulmonary Tuberculosis","Drug: ATT",,"Maulana Azad Medical College","All","10 Years to 70 Years   (Child, Adult, Older Adult)",,,"Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","F.501(134)/02-EC/MC(Aca)/16713","September 2005","March 2008","September 2008","February 3, 2009",,"February 3, 2009","Premashis Kar, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00834353"
1047,"NCT04239326","Clinical Evaluation of tNGS for Diagnosis of DR-TB","Seq&Treat","Completed","No Results Available","Tuberculosis, Multidrug-Resistant","Diagnostic Test: targeted Next Generation Sequencing (tNGS)","Point estimates, with 95% confidence intervals, of sensitivity and specificity for RIF resistance detection for each of up to 3 tNGS solutions|Point estimates, with 95% confidence intervals, of sensitivity and specificity for INH resistance detection for each of up to 3 tNGS solutions|Point estimates, with 95% confidence intervals, of sensitivity and specificity for fluoroquinolone (moxifloxacin, levofloxacin) resistance detection for each of up to 3 tNGS solutions|Point estimates, with 95% confidence intervals, of sensitivity and specificity for second-line injectable (amikacin, capreomycin, kanamycin) resistance detection for each of up to 3 tNGS solutions|Point estimates, with 95% confidence intervals, of sensitivity and specificity for pyrazinamide (PZA) resistance detection for each of up to 3 tNGS solutions|Point estimates, with 95% confidence intervals, of sensitivity and specificity for additional second-line resistance detection (bedaquiline, linezolid, clofazimine, streptomycin) for up to 3 tNGS solutions.|Comparison of drug-specific point estimates of sensitivity and specificity (with 95% confidence intervals) for up to 3 tNGS solutions against Hain MTBDRplus/sl drug-specific results.|Comparison of overall test success rate (defined as the total number of full profiles i.e. calls across all drug targets) in up to 3 tNGS solutions against success rate in Xpert MTB/RIF and Hain MTBDRplus/sl.|Summary of technical performance characteristics in up to 3 tNGS solutions including invalid and indeterminate rates, ease of use metrics, and other operational characteristics","Foundation for Innovative New Diagnostics, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","TB038","April 16, 2021","January 31, 2023","June 30, 2023","January 27, 2020",,"October 4, 2023","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India|National Institute for Communicable Diseases & Wits Health Consortium, Johannesburg, Sandringham, South Africa",,"https://ClinicalTrials.gov/show/NCT04239326"
1048,"NCT00402454","Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis",,"Completed","No Results Available","HIV Infections","Drug: isoniazid, rifampin + isoniazid or rifampin + pyrazinamide","Development of Tuberculosis|Suspension of chemoprophylaxis due to adverse effects|Suspension of chemoprophylaxis due tovoluntary withdrawal|Mortality.","Sociedad Andaluza de Enfermedades Infecciosas","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","GAEI 94/0071B|FIS 94/0071B","January 1994",,"December 1998","November 22, 2006",,"January 11, 2007","Hospital Universitario Reina Sofía, Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT00402454"
1049,"NCT03828201","Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","DRAMATIC","Recruiting","No Results Available","Tuberculosis, Multidrug-Resistant","Drug: Delamanid|Drug: Levofloxacin|Drug: Bedaquiline|Drug: Clofazimine|Drug: Linezolid","Treatment Efficacy - Frequency of ""successful treatment"" outcomes|Treatment Safety - Frequency of participants with grade 3, 4, or 5 adverse events|Efficacy outcome- Frequency of participants who survive","Boston University|Novartis Pharmaceuticals|Pfizer|Otsuka Pharmaceutical Co., Ltd.|University of California, San Francisco|Westat|National Institute of Allergy and Infectious Diseases (NIAID)|University of Colorado, Denver|Harvard Medical School (HMS and HSDM)|National Lung Hospital, Vietnam|De La Salle Health Sciences Institute, Philippines","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","220","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H39017|U01AI152980","June 7, 2022","May 2027","May 2027","February 4, 2019",,"April 12, 2024","De La Salle Health Sciences Institute, Dasmariñas, Philippines|National Lung Hospital, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03828201"
1050,"NCT02589782","Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)","TB-PRACTECAL","Unknown status","No Results Available","Tuberculosis, Multidrug-Resistant|Extensively Drug-Resistant Tuberculosis|Tuberculosis, Pulmonary","Drug: Bedaquiline|Drug: Pretomanid|Drug: Moxifloxacin|Drug: Linezolid|Drug: Clofazimine|Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.","Stage 1:Percentage of patients with culture conversion in liquid media at 8 weeks post randomisation.|Stage 1: Percentage of patients who discontinue treatment for any reason or die|Stage 2: Percentage of patients with an unfavourable outcome (failure, death, recurrence, loss to follow-up)|Stage 1: Percentage of patients with grade 3 or higher QT prolongation|Stage 1: Percentage of patients experiencing at least one Serious Adverse Event (SAE)|Stage 1:Percentage of patients experiencing at least one new grade 3 or higher Adverse Event|Stage 2: Percentage of patients with culture conversion|Stage 2: Percentage of patients with an unfavourable outcome (i.e. failure, treatment discontinuation, death, loss to follow up)|Stage 2: Percentage of patients with an unfavourable outcome (i.e. failure, treatment discontinuation, death, loss to follow up, still on treatment at censure and recurrence)|Stage 2: Median time to culture conversion|Stage 2: Percentage of patients with an SAE or new grade 3 or higher AE|Stage 2: Percentage of patients with an SAE or new grade 3 or higher AE at the end of treatment|Stage 2: Mean single ΔQTcF|Stage 2: Percentage of patients experiencing recurrence|Stage 2: Plasma drug concentrations|Stage 2: TB drug hair levels","Medecins Sans Frontieres, Netherlands|London School of Hygiene and Tropical Medicine|Global Alliance for TB Drug Development|University College, London|Drugs for Neglected Diseases|Swiss Tropical & Public Health Institute|eResearch Technology, Inc.|Ministry of Health, Republic of Uzbekistan|World Health Organization|Ministry of Public Health, Republic of Belarus|THINK TB & HIV Investigative Network|University of Liverpool|Wits Health Consortium (Pty) Ltd|Rutgers, The State University of New Jersey|University of California, San Francisco","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","552","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1541","January 2017","September 2022","December 2022","October 28, 2015",,"May 14, 2021","Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus|Helen Jospeh Hospital, Johannesburg, Gauteng, South Africa|Doris Goodwin Hospital, Pietermaritzburg, KwaZulu Natal, South Africa|THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa|King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa|Republican TB Hospital No. 2, Nukus, Karakalpakstan, Uzbekistan|Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital, Tashkent, Uzbekistan",,"https://ClinicalTrials.gov/show/NCT02589782"
1051,"NCT02208427","Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan",,"Unknown status","No Results Available","Latent Tuberculosis Infection","Drug: Rifapentine and Isoniazid for 3 months|Drug: Isoniazid for 9 months","completion rate|side effect|interruption|active TB","National Taiwan University Hospital","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","283","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201309055MINC","August 2014","December 2016","December 2016","August 5, 2014",,"December 15, 2016","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02208427"
1052,"NCT03259269","Expand New Drugs for TB [endTB]",,"Completed","No Results Available","Tuberculosis, Multidrug-Resistant","Other: This is a non-intervention observational study","End of treatment outcome","Partners in Health|Médecins Sans Frontières, France|Interactive Research and Development|Harvard Medical School (HMS and HSDM)|Epicentre","All","Child, Adult, Older Adult",,"2804","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Partners IRB 2015P001669","April 1, 2015","September 30, 2019","December 30, 2019","August 23, 2017",,"June 13, 2022","National Treatment Centre for Tuberculosis, Abovian, Armenia, Abovyan, Armenia|National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka, Dhaka, Bangladesh|Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus|Bishoftu Hospital, Bishoftu, Ethiopia|National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|RS Islam Jakarta Cempaka Putih, Jakarta, Indonesia|National Research Center for Phthisionpulmonology, Almaty, Kazakhstan|MSF Tuberculosis clinic, Mathare, Nairobi, Kenya, Nairobi, Kenya|Kara-Suu District TB hospital, Kara-Suu, Kyrgyzstan|Botshabelo Hospital, Maseru, Lesotho|Aung San Tuberculosis Hospital, Yangon, Myanmar|The Indus Hospital, Karachi, Karachi, Pakistan|Institute of Chest Diseases, Kotri, Kotri, Pakistan|Gulab Devi Chest Hospital, Lahore, Lahore, Pakistan|Socios en Salud, Carabayllo, Peru|King Dinuzulu Hospital, Durban, South Africa",,"https://ClinicalTrials.gov/show/NCT03259269"
1053,"NCT03237182","The Individualized M(X) Drug-resistant TB Treatment Strategy Study","InDEX","Terminated","No Results Available","Tuberculosis, Multidrug-Resistant","Drug: Individualized TB treatment with multiple drugs|Drug: Standardized TB treatment with multiple drugs","Culture negative survival rate|Tuberculosis treatment outcomes|Rates of adverse events|Characterization of multi drug-resistant tuberculosis strains|Drug Concentration|Measure of adherence|Evolution of HIV drug resistance|Improved assessment and management of DR-TB","Centre for the AIDS Programme of Research in South Africa","All","18 Years and older   (Adult, Older Adult)","Phase 4","205","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAP 020","June 14, 2017","December 19, 2022","December 19, 2022","August 2, 2017",,"September 1, 2023","King Dinuzulu Hospital, Durban, Kwa-Zulu Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT03237182"
1054,"NCT04550832","PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)","DECODE","Completed","No Results Available","Infections and Infestations|Pulmonary Tuberculosis","Drug: Delpazolid|Drug: Bedaquiline, Delamanid, Moxifloxacin","Efficacy Endpoint : The change in sputum mycobacterial load|primary Safety Endpoint : Proportion of patients experiencing adverse event as defined below|Secondary safety endpoints : adverse event and as below|Secondary Efficacy Endpoints : Proportion of patients who suffer relapse and as below|Secondary Efficacy Endpoints : out of patients completing 16 weeks of therapy and achieving stable culture conversion to negative (SCC)","LigaChem Biosciences, Inc.|Ludwig-Maximilians - University of Munich|Radboud University Medical Center|University of California, San Francisco","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","76","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCB01-0371-20-2-02|PanACEA-DECODE-01","October 22, 2021","January 4, 2023","September 11, 2023","September 16, 2020",,"February 22, 2024","The Aurum Institute Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa|Clinical HIV Research Unit (CHRU) University of the Witwatersrand, Johannesburg, South Africa|Ifakara Health Institute, Bagamoyo, Tanzania|National Institute for Medical Research (NIMR-MMRC), Mbeya, Tanzania|Ki'bongoto Infectious Disease Hospital (KIDH) Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania",,"https://ClinicalTrials.gov/show/NCT04550832"
1055,"NCT02711735","Safety of RUTI® Vaccination in MDR-TB Patients",,"Terminated","No Results Available","Tuberculosis, Multidrug Resistant","Biological: RUTI® Therapeutic vaccine|Biological: Matching RUTI® Placebo","Clinical safety parameters related to vaccination|IFN-y release of PBMCs in response to antigen stimulation|Mycobacterial Growth Inhibition Assay","Archivel Farma S.L.|London School of Hygiene and Tropical Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","201600136|2016-000850-36","March 18, 2020","September 9, 2020","September 9, 2020","March 17, 2016",,"July 5, 2022","""Chernivtsi Regional Clinical TB Dispensary"", II tuberculosis department of multidrug-resistant tuberculosis, Chernivtsi, Ukraine|""Ivano-Frankivsk Regional Phthisiopulmonology Center of Ivano-Frankivsk Regional Council"", Center for Pulmonary Diseases, Ivano-Frankivs'k, Ukraine|Medical Department #2 (resistant tuberculosis) of Kharkiv Regional Antituberculosis Dispensary No1, Kharkiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT02711735"
1056,"NCT02605538","Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively",,"Withdrawn","No Results Available","Cystic Fibrosis|Hepatitis A|Hepatitis B|Tuberculosis","Biological: Vaccination with vaccine against hepatitis A and B","Positive antibody response to vaccination with Twinrix(TM) in CF patients compared to healthy volunteers","Karolinska University Hospital|Karolinska Institutet","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2012/251-31/2","September 1, 2015","December 2023","December 31, 2025","November 16, 2015",,"March 18, 2024","Stockholm CF Center, KArolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02605538"
1057,"NCT00456469","Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children","ALTAC","Unknown status","No Results Available","Tuberculosis",,,"Liverpool School of Tropical Medicine|Thrasher Research Fund","All","1 Year to 14 Years   (Child)",,"500","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","06.49 TF Cuevas","May 2007",,"October 2009","April 5, 2007",,"April 5, 2007","Bushullo Major Health Centre, Awassa, Southern Region, Ethiopia",,"https://ClinicalTrials.gov/show/NCT00456469"
1058,"NCT01866579","Early Retinal Nerve Fiber Layer Change of Ethambutol Optic Neuropathy by Optical Coherence Tomography",,"Completed","No Results Available","Primary Lung Tuberculosis",,"Change in Retinal Nerve Fiber Layer thickness measured by optical coherence tomography","Yonsei University","All","20 Years to 70 Years   (Adult, Older Adult)",,"49","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","3-2013-0041","May 2013","May 2014","May 2014","May 31, 2013",,"May 20, 2014","Department of Ophthalmology, Gangnam Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01866579"
1059,"NCT00146302","Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth in Developing Countries?",,"Completed","No Results Available","Tuberculosis","Biological: Bacille Calmette Guerin (BCG)","Mortality until 12 months of age|Hospitalisations until 12 months of age|Adverse events within 12 months after intervention|Tuberculin reaction 2 and 6 months after intervention|BCG scar reaction 2 and 6 months after intervention|Assessment of antibody and cellular immune responses following intervention","Bandim Health Project|International Cooperation with Developing Countries|March of Dimes|Leiden University Medical Centre, DEPT of Parasitology, Leiden Holland|Medical Research Council Unit, The Gambia","All","up to 30 Days   (Child)","Phase 4","2320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ICA4-CT-2002-10053LBW|ICA4-CT-2002-10053|#6-FY04-51","November 2002","March 2008","March 2008","September 7, 2005",,"March 19, 2012","Bandim Health Project, Apartado 861, Bissau, Guinea-Bissau",,"https://ClinicalTrials.gov/show/NCT00146302"
1060,"NCT01442428","Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial",,"Withdrawn","No Results Available","Immune Reconstitution Inflammatory Syndrome|Immune Reconstitution Syndrome|Tuberculosis|HIV-infection/Aids","Drug: Dexamethasone|Drug: Atorvastatin|Drug: Naproxen|Drug: Placebo","Change in Clinical Symptom Score at Day 7, as measured by the 10-point visual analog scale to quantify symptom severity.|Change in serum C-reactive protein at Day 7|Days of hospitalization combined with outpatient therapeutic procedures|Study medicine discontinuation|Karnofsky Performance Status Scale at day 7 and 28;|Incidence of Adverse Events|Radiologic improvement at 2 weeks;|Mortality|CD4 count change|Recurrence of IRIS manifestations within the 8 week study period|ART or TB therapy discontinuation|Incidence of sputum acid fast bacilli (AFB) smear positivity at day 28","University of Minnesota|Pfizer|Minnesota Medical Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WS967180","January 2014","March 2016","June 2016","September 28, 2011",,"November 25, 2013","Ramathibodi Hospital, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand|Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand",,"https://ClinicalTrials.gov/show/NCT01442428"
1061,"NCT03092817","Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)",,"Completed","No Results Available","Tuberculosis|Tuberculous Meningitis|Drug-Induced Liver Injury|HIV|IRIS","Drug: Dexamethasone|Other: Placebo","Overall survival until 12 months after randomisation|Neurological disability at 12 months (modified Rankin score)|Time to new neurological event (defined as a fall in GCS of ≥2 points for ≥48 hours, new focal neurological sign, or new onset of seizures) or death by 12 months|Rate of neurological IRIS events up to 6 months from randomisation|Time to new AIDS-defining illness or death by 12 months|Serious adverse events by 12 months|HIV-associated malignancy by 12 months|Overall survival|Neurological disability|Time to new AIDS defining event or death|Rate of HIV-related malignancy|Recurrence of TBM within 24 months of follow-up","Oxford University Clinical Research Unit, Vietnam|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cipto Mangunkusumo Hospital, Jakarta, Indonesia|RSUP Persahabatan Hospital, Jakarta, Indonesia|Eijkman Oxford Clinical Research Unit, Indonesia","All","18 Years and older   (Adult, Older Adult)","Phase 3","520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","26TB","May 25, 2017","April 30, 2022","April 26, 2023","March 28, 2017",,"March 22, 2024","Cipto Mangunkusumo Hospital, Jakarta, Indonesia|Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia|RSUP Persahabatan Hospital, Jakarta, Indonesia|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT03092817"
1062,"NCT02274389","A Prospective Patient Registry of Patients Exposed to Bedaquiline",,"Completed","No Results Available","Pulmonary Multi-drug Resistant Tuberculosis","Drug: No Intervention","Percentage of Participants with Medical Indication for Bedaquiline (BDQ) Treatment and Frequency of use of Expert Medical Consultation With BDQ|Number of Participants With BDQ Susceptibility Based on Minimum Inhibitory Concentration (MIC)|Maximum Dose of BDQ|Total Duration of BDQ Treatment|Percentage of Participants with Different Drug Distribution Mechanisms Utilized for Drug Administration|Number of Participants With Clinical and Microbiologic Patient Reported Outcomes|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Comparison of Rate of Observed Outcomes With Nationally Available Reported Rates","Janssen Research & Development, LLC","All","Child, Adult, Older Adult",,"5","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR104620|RRA-12028|TMC207TBC4001","December 24, 2013","November 20, 2018","November 20, 2018","October 24, 2014",,"June 26, 2019","Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02274389"
1063,"NCT01918397","Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB","Opti-Q","Completed","Has Results","Tuberculosis, Multidrug-Resistant","Drug: Levofloxacin|Drug: Optimized background regimen (OBR)","Time to Sputum Culture Conversion|Number of Grade 3,4, and 5 AEs|Number of Patients Completing Treatment","Boston University|National Institute of Allergy and Infectious Diseases (NIAID)|Centers for Disease Control and Prevention|Macleods Pharmaceuticals, Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-32150|1U01AI100805-01A1","January 2015","March 29, 2022","March 29, 2022","August 7, 2013","May 24, 2023","May 24, 2023","Partners in Health, Lima, Peru|University of Cayetana Heredia, Lima, Peru|Stellenbosch University, Cape Town, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/97/NCT01918397/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01918397"
1064,"NCT01151189","Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)",,"Completed","Has Results","Tuberculosis|HIV Infections","Biological: MVA85A/AERAS-485|Biological: Placebo","Percentage of Participants With Adverse Events|Number of TB Cases|CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in Anti-retroviral Therapy Negative (ART -)Subjects|CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Subjects|HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART - Participants|HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Participants.|Counts of Spot-forming Units After Stimulation With AG85A Peptide Pool.|Immunogenicity of MVA85A/AERAS-485 Compared to Placebo as Described by Flow Cytometric Intracellular Cytokine Staining (ICS) of CD4+ and CD8+ T Cells After Stimulation With a Peptide Pool of Mycobacterial Antigens.|QuantiFERON (QFN) Conversion Rate in MVA85A/AERAS-485 Recipients Compared to Control Subjects Without a Diagnosis of Tuberculosis During the Trial.","Aeras|University of Oxford|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","18 Years to 50 Years   (Adult)","Phase 2","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-030-485","July 2011","May 2014","September 2014","June 28, 2010","August 26, 2015","May 24, 2016","Hopital Aristide Le Dantec, Dakar, Senegal|University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01151189"
1065,"NCT04673227","Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)",,"Unknown status","No Results Available","LTBI|BCG Vaccination Reaction|TB","Diagnostic Test: Blood draw","Peer-review publication of results of our study|Creation of new diagnostic tool and his comparision with existing IGRA test (QTF-GP and TST)","Thomayer University Hospital|Charles University, Czech Republic","All","4 Years to 70 Years   (Child, Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ThomayerH","January 2, 2020","May 26, 2020","December 26, 2022","December 17, 2020",,"December 17, 2020","Faculty of Science, Prague, Czechia|Thomayer Hospital, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT04673227"
1066,"NCT06157034","Prokinetic Effect of Selected Nutraceuticals",,"Completed","No Results Available","Pulmonary Tuberculosis|Gastro-Intestinal Disorder","Other: Placebo|Dietary Supplement: Zingier officinale powder|Dietary Supplement: Carum carvi, L powder|Dietary Supplement: Mentha spicata oil","--GIT disturbances|GIT disturbances|Body Mass Index|A self-designed / pretested questionnaire|Acid-Fast Bacillus (sputum)|Chest X-ray (CXR)|Complete blood count (CBC)","Allama Iqbal Open University Islamabad","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allama Iqbal Open University.","July 15, 2021","February 15, 2022","March 15, 2022","December 5, 2023",,"December 5, 2023","Sheikh Zayed Medical / college, Rahim Yar Khan, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT06157034"
1067,"NCT01017536","Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults",,"Completed","Has Results","Tuberculosis|HIV Infections","Biological: AERAS-402|Biological: Placebo","CD4+ Lymphocyte Count|Change in HIV Viral Load in HIV-infected, BCG-vaccinated Adult Subjects Before and After Administration of AERAS-402 (From Day 1 to Day 182)|Mtb-specific T Cell Response in HIV-infected BCG-vaccinated Adult Subjects With no Evidence of TB Disease","Aeras|Crucell Holland BV","All","21 Years to 45 Years   (Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-017-402","December 2009","March 2012","May 2012","November 20, 2009","October 13, 2014","September 9, 2016","Aurum Institute, Klerksdorp, North-West, South Africa",,"https://ClinicalTrials.gov/show/NCT01017536"
1068,"NCT00005379","Tuberculosis in a Multiethnic Inner City Population",,"Completed","No Results Available","Acquired Immunodeficiency Syndrome|HIV Infections|Lung Diseases|Tuberculosis|Mycobacterium Tuberculosis",,,"NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 100 Years   (Child, Adult, Older Adult)",,,"Other|NIH","Observational","Observational Model: Case-Control","4283|R01HL051517","August 1994","July 1999","July 1999","May 26, 2000",,"December 29, 2015",,,"https://ClinicalTrials.gov/show/NCT00005379"
1069,"NCT03159975","Safety and Immunogenicity Study of GX-70 in TB Patient",,"Withdrawn","No Results Available","Pulmonary Tuberculoses|High Risk Factors for Relapse|Treatment Failure","Drug: GX-70 by electroporation","MTD (Maximum Tolerant Dose)|IFN-γ (SFC/106 cells)|Flt3L concentration (pg/ml)","Yonsei University","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4-2016-1144","March 2018","August 2018","August 2018","May 19, 2017",,"January 11, 2019",,,"https://ClinicalTrials.gov/show/NCT03159975"
1070,"NCT00311220","Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers",,"Unknown status","No Results Available","Tuberculosis|Latent Tuberculosis|Tuberculosis Contact|Elderly","Drug: tuberculin for skin test","tuberculin skin test positive rate|quantiferon positive rate|two steps tuberculin skin test|active tuberculosis","Taichung Veterans General Hospital|Centers for Disease Control and Prevention|ChungHwa Veterans house|Taiwan Province Tau-Wein Hospital","All","0 Years and older   (Child, Adult, Older Adult)","Phase 4","300","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TCVGH-940117/439","January 2004",,"November 2006","April 5, 2006",,"April 5, 2006","Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, China",,"https://ClinicalTrials.gov/show/NCT00311220"
1071,"NCT04264221","Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging",,"Unknown status","No Results Available","Pulmonary TB","Behavioral: New management mode","TB treatment success rates|Lost to follow-up among adult drug-sensitive tuberculosis patients.|Patient satisfaction questionnaire (usually after treatment time period or 6 to 12 months).|Quality of life of TB patients|The Knowledge, Attitude and Practices (KAP) of the patients about tuberculosis|Adherence to treatment among drug-sensitive tuberculosis patients self reported and clinical record will checked for the follow up visits and drug taken|The patient-level percentage of total doses|Patient satisfaction questionnaire|The proportion of patients improving clinically through questionnaire|Perceptions of Intervention through a questionnaire|Semi-structured interview to check the Feasibility of implementation of the intervention and challenges.|To collect patient-specific cost data related to the successfully treated|Psychological Impacts Mental Health Inventory (MHI)-5; well-demonstrated reliability for detecting psychological disorders also mental health screening tool for TB patients will be used","Farman Ullah Khan|Shaheed Zulfiqar Ali Bhutto Medical University Islamabad Pakistan|Pakistan Institute of Medical Sciences|Quaid i Azam University Islamabad Pakistan|Health Science Center of Xi'an Jiaotong University","All","18 Years to 78 Years   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","F,1-1/2015/ERB/SZABMU/359","February 1, 2020","December 1, 2020","December 1, 2020","February 11, 2020",,"December 2, 2020","National TB Control Program, Islamabad, Islammabd, Pakistan|Pakistan Institute of Medical Sciences Islamabad, Islamabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT04264221"
1072,"NCT05381194","BPaL(M) Regimen for the Treatment of MDR/RR-TB",,"Recruiting","No Results Available","Multidrug- and Rifampicin-resistant Tuberculosis","Drug: BPaL(M) regimen","A microbiological failure or clinical failure or relapse|Time to sputum culture conversion during the treatment period|Proportion of culture-negative patients at specific times (weeks 4, 8, 12, 16, and 24 or 26)|Prescribed dose of Linezolid|All-cause mortality","Asan Medical Center|Pusan National University Hospital|Samsung Medical Center|Seoul National University Hospital|Severance Hospital|Chonnam National University Hospital|The Catholic University of Korea|Chungbuk National University Hospital|Ulsan University Hospital|Soon Chun Hyang University|Incheon St.Mary's Hospital|DongGuk University|National Medical Center, Seoul","All","19 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BPaL(M)","December 13, 2022","December 2027","December 2027","May 19, 2022",,"March 15, 2024","Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05381194"
1073,"NCT04048018","Performance Evaluation of the VIDAS TB-IGRA Assay.",,"Completed","No Results Available","Active Tuberculosis|Latent Tuberculosis Infection|Non-Tuberculous Mycobacterial (NTM) Pneumonia","Diagnostic Test: Blood draw and IGRA test","Positive, negative, indeterminate for tuberculosis|Sensitivity and positive and negative percent agreement for the VIDAS TB IGRA assay with comparator assay|Degree of Interference by nontuberculous mycobacteria for the VIDAS TB IGRA assay|Measurement Precision of the VIDAS TB IGRA assay results","BioMérieux","All","2 Years and older   (Child, Adult, Older Adult)",,"2401","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","B2694-CTPR","December 5, 2019","June 30, 2021","June 30, 2021","August 7, 2019",,"July 16, 2021","Stanford University, Palo Alto, California, United States|UC San Diego, San Diego, California, United States|Naional Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Illinois- Chicago, Chicago, Illinois, United States|Saint Louis University, Saint Louis, Missouri, United States|Rutgers University, Newark, New Jersey, United States|Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil|Universidade Federal Da Grande Dourados (UFGD), Dourados, Brazil|Anti-TB center of Chambéry, Chambéry, France|Lapeyronie Hospital, Montpellier, France|Anti-TB center of Nanterre, Nanterre Cedex, France|Avicenne Hospital, Paris, France|Lariboisière Hospital, Paris, France|North Hospital, Saint-Étienne, France|National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia|Hinduja Hospital, Mumbai, India|INMI L. Spallanzani, Rome, Italy|Autonomous University of Baja California, Mexicali, Mexico|TASK Applied Science, Delft Day Hospital Premises, Cape Town, South Africa|University of Cape Town Centre for Lung Infection and Immunity, South Africa, South Africa|Evelina London Children's Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04048018"
1074,"NCT01201941","Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru",,"Completed","No Results Available","Tuberculosis, Multidrug-Resistant","Other: e-Chasqui","Median ""Laboratory turn-around-time"" (TAT)|Percent laboratory errors, by type of error for health establishments in the intervention versus the control group.|DST lab Turn Around Time greater than 60 days|Culture conversion Turn Around Time|Approximate cost of the intervention as a whole and per patient|Qualitative assessment of the acceptability and usability of e-Chasqui among users in health establishments with access with to the system.","Brigham and Women's Hospital|MIT William Asbjornsen Albert Memorial Fellowship|National Institute of Allergy and Infectious Diseases (NIAID)|Bill and Melinda Gates Foundation","All","Child, Adult, Older Adult",,"1849","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2005-P-002606/2|1F31AI075897-01A1","November 2004","March 2009","March 2009","September 15, 2010",,"October 25, 2017","Socios En Salud, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT01201941"
1075,"NCT00651066","Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2","Area under the curve (AUC) of rifabutine measured (a)before introduction of ART;(b)after ART initiation (two different doses of RBT in combination with lopinavir/ritonavir)|Area under the curve (AUC) of lopinavir/ritonavir in combination with two doses of rifabutine|Safety : proportion of patients with grade 3 and grade 4 adverse events","French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","47","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS12150b","June 2010","September 2012","September 2012","April 2, 2008",,"July 17, 2013","Pham Ngoc Tach Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT00651066"
1076,"NCT00640887","Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: rifabutin in combination with efavirenz|Drug: rifabutin in combination with nevirapine|Drug: rifabutin in combination with lopinavir/ritonavir","Area under the curve (AUC) of rifabutine measured (a)before introduction of ART;(b)after ART initiation (two different doses of RBT in combination with efavirenz, nevirapine or lopinavir/ritonavir)|Area under the curve (AUC) of efavirenz, nevirapine and lopinavir/ritonavir in combination with two doses of rifabutine|Safety : proportion of patients with grade 3 and grade 4 adverse events","French National Agency for Research on AIDS and Viral Hepatitis","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS12150a","February 2009","October 2010","October 2010","March 21, 2008",,"June 20, 2011","Unit for Clinical and Biomedical TB Research (Medical Research Council), Durban, South Africa",,"https://ClinicalTrials.gov/show/NCT00640887"
1077,"NCT03000517","PK of Levofloxacin in MDR-TB Patients",,"Completed","No Results Available","Multi-drug Resistant Tuberculosis",,"AUC","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LFX/V0.1","May 4, 2016","October 27, 2017","January 24, 2018","December 22, 2016",,"January 25, 2018","German Nepal Tuberculosis Project Clinic (GENETUP), Kalimati, Kathmandu, Nepal",,"https://ClinicalTrials.gov/show/NCT03000517"
1078,"NCT04156568","A Multicentre, Cohort Study of Screening and Preventive Intervention for Latent Tuberculosis Infection in Children",,"Unknown status","No Results Available","Children LTBI","Drug: INH、RFT","Morbidity|Proportion of adverse reactions|Proportion of lost to follow-up","Beijing Children's Hospital","All","1 Day to 18 Years   (Child, Adult)","Phase 1","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BCH_LTBI study 001","November 1, 2018","September 1, 2021","December 31, 2021","November 7, 2019",,"November 7, 2019","Beijing Children's Hospital of Capital Medical University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04156568"
1079,"NCT03808636","Innovative Reagents for Improving Rapid Diagnosis of Mycobacterial Infections","TIKA_TB","Unknown status","No Results Available","Tuberculosis (TB)",,"Time of culture growth using the new culture method|Difference between the times of new and conventional culture methods.","St George's, University of London","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15.0046","June 2015","March 2019","March 2019","January 17, 2019",,"January 17, 2019","St George's NHS Healthcare Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03808636"
1080,"NCT01223976","Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis",,"Unknown status","No Results Available","Tuberculosis|Psoriasis","Other: Tuberculin skin test and Quantiferon -TB Gold test","The level of agreement between TST and QTF in patients with psoriasis in comparison with controls|Levels of TST in patients with psoriasis in comparison with healthy controls","Tel-Aviv Sourasky Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","222-10","November 2010","June 2011","August 2011","October 19, 2010",,"October 19, 2010","Tel Aviv Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01223976"
1081,"NCT02959684","Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France","STRADA","Unknown status","No Results Available","HIV|Hepatitis C|Hepatitis B|Tuberculosis",,"Comparison of the number of HIV, HBV or HCV positive patients identified in both arms of the screening strategy.|Number of tuberculosis patients identified through the modified TB screen questionnaire|Number of HIV/HBV/HCV patients linked to care after being identified through TROD screen.|Predictive value of the questionnaire TROD screen.|Predictive value of the questionnaire TB screen.|Cost-effectiveness of the TROD screen questionnaire compared with a non-targeted screening, calculated in terms of cost per QALY (quality-adjusted life years) gained through this program","University Paris 7 - Denis Diderot","All","18 Years and older   (Adult, Older Adult)",,"70000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","PROunit-STRADA2016","April 14, 2017","July 2018","July 2019","November 9, 2016",,"May 3, 2018","OFII Bordeaux, Bordeaux, France|OFII Cergy, Cergy, France|OFII Clermont-Ferrand, Clermont-Ferrand, France|OFII Grenoble, Grenoble, France|OFII Lille, Lille, France|OFII Lyon, Lyon, France|OFII Marseille, Marseille, France|OFII Melun, Melun, France|OFII Metz, Metz, France|OFII Montpellier, Montpellier, France|OFII Montrouge, Montrouge, France|OFII Nantes, Nantes, France|OFII Nice, Nice, France|OFII Orléans, Orléans, France|OFII Reims, Reims, France|OFII Rennes, Rennes, France|OFII Rouen, Rouen, France|OFII Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02959684"
1082,"NCT03266991","Treatment of Latent Tuberculosis in Socially Marginalised Citizens","DOT-LTBI","Terminated","No Results Available","Compliance, Patient","Drug: Rifapentine|Drug: Isoniazid","adherence|active tuberculosis|adverse events","Aarhus University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A101A","October 27, 2017","February 9, 2023","February 9, 2023","August 30, 2017",,"October 12, 2023","Dept of Pulmonary Medicine, Aarhus, Denmark|Dept of Pulmonary Medicine, Esbjerg, Denmark",,"https://ClinicalTrials.gov/show/NCT03266991"
1083,"NCT01650389","Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination","MVA(TB)029","Completed","No Results Available","Tuberculosis|HIV","Biological: MVA85A|Biological: Candin|Biological: BCG Vaccine SSI","Safety|Immunogenicity","Mark Hatherill|Medical Research Council|Wellcome Trust|Department for International Development, United Kingdom|University of Oxford|University of Stellenbosch|Oxford-Emergent Tuberculosis Consortium|University of Cape Town","All","up to 96 Hours   (Child)","Phase 2","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","G1100570/1|G1100570","October 2012","May 2015","May 2015","July 26, 2012",,"September 30, 2015","Desmond Tutu TB Centre (DTTC), Stellenbosch University, Khayelitsha, South Africa|South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT01650389"
1084,"NCT01999231","Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10",,"Completed","Has Results","Healthy","Biological: ESAT6-CFP10","the Cases of Adverse Events With Participant Injection of ESAT6-CFP10|the Number of Participants Who Appear the Induration and/or Redness 2h After Application of ESAT6-CFP10|the Number of Participants Who Appear the Induration and/or Redness 24h After Application of ESAT6-CFP10|the Number of Participants Who Appear the Induration and/or Redness 48h After Application of ESAT6-CFP10|the Number of Participants Who Appear the Induration and/or Redness 72h After Application of ESAT6-CFP10|the Number of Participants Who Appear the Induration and/or Redness 96h After Application of ESAT6-CFP10","Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Shanghai Public Health Clinical Center|Air Force Military Medical University, China|Proswell Medical Corporation","All","18 Years to 40 Years   (Adult)","Phase 1","32","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LTao-EC|LTao","September 2013","October 2013","December 2013","December 3, 2013","March 31, 2015","March 31, 2015",,,"https://ClinicalTrials.gov/show/NCT01999231"
1085,"NCT05285202","Clinic-based Versus Hotspot-focused Active TB Case Finding","CHASE-TB","Recruiting","No Results Available","Tuberculosis, Pulmonary|Mycobacterium Tuberculosis Infection","Other: Active TB case finding with linkage to preventive therapy (ACF/TPT)","Pulmonary bacteriologically confirmed TB notifications, hotspot vs facility|TPT initiations, hotspot vs facility|Pulmonary bacteriologically confirmed TB notifications, ACF/TPT vs control|Notification trend (intervention vs control) as assessed by Average percent change in number of TB notifications|Study-initiated TB notifications, hotspot vs facility|Number screened by study|Number diagnosed by study|Cost effectiveness (hotspot vs facility) as assessed by cost per disability-adjusted life year averted|Cost effectiveness (ACF/TPT vs no intervention) as assessed by cost per disability-adjusted life year averted|Number evaluated for latent tuberculosis infection (LTBI) with tuberculin skin testing (TST)|Number referred for TPT|Contacts screened","Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)|Walimu","All","5 Years and older   (Child, Adult, Older Adult)","Not Applicable","80000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Screening","IRB00300939|2R01HL138728","June 1, 2022","January 31, 2027","January 31, 2027","March 17, 2022",,"September 28, 2023","Walimu, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05285202"
1086,"NCT00405301","Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage",,"Completed","No Results Available","Drug Induced Hepatotoxicity|Tuberculosis","Drug: Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)","To compare the safety of different regimens of re-introduction of anti-TB drugs in drug induced liver damage.|To study the predictors of recurrence of drug induced liver damage|To study the risk factors for development of drug induced liver injury","All India Institute of Medical Sciences, New Delhi","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","175","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIIMS/MED/2006/10","December 2006","June 2008","December 2008","November 30, 2006",,"February 16, 2012","Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India|All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00405301"
1087,"NCT02128308","Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents",,"Completed","No Results Available","Healthy","Drug: Levofloxacin and Streptomycin added|Drug: Moxifloxacin and Kanamycin added","AUC (area under the plasma concentration-time curve)","Seoul National University Hospital","Male","20 Years to 50 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBPK","November 2013","December 2013","January 2014","May 1, 2014",,"May 1, 2014","Seoul National University Bundang Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02128308"
1088,"NCT00877591","Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications",,"Completed","No Results Available","Opioid Dependency|HIV Infections","Drug: Fosamprenavir/Ritonavir|Drug: Darunavir/Ritonavir|Drug: Rifampin|Drug: Rifabutin|Drug: Buprenorphine","Effect of ARV or Tuberculosis Medication on Buprenorphine","University of California, San Francisco|State University of New York at Buffalo|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 1","63","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01DA013004","April 2008","April 2013","April 2013","April 8, 2009",,"May 6, 2014","San Francisco General Hospital, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00877591"
1089,"NCT03678688","A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis",,"Completed","Has Results","Pulmonary TB","Drug: 10 mg OPC-167832|Drug: 30 mg OPC-167832|Drug: 90 mg OPC-167832|Drug: 3 mg OPC-167832|Drug: RHEZ|Drug: 30 mg OPC-167832 + 300 mg delamanid|Drug: 30 mg OPC-167832 + 400 mg BDQ|Drug: 30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ","Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA)|Stage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)|Stage 2: Cmax of Delamanid|Stage 2: Cmax,ss of Delamanid|Stage 2: Tmax of Delamanid|Stage 2: AUC0-24 of Delamanid|Stage 2: AUCτ of Delamanid|Stage 2: T1/2,z of Delamanid|Stage 2: CLss/F of Delamanid From Plasma|Stage 2: RCmax of Delamanid|Stage 2: RAUC of Delamanid|Stage 2: Cmax/Dose of Delamanid|Stage 2: AUCτ/Dose of Delamanid|Stage 2: Cmax of Bedaquiline|Stage 2: Cmax,ss of Bedaquiline|Stage 2: Tmax of Bedaquiline|Stage 2: AUC0-24 of Bedaquiline|Stage 2: AUCτ of Bedaquiline|Stage 2: T1/2,z of Bedaquiline|Stage 2: CLss/F of BDQ From Plasma|Stage 2: Cmax/Dose of Bedaquiline|Stage 2: AUCτ/Dose of Bedaquiline|Stage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs)|Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Vital Sign Values|Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters|Stage 1 and Stage 2: Change From Baseline in Lipoarabinomannan (LAM) in the Mycobacteria Growth Indicator Tube® (MGIT) System|Stage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System|Stage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA|Stage 2: Plasma Concentration of Rifampin|Stage 1: Plasma Concentration of Isoniazid|Stage 2: Cmax of DM-6705|Stage 2: Cmax,ss of DM-6705|Stage 2: Tmax of DM-6705|Stage 2: AUC0-24 for DM-6705|Stage 2: T1/2,z of DM-6705|Stage 2: Cmax of N-Desmethyl Bedaquiline|Stage 2: Cmax,ss of N-Desmethyl Bedaquiline|Stage 2: Tmax of N-Desmethyl Bedaquiline|Stage 2: AUC0-24 for N-Desmethyl Bedaquiline|Stage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline|Stage 2: Number of Participants With Clinically Significant Vital Sign Changes on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline|Stage 2: Number of Participants With Clinically Significant Changes in ECG Evaluations on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline","Otsuka Pharmaceutical Development & Commercialization, Inc.|Bill and Melinda Gates Foundation","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","122","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","323-201-00003|OPP1178898","October 18, 2018","February 14, 2022","March 11, 2022","September 20, 2018","November 18, 2023","November 18, 2023","University of Cape Town (Pty) Ltd., Cape Town, Mowbray, South Africa|Satellite Site: Task at Brooklyn Chest Hospital, Cape Town, South Africa|TASK Clinical Research Centre, Cape Town, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/88/NCT03678688/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/88/NCT03678688/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03678688"
1090,"NCT03728725","Xpert MTB/XDR Clinical Evaluation Trial",,"Completed","No Results Available","Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant","Device: Cepheid Gene Xpert MTB/XDR","Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for INH and ETH resistance detection|Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for fluoroquinolone resistance detection|Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for second-line injectable resistance detection","Foundation for Innovative New Diagnostics, Switzerland|Cepheid|PD Hinduja Hospital and Medical Research Centre, Mumbai, India|Phthisiopneumology Institute, Chisinau, Moldova|National Institute of Tuberculosis and Respiratory Disease, New Delhi, India|University of Witwatersrand, South Africa","All","18 Years and older   (Adult, Older Adult)",,"710","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","7162-02/2","July 11, 2019","August 18, 2020","August 18, 2020","November 2, 2018",,"May 19, 2021","Institute of Pthisiopenumology, Chisinau, Moldova, Republic of","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT03728725/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT03728725/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03728725"
1091,"NCT00402402","Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease",,"Completed","No Results Available","Chronic Liver Disease|Liver Transplantation|Tuberculosis","Procedure: Tuberculin skin test|Procedure: Quantiferon-TB Gold assay","Concordance between the Quantiferon-TB Gold assay and the tuberculin skin test|Correlation of the test results to the patient's risk of latent TB infection|Factors associated with discordance between the TST and the QFT-G test|Frequency of anergy in this patient population","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","06-0648-AE","October 2006","July 2007","July 2007","November 22, 2006",,"April 16, 2008","Univcersity Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00402402"
1092,"NCT01245036","Efficacy of Antituberculous Therapy in Management of Sarcoidosis",,"Completed","No Results Available","Sarcoidosis|Tuberculosis","Drug: Antituberculous therapy along with steroids","Remission rates|Relapse rates in the two groups|Treatment related adverse effects in the two groups.","Post Graduate Institute of Medical Education and Research, Chandigarh|PIMERIndia","All","15 Years to 75 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sarc/Att/01","January 2009","December 2012","March 2013","November 22, 2010",,"May 15, 2013","Deaprtment of Pulmonary Medicine, PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01245036"
1093,"NCT03545373","Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)","ACT-TB","Completed","No Results Available","Tuberculosis|Respiratory Tract Infections|Pneumonia","Drug: Azithromycin|Drug: Amoxicillin","Diagnostic accuracy of trial-of-antibiotics: proportion of patients without tuberculosis (by sputum tests) who report improvement of their baseline illness when asked 7 days after randomisation (Day 8 study visit).|Clinical impact of trial-of-antibiotics|Impact of trial-of-antibiotics on antimicrobial resistance|diagnostic value of trial-of-antibiotics in all patients including those without a valid sputum result|Economic analysis of use of trial-of-antibiotics","London School of Hygiene and Tropical Medicine|Kamuzu University of Health Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","1583","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","15232","February 25, 2019","March 14, 2020","April 14, 2020","June 4, 2018",,"April 28, 2021","University of Malawi College of Medicine, Blantyre, Southern, Malawi",,"https://ClinicalTrials.gov/show/NCT03545373"
1094,"NCT00692809","Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection","HIV-TB","Unknown status","No Results Available","Latent Tuberculosis Infection|HIV Infections|Tuberculosis",,"Precise component(s) of T cell response against M.tuberculosis compromised by HIV infection which leads to the development of severe forms of clinical tuberculosis.|Elucidation of critical events of the cellular and molecular interactions that would be useful for developing newer therapeutic strategies and vaccination.","Ministry of Science and Technology, India|Indian Council of Medical Research","All","18 Years to 65 Years   (Adult, Older Adult)",,"180","Other","Observational","Time Perspective: Prospective","SKS/LTBI/07","July 2008","March 2010","March 2010","June 6, 2008",,"September 15, 2009","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00692809"
1095,"NCT03734172","Rapid and Accurate Diagnosis of Paediatric TB (RaPaed-AIDA-TB)","RaPaed","Completed","No Results Available","Tuberculosis|Diagnoses Disease","Diagnostic Test: Sample collection","Sensitivity and Specificit of new test candidates; against a clinica/microbiological reference standard case definition","Michael Hoelscher|University of Cape Town Lung Institute|Instituto Nacional de Saúde, Mozambique|Kamuzu University of Health Sciences|Karolinska Institutet|Research Center Borstel|University of Stellenbosch|Beckman Coulter, Inc.|Cepheid|Otsuka Novel Products GmbH|University of Melbourne|Foundation for Innovative New Diagnostics, Switzerland|National Institute for Medical Research, Tanzania|Christian Medical College, Vellore, India|Ludwig-Maximilians - University of Munich","All","up to 14 Years   (Child)",,"974","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","LMU-IMPH-AIDA-02","January 21, 2019","December 31, 2022","December 31, 2022","November 7, 2018",,"May 1, 2023","Christian Medical College, Vellore, Tamil Nadu, India|University of Malawi College of Medicine, Blantyre, Malawi|Centro de Investigação e Treino em Saúde da Polana Caniço, Maputo, Mozambique|University of Cape Town Lung Institute (UCTLI), Cape Town, Cape, South Africa|NIMR - Mbeya Medical Research Programme, Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT03734172"
1096,"NCT04043390","A One-stop Shop for the Same Day Diagnosis and Management of TB and HIV",,"Completed","No Results Available","Tuberculosis|Hiv","Diagnostic Test: CRP and Molbio Truenat MTB|Diagnostic Test: CRP and Xpert ULTRA MTB/RIF|Diagnostic Test: standard test Xpert|Diagnostic Test: Culture as reference standard","Performance of two diagnostic schemes for the diagnosis of TB when compared to culture.|Agreement of two diagnostic schemes for the diagnosis of TB when compared to Xpert.|Time required for diagnosis of the two diagnostic schemes compared to Xpert.|Cost required for diagnosis of the two diagnostic schemes compared to Xpert.","Liverpool School of Tropical Medicine|REACH Ethiopia|Bingham University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-063","January 21, 2019","December 31, 2020","December 31, 2020","August 2, 2019",,"August 2, 2021","Zankli Research Centre, Kobape, Nassarawa, Nigeria",,"https://ClinicalTrials.gov/show/NCT04043390"
1097,"NCT01687504","Pharmacokinetics of Anti-TB Drugs in HIV/TB Co-infected Children in Ghana",,"Unknown status","No Results Available","Tuberculosis|HIV",,"Descriptive statistics of PK parameters (Cmax, Tmax, AUC0-8h) of rifampin, isoniazid, pyrazinamide and ethambutol in children with TB with and without HIV coinfection|Frequency of liver enzymes elevations compare to baseline, skin rashes, nausea, vomiting and treatment discontinuation or modifications due to drug side effects in children with TB with and without HIV coinfection|Relationship between genetic polymorphisms of N-acetyltransferase type 2 (NAT2) enzyme and isoniazid plasma Cmax and AUC in Ghanaian children with TB with and without HIV|Relationship between genetic polymorphisms of SLCO1B1 transporter and rifampin plasma Cmax and AUC in Ghanaian children with TB with and without HIV|Relationship between plasma Cmax and AUC of isoniazid, rifampin, ethambutol and pyrazinamide at week 4 of therapy and frequency of anti-TB treatment discontinuation or modification|Relationship between NAT2 acelator status, SLCO1B1 genotype status and anti-TB treatment completion, discontinuation or modification|Relationship between body weight, gender, nutritional status and plasma Cmax and AUC of isoniazid, rifampin, ethambutol and pyrazinamide in Ghanaian children with TB with and without HIV","The Miriam Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 14 Years   (Child)",,"106","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PK-PTBHIV01|R01HD071779","October 2012","May 2017","May 2017","September 19, 2012",,"October 11, 2012","Komfo Anokye Teaching Hospital, Kumasi, Ghana",,"https://ClinicalTrials.gov/show/NCT01687504"
1098,"NCT02534727","Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance",,"Completed","No Results Available","Tuberculosis|Non-Tuberculosis Mycobacteria",,"The primary endpoint is the AUC (0-24) in sputum and blood.|drug-specific time-concentration curves, as well as drug exposure in sputum relative to that in cavity caseum","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"215","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","150187|15-I-0187","January 27, 2016","December 31, 2020","December 31, 2020","August 28, 2015",,"March 29, 2022","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Henan Provincial Chest Hospital, Zhengzhou,, China",,"https://ClinicalTrials.gov/show/NCT02534727"
1099,"NCT01380080","REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","REMEMBER","Completed","Has Results","HIV Infection","Drug: Atripla (r)|Drug: Efavirenz|Drug: Truvada|Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Drug: Rifampin/isoniazid FDC|Drug: Isoniazid","Cumulative Probability of Death or Unknown Vital Status by Week 24|Cumulative Probability of Death by Week 24|Cumulative Probability of First AIDS Progression by Week 96|Cumulative Probability of Death or AIDS Progression by Week 24|Proportion of Participants With HIV-1 RNA Level <400 Copies/mL|CD4+ T-cell Count|CD4+ T-cell Count Change From Baseline|Time to Initiation of TB Treatment by Week 96|Proportion of Participants With TB Diagnosis by Week 96|Proportion of Participants With at Least One New Grade 3 or 4 Adverse Event That is at Least a One-grade Increase From Baseline by Week 48|Proportion of Participants With at Least One New Grade 3 or 4 Targeted Laboratory Value That is at Least a One-grade Increase From Baseline by Week 48|Proportion of Participants With Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48|Proportion of Participants With Reportable Hospitalization by Week 48|Proportion of Participants Who Prematurely Discontinued Any Component of TB Treatment by Week 48|Proportion of Participants Who Prematurely Discontinued Antiretroviral Therapy by Week 48|Cumulative Probability of Death or AIDS Progression by Week 48","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 4","851","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5274|1U01AI068636","October 2011","January 2015","April 2016","June 27, 2011","February 23, 2016","January 29, 2021","Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro,, Brazil|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port Au Prince, Haiti|Les Centres GHESKIO CRS, Port-au-Prince, Haiti|YRG CARE Medical Ctr., VHS Chennai CRS, Rajiv Gandhi Salai Taramani, Chennai, India|BJ Medical College CRS, Pune, Maharashtra, India|AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS, Eldoret, Kenya|Walter Reed Project - Kenya Med. Research Institute Kericho CRS, Kericho, Kenya|College of Med. JHU CRS (30301), Blantyre, Malawi|University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi|San Miguel CRS, San Miguel, Lima, Peru|Barranco CRS (11301), Lima, Peru|Wits HIV CRS, Johannesburg, Gauteng, South Africa|CAPRISA eThekwini CRS, Durban, KwaZulu-Natal, South Africa|Durban Adult HIV CRS, Durban, KwaZulu-Natal, South Africa|Soweto ACTG CRS (12301), Johannesburg, South Africa|Joint Clinical Research Centre (JCRC) (12401), Kampala, Uganda|Kalingalinga Clinic CRS (12801), Lusaka, Zambia|UZ-Parirenyatwa CRS, AIDS Research Unit P.O. Box A178, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT01380080"
1100,"NCT02409290","The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","STREAM","Completed","Has Results","MDR-TB","Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Moxifloxacin|Drug: Clofazimine|Drug: Ethambutol|Drug: Pyrazinamide|Drug: Isoniazid|Drug: Prothionamide|Drug: Kanamycin|Drug: Levofloxacin|Drug: Bedaquiline","STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)","IUATLD, Inc|Medical Research Council|Institute of Tropical Medicine, Belgium|Liverpool School of Tropical Medicine|Rede TB","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","588","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","78372190/18148631 (Stage 1/2)","March 2016","May 13, 2022","May 2, 2023","April 6, 2015","September 28, 2023","September 28, 2023","Armauer Hanssen Research Institute, Addis Ababa, Ethiopia|St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia|JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|BJ Medical College Civil Hospital, Ahmedabad, India|The National Institute for Research in Tuberculosis, Chennai, India|Rajan Babu Institute for Pulmonary Medicine and Tuberculosis, New Delhi, India|Institute of Phthisiopneumology 'Chiril Draganiuc', Chisinau, Moldova, Republic of|National Centre for Communicable Diseases, Ulaanbaatar, Mongolia|King Dinizulu Hospital, Durban, South Africa|Helen Joseph Hospital, Johannesburg, South Africa|Doris Goodwin Hospital, Pietermaritzburg, South Africa|Empilweni TB Hospital, Port Elizabeth, South Africa|Makerere University (Mulago Referral Hospital), Kampala, Uganda","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/90/NCT02409290/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/90/NCT02409290/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02409290"
1101,"NCT02771249","Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers",,"Completed","No Results Available","HIV Infected Population With Latent Tuberculosis","Drug: rifapentene (RPT)|Drug: darunavir/cobicistat (DRV/c)|Drug: Isoniazid (INH)|Dietary Supplement: Pyridoxine","Area-under-the-curve during the dosing interval of 0 to t (AUC0-t), maximum total plasma concentration (Cmax), time to maximum plasma concentration (t-max), terminal halflife (t1/2), apparent oral clearance (CL/F)|AEs and abnormal laboratory values graded according to the Division of AIDS AE Table, laboratory measures: hepatic &amp; renal function, lipids, complete blood count, creatine kinase &amp; lipase","National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","37","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","160112|16-CC-0112","June 3, 2016","August 17, 2021","August 17, 2021","May 13, 2016",,"April 18, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/49/NCT02771249/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02771249"
1102,"NCT02946762","TasP in Correctional Facilities",,"Completed","No Results Available","HIV|Tuberculosis","Other: Test and treat","Proportion of inmates with HIV-infection who were assessed for and offered ART initiation under TasP/UTT|Proportion of all HIV-infected inmates starting ART who are retained on ART among those who remain in the study facility|Proportion of inmates on ART with an HIV RNA <40 c/mL at 6 months of ART|Proportion of HIV-infected inmates with TB diagnosis who initiate anti-TB therapy under TasP/UTT|Proportion of inmates on ART with an HIV RNA <40 c/mL at 12 months of ART","University of North Carolina, Chapel Hill|Department for International Development, United Kingdom","All","18 Years and older   (Adult, Older Adult)","Not Applicable","419","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","15-1473","February 1, 2016","March 31, 2018","March 31, 2018","October 27, 2016",,"March 13, 2019","Lusaka Central Corrections ART Clinic, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT02946762"
1103,"NCT00749034","Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers",,"Completed","No Results Available","Tuberculosis|Healthy","Biological: VPM1002|Biological: BCG","Safety: physical examination, vital signs, ECG, liver sonography, chest X-ray, laboratory safety parameters (including haematology, coagulation, clinical chemistry and urinalysis), tolerability, recording of concomitant medication and adverse events|Immunogenicity: LST for PPD with subsequent IFN-gamma specific ELISA on supernatants of PBMC|Immunogenicity: ELISPOT for the number of IFN-gamma secreting PBMC after stimulation with PPD|Immunogenicity: whole blood stimulated with PPD and measuring IFN-gamma in the plasma by ELISA|ICS for IFN-gamma, TNF-alpha and IL-2 in CD4+ and CD8+ lymphocytes upon stimulation with PPD|Immunogenicity: ICS with other triple combinations of markers in CD4+ and CD8+ lymphocytes upon stimulation with PPD|Immunogenicity: TB85B as recall antigen for ELISA, ELISPOT, WBA and ICS|Immunogenicity: serum antibodies against PPD or AG85B","Vakzine Projekt Management GmbH","Male","18 Years to 55 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VPM1002-GE-1.01TB","September 2008","December 2009","December 2009","September 9, 2008",,"May 20, 2010","Focus Clinical Drug Development GmbH, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT00749034"
1104,"NCT00707317","T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals","TBNET-TIPS","Completed","No Results Available","Tuberculosis|Monitoring, Immunologic",,"IGRA performance|active tuberculosis on follow-up","Tuberculosis Network European Trialsgroup","All","18 Years and older   (Adult, Older Adult)",,"1843","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TBNET-TIGRA","June 2008","May 2011","May 2011","June 30, 2008",,"December 16, 2015","Cellestis Limited, Carnegie, Australia|National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria|Herlev Hospital, Herlev, Denmark|Research Center Borstel, Borstel, Germany|HIV Treatment and Clinical Research Unit, Frankfurt, Germany|Department of Infectious Diseases, Univ. of Freiburg, Freiburg, Germany|University of the Saarland, Homburg, Germany|Respiratory Medicine, University of Thessaly, Mezourlo-Larissa, Greece|Emerging Bacterial Pathogens Unit, Milan, Italy|National Institute for Infectious Diseases L. Spallanzani, Roma, Italy|WHO Collaborating Center for TB and Lung Diseases, Tradate, Italy|KNCV Tuberculosis Foundation, The Hague, Netherlands|Centro de Diagnóstico Pneumológico, Lisbon, Portugal|Clinica de Pneumologie, Marius Nasta Institute of Pneumology, Bucharest, Romania|Servei de Microbiologia, Barcelona, Spain|Karolinska Institute, Stockholm, Sweden|Centre Antituberculeux, Hôpital Cantonal Universitarie, Geneva, Switzerland|Baþkent Üniversitesi Týp Fakültesi, Ankara, Turkey|Department of Chest Diseases and Tuberculosis, Ankara, Turkey|Chest Clinic, London, United Kingdom|Imperial College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00707317"
1105,"NCT01560078","Efficacy Study of Thrice Weekly Directly Observed Treatment Short-Course Regimen in Tubercular Pleural Effusion",,"Completed","No Results Available","Tuberculosis|Pleural Effusion",,"Complete resolution of pleural effusion on ultrasonogram","All India Institute of Medical Sciences, New Delhi|Sri Venkateswara Institute of Medical Sciences University","All","15 Years to 65 Years   (Child, Adult, Older Adult)",,"360","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","T-18012/2/2005-TB/CCD","September 2006","October 2011","December 2012","March 22, 2012",,"July 12, 2013","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01560078"
1106,"NCT01872390","Start TB Patients on ART and Retain on Treatment (START Study)","START","Completed","No Results Available","Tuberculosis|HIV","Other: Combination Intervention Package|Other: Standard of Care","Percentage of TB/HIV patients newly registered during period of observation who initiate ART during TB treatment|Percentage of participants who attended 6 month clinic visit (within 1 month window) and reported ART use|Participants with cure + treatment completion at end of TB treatment|Days from TB treatment initiation to date of ART initiation|Percentage of total prescribed doses ingested for ART|Change in CD4+ count|Percentage of smear positive pulmonary TB cases that converted to smear negative after eight weeks of treatment|Percentage of total prescribed doses ingested for TB treatment|Ratio of the incremental costs of the CIP to incremental effectiveness","Columbia University|United States Agency for International Development (USAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","415","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","AAAK7103|AID-OAA-A-12-00022","April 2013","January 2016","May 7, 2021","June 7, 2013",,"July 14, 2021","Koali Health Center, Koali, Lesotho|Maluti Hospital, Mafeteng, Lesotho|St. Magdalena Health Center, Mafeteng, Lesotho|Khubetsoana Health Center, Maseru, Lesotho|Pilot Health Center, Maseru, Lesotho|Berea Hospital, Teyateyaneng, Lesotho|Good Shepherd Health Center, Teyateyaneng, Lesotho|Holy Family Health Center, Teyateyaneng, Lesotho|Kolojane Health Center, Teyateyaneng, Lesotho|Sebedia Health Center, Teyateyaneng, Lesotho|St. David Health Center, Teyateyaneng, Lesotho|St. Theresa Health Center, Teyateyaneng, Lesotho",,"https://ClinicalTrials.gov/show/NCT01872390"
1107,"NCT05917210","Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda","TEACH","Not yet recruiting","No Results Available","Tuberculosis|HIV","Behavioral: Standard TB-EC|Behavioral: Peer navigation strategy for TB-EC","Effectiveness assessed by TB treatment completion|Effectiveness assessed by Antiretroviral Therapy (ART) retention|Clinical Effectiveness assessed by TB recurrence-free survival|Clinical Effectiveness assessed by HIV RNA copy number","Yale University|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1920","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2000035416|1R01HL170926-01A1","September 2024","September 2026","September 2026","June 23, 2023",,"November 21, 2023","Primary Care Clinics, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05917210"
1108,"NCT04242472","SMS-based Mobile Health Intervention for Nutritional Status and Treatment Outcome Among TB Patients",,"Unknown status","No Results Available","Tuberculosis|Undernutrition","Behavioral: SMS-based Mobile Health intervention","Nutritional status change|Dietary practice change|Treatment outcome","Addis Ababa University|Fogarty International Center of the National Institute of Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","440","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","TB-MeNu|D43TW009127","July 2020","September 2020","March 2021","January 27, 2020",,"January 27, 2020","Addis Ababa Health Bureau, Addis Ababa, Ethiopia",,"https://ClinicalTrials.gov/show/NCT04242472"
1109,"NCT00728546","NAT2 in Re-challenge of INH in Patients With Hepatitis",,"Unknown status","No Results Available","Tuberculosis|Hepatotoxicity","Drug: Isoniazid (Rifinah)","Decrease the events of hepatotoxicity when patients are re-challenged with INH|economics evaluation of performing pharmacogenetics screening in practice","National Taiwan University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan)","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080515M","June 2008","November 2015","November 2015","August 6, 2008",,"December 27, 2012","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00728546"
1110,"NCT01926379","ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)","ENRICH","Completed","No Results Available","HIV|Tuberculosis","Behavioral: Combination intervention components|Drug: Isoniazid Prevention Therapy","Percentage of patients enrolled in HIV care who initiate IPT|Percentage of patients who are administered at least 180 doses of IPT within 9 months of IPT initiation|Percentage of participants who attended their most recent HIV clinic appointment 6 months after initiating IPT|Percentage of total prescribed ART (antiretroviral therapy) doses ingested for each month of ART treatment for the first 6 months after IPT initiation|Change in CD4+ count from initiation of IPT to 6 months later|Incidence of adverse events experienced by patients during IPT, as identified through monthly questionnaires and chart review|Percentage of total prescribed IPT doses ingested for each month of IPT treatment","Columbia University|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","338","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","AAAK3163|1R01AI100044-01","July 2013","February 2016","May 7, 2021","August 20, 2013",,"July 13, 2021","Addis Ketema Health Center, Dire Dawa, Ethiopia|Dire Dawa Health Center, Dire Dawa, Ethiopia|Gende Gerada Health Center, Dire Dawa, Ethiopia|Gende Kore Health Center, Dire Dawa, Ethiopia|Goro Health Center, Dire Dawa, Ethiopia|Legehare Health Center, Dire Dawa, Ethiopia|Melka-Jebdu Health Center, Dire Dawa, Ethiopia|Sabian Health Center, Dire Dawa, Ethiopia|Arategna Health Center, Harar, Ethiopia|Jinela Health Center, Harar, Ethiopia",,"https://ClinicalTrials.gov/show/NCT01926379"
1111,"NCT00483054","Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin","N2R","Completed","No Results Available","HIV Infections|Tuberculosis","Drug: efavirenz|Drug: nevirapine","To compare proportion of patients who achieved undetectable plasma HIV-1RNA< 50 copies/mL at 48 weeks after initiation of antiretroviral treatment between the 2 groups|to compare CD4 response at 48, 96 and 144 weeks after initiation of antiretroviral treatment, to compare adverse drugs reaction between the 2 groups","Bamrasnaradura Infectious Diseases Institute|Mahidol University|Chulalongkorn University","All","18 Years to 60 Years   (Adult)","Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","210041000824904203","January 2007","December 2008","December 2010","June 6, 2007",,"November 22, 2011","Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand",,"https://ClinicalTrials.gov/show/NCT00483054"
1112,"NCT03551795","Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor",,"Completed","No Results Available","Malignant Solid Tumor","Biological: Infusion of iNKT cells","Objective Response Rate (ORR)|Incidence of adverse events related to the infusion of cells","Xiaoyan Zhang|Shanghai Public Health Clinical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","iNKT20180427V1.1","January 1, 2018","December 30, 2021","March 31, 2022","June 11, 2018",,"May 9, 2022","Shanghai Public Health Clinical Center, Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03551795"
1113,"NCT04746547","Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB","ORCHID","Recruiting","No Results Available","Tuberculosis|Hiv","Drug: Dolutegravir 50 MG|Drug: Dolutegravir 10 MG","Pharmacokinetics (Ctrough) of DTG 50mg twice daily|Pharmacokinetics (Cmax) of DTG 50mg twice daily|Pharmacokinetics (AUC0-24h) of DTG 50mg twice daily|To develop an integrated model which will be used to estimate the primary PK parameters of DTG|Adverse events|Virological suppression|Enzyme polymorphisms","University of KwaZulu|Centre for the AIDS Programme of Research in South Africa","All","23 Months to 18 Years   (Child, Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPRISA258 (CAP258)","August 19, 2021","July 31, 2025","July 31, 2025","February 9, 2021",,"February 1, 2024","King Edward VIII Hospital, Durban, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT04746547"
1114,"NCT01663168","EARNEST Rifabutin Pharmacokinetics (PK) Substudy",,"Unknown status","No Results Available","HIV|Tuberculosis","Drug: Rifabutin","Grade 3/4 adverse events|Rifabutin and its 25-o-desacetyl metabolite pharmacokinetic parameters (from a population PK model)|Lopinavir/ritonavir pharmacokinetic parameters (from a population PK model)|Raltegravir pharmacokinetic parameters (from a population PK model)|Response to TB therapy|Rifamycin resistance","Justine Boles|Abbott|Medical Research Council","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISRCTN13074752","December 2011","January 2014","January 2014","August 13, 2012",,"August 13, 2012","JCRC Fort Portal, Fort Portal, Uganda|JCRC Gulu, Gulu, Uganda|JCRC Kabale, Kabale, Uganda|JCRC Kakira, Kakira, Uganda|Infectious Diseases Institute (IDI), Kampala, Uganda|JCRC Kampala, Kampala, Uganda|San Raphael of St Francis Hospital, Nsambya, Kampala, Uganda|JCRC Mbale, Mbale, Uganda|JCRC Mbarara, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT01663168"
1115,"NCT04551573","A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects",,"Withdrawn","No Results Available","Tuberculosis|Hiv","Drug: Rifapentine daily|Drug: Rifapentine weekly","Plasma area under the curve (AUC) of Bictegravir between groups|Maximum plasma concentrations(Cmax) of Bictegravir between groups|Concentrations at the end of dosing interval (Ctau) of Bictegravir between groups|Time to total maximum plasma concentrations (Tmax) of Bictegravir between groups|Plasma area under the curve (AUC) of tenofovir alafenamide (TAF) between groups|Maximum plasma concentrations(Cmax) of TAF between groups|Steady-state Intracellular (IC) concentration changes of tenofovir-diphosphate (TFV-DP)|Adverse Events of medications","Yale University|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2000027436","May 2021","October 2021","November 2021","September 16, 2020",,"September 20, 2021","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04551573"
1116,"NCT04520113","Kharituwe TB Contact Tracing Study",,"Active, not recruiting","No Results Available","Tuberculosis|Hiv","Behavioral: Household contact tracing","Effectiveness: ratio of secondary TB identified and started on treatment per index case in novel strategy arm compared to standard contact investigation arm|The TB prevalence ratio, comparing highly mobile to less mobile index patients|TB strain relatedness using maximum likelihood transmission trees.|Relative acceptability of each novel strategy compared to standard contact investigation|Feasibility of each strategy: proportion of potentially eligible index cases for whom a household visit was conducted|Relative fidelity of each novel strategy compared to standard contact investigation|Sustainability of each novel strategy relative to standard contact tracing|Incremental cost-effectiveness ratio for each novel strategy relative to standard contact tracing","Johns Hopkins Bloomberg School of Public Health|Perinatal HIV Research Unit of the University of the Witswatersrand|Setshaba Research Centre","All","up to 99 Years   (Child, Adult, Older Adult)","Not Applicable","15000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","R01AI147681","September 1, 2020","June 2024","June 2024","August 20, 2020",,"October 6, 2023","Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa|Setshaba Research Centre, Soshanguve, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/13/NCT04520113/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04520113"
1117,"NCT00933790","Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis",,"Completed","No Results Available","HIV Infection|Pulmonary TB","Drug: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)","unfavourable responses during treatment|Unfavorable responses during follow-up|TEADR's between the groups|Incidence of Immune Reconstitution Syndrome among the groups","Tuberculosis Research Centre, India","All","18 Years and older   (Adult, Older Adult)","Phase 3","331","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRC25","September 14, 2009","December 31, 2016","June 30, 2018","July 7, 2009",,"April 10, 2019","Tuberculosis Research Centre (ICMR), Chennai, Tamil Nadu, India|Govt. Hospital of Thoracic Medicine, Tambaram, Chennai, Tamil Nadu, India|Tuberculosis Research Centre (ICMR), Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT00933790"
1118,"NCT05947890","Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa","HVTN605A5421","Recruiting","No Results Available","HIV I Infection|Tuberculosis","Biological: MTBVAC|Biological: BCG","Number of unsolicited adverse events|Number of solicited adverse events|Number of Grade 3 or higher adverse events|Number of serious adverse events|Frequency and response of MTBVAC-reactive CD4+ cells expressing Th1 and/or Th17 cytokines|Frequency and response of MTBVAC-reactive CD8+ T cells expressing Th1 and/or Th17 cytokines|Frequency and response of BCG-reactive CD8+ T cells expressing Th1 and/or Th17 cytokines|Frequency and response of BCG-reactive CD4+ expressing Th1 and/or Th17 cytokines|Frequency and response of BCG-reactive CD4+ T cells expressing Th1 and/or Th17 cytokines|Frequency and response of MTBVAC-reactive and BCG reactive CD8+ T cells expressing Th1 and/or Th17 cytokines|Frequency and response of MTBVAC-reactive and BCG reactive CD4+ T cells expressing Th1 and/or Th17 cytokines|MTBVAC-reactive and BCG-reactive IgA, IgG, and IgM binding Abs|Gene expression profiles to evaluate innate immunogenicity in response to MTBVAC vaccination|Gene expression profiles to evaluate innate immunogenicity in response to BCG revaccination|Whole blood phenotyping to evaluate innate immunogenicity in response to MTBVAC vaccination|Whole blood phenotyping to evaluate innate immunogenicity in response to BCG revaccination|Measurement of soluble proinflammatory mediators in serum to evaluate innate immunogenicity in response to MTBVAC vaccination|Measurement of soluble proinflammatory mediators in serum to evaluate innate immunogenicity in response to BCG revaccination|Acceptability of the study products to assess the acceptability of MTBVAC vaccination|Acceptability of the study products to assess the acceptability of BCG revaccination","HIV Vaccine Trials Network|National Institute of Allergy and Infectious Diseases (NIAID)|Biofabri, S.L","All","12 Years to 55 Years   (Child, Adult)","Phase 2","276","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HVTN 605/A5421|UM1AI068614","January 30, 2024","November 30, 2024","November 30, 2024","July 17, 2023",,"March 18, 2024","Johannesburg - CHRU, Westdene, Gauteng,, South Africa|Soweto - Gauteng, Johannesburg, Gauteng, South Africa|Durban - Botha's Hill CRS, Durban, Kwa Zulu Natal, South Africa|Durban - Wentworth, Durban, Kwa Zulu Natal, South Africa|Cape Town - UCTLI, Cape Town, Western Cape, South Africa|Cape Town - Emavundleni, Cape Town, Western Cape, South Africa|Cape Town - Groote Schuur, Cape Town, Western Cape, South Africa|Worcester - SATVI, Worcester, Western Cape, South Africa|Cape Town - Khayelitsha, Cape Town, South Africa|Durban - Chatsworth, Chatsworth, South Africa|Durban eThekwini, Durban, South Africa|Durban - Isipingo, Isipingo, South Africa|Klerksdorp, Klerksdorp, South Africa|Ladysmith, Ladysmith, South Africa|Rustenburg CRS, Rustenburg, South Africa|Soshanguve, Soshanguve, South Africa",,"https://ClinicalTrials.gov/show/NCT05947890"
1119,"NCT04230395","Alcohol Reduction Among People With TB and HIV in India","HATHI","Recruiting","No Results Available","Tuberculosis|Hiv","Behavioral: CAP|Other: Usual Care","Alcohol Use: Drinking days|Alcohol Use: Heavy drinking days|Alcohol Use: Standard drinks per drinking day|Change in Alcohol Use as assessed by change in Drinking days|Change in Alcohol Use as assessed by change in heavy Drinking days|Change in Alcohol Use as assessed by change in standard drinks per drinking days|TB treatment failure, TB treatment default, or all-cause mortality|HIV-RNA Non-Suppression","Johns Hopkins University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","450","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00235134|R01AA027974","September 21, 2022","January 1, 2026","August 31, 2026","January 18, 2020",,"October 11, 2023","BJ Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India|Dr. D. Y. Patil Medical College, Pune, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04230395"
1120,"NCT04221789","TB Treatment Support Tool Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes","TB-TST","Active, not recruiting","No Results Available","Tuberculosis|Treatment Adherence","Other: TB treatment assistant","Treatment success|Treatment default","Institute for Clinical Effectiveness and Health Policy|University of Washington","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","555","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","12112019","November 17, 2020","December 31, 2023","June 1, 2024","January 9, 2020",,"May 1, 2023","IECS, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04221789"
1121,"NCT00395720","The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV",,"Completed","No Results Available","Tuberculosis|HIV Infections","Biological: MVA85A (TB vaccine)|Biological: MVA 85A","Data on adverse events|Immune responses","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB010","November 2006","July 2010","July 2010","November 3, 2006",,"March 28, 2011","Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00395720"
1122,"NCT00828529","TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer",,"Completed","No Results Available","Tuberculosis|HIV","Drug: TMC207","The primary objective is to evaluate the effect of steady-state LPV/rtv 400/100 mg twice daily on the pharmacokinetics of TMC207 and its M2 metabolite after single-dose administration of TMC207 400 mg, in healthy volunteers.|The secondary objectives are: to evaluate the effect of single-dose TMC207 on the steady-state plasma concentrations of lopinavir and ritonavir in healthy volunteers; to evaluate the short-term safety and tolerability of co-administration of single-dose","Tibotec BVBA","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR002545","February 2009","May 2009","May 2009","January 26, 2009",,"August 15, 2012",,,"https://ClinicalTrials.gov/show/NCT00828529"
1123,"NCT03948698","TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)","TIPPI","Completed","Has Results","Tuberculosis|Pediatric","Other: Innovative approached to pediatric TB care","Children Screened for TB|Children With Presumptive TB|Children With Presumptive TB Referred for Lab-based TB Diagnosis|Children With Presumptive TB Tested Using GeneXpert|Children Initiated on TB Preventive Therapy|Children Completing TB Preventive Therapy|Children Diagnosed With Active TB|Children Initiated on TB Treatment|Children Achieving Treatment Success|TB Contacts Successfully Traced|TB Contacts Screened Negative for TB|TB Contacts Eligible for Preventive Therapy","Elizabeth Glaser Pediatric AIDS Foundation","All","up to 14 Years   (Child)",,"4159533","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","EG0209","December 1, 2018","September 30, 2021","September 30, 2021","May 14, 2019","December 20, 2021","April 18, 2023","Sites in Centre, Littoral and West regions, Djoungolo, Cameroon|Bandalungwa,Binza Meteo,Kikimi,Kingasani,Kinshasa, Lingwala, Masina II, Mont Ngafula II, Ndjili, Kinshasa, Congo, The Democratic Republic of the|Adjame-Plateau-Attecoube, Abobo Est,Anyama , Koumassi-Port Bouet-Vridi, Treichville-Marcory, Abidjan, Côte D'Ivoire|Sites in Maharashtra State, Telangana State, Andhra Pradesh, Hyderabad, India|Turkana County and Homabay County sites, Nairobi, Kenya|Berea, Maseru, Mageteng, Leribe, Mohale's Hoek sites, Maseru, Lesotho|Central Region, Southern region sites, Dedza, Malawi|Singida, Tabora sites, Singida, Tanzania|Mbarara sites, Mbarara, Uganda|Harare, Manicaland, Matabeleland South, Harare, Zimbabwe","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT03948698/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03948698"
1124,"NCT04973371","Acceptability and Feasibility of Home-based TB Testing",,"Completed","No Results Available","Tuberculosis, Pulmonary|Households","Diagnostic Test: Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test","Acceptability of home-based TB testing|Feasibility of home-based TB testing|Proportion of referral uptake|Time to clinic presentation|Time-to-treatment initiation|Proportion initiating treatment","Foundation for Professional Development (Pty) Ltd|National Institutes of Health (NIH)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Medical Research Council, South Africa|Foundation for Innovative New Diagnostics, Switzerland|University of Witwatersrand, South Africa|University of California, Irvine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","98","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","R21EB023679","July 1, 2018","May 31, 2019","June 30, 2019","July 22, 2021",,"July 22, 2021","Buffalo City Metro, East London, Eastern Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04973371"
1125,"NCT04655794","Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment",,"Unknown status","No Results Available","Adverse Reaction to Drug|3HP","Drug: 3HP","sTREM1 between >= grade 2 adverse reaction (SAR group) and< grade 2 adverse reaction (Non-SAR group)|sTREM2 between >= grade 2 adverse reaction (SAR group) and< grade 2 adverse reaction (Non-SAR group)","Chang Gung Memorial Hospital","All","20 Years to 100 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201800081B0","April 19, 2018","November 20, 2020","February 12, 2021","December 7, 2020",,"December 7, 2020","Institutional Review Board Chang Gung Medical Foundation, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04655794"
1126,"NCT04526613","The Influence of Malnutrition, Diabetes Mellitus, and Helminth Infections on Biosignatures in Latent Tuberculosis in a South Indian Population",,"Active, not recruiting","No Results Available","Mycobacterium Tuberculosis|LTBI (Latent TB Infection)|Malnutrition|Diabetes Mellitus|Helminth Infections",,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","14 Years to 65 Years   (Child, Adult, Older Adult)",,"626","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999920144|20-I-N144","April 19, 2021","June 25, 2025","June 25, 2025","August 26, 2020",,"October 16, 2023","National Institute for Research In Tuberculosis, International Centers for Exel, Chennai, India",,"https://ClinicalTrials.gov/show/NCT04526613"
1127,"NCT01924286","Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone","Pred-ART","Completed","No Results Available","Immune Reconstitution Inflammatory Syndrome|HIV|Tuberculosis","Drug: Prednisone|Drug: Placebo","Development of paradoxical TB-IRIS|Time to IRIS event|Severity of IRIS events|Duration of TB-IRIS event|Mortality attributed to TB and TB-IRIS|All-cause mortality|Composite endpoint of death, hospitalization, or hepatotoxicity (using the protocol-specified definition of Grade 3 or 4 increase in ALT or bilirubin)|Other (non-TB) IRIS events|Adverse events and severe adverse events ascribed to TB treatment, ART or co-trimoxazole|Discontinuation of either ART or TB treatment for > 5 days due to adverse events|Number of hospitalizations|Corticosteroid-associated adverse events, classified by severity and relation to study drug|Laboratory safety data: Glucose|Other infections (AIDS-related, bacterial, fungal and viral) and malignancies (Kaposi's sarcoma)|All grade 1, 2, 3 and 4 adverse events (clinical and laboratory using the ACTG grading system)|Total number of days hospitalised|Laboratory safety data: Haemoglobin|Laboratory safety data: White cell count|Laboratory safety data: Serum sodium|Laboratory safety data: Serum potassium","University of Cape Town|Institute of Tropical Medicine, Belgium|Imperial College London|European and Developing Countries Clinical Trials Partnership (EDCTP)|Department of Science and Technology, South Africa","All","18 Years and older   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CIDRI_001|SP.2011.41304.074|DOH-27-0813-4336","August 30, 2013","April 2016","April 2017","August 16, 2013",,"January 19, 2018","Site B Khayelitsha HIV/TB clinic, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT01924286"
1128,"NCT03315962","Simplified Isoniazid Preventive Therapy Strategy to Reduce TB Burden","SEARCH-IPT","Completed","No Results Available","Tuberculosis|HIV/AIDS","Behavioral: SPIRIT Intervention","IPT Uptake","University of California, San Francisco|Makerere University|National Institute of Allergy and Infectious Diseases (NIAID)|Cipla Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","468","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-21030|R01AI125000","November 15, 2017","November 30, 2023","November 30, 2023","October 20, 2017",,"January 8, 2024","Infectious Diseases Research Collaboration, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT03315962"
1129,"NCT04513379","Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients",,"Unknown status","No Results Available","HIV Infections|Tuberculosis","Drug: Efavirenz 600mg|Drug: Efavirenz 400mg","Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/Milliliter at Week 48 Using the US Food and Drug Administration (FDA) Snapshot Algorithm|Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/Milliliter at Week24 Using the US Food and Drug Administration (FDA) Snapshot Algorithm|Percentage of Participants Without Confirmed Virologic Withdrawal and Without Discontinuation Due to Treatment-related Reasons at Week 24 and Week 48|Number of Participants With Tuberculosis (TB) Associated Immune Reconstitution Inflammatory Syndrome (IRIS)","Shanghai Public Health Clinical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDOSE","November 1, 2020","October 30, 2022","January 31, 2023","August 14, 2020",,"August 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04513379"
1130,"NCT04466488","Prevent TB: Choice Architecture for TPT Delivery",,"Completed","No Results Available","HIV/AIDS|Tuberculosis","Behavioral: Choice Architecture","Proportion of patients newly starting ART also initiating TPT|Proportion of established ART patients also initiating TPT|Proportion of TPT-eligible patients newly starting ART also initiating TPT|Proportion of TPT-eligible established ART patients also initiating TPT|Proportion of patients started on TPT with subsequent discontinuation|Clinic implementation of choice architecture as assess by adoption|Clinic implementation of choice architecture as assessed by fidelity|Patient characteristics associated with initiating and adhering to TPT as assessed by clinical record review|Patient characteristics associated with initiating and adhering to TPT as assessed by a structured quantitative interview","Johns Hopkins University|University of Witwatersrand, South Africa|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research","IRB00231219|R01AI150432","September 15, 2021","August 1, 2023","November 22, 2023","July 10, 2020",,"February 20, 2024","Perinatal HIV Research Unit, Soweto, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT04466488"
1131,"NCT04466293","Choice Architecture Based TB Preventive Therapy Prescribing","CAT","Completed","No Results Available","HIV/AIDS|Tuberculosis","Behavioral: Choice Architecture","Proportion of PWH initiating ART who are prescribed 3HP (or IPT)|Proportion of established ART patients who are prescribed 3HP or IPT|Proportion of all unique HIV patients during study period prescribed 3HP or IPT|Proportion completing TPT among those initiating 3HP or IPT|Adverse events among TPT recipients and non-TPT recipients|Number of TB cases diagnosed among individuals on TPT|Clinician fidelity of choice architecture implementation as assessed by file review|Clinician fidelity of choice architecture implementation as assessed by provider discussions|Clinician acceptability of choice architecture implementation as assessed by in-depth interviews with providers","Johns Hopkins University|KNCV Tuberculosis Foundation|Clinton Health Access Initiative, Zimbabwe|Aurum Institute","All","Child, Adult, Older Adult","Not Applicable","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research","IRB00227388","March 29, 2021","October 31, 2022","October 31, 2022","July 10, 2020",,"November 17, 2022","KNCV Tuberculosis Foundation, Lilongwe, Malawi|Aurum Institute, Maputo, Mozambique|Clinton Health Access Initiative, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT04466293"
1132,"NCT04463680","Rifampin and the Contraceptive Implant",,"Completed","Has Results","Contraception|Tuberculosis","Drug: Rifampin 600 MG","Serum Etonogestrel Concentrations","University of Colorado, Denver|Merck Sharp & Dohme LLC","Female","18 Years to 45 Years   (Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19-2829","September 23, 2020","February 22, 2022","February 22, 2022","July 9, 2020","May 9, 2023","May 16, 2023","University of Colorado Denver, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/80/NCT04463680/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04463680"
1133,"NCT02980016","Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals","WHIP3TB","Completed","No Results Available","Tuberculosis|HIV","Drug: rifapentine + isoniazid|Drug: Isoniazid","Treatment completion (part A)|TB incidence (part B)|TB incidence (part A)|All-cause mortality (part A)|Permanent discontinuation of therapy due to treatment-related adverse events (part A)|Treatment completion (part B)|All-cause mortality (part B)|Permanent discontinuation of therapy due to treatment-related adverse events (part B)|Cost per TB case prevented|Cost per death averted|Cost per disability adjusted life year (DALY) averted by study arm","The Aurum Institute NPC|Aurum Institute|London School of Hygiene and Tropical Medicine|Johns Hopkins University","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","4027","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","3HP-AUR1-1-170","November 2016","October 18, 2019","October 18, 2019","December 2, 2016",,"October 30, 2019","The Aurum Institute NPC, Johannesburg, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT02980016"
1134,"NCT02043080","Optimizing Clinical Outcomes in HIV-Infected Adults & Children",,"Completed","No Results Available","Tuberculosis Diagnosis|HIV","Other: Xpert MTB/RIF Tuberculosis diagnostic tool","Proportions of adult and paediatric patients receiving appropriate TB treatment in each study phase|Clinical outcomes of subjects screened using the Xpert MTB/RIF algorithm compared to existing standard of care.","University of North Carolina, Chapel Hill|Centers for Disease Control and Prevention","All","up to 99 Years   (Child, Adult, Older Adult)","Not Applicable","1436","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-1402","August 2012","March 2016","April 2017","January 23, 2014",,"August 3, 2017","Centre for Infectious Disease Research in Zambia, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT02043080"
1135,"NCT04166474","Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin","DoRIS","Active, not recruiting","No Results Available","Hiv|Tuberculosis","Drug: Dolutegravir","Change in pharmacokinetic parameter Cmin of dolutegravir|Change in pharmacokinetic parameter AUC of dolutegravir|Change in pharmacokinetic parameter Cmax of dolutegravir|Number of participants with Grade 3 and above adverse events as assessed by DAIDS (corrected v2.1 July 2017)","Helen Reynolds|Infectious Disease Institute, Kampala, Uganda|Desmond Tutu HIV Centre|University of Liverpool","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UoL001452","November 18, 2021","January 2024","April 2024","November 18, 2019",,"November 13, 2023","Desmond Tutu Health Foundation, Cape Town, South Africa|Infectious Diseases Institute, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04166474"
1136,"NCT04121195","Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load","DERIVE","Active, not recruiting","No Results Available","HIV/AIDS|Tuberculosis","Drug: Dose escalation","Plasma Cmax of ritonavir-boosted Atazanavir|Plasma AUC of ritonavir-boosted Atazanavir|Plasma Clearance of ritonavir-boosted Atazanavir|Intracellular clearance of ritonavir-boosted Atazanavir|Plasma Cmax of ritonavir-boosted Atazanavir when given with 1200mg rifampicin|Plasma AUC of ritonavir-boosted Atazanavir when given with 1200mg rifampicin|Plasma Clearance of ritonavir-boosted Atazanavir when given with 1200mg rifampicin|Intracellular concentration of ritonavir-boosted atazanavir|Intracellular concentration of DTG|Intracellular concentration of RIF|Grade 3 adverse events (by DAIDS)","University of Liverpool|European and Developing Countries Clinical Trials Partnership (Funder)|Joint Clinical Research Centre, Kampala, Uganda|University of Cape Town, Cape Town, South Africa|Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda|University of Turin, Turin, Italy","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","28","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DERIVE","October 30, 2020","May 20, 2022","August 20, 2023","October 9, 2019",,"August 9, 2022","Joint Clinical Research Centre, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04121195"
1137,"NCT03947138","A Study of GC3107(BCG Vaccine) in Healthy Infants",,"Completed","No Results Available","BCG Vaccination Reaction|Tuberculosis","Biological: GC3107|Biological: Intradermal BCG SSI inj.","Proportion of subjects with maximum diameter of induration ≥ 5mm in the tuberculin skin test|Proportion of subjects with maximum diameter of induration <5mm, ≥ 5mm to <10mm and ≥10mm in the tuberculin skin test|Proportion of subjects with maximum diameter of erythema ≥ 5mm in the tuberculin skin test","Green Cross Corporation|GC Biopharma Corp","All","up to 4 Weeks   (Child)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","GC3107_P3","August 6, 2019","June 20, 2022","September 6, 2022","May 13, 2019",,"November 2, 2022","The Catholic Universitiy of Korea St. vincent's Hospital, Suwon, Korea, Republic of|Greencross, Yongin, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03947138"
1138,"NCT03923231","Pharmacokinetics of Atazanavir in Special Populations","VirTUAL WP5","Completed","No Results Available","HIV/AIDS|Tuberculosis","Drug: Atazanavir 300mg/ Ritonavir 100 mg once daily|Drug: Atazanavir 250 mg / ritonavir 80 mg","Atazanavir Cmax|Atazanavir AUC0-24|Atazanavir Ctau|Comparison of geometric mean of atazanavir Cmax with healthy adult population|Comparison of geometric mean of atazanavir AUC0-24 with healthy adult population|Comparison of geometric mean of atazanavir Ctau with healthy adult population","University of Liverpool|Infectious Diseases Institute, Makerere University College of Health Sciences|Joint Clinical Research Centre- Kampala|Desmond Tutu HIV Foundation|University of Cape Town|European and Developing Countries Clinical Trials Partnership (EDCTP) - funder","All","Child, Adult, Older Adult",,"32","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VirTUAL WP5","September 2, 2019","May 1, 2020","November 30, 2022","April 22, 2019",,"May 9, 2023","Desmond Tutu HIV Foundation, Cape Town, Western Cape, South Africa|University of Cape Town, Cape Town, Western Cape, South Africa|Infectious Diseases Institute, Kampala, Uganda|Joint Clinical Research Centre, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT03923231"
1139,"NCT00523458","A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV","OPTI-NNRTI","Terminated","No Results Available","HIV Infections|Tuberculosis","Drug: efavirenz or nevirapine","Decline in HIV RNA in plasma Rise in CD4 cell count","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 4","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Stanford Protocol ID: 95564","July 2007","March 2008","March 2008","August 31, 2007",,"July 22, 2011","Hospital Universitario Prof. Edgard Santos/Universidade Federal da Bahia, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT00523458"
1140,"NCT04972903","Impact of Malnutrition on Pharmacokinetic or Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children","TB-Speed TB-PK","Unknown status","No Results Available","Tuberculosis|Pulmonary",,"Effect of SAM on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB|Effect of SAM on minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB|Effect of SAM on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB|Effect of HIV-infection and antiretroviral treatment on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM|Effect of HIV-infection and antiretroviral treatment on Minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM|Effect of HIV-infection and antiretroviral treatment on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM|WHO-based dosages will achieve rifampicin, isoniazid, pyrazinamide, and ethambutol drug concentrations above the target therapeutic concentrations in HIV-TB co-infected children with and without SAM|Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on CL/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB|Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on V/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB|Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on Ka of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB|Relationship between all-cause mortality in children with TB and SAM, and Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.|Relationship between all-cause mortality in children with TB and SAM, and the minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.|Relationship between all-cause mortality in children with TB and SAM, and Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.|Rifampicin protein binding in relation with malnutrition and albuminemia","Institut National de la Santé Et de la Recherche Médicale, France|National Agency for Research on AIDS and Viral Hepatitis (ANRS)","All","6 Months to 5 Years   (Child)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-17","August 2021","December 2022","December 2022","July 22, 2021",,"July 22, 2021","Mulago National Referral Hospital, Kampala, Uganda|Mbarara Regional Hospital, Mbarara, Uganda|The University Teaching Hospital, Lusaka, Zambia|Arthur Davison Children Hospital, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT04972903"
1141,"NCT02508610","DNA Sequencing of MDR TB in Eastern Siberia",,"Unknown status","No Results Available","Tuberculosis|HIV",,"TB drug-susceptibility testing|The proportion of patients below the expected Cmax range|The proportion of patients below the expected AUC range|Correlation of Cmax with the primary outcome|Correlation of AUC with the primary outcome","University of Virginia","All","15 Years and older   (Child, Adult, Older Adult)",,"630","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","17142","November 2013","November 2018","November 2018","July 27, 2015",,"May 12, 2016","Institute of Epidemiology & Microbiology of Scientific Center, Timiryazeva, Irkutsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02508610"
1142,"NCT03199690","A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers","RADIO","Unknown status","No Results Available","HIV-1-infection|Tuberculosis","Drug: Dolutegravir|Drug: Rifampicin","To investigate the pharmacokinetics of DTG 50 or 100 mg OD in the presence of RIF 600 mg OD in healthy volunteers as measured by trough concentration (Ctrough)|To investigate the pharmacokinetics of DTG 50 or 100 mg OD in the presence of RIF 600 mg OD in healthy volunteers as measured by maximum observed plasma concentration (Cmax)|To investigate the pharmacokinetics of DTG 50 or 100 mg OD in the presence of RIF 600 mg OD in healthy volunteers as measured by elimination half-life (t1/2)|To investigate the pharmacokinetics of DTG 50 or 100 mg OD in the presence of RIF 600 mg OD in healthy volunteers as measured by time point at Cmax (Tmax)|To investigate the pharmacokinetics of DTG 50 or 100 mg OD in the presence of RIF 600 mg OD in healthy volunteers as measured by total drug exposure.","St. Stephens Clinical Research|St Stephens Aids Trust","All","18 Years to 60 Years   (Adult)","Phase 1","16","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SSCR103","October 2017","March 2018","March 2018","June 27, 2017",,"October 23, 2017",,,"https://ClinicalTrials.gov/show/NCT03199690"
1143,"NCT03154320","A Trial of Same-Day Testing and Treatment to Improve Outcomes Among Symptomatic Patients Newly Diagnosed With HIV",,"Completed","No Results Available","HIV/AIDS|Tuberculosis","Other: Same-Day Treatment|Other: Standard treatment","Retention in care with viral suppression|Mortality|Mean treatment cost per participant|Viral suppression|Adherence by medication possession ratio|Adherence by 3-day self-report|Treatment failure|TB testing characteristics|Time in clinic|Coping with HIV diagnosis|Connectedness to Treatment Setting|TB diagnosis after ART initiation|Incidence of immune reconstitution inflammatory syndrome (IRIS)|Adverse events|Measure of hope and optimism|Patient satisfaction|Time to death|Last missed dose of medication","Brigham and Women's Hospital|Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic|Weill Medical College of Cornell University|Florida International University|University of California, Davis|Analysis Group, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AI131998","November 6, 2017","April 16, 2021","April 16, 2021","May 16, 2017",,"September 9, 2022","GHESKIO, Port-au-Prince, Haiti",,"https://ClinicalTrials.gov/show/NCT03154320"
1144,"NCT02127983","Engaging Informal Health Care Providers on Case Detection and Treatment Initiation Rates for TB and HIV in Rural Malawi (Triage Plus)","Triage","Completed","No Results Available","Tuberculosis|HIV","Behavioral: Early intervention|Behavioral: Delayed intervention","TB and HIV treatment initiation|TB and HIV diagnostic uptake rates.","Liverpool School of Tropical Medicine|Research for Equity And Community Health REACH Trust|Ministry of Health and Population, Malawi|LHL International Tuberculosis Foundation|University of Warwick","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","200000","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","TriagePlus","January 2009","December 2011","December 2012","May 1, 2014",,"May 1, 2014","REACH Trust, Lilongwe, Malawi",,"https://ClinicalTrials.gov/show/NCT02127983"
1145,"NCT03800381","Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet",,"Recruiting","No Results Available","Tuberculosis|Human Immunodeficiency Virus|Coinfection","Other: Observational PK study","Peak concentration (Cmax) of isoniazid, rifampin and pyrazinamide in the new pediatric HRZ FDC tablet.|Area under the time-concentration curve from 0-8 hours (AUC0-8h) of isoniazid, rifampin and pyrazinamide in the new pediatric HRZ FDC tablet.|Cmax of isoniazid, rifampin and pyrazinamide in children with TB with and without HIV coinfection|AUC0-8h of isoniazid, rifampin and pyrazinamide in children with TB with and without HIV coinfection.|AUC0-8h of isoniazid, rifampin and pyrazinamide in the new versus old pediatric HRZ FDC tablet.|Cmax of isoniazid, rifampin and pyrazinamide in the new versus old pediatric HRZ FDC tablet.|Proportion of children treated with new pediatric HRZ FDC tablet who develop with liver enzymes elevations.|Identify optimal weight-band dosages of the new HRZ FDC tablet","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 14 Years   (Child)",,"92","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201801820 - HRZ PK -N|5R01HD071779-11","January 28, 2019","August 31, 2024","August 31, 2024","January 11, 2019",,"December 7, 2023","Kwame Nkrumah University of Science and Technology, Kumasi, Ghana",,"https://ClinicalTrials.gov/show/NCT03800381"
1146,"NCT02013245","Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.","MTBVAC","Completed","Has Results","Tuberculosis|Healthy","Biological: MTBVAC live vaccine|Biological: Commercially available BCG live vaccine","Number of Participants With Adverse Events up to 210 Days After Vaccination|Number of Participants With Three-cytokine-positive CD4+ T-cell Response","Biofabri, S.L|Universidad de Zaragoza|Centre Hospitalier Universitaire Vaudois|TuBerculosis Vaccine Initiative","All","18 Years to 45 Years   (Adult)","Phase 1","36","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MTBVAC-01","January 2013","June 2014","November 2014","December 17, 2013","March 24, 2017","March 24, 2017","Centre Hospitalier Universitaire Vaudois, Lausanne, Canton of Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT02013245"
1147,"NCT02654613","Scaling up TB and HIV Treatment Integration","SUTHI","Completed","No Results Available","HIV|Tuberculosis","Other: Quality Improvement Model of Care","Mortality|HIV testing rates|Intensified Case Finding for TB|Cotrimoxazole for HIV-TB patients|Retention in HIV-TB patients|ART initiation in HIV-TB co-infected patients|Integrated Data Management System|HIV and TB Adherence Strategy","Centre for the AIDS Programme of Research in South Africa|BroadReach Health Care|Institute for Healthcare Improvement","All","Child, Adult, Older Adult","Not Applicable","8000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CAP013","June 1, 2015","December 30, 2020","December 30, 2020","January 13, 2016",,"February 1, 2021","CAPRISA eThekwini Clinical Research Site, Durban, KwaZulu Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT02654613"
1148,"NCT01699633","Rifampin and Nevirapine Interactions in Young Children",,"Unknown status","No Results Available","Tuberculosis|HIV",,"Area under time curve (AUC) of nevirapine|Number of children with grade 3 or 4 liver enzymes elevations compared to baseline, new onset of skin rash, nausea, vomiting or treatment modification due to drug side effects|Number of children with nevirapine 12-hour post-dose concentration (C12h) < 3000 ng/mL|Time to HIV-1 RNA suppression below 50 copies/mL and change in CD4 cell count from baseline|Peak concentration (Cmax) and concentration at 12-hours (C12h) post-dose of nevirapine","The Miriam Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 35 Months   (Child)",,"58","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PK-TBHIV02|R01HD071779","October 2012","May 2017","May 2017","October 4, 2012",,"October 12, 2012","Komfo Anokye Teaching Hospital, Kumasi, Ghana",,"https://ClinicalTrials.gov/show/NCT01699633"
1149,"NCT01156623","Endobronchial Ultrasound Guided Transbronchial Aspiration (EBUS-TBNA) in Non Small Cell Lung Cancer (NSCLC) in a Tuberculosis-endemic Country",,"Completed","No Results Available","Non-small Cell Lung Cancer","Procedure: EBUS-TBNA","Diagnostic accuracy","Chang Gung Memorial Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","98-3639A3","June 2010","October 2012","August 2013","July 5, 2010",,"February 12, 2015","Chang Gung Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01156623"
1150,"NCT01637558","Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)","DATiC","Completed","No Results Available","Tuberculosis|HIV","Drug: 8 hourly LPV/r during TB treatment|Drug: Nevirapine|Drug: Lopinavir/Ritonavir","Area under the concentration time curve (AUC) for rifampicin, isoniazid, pyrazinamide, ethambutol, lopinavir and nevirapine","University of Cape Town|Liverpool School of Tropical Medicine|Uppsala University|University of North Carolina","All","1 Month to 12 Years   (Child)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DATiC","November 2012","July 31, 2017","July 31, 2017","July 11, 2012",,"October 27, 2017","Queen Elizabeth Central Hospital, Blantyre, Malawi|Red Cross Childrens Hospital, Cape Town, Western Cape, South Africa|KIDCRU, Tygerberg Hospital, Department of Paediatrics and Child Health, Stellenbosch University, South Africa., Cape Town, Western Cape, South Africa|Desmond Tutu Centre, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT01637558"
1151,"NCT02415985","Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly",,"Completed","No Results Available","HIV|Tuberculosis","Drug: Lopinavir/r will be supplied by NHSO/GPO|Drug: Rifabutin","pharmacokinetics of rifabutin Cmax|adverse events|viral load|CD4|Monodrug resistant TB|death|AIDS event|TB cure|TB relapse|Multidrug-resistant TB (MDR TB)|TB treatment failure|Extensively drug resistant TB (XDR TB)|weight gain|defervescence|Karnofsky score","The HIV Netherlands Australia Thailand Research Collaboration|Bamrasnaradura Infectious Diseases Institute|Chulalongkorn University","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","HIV-NAT 116","June 2015","December 2019","December 2019","April 14, 2015",,"February 12, 2020","Chest Division, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand|HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok, Thailand|Infectious Diseases, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand|Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand",,"https://ClinicalTrials.gov/show/NCT02415985"
1152,"NCT01344148","Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.",,"Unknown status","No Results Available","AIDS","Drug: INH RIF Rifb PZA EMB AZT 3TC D4T EFV","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Patients long-term survival.","Shanghai Public Health Clinical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008ZX10001-008","February 2009","June 2011","June 2013","April 28, 2011",,"April 28, 2011","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01344148"
1153,"NCT00695734","Detection of Latent Tuberculosis in Hemodialysis Patients",,"Completed","No Results Available","Chronic Renal Failure",,"Relative performance of tuberculin skin test and interferon gamma release assays for detecting latent tuberculosis infection|Agreement between tuberculin skin test and interferon gamma release assays as well as agreement between interferon gamma release assays","University Hospital, Geneva|Ligue Pulmonaire Genevoise","All","18 Years and older   (Adult, Older Adult)",,"62","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","JJanssens 4","January 2007","January 2008","January 2008","June 12, 2008",,"June 12, 2008","Geneva University Hospital, Geneva, Geneva 14, Switzerland",,"https://ClinicalTrials.gov/show/NCT00695734"
1154,"NCT01061593","Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV",,"Completed","No Results Available","Tuberculosis|HIV","Dietary Supplement: Immunoxel|Other: Placebo","To compare the efficacy of combination of Immunoxel with anti-TB treatment versus anti-TB treatment with placebo in adults with sputum smear positive pulmonary tuberculosis|To confirm the safety of Immunoxel as demonstrated by Liver functions tests (ALT and bilirubin) and hemoglobin; effect on TB-associated wasting by measuring body weight. Effect on lymphocytes and CD4+ cells, CD4/CD8 ratio among those who have HIV.","Lisichansk Regional Tuberculosis Dispensary|Ekomed LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","269","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LRTBD-2259","January 2010","March 2015","April 2015","February 3, 2010",,"May 20, 2015","Misheel Lung surgery hospital,, Ulaanbaatar, Ulaanbaatar region, Mongolia|Kharkiv Medical National University, Kharkiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01061593"
1155,"NCT01751568","Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB",,"Completed","Has Results","HIV Infections|Tuberculosis","Drug: Raltegravir","Number of Participants Who Permanently Discontinued Treatment Due to Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir|Number of Participants Who Experienced Death, Grade 4 Life-threatening Adverse Events Deemed at Least Possibly Related to Raltegravir|Number of Participants Who Experienced Grade 4 Non-life Threatening Adverse Event(s) Deemed as Probably or Definitely Related to Raltegravir|Number of Participants Who Experienced Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir|Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC12h)|Pharmacokinetic (PK) Parameter: Concentration at 12h (C12)|Number of Participants Who Failed to Respond Virologically at Week 8, Which Means Having HIV RNA (Copies/mL) Greater Than 400 Copies/mL AND Less Than 1-log10 Drop From Baseline|Number of Participants Who Developed of New Opportunistic Infection(s) (OIs)","National Institute of Allergy and Infectious Diseases (NIAID)","All","4 Weeks to 11 Years   (Child)","Phase 1|Phase 2","40","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1101|11831|IMPAACT P1101","November 12, 2014","November 27, 2019","November 27, 2019","December 18, 2012","December 21, 2020","November 5, 2021","Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Cape Town, Western Cape Province, South Africa","""Study Protocol: Version 3.0"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT01751568/Prot_003.pdf|""Study Protocol: Letter of Amendment 1"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT01751568/Prot_004.pdf|""Study Protocol: Letter of Amendment 2"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT01751568/Prot_005.pdf|""Statistical Analysis Plan: Primary Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT01751568/SAP_001.pdf|""Statistical Analysis Plan: Pharmacokinetic Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT01751568/SAP_002.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT01751568/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01751568"
1156,"NCT01704144","Rifampin and Efavirenz Interactions in Older Children",,"Unknown status","No Results Available","HIV|Tuberculosis",,"Area under time curve from time 0-24 hours(AUC0-24h) of efavirenz|Number of children with grade 3 or 4 liver enzymes elevations compared to baseline, new onset of skin rash, nausea, vomiting or treatment modification due to drug side effects|Number of children with efavirenz 24-hour post-dose concentration (C24h) < 1000 ng/mL|Number of children who discontinue efavirenz therapy due to drug side effects|Trough concentration (C24h) of efavirenz|AUC, Cmax and clearance of efavirenz on and off rifampin-containing anti-Tb therapy in HIV/TB co-infected patients","The Miriam Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 14 Years   (Child)",,"160","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PK-PTBHIV03|R01HD071779","October 2012","May 2017","May 2017","October 11, 2012",,"October 17, 2012","Komfo Anokye Teaching Hospital, Kumasi, Ghana",,"https://ClinicalTrials.gov/show/NCT01704144"
1157,"NCT00992069","Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers",,"Completed","No Results Available","Tuberculosis|HIV","Drug: Efavirenz (EFV)|Drug: TMC207","Area under curve (AUC) over 336 hours of TMC207, measured when dosed alone and when dosed together with efavirenz (EFV) 600 mg daily|Signs or symptoms of toxicity ranked Grade 2 or higher, according to the DAIDS adverse event (AE) grading table|Maximum observed plasma or serum concentration (Cmax) and oral clearance (CL/F) of TMC207 and AUC, Cmax, and CL/F of the M2 metabolite of TMC207 when dosed alone and when dosed together with EFV 600 mg daily|AUC over 24 hours, Cmax, Cmin, CL/F, and elimination half-life (T1/2) of EFV and host EFV metabolism genotype status (CYP2B6) obtained from whole blood samples taken at screening|Correlation between AUC over 24 hours of EFV and AUC over 336 hours of TMC207","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","37","NIH","Interventional","Allocation: N/A|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5267|10749|ACTG A5267","December 2009","December 2010","December 2010","October 8, 2009",,"November 1, 2021","Ucsf Aids Crs, San Francisco, California, United States|Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States|Unc Aids Crs, Chapel Hill, North Carolina, United States|The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States|Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00992069"
1158,"NCT01579214","Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda",,"Completed","Has Results","HIV|Tuberculosis","Other: Cellular Phone Text Messages","Participants Initiating Antiretroviral Therapy (ART) Within 28 Days of Abnormal Result|Clinic Return Within 28 Days of Abnormal CD4 Count Result","Massachusetts General Hospital|Mbarara University of Science and Technology|Fogarty International Center of the National Institute of Health|Harvard University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","183","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2011P001538|R24TW007988","July 2012","December 2013","April 2015","April 17, 2012","December 8, 2017","January 4, 2018","ISS Clinic, Mbarara Regional Referral Hospital, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT01579214"
1159,"NCT03702049","Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV","3HP-LTBI","Completed","No Results Available","Latent Tuberculosis Infection","Behavioral: Nurse-led Community Health Worker TBI (RN/CHW TBI) program","Completion of TBI treatment|Drug use|Alcohol use|Depression|Health Care Access|Shelter Stability","University of California, Irvine|University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R21MD012696 [HS# 2018-4698]|R21MD012696","January 24, 2019","May 29, 2020","September 4, 2020","October 10, 2018",,"April 9, 2021","Los Angeles Christian Health Centers (LACHC), Los Angeles, California, United States|Union Rescue Mission, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03702049"
1160,"NCT01424826","The Effect of Intermittent Rifampicin on Raltegravir","RIFRAL","Completed","No Results Available","HIV|Tuberculosis","Drug: Raltegravir|Drug: Rifampicin","Change in raltegravir area under the curve (AUC) 0-12h|Number of participants with adverse events","Helen Reynolds|Liverpool University Hospitals NHS Foundation Trust|University of Liverpool","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UoL000643|2010-021461-73","January 2012","June 2013","July 2013","August 29, 2011",,"October 31, 2013","Royal Liverpool & Broadgreen Univeristy Hospitals NHS Trust, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01424826"
1161,"NCT01677871","Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease",,"Unknown status","No Results Available","Chronic Liver Disease With Tuberclosis","Drug: 2HRZE/4HR|Drug: 2HRLE/4HR|Drug: 9HLE|Drug: 9RLE","Successful completion of modified ATT (ANTI TUBERCULAR TREATMENT) regimen.|Worsening of CTP (CHILD TURCOTTE PUGH) score to ≥10 for patients with compensated cirrhosis,|Failure to re-institute the assigned ATT (ANTI TUBERCULAR TREATMENT) regimen after development of an episode of hepatotoxicity. (I.e. second episode of hepatotoxicity.|Survival","Institute of Liver and Biliary Sciences, India","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILBS-ATT-01","September 2012","September 2014","September 2014","September 3, 2012",,"December 17, 2013","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01677871"
1162,"NCT06281834","Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention",,"Not yet recruiting","No Results Available","Pediatric HIV Infection|Latent Tuberculosis","Drug: Rifapentine|Drug: Dolutegravir","Dolutegravir AUC during weekly rifapentine/isoniazid|Rifapentine AUC|Proportion of participants experiencing severe (grade 3 or 4) clinical or laboratory adverse events","Brigham and Women's Hospital|APIN Public Health Initiatives|University of Cape Town","All","4 Weeks to 11 Years   (Child)","Phase 1","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2024P000306","May 2024","February 2027","June 2027","February 28, 2024",,"February 28, 2024",,,"https://ClinicalTrials.gov/show/NCT06281834"
1163,"NCT00620438","Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients",,"Unknown status","No Results Available","HIV Infections|Tuberculosis","Drug: Lumefantrine-artemether and nevirapine|Drug: lumefantrine-artemether and efavirenz|Drug: Lumefantrine-artemether and rifampicin","Pharmacokinetics of lumefantrine in patients receiving either nevirapine, efavirenz or rifampicin","Makerere University|Health Research Board, Ireland","All","18 Years to 60 Years   (Adult)","Phase 4","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPR 005","February 2008","July 2011","July 2011","February 21, 2008",,"December 6, 2010","Infectious Diseases Institute, Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT00620438"
1164,"NCT00476853","Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: HAART containing nevirapine","Efficacy of nevirapine based HAART 400 mg/day versus 600 mg/day on HIV-1 load as measured by HIV-1 RNA quantification in plasma|Safety and tolerability of nevirapine based HAART 400 mg/day versus 600 mg/day|Nevirapine level at week 2, 4 and 12 and 12 hour PK at week 4 (only 20 patients)|Immune recovery syndrome, adherence, clinical improvement, incidence of new/recurrent AIDS events (CDC class C) between two group|Time to mortality or new/recurrent AIDS events (CDC class C), 1 year mortality rate of TB/HIV patients, emerging of ARV resistant especially nevirapine, emerging of anti-TB resistance","The HIV Netherlands Australia Thailand Research Collaboration|other sponsors:Japanese MOPH|Labor and Welfare|Thai MOPH|Thai GPO|Bamrasnaradura Infectious Diseases Institute|Chiang Rai Hospital|King Chulalongkorn Memorial Hospital|Central General Chest Institute|The Research Institute of Tuberculosis (Japan)","All","18 Years to 60 Years   (Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIV-NAT 033","October 2005","September 2008","December 2009","May 22, 2007",,"July 17, 2020","The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand|Chiangrai Hospital, Chiang Rai, Thailand|Mae Chan Hospital, Chiang Rai, Thailand|Phan Hospital, Chiang Rai, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand|Central Chest Hospital, Nonthaburi, Thailand",,"https://ClinicalTrials.gov/show/NCT00476853"
1165,"NCT00120510","Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Efavirenz|Drug: Lamivudine/Zidovudine","Survival|Safety and drug-associated side effects and toxicities of the study drugs|Pattern and frequency of antiretroviral drug resistance during ART|Occurrence and clinical outcome of opportunistic infections, viral coinfections, and immune reconstitution syndromes observed during ART|TB treatment outcomes in patients with active pulmonary TB at enrollment|Quality of life scores based on self-report questionnaires|Adherence based on self-report questionnaires and dosage count|Cost of therapy|Plasma HIV-1 RNA below limits of quantitation after initiating ART|Absolute CD4 cell count change from baseline in subjects who initiate ART","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","816","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIPRA HT 001|5K24AI051966-03|10403","July 2007","September 2009","September 2009","July 18, 2005",,"October 15, 2014","Les Centres GHESKIO CIPRA CRS, Port au Prince, Haiti",,"https://ClinicalTrials.gov/show/NCT00120510"
1166,"NCT00096850","Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Atazanavir|Drug: Rifampin|Drug: Ritonavir","Pharmacokinetic parameters of ritonavir (RTV)-boosted ATV when administered concurrently with RIF|Safety and tolerability of RTV-boosted ATV when coadministered with RIF|Pharmacokinetics of RIF|Copy number of cellular drug transporter RNA in peripheral blood mononuclear cells (PBMCs)|UDP-glucuronosyltransferase (UGT)-1A1 genotype|Serum bilirubin concentration|urine thromboxane and prostacyclin concentrations","National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group","All","18 Years to 55 Years   (Adult)","Not Applicable","18","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5213|10021|ACTG A5213",,,"December 2007","November 17, 2004",,"November 1, 2021","Stanford CRS, Palo Alto, California, United States|The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States|Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00096850"
1167,"NCT01048697","Effect of Weight and/or Obesity on Ethambutol Drug Concentrations",,"Completed","Has Results","Obesity|Tuberculosis","Drug: Ethambutol","Total Clearance of Ethambutol","Texas Tech University Health Sciences Center|National Center for Research Resources (NCRR)|University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","18","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","TTUHSC 030032|5UL1RR024982-02","January 2010","December 2010","December 2010","January 14, 2010","January 24, 2013","January 24, 2013","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01048697"
1168,"NCT03800407","Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection",,"Recruiting","No Results Available","Tuberculosis|Human Immunodeficiency Virus|Coinfection","Other: Observational study","TB coinfection status and HIV RNA < 200 copies/mL on EFV-based ART in HIV-infected children.|Efavirenz plasma mid-dose concentration and HIV RNA suppression < 200 copies/mL.|Random efavirenz concentration below the limit of detection (poor ART adherence) and HIV RNA suppression rate.|CYP2B6 516G>T genotype status and random efavirenz concentration below the limit of detection (poor ART adherence).|CYP2B6 516G>T genotype status and HIV RNA suppression < 200 copies/mL.|TB coinfection status and risk of virological failure on EFV-based ART.","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 14 Years   (Child)",,"382","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201801820 TB/HIV - N|2R01HD071779|5R01HD071779-10","January 28, 2019","May 31, 2024","November 30, 2024","January 11, 2019",,"May 16, 2023","Kwame Nkrumah University of Science and Technology, Kumasi, Ghana",,"https://ClinicalTrials.gov/show/NCT03800407"
1169,"NCT05342064","Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service","TB_GAPS","Recruiting","No Results Available","Tuberculosis|HIV Coinfection|Tuberculosis Infection","Other: patient-centered TB preventive therapy|Other: TB preventive therapy adherence support","TB screening|TB diagnosis|TPT prevention outcomes|Cost-effectiveness|Proportion of participants selecting 3HP and the proportion selecting 6H when offered a choice within a decentralized model|Proportion of participants completing 6H and the proportion completing 3HP among participants randomized to standard support vs. bidirectional messaging|Proportion of participants initiated on TPT in the control phase vs. the intervention phase|Description of the number of participants with different TB treatment and TPT outcomes at the completion of respective therapies|Number of life years saved through novel TPT approaches|Number of active TB cases averted through novel TPT approaches|Measure the association between participant factors and screening and diagnostic positivity rates|Laboratory turnaround time|Result reporting rate|Time-to-treatment initiation|Diagnostic performance of mask sampling with differing forms of quiet and forced expiration (i.e., talking, singing) against standard approaches of sampling|Compare alternative stool processing techniques and molecular diagnostics/tests of MTB resistance against clinical and microbiologic reference standards|Compare Alere-LAM diagnostic accuracy with that of the SILVAMP-LAM with both spot and early-morning urine samples|Analyze different processing approaches for oral swabs prior to testing by Xpert Ultra vs. other microbiological diagnostic and drug susceptibility tests|Compare clinician read of chest radiograph with point-of-care ultrasound interpretation to determine agreement and additive yield of each method|Prevalence of extrapulmonary TB by means of point of care ultrasound in participants diagnosed with TB|Assess ultrasound inter-reader agreement between hands-on operators|Assess ultrasound inter-reader agreement between hands-on operators AND remote expert reviewers|Compare the proportion of clinician and computer aided detection chest radiograph interpretation with algorithmic approaches against clinical and microbiologic reference standards|Sensitivity of point of care CRP versus the WHO symptom screening|Specificity of point of care CRP versus the WHO symptom screening|Area under the receiver operator curve of point of care CRP versus the WHO symptom screening|Sensitivity of chest radiography versus the WHO symptom screening|Area under the receiver operator curve of chest radiography versus the WHO symptom screening|Specificity of chest radiography versus the WHO symptom screening|Sensitivity of SILVAMP-LAM versus the WHO symptom screening|Area under the curve of SILVAMP-LAM versus the WHO symptom screening|Specificity of SILVAMP-LAM versus the WHO symptom screening|Sensitivity of Xpert Ultra performed on an oral/buccal swab versus Xpert Ultra completed on sputum or gastric aspirate|Specificity of Xpert Ultra performed on an oral/buccal swab versus Xpert Ultra completed on sputum or gastric aspirate|Area under the ROC curve of Xpert Ultra performed on an oral/buccal swab versus Xpert Ultra completed on sputum or gastric aspirate|Sensitivity of Xpert Ultra performed on stool versus Xpert Ultra completed on sputum or gastric aspirate|Specificity of Xpert Ultra performed on stool versus Xpert Ultra completed on sputum or gastric aspirate|Area under the receiver operator curve of Xpert Ultra performed on stool versus Xpert Ultra completed on sputum or gastric aspirate|Sensitivity of LF-LAM versus Xpert Ultra completed on sputum or gastric aspirate|Specificity of LF-LAM versus Xpert Ultra completed on sputum or gastric aspirate|Area under the receiver operator curve of LF-LAM versus Xpert Ultra completed on sputum or gastric aspirate|Sensitivity of Xpert Ultra performed on a gelatin filter removed from a participant's mask versus Xpert Ultra completed on sputum or gastric aspirate|Specificity of Xpert Ultra performed on a gelatin filter removed from a participant's mask versus Xpert Ultra completed on sputum or gastric aspirate|Area under the receiver operator curve of Xpert Ultra performed on a gelatin filter removed from a participant's mask versus Xpert Ultra completed on sputum or gastric aspirate|Sensitivity of point of care ultrasound versus Xpert Ultra completed on sputum or gastric aspirate|Specificity of point of care ultrasound versus Xpert Ultra completed on sputum or gastric aspirate|Area under the receiver operator curve of point of care ultrasound versus Xpert Ultra completed on sputum or gastric aspirate|Sensitivity of Xpert Host Response Cartridge on blood specimen versus Xpert Ultra completed on sputum or gastric aspirate|Specificity of Xpert Host Response Cartridge on blood specimen versus Xpert Ultra completed on sputum or gastric aspirate|Area under the receiver operator curve of Xpert Host Response Cartridge on blood specimen versus Xpert Ultra completed on sputum or gastric aspirate|Sensitivity of chest radiography for TB screening compared to the sensitivity of the WHO symptom screening using the McNemar test|Sensitivity of SILVAMP-LAM for TB screening compared to the sensitivity of the WHO symptom screening using the McNemar test","Baylor College of Medicine|Centers for Disease Control and Prevention|London School of Hygiene and Tropical Medicine|University of Ottawa|University of Stellenbosch","All","Child, Adult, Older Adult","Not Applicable","6500","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","H-51421","July 11, 2023","December 2024","September 2025","April 22, 2022",,"August 16, 2023","Baylor College of Medicine Children's Foundation, Mbabane, Swaziland",,"https://ClinicalTrials.gov/show/NCT05342064"
1170,"NCT03346018","Immunologic Markers for the Differential Diagnosis Between Uveitis-TBC and Uveitis-SARC (TBC-SARC)","TBC-SARC","Unknown status","No Results Available","Uveitis Tuberculous|Uveitis Sarcoid","Diagnostic Test: Analysis of aqueous humor and plasma samples","Identify, in the aqueous humor and in the blood of patients suffering from granulomatous uveitis the presence of immunologic markers that distinguish between uveitis of tuberculous etiology and uveitis by sarcoidosis","Arcispedale Santa Maria Nuova-IRCCS","All","18 Years to 90 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017/0103969","November 3, 2017","August 30, 2021","December 30, 2021","November 17, 2017",,"July 14, 2020","IRCCS/AUSL Reggio Emilia Hospital, Reggio Emilia, Italy",,"https://ClinicalTrials.gov/show/NCT03346018"
1171,"NCT04482231","Antibiotic Observatory for Respiratory Diseases, Apart From Tuberculosis and Reportable Diseases","AORD","Completed","No Results Available","Antibiotic Sore Tongue",,"Appropriateness of antibiotic prescription|inappropriatness of antibiotic prescription|international recommendations|patients profile with inappropriate antibiotic therapy|patients profile with infectious disease","University of Monastir","All","18 Years to 90 Years   (Adult, Older Adult)",,"9944","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","BAROMETRE","January 2, 2018","August 31, 2018","August 31, 2018","July 22, 2020",,"July 22, 2020","Emergency department of fattouma bourguiba university hospital, Monastir, Tunisia",,"https://ClinicalTrials.gov/show/NCT04482231"
1172,"NCT06306430","Detection of Lipoarabinomannan in Urine Evaluation of the STANDARDTMF TBLAMFIA and Its Impact on the Initial TB Diagnosis","uLAMTBFIA","Not yet recruiting","No Results Available","Tuberculosis|Diagnoses Disease","Device: STANDARDTM F TB LAM FIA","Evaluate the diagnostic performance of a new test based on the detection of lipoarabinomannan (LAM) antigen in human urine using immunoassay|Exploratory Objectives Evaluate if the test can be used as marker of treatment response (only for PTB subjects)","Ospedale San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"550","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","uLAM TB FIA","April 2024","October 2024","October 2025","March 12, 2024",,"March 12, 2024","Emerging Bacterial Pathogens Unit, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT06306430"
1173,"NCT03800394","Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents",,"Recruiting","No Results Available","Human Immunodeficiency Virus (HIV)|Tuberculosis|Coinfection","Other: Observational PK study","Average concentration (Cav) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.|Area under the time-concentration curve 0-24 hours (AUC0-24h) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.|Cav of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.|AUC0-24h of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.|Effect of age on TFV-DP and FTC-TP Cav.|Effect of age on TFV-DP and FTC-TP AUC0-24h .|Intracellular TFV-DP and FTC-TP Cav in adolescents compared to that in historical adult controls.|Intracellular TFV-DP and FTC-TP AUC0-24h in adolescents compared to that in historical adult controls.|Relationship between Adenosine triphosphate (ATP)-binding cassette subfamily C, member 2 (ABCC2), member 4 (ABCC4) and member 10 (ABCC10) SNPs and TFV-DP and FTC-TP AUC0-24h.|Prevalence and covariates of intracellular TFV-DP Cav < 95 fmol/106 cells in adolescents.","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 19 Years   (Child, Adult)",,"382","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB201801820 - PKAdol|2R01HD071779","January 28, 2019","August 31, 2024","August 31, 2024","January 11, 2019",,"December 7, 2023","Kwame Nkrumah University of Science and Technology, Kumasi, Ghana",,"https://ClinicalTrials.gov/show/NCT03800394"
1174,"NCT02768909","Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB",,"Unknown status","No Results Available","Tuberculosis, Pulmonary|e-Nose","Device: E-Nose|Other: Survey & Physical Exam|Other: Chest X-ray|Other: Sputum Samples|Device: Follow Up 5 days after beginning of Tx.|Device: Follow Up 15 days after beginning of Tx.|Device: Follow Up 30 days after beginning of Tx.|Device: Follow Up 60 days after beginning of Tx.","Diagnostic Accuracy of the electronic nose signal value to differentiate patients with Pulmonary TB.|Average Days needed to observed a negative result with the device after initiation of treatment.|Number of Adverse Effects related to the used of the device, assess by the CTCAE","Universidad Central de Venezuela|The ENose Company, Zutphen, Netherlands|Foundation for Research in Mycobacteria (FUNDAIM)","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EN001","January 2015","December 2016","February 2017","May 11, 2016",,"May 11, 2016","Instituto de Biomedicina, Caracas, DC, Venezuela",,"https://ClinicalTrials.gov/show/NCT02768909"
1175,"NCT03821285","Respiratory Function in Patients With Post-tuberculosis Lung Impairment",,"Unknown status","No Results Available","Lung Diseases, Obstructive|Pulmonary Rehabilitation|Lung TB","Procedure: Pulmonary Rehabilitation","6-min walking test|dyspnoea|muscle fatigue|health related quality of life|health status","Università degli Studi dell'Insubria|Fondazione Salvatore Maugeri|Azienda Ospedaliero Universitaria di Sassari|Instituto Nacional de Enfermedades Respiratorias","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2215CE","February 14, 2019","July 31, 2020","January 14, 2021","January 29, 2019",,"January 29, 2019","ICS Maugeri, IRCCS, Tradate, Varese, Italy",,"https://ClinicalTrials.gov/show/NCT03821285"
1176,"NCT04938596","Airborne Preventive Measures to Reduce New TB Infections in Household Contacts","TBMask","Recruiting","No Results Available","Tuberculosis, Pulmonary|Household Contacts|Tuberculosis","Combination Product: Respiratory bundle","Participation rate|Study compliance|Completion rate|Acceptability of the intervention|New tuberculosis infections","Pontificia Universidad Catolica de Chile|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile|Agencia Nacional de Investigación y Desarrollo","All","Child, Adult, Older Adult","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1211225","October 4, 2021","March 2024","August 2024","June 24, 2021",,"November 18, 2023","Pontificia Universidad Católica de Chile, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT04938596"
1177,"NCT03785106","Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals",,"Active, not recruiting","No Results Available","HIV-infected Participants With Latent TB Infection in High TB Burden Country","Drug: Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)|Drug: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)","efficacy in preventing active TB (proportion of participants that do not have active TB by the end of the study)|safety of the regimens (proportion of participants that do not have any side effects throughout the study period)|tolerability to the regimens (proportion of participants that can complete the treatment course)|prevalence of drug resistance of MTB|severity of the condition|presence of symptoms|level of CBC|level of ALT|level of AST|level of total bilirubin|level of ALK|level of creatinine|death|when TB culture becomes positive|when TB is confirmed by clinical examination|adherence to LTBI treatment|consistency of taking LTBI treatment|treatment discontinuation|discontinuation of study due to adverse drug reactions|CD4 count|CD4 count to confirmed or probable TB|time it takes for TB to be confirmed by IGRA|TST result at baseline","The HIV Netherlands Australia Thailand Research Collaboration|King Chulalongkorn Memorial Hospital|Police General Hospital|Pranangklao Hospital|Taksin Hospital|Bhumibol Adulyadej Hospital|Klang Hospital|Chiang Rai Prachanukroh Hospital|Sanpatong Hospital|Queen Sawang Vadhana Memorial Hospital|Buddhachinnaraj Hospital|Maharat Nakhon Ratchasima Hospital|HatYai Hospital|Srinagarind Hospital, Khon Kaen University|Sisaket Hospital|The Public Health Centre 28 Krung thon buri","All","18 Years and older   (Adult, Older Adult)","Phase 3","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HIV-NAT 255","August 15, 2019","March 2038","March 2038","December 24, 2018",,"February 28, 2024","Klang Hospital, Bangkok, Thailand|Bhumibol Adulyadej Hospital, Bangkok, Thailand|HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Police General Hospital, Bangkok, Thailand|Taksin Hospital, Bangkok, Thailand|the Public Health Centre 28 Krung thon buri, Bangkok, Thailand|Sanpatong Hospital, Chiang Mai, Thailand|Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand|Queen Savang Vadhana Memorial Hospital, Chon Buri, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand|Pranangklao Hospital, Nonthaburi, Thailand|Buddhachinnaraj Hospital, Phitsanulok, Thailand|Sisaket Hospital, Sisaket, Thailand|Hatyai Hospital, Songkhla, Thailand",,"https://ClinicalTrials.gov/show/NCT03785106"
1178,"NCT00491933","Quantiferon-TB Gold in the Assessment of Latent TB in Patients Candidate to Treatment or Treated With TNFα Antagonists","TNFTB","Unknown status","No Results Available","Rheumatoid Arthritis|Spondylarthritis|Tuberculosis","Procedure: Quantiferon-TB Gold assay|Procedure: Tuberculin skin test","Concordance between the QFT-G assay and the tuberculin skin test|Correlation of the test results to the patient's risk of LTBI|Factors associated with discordance between the TST and the QFT-G test|Frequency of indeterminate results","ASST Fatebenefratelli Sacco","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HS-RHEU-2007-001","June 2007",,"October 2007","June 26, 2007",,"June 26, 2007","Rheumatology Unit, Ospedale L. Sacco Polo Universitario, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT00491933"
1179,"NCT05845112","Start Taking Action For TB Diagnosis","START4ALL","Not yet recruiting","No Results Available","Diagnosis|Tuberculosis","Diagnostic Test: Molecular Diagnostics|Diagnostic Test: Qualitative C-Reactive Protein (CRP)|Diagnostic Test: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP|Diagnostic Test: Urine lateral flow tests|Diagnostic Test: Portable Chest X Ray Image Acquisition","Primary study endpoint|Secondary study endpoint (1)|Secondary study endpoint (2)","Liverpool School of Tropical Medicine","All","1 Year and older   (Child, Adult, Older Adult)",,"15300","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","22-084","September 2023","October 2024","October 2026","May 6, 2023",,"May 6, 2023",,,"https://ClinicalTrials.gov/show/NCT05845112"
1180,"NCT05036694","Diagnostic Performance of a Novel Lipoarabinomannan.","FUJILAM","Unknown status","No Results Available","HIV Primary Infection","Device: FUJILAM KIT","To investigate the diagnostic performance of FujiLAM in ambulatory HIV positive patients.|To assess the sensitivity of FujiLAM at different levels of CD4 count.","Médecins Sans Frontières, Kenya|Epicentre","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","550","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ANRS12429","September 2021","September 2022","December 2022","September 8, 2021",,"September 8, 2021",,,"https://ClinicalTrials.gov/show/NCT05036694"
1181,"NCT00424684","Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation",,"Withdrawn","No Results Available","Chronic Liver Disease|TB","Procedure: collection of blood sample","To assess the concordance between the QFT-G IT assay and the TST in patients with end stage liver disease awaiting liver transplantation and to relate the test results to the patient's risk of latent TB infection.|To assess the factors that are associated with discordance between the TST and the QFT-G test|To assess for laboratory parameters that may influence the QFT-G IT assay, such as lymphocyte count and liver function tests.|To assess the frequency of anergy in this patient population.","University of Pittsburgh|Cellestis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB#0611163","January 2007",,,"January 19, 2007",,"May 7, 2020","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00424684"
1182,"NCT05917340","Intensified Short Course Regimen for TBM in Adults","INSHORT","Not yet recruiting","No Results Available","Tuberculous Meningitis","Drug: High dose rifampicin (25mg/kg)|Drug: Moxifloxacin 400mg|Drug: Aspirin 150 mg|Drug: Isoniazid|Drug: Pyrazinamide|Drug: Steroid|Drug: Rifampicin|Drug: HRZE|Drug: HRE","Mortality rate|Disability rate|Maximum Plasma Concentration [Cmax] of high dose rifampicin, isoniazid, pyrazinamide and moxifloxacin (Subset of patients)|Time for maximal concentration of high dose rifampicin, isoniazid, pyrazinamide and moxifloxacin (Subset of patients)|Area Under the Curve (AUC) of high dose rifampicin, isoniazid, pyrazinamide and moxifloxacin (Subset of patients)|Grade 3 & 4 adverse events|Quality of life (QoL) in both the arms and change in QoL during the follow up","Indian Council of Medical Research|All India Institute of Medical Sciences, Jodhpur|Christian Medical College, Vellore, India|Jawaharlal Institute of Postgraduate Medical Education & Research|North Eastern Indira Gandhi Regional Institute of Health ans Medical Sciences|Madras Medical College|Rural Development Trust Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","372","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIRT-IEC No:2023 003","March 2024","September 2027","September 2027","June 23, 2023",,"December 21, 2023","ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT05917340"
1183,"NCT03224065","NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy",,"Unknown status","No Results Available","Non - Tuberculosis Mycobacteria Lung Disease","Diagnostic Test: Genotype detected through GenSeizer high-throughput gene capture technology","Culture conversion rate|Initial time of sputum culture conversion|Chest CT|Blood routine test|liver function test|kidney function test","Shanghai Pulmonary Hospital, Shanghai, China","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","246","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K17-144","October 9, 2017","September 30, 2020","September 30, 2020","July 21, 2017",,"September 18, 2019","Haiqing Chu, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03224065"
1184,"NCT03896750","Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function",,"Not yet recruiting","No Results Available","Renal Impairment|Tuberculosis","Drug: PA-824","Apparent clearance of drug from plasma after drug administration (CL/F)|Apparent first-order terminal elimination rate constant (Lambda z) of pretomanid|Apparent volume of distribution (Vd/F)|Area under the plasma concentration-time curve from time zero to infinity (AUC-infinity)|Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)|Cumulative amount of pretomanid excreted into the urine from time 0 to the time t (Ae(0-t))|Fraction of pretomanid dose excreted into the urine (Ae%Dose)|Maximum plasma concentration of pretomanid (Cmax)|Renal clearance (CLR) of pretomanid|Terminal-phase elimination half-life (t1/2)|Time to peak (maximum) (Tmax)|Concentrations of pretonamid metabolites (M19 and M50) in plasma and urine|Excretion of representative metabolites M19 and M50 in urine|Mean change from baseline in alanine aminotransferase (ALT)|Mean change from baseline in aspartate aminotransferase (AST)|Mean change from baseline in blood urea nitrogen (BUN)|Mean change from baseline in creatinine|Mean change from baseline in estimated glomerular filtration rate (eGFR)|Mean change from baseline in hemoglobin|Mean change from baseline in magnesium|Mean change from baseline in potassium|Mean change from baseline in total bilirubin|Mean change in blood pressure from baseline|Mean change in oral temperature from baseline|Mean change in pulse from baseline|Mean change in the ECG QTc interval from baseline|Number of subjects reporting adverse events (AEs)|Plasma levels of representative metabolites M19 and M50","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","36","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-0037","December 7, 2023","January 16, 2025","July 14, 2025","April 1, 2019",,"November 18, 2023","Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03896750"
1185,"NCT05452616","Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis","SaDAPT","Active, not recruiting","No Results Available","Human Immunodeficiency Virus (HIV) Infection","Other: ART first- Therapeutic use trial|Other: TB results first- Therapeutic use trial","HIV viral suppression <400 copies/mL|Retention in care|Engagement in care|Disengagement from care|Lost to follow-up|Non-traumatic mortality|Serious adverse events (SAEs)|TB-Immune reconstitution inflammatory syndrome (IRIS)|Incidence of TB disease (microbiologically confirmed and/or clinical diagnosis)|HIV viral suppression","University Hospital, Basel, Switzerland|Swiss National Science Foundation|SolidarMed Lesotho|Kamuzu University of Health Sciences, Malawi|Swiss Tropical & Public Health Institute|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|London School of Hygiene and Tropical Medicine","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","611","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AO_2022-00031; am22Labhardt","October 19, 2022","December 2024","December 2024","July 11, 2022",,"March 8, 2024","SolidarMed Lesotho, Premium House #224, Kingsway, Maseru West, Maseru, Lesotho|Kamuzu University of Health Sciences, Helse Nord Tuberculosis Initiative, Blantyre, Malawi","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/16/NCT05452616/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT05452616"
1186,"NCT03338621","Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients",,"Completed","Has Results","Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Tuberculosis, MDR|Tuberculosis|Drug-Resistant Tuberculosis","Drug: Pretomanid|Drug: Bedaquiline|Drug: Moxifloxacin|Drug: Pyrazinamide|Drug: HRZE|Drug: HR","Number of Participants With Culture Negative Status by 8 Weeks|Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months)|Time to Culture Negative Status","Global Alliance for TB Drug Development","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","455","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SimpliciTB (B-Pa-M-Z) NC-008","July 30, 2018","July 1, 2021","June 10, 2022","November 9, 2017","November 8, 2023","March 7, 2024","Evandro Chagas, Rio de Janeiro, Brazil|FIOCRUZ, Rio de Janeiro, Brazil|National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Institut Perubatan Respiratori, Kuala Lumpur, Malaysia|Lung Center of Philippines, Manila, Philippines|Tropical Disease Foundation, Manila, Philippines|Moscow City Research and Practice Tuberculosis Treatment Centre, Moscow, Russian Federation|Central TB Research Institute of the Federal Agency of Scientific Organizations, Moscow, Russian Federation|Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University, Moscow, Russian Federation|Research Institute of the Phthisiopulmonology, Sankt Petersburg, Russian Federation|Ural Research Institute of Phthisiopulmonology, Yekaterinburg, Russian Federation|THINK, Pietermaritzburg, KwaZulu Natal, South Africa|Madibeng Centre for Research, Brits, South Africa|TASK, Cape Town, South Africa|University of Cape Town Lung Institute, Cape Town, South Africa|Enhancing Care Foundation, Durban, South Africa|CHRU, King Dinuzulu, Durban, South Africa|CHRU, Helen Joseph Hospital, Johannesburg, South Africa|PHRU, Tshepong Hospital, Klerksdorp, South Africa|CHRU, Empilweni TB Hospital, Port Elizabeth, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Ifakara Health Institute, Bagamoyo, Tanzania|NIMR-Mbeya, Mbeya, Tanzania|Kilimanjaro Clinical Research Institute, Moshi, Tanzania|Mwanza Intervention Trials Unit, Mwanza, Tanzania|Case Western Reserve University, Kampala, Uganda","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/21/NCT03338621/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/21/NCT03338621/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03338621"
1187,"NCT00676754","Epidemiology of MDR-TB in Peru","Estudio Epi","Unknown status","No Results Available","TB Multi-drug Resistant","Procedure: Statens Serum Institut RT23 2TU tuberculin","Risk of TB infection among the household members|Relative risk of specific DR mutations in index case across household contacts who acquire TB from strain matching the index case strain, vs. disease-free contacts; and cases whose contacts do/do not convert from negative to positive PPD skin test.","Harvard University Faculty of Medicine|Harvard School of Public Health (HSPH)|Brigham and Women's Hospital|Socios En Salud Sucursal, Peru|National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult",,"18544","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","07-0002|5U19AI076217|R01AI057786","September 2009","September 2014","September 2014","May 13, 2008",,"March 29, 2013","Socios En Salud Sucursal Peru, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT00676754"
1188,"NCT04437836","Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic","HighRif C","Completed","No Results Available","Clinical Trial","Drug: Evaluation of high dose rifampicin in children","Evaluation of high dose rifampicin|Plasma concentration|Time","Kilimanjaro Clinical Research Institute|European and Developing Countries Clinical Trials Partnership (EDCTP)","All","1 Year to 14 Years   (Child)","Phase 1|Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TMA2017CDF-1876-HighRif C","July 1, 2019","June 30, 2022","December 31, 2023","June 18, 2020",,"February 15, 2024","Kilimanjaro Clinical Research Institute, Moshi, Kilimanjaro, Tanzania|Hydom Hospital, Babati, Manyara, Tanzania|Mt. Meru Hospital, Arusha, Tanzania|Huruma Hospital, Moshi, Tanzania",,"https://ClinicalTrials.gov/show/NCT04437836"
1189,"NCT05027958","Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung",,"Recruiting","No Results Available","Healthy|Latent Tuberculosis Infection (LTBI)","Drug: Tuberculin Purified Protein Derivative","pulmonary immune response to mycobacterial antigens|location and longevity of immune cell activity in the pulmonary parenchyma and thoracic lymph nodes","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 64 Years   (Adult)","Early Phase 1","100","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","210027|21-H-0027","May 3, 2022","January 1, 2026","January 1, 2026","August 31, 2021",,"March 29, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05027958"
1190,"NCT00810407","Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients",,"Completed","Has Results","Tuberculosis|Non-tuberculous Mycobacterial Diseases (Including MAC Disease)","Drug: rifabutin","Number of Participants With Treatment-Related Adverse Events|Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert|Number of Participants With Treatment-Related Adverse Events by Diagnosis|Number of Participants With Treatment-Related Adverse Events by Gender|Number of Participants With Treatment-Related Adverse Events by Age|Clinical Efficacy Rate|Clinical Efficacy Rate by Diagnosis|Clinical Efficacy Rate by Gender|Clinical Efficacy Rate by Age","Pfizer","All","Child, Adult, Older Adult",,"628","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A0061006","November 2008","July 2016","July 2016","December 18, 2008","March 7, 2019","March 7, 2019",,,"https://ClinicalTrials.gov/show/NCT00810407"
1191,"NCT04122404","POC Strategies to Improve TB Care in Advanced HIV Disease","TBPOC","Completed","No Results Available","Extrapulmonary Tuberculosis|Tuberculosis, Pulmonary|Human Immunodeficiency Virus (HIV)|Acquired Immunodeficiency Syndrome","Diagnostic Test: LF-LAM","Time to TB treatment initiation|TB related morbidity|TB case detection|Time to TB diagnosis|Time to all-cause mortality.","University of Southern Denmark|Odense University Hospital|National Tuberculosis Control Programme, Ghana|Odense Patient Data Explorative Network|University of Ghana|Tema General Hospital, Ghana|Lekma Hospital, Ghana|Korle-Bu Teaching Hospital, Ghana","All","18 Years and older   (Adult, Older Adult)","Not Applicable","425","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OP_861","October 14, 2019","January 30, 2022","January 30, 2022","October 10, 2019",,"May 23, 2022","Korle Bu Teaching Hospital, Accra, Ghana|Tema General Hospital, Tema, Ghana|Lekma Hospital, Teshie, Ghana",,"https://ClinicalTrials.gov/show/NCT04122404"
1192,"NCT05091580","Effectiveness and Cost-Effectiveness of Depression Treatment for Individuals With TB in South Africa",,"Recruiting","No Results Available","Depression|Tuberculosis","Behavioral: Interpersonal Counseling|Behavioral: Enhanced treatment as usual","TB treatment success rate|Depression remission rate","New York State Psychiatric Institute|Columbia University|Desmond Tutu HIV Foundation|University of Cape Town|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1410","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8217|R01AI148461","March 23, 2023","December 31, 2025","September 30, 2026","October 25, 2021",,"July 17, 2023","Desmond Tutu HIV Foundation, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT05091580"
1193,"NCT04412239","To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic","Coronavirus19","Unknown status","No Results Available","TB - Tuberculosis|Patient Satisfaction","Behavioral: Patient-centred advice on Telephone Consultation in TB Patients:","Efficiency of the telephone consultation,|Patient satisfaction|Adherence Rate","Health Science Center of Xi'an Jiaotong University|Pakistan Institute of Medical Sciences Islamabad Pakistan|District Headquarter Hospital Bannu Pakistan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NO, F6-2017/NTP-ADMIN","April 20, 2020","December 20, 2020","December 20, 2020","June 2, 2020",,"November 18, 2020","Dhq Bannu Kpk, Bannu, KPK, Pakistan|District Bannu TB Control Center, Bannu, KPK, Pakistan",,"https://ClinicalTrials.gov/show/NCT04412239"
1194,"NCT06221735","Evaluating the Accuracy of New Tests for TB Infection Diagnosis","TB infection","Not yet recruiting","No Results Available","Latent Tuberculosis|TB Infection|Tuberculosis","Diagnostic Test: Cy-TB test|Diagnostic Test: STANDARD F TB-Feron FIA test","Sensitivity|Specificity","Freundeskreis Für Internationale Tuberkulosehilfe e.V","All","18 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TBI Testing","April 2024","December 2024","December 2025","January 24, 2024",,"February 20, 2024","Vietnam National Lung Hospital, Ha Noi, Vietnam",,"https://ClinicalTrials.gov/show/NCT06221735"
1195,"NCT04557176","TB Screening Improves Preventive Therapy Uptake","TB SCRIPT","Active, not recruiting","No Results Available","Tuberculosis|Latent Tuberculosis|Tuberculosis Prevention|HIV","Device: CRP, point-of-care assay","Microbiologically-confirmed incident TB and all-cause mortality|TB incidence: number diagnosed|TB incidence: incidence|TB incidence: Time to microbiologically-confirmed incident TB diagnosis|TB incidence: incidence rate|TB incidence: drug resistant TB|TB incidence: drug resistant TB among people receiving TPT|Mortality: number of deaths from any cause|Mortality: time to death from any cause|Mortality: all-cause death rate|Mortality: number who died from TB|TPT uptake: number screen-negatives prescribed TPT|TPT uptake: number screen-positives prescribed TPT|TPT uptake: number initiated on TPT|TPT uptake: time to TPT initiation|TPT uptake: number completing TPT|Prevalent TB diagnosis: number microbiologically-confirmed prevalent TB cases detected by screening test|Prevalent TB diagnosis: number microbiologically-confirmed prevalent TB cases missed by screening test|Prevalent TB diagnosis: number diagnosed with microbiologically-confirmed prevalent TB|Prevalent TB treatment: Number treated for prevalent TB|Prevalent TB treatment: number with microbiologically-confirmed prevalent TB completing treatment|Prevalent TB treatment: time to treatment of microbiologically-confirmed prevalent TB","University of California, San Francisco|Makerere University|Infectious Diseases Research Collaboration, Uganda|Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1719","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Screening","18-25623|1R61HL146365-01A1","November 16, 2020","March 15, 2025","March 15, 2025","September 21, 2020",,"November 29, 2023","Kampala Capital City Authority Clinic, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04557176"
1196,"NCT02627209","The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis","uveitis","Unknown status","No Results Available","Sarcoidosis|Tuberculosis","Other: spectrophotometric assay|Other: radial immunodiffusion","Analysis of serum angiotensin converting enzyme level|Analysis of serum lysozyme level","Ozlem Sahin|Dünyagöz Hospital","All","9 Years to 86 Years   (Child, Adult, Older Adult)","Not Applicable","280","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DGH-070","June 2014","February 2016","January 2017","December 10, 2015",,"December 10, 2015","DunyaGoz hospital Tunus caddesi no.28 kavaklidere, Cankaya, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT02627209"
1197,"NCT04556981","Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV","MESA-TB","Completed","No Results Available","Human Immunodeficiency Virus","Biological: M72/AS01E Mycobacterium tuberculosis vaccine|Biological: Placebo","Number of Participants With Solicited Adverse Events (AEs) Through 7 Days Post Each Dose of Study Intervention|Number of Participants With Unsolicited AEs Through 28 Days Post Each Dose of Study Intervention|Number of Participants With Serious AEs (SAEs) through end of study|Number of Participants With Potential Immune-mediated Diseases (pIMDs)|Number of Participants With Clinically Significant Safety Laboratory Assessments Grade 3 or Above|M72-specific Antibody Concentrations Pre- and Post-vaccination Through the End of the Study|Frequency of M72-specific CD4+ T Cells and CD8+ T Cells Response Pre- and Post-vaccination Through the End of the Study|Magnitude of M72-specific CD4+ T Cells and CD8+ T Cells Response Pre- and Post-vaccination Through the End of the Study|Polyfunctionality of M72-specific CD4+ T cells and CD8+ T cells Response pre- and Post-vaccination Through the End of the Study","Bill & Melinda Gates Medical Research Institute|Wellcome Trust","All","16 Years to 35 Years   (Child, Adult)","Phase 2","402","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gates MRI-TBV02-202|221698/Z/20/Z","November 17, 2020","August 12, 2022","August 12, 2022","September 21, 2020",,"June 13, 2023","Wits RHI, Johannesburg, Gauteng, South Africa|Ekhaya VAC, Cape Town, Khayelitsha, South Africa|CAPRISA, Durban, Kwazulu-Natal, South Africa|The Aurum Institute, Klerksdorp, North West, South Africa|Desmond Tutu HIV Foundation, Cape Town, Western Cape, South Africa|SATVI, Worcester, Western Cape, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT04556981/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT04556981/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04556981"
1198,"NCT01214993","A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects",,"Completed","No Results Available","Infections, Human Immunodeficiency Virus and Tuberculosis","Drug: GSK1349572|Drug: Placebo|Drug: Iohexol Injection|Drug: Para-aminohippurate infusion","Glomerular Filtration Rate (GFR) as measured by iohexol plasma clearance at days -1, 7 and 14|Serum creatinine, creatinine clearance (CrCL) as measured by 24-hour urine collection, and extra-glomerular creatinine excretion (EGCE) at days -1, 7, 14 and follow-up|Serum concentrations of Cystatin-C, 24-hour urinary excretions of albumin, total protein, beta2-microblobulin, N-acetyl-beta-d-glucosaminidase (NAG) and retinol binding protein at days -1, 7, 14 and at follow-up|Effective renal plasma flow (ERPF) as measured by plasma clearance of Para Aminohippurate (PAH) at days -1, 7 and 14|Safety and tolerability parameters, including adverse event, concurrent medication, clinical laboratory and vital signs assessments.|Day 14 GSK1349572 PK parameters including area under the concentration curve (AUC)(0-tau), AUC(0-24), concentration (C)max, C0, and Ctau.","ViiV Healthcare|Shionogi|GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","114819","October 2010","November 2010","November 2010","October 5, 2010",,"June 11, 2012","GSK Investigational Site, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01214993"
1199,"NCT03822156","Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Cavity|Bronchoscopy|Acid Fast Bacilli Infection|Multi-drug Resistant Tuberculosis|Transmission|Insolation","Other: Observation of AFB smear/culture","TLSD|TLCD|ACSD|TCV/RLV|TTV/RLV|Radiological measure for Tb lesions including cavity size, number|Admission Duration|Isolation Duration|Hemoptysis /Bronchial artery embolization (BAE)|TB PCR, XPERT","University of Ulsan|Ulsan University Hospital","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UUlsan|KCT0003707","January 1, 2010","June 30, 2018","June 30, 2018","January 30, 2019",,"June 25, 2019","Ulsan University Hospital, 877 Bangeojin Sunwhando-ro, Ulsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03822156"
1200,"NCT03277742","Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz",,"Withdrawn","No Results Available","Pulmonary Tuberculosis|Diabetes Mellitus, Type 2","Behavioral: Community intervention|Drug: Standard of care","Treatment success|Blood glucose control","Instituto Nacional de Salud Publica, Mexico|National Council of Science and Technology, Mexico","All","20 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CI 1422","September 20, 2017","May 2020","December 2020","September 11, 2017",,"May 15, 2020","Centro de Salud Camerino Mendoza, Orizaba, Veracruz, Mexico",,"https://ClinicalTrials.gov/show/NCT03277742"
1201,"NCT00005741","Indigenous Outreach Among Injection Drug Users to Treat and Control TB",,"Completed","No Results Available","Lung Diseases|Tuberculosis",,,"National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"NIH","Observational",,"4950|R01HL055760","September 1995",,"August 2001","May 26, 2000",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00005741"
1202,"NCT00005740","TB Contact Investigation: Behavioral Intervention",,"Completed","No Results Available","Lung Diseases|Tuberculosis",,,"National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"NIH","Observational",,"4949|R01HL055752","September 1995",,"August 2000","May 26, 2000",,"May 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00005740"
1203,"NCT00005738","Promoting Adherence to TB Regimens in Latino Adolescents",,"Completed","No Results Available","Lung Diseases|Tuberculosis",,,"San Diego State University|National Heart, Lung, and Blood Institute (NHLBI)","Male","up to 100 Years   (Child, Adult, Older Adult)",,,"Other|NIH","Observational",,"4947|R01HL055738","September 1995",,"August 2001","May 26, 2000",,"January 12, 2016",,,"https://ClinicalTrials.gov/show/NCT00005738"
1204,"NCT03941210","Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients","miRNA","Unknown status","No Results Available","HIV Infection|Tuberculosis Infection","Other: Detection of molecular Biomarkers","miRNA expression profile in a cohort of patients with a HIV infection and Tuberculosis and correlate it with their clinical evolution","ANRS, Emerging Infectious Diseases","All","18 Years to 100 Years   (Adult, Older Adult)",,"134","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","ANRS 12358","March 1, 2018","March 1, 2020","March 1, 2020","May 7, 2019",,"January 7, 2020","Institut Pasteur du Cambodge, Phnom Penh, Cambodia",,"https://ClinicalTrials.gov/show/NCT03941210"
1205,"NCT00925249","Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy",,"Unknown status","No Results Available","Rheumatoid Arthritis|Tuberculosis",,"Primary endpoints are the results of the QFT-G test (defined as positive, negative or indeterminate) and the results of the TST (defined as positive or negative).|Secondary endpoints include the percentage and numbers of CD45RO (memory T cells), the response PHA intradermal antigen placement, numbers of hypoergic TSTs, and the results of cell mediated immunity (CMI) assays.","Walter Reed Army Medical Center|National Naval Medical Center","All","18 Years and older   (Adult, Older Adult)",,"90","U.S. Fed","Observational","Time Perspective: Prospective","6950","May 2009","May 2011","June 2011","June 22, 2009",,"December 14, 2009","Walter Reed Army Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00925249"
1206,"NCT02538952","Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons","XPRES","Completed","No Results Available","Tuberculosis|Human Immunodeficiency Virus","Device: Xpert device|Other: Intensified TB Case Finding (ICF)","TB diagnostic sensitivity among adults (>12 years old). Sensitivity proportions will be estimated using laboratory data on TB diagnoses (see ""Description"" below).|All-cause mortality|Clinician TB screening compliance. Compliance proportions will be estimated using data from study questionnaires (see ""Description"" below).|The proportion of patients screening positive for TB at the HIV clinic enrollment visit. Proportions screening positive will be estimated using data from study questionnaires (see ""Description"" below).|The proportion of patients diagnosed with TB at HIV clinic enrollment. Proportions diagnosed with TB will be estimated using data from study questionnaires and laboratory tests.|TB diagnostic sensitivity among children (<=12 years old). Sensitivity proportions will be estimated using laboratory data on TB diagnoses (see ""Description"" below).|TB screening algorithm sensitivity among children (<=12 years old). Sensitivity proportions will be estimated using laboratory data on TB diagnoses and questionnaire data on the screening algorithm (see ""Description"" below).|Diagnostic sensitivity of Xpert in diagnosing culture-positive drug resistant TB.|TB incidence|TB treatment outcomes. The incidence rate will be estimated using data from study questionnaires (see ""Description"" below).|Hospitalization rates. Incidence of hospitalization rates will be estimated from study questionnaires.|Xpert diagnostic sensitivity. Sensitivity proportions will be estimated using laboratory data on TB diagnoses (see ""Description"" below).|The proportion of attempts to use Xpert where Xpert was considered inoperable. These data will be obtained from study questionnaires.|Median turnaround time for sputum samples from the time of sample collection to the time the patient was initiated on TB treatment. These data will be obtained from study questionnaires.","Centers for Disease Control and Prevention|Botswana Ministry of Health|University of Pennsylvania","All","Child, Adult, Older Adult","Phase 4","18696","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CDC-CGH-6294","August 1, 2012","July 1, 2017","July 1, 2017","September 2, 2015",,"June 25, 2019","22 HIV care and Treatment clinics in Botswana, Multiple Locations, Multiple, Botswana",,"https://ClinicalTrials.gov/show/NCT02538952"
1207,"NCT02331056","Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?",,"Completed","No Results Available","Pulmonary Neoplasm|Pulmonary Tuberculosis","Other: fluid loading|Procedure: thoracoscopic pulmonary lobectomy|Procedure: thoracotomy","Changes from baseline in SVV, SVI after fluid loading","Samsung Medical Center","All","20 Years to 75 Years   (Adult, Older Adult)",,"79","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2014-06-053-002","July 2014","June 2015","June 2015","January 5, 2015",,"October 7, 2016","Samsung medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02331056"
1208,"NCT05636254","Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes",,"Recruiting","No Results Available","Tuberculous Meningitis|Tuberculous Arachnoiditis","Diagnostic Test: MRI Brain and spine|Diagnostic Test: Reference standard diagnostic criteria","Sensitivity and specificity of sulcal tuberculomas in the diagnosis of tubercular meningitis|Correlation of imaging findings with clinical outcomes|Clinical or imaging features of spinal tubercular arachnoiditis|Factors determining outcomes in patients with spinal tubercular arachnoiditis|Treatment trends in patients with spinal tubercular arachnoiditis","All India Institute of Medical Sciences, New Delhi","All","14 Years and older   (Child, Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Other","IECPG-36/27.01.2022","January 27, 2022","January 2024","February 2024","December 5, 2022",,"December 5, 2022","All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT05636254"
1209,"NCT03251196","TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB","TBSEQUEL","Unknown status","No Results Available","Respiratory Tract Infections|Tuberculosis, Pulmonary","Other: No Intervention, and Observational Study","Severe pulmonary function impairment|Changes in impairment of pulmonary function","The Aurum Institute NPC|Ludwig-Maximilians - University of Munich|Research Center Borstel|University of Witwatersrand, South Africa|Mbeya Medical Research Centre NIMR|Ministry of Health Instituto Nacional de Saude|Medical Research Council Unit, The Gambia|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LMU-IMPH-TB Sequel-01","September 22, 2017","June 30, 2022","June 30, 2022","August 16, 2017",,"January 13, 2021","The MRC-Unit, Fajara, Gambia|Instituto Nacional de Saúde, Maputo, Mozambique|The Clinical HIV Research Unit, Johannesburg, Gauteng, South Africa|NIMR-Mbeya Medical Research Centre, Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT03251196"
1210,"NCT04734652","INSTI's For The Management of HIV-associated TB","INSIGHT","Active, not recruiting","No Results Available","HIV/AIDS|Tuberculosis, Pulmonary","Combination Product: Biktarvy®|Combination Product: TLD- fixed-drug combination single tablet","Viral suppression rate|Viral suppression rates|BIC Drug concentrations (""Area under the plasma concentration versus time curve (AUC)""|BIC Drug concentrations [Peak Plasma Concentration (Cmax)]|BIC Drug concentrations [Trough/Minimum Plasma Concentration Ctrough)|The incidence of TB associated IRIS|The tolerability of treatment in each arm|Frequency of ART drug resistance mutations","Centre for the AIDS Programme of Research in South Africa|Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|University of Cape Town|Medical Research Council, South Africa","All","18 Years to 105 Years   (Adult, Older Adult)","Phase 2","122","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPRISA 093|1R01AI152142-01","February 18, 2022","January 19, 2024","August 31, 2024","February 2, 2021",,"April 3, 2024","CAPRISA Springfield Clinical Research Site, Durban, KwaZulu-Natal, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/52/NCT04734652/Prot_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/52/NCT04734652/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT04734652"
1211,"NCT03934931","Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)",,"Active, not recruiting","Has Results","Tuberculosis|Latent Tuberculosis|HIV/AIDS","Other: Streamlined weekly DOT visits|Other: Weekly DOT visit reminders|Other: Cost reimbursement DOT|Other: 99DOTS|Other: Weekly SAT dosing reminders/check-ins|Other: Cost reimbursement SAT","Proportion of Participants Who Accepted and Completed 3HP|Proportion of Participants Who Accepted 3HP Treatment|Proportion of Participants Who Completed 3HP Treatment|Proportion of People Who Discontinued 3HP Treatment Due to Adverse Events/Intolerance|Cumulative Incidence of Tuberculosis (TB)|Cumulative Incidence of TB|Cost Effectiveness (Patient Perspective)|Cost Effectiveness (Health System Perspective)|Cost Effectiveness (Overall Perspective)|Visit Cost Reimbursement - Overall|Visit Cost Reimbursement|Time to Complete Clinic Visit - Mean Minutes|Time to Complete Clinic Visit - Median Minutes|Short Messages Service (SMS) or Interactive Voice Response (IVR) Phone Call Reminders Delivered - Clinic Visits|Screening for Active TB|Screening for Side Effects|Dosing Confirmation Via 99DOTS (SAT Only)|SMS or IVR Phone Call Reminders Delivered - Medication Dosing (SAT Only)|SMS or IVR Phone Calls Delivered - Weekly check-in (SAT Only)|SMS or IVR Phone Call Reminders Delivered - Missed Dose (SAT Only)|SMS or IVR Phone Call Missed Appointment Reminders Delivered|Follow up (Phone Calls or Home Visits) for Negative Response to Weekly SMS or IVR Phone Call check-in (SAT Only)|Costs of Preventive Services|Participant Satisfaction|Barriers to 3HP Delivery From the Provider/Clinic Perspective|Barriers to 3HP Completion From the Patient Perspective","University of California, San Francisco|Makerere University|Johns Hopkins Bloomberg School of Public Health|University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","1656","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","R01HL144406","July 13, 2020","September 29, 2022","November 8, 2024","May 2, 2019","November 7, 2023","November 18, 2023","Mulago Immune Suppression Syndrome (ISS) Clinic, Kampala, Uganda","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT03934931/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT03934931/SAP_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT03934931/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03934931"
1212,"NCT02348177","Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB",,"Completed","No Results Available","Acquired Immunodeficiency Syndrome|Tuberculosis","Drug: lopinavir with ritonavir in 1:1 ratio|Drug: Lopinavir/ritonavir 4:1","Modelled C0/morning trough|C0/morning trough|ALT|ECG","Drugs for Neglected Diseases|University of Cape Town|Medecins Sans Frontieres, Netherlands|French Development Agency|UBS Optimus Foundation","All","2 Weeks and older   (Child, Adult, Older Adult)","Phase 4","96","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DNDiHIVPed001","January 2013","December 2016","December 2016","January 28, 2015",,"May 11, 2017","The Children's Infectious Disease Clinical Research Unit; University of Stellenbosch, Cape Town, Western Cape, South Africa|Enhancing Care Foundation; Wendworth Hospital, Durban, South Africa|Perinatal HIV Research Unit, Johannesburg, South Africa|Shandukani Research WRHI, Johannesburg, South Africa|Empilweni Services and Research Unit, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT02348177"
1213,"NCT03808597","Digital Health Promotion in Iringa, Tanzania",,"Completed","No Results Available","HIV Infections|Tuberculosis|Cysticercosis|Tapeworm Pork","Other: Digital health promotion intervention","Baseline Health knowledge score|Change from Baseline Health knowledge score, immediately after exposure|Change from Baseline Health knowledge score at 3 months|Change from Baseline Health knowledge score at 6 months|Change from Baseline Health knowledge score at 12 months|Participants own perspectives on the intervention (qualitative)","University of Oslo|National Institute for Medical Research, Tanzania|Sokoine University of Agriculture|Technical University of Munich","All","15 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","DigI","April 1, 2019","June 1, 2020","June 1, 2020","January 17, 2019",,"November 4, 2020","National Institute for Medical Research / Muhimbili University, Dar es Salaam, Dar, Tanzania|Idodi, Iringa, Tanzania|Izazi, Iringa, Tanzania|Kimande, Iringa, Tanzania|Migoli, Iringa, Tanzania|Sokoine University of Agriculture, Morogoro, Tanzania","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/97/NCT03808597/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03808597"
1214,"NCT02281643","Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana","Map2Co","Completed","No Results Available","Mansonella Perstans Infection|Buruli Ulcer|Tuberculosis|Co-infection","Drug: Doxycycline","Microfilarial assessment|Demonstrate development of a T helper type 1 immunity through Immunological profile of cellular immune responses","Kwame Nkrumah University of Science and Technology|University of Bonn|Heinrich-Heine University, Duesseldorf","All","9 Years to 55 Years   (Child, Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","GZ:JA 1479/5-1","October 2014","March 15, 2017","March 15, 2017","November 2, 2014",,"March 23, 2017","Agogo Presbyterian Hospital, Agogo, Asante Akim North District, Ghana",,"https://ClinicalTrials.gov/show/NCT02281643"
1215,"NCT01730664","PK/PD of Ertapenem In Patients With TB",,"Completed","No Results Available","PK of Ertapenem in TB Patients","Drug: ertapenem","AUC|Safety: number of patients with organ dysfunction","University Medical Center Groningen","All","18 Years to 64 Years   (Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ETB/V0.2","January 26, 2017","July 13, 2017","July 13, 2017","November 21, 2012",,"August 25, 2017","UMCG - Tuberculosis Center, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01730664"
1216,"NCT01932268","A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin",,"Completed","No Results Available","Chronic Kidney Disease|Tuberculosis","Drug: Rifampicin","a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after Rifampicin administration","Seoul National University Hospital","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Colchicine_RFP 2011_1","January 2011","December 2011","December 2011","August 30, 2013",,"August 30, 2013",,,"https://ClinicalTrials.gov/show/NCT01932268"
1217,"NCT01158755","Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study",,"Completed","No Results Available","Meningitis, Tuberculous|Pharmacokinetics|Pharmacodynamics|Tolerability","Drug: Moxifloxacin","Rifampicin and Moxifloxacin concentration in plasma and CSF|Early and late mortality","Universitas Padjadjaran|Radboud University Medical Center","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB-201006.01","October 2010","December 2011","June 2012","July 8, 2010",,"June 7, 2012","Hasan Sadikin General Hospital, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT01158755"
1218,"NCT05458089","18F-FDG PET/CT in the Diagnosis of Tuberculous Pericarditis",,"Completed","No Results Available","Diagnostic Self Evaluation","Diagnostic Test: 18F-FDG","the diagnostic sensitivity of 18F-FDG PET/CT for tuberculous pericarditis","Wuxi No. 4 People's Hospital","All","48 Years to 81 Years   (Adult, Older Adult)",,"11","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","Wuxi4PH-2022-01","January 1, 2015","February 28, 2022","February 28, 2022","July 14, 2022",,"July 14, 2022",,,"https://ClinicalTrials.gov/show/NCT05458089"
1219,"NCT05610098","Gene Expression Profiles in Spinal Tuberculosis.","SpinalTBX","Recruiting","No Results Available","Tuberculosis, Spinal|Tuberculosis, Osteoarticular|Tuberculosis|Mycobacterium Infections|Infections|Bone Diseases, Infectious|Musculoskeletal Diseases|Spinal Disease|Spondylitis|Spondylitis; Tuberculosis (Manifestation)|Spondylodiscitis|Positron-Emission Tomography|Diagnostic Imaging|Diagnostic Techniques and Procedures",,"Clinical phenotype of spinal TB|mRNA gene expression profiles of spinal TB|MRI vs. PET/CT at the site of disease (spine level)|Whole Genome Sequencing of Mtb. isolates|PET/CT changes over 12 months","University of Cape Town|University of Zurich","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HREC 243/2022|AOS-DIA-22-029-TRA","October 25, 2022","December 2025","December 2025","November 9, 2022",,"November 9, 2022","Groote Schuur Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT05610098"
1220,"NCT05842161","South Africa Smoking Cessation and Engagement in HIV/TB Care Care",,"Not yet recruiting","No Results Available","HIV Infections|Tuberculosis|Smoking Cessation","Behavioral: QUIT-AD|Other: Enhanced Treatment as Usual","Feasibility of intervention|Acceptability of intervention|Short-term point prevalence smoking abstinence|Average number of cigarettes smoked over the past 7 days|Favorable HIV/TB treatment outcome","Massachusetts General Hospital|Boston University|University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Not Applicable","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2023P000792|R34DA057169","February 1, 2024","January 1, 2026","April 30, 2026","May 3, 2023",,"January 10, 2024","University of Cape Town, Rondebosch, South Africa",,"https://ClinicalTrials.gov/show/NCT05842161"
1221,"NCT05739695","A Trial of Radial EBUS Versus VBN for the Peripheral Pulmonary Lesions",,"Recruiting","No Results Available","Lung Cancer|Tuberculosis|Pneumonia","Diagnostic Test: Virtual bronchoscopy navigation|Diagnostic Test: radial EBUS","Diagnostic Efficacy of navigational bronchoscopy in each study arm|Efficacy of each endoscopic biopsy modality in confirmation of final diagnosis","Ilya Sivokozov|Central TB Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VBN-REBUS","February 1, 2022","December 1, 2024","March 1, 2025","February 22, 2023",,"February 6, 2024","Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russian Federation|Kurgan Regional Oncological Dispensary, Kurgan, Russian Federation|Central TB Research Institute, Moscow, Russian Federation|P. Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation|National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation|Tomsk Regional Oncological Dispensary, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05739695"
1222,"NCT04207112","Economic Evaluation of New MDR TB Regimens","PRACTECAL-EE","Unknown status","No Results Available","Multi-drug Resistant Tuberculosis|Extensively Drug-Resistant Tuberculosis|Pulmonary Tuberculoses","Drug: Bedaquiline|Drug: Pretomanid|Drug: Moxifloxacin|Drug: Linezolid|Drug: Clofazimine|Drug: Standard Drugs","Incremental cost incurred per disability adjusted life year (DALY) averted: Societal Perspective|Incremental cost per disability adjusted life year (DALY) averted: Provider Perspective|Mean cost per month of treatment|Mean cost per course of treatment for different types of patients|Incremental total cost of intervention for the trial population|Incremental total cost of intervention for the modelling cohort","Medecins Sans Frontieres, Netherlands|London School of Hygiene and Tropical Medicine|Ministry of Health, Republic of Uzbekistan|Ministry of Public Health, Republic of Belarus|THINK TB & HIV Investigative Network|University of Liverpool|Wits Health Consortium (Pty) Ltd|LSHTM Clinical Research Department","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PRACTECAL-EE","October 20, 2020","July 30, 2022","July 31, 2022","December 20, 2019",,"May 14, 2021","Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus|Helen Joseph Hospital, Johannesburg, Gauteng, South Africa|Doris Goodwin Hospital, Pietermaritzburg, KwaZulu Natal, South Africa|THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa|King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa|Republican TB Hospital No. 2, Nukus, Karakalpakstan, Uzbekistan|Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital, Tashkent, Uzbekistan",,"https://ClinicalTrials.gov/show/NCT04207112"
1223,"NCT04600232","TB-LAM in the Diagnosis of TB",,"Unknown status","No Results Available","HIV Infections|Tuberculosis|Non-Tuberculous Mycobacterial Pneumonia","Diagnostic Test: Alere TB-LAM","Sensitivity against microbiological reference standard|Specificity against microbiological reference standard|Sensitivity against composite reference standard|Specificity against composite reference standard","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TB-LAM","October 2020","January 2021","February 2021","October 23, 2020",,"October 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04600232"
1224,"NCT04081077","PRACTECAL-PKPD Sub Study","PRACTECAL-PKPD","Unknown status","No Results Available","Multi-drug Resistant Tuberculosis|Extensively Drug-Resistant Tuberculosis|Pulmonary Tuberculosis","Drug: Bedaquiline|Drug: Pretomanid|Drug: Moxifloxacin|Drug: Linezolid|Drug: Clofazimine","Pharmacokinetic: Cmax|Pharmacokinetic: AUC|Pharmacokinetic: T1/2|Pharmacokinetic: Tmax|Pharmacodynamics: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Pharmacodynamics: Culture Conversion 24 weeks post treatment [Efficacy]","Medecins Sans Frontieres, Netherlands|London School of Hygiene and Tropical Medicine|Global Alliance for TB Drug Development|University College, London|Drugs for Neglected Diseases|Swiss Tropical & Public Health Institute|eResearch Technology, Inc.|Ministry of Health, Republic of Uzbekistan|World Health Organization|Ministry of Public Health, Republic of Belarus|THINK TB & HIV Investigative Network|University of Liverpool|Wits Health Consortium (Pty) Ltd|Hackensack Meridian Health|University of California, San Francisco|Minsk Republican Research and Practical Centre for Pulmonology and Tuberculosis","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRACTECAL-PKPD","August 6, 2019","September 30, 2022","September 30, 2022","September 9, 2019",,"May 14, 2021","Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus|Helen Jospeh Hospital, Johannesburg, Gauteng, South Africa|Doris Goodwin Hospital, Pietermaritzburg, KwaZulu Natal, South Africa|THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa|King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT04081077"
1225,"NCT04325438","The Impact of Pharmacists' Interventions on the Quality of Life of HIV-TB Co-infection Outpatients in Indonesia",,"Completed","No Results Available","Pharmaceutical Care|HIV/AIDS|Tuberculosis","Other: Pharmaceutical Care","Monthly evaluation on the participants' quality of life (utility) using the EQ5D-5L questionanire between groups|Comparison of difference in CD4 cell counts between groups|Comparison of difference in plasma HIV RNA (viral load) between groups|Comparison of difference in participants' medication adherence between groups|Comparison of difference in participants' persistence to attend the study sessions between groups","Bekasi City Public Hospital|University of Groningen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HIVTB-INDO2017","April 1, 2017","February 28, 2019","March 30, 2019","March 27, 2020",,"March 27, 2020","Persahabatan public hospital, Jakarta, Jakarta Timur, Indonesia|Bekasi city hospital, Bekasi, West Java, Indonesia|Ciptomangunkusumo public hospital, Jakarta Pusat, Indonesia",,"https://ClinicalTrials.gov/show/NCT04325438"
1226,"NCT04830462","Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation",,"Completed","No Results Available","Latent Tuberculosis|Diabetes Mellitus, Type 2","Drug: Rifampicin 300 Mg Oral Capsule|Drug: Isoniazid 300 Mg ORAL TABLET","OGTT (oral glucose tolerance test)|Changes in insulin production|Changes in insulin resistance|Changes in low-grade inflammatory markers and in adipokines|INF-gamma change|Changes in body composition","Herlev and Gentofte Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-20028894 or 126496","April 15, 2021","May 1, 2023","May 1, 2023","April 5, 2021",,"May 16, 2023","Herlev-Gentofte Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04830462"
1227,"NCT06047795","Endurance Training in Patients With Post-TB Lung Disease",,"Recruiting","No Results Available","Tuberculosis|Post-Tuberculous Pleural Fibrosis|Post-Tuberculous Bronchiectasis","Other: Experimental|Other: Control","Functional capacity|Dyspnea|Forced Expiratory Volume in 1 second (FEV1)|Forced vital Capacity (FVC)|Peak Expiratory Flow (PEF)","Riphah International University","All","18 Years to 50 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rec/01657 Safa Marwa","September 11, 2023","February 2024","March 2024","September 21, 2023",,"September 21, 2023","Green Star NGO, Peshawar, KPK, Pakistan",,"https://ClinicalTrials.gov/show/NCT06047795"
1228,"NCT04119375","Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes",,"Completed","No Results Available","Tuberculosis|Adherence, Patient|Adherence, Medication|Drug-resistant Tuberculosis","Behavioral: Keheala Mobile Health Platform and Behavioral Interventions|Behavioral: Social and Behavior Change Communication (SBCC)|Behavioral: SMS Reminder|Other: Standard of Care","Unsuccessful Health Outcomes|Deaths|Adherence","Massachusetts Institute of Technology|Keheala|United States Agency for International Development (USAID)|Kenya National Tuberculosis, Leprosy and Lung Disease Program|McGill University","All","Child, Adult, Older Adult","Not Applicable","16146","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Keheala Stage 2","April 13, 2018","May 31, 2020","July 30, 2021","October 8, 2019",,"January 21, 2022","Kenya National TB Program, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT04119375"
1229,"NCT02178592","Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection",,"Completed","Has Results","Infection, Human Immunodeficiency Virus|HIV Infections","Drug: DTG 50 mg|Drug: EFV 600 mg","Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United States (US) Food and Drug Administration (FDA) Snapshot Algorithm|Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 48 in EFV Arm Using the Modified Snapshot Algorithm|Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 24 in Both EFV and DTG Arms Using the Modified Snapshot Algorithm|Percentage of Participants Without Confirmed Virologic Withdrawal and Without Discontinuation Due to Treatment-related Reasons at Week 24 and Week 48|Change From Baseline in Cluster of Differentiation 4 (CD4+) Counts at Week 24 and Week 48|Number of Participants With Serious Adverse Event (SAE) and Common (>=5%) Non-serious AE (Non-SAE) - Randomized Phase|Number of Participants With SAE and Common (>=5%) Non-SAE - OLE Phase|Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities - Randomized Phase|Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities- Randomized Phase + OLE Phase|Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities- Randomized Phase|Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities - Randomized Phase + OLE Phase|Percent Change From Baseline in the Fasting Lipid Profile at Week 24 and Week 48|Change From Baseline in the Fasting Lipid Profile for Total Cholesterol/HDL Ratio at Week 24 and Week 48|Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - Randomized Phase|Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - OLE Phase|Number of Participants With Tuberculosis (TB) Associated (Assoc.) Immune Reconstitution Inflammatory Syndrome (IRIS)|Number of Participants With Treatment-emergent Genotypic Resistance|Number of Participants With Treatment-emergent Phenotypic Resistance","ViiV Healthcare|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","117175","January 23, 2015","November 2, 2017","March 6, 2020","July 1, 2014","February 21, 2019","January 12, 2021","GSK Investigational Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Manaus, Amazonas, Brazil|GSK Investigational Site, Salvador, Bahía, Brazil|GSK Investigational Site, Rio de Janeiro, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Cuernavaca, Morelos, Mexico|GSK Investigational Site, DF, Mexico|GSK Investigational Site, San Miguel, Lima, Peru|GSK Investigational Site, Iquitos, Loreto, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Orel, Russian Federation|GSK Investigational Site, Saint Petersburg, Russian Federation|GSK Investigational Site, Soweto, Gauteng, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Bloemfontein, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Klerksdorp, South Africa|GSK Investigational Site, Observatory, Cape Town, South Africa|GSK Investigational Site, Westdene, South Africa|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Khon Kaen, Thailand","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/92/NCT02178592/Prot_002.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/92/NCT02178592/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02178592"
1230,"NCT05220163","Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19",,"Recruiting","No Results Available","Tuberculosis|COVID-19|HIV Infections","Diagnostic Test: CAD|Diagnostic Test: Xpert","Time to detection of microbiologically proven TB|Feasibility of CAD + POC Xpert performed by minimally trained healthcare workers|Number of infectious TB cases detected (defined by cough aerosol sampling system [CASS] and/or smear and/or cavitatory disease positive)|Time-specific proportion of participants initiated on TB treatment up to 60 days post-sample donation in each arm (7-, 14-, 30- and 60-days)|Time to TB treatment initiation (both the median time to treatment in each group and time to event [treatment] analyses will be conducted)|Yield of culture positive TB in household contacts of index participants|NPV and false negative rate (TB cases missed per 1 000 persons screened) of CAD and other screening tests for TB|Reduction in number of sputum induction procedures and/or Xpert tests performed|Global and country-specific cost-effectiveness analysis for each strategy|Transmission and disease burden impact using modelling based on exposure scores, imaging, and CASS|Rates or prevalence of microbiological versus probable (clinical TB)|Proportion of culture-positive TB cases completing three- and six-months of TB treatment in each study arm|Middleware/dashboard design requirements and deployment models for each strategy|Feasibility and yield of POC Xpert (Xpress cartridge) for COVID-19 detection|Feasibility and performance of CAD4COVID for PCR-positive COVID-19 detection|Feasibility of a novel mass screening strategy for COVID-19 that uses pooling of specimen from a group of COVID-19 suspects","University of Cape Town|European and Developing Countries Clinical Trials Partnership (EDCTP)|Zambart|Biomedical Research and Training Institute|Ospedale San Raffaele|Radboud University Medical Center|Foundation for Innovative New Diagnostics, Switzerland|University of Stellenbosch","All","18 Years and older   (Adult, Older Adult)","Not Applicable","26200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","XACT-19","February 23, 2022","January 2025","March 2025","February 2, 2022",,"April 5, 2022","University of Cape Town, Cape Town, Western Cape, South Africa|Helen Ayles, Lusaka, Zambia|Junior Mutsvangwa, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT05220163"
1231,"NCT02754765","Evaluating Newly Approved Drugs for Multidrug-resistant TB","endTB","Completed","No Results Available","Tuberculosis, Multidrug-Resistant|Infection, Bacterial|Pulmonary Tuberculoses","Drug: Bedaquiline|Drug: Delamanid|Drug: Clofazimine|Drug: Levofloxacin|Drug: Moxifloxacin|Drug: Linezolid|Drug: Pyrazinamide|Drug: Control arm MDR-TB regimen, consistent with WHO guidelines","Week 73 Efficacy|Week 104 Efficacy|Early Treatment Response (culture conversion)|Week 39 Efficacy|Week 73 Survival|Week 104 Survival|Week 73 Safety|Week 104 Safety|Week 73 Safety: proportion of patients with AESIs|Week 104 Safety: proportion of patients with AESIs","Médecins Sans Frontières, France|Partners in Health|Harvard Medical School (HMS and HSDM)|Epicentre|Institute of Tropical Medicine, Belgium|Socios En Salud, Peru|Interactive Research and Development","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","754","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSF ERB-1555","December 2016","June 2023","June 2023","April 28, 2016",,"August 23, 2023","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia|Aundh Chest Hospital, Pune, India|Center of Phthisiopulmonology of Almaty Health Department, Almaty, Kazakhstan|National Center for Tuberculosis Problems, Almaty, Kazakhstan|City Centre of Phthisiopulmonology, Nur-Sultan, Kazakhstan|Partners In Health Lesostho, Maseru, Lesotho|The Indus Hospital, Karachi, Pakistan|Institute of Chest Disease,, Kotri, Pakistan|Centro de Investigación del Hospital Nacional Hipólito Unanue, Lima, Peru|Centro de Investigación de Enfermedades Neumológicas del Hospital Nacional Sergio Bernales, Lima, Peru|Hospital Nacional Dos de Mayo Parque Historia de la Medicina, Lima, Peru|Medecins Sans Frontieres Belgium, Khayelitsha, South Africa","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/65/NCT02754765/ICF_008.pdf","https://ClinicalTrials.gov/show/NCT02754765"
1232,"NCT05069688","Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin",,"Recruiting","No Results Available","Pediatric HIV Infection|Tuberculosis Infection","Drug: rifampicin","Dolutegravir AUC during standard-dose rifampicin|Dolutegravir AUC during high-dose rifampicin|Rifampicin maximum concentration (Cmax) during standard-dose rifampicin|Rifampicin Cmax during high-dose rifampicin|Proportion of participants experiencing severe (grade 3 or 4) clinical or laboratory adverse events","Brigham and Women's Hospital|APIN Public Health Initiatives|University of Cape Town","All","4 Weeks to 5 Years   (Child)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021P002401","July 7, 2023","March 31, 2025","March 31, 2025","October 6, 2021",,"July 28, 2023","University College Hospital/ University of Ibadan, Ibadan, Oyo State, Nigeria",,"https://ClinicalTrials.gov/show/NCT05069688"
1233,"NCT00495326","Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)","CARINEMO","Completed","No Results Available","Tuberculosis|Aids|Hiv Infections","Drug: Nevirapine based therapy|Drug: Efavirenz based therapy|Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)","Viral load measure (Virological failure will be defined after 2 consecutive measures as : More than 1 log10 increase in plasma HIV-1 RNA concentration for patients with detectable viral load (> 50 copies/mL) at the previous dosage.)|New or recurrent stage 3 or 4 HIV/AIDS related events|Deaths after one year|Severe drugs side effects|Immune Reconstitution Syndrome(IRIS)|Increase of CD4 cell count induced by HAART|Pharmacokinetic profile of nevirapine when combined with rifampicin|Rifampicin plasma concentration dosage","French National Agency for Research on AIDS and Viral Hepatitis|Medecins Sans Frontieres, Netherlands","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","570","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANRS 12146 CARINEMO","December 2007","April 2011","April 2011","July 3, 2007",,"February 15, 2012","Health centre of Alto Mae, Chamanculo district, Maputo, Mozambique|Health centre of Josue Macao, Maputo, Mozambique|Health centre of Malavane, Maputo, Mozambique",,"https://ClinicalTrials.gov/show/NCT00495326"
1234,"NCT06253715","Shortened Regimen for Drug-susceptible TB in Children","SMILE-TB","Not yet recruiting","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Tuberculosis, Lymph Node|Mycobacterium Tuberculosis","Drug: Isoniazid|Drug: Rifampin|Drug: Pyrazinamide|Drug: Ethambutol|Drug: Rifapentine|Drug: Moxifloxacin","TB disease-free survival at 48-weeks|Proportion of participants with grade 3 or higher adverse events over 28 weeks|TB disease-free survival at 72-weeks|Adherence to treatment regimens|Tolerability as assessed by proportion of participants who discontinue treatment|Rifapentine Area under the curve (AUC0-24)|Rifapentine minimal concentration (Cmin)|Rifapentine peak concentration (Cmax)|Moxifloxacin AUC0-24|Moxifloxacin Cmin|Moxifloxacin Cmax|Parent/guardian and/or participant reported palatability and acceptability of study regimen|Adherence as assessed by proportion of participants who have taken at least 90% of their doses|Risk Stratification Algorithm|Cost-effectiveness of the HPZM regimen compared with the HRZ(E) regimen","Johns Hopkins University|United States Agency for International Development (USAID)","All","0 Days to 9 Years   (Child)","Phase 3","860","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00388853","September 30, 2024","September 30, 2027","September 30, 2027","February 12, 2024",,"February 12, 2024","Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia|Instituto Nacional de Saúde (INS), Maputo, Mozambique|Africa Health Research Institute (AHRI), Durban, South Africa|MU-JHU Care Ltd, Kampala, Uganda|University of Zambia, School of Medicine, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT06253715"
1235,"NCT03187964","Xpert Ultra and Xpert HIV-VL in People Living With HIV",,"Completed","No Results Available","HIV/AIDS|TB - Tuberculosis|Antiretroviral Therapy, Highly Active","Diagnostic Test: PLHIV Point of Care Xpert Ultra|Diagnostic Test: PLHIV Point of Care Xpert VL","Treatment time|TB diagnosis time|Urine LF-LAM, urine FujiLAM and urine Xpert Ultra in people investigated for TB|Tongue swab and oral wash Xpert Ultra, tongue swab in-house PCR, and tongue swab culture in people investigated for TB|Candidate host RNA blood signatures for active TB specified in Turner LRM et al., 2020 in people investigated for TB|HIV DST or adherence counselling|Time to referral for HIV regimen adjustment or adherence counselling in patients without virologic suppression|Initial lost to follow-up","University of Stellenbosch","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1053","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Diagnostic","N14/10/136","February 5, 2018","January 16, 2022","April 4, 2022","June 15, 2017",,"April 5, 2022","Kraaifontein Community Health Centre, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT03187964"
1236,"NCT02653404","IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection","TBTubercolar","Unknown status","No Results Available","Tuberculosis, Pulmonary|Interferon-gamma Release Tests|Tuberculin Test","Other: IGRA test (QTF-GIT)","Number of patients with concordance of QTF-GIT test and TST,among children exposed to TB|Number of patients with positivity of QTF-GIT in comparison with TST among children with active tuberculosis disease|Number of patients with a negative QTF-GIT test in comparison of TST, among non-infected children","University of Siena","All","1 Month to 17 Years   (Child)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","IGRAManPed2014","April 2015","April 2019","December 2020","January 12, 2016",,"May 5, 2017","UOC Pediatria, USL9, Grosseto, Grosseto, GR, Italy|UOC Pediatria c/o Policlinico Le Scotte, Viale Mario Bracci 16, Siena, SI, Italy|UOC Malattie Infettive Universitarie c/o Policlinico Le Scotte, Viale Mario Bracci 16, Siena, Italy",,"https://ClinicalTrials.gov/show/NCT02653404"
1237,"NCT00313066","Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion",,"Unknown status","No Results Available","Tuberculosis|Tuberculous Pleurisy|Malignant Pleural Effusion|Empyema",,,"Taichung Veterans General Hospital|Ton General Hospital","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Defined Population|Time Perspective: Other","940513/C05092","November 2005",,"November 2006","April 11, 2006",,"April 11, 2006","Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, China",,"https://ClinicalTrials.gov/show/NCT00313066"
1238,"NCT05175794","Triage Test for All Oral DR-TB Regimen (TRiAD Study)",,"Recruiting","No Results Available","Drug Resistant Tuberculosis|MDR-TB|XDR-TB|Tuberculosis","Diagnostic Test: Xpert® MTB/XDR","Time to initiation|Proportion of patients with favorable treatment outcomes|Adverse Drug Reactions|Mortality|Time to culture Conversion|HR TB Prevalence|XDR TB Prevalence|Proportion of patients with Bedaquiline and linezolid resistance not eligible for short course treatment|Clinical utility of the Tuberculosis Molecular Bacterial Load Assay (TB-MBLA) compared to routine culture to monitor DR-TB treatment response|Feasibility of Tuberculosis Molecular Bacterial Load Assay (TB-MBLA) will be compared to routine culture in bacteriological follow-up for people on DR-TB treatment|Accuracy of Xpert XDR testing compared to WGS|Quality of Xpert XDR testing|Resistance profile of sputum samples for identification of drug resistance mutations as per pre-existing probes within the Xpert XDR assay|Cost effectiveness|Operational Feasibility of patient triaging","Centre for the AIDS Programme of Research in South Africa|KNCV Tuberculosis Foundation|Amsterdam Institute for Global Health and Development|Ospedale San Raffaele|Foundation for Innovative New Diagnostics, Switzerland|National Institute for Medical Research, Tanzania|University of St Andrews|Global Alliance for TB Drug Development|Wits Health Consortium (Pty) Ltd|Institute of Human Virology, Nigeria|Ethiopian Public Health Institute","All","18 Years to 70 Years   (Adult, Older Adult)",,"1280","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAPRISA 094|TRIAD","May 26, 2022","December 31, 2024","June 1, 2025","January 4, 2022",,"February 20, 2024","Ethiopian Public Health Institute (EPHI), Gulele, Addis Ababa, Ethiopia|Institute of Human Virology Nigeria, Yaba, Lagos State, Nigeria|CAPRISA Springfield Research Clinic, Durban, KwaZulu-Natal, South Africa|Clinical HIV Research Unit (CHRU), WITS Health Consortium, Bethelsdorp, Port Elizabeth, South Africa","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/94/NCT05175794/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT05175794"
1239,"NCT00414414","A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection",,"Withdrawn","No Results Available","Tuberculosis|HIV Infections","Drug: Prednisone|Drug: placebo","Our primary objective is to determine if 30-day survival will be improved with addition of prednisone to quadruple standard TB therapy. We will measure all cause mortality at 30 days.|Our secondary endpoints will involve the measurement of clinical, laboratory and radiological parameters and adverse reactions.","Ottawa Hospital Research Institute|Ontario Lung Association","All","17 Years and older   (Child, Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006301-01H","February 2007","June 2009","June 2009","December 21, 2006",,"April 4, 2017","The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Erendale Hospital, Pietermaritzburg, KwaZulu Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT00414414"
1240,"NCT04179344","Usability Study of IeHS in Indonesia",,"Completed","No Results Available","Human Immunodeficiency Virus|Tuberculosis|Interpersonal Relations|Mobile Phone Use|Adult","Other: Integrated e-healthcare services (IeHS) web-based app","Tasks completion success|Numbers of tasks errors|Average time to complete each task|system usability scale (SUS) score|Participant experience using the IeHS web-based app","Bekasi City Public Hospital|University of Groningen","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","IeHS_Indonesia","August 5, 2019","October 31, 2019","October 31, 2019","November 27, 2019",,"November 27, 2019","Bekasi public hospital, Bekasi, West Java, Indonesia|Padang, Padang, West Sumatra, Indonesia|Jakarta, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04179344"
1241,"NCT01087190","Isoniazid (INH) Treatment Based on ELISPOT Assay",,"Completed","No Results Available","Kidney Transplant Recipient","Drug: Isoniazid treatment","Development of tuberculosis (the rate of tuberculosis after transplantation)|All cause deaths|INH-associated adverse drug reactions|Graft failure","Asan Medical Center","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","831","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2010-0009","June 2010","May 2013","November 2013","March 16, 2010",,"December 12, 2013","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01087190"
1242,"NCT00311298","Nutrition, Diabetes and Pulmonary TB/HIV",,"Completed","No Results Available","Tuberculosis|HIV|Diabetes","Dietary Supplement: Multimicronutrients|Dietary Supplement: Energy and proteins","Weight gain|Grip strength|Arm muscle and arm fat areas|Physical activity|HIV load|CD4 count|Serum acute phase reactants|Mortality","University of Copenhagen|National Institute for Medical Research, Tanzania|The Danish Medical Research Council|Danish Council for Development Research","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","1250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NIMR-UC-2006-01","April 2006","March 2009","March 2009","April 5, 2006",,"August 4, 2009","Mwanza Medical Centre, NIMR, Mwanza, Tanzania",,"https://ClinicalTrials.gov/show/NCT00311298"
1243,"NCT02961569","Comparison Between Two Strategies for the Diagnosis of TB",,"Completed","No Results Available","Pulmonary TB","Procedure: sputum collection for acid fast bacilli","Comparison between the sensitivities of the two strategies for detection of Acid fast bacilli (AFB) on direct stain","Hopital Lariboisière","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TBsputum","July 2016","April 2017","April 2017","November 11, 2016",,"April 28, 2017","Hôpital Lariboisière, Paris, Ile-de-France, France",,"https://ClinicalTrials.gov/show/NCT02961569"
1244,"NCT05221502","Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB",,"Active, not recruiting","No Results Available","Pulmonary TB","Drug: Delamanid + Bedaquiline + OPC-167832 10 mg|Drug: Delamanid + Bedaquiline + OPC-167832 30 mg|Drug: Delamanid + Bedaquiline + OPC-167832 90 mg|Drug: RHEZ","Incidence of Treatment Emergent Adverse Events|Incidence of potentially clinically significant changes of laboratory tests from baseline and abnormalities in the vital signs, physical examinations, electrocardiograms (ECGs) at each visit were assessed and at end of study.|Number of participants with a grade 3 or higher AE|Number of all cause Treatment Discontinuation|Sputum culture conversion (SCC) in Mycobacteria Growth Indicator Tube® (MGIT)|Proportion of participants who achieve SCC in MGIT by 8 weeks of treatment|Time to detection of MGIT cultures|Proportion of participants who convert sputum LAM to negative by 8 weeks of treatment and by end of treatment|Proportion of participants who develop drug resistance|Time to Sputum Culture Conversion (SCC) of each treatment group.","Otsuka Pharmaceutical Development & Commercialization, Inc.|Bill and Melinda Gates Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","122","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","323-201-00006","April 12, 2022","April 2024","April 2024","February 3, 2022",,"January 5, 2024","Aurum Institute - Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa|TASK Applied Science, Brooklyn Chest Hospital Premises, Cape Town, South Africa|University of CapeTown Lung Center Institute, Cape Town, South Africa|Themba Lethu Clinic Clinical HIV Research Unit (CHRU), Johannesburg, South Africa|Perinatal HIV Research Unit Tshepong Hospital Complex, Klerksdorp, South Africa|Setshaba Research Center, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT05221502"
1245,"NCT02135289","The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID","IGRA","Completed","No Results Available","Inflammatory Bowel Disease|Crohn Disease|Ulcerative Colitis|Tuberculosis|Immune-mediated Inflammatory Disease",,"IGRA positivity|IGRA conversion","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"9160","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IGRA","March 2012","July 31, 2019","July 31, 2019","May 9, 2014",,"April 29, 2020","Prince of Wales Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT02135289"
1246,"NCT05040126","Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India","mBPaL","Active, not recruiting","No Results Available","Pre-Extensively Drug-Resistant Pulmonary TB|Treatment Intolerant Multidrug-Resistant Pulmonary TB|Non-responsive Multidrug-Resistant Pulmonary TB","Drug: Linezolid|Drug: Bedaquiline|Drug: Pretomanid","Sustained Treatment success|Proportion of serious adverse events|proportion of patients died|proportion of patients with Treatment Failure|proportion of patients with Lost-to-follow up","Tuberculosis Research Centre, India|International Union Against Tuberculosis and Lung Diseases|Sarvodaya Charitable Trust Hospital, Ghatkopar, Mumbai|Shatabdi Centenary Hospital, Govandi, Mumbai|King George's Medical College and Hospital, Lucknow|SN Medical College, Agra|Govt Medical College & Hospital, Bhavnagar|Govt. Medical College & Hospital, Surat|National Institute for Tuberculosis and Respiratory Diseases, New Delhi|Rajan Babu Institute of Pulmonary Medicine and Tuberculosis, Delhi|Govt.Rajaji Medical college and hospital, Madurai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021 004","October 7, 2021","December 31, 2024","December 31, 2024","September 10, 2021",,"January 3, 2024","S N Medical College, Agra, Uttarpradesh, India",,"https://ClinicalTrials.gov/show/NCT05040126"
1247,"NCT04642755","Comorbidities and Coinfections in Latent TB","COMBINE-TB","Recruiting","No Results Available","Latent Tuberculosis|Diabete Mellitus|Malnutrition|Helminth Infection",,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures","Tuberculosis Research Centre, India|National Institutes of Health (NIH)","All","14 Years to 65 Years   (Child, Adult, Older Adult)",,"300","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020005|AI001065-08","April 19, 2021","March 2026","March 2026","November 24, 2020",,"November 22, 2023","National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT04642755"
1248,"NCT05423847","Triage UltraSound in Tb Endemic Regions","TrUST","Recruiting","No Results Available","Tuberculosis|Lower Resp Tract Infection|Pneumonia","Diagnostic Test: POCUS","Sensitivity of LUS for the detection of TB|Specificity of LUS for the detection of TB|Sensitivity of FASH PLUS for the detection of TB|Specificity of FASH PLUS for the detection of TB|Sensitivity of combined LUS and FASH PLUS features for the detection of TB|Specificity of combined LUS and FASH PLUS features for the detection of TB|Sensitivity of AI-interpreted LUS for the detection of TB|Specificity of AI-interpreted LUS for the detection of TB|Sensitivity of AI-interpreted FASH PLUS for the detection of TB|Specificity of AI-interpreted FASH PLUS for the detection of TB|Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS|Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support","Centre Hospitalier Universitaire Vaudois|National University Hospital for tuberculosis, Cotonou, Benin|Ecole Polytechnique Fédérale de Lausanne|University of Witwatersrand, South Africa|National University Hospital (CNHU point G), Bamako, Mali","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CGRB11362","October 14, 2021","April 14, 2023","October 14, 2025","June 21, 2022",,"June 21, 2022","CNHUPPC, Cotonou, Atlantic, Benin|CHU point G, Bamako, Mali|Wits Rural University, Acornhoek, South Africa",,"https://ClinicalTrials.gov/show/NCT05423847"
1249,"NCT02057796","Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","STATIS","Completed","No Results Available","HIV-1 Infection","Device: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|Drug: ART (Atripla, Truvada, Efavirenz, Combivir)|Drug: Rifampin, isoniazid, pyrazinamide, ethambutol","All-cause mortality and incidence of invasive bacterial infections|Incidence of confirmed/probable/possible TB|Incidence of grade 3 or 4 adverse events","ANRS, Emerging Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Phase 4","1050","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ANRS 12290","September 2014","April 2018","April 2018","February 7, 2014",,"October 19, 2020","Sihanouk Hospital Center of Hope, Phnom Penh, Cambodia|CePReF Centre de Prise en charge de Recherche et de Formation, Abidjan, Yopougon, Côte D'Ivoire|ISS ImmunoSuppression Service, Mbarara, Uganda|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT02057796/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02057796"
1250,"NCT04826809","New Reusable Mask Design With Superior Filtration and Fit",,"Completed","Has Results","Covid19|Tuberculosis|Respiratory Viral Infection","Device: N95 mask|Device: Nordell single E-100 layer mask|Device: Nordell double E-100 layer mask","Comparison of Fit Tests|Comfort Level of Nordell Double E-100 Layer Mask|Ability to Breathe With Nordell Double E-100 Layer Mask","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-011897","April 9, 2021","October 27, 2022","October 27, 2022","April 1, 2021","July 7, 2023","July 7, 2023","Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT04826809/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04826809"
1251,"NCT03302299","Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)","ADEPTT","Completed","Has Results","Tuberculosis|HIV/AIDS|Alcohol Abuse","Drug: Isoniazid 300 Mg ORAL TABLET|Drug: Pyridoxine 25 Mg Oral Tablet","Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity|Number of Participants Who Discontinued Treatment|Percentage of Participants With Suboptimal INH Medication Adherence|Self-reported INH Medication Adherence: Number of Days Taking INH in the Past 30 Days|Self-reported INH Medication Adherence by the Self Rating Single Item (SRSI) Scale","University of California, San Francisco|Boston University|Boston Medical Center|Mbarara University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Phase 4","302","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2U01AA020776-06","April 7, 2017","April 1, 2021","April 1, 2021","October 5, 2017","October 19, 2023","October 19, 2023","Mbarara University of Science and Technology/Mbarara Regional Referral Hospital, Mbarara, Uganda","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/99/NCT03302299/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03302299"
1252,"NCT02715271","Study of TB Lesions Obtained in Therapeutical Surgery","SH-TBL","Active, not recruiting","No Results Available","Tuberculosis|Thoracic Surgery|Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant","Procedure: therapeutical surgery for TB","Description of Clinical and Epidemiological Data of the TB patients enrolled|Description of the Histopathological characteristics of the TB lesions of TB patients enrolled|Obtention of a genic-proteomic profile of TB lesions tissues which correlate to the histopathology of the granulomas and/or the clinic-pathological features of TB patients|Change in Immunological responses|Change in Health Quality of Life Measurements","Fundació Institut Germans Trias i Pujol|National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia","All","Child, Adult, Older Adult",,"192","Other","Observational","Observational Model: Cohort|Time Perspective: Other","SH-TBL-1","September 2016","July 2025","July 2025","March 22, 2016",,"March 1, 2024","National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia","""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/71/NCT02715271/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02715271"
1253,"NCT02911740","Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama",,"Withdrawn","No Results Available","Tuberculosis|HIV|Histoplasmosis","Other: Urine LAM Ag test","Dual therapy duration|Physician questionnaire|Creatinine change during hospitalization|Number of diagnostic tests performed during hospitalization|Mortality during hospital stay","University of Florida|Hospital Santo Tomas","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","IRB201600869","November 2017","August 2018","August 2018","September 22, 2016",,"December 26, 2017",,,"https://ClinicalTrials.gov/show/NCT02911740"
1254,"NCT05628454","Comparison of Three Different Puncture Techniques in EBUS-TBNA",,"Recruiting","No Results Available","Lung Cancer|Sarcoidosis|Tuberculosis","Procedure: Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling|Procedure: Endobronchial ultrasound-guided transbronchial needle aspiration|Procedure: Endobronchial ultrasound-guided transbronchial needle capillary sampling","Diagnostic accuracy of three different puncture methods according to pathological diagnosis|Blood contamination of samples|Bleeding of operation|Acquisition of tissue core of three different puncture methods according to the judgment of the pathologist","Beijing Friendship Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","BFH20221019005","November 1, 2022","November 1, 2024","November 1, 2024","November 28, 2022",,"November 28, 2022","Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05628454"
1255,"NCT02984579","Line Probe Assay Evaluation Study","YD","Completed","No Results Available","Multidrug-Resistant Tuberculosis|Isoniazid Resistant Pulmonary Tuberculosis|Rifampicin Resistant Tuberculosis|Pulmonary Tuberculoses","Device: YD REBA MTB-MDR|Device: Hain Genotype MTBDRplus V1|Device: Hain Genotype MTBDRplus V2","INH/RIF Resistance Detection|Multi-Drug Resistant TB detection","Foundation for Innovative New Diagnostics, Switzerland|Research Center Borstel|National Institute for Communicable Diseases, South Africa|Institute of Tropical Medicine, Belgium","All","18 Years and older   (Adult, Older Adult)",,"888","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","YD7012-03","March 2015","January 2016","January 2016","December 7, 2016",,"February 14, 2017",,,"https://ClinicalTrials.gov/show/NCT02984579"
1256,"NCT00000955","Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Tuberculin Purified Protein Derivative","To estimate the percentage of HIV-infected individuals who demonstrate the booster effect|To determine the relationships among the booster effect, CD4+ cell count, and other HIV-related patient characteristics|To determine the relationship of boosting to CD4+ cell counts, HIV exposure categories, demographics, and TB risk categories|To determine the relationship of induration size after the first PPD skin test to that after the second PPD skin test","National Institute of Allergy and Infectious Diseases (NIAID)|Warner Lambert - Parke Davis","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","864","NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CPCRA 008|11560",,"December 1992","December 1992","August 31, 2001",,"October 1, 2013","Hill Health Corp, New Haven, Connecticut, United States|Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States|Veterans Administration Med Ctr / Regional AIDS Program, Washington, District of Columbia, United States|AIDS Research Alliance - Chicago, Chicago, Illinois, United States|Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States|Comprehensive AIDS Alliance of Detroit, Detroit, Michigan, United States|Henry Ford Hosp, Detroit, Michigan, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Addiction Research and Treatment Corp, Brooklyn, New York, United States|Clinical Directors Network of Region II, New York, New York, United States|Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York, New York, United States|Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland, Oregon, United States|Richmond AIDS Consortium, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00000955"
1257,"NCT01705041","Preliminary Evaluation of a Point-Of-Care Liver Function Test","DFA","Completed","No Results Available","HIV|Tuberculosis|Drug-Induced Liver Injury","Device: Diagnostics for All liver function test (LFT)","percent agreement with gold standard test","PATH","All","18 Years and older   (Adult, Older Adult)","Not Applicable","700","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DFA LFT Study","June 2012","August 2012","December 2012","October 12, 2012",,"January 31, 2013","Hospital for Tropical Diseases, Ho Chi minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT01705041"
1258,"NCT03504072","Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh",,"Unknown status","No Results Available","Spondyloarthritis","Drug: Tofacitinib 5 mg,|Drug: Etanercept","Occurrence of Tuberculosis|improvement of disease activity measures of spondyloarthritis by >40%","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","18 Years and older   (Adult, Older Adult)","Phase 4","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018/547","January 16, 2018","June 30, 2019","December 31, 2019","April 20, 2018",,"April 23, 2018","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT03504072"
1259,"NCT00468104","Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas","CPE","Completed","Has Results","Pleural Effusion Associated With Pulmonary Infection|Bacterial Pleural Effusion Other Than Tuberculosis","Drug: Alteplase|Drug: Placebo","No Surgical Intervention|Number of Participants With Pneumonia That Responded to Therapy|Number of Participants With Pleural Effusion/Empyema That Responded to Therapy|Number of Participants With Shortness of Breath That Responded to Therapy|Number of Participants With Clinical Symptoms of Sepsis That Responded to Therapy","Midwest Pulmonary and Critical Care|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11415","April 2004","October 2008","August 2009","May 2, 2007","April 24, 2012","April 30, 2012","Nebraska Methodist Hospital, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00468104"
1260,"NCT01663701","Simplified Severe Sepsis Protocol-2 (SSSP-2) in Zambia","SSSP-2","Completed","No Results Available","Sepsis|Severe Sepsis|Tuberculosis","Other: Simplified severe sepsis protocol|Other: Usual care","In-hospital all cause mortality|28-day all-cause mortality|In-hospital all cause mortality adjusted for illness severity|28-day all cause mortality adjusted for baseline illness severity|Cumulative adverse events|Treatment cost per patient|Antibiotic changed due to culture results","Vanderbilt University|National Institutes of Health (NIH)|Fogarty International Center of the National Institute of Health|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","212","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SSSP-2|R24TW007988","October 2012","November 2013","January 2014","August 13, 2012",,"September 30, 2021","University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT01663701"
1261,"NCT01165840","Effect of Weight and/or Obesity on Dapsone Drug Concentrations",,"Completed","Has Results","Obesity|Leprosy|Tuberculosis","Drug: Dapsone","Serum Clearance","Texas Tech University Health Sciences Center|National Center for Research Resources (NCRR)","All","18 Years and older   (Adult, Older Adult)","Phase 4","37","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMAIRB97|5UL1RR024982-02","July 2010","May 2012","May 2012","July 20, 2010","July 21, 2016","July 21, 2016","University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01165840"
1262,"NCT05122026","Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV","DOLPHIN Moms","Recruiting","No Results Available","HIV Seropositivity|Pregnancy|Tuberculosis Infection","Drug: Rifapentine|Drug: Isoniazid","Mortality|Targeted serious adverse events (SAEs)|PK sampling of Dolutegravir - Cl/F parameter|PK sampling of Dolutegravir - AUC parameter|PK sampling of Dolutegravir - Ctau parameter|HIV-1 RNA viral load- maternal|DTG Dose selection|PK sampling of RPT - AUC parameter|PK sampling of RPT - Ctau parameter|Adverse Events- maternal|Adverse Events- pregnancy|Adverse Events- infant|HIV infection- infant|Infant growth parameters- HAZ|Infant growth parameters- WAZ|Infant growth parameters- HCAZ|TB disease-maternal|TB disease-infant|Treatment adherence- HP","The Aurum Institute NPC|Johns Hopkins University|Weill Medical College of Cornell University|University of Washington","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00299011|3HP-MOMS-AUR1-6-351","January 17, 2024","December 31, 2024","March 31, 2025","November 16, 2021",,"March 18, 2024","The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa|Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital, Klerksdorp, North-West, South Africa|FAMily Centre for Research with Ubuntu (FAMCRU), Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT05122026"
1263,"NCT05124665","Interrupting HIV and TB Stigma in the Household in Uganda",,"Completed","Has Results","Hiv|Tuberculosis|Social Behavior|Stigma, Social|Stigmatization","Behavioral: Social Support","Proportion of Contacts Accepting HIV Testing|Change in Score of Perceived HIV Stigma|Change in Score of Perceived TB Stigma|Change in Effects of Perceived HIV Stigma on HIV Test Uptake|Change in Effects of Perceived TB Stigma on HIV Test Uptake|Proportion of Index Patient Nominated Household Members Who Accept HIV Test|Number of Social Support Household Contacts Deciding to Test for HIV","Yale University|Fogarty International Center of the National Institute of Health|New York University|Makerere University|Walimu|National Institute of Mental Health (NIMH)","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","612","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","1R21TW011270|1R21TW011270-01|2000024852","October 25, 2021","July 29, 2022","August 30, 2022","November 18, 2021","February 14, 2024","February 14, 2024","Makerere University, Kampala, Uganda","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/65/NCT05124665/Prot_SAP_002.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/65/NCT05124665/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05124665"
1264,"NCT03862261","Integrating Pediatric TB Services Into Child Healthcare Services in Africa","INPUT","Completed","No Results Available","Tuberculosis|Children, Only|Diagnosis|Delivery of Health Care","Other: Integrated pediatric TB services","Proportion of children diagnosed with active TB|Proportion of children screened for TB|Proportion of screened children who have a sample collected|Proportion of children diagnosed with TB among presumptive TB cases|Time from screening to clinical or bacteriologic diagnosis|Time from diagnosis to treatment initiation|Proportion of cases with a bacteriologically confirmed diagnosis|Proportion of children who initiate TB treatment among those diagnosed|Treatment outcome|Adherence to the TB treatment","Elizabeth Glaser Pediatric AIDS Foundation|UNITAID|University of Sheffield|Kenya Ministry of Health|Cameroon Ministry of Public Health","All","up to 5 Years   (Child)","Not Applicable","1715","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EG0214","May 10, 2019","June 30, 2021","December 31, 2021","March 5, 2019",,"March 23, 2022","Hopital de District Akonolinga, Akonolinga, Centre, Cameroon|Hopital de District Soa, Soa, Centre, Cameroon|Hopital de District Loum, Loum, Littoral, Cameroon|Hopital de District Foumban, Mbanga, Littoral, Cameroon|Hopital de District Dschang, Dschang, West, Cameroon|Hopital de District Mbouda, Mbouda, West, Cameroon|Kendu Sub County Hospital, Kendu Bay, Homa Bay, Kenya|Ndhiwa Sub county Hospital, Ndhiwa, Homa Bay, Kenya|Kakuma Mission Hospital, Kakuma, Turkana, Kenya|Lokitaung sub-county hospital, Lokitaung, Turkana, Kenya|Lopiding Sub County Hospital, Lopiding, Turkana, Kenya|Homa Bay County Referral Hospital, Homa Bay, Kenya",,"https://ClinicalTrials.gov/show/NCT03862261"
1265,"NCT02536768","Evaluation of South Africa's National Adherence Strategy","ENHANCE","Completed","No Results Available","HIV|Tuberculosis|Diabetes|Hypertension","Behavioral: Minimum package of interventions to improve ART adherence","Alive and in care using clinical records|HIV viral supression using lab data","Boston University|World Bank (Lead institution)|Republic of South Africa National Department of Health (Lead institution)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8020","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","H-34074|7173709","September 2015","April 30, 2018","April 30, 2018","September 1, 2015",,"July 30, 2019","Johannesburg Site, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT02536768"
1266,"NCT03665402","A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status",,"Completed","No Results Available","Tuberculosis|Drug-Induced Liver Injury|Adverse Drug Event","Drug: Isoniazid","Liver toxicity|Drug exposure","Seoul National University Hospital|Ministry of Health & Welfare, Korea","All","20 Years to 45 Years   (Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","INH NAT2","May 13, 2018","December 31, 2018","March 31, 2019","September 11, 2018",,"February 28, 2020","Seoul National University Hospital Clinical Trials Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03665402"
1267,"NCT03919812","Immunomodulatory Vitamin D in Thalassemia","ThalTB","Completed","No Results Available","Thalassemia|Tuberculosis|Vitamin D Deficiency","Dietary Supplement: Cholecalciferol supplementation","The outcome measure was the change in the proportion of monocyte subsets","Universitas Padjadjaran|Hasan Sadikin General Hospital","All","1 Year to 17 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB-201804.01","April 1, 2018","July 15, 2018","August 15, 2018","April 18, 2019",,"April 19, 2019","Klinik Thalassemia Rumah Sakit Dr. Hasan Sadikin Bandung, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT03919812"
1268,"NCT02090374","Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen",,"Completed","Has Results","Allergic Rhinitis|Asthma|Latent Tuberculosis","Other: Poly ICLC|Other: Poly I:C|Other: R848|Other: Timothy Grass Pollen|Other: Vitamin D|Other: Tuberculin","IFN-y Protein Response in Mucosal Lining Fluid","Imperial College London","All","18 Years to 60 Years   (Adult)","Not Applicable","93","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13SM1837|P45058","March 2014","March 2017","March 2017","March 18, 2014","November 3, 2021","November 5, 2021","Imperial Clinical Respiratory Research Unit (ICRRU), St Mary's Hospital, Paddington, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/74/NCT02090374/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02090374"
1269,"NCT00915330","Rapid On-site Cytopathologic Evaluation in the Diagnosis of Hilar/Mediastinal Adenopathy",,"Completed","No Results Available","Lung Cancer|Sarcoidosis|Tuberculosis","Procedure: Rapid on-site cytopathologic evaluation (ROSE)|Procedure: TBNA","Examine the diagnostic yield of the TBNA with ROSE arm versus the diagnostic yield of TBNA alone arm|Examine the percentage of inadequate samples in the TBNA with ROSE arm versus the TBNA alone arm|Examine the number of biopsy sites in the TBNA with ROSE arm versus the TBNA alone arm|Examine the complication rate of bronchoscopy in the TBNA with ROSE arm versus the TBNA alone arm","Maggiore Bellaria Hospital, Bologna","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","164","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Diagnostic","01-Trisolini","May 2009","February 2010","February 2010","June 8, 2009",,"February 19, 2010","Maggiore Hospital, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT00915330"
1270,"NCT01864603","Sustainable East Africa Research in Community Health","SEARCH","Completed","Has Results","HIV|Tuberculosis|Hypertension|Diabetes|Maternal Child Health|Cost Effectiveness","Other: Universal ART in a streamlined care model|Other: Annual Community Health Campaigns|Other: Targeted PrEP and Targeted testing interventions|Other: Baseline community-based HIV and multi-disease testing","Cumulative HIV Incidence|HIV Incidence|Incident TB Associated With HIV|Overall Mortality|HIV-free Infant Survival|Percent of HIV+ Adults With HIV RNA <=500 c/mL|Time in Care for HIV+ Adults With Baseline Viremia|Cumulative Incidence of ART-initiation|Hypertension Control|Adherence to PrEP Treatment|Average Adults' on- and Off-farm Employment|Year 3 Viremia Among ART-experienced Persons With Baseline Viremia|Linkage to Care|HIV Incidence Rate|Prevalence of Transmitted HIV Drug-resistance Mutations|Prevalence of Chronic Kidney Disease (CKD)|Total Costs of Programming (ART)","University of California, San Francisco|Infectious Diseases Research Collaboration, Uganda|Makerere University|Kenya Medical Research Institute|Gilead Sciences|World Bank|National Institute of Allergy and Infectious Diseases (NIAID)|United States President's Emergency Plan for AIDS Relief|Bill and Melinda Gates Foundation","All","Child, Adult, Older Adult","Not Applicable","150395","Other|Industry|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","SEARCH","April 2013","April 2021","April 2021","May 29, 2013","March 2, 2022","March 2, 2022","Nyanza Province Kenya, Nyanza Province, Kenya|Eastern Uganda, Mbale/Tororo Region, Uganda|Southwestern Uganda, Mbarara Region, Uganda","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT01864603/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT01864603/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01864603"
1271,"NCT00972699","Mentor Mothers: A Sustainable Family Intervention in South African Townships",,"Completed","No Results Available","Human Immunodeficiency Virus|Acquired Immune Deficiency Syndrome|Tuberculosis","Behavioral: Peer support and mentoring","Baby's health status|Maternal adherence: baby's and mother's health.","University of California, Los Angeles|National Institute of Mental Health (NIMH)|Human Sciences Research Council","Female","18 Years and older   (Adult, Older Adult)","Phase 2","1200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R01MH077553|DAHBR 9A-ASPA","July 2008","December 2011","December 2011","September 7, 2009",,"May 3, 2013","HSRC Sweetwaters Site, Pietermaritzburg, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT00972699"
1272,"NCT04568967","TB-CAPT EXULTANT - HIV",,"Recruiting","No Results Available","Tuberculosis|HIV Coinfection|Diagnoses Disease","Diagnostic Test: Concentrated urine with Xpert Ultra|Diagnostic Test: Stool with Xpert Ultra","proportion of participants diagnosed with microbiologically confirmed TB and started on TB treatment within 72 hours of enrolment|Eight-week all-cause mortality|The proportion of participants who are diagnosed with TB (irrespective of bacteriological confirmation) and started TB treatment within 72 hours of enrolment.","Foundation for Innovative New Diagnostics, Switzerland|Ludwig-Maximilians - University of Munich|Instituto Nacional de Saúde, Mozambique|Centro de Investigação em Saúde de Manhiça|National Institute for Medical Research, Tanzania|Ifakara Health Institute|Ospedale San Raffaele|Swiss Tropical & Public Health Institute|African Society for Laboratory Medicine|Heidelberg University|Barcelona Institute for Global Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TB043-3/1","September 5, 2022","June 30, 2024","December 30, 2024","September 29, 2020",,"January 18, 2024","Centro de Investigação em Saúde de Manhiça-Fundação, Manhiça, Vila Da Manhiça, Mozambique|Instituto Nacional de Saúde (INS), Maputo, Mozambique|Ifakara Health Institute (IHI), Bagamoyo, Tanzania|National Institute of Medical Research (NIMR), Mbeya, Tanzania",,"https://ClinicalTrials.gov/show/NCT04568967"
1273,"NCT03537170","Dietary Assessment and Prevalence of Refeeding Syndrome in High-risk TB Patients in Chhattisgarh, India",,"Completed","No Results Available","Tuberculosis|Refeeding Syndrome|Severe Malnutrition",,"Inpatient caloric intake|Incidence of refeeding syndrome","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)",,"31","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201710162","November 23, 2017","February 14, 2018","February 14, 2018","May 25, 2018",,"May 25, 2018","Jan Swasthya Sahyog, Ganiyari, Chhattisgarh, India",,"https://ClinicalTrials.gov/show/NCT03537170"
1274,"NCT00129649","Service Development: Assessing Non-attendance Rates in Outpatient Clinics",,"Completed","Has Results","Asthma|Sleep Apnea Syndromes|Tuberculosis|COPD","Behavioral: Telephone reminder call","Attendance Rates at Respiratory Outpatient Clinics","Imperial College London","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","504","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","NHLICX3806","October 2005","October 2006","November 2006","August 12, 2005","February 5, 2020","February 5, 2020","NHLI Imperial College, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00129649"
1275,"NCT01381757","Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali",,"Terminated","No Results Available","Tuberculosis, Pulmonary|Mycobacterium Tuberculous|Antitubercular Agents|Tuberculosis, Mulutidrug-Resistant|Extensively Drug-Resistant|Extensibely Drug-Resistant Tuberculosis",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)",,"34","NIH","Observational","Time Perspective: Prospective","999911175|11-I-N175","May 31, 2011",,"March 5, 2013","June 27, 2011",,"April 5, 2018","National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States|University of Bamako, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT01381757"
1276,"NCT01167452","Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations",,"Completed","Has Results","Obesity|Pharmacokinetics|MRSA|Tuberculosis|PCP","Drug: Sulfamethoxazole/trimethoprim","Elimination Rate Constants for Sulfamethoxazole and Trimethoprim","Texas Tech University Health Sciences Center|National Center for Research Resources (NCRR)|University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMA IRB A10-3592|5UL1RR024982-02","July 2010","May 2012","May 2012","July 22, 2010","November 2, 2016","June 14, 2017","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01167452"
1277,"NCT00004276","Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections",,"Completed","No Results Available","HIV Infections|Mycobacterium Infections|Tuberculosis","Drug: thalidomide",,"National Center for Research Resources (NCRR)|National Institute of Allergy and Infectious Diseases (NIAID)|Rockefeller University|Office of Rare Diseases (ORD)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","NIH|Other","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","199/11682|RU-0300395","September 1990",,"June 1999","October 19, 1999",,"June 24, 2005",,,"https://ClinicalTrials.gov/show/NCT00004276"
1278,"NCT04743583","Prevalence and Malignant Involvement of Calcified Intrathoracic Lymph Nodes in Patients Undergoing Endosonography",,"Completed","No Results Available","Lymphadenopathy|Lung Cancer|Sarcoidosis|Tuberculosis","Device: Endosonography B-mode examination","prevalence of metastatic involvement in intrathoracic lymph nodes featuring calcifications of any type|The prevalence of metastatic involvement from lung cancer linked to 5 predefined patterns of lymph node calcification at B-mode ultrasound examination carried out during endosonography|The interobserver agreement for the identification of 5 predefined patterns of lymph node calcification at endosonographic B-mode ultrasound examination|The prevalence of actionable mutations in the overall cohort of calcified lymph nodes identified with endosonography","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years to 90 Years   (Adult, Older Adult)",,"362","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","3872","March 20, 2021","April 30, 2022","December 31, 2022","February 8, 2021",,"January 10, 2023","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04743583"
1279,"NCT00002104","Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV",,"Completed","No Results Available","Mycobacterium Avium-Intracellulare Infection|HIV Infections|Tuberculosis, Mycobacterium Infection","Drug: Thalidomide",,"Aaron Diamond AIDS Research Center|NIH AIDS Clinical Trials Information Service","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1",,"Other","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","133A",,,,"August 31, 2001",,"June 24, 2005","Bellevue Hosp Ctr, New York, New York, United States|Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00002104"
1280,"NCT02500277","Yield of Cryoprobe vs Flexible Forceps Pleural Biopsy","COFFEE","Completed","No Results Available","Pleural Effusion|Pleurisy|Tuberculosis|Metastatic Malignancy","Device: Cryoprobe pleural biopsy first|Device: Flexible forceps biopsy first","Yield of pleural biopsy obtained with the routine flexible thoracoscopic biopsy forceps versus that obtained with a flexible cryoprobe during semirigid thoracoscopy|Biopsy size|Duration of procedure|Ease of biopsy VAS|Artifacts|Tissue depth|Bleeding","Post Graduate Institute of Medical Education and Research, Chandigarh|PGIMER","All","12 Years to 79 Years   (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NK/1815/Res/2439","January 2015","July 2018","July 2018","July 16, 2015",,"August 31, 2018","PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT02500277"
1281,"NCT01459120","Comparison of Door-to-door Versus Community Gathering to Provide HIV Counseling and Testing Services in Rural Lesotho","DoDoPi","Completed","No Results Available","HIV/AIDS|Tuberculosis|Diabetes Mellitus|Arterial Hypertension","Other: Door-to-door|Other: Pitso","Proportion of newly tested HIV-positive clients over all clients tested for HIV during the campaigns|Proportion of clients newly tested HIV-positive who enrolled into HIV/AIDS care within one month over all clients newly tested HIV-positive during the campaigns|Overall number newly tested HIV-positive and enrolled into chronic HIV/AIDS-care at each facility|Absolute number of newly tested HIV-positive clients|Absolute number of clients newly tested HIV-positive who enrolled into HIV/AIDS care|CD4-count among clients newly tested HIV-positive|Clinical WHO-stage among clients newly tested HIV-positive|Proportion of clients screened positive for Tuberculosis during the campaigns|Proportion of first-time HIV-testers among all clients accessing the testing services|Proportion of clients with positive tuberculosis screening who return 3 sputum-bottles within ≤ 5 days to the facility|Proportion of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.|Demographic characteristics of clients accessing the voluntary counseling and testing services|Absolute number of clients accessing the services at the campaigns who have a positive screening for Tuberculosis|Absolute number of clients with positive tuberculosis screening who return 3 sputum-bottles within ≤ 5 days to the facility|Absolute number of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.","SolidarMed|Paray Mission Hospital, Thaba-Tseka|Seboche Hospital, Botha-Bothe","All","Child, Adult, Older Adult","Not Applicable","1800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DoDoPi-1","October 2011","February 2012","February 2012","October 25, 2011",,"February 9, 2012","Seboche Hospital, Seboche, Botha-Bothe, Lesotho|Paray Hospital, Thaba-Tseka, Lesotho",,"https://ClinicalTrials.gov/show/NCT01459120"
1282,"NCT00814827","Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma",,"Active, not recruiting","No Results Available","Nontuberculous Mycobacteria|Mycobacterium Tuberculosis|Opportunistic Infections",,"Identification of the presence of autoantibodies to IFNy in HIV-negative Thai and Taiwanese patients with disseminated NTM and OI who are followed at the participating institutions.|Identification of predisposing factors for the development of autoimmunity to cytokines and/or their receptors.|Identification of other autoantibodies that might manifest similarly to patients with autoantibodies to IFNg.|Characterization of the natural history and specific microbiology in HIV-negative patients with disseminated NTM and other OI and to determine any statistically significant differences from MTB controls or healthy blood bank donors.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)",,"224","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999909060|09-I-N060","January 7, 2010",,,"December 25, 2008",,"March 21, 2024","National Taiwan University, Taiwan, China|National Cheng Kung University, Tainan, Taiwan|National Siriraj Hospital, Mahidol Universtiy, Bangkok, Thailand|Ramathibodi Hospital, Mahidol Universtiy, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT00814827"
1283,"NCT00810446","Safety And Efficacy Of Rifabutin In HIV Patients",,"Completed","Has Results","Non-tuberculous Mycobacterial Diseases|Tuberculosis|Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections","Drug: rifabutin","Number of Patients With Adverse Drug Reactions in This Surveillance|The Number of Participants Who Experienced an Adverse Drug Reaction Not Expected From the Local Product Document (Unknown Adverse Drug Reactions)|Number of Participants With Adverse Drug Reactions by Gender|Number of Participants With Adverse Drug Reactions by Age|Number of Participants With Adverse Drug Reactions by Diagnosis|Clinical Response Rate (Therapeutic)|Clinical Response Rate (Therapeutic) by Gender|Clinical Response Rate (Therapeutic) by Age|Clinical Response Rate (Therapeutic) by Diagnosis","Pfizer","All","Child, Adult, Older Adult",,"72","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A0061007","June 2009","March 2018","March 2018","December 18, 2008","August 2, 2019","August 2, 2019",,"""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT00810446/SAP_000.pdf|""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT00810446/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT00810446"
1284,"NCT00645697","Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization","AVA-ION","Completed","No Results Available","Neovascularization|Tuberculosis|Multifocal Serpiginous Choroiditis|Harada Toxoplasmosis",,"Best corrected visual acuity gain after bevacizumab therapy.|fluorescein leakage of ocular neovascularization by fluorescein angiography and macular thickness by Optical Computed tomography.","Rafic Hariri University Hospital|Heidelberg University|University Hospital Tuebingen|University Hospital Freiburg","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1955AM","January 2007","March 2008","March 2008","March 28, 2008",,"March 28, 2008","American University of Beirut, Beirut, Lebanon",,"https://ClinicalTrials.gov/show/NCT00645697"
1285,"NCT03886701","Doravirine, Rifapentine and Isoniazid Interaction","DORIIS","Completed","Has Results","Latent Tuberculosis|Human Immunodeficiency Virus|Rifamycins Causing Adverse Effects in Therapeutic Use|Drug Interaction Potentiation","Drug: Doravirine (DOR)|Drug: Rifapentine (RPT)|Drug: Isoniazid (INH)","Doravirine Maximum Concentration (Cmax)|Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12)|Doravirine Oral Clearance (CL/F)|Adverse Event","Walter K. Kraft|Merck Sharp & Dohme LLC|Thomas Jefferson University","All","18 Years to 60 Years   (Adult)","Phase 1","11","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12690","April 22, 2019","May 20, 2019","May 20, 2019","March 22, 2019","March 3, 2020","March 27, 2020","Thomas Jefferson University Clinical Research Unit, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/01/NCT03886701/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03886701"
1286,"NCT06347939","Mediastinal EBUS Cryobiopsy Study In Sweden","MECRIS","Not yet recruiting","No Results Available","Mediastinal Lymphadenopathy|Lung Cancer|Sarcoidosis|Lymphoma|Tuberculosis","Diagnostic Test: Mediastinal lymph nodes cryobiopsies","Number of mediastinal cryobiopsies needed per patient to lead to a definite diagnosis.|Adequacy of mediastinal cryobiopsies for PDL1 analysis in lung cancer.","Region Skane","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2023-06638-01","April 1, 2024","April 1, 2026","December 31, 2028","April 4, 2024",,"April 4, 2024",,,"https://ClinicalTrials.gov/show/NCT06347939"
1287,"NCT02639936","New Generation IGRA in Immunocompromised Individuals","TBnet#54","Unknown status","No Results Available","Monitoring, Immunologic|Active Tuberculosis|Tuberculosis in Solid Organ Transplant Recipients|Tuberculosis in Marrow Transplant Recipients|Tuberculosis in Rheumatoid Arthritis|Tuberculosis in Chronic Renal Failure|Tuberculosis in HIV-infected Individuals",,"Specificity|Sensitivity|Indeterminate results|Association with exposure|Progression","Tuberculosis Network European Trialsgroup","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TBnet study #54","December 2015","December 2017","December 2019","December 28, 2015",,"August 9, 2016","Rigshospitalet, Kopenhagen, Denmark|Research center Borstel, Borstel, Germany|Freiburg University, Freiburg, Germany|Saarland University, Homburg, Germany|University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy|San Raffaele Scientific institute, Milano, Italy|National Institute for Infectious Diseases L. Spallanzani, Rome, Italy|Department of Pneumology & Allergology, Chisinau, Moldova, Republic of|Department of Infectious Diseases; Oslo University, Oslo, Norway|Warszawski Uniwersytet Medyczny, Warszawa, Poland|Centro de Diagnóstico Pneumológico, Vila Nova de Gaia, Portugal|Marius Nasta Institute of Pneumology, Bucharest, Sector 5, Romania|Institut d'Investigació Germans Trias i Pujol, Badalona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Department of Respiratory Medicine, Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02639936"
1288,"NCT01298336","Treatment of Mycobacterium Xenopi Pulmonary Infection","CAMOMY","Completed","No Results Available","Atypical; Mycobacterium, Pulmonary, Tuberculous","Drug: Clarithromycin|Drug: Moxifloxacin","Sputum conversion at 6 months under three antibiotics treatment (Rifampin, ethambutol and a third drug clarithromycin or moxifloxacin)|Sputum conversion at 3, 6, 9 and 12 months of treatment in the two different arms (clarithromycin containing regimen versus moxifloxacin containing regimen|Clinical and radiological outcome after 3, 6 and 12 months of treatment according to the treatment arm|Mortality after 12 months of treatment in the two compared regimen|Gastrointestinal toxicity and hematotoxicity after 1- 3- 6- 9- 12- months of treatment","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","Phase 3","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRCN10-DR-ANDREJAK-MELLE","March 2, 2011","March 2019","March 2019","February 17, 2011",,"July 20, 2020","CH Abbeville, Abbeville, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Argenteuil, Argenteuil, France|CHU Besançon, Besançon, France|Assistance Publique Hôpitaux de Paris CHU Avicenne, Bobigny, France|CHU Brest La Cavale, Brest, France|CH Béthune, Béthune, France|CHU Caen, Caen, France|CH Cannes, Cannes, France|CHU Clermont Ferrand Hôpital Gabriel Mont pied, Clermont Ferrand, France|CH Compiègne, Compiègne, France|CH Sud Francilien, Corbeil-Essonnes, France|Centre Intercommunal de Créteil, Creteil, France|CHU Dijon, Dijon, France|CH Gonesse, Gonesse, France|CHU Grenoble, Grenoble, France|Assistance Publique Hôpitaux de Paris Hôpital Bicetre, Le Kremlin-Bicêtre, France|CH Le MANS, Le Mans, France|CH Intercommunal Meulan, Les Mureaux, France|CHU Lille Hôpital Calmette, Lille, France|CHU Limoges Hôpital de Cluzeau, Limoges, France|CHU Lyon Hôpital La Croix Rousse, Lyon, France|Hopital Saint-Joseph, Marseille, France|Assistance Publique Hôpitaux de Marseille, Marseille, France|CHU Montpellier Hôpital Arnaud de Villeneuve, Montpellier, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|Chr Orleans, Orléans, France|Assistance Publique Hôpitaux de Paris Hôpital Saint Louis, Paris, France|Assistance Publique Hôpitaux de Paris Hôpital Saint Antoine, Paris, France|Centre National de Reference Des Mycobactéries, Paris, France|Assistance Publique Hôpitaux de Paris Hôpital BICHAT, Paris, France|Assistance Publique Hôpitaux de Paris, hôpital TENON, Paris, France|CHU Bordeaux Hôpital Haut Leveque, Pessac, France|CHU Poitiers, Poitiers, France|Hopital René DUBOS, Pontoise, France|CHU Reims, Reims, France|CHU de Rennes Hôpital Ponchaillou, Rennes, France|CH de Roubaix, Roubaix, France|CHU Rouen, Rouen, France|CHU de Saint Etienne, Saint Etienne, France|CH de Saint Quentin, Saint Quentin, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU de Strasbourg, Strasbourg, France|Hôpital FOCH, Suresnes, France|CHU Toulouse, Toulouse, France|CH de Tourcoing, Tourcoing, France|CHU Tours Hôpital BRETONNEAU, Tours, France|CH Troyes, Troyes, France|CH de Valenciennes, Valenciennes, France|CHU Nancy, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT01298336"
1289,"NCT00002085","A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy",,"Completed","No Results Available","Mycobacterium Avium-Intracellulare Infection|HIV Infections|Tuberculosis, Mycobacterium Infection","Drug: Azithromycin",,"Pfizer|NIH AIDS Clinical Trials Information Service","All","1 Day and older   (Child, Adult, Older Adult)","Not Applicable",,"Industry","Interventional","Primary Purpose: Treatment","058D|066-169",,,,"August 31, 2001",,"June 24, 2005","Pfizer Central Research, Groton, Connecticut, United States|Natl Cancer Institute / Metabolism Branch, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00002085"
1290,"NCT00342017","The Effect of Parasitic Worm Infections on the Immune Response to Tuberculosis Bacteria",,"Completed","No Results Available","Intestinal Helminth Infection|Filarial Infection",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","6 Years to 65 Years   (Child, Adult, Older Adult)",,"5200","NIH","Observational",,"999901261|01-I-N261","May 20, 2002","September 2, 2008",,"June 21, 2006",,"July 2, 2017","Tuberculosis Research Centre, Chennai, India",,"https://ClinicalTrials.gov/show/NCT00342017"
1291,"NCT03383211","Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers","IMMUNEO","Completed","No Results Available","HIV Infections|Neonatal Infection|LTBI - Latent Tuberculosis Infection|Immune Tolerance","Other: RNAseq","Changes in immune-associated transcripts","George Washington University|Universitatea de Stat de Medicina si Farmacie Nicolae Testemiţanu|Children's National Research Institute|DC-Center for Aids Research (DC-CFAR)|SeqLL, Inc.","Female","18 Years to 45 Years   (Adult)",,"125","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GWMDA2017","June 16, 2017","September 1, 2020","June 30, 2021","December 26, 2017",,"October 20, 2021","Clinical Municipal Hospital No. 1, Chisinau, Moldova, Republic of|National Center for Mother and Child Health, Chisinau, Moldova, Republic of",,"https://ClinicalTrials.gov/show/NCT03383211"
1292,"NCT01955824","A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy",,"Completed","No Results Available","Lung Cancer|Tuberculosis|Sarcoidosis|Interstitial Lung Disease","Drug: 1% lignocaine|Drug: 2% lignocaine","Cough suppression (by Operator and Patient)|Pain control","Post Graduate Institute of Medical Education and Research, Chandigarh|PIMERIndia","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Bron/Lig/Tr-1","May 2014","November 2014","November 2014","October 8, 2013",,"December 30, 2014","Bronchoscopy suite, PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01955824"
1293,"NCT01836822","Bronchoscopic Sampling Techniques in Sarcoidosis",,"Unknown status","No Results Available","Mediastinal Lymph Node Enlargement|Sarcoidosis|Tuberculosis|Lymphomas","Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA)|Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|Procedure: Bronchoalveolar lavage (BAL)|Procedure: Endobronchial forceps biopsy","Accuracy of different bronchoscopic sampling methods in making the diagnosis of sarcoidosis.|Adequacy of cytologic and histopathologic specimens collected by different sampling method as the diagnostic samples enabling confirmation of granulomatous lymph node disease.","Medical University of Warsaw","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","IPU-DIMPA-WUM13(1)","March 2013","March 2014","May 2014","April 22, 2013",,"February 12, 2014","Department of Internal Medicine, Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT01836822"
1294,"NCT04033718","Inpatient Package to Reduce HIV and AIDS-related Death in Zambia","IPADZ","Recruiting","No Results Available","HIV/AIDS|Transitions of Care|Hospitalization|Tuberculosis|HIV Testing|Cryptococcosis","Diagnostic Test: Inpatient lab bundling|Behavioral: Inpatient navigation","Coinfection diagnosis","University of Alabama at Birmingham|University Teaching Hospital|University of Maryland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","300003461","October 1, 2021","June 30, 2024","June 30, 2024","July 26, 2019",,"March 20, 2024","University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT04033718"
1295,"NCT05526911","A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults",,"Completed","No Results Available","Pulmonary Disease|Tuberculosis, Pulmonary|Tuberculosis|Multi Drug Resistant Tuberculosis|Drug Sensitive Tuberculosis|Drug-resistant Tuberculosis|Mycobacterium Tuberculosis Infection","Drug: TBAJ-876|Drug: Midazolam|Drug: Digoxin|Drug: TLD","TBAJ-876 effect on the pharmacokinetics of the CYP-3A4 substrate midazolam and the inhibition potential of TBAJ-876 on P-gp in healthy adult subjects|TBAJ-876 effect on the pharmacokinetics of the P-gp substrate digoxin|Number of Participants with Treatment-Related Adverse Events in Group 1 Population|Number of Participants with Treatment-Related Adverse Events in Group 2 Population","Global Alliance for TB Drug Development","All","18 Years to 55 Years   (Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBAJ-876-CL002","July 20, 2022","August 28, 2022","August 28, 2022","September 2, 2022",,"May 19, 2023","TKL Research, Inc., Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05526911"
1296,"NCT04493671","Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults",,"Completed","No Results Available","Pulmonary Disease|Tuberculosis, Pulmonary|Tuberculosis|Multi Drug Resistant Tuberculosis|Drug Sensitive Tuberculosis|Drug-resistant Tuberculosis|Mycobacterium Tuberculosis Infection","Drug: TBAJ-876 10mg|Drug: TBAJ-876 25mg|Drug: TBAJ-876 50mg|Drug: TBAJ-876 100mg|Drug: TBAJ-876 200mg|Drug: TBAJ-876 400mg|Drug: TBAJ-876 Dose XXXmg for Food cohort|Drug: TBAJ-876 XXXmg for Part 2|Drug: Matching Placebo for TBAJ-876 tablet","Physical examination [Safety and Tolerability]|Vital signs [Safety and Tolerability]|12-lead safety ECGs [Safety and Tolerability]|Coagulation tests [Safety and Tolerability]|Urine pregnancy test (females only) [Safety and Tolerability]|FSH test (Post-menopausal females) [Safety and Tolerability]|PK blood collection [Safety and Tolerability]|AUCExtrap [Pharmacokinetic Analysis]|AUCinf [Pharmacokinetic Analysis]|AUClast [Pharmacokinetic Analysis]|AUCtau [Pharmacokinetic Analysis]|Cavg [Pharmacokinetic Analysis]|Clast [Pharmacokinetic Analysis]|CL/F [Pharmacokinetic Analysis]|CLss/F [Pharmacokinetic Analysis]|Cmax [Pharmacokinetic Analysis]|RAUC [Pharmacokinetic Analysis]|RCmax [Pharmacokinetic Analysis]|Tlast [Pharmacokinetic Analysis]|Tmax [Pharmacokinetic Analysis]|T1/2 [Pharmacokinetic Analysis]|Vz/F [Pharmacokinetic Analysis]|λz [Pharmacokinetic Analysis]","Global Alliance for TB Drug Development","All","19 Years to 50 Years   (Adult)","Phase 1","107","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TBAJ-876-CL-001","June 8, 2020","June 16, 2022","November 15, 2022","July 30, 2020",,"November 21, 2022","Worldwide Clinical Trials, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04493671"
1297,"NCT04677842","European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol","EPPICC","Active, not recruiting","No Results Available","HIV Infections|Tuberculosis Infection|Hepatitis C|Covid19","Drug: ART Therapy","CD4 count in adulthood of young people with HIV assessed using routine clinical data|2. Viral suppression in adulthood of young people with HIV assessed using routine clinical data|Viral suppression defined as <50 copies, <400 copies and 1000 copies/mL) upto 144 weeks.|CD4 change from drug start up to 144 weeks|Cumulative incidence of virological failure (>1000 copies/mL)|From start of novel drug of interest through to earliest date of the following: death, loss to follow-up, discontinuation of drug or last visit","PENTA Foundation|MRC Clinical Trials Unit at UCL|Centre Hospitalier Universitaire Saint Pierre|German Pediatric and Adolescent HIV Cohort (GEPIC), GERMANY|Greece Cohort, GREECE|Register for HIV infection in children, ITALY|ATHENA ,THE NETHERLANDS|Polish Paediatric Cohort, POLAND|HSM/CHLN Lisbon, PORTUGAL|Centro Hospitalar do Porto|Victor Babes Hospital Cohort, Bucharest, ROMANIA|Republican Hospital of Infectious Diseases, St Petersburg, RUSSIA|Irkutsk AIDS Centre, RUSSIA|The City HIV Centre, St Petersburg, RUSSIA|CoRISpe-cat cohort of HIV-infected children, SPAIN|CoRISpe-S cohort of HIV-infected children, SPAIN|Karolinska Institutet|Swiss Mother and Child HIV Cohort Study, SWITZERLAND|Programs for HIV Prevention and Treatment (PHPT), THAILAND|National Surveilliance of HIV in Pregnancy and Childhood and Collaborative HIV Paediatric Study (CHIPS)|Collaborative HIV Paediatric Study (CHIPS)|Ukraine Paediatric HIV Cohort, UKRAINE","All","up to 17 Years   (Child)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","EPPICC","January 1, 2013","November 11, 2020","January 1, 2025","December 21, 2020",,"December 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04677842"
1298,"NCT03084614","CD8 Reactivity to Microorganisms in Blood and Breast Milk",,"Terminated","No Results Available","Immune Modulation|Tuberculosis|Leprosy|Pertussis|Lyme Disease",,"To compare the in vitro and mouse model immune stimulatoryproperties of lysates derived from microbe-specific CDB+ T cellenriched sources.|To compare how the in vitro and mouse model immune stimulatoryproperties of breast milk vary with the microbe specific CDB+ T cellconcentration.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)",,"10","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","170068|17-I-0068","March 28, 2017","February 16, 2018","November 8, 2019","March 21, 2017",,"November 14, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03084614"
1299,"NCT03152903","Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence",,"Active, not recruiting","No Results Available","Prevention of TB Recurrence","Biological: VPM1002 (Recombinant BCG Vaccine)|Other: Placebo","Percentage of bacteriologically confirmed TB recurrence cases|Percentage of overall TB recurrence (i.e. either bacteriologically confirmed or clinically diagnosed TB recurrence)|Safety assessed by Solicited local and regional reactogenicity and Unsolicited adverse events and SAEs","Serum Institute of India Pvt. Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","2000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VPM1002-IN-3.01TBR","December 15, 2017","April 30, 2024","July 30, 2024","May 15, 2017",,"April 8, 2024","International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh|Mahavir Hospital & Research Centre, Hyderabad, Hyderabad, Andhra Pradesh, India|Government Medical College, Jammu, Jammu, Jammu And Kashmir, India|B.J. Govt. Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Mahatma Gandhi Institute of Medical Sciences, Sevagram, Sevagram, Maharashtra, India|Christian Medical College and Hospital, Ludhiana, Ludhiana, Punjab, India|MV Hopsital for Diabetes Pvt Ltd, Chennai, Chennai, Tamil Nadu, India|Sri Ramachandra Hospital Chennai, Chennai, Tamil Nadu, India|Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, Tamil Nadu, India|Christian Medical College and Hospital, Vellore, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT03152903"
1300,"NCT04645836","Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.",,"Completed","No Results Available","Pulmonary TB|TB","Behavioral: New management mode","TB treatment success rates|Adherence to treatment among drug-sensitive tuberculosis patients self reported and clinical record will checked for the follow up visits and drug taken|Health related Quality of Life of TB patients|Lost To Follow|Patient satisfaction questionnaire","Health Science Center of Xi'an Jiaotong University|Pakistan Institute of Medical Sciences|Quaid i Azam University Islamabad Pakistan","All","18 Years to 78 Years   (Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","FUKhan","September 1, 2020","December 30, 2021","December 30, 2021","November 27, 2020",,"June 29, 2022","Pakistan Institute of Medical Sciences Islamabad, Islamabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT04645836"
1301,"NCT00932854","A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY)","REMEDY","Unknown status","No Results Available","Isolated Mediastinal Lymphadenopathy|Sarcoidosis|Tuberculosis|Lung Cancer|Lymphoma","Procedure: EBUS","Number of mediastinoscopies prevented and healthcare costs|Length of hospital stay|Sensitivity and false negative rate of endobronchial ultrasound","University College London Hospitals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","REMEDY 09/0090","July 2009","April 2011","October 2011","July 3, 2009",,"October 18, 2011","University College London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00932854"
1302,"NCT03722472","Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults",,"Completed","Has Results","Pulmonary TB","Biological: ID93 + GLA-SE","Local Injection Site Reactogenicity|Systemic Reactogenicity|All Adverse Events|Serious Adverse Events|IgG Antibody Response Rate|IgG Antibody Response Magnitude|Cytokine Response|T Cell Response","Access to Advanced Health Institute (AAHI)|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 55 Years   (Adult)","Phase 1","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IDRI-TBVPX-120|DMID 17-0104|272201400041C-0-0-1","October 2, 2018","June 15, 2020","June 15, 2020","October 29, 2018","June 1, 2023","June 1, 2023","Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/72/NCT03722472/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/72/NCT03722472/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03722472"
1303,"NCT04850742","Feasibility of Tracheobronchial Reconstruction Using Bioengineered Aortic Matrices",,"Unknown status","No Results Available","Trachea Diseases|Tracheal Stenosis|Lung Cancer|Tuberculosis; Tracheitis|Airway Disease","Procedure: Cryopreserved aorta","90-day mortality|90-day morbidity","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201812035DINC","January 1, 2019","December 31, 2023","March 2024","April 20, 2021",,"May 11, 2021","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04850742"
1304,"NCT03025516","Performance Evaluation of TB Breath- and Cough-testing Platforms",,"Unknown status","No Results Available","Pulmonary TB|Diagnoses Diseases","Device: Rapid Biosensor Systems (RBS) TB Breathalyser|Device: eNose AeonoseTM","Microbiological TB Diagnosis","Find|Universidad Peruana Cayetano Heredia|University of Cape Town","All","18 Years and older   (Adult, Older Adult)",,"360","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P07212-00","May 29, 2017","December 2017","December 2017","January 19, 2017",,"July 21, 2017","Nolungile Clinic, University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT03025516"
1305,"NCT00741169","TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.",,"Completed","No Results Available","Hepatitis C|HCV|Tuberculosis|Rifampin|Pharmacokinetics","Drug: TMC435350|Drug: Rifampin|Drug: TMC435350+rifampin","Pharmacokinetic (PK) profile of TMC435350|Pharmacokinetic (PK) profile of rifampin and 25-deacetylrifampin|The number of participants reporting adverse events as a measure of safety and tolerability.","Tibotec Pharmaceuticals, Ireland","All","18 Years to 55 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR015412","June 2008","December 2008","December 2008","August 26, 2008",,"April 18, 2013",,,"https://ClinicalTrials.gov/show/NCT00741169"
1306,"NCT02027480","Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study","iMACS","Completed","No Results Available","HIV (Human Immunodeficiency Virus)|AIDS (Acquired Immune Deficiency Syndrome)|Tuberculosis|Non-communicable Diseases (NCD)",,"Change in mean high-sensitivity C-reactive protein (hsCRP) levels measured in mg/L|Change in mean interleukin-6 (IL-6) levels measured in ng/mL|Prevalence (% of participants) of smoking in the study population|Prevalence (% of participants) of high BMI in the study population|Prevalence (% of participants) of cotinine in blood in the study population.|Prevalence (% of participants) of hypertension in the study population.|Prevalence (% of participants) of diabetes in the study population.|Prevalence (% of participants) of overweight/obesity in the study population.|Prevalence (% of participants) of tuberculosis in the study population.","Columbia University|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"685","Other|NIH","Observational","Time Perspective: Prospective","AAAM2314","March 2014","October 2015","October 2015","January 6, 2014",,"December 24, 2015","Ahero Sub District Hospital, Ahero, Nyanza, Kenya|Ambira Sub District Hospital, Ambira, Nyanza, Kenya|Awasi Mission, Awasi, Nyanza, Kenya|Bondo District Hospital, Bondo, Nyanza, Kenya|Nyakach District Hospital, Kisumu, Nyanza, Kenya|Masogo Sub District Hospital, Masogo, Nyanza, Kenya|Nyangoma Dispensary, Nyangoma, Nyanza, Kenya|Sigomere Health Centre, Sigomere, Nyanza, Kenya|Sondu Health Center, Sondu, Nyanza, Kenya",,"https://ClinicalTrials.gov/show/NCT02027480"
1307,"NCT01785927","The Safety of Tuberculosis Treatments by Oral Inhalation",,"Unknown status","No Results Available","Healthy","Other: ABCD","Cytokine levels (Tumor Necrosis Factor-α and Interleukin-1β)|Liver function tests (tB/dB, AST, ALT, ALP)","Prince of Songkla University|National Research Council of Thailand","All","18 Years to 45 Years   (Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","RES.no. 18/2554","February 2013","April 2013","April 2013","February 7, 2013",,"February 7, 2013","Songklanagarind Hospital, Hat Yai, Songkla, Thailand",,"https://ClinicalTrials.gov/show/NCT01785927"
1308,"NCT05493267","A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB",,"Recruiting","No Results Available","MDR-TB|Immunotherapy","Drug: Vγ2Vδ2 T lymphocyte-based immunotherapy|Drug: Treatment regimens for MDR-TB","Sputum smear and culture negative conversion|Radiographic changes","Shanghai Pulmonary Hospital, Shanghai, China|Shanghai Public Health Clinical Center|Huashan Hospital|No.85 Hospital, Changning, Shanghai, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L20-209","August 3, 2022","August 3, 2025","August 3, 2027","August 9, 2022",,"August 10, 2022","Shanghai Pulmonary Hospital, Shanghai, China, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05493267"
1309,"NCT05278988","A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB",,"Recruiting","No Results Available","MDR-TB","Drug: PRS Regimen V|Drug: MDR-TB Treatment Regimen(WHO)","patient cure rate|Early bactericidal activity (EBA)|Time to culture positivity|Sputum conversion rate|Radiology changes|Relapse rate one and two years after treatment completion.|Time to Cure by Primary Endpoint criteria","Shanghai Pulmonary Hospital, Shanghai, China|Shanghai Public Health Clinical Center|No.85 Hospital, Changning, Shanghai, China|Ganzhou Fifth People's Hospital, China|Weifang Second People's Hospital, China|Anhui Chest Hospital|Fourth Taiyuan People's Hospital, China|Shanghai Pudong New Area Pulmonary Hospital, China|Huashan Hospital|Zhengzhou Sixth People's Hospital, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K21-024","April 1, 2021","September 30, 2024","September 30, 2024","March 15, 2022",,"August 8, 2022","Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05278988"
1310,"NCT04124055","Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania",,"Completed","No Results Available","MDR-TB","Diagnostic Test: Therapeutic drug monitoring (TDM)","Drug exposure","Jan-Willem C Alffenaar|Kibong'oto Infectious Diseases Hospital|University of Virginia|University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","51","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S-DBS-TDM-001","September 24, 2019","December 15, 2019","December 31, 2019","October 11, 2019",,"October 30, 2020","Kibong'oto infectious diseases hospital, Kibong'oto, Tanzania",,"https://ClinicalTrials.gov/show/NCT04124055"
1311,"NCT03069534","Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB","rhIL-2","Unknown status","No Results Available","MDR TB","Drug: RhIL-2","Cure rate|sputum smear/culture conversion rate","The First Affiliated Hospital with Nanjing Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","rhIL-2 Therapy ON MDR-TB","June 1, 2009","June 1, 2019","March 1, 2020","March 3, 2017",,"March 3, 2017","the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03069534"
1312,"NCT05405296","Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2)","Truenat COMBO","Active, not recruiting","No Results Available","TB|COVID-19","Device: Truenat™ MTB Plus/COVID-19","Point estimates of sensitivity and specificity of Truenat™ MTB Plus/COVID-19|Point estimates of sensitivity and specificity of Truenat™ MTB Plus/COVID-19, with 95% confidence intervals, using a country-approved RT-PCR COVID-19|Point estimates of sensitivity and specificity of Truenat™ MTB Plus/COVID-19multiplex for TB detection compared to Xpert Ultra among presumptive TB patients using a MRS|Estimate of the proportion of presumptive TB patients with COVID-19|Estimate of the proportion of TB patients (confirmed by MRS) with COVID-19|Analysis of survey responses using proportions and Linkert scale averages","Foundation for Innovative New Diagnostics, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"1480","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TB050","August 30, 2022","April 2024","September 2024","June 6, 2022",,"January 18, 2024","Makarere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT05405296"
1313,"NCT00212550","Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb",,"Completed","No Results Available","Pulmonary TB","Procedure: Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.",,"NYU Langone Health","All","21 Years to 75 Years   (Adult, Older Adult)",,"10","Other","Observational","Time Perspective: Prospective","9250-04B","January 2006","February 2010","January 2012","September 21, 2005",,"March 31, 2016","NYU School of Medicine Division of Pulmonary and Critical Care, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00212550"
1314,"NCT04874948","Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Bacterial Infections Respiratory|Lung Diseases|Mycobacterium Infections","Drug: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043","Maximum Observed Plasma Concentration (Cmax) of total radioactivity|Time to attain maximum observed plasma concentration (tmax) of total radioactivity|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of total radioactivity|Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of total radioactivity|Terminal elimination rate constant (Kel) of total radioactivity|Terminal elimination half-life (t1/2) of total radioactivity|Cumulative amount excreted in urine (Ae urine) of total radioactivity|Cumulative amount of total radioactivity excreted in feces (Ae feces)|Cumulative amount of total radioactivity excreted in vomit, if produced (Ae vomit)|Total amount of total radioactivity excreted (Ae total)|Fraction of the total radioactivity administered excreted in urine (%) (Fe urine) of total radioactivity|Fraction of the total radioactivity administered excreted in feces (%) (Fe feces)|Fraction of the total radioactivity administered excreted in vomit(%) (Fe vomit)|Fraction of the total radioactivity administered (Fe total) excreted in urine, feces, and vomit (if produced) (%)|Maximum Observed Plasma Concentration (Cmax) of BTZ-043 and main metabolites|Time to attain maximum observed plasma concentration (tmax) of BTZ-043 and main metabolites|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of BTZ-043 and main metabolites|Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of BTZ-043 and main metabolites|Terminal elimination half-life of total radioactivity (t1/2) of BTZ-043 and main metabolites|Terminal elimination rate constant (Kel) of BTZ-043 and main metabolites|Fraction of the dose administered excreted in urine (%) (Fe urine) of BTZ-043 and main metabolites|Cumulative amount excreted in urine (Ae urine) of BTZ-043 and main metabolites|Apparent oral clearance (CL/F) of BTZ-043|Apparent volume of distribution (Vz/F) at terminal phase of BTZ-043|Renal clearance (CL r) of BTZ-043|Number of participants with treatment-related adverse events oncerning safety laboratory graded using the most current version of the MedDRA:|Number of participants with treatment-related adverse events concerning vital signs graded using the most current version of the MedDRA:|Number of participants with treatment-related adverse events concerning physical examination graded using the most current version of the MedDRA:|Number of participants with treatment-related adverse events concerning 12-lead electrocardiogram graded using the most current version of the MedDRA:","Michael Hoelscher|Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institut|Ludwig-Maximilians - University of Munich","Male","18 Years to 55 Years   (Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMU-IMPH-BTZ-043-03","September 21, 2021","October 15, 2021","October 15, 2021","May 6, 2021",,"October 27, 2021","PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04874948"
1315,"NCT05685641","Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City","PREVALIOCDMX","Not yet recruiting","No Results Available","Acquired Immunodeficiency Syndrome|Histoplasmosis AIDS|Tuberculosis Infection|Cryptococcal Meningitis","Diagnostic Test: Histoplasma Urine Antigen Lateral Flow Antigen test|Diagnostic Test: Cryptococcal Lateral Flow Antigen test|Diagnostic Test: Tuberculosis-lipoarabinomannan Lateral Flow Antigen test","Time until opportunistic infection treatment initiation|AIDS-related mortality at 30 days|AIDS-related mortality at 90 days|Monthly incidence of histoplasmosis, cryptococcosis and tuberculosis|Time until antiretroviral treatment initiation","National Institute of Respiratory Diseases, Mexico|National Institute of Cancerology|Hospital General Dr. Manuel Gea González|National Institute of Medical Sciences and Nutrition, Salvador Zubiran","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","211","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","181250","April 1, 2023","March 30, 2024","September 30, 2024","January 17, 2023",,"January 17, 2023","General Hospital Dr. Manuel Gea Gonzalez, Mexico City, Mexico|National Center of Nutrition and Medical Sciences, Mexico City, Mexico|National Institute of Cancerology, Mexico City, Mexico|National Institute of Respiratory Diseases, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT05685641"
1316,"NCT03590600","A Single Ascending Dose Study of BTZ043",,"Completed","No Results Available","Tuberculosis|Tuberculosis, Pulmonary|Bacterial Infections|Lung Diseases|Mycobacterium Infections","Drug: BTZ-043|Drug: Placebo","Number of participants with treatment-related adverse events concerning ECG as assessed by CTCAE v4.03 (Common Terminology Criteria for Adverse Events)|Number of participants with treatment-related adverse events concerning safety laboratory as assessed by CTCAE v4.03|Number of participants with treatment-related adverse events concerning vital signs as assessed by CTCAE v4.03|Number of participants with treatment-related adverse events concerning clinical observations as assessed by CTCAE v4.03|Pharmacokinetic assessment of BTZ-043 after a single oral dose|Determining the effect of sex differences on systemic exposure by analyzing the PK of BTZ-043 in male and female participants.","Michael Hoelscher|German Center for Infection Research|German Federal Ministry of Education and Research|Hans Knöll Institute (HKI)|Ludwig-Maximilians - University of Munich","All","18 Years to 55 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LMU-IMPH-BTZ043-01","June 7, 2018","August 14, 2018","March 5, 2019","July 18, 2018",,"March 7, 2019","Nuvisan, Neu-Ulm, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT03590600"
1317,"NCT01475409","A Study on Changes in IFN-gamma Levels Following Anti-TNF Treatment in Patients Undergoing Serial QuantiFERON-TB Gold In-Tube",,"Completed","No Results Available","Inflammatory Rheumatic Diseases","Biological: QuantiFERON-TB Gold In-Tube (QFT-GIT)","Change from baseline in IFN-gamma plasma levels following serial QFT-GIT testing during the treatment with anti-TNF agents|Performance of QFT-GIT and its agreement with TST in patients under consideration for anti-TNF agents","University of Roma La Sapienza","All","18 Years and older   (Adult, Older Adult)","Not Applicable","119","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","URomLS01","July 2008","February 2010","February 2011","November 21, 2011",,"November 21, 2011",,,"https://ClinicalTrials.gov/show/NCT01475409"
1318,"NCT03896685","Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","endTB-Q","Active, not recruiting","No Results Available","Tuberculosis, Multidrug-Resistant|Tuberculosis|Pulmonary Tuberculoses|Mycobacterial Infections|Bacterial Infections|Gram-Positive Bacterial Infections","Drug: Bedaquiline 100 MG|Drug: Delamanid 50 MG Oral Tablet|Drug: Clofazimine 100 MG Oral Capsule|Drug: Linezolid 600Mg Tab|Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines","Week 73 Efficacy: Proportion of participants with favorable outcome at Week 73|Week 104 Efficacy: Proportion of participants with favorable outcome at Week 104|Early Treatment Response (culture conversion)|Week 39 Efficacy: Proportion of participants with favorable outcome at Week 39|Week 73 Failure/Relapse|Week 104 Failure/Relapse|Week 73 Survival|Week 104 Survival|Week 73 AEs and SAEs|Week 104 AEs and SAEs|Week 73 AESIs|Week 104 AESIs","Médecins Sans Frontières, France|Partners in Health|Harvard Medical School (HMS and HSDM)|Epicentre|Institute of Tropical Medicine, Belgium|Socios En Salud, Peru|Interactive Research and Development|University of San Francisco","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","323","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSF ERB-1761","April 6, 2020","September 2024","November 2024","April 1, 2019",,"July 21, 2023","Aundh Chest Hospital, Pune, India|National Center for Tuberculosis Problems, Almaty, Kazakhstan|State Municipal Enterprise on the right of economic management ""City Centre of Phthisiopulmonology"" of Nur-sultan city's administration, Nur-Sultan, Kazakhstan|Partners In Health Lesostho, Maseru, Lesotho|The Indus Hospital, Karachi, Pakistan|Institute of Chest Disease,, Kotri, Pakistan|Centro de Investigación del Hospital Nacional Hipólito Unanue, Lima, Peru|Centro de Investigación de Enfermedades Neumológicas del Hospital Nacional Sergio Bernales, Lima, Peru|Hanoi Lung Hospital, Hanoi, Vietnam|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam","""Informed Consent Form: endTB-Q_Research Screening Adult Consent_Assent form V4.3"", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT03896685/ICF_006.pdf|""Informed Consent Form: endTB-Q_Research Screening Parental Consent form V4.3"", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT03896685/ICF_007.pdf|""Informed Consent Form: endTB-Q_Research Adult Consent_Assent form v4.3"", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT03896685/ICF_008.pdf|""Informed Consent Form: endTB-Q_Research Parental Consent form v4.3"", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT03896685/ICF_009.pdf|""Informed Consent Form: endTB-Q_Pregnant Partner Consent form V4.3"", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT03896685/ICF_010.pdf|""Informed Consent Form: endTB-Q_Treatment during pregnancy_Consent form V4.3"", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT03896685/ICF_011.pdf","https://ClinicalTrials.gov/show/NCT03896685"
1319,"NCT00480558","A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both",,"Completed","No Results Available","HIV Infections|TB","Biological: MVA 85A","To assess the safety of a single intradermal injection of 5 x 107p.f.u. MVA85A.|To assess the effect of a single vaccination with MVA85A in asymptomatic participants who are infected with M.Tb or HIV or both on the immune response, both to antigen 85A (the antigen in the vaccine) and to ESAT6/CFP10 antigens (M.tb specific).","University of Oxford|University of Cape Town","All","21 Years to 50 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB011","July 2007","January 2011","January 2011","May 31, 2007",,"March 28, 2011","University Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT00480558"
1320,"NCT05174741","Pulmonary Rehabilitation in Non-chronic Obstructive Pulmonary Disease Patients.",,"Not yet recruiting","No Results Available","Pneumonia|Pulmonary Fibrosis|Tuberculosis|Bronchiectasis|Asthma","Other: Conventional Chest Physiotherapy|Other: Aerobic training Group","Forced Expiratory Volume in 1 second (FEV1)|Forced vital Capacity (FVC)|Peak Expiratory Flow (PEF)|Health related Quality of life","Riphah International University","All","30 Years to 60 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Rec/00882 Aleena Ashraf","April 2023","February 2024","February 2024","January 3, 2022",,"February 21, 2023","Pakistan railway hospital, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT05174741"
1321,"NCT02454569","Vicente Ferrer HIV Cohort Study","VFHCS","Recruiting","No Results Available","HIV|Tuberculosis|Cryptococcosis|Opportunistic Infections|Noncommunicable Diseases",,"Mortality","Rural Development Trust Hospital","All","Child, Adult, Older Adult",,"30000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VFHCS","September 2009","September 2039","January 2040","May 27, 2015",,"March 29, 2023","RDT Hospital, Battalapalli, AP, India",,"https://ClinicalTrials.gov/show/NCT02454569"
1322,"NCT04232384","Comparison of ""Roll-over' Technique With Standard Abdominal Paracentesis in Suspected Peritoneal Carcinomatosis","ROLLON","Terminated","No Results Available","Ascites|Peritoneal Carcinomatosis|Peritoneum Neoplasm|Tuberculous Peritonitis","Procedure: Standard Paracentesis|Procedure: Roll Over Paracentesis","Yield of malignant cells|Cellularity of the smear of the smear","Post Graduate Institute of Medical Education and Research, Chandigarh|PGIMER","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","71","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","NK/6111/DM/055","June 15, 2020","July 1, 2021","July 1, 2021","January 18, 2020",,"March 17, 2022","Postgraduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT04232384"
1323,"NCT06354621","Impact of Vitamin D Supplementation on Fetomaternal Outcomes in LTBI Pregnant Females","RCT","Completed","No Results Available","Maternal and Child Health","Dietary Supplement: Vitamin-D supplementation","Pre-Eclampsia (Maternal Outcome)|Gestational Diabetes Mellitus (Maternal Outcome)|C/Section delivery (Maternal Outcomes)|Low Birth Weight (Foetal Outcome)|Pre-Term delivery (Foetal Outcome)|Apgar Score (Foetal Outcome)|Improvement in maternal vitamin-D levels","University of the Punjab","Female","18 Years to 35 Years   (Adult)","Phase 1|Phase 2","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","D/185/FIMS","September 1, 2023","February 28, 2024","March 20, 2024","April 9, 2024",,"April 9, 2024","University of the Punjab, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT06354621"
1324,"NCT02747654","Isoniazid Dosage Prediction Model Development",,"Unknown status","No Results Available","NAT2 Genotype","Genetic: genotype","Serum concentrations of INH","Samsung Medical Center","All","17 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC-2013-07-155-002","June 2014","December 2016",,"April 22, 2016",,"April 22, 2016","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02747654"
1325,"NCT05382130","INTEGrating Ag-RDTs for COVID-19 in MNCH,HIV and TB Services in Cameroon and Kenya","INTEGRATE","Completed","No Results Available","COVID-19","Diagnostic Test: Test all","SARS-CoV-2 case detection rate|Proportion of contacts tested for SARS-CoV2 infection|Proportion of contacts identified with SARS-CoV-2 infection|Testing rates, linkage to care, disease progression, treatment and final outcome for SARS-CoV-2 infected patients|Linkage to care for SARS-CoV-2 infected patients|Disease progression, treatment and final outcome for SARS-CoV-2 infected patients|Feasibility and acceptability of integrating the model and the cost of the test-all versus screen-and-test models","Elizabeth Glaser Pediatric AIDS Foundation|UNITAID|Kenya Ministry of Health|Ministry of Public Health, Cameroon","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","152082","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","EG0274","May 17, 2022","March 31, 2023","March 31, 2023","May 19, 2022",,"January 11, 2024","Health facilities in Cameroon, Yaoundé, Cameroon|Health facilities in Kenya, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT05382130"
1326,"NCT01805258","Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB","""NVP""","Completed","No Results Available","HIV/TB Co-infection","Drug: Nevirapine|Drug: Efavirenz","Virological suppression at 48 weeks.|Number of Participants with Adverse Events especially Hepatotoxicity as a measure of Safety.","All India Institute of Medical Sciences, New Delhi|National AIDS Control Organisation","All","18 Years to 60 Years   (Adult)","Phase 3","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKS/NACO-1/2006-07","June 2007","December 2012","February 2013","March 6, 2013",,"March 26, 2013","All India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT01805258"
1327,"NCT03164291","Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex",,"Completed","No Results Available","Nontuberculous Mycobacterial Infections","Drug: Rifabutin","Clinical and microbiological outcomes (e.g. clinical symptoms, laboratory cultures)|Microbiological Cultures","The University of Texas Health Science Center at Tyler|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","072","June 1984","September 2006","May 18, 2017","May 23, 2017",,"May 23, 2017","The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03164291"
1328,"NCT03106727","Evaluating the Impact of a Community Health Worker Program in Neno, Malawi",,"Completed","No Results Available","HIV/AIDS|Hypertension|Asthma|Diabetes|Epilepsy|Mental Health Disorder|Malnutrition|Tuberculosis|Antenatal Care|Family Planning","Behavioral: Household model","HIV|Hypertension|Asthma|Diabetes|Epilepsy|Mental Health|Malnutrition|Tuberculosis|Family Planning|Antenatal Care|ART Initiation|EID|HTC|Malnutrition - Cured|Tuberculosis Treatment|Modern Family Planning Methods|Newly Initiated Family Planning|ANC Coverage|4+ ANC Visits|CHW Retention","Partners in Health|University of Warwick","All","Child, Adult, Older Adult","Not Applicable","122395","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","16/11/1694","March 1, 2017","July 31, 2019","July 31, 2019","April 10, 2017",,"September 23, 2019","Partners In Health / Abwenzi Pa Za Umoyo, Neno, Malawi",,"https://ClinicalTrials.gov/show/NCT03106727"
1329,"NCT01190540","Integrated Infectious Disease Capacity-Building Evaluation","IDCAP","Completed","No Results Available","Capacity Building|Support for Midlevel Health Professionals|Diagnostic Training","Behavioral: Training and supervision|Behavioral: Training and Supervision|Behavioral: Integrated Management of Infectious Disease (IMID)","Model of Integrated Capacity Building Program|Competence of individual clinicians|Practice of individual clinicians|Clinical performance indicators|Reduce Infection, Illness, and Mortality Rates","University of Washington|Makerere University|Accordia Global Health Foundation","All","Child, Adult, Older Adult","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","42657-EG","November 2008","August 2012","August 2012","August 27, 2010",,"December 3, 2014","Infectious Disease Institute, Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01190540"
1330,"NCT03563599","A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)",,"Completed","No Results Available","Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB","Drug: Telacebec (Q203)|Drug: Rifafour e-275","The EBA (early bactericidal activity) of telacebec (Q203)","Qurient Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Q203-TB-P2-ZA001","July 23, 2018","September 9, 2019","September 9, 2019","June 20, 2018",,"September 10, 2019","TASK Applied Science, Cape Town, South Africa|UCT Lung Institute, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT03563599"
1331,"NCT01577264","Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)",,"Terminated","No Results Available","Rheumatoid Arthritis|Crohn's Disease",,"Incidence of Tuberculosis infection or reactivation during the study|Change from Baseline in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) in Rheumatoid Arthritis (RA) patients at Week 26|Change from Baseline in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) in Rheumatoid Arthritis (RA) patients at Week 52|Change from Baseline in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) in Rheumatoid Arthritis (RA) patients at Week 78|Change from Baseline in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) in Rheumatoid Arthritis (RA) patients at Week 104|Change from Baseline in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) in Rheumatoid Arthritis (RA) patients at Week 130|Change from Baseline in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) in Rheumatoid Arthritis (RA) patients at Week 156|Change from Baseline in Harvey Bradshaw Index (HBI) in Crohn's Disease patients (CD) at Week 26|Change from Baseline in Harvey Bradshaw Index (HBI) in Crohn's Disease patients (CD) at Week 52|Change from Baseline in Harvey Bradshaw Index (HBI) in Crohn's Disease patients (CD) at Week 78|Change from Baseline in Harvey Bradshaw Index (HBI) in Crohn's Disease patients (CD) at Week 104|Change from Baseline in Harvey Bradshaw Index (HBI) in Crohn's Disease patients (CD) at Week 130|Change from Baseline in Harvey Bradshaw Index (HBI) in Crohn's Disease patients (CD) at Week 156|Incidence of Adverse Events during the study","UCB Pharma","All","18 Years and older   (Adult, Older Adult)",,"199","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RA0091","August 2011","October 2015","October 2015","April 13, 2012",,"November 10, 2015","13, Ekaterinburg, Russian Federation|28, Ekaterinburg, Russian Federation|12, Kazan, Russian Federation|16, Kazan, Russian Federation|11, Moscow, Russian Federation|14, Moscow, Russian Federation|24, Moscow, Russian Federation|25, Moscow, Russian Federation|31, Moscow, Russian Federation|34, Moscow, Russian Federation|36, Moscow, Russian Federation|40, Moscow, Russian Federation|42, Moscow, Russian Federation|45, Moscow, Russian Federation|5, Moscow, Russian Federation|7, Moscow, Russian Federation|8, Moscow, Russian Federation|9, Moscow, Russian Federation|23, Novgorod, Russian Federation|20, Orenburg, Russian Federation|21, Orenburg, Russian Federation|29, Orenburg, Russian Federation|43, Perm, Russian Federation|39, Petrozavodzk, Russian Federation|1, Saint Petersburg, Russian Federation|3, Saint Petersburg, Russian Federation|4, Saint Petersburg, Russian Federation|6, Saint Petersburg, Russian Federation|15, Samara, Russian Federation|18, Samara, Russian Federation|41, Samara, Russian Federation|33, Saratow, Russian Federation|17, Shakhty, Russian Federation|19, St. Petersburg, Russian Federation|10, Taganrog, Russian Federation|26, Tolyatti, Russian Federation|22, Ufa, Russian Federation|27, Ufa, Russian Federation|32, Ufa, Russian Federation|35, Ufa, Russian Federation|37, Ufa, Russian Federation|38, Ufa, Russian Federation|55, Ufa, Russian Federation|30, Ulyanovsk, Russian Federation|2, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01577264"
1332,"NCT03435146","Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)","IMPAACT4TB","Completed","No Results Available","Respiratory Tract Infections|HIV Infections","Combination Product: 3HP plus DTG +2NRTIs","PK sampling of Dolutegravir - Ctau|PK sampling of Dolutegravir - AUC parameter|PK sampling of Dolutegravir - Cmin parameter|Adverse Events (Primary)|HIV-1 RNA viral load|PK sampling of RPT - AUC parameter|PK sampling of RPT - Cmax parameter|PK sampling of RPT - Cmin parameter|PK sampling of INH - AUC parameter|PK sampling of INH - Cmax parameter|PK sampling of INH - Cmin parameter|DTG Dose selection","The Aurum Institute NPC|Johns Hopkins University|University of California","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","135","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3HP DTG AUR1-6-212 IMPAACT4TB","January 18, 2018","December 7, 2022","December 7, 2022","February 15, 2018",,"February 2, 2023","The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT03435146/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03435146"
1333,"NCT05046366","Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.",,"Recruiting","No Results Available","Artificial Intelligence|Deep Learning|Pathology, Molecular|Medical Informatics|Database|Lung Cancer|Pulmonary Tuberculosis|Covid19",,"The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule).|The outcome of clinical diagnosis of suspected patients with pulmonary tuberculosis (Positive/Negative).|The outcome of clinical diagnosis of suspected patients with COVID-19 (Positive/Negative).|Treatment response of anti-cancer therapy at first evaluation in patients with lung cancer/pulmonary nodules (CR, PR, PD, SD).|Treatment response of anti-inflammation and antiviral therapy at first evaluation in patients with COVID-19 (effective/ineffective treatment).|Treatment response of antituberculous bacilli and anti-inflammation therapy at first evaluation in patients with pulmonary tuberculosis.|Progression free survival|Overall survival|Whole genome sequencing of blood samples|Whole-genome sequencing of tissue samples|Whole genome sequencing of exhaled air condensate samples|Whole genome sequencing of urine samples|Transcriptome sequencing of blood samples|Transcriptome sequencing of tissue samples|Transcriptome sequencing of exhaled air condensate samples|Transcriptome sequencing of urine samples|Metabolomics of blood samples|Metabolomics of tissue samples|Metabolomics of exhaled air condensate samples|Metabolomics of urine samples|Proteomics of blood samples|Proteomics of tissue samples|Proteomics of exhaled air condensate samples|Proteomics of urine samples|sex (male/female)|age (years)|weight (kilograms)|height (meters)|heart rate in each minute|blood pressure (mmHg)|Forced vital capacity (FVC)|forced expiratory volume in one second (FEV1)|peak expiratory flow (PEF)|carbon monoxide diffusion capacity (DLCO)|St. George's Respiratory Questionnaire(SGRQ)|C-reactive protein in blood(mg/L)|total protein in blood(umol/L)|aspartate aminotransferase in blood(U/L)|glutamic-pyruvic transaminase in blood(U/L)|D-dimer in blood(ug/L)|fibrinogen in blood(g/L)|Active part thrombin time in blood(APTT)|prothrombin time in blood(PT)|thrombin time in blood (TT)|leucocytes in blood(×109/L)|neutrophils in blood(×109/L)|lymphocytes in blood(×109/L)|monocytes in blood(×109/L)|eosinophils in the blood(×109/L)|platelets in the blood(×109/L)|Carcinoembryonic Antigen (ug/L)|Cytokeratin 19 fragment (ug/L)|Squamous Cell Carcinoma Antigen(ug/L)|Nervous specific enolase (U/mL)|Tissue Polypeptide Specific Antigen(ug/L)|Cancer antigen 125 (U/mL)|Cancer antigen 15-3 (U/mL)|Bombesin (U/mL)|β2-microglobulin (U/mL)|the outcome of Etiological detection","Wuhan Union Hospital, China","All","18 Years to 90 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","[2021]IEC(491)","October 1, 2021","December 2023","December 2024","September 16, 2021",,"November 16, 2021","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05046366"
1334,"NCT02807025","Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases","RESPI-SAM","Unknown status","No Results Available","IPF|Sarcoidosis|Tuberculosis|Asthma|COPD|Healthy",,"Measurement of levels of inflammation, coagulation, complement activation and fibrosis in MLF|Transcriptomics on upper and lower airway cell samples","Imperial College Healthcare NHS Trust","All","18 Years to 65 Years   (Adult, Older Adult)",,"72","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","15/LO/0444","September 2015","December 31, 2017","December 31, 2017","June 21, 2016",,"March 6, 2017","Imperial College NHS trust , St Mary's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02807025"
1335,"NCT03458338","Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa","RenalOne","Completed","No Results Available","Chronic Kidney Diseases|Diabetes Mellitus|Hypertension|Tuberculosis|Schistosomiasis|HIV Infections","Diagnostic Test: estimated glomerular filtration rate and albuminuria","Point prevalence of chronic kidney disease measured by lab values|Risk factors for chronic kidney disease measured by lab values and questionnaire","University Hospital, Basel, Switzerland|Swiss Tropical & Public Health Institute|Ifakara Health Institute","All","18 Years to 100 Years   (Adult, Older Adult)",,"1006","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","RenalOne","December 8, 2010","May 30, 2011","May 30, 2011","March 8, 2018",,"March 8, 2018","Universitätsspital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT03458338"
1336,"NCT04857814","Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases",,"Completed","No Results Available","Progressive Fibrosing Interstitial Lung Disease|Lung Transplant|Cystic Fibrosis|Bronchiectasis|Pulmonary Tuberculosis","Device: ADAMM- RSM Device","Length of time wearing device (days)|Prediction of respiratory exacerbations- Number of emergency room visits|Prediction of respiratory exacerbations- Number of hospital admissions","University of Alberta","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00097162","July 1, 2021","March 1, 2023","March 1, 2023","April 23, 2021",,"April 19, 2023","University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04857814"
1337,"NCT04869462","DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)","DOSTILCU","Completed","No Results Available","Prostate Cancer|Kidney Cancer|Congenital Abnormality of Kidney|Nephrolithiasis|Kidney Tuberculosis|Nephritis|Kidney Injury|Hydronephrosis",,"Rate of slippage / movement of the clip in relationship to the total number of used clips.|Rate of Adverse events (intra- and postoperative)","Aesculap AG","All","18 Years and older   (Adult, Older Adult)",,"67","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AAG-O-H-2041","May 27, 2021","January 26, 2022","January 29, 2022","May 3, 2021",,"April 12, 2022","Ortenau Klinikum Klinik für Urologie und Kinderurologie, Offenburg, Germany",,"https://ClinicalTrials.gov/show/NCT04869462"
1338,"NCT06338215","Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality","UNATI","Not yet recruiting","No Results Available","All Cause Mortality|Cardiovascular Diseases|Invasive Cancer|Liver Cirrhosis|Type 2 Diabetes|Depression|Dementia|Injury Traumatic|Tuberculosis|Infections","Behavioral: Moderate Alcohol Drinking Pattern|Behavioral: Abstention","Comparison between groups of the incidence of a global Index of all-cause mortality and other alcohol-related diseases|Comparison between groups of the incidence of the most severe outcomes","Clinica Universidad de Navarra, Universidad de Navarra","All","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","UNATI_2024|101097681","May 1, 2024","June 30, 2028","June 30, 2029","March 29, 2024",,"March 29, 2024","University of Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT06338215"
1339,"NCT05110950","Endobronchial Ultrasound Needle Aspiration With and Without Suction",,"Not yet recruiting","No Results Available","Mediastinal Lymphadenopathy|Hilar Lymphadenopathy|Lymphoma|Lung Neoplasms|Sarcoidosis|Tuberculosis|EGF-R Positive Non-Small Cell Lung Cancer|PDL1 Gene Mutation|ALK Translocation|ROS1 Gene Mutation","Procedure: No suction EBUS-TBNA|Procedure: Passive suction through dedicated EBUS-TBNA syringe|Procedure: Manual applied suction EBUS-TBNA through a pistol-grip syringe holder","To compare the diagnostic yield of active suction vs passive suction vs no suction EBUS-TBNA in the diagnosis of hilar/mediastinal adenopathies|Adeguacy for molecular assessment in lung cancer|Qualitative evaluation of the sample by the pathologist","Università Politecnica delle Marche","All","18 Years and older   (Adult, Older Adult)","Not Applicable","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","AspiraTE2021","June 1, 2022","June 26, 2022","June 26, 2024","November 8, 2021",,"May 26, 2022","Pulmonary Diseases Unit, Department of Immunoallergic and Respiratory Diseases, Azienda Ospedaliero Universitaria 'Ospedali Riuniti' Ancona, Ancona, Italy",,"https://ClinicalTrials.gov/show/NCT05110950"
1340,"NCT01589289","Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC","Nidiag-Neuro","Completed","No Results Available","Neurological Disorders|Cerebral Malaria|Bacterial Meningitis|Central Nervous System Tuberculosis|Neurosyphilis|Cryptococcal Meningitis","Device: Immunochromatographic HAT tests (DSD)|Device: Card Agglutination Trypanosoma Test|Device: TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|Device: TB 3-marker RDT (Tulip diagnostics)|Device: Cryptococcal Antigen Lateral Flow Assay (Immy)","Prevalence of HAT and other NTDs/IDs|Identification of reliable diagnostic tests|Predictive values of RDTs|Identification of clinical and laboratory diagnostic indicators|Cure rate|Cost-effectiveness of the diagnostic tests","Institute of Tropical Medicine, Belgium|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|University Hospital, Geneva","All","5 Years and older   (Child, Adult, Older Adult)","Phase 3","352","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","WP2-01-NEU","September 2012","January 2015","May 2015","May 1, 2012",,"January 18, 2016","Reference Hospital Mosango, Mosango, Bandundu, Congo, The Democratic Republic of the",,"https://ClinicalTrials.gov/show/NCT01589289"
1341,"NCT03228095","Volatiles in Breath and Headspace Analysis - Diagnostic Markers","Volatolome","Enrolling by invitation","No Results Available","Tuberculosis|Gastric Cancer|Peptic Ulcer|Atrophic Gastritis|Intestinal Metaplasia|Gastric Dysplasia|Colorectal Cancer|Colorectal Polyp|Colorectal Adenoma|Pancreatic Cancer|Pancreatitis, Chronic|Liver Cancer|Liver Cirrhosis|Flu, Human|Other Infectious Diseases|Inflammatory Bowel Diseases","Diagnostic Test: VOC detection in breath and in skin headspace|Diagnostic Test: Breath sampling|Procedure: Upper endoscopy with biopsies|Procedure: Colonoscopy with biopsies|Procedure: Whole blood/ Plasma / serum sampling|Diagnostic Test: Faecal sampling|Procedure: Histological examination of surgical specimen|Diagnostic Test: Headspace analysis for biological material","Specific VOC detected|Performance of nanoarray sensor testing to detect target lesions and diseases|Specific VOC patterns for target disease or lesion and risk groups|VOC pattern changes following treatment|VOC pattern changes in relapse of disease for early recognition and treatment|Groups of gastrointestinal microbiota correlating to VOCs","University of Latvia|Technion, Israel Institute of Technology|Riga East University Hospital|JLM Innovation GmbH","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017/20329","July 24, 2017","December 20, 2019","December 31, 2025","July 24, 2017",,"August 21, 2018","University of Latvia, Riga, Latvia",,"https://ClinicalTrials.gov/show/NCT03228095"
1342,"NCT05510973","Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi",,"Active, not recruiting","No Results Available","Opportunistic Infections, HIV-Related|Cryptococcal Infections|AIDS With Tuberculosis|AIDS-related Kaposi Sarcoma|AIDS and Infections","Other: Enhanced package for AHD care","Proportion of AHD patients alive and retained in care|Proportion of AHD patients in care and treatment virally suppressed|Cost analysis of implementing the hub and spoke enhanced AHD package of care","Elizabeth Glaser Pediatric AIDS Foundation|Bill and Melinda Gates Foundation","All","Child, Adult, Older Adult","Not Applicable","700","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","EG0264","June 1, 2021","March 31, 2023","June 30, 2023","August 22, 2022",,"February 15, 2023","Mlambe Mission Hospital, Mlambe, Blantyre, Malawi|Lobi rural hospital, Lobi, Dedza, Malawi|Mua Mission Hospital, Mtakataka, Dedza, Malawi|Kapiri Mission Hospital, Kapiri, McHinji, Malawi|Domasi Rural Hospital, Domasi, Zomba, Malawi|Chiradzulu District Hospital, Chiradzulu, Malawi|Dedza district hospital, Dedza, Malawi|Mchinji District Hopsital, Mchinji, Malawi|St Michael's Guilleme Community Hospital, Mchinji, Malawi|Ntcheu District Hospital, Ntcheu, Malawi|Sister Theresa Community Hospital, Ntcheu, Malawi|Malamulo Mission Hospital, Thyolo, Malawi|Saint Luke's Mission Hospital, Zomba, Malawi",,"https://ClinicalTrials.gov/show/NCT05510973"
1343,"NCT05472051","Health and Migration Trajectories of Housekeepers in Bamako","2DM2K","Completed","No Results Available","HIV Infections|Hepatitis B|Hepatitis C|Tuberculosis|STIs|Sex Behavior","Other: Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO","Acceptability of the community-based offer of healthcare services|Prevalence of infectious diseases among housekeepers attending the community-based healthcare services and accepting screening|Pregnancy|HBV Vaccin|Mental health","ANRS, Emerging Infectious Diseases","Female","12 Years and older   (Child, Adult, Older Adult)",,"644","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","ANRS 0005s","February 28, 2022","June 22, 2023","June 22, 2023","July 25, 2022",,"March 12, 2024","ADDAD, Bamako, Niamakoro, Sièbougouni, Rue 173, Porte 146, Mali",,"https://ClinicalTrials.gov/show/NCT05472051"
1344,"NCT03226379","Driving Reduced AIDS-associated Meningo-encephalitis Mortality","DREAMM","Completed","No Results Available","AIDS-Related Opportunistic Infections|Meningo-encephalitis|Cryptococcal Meningitis|Bacterial Meningitis|Tuberculous Meningitis|Cerebral Toxoplasmosis","Other: DREAMM","2-week all-cause mortality|10-week all-cause mortality|4-week all-cause mortality|10-week and 6-month rate of death|Time to appropriate investigation: lumbar puncture, brain imaging|Time to appropriate, microbiologically guided treatment|Prevalence of cryptococcal, tuberculous and bacterial meningitis and toxoplasma meningo-encephalitis and neurosyphilis|Time to ART initiation|6-month all-cause mortality","St George's, University of London|European and Developing Countries Clinical Trials Partnership (EDCTP)|National Agency for Research on AIDS and Viral Hepatitis (ANRS)|Institut Pasteur|National Institute for Medical Research, Tanzania|Amana Hospital, Dar es Salaam, Tanzania|University of North Carolina Project-Malawi (UNC Project), Lilongwe, Malawi|Kamuzu Central Hospital|Yaounde Central Hospital|Zomba Central Hospital, Zomba, Malawi|Lighthouse Trust|Mwananyamala Hospital, Dar es Salaam, Tanzania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","495","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","16.0091","April 23, 2016","April 2021","September 2021","July 21, 2017",,"May 4, 2022","Hôpital Central Yaoundé, Yaoundé, Cameroon|Kamuzu Central Hospital, Lilongwe, Malawi|Zomba Central Hospital, Zomba, Malawi|Amana Hospital, Dar es Salaam, Tanzania|Mwananyamala Hospital, Dar es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT03226379"
1345,"NCT05282173","Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa","Siyakhana","Completed","No Results Available","Substance-Related Disorders|Mental Disorder|Social Stigma|Depression|Treatment Adherence and Compliance|Health Care Utilization|Attitude of Health Personnel|Hiv|Tuberculosis|Mental Health Disorder|Community Health Workers|Health Care Delivery","Behavioral: Siyakhana CHW Training","CHW stigma towards substance use|CHW stigma towards depression|Training Feasibility|Acceptability|CHW Training Fidelity","University of Maryland, College Park|Medical Research Council, South Africa|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","EC039-10/2021|R34MH122268","June 8, 2022","August 1, 2023","August 1, 2023","March 16, 2022",,"March 27, 2024","South African Medical Research Council, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT05282173"
1346,"NCT02129244","A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes",,"Active, not recruiting","No Results Available","MDR-TB|HIV","Other: NCM-Plus","Proportion of patients who experience successful treatment outcomes|Proportion of patients who experience successful treatment outcomes based on HIV co-infection|Proportion of patients who experience successful treatment outcomes based on sex and gender|Proportion of patients who experience successful treatment outcomes based on age","Johns Hopkins University|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Medical Research Council, South Africa","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","3600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","NA_00078899|RO1 104488-01A1","October 2014","November 2020","May 2024","May 2, 2014",,"June 8, 2023","Regus Primary Office, Westville, Durban, South Africa|Catherine Booth Hospital, Amatikulu, KwaZulu-Natal, South Africa|King George V Hospital, Durban, South Africa|Fort Gray Hospital, East London, South Africa|Don McKenzie, Ethekwini, South Africa|Dunstan Farrell Hospital, Hibberdene, South Africa|Hlabisa Hospital, Hlabisa, South Africa|Manguzi, Manguzi, South Africa|Nkqubela, Mdantsane, South Africa|Fosa Hospital, Newlands West, South Africa|Doris Goodwin Hospital, Pietermaritzburg, South Africa|Marjorie Parrish Hospital, Port Alfred, South Africa|Jose Pearson Hospital, Port Elizabeth, South Africa|Murchison Hospital, Port Shepstone, South Africa|St Margaret's MDR-TB Hopsital, Umzimkulu, South Africa",,"https://ClinicalTrials.gov/show/NCT02129244"
1347,"NCT02673879","IMPI 2 - A Trial of Intrapericardial Alteplase in Large Pericardial Effusion","IMPI-2","Unknown status","No Results Available","Pericardial Effusion","Other: Pericardiocentesis with Alteplase|Other: Conventional Pericardiocentesis","Composite outcome of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.|Major bleeding|Clinically relevant non-major bleeding|Any bleeding|Other adverse events|Persistent pericardial effusion without cardiac tamponade|Recurrent pericardial effusion without cardiac tamponade|Hospitalisation for any cause; and death from any cause|Cardiac tamponade requiring pericardiocentesis|Constrictive pericarditis|Death","University of Cape Town|Walter Sisulu University|Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","2176","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HREC REF No. 370/2015","February 2016","July 2019","January 2020","February 4, 2016",,"May 2, 2018","Groote Schuur Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02673879"
1348,"NCT02527486","Seoul National University Airway Registry",,"Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Asthma With Chronic Obstructive Pulmonary Disease|Bronchiectasis|Inactive Tuberculosis of Lung|Chronic Obstructive Airway Disease",,"Death (time to death)|post-bronchodilator FEV1 change rates","Seoul National University Hospital","All","20 Years to 90 Years   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AW_registry","September 2011","December 2021","December 2031","August 19, 2015",,"August 19, 2015","Seoul National University Bundang Hospital, Seongnam, Gyeonggi-Do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02527486"
1349,"NCT05042063","Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease",,"Recruiting","No Results Available","Cough|COPD|GERD|Asthma|Tuberculosis|Non-Tuberculous Mycobacterial Pneumonia|COVID-19 Pneumonia","Device: Hyfe Cough Tracker|Device: Hyfe Air","Correlation between subjective perception of cough and objective frequency|Sensitivity of the system discriminating coughs|Specificity of the system discriminating coughs|Positive predictive value (PPV) of the system discriminating coughs|Negative predictive value (NPV) of the system discriminating coughs|Construction of an annotated cough dataset|Sensitivity of the system differentiating coughs caused by different conditions|Specificity of the system differentiating coughs caused by different conditions","Clinica Universidad de Navarra, Universidad de Navarra|Centre de Recherche du Centre Hospitalier de l'Université de Montréal|Hyfe Inc","All","5 Years to 100 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PI_2021/72","September 15, 2021","April 15, 2022","September 15, 2026","September 13, 2021",,"November 10, 2021","Clinica Universidad de Navarra, Pamplona, Navarra, Spain","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/63/NCT05042063/Prot_SAP_002.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/63/NCT05042063/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT05042063"
1350,"NCT05868005","Delivering a Multi-disease Screening Tool to Migrant Populations","ISMiHealth","Recruiting","No Results Available","Hiv|Hepatitis B|Hepatitis C|Tuberculosis|Chagas Disease|Schistosomiasis|Strongyloidiasis|Female Genital Mutilation Type I Status|Female Genital Mutilation Type II Status|Female Genital Mutilation Type III Status","Other: Clinical decision support system for screening of migrants using the ISMiHealth software tool.","Comparison of the detection rate per month of all aggregated infections (HIV, HBV, HCV, TB, T.cruzi, S.stercoralis and Schistosoma spp. infections) between the intervention and control centres|Comparison of the detection rate per month of each individual condition, the infections and FGM cases, between the intervention and control centres|Comparison of the number of early HIV diagnoses|Comparison of the number of early HBV and HCV diagnoses|Comparison of the number of screening tests performed for all aggregated infections|Comparison of the the number of screening tests performed for each individual condition|Associations between the screening performance of all aggregated infections (yes/no) and patients' age (in years) will be analysed using the data collected from the EPR system|Associations between the screening performance of all aggregated infections (yes/no) and the time that patients have been registered in the Spanish National Health System (in years) will be analysed using the data collected from the EPR system|Associations between the screening performance of all aggregated infections (yes/no) and patients' sex (female/male) will be analysed using the data collected from the EPR system|Associations between the screening performance of all aggregated infections (yes/no) and patients' area of birth (Africa/Latin America/Asia/Eastern Europe) will be analysed using the data collected from the EPR system|Associations between the screening performance of all aggregated infections (yes/no) and the region where the PCC is located (Terres de l'Ebre/Lleida/Tarragona/Costa de Ponent) will be analysed using the data collected in the SISAP database|Associations between the screening performance of all aggregated infections (yes/no) and the type of region where the PCC is located in Catalonia, Spain (urban/rural) will be analysed using the data collected in the SISAP database|Associations between the screening performance of all aggregated infections (yes/no) and if the patient fulfilled the criteria of the screening recommendation (yes/no) will be analysed using the data collected from the EPR system|Associations between the screening performance of all aggregated infections (yes/no) and the arm of the study (Intervention/Control) will be analysed using the data collected from the EPR system|Associations between the screening performance of all aggregated infections (yes/no) and patients' immunosuppression status (yes/no) will be analysed using the data collected from the EPR system|Associations between the screening performance of all aggregated infections (yes/no) and the presence of another condition (yes/no) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and patients' age (in years) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and the time that patients have been registered in the Spanish Health System (in years) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and patients' sex (female/male) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and patients' area of birth (Africa/Latin America/Asia/Eastern Europe) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and the region where the PCC is located (Terres de l'Ebre/Lleida/Tarragona/Costa de Ponent) will be analysed using data collected in the SISAP database|Associations between the screening performance of each individual condition (yes/no), including FGM, and the type of region where the PCC is located in Catalonia, Spain (urban/rural) will be analysed using the data collected in the SISAP database|Associations between the screening performance each individual condition (yes/no), including FGM, and if the patient fulfilled the criteria of the screening recommendation (yes/no) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and the arm of the study (Intervention/Control) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and patients' immunosuppression status (yes/no) will be analysed using the data collected from the EPR system|Associations between the screening performance of each individual condition (yes/no), including FGM, and the presence of another condition (yes/no) will be analysed using the data collected from the EPR system|Associations between the screening performance of HIV (yes/no) and the CD4 cell count (cell/µL) will be analysed using the data collected from the EPR system|Associations between the screening performance of HIV (yes/no) and the viral load (copies/mL) will be analysed using the data collected from the EPR system|Associations between the screening performance of HBV and/or HCV (yes/no) and the levels of platelets (U/µL) will be analysed using the data collected from the EPR system|Associations between the screening performance of HBV and/or HCV (yes/no) and the levels of transaminases (U/L) will be analysed using the data collected from the EPR system|Associations between the screening performance of HBV and/or HCV (yes/no) and the levels of bilirubin (mg/dL) will be analysed using the data collected from the EPR system|Associations between the screening performance of HBV and/or HCV (yes/no) and the levels of clotting parameters [such as prothrombin (seconds), fibrinogen (mg/dL), among others] will be analysed using the data collected from the EPR system|Number of diagnosed individuals with follow-up visits in the hospital of reference|Number of diagnosed individuals under treatment","Barcelona Institute for Global Health|Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina|Distrito Sanitario Poniente de Almería|Hospital de Poniente|Universidad de Granada|Consorci d'Atenció Primària de Salut de l'Eixample","All","18 Years and older   (Adult, Older Adult)","Not Applicable","980","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","PI21/00651","October 23, 2023","September 2024","September 2024","May 22, 2023",,"March 6, 2024","Servicio Andaluz de Salud (SAS) (administration of the participant PCCs in Andalusia), Almería, Andalusia, Spain|Institut Català de la Salut (ICS) (administration of the participant PCCs in Catalonia), Tortosa, Catalonia, Spain","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/05/NCT05868005/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/05/NCT05868005/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT05868005"
1351,"NCT03993093","Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre","ADC","Completed","No Results Available","HIV Infections|Tuberculosis|Candidiasis, Esophageal|Cryptococcosis|Leishmaniasis|Toxoplasmosis","Other: CD4 cell count","Prevalence of AIDS defining OIs|Compare CD4 cell in cases of HIV with OIs with CD4 cell of HIV patients without OIs","Singh, Ranjan Kumar, M.D.","All","5 Years and older   (Child, Adult, Older Adult)",,"257","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SinghRK1","June 1, 2019","February 28, 2020","March 15, 2020","June 20, 2019",,"March 19, 2020","ART centre, Sadar Hospital, Khagaria, Bihar, India",,"https://ClinicalTrials.gov/show/NCT03993093"
1352,"NCT05049395","HFNO Reducing the Incidence of Hypoxia for Hysteroscopy Sedated With Propofol",,"Unknown status","No Results Available","Endometritis|Tuberculous Endometritis|Subseptate Uterus|Endometrial Polyps","Device: High Flow Nasal Cannula oxygen (HFNO)|Device: Regular oxygen","The incidence of hypoxia|The incidence of sub-clinical respiratory depression","RenJi Hospital","Female","20 Years to 50 Years   (Adult)","Not Applicable","960","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","RJ20210904","September 30, 2021","September 2022","September 2022","September 20, 2021",,"October 1, 2021","Renji Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05049395"
1353,"NCT02045394","Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study",,"Completed","No Results Available","Lung Cancer|Tuberculosis|Bronchiectasis|Pneumonia|Acute Bronchitis|Chronic Obstructive Pulmonary Disease|Cryptogenic Haemoptysis","Other: Chest X-ray|Other: computed tomography of the chest|Procedure: Bronchoscopy","Percentage of patients presenting with haemoptysis affected by lung cancer, tuberculosis, bronchiectasis, pneumonia, acute bronchitis, cryptogenic haemoptysis or other causes.|Sensitivity and specificity of chest X-ray, chest CT scan and bronchoscopy alone and in combination in the diagnosis of different causes of haemoptysis.|Percentage and severity of recurrence of haemoptysis in the follow-up period.|Sensitivity and specificity of bronchoscopy in localizing the bleeding side and lobe in relation to the timing of the haemoptysis.|Patient survival in the follow-up period.","University of Milan","All","18 Years and older   (Adult, Older Adult)",,"610","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HAEMOPTYSIS76","June 2013","October 2015",,"January 24, 2014",,"December 3, 2015","Pneumologia, Azienda Ospedaliero Universitaria, Ancona, Italy|USC Pneumologia, Azienda Ospedaliera della Provincia di Lodi, Lodi, Italy|U.O. di Pnuemologia, Azienda Ospedaliera, Carlo Poma, Mantova, Italy|Respiratory Unit, San Paolo Hospital, Dipartimento Scienze della Salute, Università degli Studi di Milano., Milan, Italy|A.O.U. Maggiore della Carità - S.C.D.O. Pneumologia, Novara, Italy|Clinica Pneumotisiologica, AOU Sassari, Sassari, Italy",,"https://ClinicalTrials.gov/show/NCT02045394"
1354,"NCT00866190","Dose Escalation Study of SQ109 in Healthy Adult Volunteers",,"Completed","No Results Available","TB Multi-drug Resistant","Drug: SQ109|Drug: Placebo","Safety and tolerability evaluated by a review of physical examinations, color and visual acuity tests, funduscopic examinations, neurological examinations, vital signs assessments, 12-lead ECGs, routine clinical laboratory tests, and AE assessments.|Serial blood samples for the measurement of the plasma levels of SQ109 will be collected. Pharmacokinetic variables will be assessed.","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","10","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","08-0048|N01AI80024C|SQ-109","April 2009","November 2009","November 2009","March 20, 2009",,"November 6, 2011","Quintiles Phase I Services, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00866190"
1355,"NCT03870061","Evaluation of an Infant Immunization Encouragement Program in Nigeria",,"Completed","No Results Available","Tuberculosis|Diphtheria|Tetanus|Pertussis|Hepatitis B|Haemophilus Influenzae Type b Infection|Pneumonia, Bacterial|Measles|Rotavirus Infections|Polio|Yellow Fever","Behavioral: All Babies Are Equal Initiative (conditional cash transfer program)","The probability that a 12- to 16-month-old in a community served by a study clinic received BCG (based on caregivers' report of their child's vaccination history)|The probability that a 12- to 16-month-old in a community served by a study clinic received at least one dose of PENTA (based on caregivers' report of their child's vaccination history)|The probability that a 12- to 16-month-old in a community served by a study clinic received Measles 1 (based on caregivers' report of their child's vaccination history)|The probability that a 12- to 16-month-old in a community served by a study clinic is fully immunized (loose and strict) (based on caregivers' report of their child's vaccination history)|The timeliness of vaccination, particularly for Measles 1, among 12- to 16-month-olds in communities served by a study clinic (based on caregivers' report of their child's vaccination history)|The average number of vaccines received per 12- to 16-month-old child in communities served by a study clinic (based on caregivers' report of their child's vaccination history)|The percentage of 12- to 16-month-olds in communities served by a study clinic who received at least one injectable vaccine (based on caregivers' report of their child's vaccination history)|The probability that a 12 to 16-month old in a community served by a study clinic received at least one dose of PCV?|The change over time in the volume of BCG, Penta 1, Penta 2, Penta 3, and Measles vaccinations recorded in clinic administrative records between treatment and control","GiveWell|New Incentives|All Babies are Equal Initiative","All","12 Months to 16 Months   (Child)","Not Applicable","5187","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","001","July 1, 2018","February 20, 2020","February 20, 2020","March 11, 2019",,"March 31, 2020","Primary Health Care facilities across Jigawa State, Various Cities, Jigawa, Nigeria|Primary Health Care facilities across Katsina State, Various Cities, Katsina, Nigeria|Primary Health Care facilities across the Zamfara State, Various Cities, Zamfara, Nigeria","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/61/NCT03870061/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03870061"
1356,"NCT03341195","Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan",,"Unknown status","No Results Available","Tuberculosis|Polio|Diphtheria|Pertussis|Tetanus|Haemophilus Influenzae Type b Infection|Hepatitis B|Pneumococcal Infection","Behavioral: SMS messages and automated calls","The primary outcome will measure the number of children who got vaccinated for routine immunization scheduled at 6, 10 and 14 weeks of life|The secondary outcome will measure the mean improvement in on-time vaccination for routine immunization scheduled at 6, 10 and 14 weeks of life","Aga Khan University|Grand Challenges Canada|University of British Columbia","All","1 Day to 14 Days   (Child)","Not Applicable","3850","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4320-Ped_ERC-16","January 2018","July 2018","September 2018","November 14, 2017",,"November 17, 2017",,,"https://ClinicalTrials.gov/show/NCT03341195"
1357,"NCT04947475","Project MATLINK: Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community","MATLINK","Active, not recruiting","No Results Available","Opioid-use Disorder|HIV Infections|Tuberculosis|Hepatitis C|Hepatitis B|Depression|Syphilis","Behavioral: SBIRT","Enrollment on OAT|OAT Knowledge|OAT Attitudes|Interest in OAT|OAT Difficulty|OAT Importance","Yale University|Ukrainian Institute on Public Health Policy|AFEW Kyrgyzstan|AFI - Act For Involvement|National Institute on Drug Abuse (NIDA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","835","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1407014374|2R01DA029910-06","January 1, 2017","July 31, 2024","July 31, 2024","July 1, 2021",,"November 3, 2023","AIDS Foundation East-West, Bishkek, Kyrgyzstan|AFI - Act for Involvement, Chisinau, Moldova, Republic of|Ukrainian Institute for Public Health Policy, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04947475"
1358,"NCT05337163","A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China",,"Completed","No Results Available","Lung Cancer|Small Cell Lung Cancer|Non-Small Cell Lung Cancer|Squamous Cell Carcinoma|Adenocarcinoma|Large Cell Carcinoma|Adenosquamous Carcinoma|Sarcomatoid Carcinoma|Respiratory Tract Infection|Acute Bronchitis|Pneumonia|Chronic Bronchitis|Chronic Obstructive Pulmonary Disease|Tuberculosis|Lung Neoplasm|Pulmonary Interstitial Fibrosis","Diagnostic Test: Diagnostic Test: Sputum DNA methylation analysis|Procedure: chest CT or pathological examination","Sensitivity|Specificity|Consistency Rate|Kappa Coefficient","Creative Biosciences (Guangzhou) Co., Ltd.|Guangzhou Xiangkang Medical Research Co., Ltd.","All","Child, Adult, Older Adult",,"659","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KLM2021-02","February 25, 2022","May 6, 2023","August 29, 2023","April 20, 2022",,"October 30, 2023","Nanfang Hospital of Southern Medccal University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05337163"
1359,"NCT02596087","Improving Quality by Maintaining Accurate Problems in the EHR","IQ-MAPLE","Completed","No Results Available","Asthma|Atrial Fibrillation|Chronic Obstructive Pulmonary Disease|Coronary Artery Disease|Congestive Heart Failure|Hyperlipidemia|Hypertension|Myocardial Infarction|Sickle Cell Disease|Sleep Apnea|Smoking|Stroke|Tuberculosis","Other: Problem List Suggestion","Measuring the rate of acceptance of alerts calculated by number of acceptances for each alert divided by the total number of unique presentations of the alert|Determining the effect of problem list completion by comparing the number of study-related problems added to problem lists in the electronic health record|Determining the quality of care impact of adding suggested problems to the problem list based on 4 outcome measures from NCQA's HEDIS 2013 measure set|Evaluating process measures using key process measures for each study condition from CMS, NHLBI, and NQMC","Brigham and Women's Hospital|Geisinger Clinic|Oregon Health and Science University|Vanderbilt University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2386","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","2009P001846-14","April 2016","March 2018",,"November 4, 2015",,"February 8, 2023","Brigham and Women's Hospital, Boston, Massachusetts, United States|Oregon Health and Science University, Portland, Oregon, United States|Holy Spirit Hospital, Camp Hill, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02596087"
1360,"NCT02913365","Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis",,"Unknown status","No Results Available","Hemoptysis|Haemoptysis|Lung Disease|Pneumonia|Tuberculosis|Bronchiectasis|Respiratory Tract Infections|Respiratory Tract Diseases|Bronchitis|Mycobacterium Infections|Bronchial Disease|Pulmonary Hemorrhage|Signs and Symptoms|Signs and Symptoms, Respiratory|Pathologic Processes|Mycosis|Hemorrhage|Lung Cancer|Pulmonary Embolism|Arteriovenous Fistula",,"Etiologies of hemoptysis|Sensitivity of chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography.|All-cause mortality at 2 years|Smoking status|Age|Gender|International Normalized Ratio|Partial Thromboplastin Time|Platelet count","Université de Sherbrooke","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","12-099","October 2012","June 2017","June 2017","September 23, 2016",,"September 23, 2016","Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02913365"
1361,"NCT03159364","Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections",,"Unknown status","No Results Available","Pathogen Infection|EBV Infection|CMV Infection|Adenovirus Infection|BKV Infection|Fungus Infection|Tuberculosis","Biological: pathogen-specific CTLs","Using CTCAE 4 standard to evaluate the level of adverse events after receiving autologous or allogenic pathogen-specific CTL infusion|Viral load change after Virus-CTL infusion|The incidence of CTL infusion syndrome mimicking grade Ⅱ~Ⅳ GVHD within 30 days after the last dose of CTL infusion|Reconstitution of anti-microbial immunity monitored by flow cytometry|Number of patients with chronic GVHD-like symptom","Shenzhen Geno-Immune Medical Institute","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-17009","July 15, 2017","July 31, 2020","December 31, 2021","May 18, 2017",,"September 19, 2019","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03159364"
1362,"NCT01766830","Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)",,"Completed","No Results Available","Visceral Leishmaniasis|Human African Trypanosomiasis|Enteric Fever|Melioidosis|Brucellosis|Leptospirosis|Relapsing Fever|Rickettsial Diseases|HIV|Tuberculosis|Malaria|Amoebic Liver Abscess","Device: rk28 ICT|Device: IT LEISH (rK39)|Device: Immunochromatographic HAT test|Device: HAT Serostrip|Device: Card Agglutination Trypanosoma Test (CATT)-10|Device: Typhidot M|Device: S. typhi IgM/IgG|Device: Test-it Typhoid IgM|Device: Test-it Leptospirosis IgM|Device: Leptospira IgG/IgM","Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs)|Identification of clinical and laboratory diagnostic indicators|Identification of reliable Rapid Diagnostic Tests (RDTs)|Predictive values of RDTs|Cost-effectiveness of the diagnostic tests","University Hospital, Geneva|Institute of Tropical Medicine, Belgium|B.P. Koirala Institute of Health Sciences|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|University of Khartoum|Sihanouk Hospital Center of HOPE","All","5 Years and older   (Child, Adult, Older Adult)","Not Applicable","1927","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","WP2-01-FEV|260260","January 2013","October 2014","July 2016","January 11, 2013",,"October 27, 2016","Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia|Reference Hospital Mosango and Kasay Health Centre, Mosango, Bandundu, Congo, The Democratic Republic of the|Institut National de Recherche Biomédicale, Kinshasa, Congo, The Democratic Republic of the|Dhankuta District hospital, Dhankuta, Koshi Zone, Nepal|BP Koirala Institute of Health Sciences, Dharan, Nepal|Tabarak Allah Hospital, Tabarak Allah, Gedaref, Sudan|University of Khartoum, Khartoum, Sudan",,"https://ClinicalTrials.gov/show/NCT01766830"
1363,"NCT03459768","Cohort Study on People Who Inject Drugs in Senegal","CoDISEN","Unknown status","No Results Available","Drug Addiction|HIV/AIDS|Hepatitis C, Chronic|Hepatitis C, Acute|Hepatitis B, Chronic|Hepatitis B Acute|Tuberculosis|Sexually Transmitted Diseases|Psychiatric Disorder",,"incidence of HIV|incidence of hepatitis C infection (HCV)|incidence of hepatitis B infection (HBV)|incidence of relevant coinfections and comorbidities|Retention rate and its determinants|mortality rate and determinants|Access to treatment of HCV, HBV infections and other coditions requiring specific therapeutical management|Effectiveness of tuberculosis regimens","French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases","All","18 Years and older   (Adult, Older Adult)",,"208","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ANRS 12334 CoDISEN","August 24, 2016","June 30, 2021","June 30, 2021","March 9, 2018",,"June 8, 2021","CEPIAD, Dakar, Senegal",,"https://ClinicalTrials.gov/show/NCT03459768"
1364,"NCT02889757","The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acetylcysteine (NAC)",,"Unknown status","No Results Available","Protective Effect in TB-DIH|TB-DIH Means: Drug Induced Liver Function Abnormalities","Drug: Acteylcysteine","the incidence of DIH|the incidence for other side effects","Far Eastern Memorial Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","T-6621","January 2017","December 2018","June 2019","September 7, 2016",,"September 13, 2016","Far Eastern Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02889757"
1365,"NCT03681860","EMaBS TB Vaccine Study",,"Completed","No Results Available","Safety|Immunogenicity","Biological: ChAdOx185A|Biological: MVA85A|Biological: BCG","Safety: Solicited Adverse Events|Immunogenicity: T-cell response to 85A|Immunogenicity: antibodies to 85A|Exploratory immunology: Flow cytometry|Exploratory immunology: gene expression|Exploratory immunology: mycobacterial killing assay","University of Oxford|MRC/UVRI and LSHTM Uganda Research Unit","All","12 Years to 49 Years   (Child, Adult)","Phase 1|Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB042","July 1, 2019","May 24, 2021","May 24, 2021","September 24, 2018",,"August 5, 2022","MRC/UVRI and LSHTM Uganda Research Unit, Entebbe Hospital, Entebbe, Uganda|Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, Oxfordshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/60/NCT03681860/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03681860"
1366,"NCT01159886","Patient-posture and Ileal-intubation During Colonoscopy","PIC","Unknown status","No Results Available","Colonoscopy","Procedure: Ileal intubation","Ileal intubation achieved or not|Time taken to intubate the ileum after cecal intubation|Depth of ileal intubation|Influence of endoscopist experience on successful ileal intubation|Abnormal ileal findings","Post Graduate Institute of Medical Education and Research, Chandigarh|PIMERIndia","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","SDLD001","June 2010","January 2011","March 2011","July 12, 2010",,"July 12, 2010","School of Digestive and Liver Diseases (SDLD), IPGME & R, Kolkata, Kolkata, India",,"https://ClinicalTrials.gov/show/NCT01159886"
1367,"NCT00202410","Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: Bacille of Calmette-Guerin|Other: placebo","number of gad-enhancing lesions in T1|number of lesions in T1 and new lesions in T2|volume of T2 lesions|volume of T1 lesions (black holes)","S. Andrea Hospital|Italian Multiple Sclerosis Foundation|Istituto Superiore di Sanità","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NEU - BCG - 01","November 2001","September 2007","April 2008","September 20, 2005",,"May 19, 2011","Department of Neurology - University of Rome La Sapienza, Rome, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT00202410"
1368,"NCT00925535","Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)",,"Completed","No Results Available","Healthy Volunteers","Drug: Lersivirine|Drug: Rifabutin","Lersivirine plasma pharmacokinetic parameters: AUC24, Cmax, Tmax, and C24h|Rifabutin and 25-O-desacetyl-rifabutin plasma pharmacokinetic parameters: AUC24, Cmax, Tmax, and C24h|Safety and toleration assessed by spontaneous reporting of adverse events, vital signs, 12 lead ECG and laboratory safety assessments","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A5271043","May 2010","August 2010","August 2010","June 22, 2009",,"September 21, 2010","Pfizer Investigational Site, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00925535"
1369,"NCT03070405","The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects",,"Unknown status","No Results Available","Healthy Volunteers","Drug: Tenofovir disoproxil fumarate 300mg|Drug: Para-aminosalicylic acid Ca granule 5.28 g","Peak plasma concentration (Cmax) of tenofovir|Area under the plasma concentration versus time curve (AUC) of tenofovir|Volume of distribution of tenofovir|Time of peak plasma concentration(Tmax) of tenofovir|Plasma half-life of tenofovir|Renal clearance of tenofovir|Amount of tenofovir excreted in urine|Peak plasma concentration of PAS|Area under the plasma concentration versus time curve (AUC) of PAS|Renal clearance of PAS|Volume of distribution of PAS|Time of peak plasma concentration of PAS|Plasma half-life of PAS|Amount of PAS excreted in urine","Inje University","Male","18 Years to 45 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","16-0138","October 2016","March 2017","May 2017","March 3, 2017",,"March 3, 2017",,,"https://ClinicalTrials.gov/show/NCT03070405"
1370,"NCT01012284","A Study of TMC207 in Patients With Moderately Impaired Hepatic Function",,"Completed","No Results Available","Moderate Hepatic Impairment","Drug: TMC207","Maximum plasma concentration of TMC207|Time to reach the maximum plasma concentration of TMC207|Area under curve from time of administration up to 72 hours post dosing of TMC207|Area under curve from time of administration up to the last time point with a measurable concentration post dosing of TMC207|Area under curve extrapolated to infinity of TMC207|Maximum plasma concentration of N-monodesmethyl metabolite|Time to reach the maximum plasma concentration of N-monodesmethyl metabolite|Area under curve from time of administration up to 72 hours post dosing of N-monodesmethyl metabolite|Area under curve from time of administration up to the last time point with a measurable concentration post dosing of N-monodesmethyl metabolite|Area under curve extrapolated to infinity of N-monodesmethyl metabolite|Number of patients with adverse events as a measure of safety and tolerability","Tibotec BVBA","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR007501|TMC207-TiDP13-C112|2009-016437-99","January 2010","January 2011","January 2011","November 13, 2009",,"December 20, 2012",,,"https://ClinicalTrials.gov/show/NCT01012284"
1371,"NCT00480454","Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines",,"Completed","No Results Available","TB","Biological: MVA 85A","Dose selection, safety and immunogenicity of MVA85A vaccines in 4 month old healthy Gambian infants|Impact of MVA85A on the immunogenicity of EPI vaccines (DTwPHib, Hep B) and vice versa when administered simultaneously to children who have had BCG vaccine within the first two weeks of life.","University of Oxford|Medical Research Council","All","2 Months to 3 Months   (Child)","Phase 1","214","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB012","October 2006","December 2009","December 2009","May 31, 2007",,"February 9, 2010","MRC, Banjul, Gambia",,"https://ClinicalTrials.gov/show/NCT00480454"
1372,"NCT02076685","NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis",,"Unknown status","No Results Available","Hepatotoxicity","Drug: isoniazid","successful re-use of isoniazid for TB treatment","National Taiwan University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","200805015M","November 2007","November 2015","November 2015","March 3, 2014",,"March 17, 2014","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02076685"
1373,"NCT03149848","Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects",,"Completed","Has Results","Infection, Human Immunodeficiency Virus|HIV Infections","Drug: Cabotegravir|Drug: Rifabutin","Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau])|Assessment of Plasma CAB PK Parameter: Maximum Observed Concentration (Cmax)|Assessment of Plasma CAB PK Parameter: Concentration at the End of the Dosing Interval (Ctau)|Assessment of Plasma CAB PK Parameter: Time of Occurrence of Cmax (Tmax)|Assessment of Plasma CAB PK Parameter: Terminal Phase Half-life (t1/2)|Assessment of Plasma CAB PK Parameter: The Apparent Oral Clearance (CL/F)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Concurrent Medication Assessment in Treatment Period 1 and 2|Assessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes|Assessment of Hematology Parameters: Hematocrit and Reticulocytes/Erythrocytes (R/E)|Assessment of Hematology Parameter: Hemoglobin|Assessment of Hematology Parameter: Eryrocyte Mean Corpuscular Hemoglobin|Assessment of Hematology Parameter: Erythrocye Mean Corpuscular Volume|Assessment of Hematology Parameters: Erythrocytes and Reticulocytes|Assessment of Hematology Parameters: Erythrocytes Distribution Width (EDW)|Assessment of Clinical Chemistry Parameters: Albumin and Protein|Assessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT)|Assessment of Clinical Chemistry Parameters: Direct Bilirubin (DB), Bilirubin and Creatinine|Assessment of Clinical Chemistry Parameters: Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea|Number of Participants With Abnormal Urinalysis Result|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Pulse Rate","ViiV Healthcare|GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205712|2017-000103-25","June 6, 2017","September 6, 2017","September 7, 2017","May 11, 2017","February 4, 2019","September 17, 2020","GSK Investigational Site, Cambridge, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT03149848/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT03149848/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03149848"
1374,"NCT02878447","The Utility of Radiotherapy in the Management of Haemoptysis Secondary to Aspergillomata and Structural Lung Diseases",,"Unknown status","No Results Available","Haemoptysis","Radiation: External beam radiotherapy","Composite end-point of time to recurrent life-threatening haemoptysis, or death|Six minute walk test|Time to massive haemoptysis (>200mL per day)|Fev1/FVC|Total lung capacity (TLC) Total lung capacity (TLC)|Diffusion capacity (DLCO) Total lung capacity (TLC)|Radiological change in volume (maximum diameters in three planes)|Number of complications associated with Radiotherapy","University of Stellenbosch","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","M15/09/033","June 2016","March 2018","March 2019","August 25, 2016",,"October 26, 2017","University of Stellenbosch, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02878447"
1375,"NCT00654316","Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine",,"Completed","No Results Available","TB","Biological: BCG","The occurence and severity of local side-effects The occurence and severity of systemic side-effects|The induction of T cell responses (as measured by an interferon-gamma Elispot assay). Other exploratory cellular immunology assays will be performed as such assays are developed.","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TB006","February 2004","November 2005","November 2005","April 7, 2008",,"April 7, 2008","Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00654316"
1376,"NCT02816229","Endobronchial Valves in Inoperable Patients With Haemoptysis",,"Unknown status","No Results Available","Haemoptysis","Device: Insertion of endobronchial valve","Rate of termination of haemoptysis|Time to recurrence of haemoptysis|Improvement in exercise performance|Improvement in lung function|Recurrence of infection/tuberculsis|EBV related complications","University of Stellenbosch","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","N10/11/386","January 2019","December 2019","March 2020","June 28, 2016",,"October 12, 2018",,,"https://ClinicalTrials.gov/show/NCT02816229"
1377,"NCT03510468","Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)",,"Completed","Has Results","Healthy Volunteers","Drug: Tenofovir alafenamide|Drug: Rifapentine|Drug: Isoniazid (INH)|Dietary Supplement: Pyridoxine","Plasma Area Under the Curve (AUC) for Tenofovir (TFV) During the Dosing Interval of 0 to 24 Hours (AUC0-24hr)","National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","51","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","180087|18-CC-0087","June 12, 2018","November 15, 2022","December 21, 2022","April 27, 2018","October 25, 2023","October 25, 2023","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT03510468/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03510468"
1378,"NCT03278483","Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)","TBL","Completed","No Results Available","Diabetes Mellitus|Tuberculin (Skin Test) Positive","Drug: Isoniazid 300 mg Oral Tablet|Drug: Rifampin 600 mg Oral Tablet","Efficacy of treatment with rifampicin compared to efficacy of treatment with isoniazid|Toxicity (neuropathy)|Adherence|Toxicity (liver function)","Instituto Nacional de Salud Publica, Mexico|Instituto Nacional de Enfermedades Respiratorias|Instituto Nacional de Ciencias Medicas y Nutrición","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","396","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1341","February 28, 2019","February 28, 2019","February 28, 2019","September 11, 2017",,"April 26, 2019","Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT03278483"
1379,"NCT03086213","Comparative Study of Nonintubated Uniport Thoracoscopic Surgery Using Thoracic Paravertebral Nerve Block Versus Intercostal Nerve Block for Peripheral Solitary Pulmonary Nodule Patients",,"Completed","Has Results","Peripheral Solitary Pulmonary Nodule or Tuberculoma","Drug: Propofol|Drug: Sulfentanyl|Drug: Dexmedetomidine|Drug: Lidocaine|Drug: Ropivacaine","Comparing the Inflammatory Markers During the Operation After the Intervention of the Each Group|Concentration of Cortisol at Different Point During the Operation|Comparing the Hemodynamics of the Intervention of the Each Group During the Operation|Comparing the Blood Gas Analysis After the Intervention of the Each Group|Number of Participants With Puncture Related Complications","Shenzhen Third People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","19800911","March 1, 2017","September 1, 2019","September 5, 2019","March 22, 2017","May 7, 2020","May 7, 2020","the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/13/NCT03086213/SAP_000.pdf|""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/13/NCT03086213/Prot_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/13/NCT03086213/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03086213"
1380,"NCT03733093","PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)",,"Active, not recruiting","No Results Available","HIV",,"Description of disease course|Characteritics of study population|ARV Genotypic Resistance Mutations","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"1377","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999919014|19-I-N014","August 22, 2019","December 31, 2024","December 31, 2025","November 7, 2018",,"March 13, 2024","C.H. Rennie Hospital, Kakata, Liberia|John F. Kennedy (JFK) Medical Center, Monrovia, Liberia|Redemption Hospital, Monrovia, Liberia|Duport Road Clinic, Paynesville, Liberia",,"https://ClinicalTrials.gov/show/NCT03733093"
1381,"NCT04117984","Swaziland HIV Incidence Measurement Survey 2","SHIMS2","Completed","No Results Available","HIV/AIDS",,"HIV incident rate among adults 15 years and older|Sub-national prevalence of suppressed HIV viral load (<1,000 copies/mL) among adults 15 and older|HIV prevalence of children ages 0-14|HIV Prevalence in 2016 among adults 15 years and older|HIV incidence estimates among young women aged 18-24 in 2011 versus 2016|Incidents of HIV infection among adults from risky behaviors|Mean population viral load among adults living with HIV|Prevalence of adult viral suppression in 2011 versus 2016|CD4+ count distribution of adults living with HIV|Enrollment rate in HIV care among adults with prevalent HIV infection|Prevalence of antiretroviral therapy (ART) use among adults and children with prevalent HIV infection|Uptake of HIV testing and ART use among women recently pregnant or breastfeeding|Prevalence of transmitted antiretroviral (ARV) drug resistance (DR) among adults and children with recent HIV infection|Prevalence of viral suppression among adults and children on ART|Incidence of reported sexual behavior associated with HIV transmission risk among adults|Percentage of prior testing and knowledge of HIV status among adults|Prevalence of male circumcision among men 15 years and older and among male children|Uptake of tuberculosis services among adults|Acceptability rate of early ART use among adults who test HIV sero-positive and self report as not currently on ART|Prevalence of HIV infection among children|Enrollment rate in HIV care among HIV-infected children|CD4+ count distribution of children living with HIV|Prevalence of sub-national viral suppression among children living with HIV|Prevalence of sexual behavior and debut associated with HIV transmission risk among participants aged 10-14 years","Columbia University|Centers for Disease Control and Prevention|Ministry of Health, Swaziland","All","Child, Adult, Older Adult",,"15429","Other|U.S. Fed","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","AAAQ8889|U2GGH001271","August 30, 2016","December 31, 2017","December 31, 2019","October 7, 2019",,"February 9, 2023","ICAP at Columbia University, Mbabane, Swaziland",,"https://ClinicalTrials.gov/show/NCT04117984"
1382,"NCT03449602","Minirigid Versus Conventional Rigid Thoracoscopy in Undiagnosed Pleural Effusions","MICRO","Recruiting","No Results Available","Pleural Effusion","Device: Mini-thoracoscopy|Device: Conventional rigid thoraoscopy","Diagnostic sensitivity (intention-to-treat)|Diagnostic sensitivity (per protocol)|Sedative and analgesic dose|Pain scores by visual analog scale|Diagnostic specificity|Adverse effects|Scope maneuverability|Ease of obtaining biopsy|Incision size|Procedure duration|Pain scores by Wong Baker FACES pain rating scale","Post Graduate Institute of Medical Education and Research, Chandigarh|PGIMER","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NK/3695/Res","March 1, 2018","September 30, 2023","September 30, 2023","February 28, 2018",,"March 29, 2023","Postgraduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT03449602"
1383,"NCT01356979","Outcome of Patients Undiagnosed Under Medical Thoracoscopy",,"Completed","No Results Available","Pleural Diseases","Procedure: Medical thoracoscopy","Accuracy of medical thoracoscopy for patients diagnosed as fibrinous pleuritis.|To determine the factors which point the false positive diagnosis of fibrinous pleuritis.","Eskisehir Osmangazi University","All","20 Years to 85 Years   (Adult, Older Adult)",,"355","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","052011/15","February 2002","May 2009","June 2009","May 20, 2011",,"September 25, 2012","ESOGU Medical Faculty Department of Chest Diseases, Eskisehir, Meselik - Eskisehir, Turkey",,"https://ClinicalTrials.gov/show/NCT01356979"
1384,"NCT04150224","Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169",,"Completed","Has Results","Healthy Subjects","Drug: PBTZ169 640 mg OD|Drug: PBTZ169 640 mg BiD|Drug: PBTZ169 960 mg SD|Drug: PBTZ169 1280 mg SD|Drug: PBTZ169 1280 mg MD","Number of Adverse Events|Number of Subjects With AEs|CS Changes in Vital Signs|ECG Results (Safety and Tolerability)|Laboratory Examinations Results (Safety and Tolerability)|Results of Physical Examination: CS Deviations|Peak Plasma Concentration (Сmax)|Trough Concentration With Repeated Administration (Ctrough)|Time to Reach Maximum Concentration (Tmax)|Plasma Half-life Time (T1/2)|Area Under the Concentration-time Curve (AUC0 t)|Area Under the Concentration-time Curve (AUC0-∞)|Area Under the Concentration-time Curve (AUC0-24)|Total Clearance (Clt/F)|Volume of Distribution (Vd/F)|Elimination Constant Kel|Relative Bioavailability|Relative Degree of Absorption|Number of Subjects With CS Changes in Vital Signs","Nearmedic Plus LLC","All","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PBTZ169-Z00-C01-3","July 3, 2018","November 23, 2018","February 1, 2019","November 4, 2019","February 28, 2020","February 28, 2020","Clinical hospital at the Yaroslavl station of the Open Joint Stock Company Russian Railways, Yaroslavl, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/24/NCT04150224/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04150224"
1385,"NCT05797649","Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis",,"Recruiting","No Results Available","Pleural Effusion|Heart Failure|Malignant Neoplasm|Fluid Overload|Hypoalbuminemia|Renal Failure|Cirrhosis|Infections",,"Comparison of the diagnostic performance of PF NTproBNP level in the diagnosis of HF-associated pleural effusions with other conventional biochemical criteria|To measure the PF NTproBNP level in patients with pleural effusion of various aetiologies|Correlation of clinical factors that may affect the levels of pleural fluid NTproBNP such as echocardiographic features, presence of comorbidities, nutritional status, serum albumin level, levels of inflammatory markers and presence of infection|To correlate the PF NTproBNP levels with the echocardiographic features and prognosis of patients with heart failure","Chinese University of Hong Kong|Roche Diagnostics","All","18 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NTProBNPPleuralEffusion1","July 1, 2023","November 30, 2025","November 30, 2025","April 4, 2023",,"October 23, 2023","Prince of Wales Hospital, Hong Kong, New Territories, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05797649"
1386,"NCT05675176","Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer",,"Completed","No Results Available","Non-muscle-invasive Bladder Cancer","Drug: BCG","Complications","National and Kapodistrian University of Athens","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15306/26-7-22","April 12, 2020","October 20, 2022","October 20, 2022","January 9, 2023",,"January 11, 2023","Themistoklis Bellos, Marathon, Attica, Greece",,"https://ClinicalTrials.gov/show/NCT05675176"
1387,"NCT00910806","TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)",,"Completed","No Results Available","HIV Infections","Drug: TMC207; nevirapine","The primary objective is to evaluate the effect of steady-state NVP 200 mg twice daily on the pharmacokinetics of TMC207 and its M2 metabolite after single-dose administration of TMC207 400 mg, in HIV-1 infected patients|The effect of single-dose TMC207 on the steady-state plasma concentrations of NVP will be evaluated.|The short-term safety and tolerability of coadministration of single-dose TMC207 and steady-state NVP will be evaluated in HIV-1 infected patients.","Tibotec BVBA","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR015793","June 2009","June 2010","June 2010","June 1, 2009",,"April 2, 2014","George, South Africa",,"https://ClinicalTrials.gov/show/NCT00910806"
1388,"NCT01583972","Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function",,"Completed","No Results Available","Vitamin A Deficiency","Dietary Supplement: retinyl palmitate|Dietary Supplement: Placebo","Thymus size measured by ultrasound|peripheral blood naive T-helper lymphocyte concentration|T-cell receptor excision circle (TREC) level in peripheral blood mononuclear cells (PBMC)|T-cell response to BCG (Bacillus Calmette-Guérin; to protect against tuberculosis) and oral polio virus (OPV) immunization|Antibody response to oral polio virus (OPV) immunization|T-cell and antibody response to tetanus toxoid (TT) and hepatitis B virus (HBV) vaccinations given at 6, 10 and 14 wk of age|bacterial translocation to blood|vitamin A status by modified, relative dose-response (MRDR) test|bulging fontanelle","USDA, Western Human Nutrition Research Center|International Centre for Diarrhoeal Disease Research, Bangladesh|World Health Organization","All","up to 48 Hours   (Child)","Not Applicable","300","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","N3-TSA-003|PR-10012","January 2012","July 2013","August 2014","April 24, 2012",,"August 26, 2014","International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT01583972"
1389,"NCT01291563","TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions",,"Completed","No Results Available","Healthy Volunteer","Drug: Moxifloxacin|Drug: TMC207|Drug: TMC207 placebo|Drug: Moxifloxacin placebo","ECG evaluation as a measure of QT and QTc interval|ECG evaluation as a measure of non-QT interval electrocardiogram parameters (RR interval, HR, PR and QRS interval)|Plasma concentrations of TMC207 and its N-monodesmethyl metabolite (M2)|Evaluation of the concentration-effect relationship for QT/QTc for TMC207 and M2|Evaluation of the number of volunteers with adverse events, blood and urine tests, blood pressure and pulse tests, and ECGs as measures of safety and tolerability","Tibotec BVBA","All","18 Years to 55 Years   (Adult)","Phase 1","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR017167|TMC-207-TBC1003","February 2011",,"April 2011","February 8, 2011",,"November 6, 2012",,,"https://ClinicalTrials.gov/show/NCT01291563"
1390,"NCT00720954","Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy",,"Completed","No Results Available","Pleural Effusion|Pleural Diseases","Procedure: Ct-guided pleural needle biopsy|Procedure: Thoracoscopy","Efficacy and safety of both thoracoscopy and CT-guided pleural needle biopsy for diagnosis of pleural diseases|Determine the efficacy of pleural needle biopsy and thoracoscopy in relation to CT findings.","Eskisehir Osmangazi University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","124","Other","Interventional","Allocation: Randomized|Primary Purpose: Diagnostic","2007.11.008","January 2006","June 2008","June 2008","July 23, 2008",,"July 23, 2008","ESOGU MEDICAL FACULTY DEPARTMENT of CHEST DISEASES, Eskisehir, Turkey",,"https://ClinicalTrials.gov/show/NCT00720954"
1391,"NCT01802203","trūFreeze® Spray Cryotherapy Patient Registry",,"Completed","No Results Available","Barrett Esophagus|Esophageal Dysplasia|Esophageal Neoplasm|Esophageal Stenosis|Bronchial Neoplasm|Stenosis of Bronchus or Trachea","Device: truFreeze Spray Cryotherapy","Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.|Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.","US Endoscopy Group Inc.","All","18 Years and older   (Adult, Older Adult)",,"275","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","003","April 2013","January 2022","April 2022","March 1, 2013",,"July 25, 2022","Scripps Green Hosptial, La Jolla, California, United States|University of Colorado Denver, Denver, Colorado, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Ochsner Medical Center, Kenner, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|ProHEALTH Care Associates, Lake Success, New York, United States|NYU, New York, New York, United States|University of Rochester/Strong Memorial Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Ahuja Medical Center-CWR University Hosptials, Beachwood, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01802203"
